{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "collapsed_sections": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "5zK70MJd_DAS"
      },
      "source": [
        "<a href=\"https://nbviewer.jupyter.org/github/alisonmitchell/Stock-Prediction/blob/main/Sentiment_Analysis/NLP_Text_Preprocessing_and_Classification.ipynb\" \n",
        "   target=\"_parent\">\n",
        "   <img src=\"https://raw.githubusercontent.com/jupyter/design/master/logos/Badges/nbviewer_badge.svg\" \n",
        "      width=\"109\" height=\"20\" alt=\"render in nbviewer\">\n",
        "</a>"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "0uJS3r3xKr9w"
      },
      "source": [
        "# NLP - Text Preprocessing and Classification\n",
        "\n",
        "## 1. Introduction\n",
        "Text preprocessing is an approach for cleaning and preparing text data for NLP tasks before training a model. Various preprocessing steps in an NLP pipeline, including text normalisation techniques for transforming a text into a canonical (standard) form to reduce noise, will be investigated using NLTK and spaCy libraries on AstraZeneca market news articles collected by web scraping from [Investing.com](https://https://www.investing.com/).  \n",
        "\n",
        "Text classification is the problem of assigning categories to text data according to its content. Different techniques to extract information from raw text data for training a classification model will be explored including Bag of Words, TF-IDF and Word Embedding.\n",
        "\n",
        "One of the primary applications of NLP is to cut through the noise (high dimensionality from large volumes of text) and identify the signal (extract the main topics). Topic modelling is the practice of using a quantitative algorithm to automatically output the key topics that a body of text is about. Here, the Latent Dirichlet Allocation (LDA) algorithm from the Gensim package will be used.\n",
        "\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "4Qjj5unAmOjK"
      },
      "source": [
        "## 2. Install/import libraries"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "1zhVb8gHyOKe",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "415ae510-ae88-4b54-8250-548394340e96"
      },
      "source": [
        "!pip -q install spacy\n",
        "!python -m spacy download en\n",
        "!pip install -q pyLDAvis\n",
        "!pip install contractions"
      ],
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "2022-11-06 11:31:11.881909: E tensorflow/stream_executor/cuda/cuda_driver.cc:271] failed call to cuInit: CUDA_ERROR_NO_DEVICE: no CUDA-capable device is detected\n",
            "\u001b[38;5;3m⚠ As of spaCy v3.0, shortcuts like 'en' are deprecated. Please use the\n",
            "full pipeline package name 'en_core_web_sm' instead.\u001b[0m\n",
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting en-core-web-sm==3.4.1\n",
            "  Downloading https://github.com/explosion/spacy-models/releases/download/en_core_web_sm-3.4.1/en_core_web_sm-3.4.1-py3-none-any.whl (12.8 MB)\n",
            "\u001b[K     |████████████████████████████████| 12.8 MB 4.2 MB/s \n",
            "\u001b[?25hRequirement already satisfied: spacy<3.5.0,>=3.4.0 in /usr/local/lib/python3.7/dist-packages (from en-core-web-sm==3.4.1) (3.4.2)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.10 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (3.0.10)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2.0.8)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (57.4.0)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2.0.7)\n",
            "Requirement already satisfied: wasabi<1.1.0,>=0.9.1 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (0.10.1)\n",
            "Requirement already satisfied: pathy>=0.3.5 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (0.6.2)\n",
            "Requirement already satisfied: typing-extensions<4.2.0,>=3.7.4 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (4.1.1)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (21.3)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (1.0.9)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (3.0.8)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2.11.3)\n",
            "Requirement already satisfied: thinc<8.2.0,>=8.1.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (8.1.5)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (3.3.0)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<1.11.0,>=1.7.4 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (1.10.2)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (4.64.1)\n",
            "Requirement already satisfied: typer<0.5.0,>=0.3.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (0.4.2)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2.23.0)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2.4.5)\n",
            "Requirement already satisfied: numpy>=1.15.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (1.21.6)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (1.0.3)\n",
            "Requirement already satisfied: zipp>=0.5 in /usr/local/lib/python3.7/dist-packages (from catalogue<2.1.0,>=2.0.6->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (3.10.0)\n",
            "Requirement already satisfied: pyparsing!=3.0.5,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from packaging>=20.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (3.0.9)\n",
            "Requirement already satisfied: smart-open<6.0.0,>=5.2.1 in /usr/local/lib/python3.7/dist-packages (from pathy>=0.3.5->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (5.2.1)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2.10)\n",
            "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (3.0.4)\n",
            "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (1.24.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2022.9.24)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.7/dist-packages (from thinc<8.2.0,>=8.1.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (0.0.3)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.7/dist-packages (from thinc<8.2.0,>=8.1.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (0.7.9)\n",
            "Requirement already satisfied: click<9.0.0,>=7.1.1 in /usr/local/lib/python3.7/dist-packages (from typer<0.5.0,>=0.3.0->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (7.1.2)\n",
            "Requirement already satisfied: MarkupSafe>=0.23 in /usr/local/lib/python3.7/dist-packages (from jinja2->spacy<3.5.0,>=3.4.0->en-core-web-sm==3.4.1) (2.0.1)\n",
            "\u001b[38;5;2m✔ Download and installation successful\u001b[0m\n",
            "You can now load the package via spacy.load('en_core_web_sm')\n",
            "\u001b[K     |████████████████████████████████| 1.7 MB 5.6 MB/s \n",
            "\u001b[?25h  Installing build dependencies ... \u001b[?25l\u001b[?25hdone\n",
            "  Getting requirements to build wheel ... \u001b[?25l\u001b[?25hdone\n",
            "  Installing backend dependencies ... \u001b[?25l\u001b[?25hdone\n",
            "    Preparing wheel metadata ... \u001b[?25l\u001b[?25hdone\n",
            "  Building wheel for pyLDAvis (PEP 517) ... \u001b[?25l\u001b[?25hdone\n",
            "  Building wheel for sklearn (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting contractions\n",
            "  Downloading contractions-0.1.72-py2.py3-none-any.whl (8.3 kB)\n",
            "Collecting textsearch>=0.0.21\n",
            "  Downloading textsearch-0.0.24-py2.py3-none-any.whl (7.6 kB)\n",
            "Collecting anyascii\n",
            "  Downloading anyascii-0.3.1-py3-none-any.whl (287 kB)\n",
            "\u001b[K     |████████████████████████████████| 287 kB 4.9 MB/s \n",
            "\u001b[?25hCollecting pyahocorasick\n",
            "  Downloading pyahocorasick-1.4.4-cp37-cp37m-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (106 kB)\n",
            "\u001b[K     |████████████████████████████████| 106 kB 64.1 MB/s \n",
            "\u001b[?25hInstalling collected packages: pyahocorasick, anyascii, textsearch, contractions\n",
            "Successfully installed anyascii-0.3.1 contractions-0.1.72 pyahocorasick-1.4.4 textsearch-0.0.24\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "3TQ6gjjzoEJn",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "4f6de22e-7541-4e6a-88ca-76b234abe6c7"
      },
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "import csv\n",
        "import nltk\n",
        "import re\n",
        "import pprint\n",
        "import string\n",
        "import contractions\n",
        "import spacy\n",
        "import en_core_web_sm\n",
        "import gensim\n",
        "import gensim.corpora as corpora\n",
        "import pyLDAvis\n",
        "import pyLDAvis.gensim_models as gensimvis\n",
        "import warnings\n",
        "warnings.filterwarnings('ignore')\n",
        "\n",
        "%matplotlib inline\n",
        "from contractions import contractions_dict\n",
        "\n",
        "from nltk import word_tokenize\n",
        "nltk.download('punkt')\n",
        "nltk.download('stopwords')\n",
        "nltk.download('wordnet')\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.stem import PorterStemmer\n",
        "from nltk.stem.snowball import SnowballStemmer\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "\n",
        "from sklearn.feature_extraction.text import CountVectorizer, TfidfVectorizer\n",
        "from sklearn.manifold import TSNE\n",
        "from sklearn import linear_model\n",
        "\n",
        "from IPython.display import clear_output\n",
        "\n",
        "from spacy import displacy\n",
        "\n",
        "from gensim.utils import simple_preprocess\n",
        "from gensim.models import CoherenceModel\n",
        "from pprint import pprint\n"
      ],
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/past/types/oldstr.py:5: DeprecationWarning: Using or importing the ABCs from 'collections' instead of from 'collections.abc' is deprecated since Python 3.3,and in 3.9 it will stop working\n",
            "  from collections import Iterable\n",
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Unzipping tokenizers/punkt.zip.\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Unzipping corpora/stopwords.zip.\n",
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "AQtxQDmun_zo"
      },
      "source": [
        "## 3. Import data\n",
        "Read in text file of articles collected by web scraping from Investing.com. Data has been prepared for further processing by appending ---newarticle--- to the body text of each article. This will then be specified as the separator for splitting the string into a list using the split() method. New lines will also be removed."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mvNOTVmt-VB-",
        "outputId": "84a3ff7d-acfd-46fe-fe6c-647384e9d8cf"
      },
      "source": [
        "txt_file = open(\"azn_body_text_202230.txt\")\n",
        "articles = txt_file.read().replace('\\\\n', ' ').split('---newarticle---')\n",
        "articles"
      ],
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[' AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast cancer.\\n\\nThe Anglo-Swedish pharma giant AZN, +1.77% AZN, +0.56% said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations.AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer SettingsAstraZeneca\\'s Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal CordAstraZeneca (NASDAQ: AZN) announced on Tuesday that its COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]) has been given full Marketing Authorisation (MA) in the European Union (EU).\\n\\nVaxzevria was originally granted a conditional Marketing Authorisation (cMA) by the EU. AstraZeneca stated, “As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the European Medicines Agency (EMA) has now granted a full MA.”\\n\\nIskra Reic, EVP, Vaccines and Immune Therapies, AstraZeneca commented, “The move from conditional to full marketing authorisation for Vaxzevria is an important confirmation by the EMA of the safety and efficacy of Vaxzevria, demonstrating that the benefits continue to outweigh the potential risks. Vaxzevria is estimated to have helped save over six million lives in the first year of vaccination, which reflects the strength of the evidence showing Vaxzevria’s protection against severe disease and death caused by COVID-19.”by\\n\\nThe European Medicines Agency (EMA) has granted full Marketing Authorisation to AstraZeneca Plc\\'s AZN COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]).\\n\\nCOVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]). Vaxzevria was initially granted a conditional Marketing Authorisation due to the urgency of the COVID-19 pandemic. As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the EMA has now granted full approval.\\n\\nThe approval covers the use of Vaxzevria in both a primary vaccination series and as both a heterologous (with an approved mRNA COVID-19 vaccine) or homologous (all the same vaccine) third-dose booster.\\n\\nRelated: AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial.\\n\\nAstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial. Vaxzevria has been demonstrated to be effective against all forms of COVID-19, from mild symptomatic to severe disease, including hospitalization and death, according to clinical studies and real-world evidence.\\n\\nThese include an expert review of data from 52 real-world studies that showed that Vaxzevria and the available mRNA COVID-19 vaccines provide equally effective protection against hospitalization and death from COVID-19 following three doses.\\n\\nThere is also a substantial body of evidence supporting boosting with Vaxzevria following all primary vaccination schedules tested to date.\\n\\nPrice Action: AZN shares are up 1.82% at $59.88 during the premarket session on the last check Tuesday.\\n\\nAZN shares are up 1.82% at $59.88 during the premarket session on the last check Tuesday. Photo by Paul McManus from Pixabay\\n\\n© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca\\'s COVID-19 Shot, Tesla Eyes Cybertruck Commercialization Next Year: Top Stories Tuesday, Nov. 1by\\n\\nThe European Commission has approved AstraZeneca plc AZN and Sanofi SA’s SNY Beyfortus (nirsevimab) long-acting antibody to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.\\n\\nand Beyfortus (nirsevimab) long-acting antibody to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions.\\n\\nIn the pivotal MELODY efficacy trial, Beyfortus met its primary endpoint of reducing the incidence of medically attended lower respiratory tract infections (LRTI) caused by RSV by 74.5% vs. placebo through day 151 with a single dose.\\n\\nBeyfortus also demonstrated a comparable safety and tolerability profile to\\n\\nSwedish Orphan Biovitrum AB\\'s BIOVF Synagis (palivizumab) in the MEDLEY Phase 2/3 trial.\\n\\nSynagis (palivizumab) in the MEDLEY Phase 2/3 trial. Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalizations. It was estimated that there were 26,300 in-hospital deaths of children younger than five years.\\n\\nPrice Action: SNY shares are up 0.61% at $43.10, and AZN shares are up 0.15% at $60.02 during the premarket session on the last check Friday.\\n\\n© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.© Reuters AstraZeneca shares will get lift from heartburn drug litigation closure, says Citi\\n\\nAZN +0.56% Add to/Remove from a Portfolio LFCOF 0.00% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nAstraZeneca PLC (NASDAQ: ) can get a boost from the probability that it will close out its US kidney damage lawsuit in New Jersey prior to the first bellwether case in March 2023, according to analysts at Citi.\\n\\nThe UK pharma is one of several firms embroiled in US legal action over possible damage caused by proton pump inhibitor (PPI) heartburn drugs such as Nexium, launched by Astra in the US in 2001.\\n\\nThe Citi analysts believe the most likely outcome is that the judge is delaying her response to the Defendant Motion for summary judgement on the grounds of pre-emption, to encourage the plaintiffs to settle.\\n\\n“Alternatively, but with a lower probability, Judge Cecchi may have delayed the start of the bellwether cases as she disagrees with the conclusions of Special Master Reisman and grants the defendant\\'s motion to dismiss on grounds of pre-emption,\" they said.\\n\\nEither scenario would be materially positive to Astra\\'s depressed share price, the US bank\\'s analysts added, as would positive interim DESTINY-Breast06 data with Enhertu at the year-end and positive TROPION-Lung-01 data in March 2023.\\n\\nThe Citi analysts said their 2023 and 2024 core EPS forecasts for Astra are 5% and 17% above consensus and repeated them alongside a price target of £130 and a \\'buy\\' recommendation.\\n\\nShares in Astra rose 1% to £103.56.\\n\\nRead more on Proactive Investors UK\\n\\nDisclaimerBy Benzinga\\n\\nThe crypto party started as corporate earnings-induced optimism and hopes of a Fed thawing perked up risk appetite in the financial markets. Ethereum (CRYPTO: ETH), the second...Astrazeneca\\'s Beyfortus receives EU approval\\n\\nAZN +0.56% Add to/Remove from a Portfolio UK100 +2.03% Add to/Remove from a Portfolio\\n\\nAstraZeneca (NASDAQ: ) stated that Beyfortus was now the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy, at term or pre-term, or with specific health conditions.\\n\\nThe 100-listed group said the European Commission was the first regulatory body to grant approval to Beyfortus, with the approval based on results from the drug\\'s clinical development programme and follows a recommendation from The Committee for Medicinal Products for Human Use of the European Medicines Agency in September.\\n\\nIn AZN\\'s \"pivotal\" MELODY efficacy trial, Beyfortus met its primary endpoint of reducing the incidence of medically attended lower respiratory tract infections caused by RSV by 74.5% versus placebo through day 151 with a single dose.\\n\\nIskra Eric, AZN\\'s executive vice president of vaccines and immune therapies, said: \"Beyfortus is the first single-dose preventative option against respiratory syncytial virus to gain approval in Europe and is also the first and only preventative option approved for a broad infant population.\\n\\n\"Today\\'s marketing authorisation of Beyfortus marks a significant achievement for the scientific community and addresses a persistent, global unmet need in RSV prevention.\"\\n\\nReporting by Iain Gilbert at Sharecast.com\\n\\nRead more on Sharecast.com© Reuters. AstraZeneca says Evusheld approved for treatment of COVID-19 in EU\\n\\nAZN +0.56% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nhas said its long-acting antibody combination Evusheld (tixagevimab and cilgavimab, formerly AZD7442) has been approved in the EU for the treatment of COVID-19.\\n\\nThe approval by the European Commission covers people over the age of 12 years who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19, the pharmaceuticals group said.\\n\\nThe European Commission’s approval was based on results from the TACKLE phase III treatment trial which showed that Evusheld significantly reduced the risk of severe COVID-19 or death.\\n\\nThe recommended dose of Evusheld for treatment in Europe is 300mg of tixagevimab and 300mg of cilgavimab, administered as two separate, sequential IM injections, AstraZeneca (NASDAQ: ) noted.\\n\\n\"Many people, including those who are immunocompromised, older adults and those with underlying health conditions, are at high risk of severe disease, hospitalisation and death if they become infected. Evusheld, delivered in a convenient intramuscular formulation, is now a much-needed new COVID-19 treatment option for these vulnerable populations,\" commented Dr Michel Goldman, professor at the Institute for Interdisciplinary Innovation in Healthcare, Université Libre de Bruxelles, and former executive director of the European Innovative Medicines Initiative in a statement.\\n\\nIskra Reic, executive vice president of vaccines and immune therapies at AstraZeneca, added: \"COVID-19 remains an ongoing health concern for millions of Europeans and around the world, especially for those who may not be well-protected against the virus from vaccination. With this approval, Evusheld is now the only long-acting antibody combination available for both prevention and treatment of COVID-19 in Europe, allowing us to protect even more people from this devastating disease.\"\\n\\nRead more on Proactive Investors UK\\n\\nDisclaimer© Reuters AstraZeneca gets its third regulatory green light in a matter of weeks for asthma drug\\n\\nAZN +0.56% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nAstraZeneca PLC (LON: ) said its Tezspire treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids don’t work.\\n\\nIt is the third approval in a matter of weeks for the product, a potential challenger to market leader Dupxient. It was developed in collaboration with US giant Amgen (NASDAQ: ).\\n\\nIn clinical trials, the drug was shown to lower what the researchers called ‘asthma exacerbations’ by 56%.\\n\\n\"Tezspire is the first and only biologic approved by the Japanese Ministry of Health, Labour and Welfare that has been shown to consistently and significantly reduce attacks in exacerbation trials in a broad population of severe asthma patients irrespective of biomarker levels,” Mene Pangalos, head of biopharmaceutical research at AZ.\\n\\n“Tezspire has the potential to improve outcomes for many patients with severe asthma and we are working to make this important medicine available in Japan as quickly as possible.”\\n\\nAnalysts believe Tezspire could be a big seller with peak sales projected to be in the order of US$2.5bn.\\n\\nRead more on Proactive Investors UK\\n\\nDisclaimer© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo\\n\\nAZN +0.56% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\n(Reuters) - Shares of LogicBio Therapeutics skyrocketed on Monday after Britain\\'s AstraZeneca (NASDAQ: )\\'s said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.\\n\\nLoigBio\\'s shares, which have traded below $1 since February, were up 637% at $2 before the bell, close to AstraZeneca\\'s offer price of $2.07 per share.\\n\\nLogicBio is developing gene editing therapies to treat pediatric rare disease like methylmalonic acidemia, where the body cannot break down certain proteins and fats.\\n\\nAstraZeneca said the deal would accelerate growth of its Alexion (NASDAQ: ) unit, which it acquired for $39 billion last year, in the field of genomic medicine.By Benzinga\\n\\nThe crypto party started as corporate earnings-induced optimism and hopes of a Fed thawing perked up risk appetite in the financial markets. Ethereum (CRYPTO: ETH), the second...© Reuters AstraZeneca says Imjudo-Imfinzi combination approved for advanced liver cancer in US\\n\\nAZN +0.56% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nAstraZeneca PLC (LON: ) announced that the US Food and Drug Administration (FDA) has approved the company\\'s Imjudo (tremelimumab) drug in combination with Imfinzi (durvalumab) for treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.\\n\\nThe approval is based on results from the HIMALAYA Phase III trial, which showed that a single priming dose of the anti-CTLA-4 antibody Imjudo added to the anti-PD-L1 antibody Imfinzi reduced the risk of death by 22% compared with sorafenib, the pharmaceuticals company said.\\n\\nLiver cancer is the third-leading cause of cancer death and the sixth most commonly diagnosed cancer worldwide. It is the fastest-rising cause of cancer-related deaths in the US, with approximately 36,000 new diagnoses each year, the 100-listed company said.\\n\\nIn a statement, Dave Fredrickson, executive vice president, oncology business unit at AstraZeneca, commented: \"With this first regulatory approval for Imjudo, patients with unresectable liver cancer in the US now have an approved dual immunotherapy treatment regimen that harnesses the potential of CTLA-4 inhibition in a unique combination with a PD-L1 inhibitor to enhance the immune response against their cancer.\"\\n\\nDr Ghassan Abou-Alfa, attending physician at Memorial Sloan Kettering Cancer Center (MSK), and principal investigator in the HIMALAYA Phase III trial, said: \"Patients with unresectable liver cancer are in need of well-tolerated treatments that can meaningfully extend overall survival. In addition to this regimen demonstrating a favourable three-year survival rate in the HIMALAYA trial, safety data showed no increase in severe liver toxicity or bleeding risk for the combination, important factors for patients with liver cancer who also have advanced liver disease.\"\\n\\nRegulatory applications for Imjudo in combination with Imfinzi are currently under review in Europe, Japan and several other countries for the treatment of patients with advanced liver cancer based on the HIMALAYA results, AstraZeneca said.\\n\\nRead more on Proactive Investors UK\\n\\nDisclaimer© Reuters. AstraZeneca-Merck\\'s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October\\'s Key PDUFA Catalysts Biotech Investors Must Know\\n\\nAZN +0.56% Add to/Remove from a Portfolio IXIC +1.28% Add to/Remove from a Portfolio KECR +3.15% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nMost FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.\\n\\nNMEs are considered a measure of innovation in drug research, as they contain active moieties or ingredients that haven’t been previously approved by the Food and Drug Administration.\\n\\nAmong the positive verdicts, bluebird bio, Inc.’s (NASDAQ: BLUE) $3 million gene therapy Skysona was approved for treating a rare neurodegenerative disorder in boys and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) scored a win for its amyotrophic sclerosis treatment Revance Therapeutics, Inc.’s (NASDAQ: RVNC) Botox rival Daxxify was approved for treating frown lines.\\n\\nSpectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) had a mixed month, as its Rolvedon was approved for treating chemotherapy-induced neutropenia, but its lung cancer drug did not get the backing of an FDA panel.\\n\\nHere are the key PDUFA dates scheduled for October:\\n\\nWill Theratech Score A Win For A More Convenient Formulation Of Its HIV Drug? Company: Theratechnologies, Inc. (NASDAQ: THTX)\\n\\nType of Application: supplemental biologic license application\\n\\nCandidate: Trogarzo\\n\\nIndication: HIV-1\\n\\nDate: Oct. 3\\n\\nIn the fourth quarter of 2021, the company filed the sBLA for intravenous push mode of administration of its Trogarzo for treating human immunodeficiency virus type 1, or HIV-1. Trogarzo was first approved by the FDA in March 2018 to treat adult patients with multidrug-resistant HIV. In the quarter that ended on May 31, the drug generated sales of $7.852 million for Theratech.\\n\\nAlnylam On Course For Snagging Label Expansion For Oxlumo? Company: Alnylam, Inc. (NASDAQ: ALNY)\\n\\nType of Application: supplemental new drug application\\n\\nCandidate: Oxlumo\\n\\nIndication: hyperoxaluria Type 1\\n\\nDate: Oct. 6\\n\\nOxlumo, which goes by the generic name lumasiran, an RNAi therapeutic, is being evaluated for the reduction of plasma oxalate in patients with advanced hyperoxaluria type 1 – a rare disorder that mainly affects the kidneys due to the accumulation of a substance called oxalate, which is normally filtered through the kidneys and excreted in the urine.\\n\\nThis therapy was first approved in 2020 for lowering urinary oxalate labels in pediatric and adult patients. In the second quarter, it fetched the company $15 million in sales, down only 2% sequentially.\\n\\nSee also: Alzheimer\\'s Progression Slowed Down By Biogen (NASDAQ: )\\'s New Drug In Late-Stage Study: Analyst Sees 25%\\n\\nCan Third Time Be Charm For scPharma Company: scPharmaceuticals, Inc. (NASDAQ: SCPH)\\n\\nType of Application: NDA\\n\\nCandidate: Furoscix\\n\\nIndication: worsening heart failure due to congestion\\n\\nDate: Oct. 8\\n\\nFuroscix is a proprietary, subcutaneously-delivered furosemide solution, that is being evaluated as an outpatient alternative for the treatment of worsening congestive heart failure. This is scPharma\\'s third try for Furoscix following a complete response letter in 2018 and 2020.\\n\\n’Go’ or ‘no-Go’ for Amicus’s Pome Disease Treatment? Company: Amicus Therapeutics, Inc. (NASDAQ: FOLD)\\n\\nType of Application: BLA\\n\\nCandidate: cipaglucosidase alfa\\n\\nIndication: Pompe disease\\n\\nDate: Oct. 29\\n\\nAT-GAA is an investigational 2-component therapy that consists of cipaglucosidase alfa, administered in conjunction with miglustat, which is yet to be approved by the FDA. The 2-component therapy is being evaluated for an inherited lysosomal disorder called Pome disease.\\n\\nThe disease can be debilitating and is characterized by severe muscle weakness that worsens over time. It ranges from a rapidly fatal infantile form with significant impacts on heart function to a more slowly progressive, late-onset form primarily affecting skeletal muscle. It is estimated that Pompe disease affects approximately 5,000 to 10,000 people worldwide.\\n\\nSupernus Hopes For No Hiccups In Parkinson Disease Drug Approval Company: Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)\\n\\nType of Application: NDA\\n\\nCandidate: apomorphine infusion device (SPN-830)\\n\\nIndication: OFF episodes in Parkinson’s disease\\n\\nDate: Early October\\n\\nSupernus’s initial application seeking approval for SPN-830 was shot down with a refuse-to-file letter in November 2020, citing an insufficiently completed application to allow a substantiative review. Following a resubmission, the FDA accepted the application and assigned a PDUFA date sometime in early October.\\n\\nAlso read: Best Biotech Stocks Right Now\\n\\nAstraZeneca (NASDAQ: ) Knocks At FDA Altar For Liver Cancer Combo Treatment Company: AstraZeneca, plc. (NASDAQ: AZN)\\n\\nType of Application: BLA/sBLA\\n\\nCandidate: Tremelimumab + Imfinzi\\n\\nIndication: Unresectable hepatocellular carcinoma\\n\\nDate: Q4\\n\\nThe FDA accepted AstraZeneca’s BLA for tremelimumab for priority review, supporting the indication of a single priming dose of the anti-CTLA4 antibody added to Imfinzi, for treating patients with unresectable hepatocellular carcinoma. A sBLA has also been submitted for Imfinzi for the indication.\\n\\nThis novel dose and schedule of the combination is called the STRIDE regimen - Single Tremelimumab Regular Interval Durvalumab. HCC, according to the company, is the most common type of liver cancer, and about 26,000 people in the U.S. are afflicted by advanced, unresectable HCC each year.\\n\\nMerck-AstraZeneca Await Approval For Prostate Cancer Como Therapy Company: Merck & Co., Inc. (NYSE: MRK) & AstraZeneca\\n\\nType of Application: sNDA\\n\\nCandidate: Lynparza in combination with Abiraterone and Prednisone or Prednisolone\\n\\nIndication: prostate cancer\\n\\nDate: Q4\\n\\nThe application was accepted and granted priority review by the FDA for the treatment of adult patients with metastatic castration-resistant prostate cancer.\\n\\nAdcom Calendar:\\n\\nFDA’s Cardiovascular and Renal Drugs Advisory Committee will meet on Oct. 26 to discuss GlaxoSmithKline plc’s (NYSE: GSK) NDA for hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat tablets as a treatment option for anemia resulting from chronic kidney disease.\\n\\nThe Oncologic Drugs Advisory Committee is scheduled to meet on Oct. 28 to discuss the BLA submitted by Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for its 1311-omburtamab solution, injectable formulation, for treating neuroblastoma with central nervous system/leptomeningeal metastases.\\n\\nOn Oct. 31, the Endocrinologic and Metabolic Drugs Advisory Committee will deliberate on Ispen S.A.’s(OTC: IPSEY) palovarotene capsules for the proposed indication of heterotopic ossification in adults and children. It is a condition in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bones.\\n\\n© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.\\n\\nRead the original article on Benzinga© Reuters. FILE PHOTO: Pascal Soriot, chief executive of pharmaceuticals company AstraZeneca, attends an interview with Reuters in Shanghai, China, November 4, 2019. REUTERS/Brenda Goh/File Photo\\n\\nAZN +0.56% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nBy Aimee Donnellan and Natalie Grover\\n\\nLONDON (Reuters) - AstraZeneca (NASDAQ: ) may not stay in the vaccine business in the long run, its CEO told Reuters on Tuesday, showing how quickly fortunes have changed for the drugmaker that produced one of the first COVID-19 shots but has since lost out to rivals. Production delays, probes by regulators following rare cases of severe side effects, and concerns about its relatively short shelf life compared with other shots have stymied adoption of the company\\'s COVID-19 vaccine.\\n\\nNow, in the third year of the pandemic amid a global vaccine supply glut, its use has diminished in much of the developed world as countries have inoculated large numbers of people and prefer Pfizer (NYSE: ) and Moderna (NASDAQ: )\\'s mRNA vaccines as boosters.\\n\\nAstraZeneca\\'s COVID vaccine has still not won U.S. approval.\\n\\nThe London-listed company is building on its portfolio of antibody therapies, including for COVID-19, the respiratory virus RSV and other viruses, Soriot said in a Reuters Newsmaker interview on Tuesday.\\n\\nBut on the future of its COVID vaccines business, he said: \"I can\\'t be sure we will be there or not.\"\\n\\nHe also said he wasn\\'t sure if AstraZeneca would broaden its roster of vaccines for other infections either, adding that the company was looking into it.\\n\\nInvestors have speculated about the future of the vaccine business given slowing sales of the COVID shot as initial sales contracts have been fulfilled, stiff competition from mRNA vaccines and its relatively little expertise in the field.\\n\\nThe company created a separate division for vaccines and antibody therapies late last year.\\n\\nStill, Soriot said he did not regret the company\\'s work with Oxford University to develop a COVID vaccine, given they had delivered billions of doses and saved an estimated 6 million lives across the globe.\\n\\nThe inoculation was AstraZeneca\\'s second best-selling product in 2021 with sales of $3.9 billion.\\n\\nAstraZeneca is also looking for bolt-on acquisitions, including small and mid-sized companies specialising in oncology and cardiovascular treatments, Soriot added.\\n\\n\"We always look for external opportunities,\" he said.\\n\\nKEEP ON DOING THIS JOB\\n\\nThe CEO has presided over a quadrupling of AstraZeneca\\'s share price in his decade at the helm.\\n\\n\"I can keep doing this job for many years,\" he said.\\n\\nThe 63-year old was once seen as a natural successor to outgoing Chairman Leif Johansson.\\n\\nBut in July, Soriot quashed speculation he was planning to retire any time soon, saying he expected to work with the company\\'s newly announced chairman-designate Michel Demare for many years to come.\\n\\nSoriot was tasked with turning around a troubled AstraZeneca - hit by a string of key patent losses and a spate of clinical trial failures - in October 2012, following a stint at pharma peer Roche.\\n\\nWith the Frenchman at the helm, the fortunes of the Anglo-Swedish drugmaker changed dramatically.\\n\\nHe sharpened focus on speciality medicines and the lucrative field of oncology, made acquisitions to refill the company\\'s medicine cabinet, fended off a hostile takeover from U.S. pharma giant Pfizer, and invested heavily in R&D to improve the company\\'s lacklustre drug development success rate.\\n\\nHowever, he warned on Tuesday that fewer new medicines would be developed going forward due to U.S. drug price laws passed last week.\\n\\nAsked about inflationary pressures, Soriot said: \"We are going to have to become more innovative and productive. We can\\'t expect our selling prices to go up.\"\\n\\nSales in China, which account for close to a fifth of the company\\'s total annual revenue, have dipped in recent quarters due to lower drug prices and as COVID lockdown measures kept some patients from being diagnosed and seeking cancer care.\\n\\nOn Tuesday, Soriot said sales were picking up in the third quarter in the world\\'s second-largest market for pharmaceuticals - and he expected the country to play a more significant role in the global market over the next decade.\\n\\nGraphic: AstraZeneca\\'s shares while CEO Soriot has been at the helm https://fingfx.thomsonreuters.com/gfx/mkt/zjvqkblqgvx/AZ.PNG© Reuters. People pose with syringe with needle in front of displayed AstraZeneca logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration/Files\\n\\nAZN +0.56% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nBy Pushkala Aripaka and Natalie Grover\\n\\nLONDON (Reuters) -Europe\\'s medicines regulator has backed using AstraZeneca (NASDAQ: )\\'s preventative COVID-19 therapy as a treatment for the disease and also endorsed another medicine as preventative option for another common virus.\\n\\nThe regulator\\'s recommendations are usually followed by the European Commission when it takes a final decision on drug approvals.\\n\\nAstraZeneca said on Friday the European Medicines Agency (EMA) had backed Evusheld as a treatment for adults and adolescents with COVID who do not need supplemental oxygen and who are at increased risk of their disease worsening.\\n\\nLast month, Japan became the first country to approve the long-acting antibody as a treatment for COVID - making Evusheld the first such therapy authorised for both prevention and treatment of the viral disease.\\n\\nEvusheld had previously had largely secured global approvals, including in Europe, as a preventative therapy for people with compromised immune systems who see little or no benefit from COVID vaccines.\\n\\nAstraZeneca is leaning on Evusheld to help offset tepid sales of its COVID vaccine that has rapidly lost ground to mRNA shots in the fight against the rapidly evolving virus.\\n\\nEvusheld, first launched in December, generated $914 million in the first half of 2022 for the Anglo-Swedish drugmaker.\\n\\nSeparately on Friday, the EMA also endorsed AstraZeneca and partner Sanofi (EPA: )\\'s experimental long-acting therapy Beyfortus for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV).\\n\\nRSV causes thousands of hospitalisations and deaths globally each year in toddlers and the elderly, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine since the virus was first discovered in 1956.\\n\\nBut there is one therapy, Synagis, also developed by AstraZeneca but sold by Swedish Orphan Biovitrum in the United States.\\n\\nIt is designed to prevent lower respiratory tract infections caused by RSV in high-risk infants and requires up to five injections to cover a typical RSV season.\\n\\nMeanwhile, if Beyfortus were approved, it would be the first single-dose preventative RSV therapy for the broad infant population - including those born healthy or are deemed high-risk - during their first RSV season.© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid\\n\\nAZN +0.56% Add to/Remove from a Portfolio\\n\\n(Reuters) - said on Friday its drug for preventing infant RSV, Beyfortus (nirsevimab), was recommended for approval in the European Union by a European Medicines Agency committee.\\n\\nThe drugmaker also said if Beyfortus is approved, it would become the first protective option for newborn and infant population against RSV lower respiratory tract disease.© Reuters. Market movers: Property groups fall as Goldman/JPMorgan reduce price targets\\n\\nFDX +1.12% Add to/Remove from a Portfolio AZN +0.56% Add to/Remove from a Portfolio BLND +1.60% Add to/Remove from a Portfolio IDSI +3.67% Add to/Remove from a Portfolio TGTB34 0.00% Add to/Remove from a Portfolio\\n\\nShares in Land Securities and British Land fell today after both property groups were downgraded by Goldman Sachs (NYSE: ), while JP Morgan lowered its price targets on both companies.\\n\\nGoldman Sachs downgraded British Land to neutral from buy and reduced its price\\n\\ntarget to 410p from 580p, while JPMorgan (NYSE: ) cut its price target to 530p from 700p but retained its overweight rating.\\n\\nOn Land Securities, Goldman Sachs lowered its rating to sell from neutral and cut its price target to 500p from 650p, while JPMorgan retained its neutral rating but with a lower price target of 650p down from 900p.\\n\\nLand Securities fell 2.7% and British Land fell 0.7%.\\n\\nCapita lifted by double dose of good news\\n\\nShares in advanced after it reported a contract extension with Barnet Council and the disposal of its subsidiary Pay360 Ltd to Access PaySuite.\\n\\nShares in the outsourcing services group rose 6.6% after securing the contract extension with the north London council that is worth £42.7mln, although with indexation and potential additional work it could be worth up to £57mln.\\n\\nSeparately, Capita said it agreed to dispose of Pay360 to the division of Access Group for £150mln on a cash-free, debt-free basis.\\n\\nCapita said the sale will help reduce its debt, provide additional liquidity, and allow it to enhance its digital offerings for clients and build a more focused and sustainable business for the long term.\\n\\nRoyal Mail falls after FedEx warning\\n\\nShares in dipped today following the profits warning by US peer pulled its full year guidance after warning that first quarter profits would miss estimates as a global demand slowdown accelerates.\\n\\nIt cited \"macroeconomic weakness\" in Asia and \"service challenges\" in Europe.\\n\\nInvestors took the view that industry challenges would be the same for Royal Mail which also faces the prospect of more industrial action as employees strike over higher pay.\\n\\nRoyal Mail workers represented by the Communication Workers Union (CWU) had planned a walkout on 9 September 2022 but are now planning to strike on September 30 and October 1 2022.\\n\\nShares fell 10.5% to 223.5p.\\n\\nEU drug approvals boost AstraZeneca (NASDAQ: )\\n\\nwas a rare riser in the after it said today it had received two recommendations for drug approvals in the EU, while a drug for blood disorder paroxysmal nocturnal haemoglobinuria met its primary endpoint in a phase three trial.\\n\\nThe group said its Beyfortus drug, which it develops with Sanofi (EPA: ). for the prevention of lower respiratory tract disease in newborns and infants has been recommended for marketing authorisation in the European Union\\n\\nMeanwhile, AstraZeneca\\'s Evusheld Covid antibody treatment has been recommended for marketing authorisation in the EU for adults with the virus at risk of progressing to severe disease.\\n\\nThe company explained phase III treatment data showed reduced risk of severe Covid or death.\\n\\nShares rose 1.7% following the news.\\n\\nRead more on Proactive Investors UK\\n\\nDisclaimerBy Benzinga\\n\\nThe crypto party started as corporate earnings-induced optimism and hopes of a Fed thawing perked up risk appetite in the financial markets. Ethereum (CRYPTO: ETH), the second...3/3 © Reuters. FILE PHOTO: Tablet bottles for AstraZeneca\\'s cancer medicine Lynparza seen in an undated handout image provided to Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS 2/3\\n\\nAZN +0.56% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\n(Reuters) - AstraZeneca (NASDAQ: ) said on Thursday its drug Lynparza, developed with U.S.-based Merck & Co, was approved by the European Union as an adjuvant treatment for patients with a form of a genetically mutated early-stage breast cancer.© Reuters Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial\\n\\nAZN +0.56% Add to/Remove from a Portfolio IXIC +1.28% Add to/Remove from a Portfolio OTIC -2.81% Add to/Remove from a Portfolio BEAM -2.75% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio\\n\\nHere\\'s a roundup of top developments in the biotech space over the last 24 hours:\\n\\nStocks In Focus Arcutis Psoriasis Treatment Scores FDA Approval The FDA approved Arcutis Biotherapeutics Inc\\'s (NASDAQ: ARQT) Zoryve (roflumilast) cream 0.3% for plaque psoriasis, including intertriginous areas, in patients 12 years of age or older.\\n\\nIt is the first and only topical phosphodiesterase-4 inhibitor approved for plaque psoriasis.\\n\\nThe commercial product is expected to be available by mid-August.\\n\\nArcutis expects to draw an additional $125 million from the company\\'s debt facility with SLR Capital Partners.\\n\\nShares are up 3.05% at $25 during the premarket session.\\n\\nFDA Removes Clinical Hold On Celyad\\'s Colorectal Cancer Trial The FDA has lifted the clinical hold on Celyad Oncology SA\\'s (NASDAQ: CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the company made changes to the eligibility criteria for the trial.\\n\\nIn February, the company voluntarily paused the CYAD-101-002 trial to investigate reports of two fatalities in the study.\\n\\nThe FDA subsequently put the trial on clinical hold in March.\\n\\nShares are up 40.9% at $2.41 during the premarket session.\\n\\nHUTCHMED Starts Midstage Tazemetostat Study For Lymphoma Setting HUTCHMED (China) Limited (NASDAQ: HCM) initiated a bridging Phase 2 study of tazemetostat in China for relapsed/refractory follicular lymphoma (R/R FL).\\n\\nThe first patient received their first dose on July 29.\\n\\nThe primary objective is to evaluate the efficacy of tazemetostat in R/R FL patients with mutations in EZH21 (Cohort 1).\\n\\nThe secondary objectives are to evaluate the efficacy of tazemetostat for R/R FL with EZH2 wild-type.\\n\\nRelated: Biotech Investors: August\\'s Key PDUFA Catalysts You Must Know.\\n\\nFDA Signs Off On Eledon Pharma\\'s Tegoprubart For Kidnety Transplant Rejection The FDA has cleared Eledon Pharmaceuticals Inc\\'s (NASDAQ: ELDN) Investigational New Drug (IND) application to evaluate tegoprubart for preventing organ rejection in patients receiving a kidney transplant.\\n\\nThe IND-opening phase 2 study will enroll approximately 120 participants undergoing a kidney transplant.\\n\\nKazia Shares Fall After Update From Pivotal Brain Tumor Trial Kazia Therapeutics Limited (NASDAQ: KZIA) said GBM AGILE, a pivotal study for paxalisib in newly diagnosed glioblastoma, did not meet pre-defined criteria for continuing to a second stage.\\n\\nPatients enrolled in the first stage of the paxalisib arm will continue on treatment as per protocol, and in follow-up, until completion of the final analysis, which Kazia anticipates receiving in the second half of 2023.\\n\\nThe company will not open the study\\'s paxalisib arm in Germany or China.\\n\\nShares are down 38.3% at $2.24 during the premarket session.\\n\\nFDA Places Clinical Hold On Beam Therapeutics\\' IND Application For Blood Cancer Study The FDA has placed a clinical hold on Beam Therapeutics Inc\\'s (NASDAQ: BEAM) BEAM-201 Investigational New Drug (IND) application for relapsed/refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma.\\n\\nThe BEAM-201 IND was submitted at the end of June. The FDA indicated it would provide Beam with an official clinical hold letter within 30 days. Beam plans to provide additional updates pending discussion with the FDA.\\n\\nOtonomy Shares Sink After Stopping Midstage Tinnitus Study Otonomy Inc (NASDAQ: OTIC) has announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all time points.\\n\\nThe 153-subject study did show a higher response rate than placebo in a prospectively defined patient subgroup with tinnitus duration of fewer than six months (population studied in Phase 1/2 trial).\\n\\nThe overall results do not support further development of OTO-313.\\n\\nShares are slipping 60.8% at 56 cents during the premarket session.\\n\\nAstraZeneca (NASDAQ: ) Cuts Innate-Partnered Phase 3 Trial In Head, Neck Cancer Innate Pharma SA\\'s (NASDAQ: IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ: AZN) did not meet a pre-defined threshold for efficacy.\\n\\nBased on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.\\n\\nThere were no new safety findings. AstraZeneca plans to share the data in due course.\\n\\nIPHA shares are down 16.3% at $2.68 during the premarket session.\\n\\nALX Oncology\\'s Evorpacept Fast Tracked In US For Head, Neck Cancer The FDA has granted Fast Track designation to ALX Oncology Holdings Inc\\'s (NASDAQ: ALXO) evorpacept in combination with Merck & Co Inc\\'s (NYSE: MRK) Keytruda for the first-line treatment of PD-L1 positive advanced head and neck squamous cell carcinoma.\\n\\nThe FDA\\'s decision is informed by the results of ALX Oncology\\'s phase 1 study that showed preliminary antitumor activity and a favorable safety profile.\\n\\nShares are up 5.48% at $10.26 during the premarket session.\\n\\nOfferings TherapeuticsMD Inc (NASDAQ: TXMD) has received a $15-million private investment in the company\\'s common stock and a new series of preferred stock from Rubric Capital Management LP.\\n\\nOn The Radar Earnings Cerevel Therapeutics Holdings Inc (NASDAQ: CERE): Before the market open.\\n\\n© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.\\n\\nRead at Benzinga\\n\\nRead the original article on Benzinga© Reuters\\n\\nEUR/USD +2.12% Add to/Remove from a Portfolio UK100 +2.03% Add to/Remove from a Portfolio XAU/USD +3.17% Add to/Remove from a Portfolio FCHI +2.77% Add to/Remove from a Portfolio DE30 +2.51% Add to/Remove from a Portfolio HNKG_p +1.07% Add to/Remove from a Portfolio AZN +0.56% Add to/Remove from a Portfolio Gold +3.36% Add to/Remove from a Portfolio LCO +4.31% Add to/Remove from a Portfolio CL +5.02% Add to/Remove from a Portfolio AZN +1.77% Add to/Remove from a Portfolio 2222 -0.29% Add to/Remove from a Portfolio\\n\\nBy Peter Nurse\\n\\nInvesting.com - European stock markets largely edged higher Monday, starting the new week on a cautious note as investors digested weak Chinese economic data.\\n\\nBy 04:15 ET (08:15 GMT), the in Germany traded 0.1% lower, but the in France rose 0.2%, and U.K.’s traded 0.2% higher.\\n\\nEconomic data released earlier Monday showed China’s economic growth rate unexpectedly slowing in July, prompting the country’s central bank to in a surprise move.\\n\\ngrew 3.8% in July from a year earlier, with the growth rate below the 4.6% increase expected, while rose 2.7% from a year ago, missing forecasts for 5.0% growth and the 3.1% growth seen in June.\\n\\nChina\\'s economy, the world’s second largest, is struggling to shake off the June quarter\\'s hit to growth from strict COVID restrictions.\\n\\nOn the flip side, back in Europe, Denmark’s economy grew faster than expected in the second quarter, expanding 0.7% from the first three months of the year, after contracted 0.5% in the first quarter of 2022.\\n\\nThe raised interest rates by a half-point in July and is expected to do the same in September, even though the risk of a Eurozone recession has reached the highest level since November 2020 as energy shortages threaten to drive already record inflation higher still.\\n\\nIn corporate news, AstraZeneca (LON: ) (NASDAQ: ) stock rose 2.6% after the drugmaker said its cancer drug, Enhertu, delayed the progression of a form of advanced breast cancer in previously treated patients, boosting prospects of more regulatory approvals.\\n\\nHenkel (ETR: ) stock rose 0.4% after the German consumer-goods company said sales rose in the first half of the year but that earnings fell, hurt by increasing raw-material and logistics prices.\\n\\nOil prices fell Monday, weighed by a potential increase in supply by oil giant Saudi Aramco (TADAWUL: ) as well as concerns of slowing growth in China, the world\\'s second-largest economy.\\n\\nSaudi Aramco stands ready to raise crude oil output to its maximum capacity of 12 million barrels per day if requested to do so by the Saudi Arabian government, Chief Executive Amin Nasser said Sunday, as the state-owned energy firm announced one of the largest quarterly profits in history.\\n\\nBy 04:15 ET, futures traded 1.9% lower at $90.39 a barrel, while the contract fell 1.7% to $96.49.\\n\\nAdditionally, fell 0.7% to $1,802.15/oz, while traded 0.3% lower at 1.0229.© Reuters. FILE PHOTO: Signage is seen outside the entrance of the London Stock Exchange in London, Britain. Aug 23, 2018. REUTERS/Peter Nicholls/File Photo\\n\\nUK100 +2.03% Add to/Remove from a Portfolio AZN +0.56% Add to/Remove from a Portfolio FTSE +2.03% Add to/Remove from a Portfolio A1ZN34 -0.97% Add to/Remove from a Portfolio ENRY +2.33% Add to/Remove from a Portfolio\\n\\nBy Sruthi Shankar\\n\\n(Reuters) -UK\\'s edged up on Monday as gains in drugmaker AstraZeneca (NASDAQ: ) and consumer stocks relieved pressure from mining and oil heavyweights after data showed China\\'s economy unexpectedly slowed last month.\\n\\nThe blue-chip FTSE 100 added 0.2% to hold near 10-week highs, while the midcap inched up 0.1%.\\n\\nInvestors are awaiting the UK employment report as well as consumer prices data later this week to gauge the state of the labour market and inflation.\\n\\nThe data could offer clues on whether the Bank of England opts for a second consecutive 50-basis-point-rate hike at its September meeting.\\n\\nThe mood was dull in Asian and European stock markets, with investors turning to defensive sectors such as healthcare and consumer staples amid worries about the health of the world\\'s second-largest economy.\\n\\nAstraZeneca gained 2.6% after the drugmaker said its cancer drug, Enhertu, developed with Japan\\'s Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients.\\n\\nOil major Shell (LON: ) and miners Rio Tinto (LON: ) and Anglo American (LON: ) slipped, in tandem with weaker commodity prices, after the release of the China data. [O/R] [MET/L]\\n\\nThe FTSE 100 has outperformed its global peers this year due to its large exposure to commodity stocks that have surged on the back of a jump in oil and metal prices. A weakening pound has also boosted dollar earners in the index.\\n\\n\"Whether this trend will continue ultimately hinges on the outlook for global energy stocks relative to the broad market,\" BCA Research analysts wrote in a note.\\n\\nThe FTSE 100 is up nearly 2% so far this year, while the MSCI world equities index has shed almost 13%.\\n\\n\"Our energy strategists remain bullish on oil. Their expectation that will breach $110/bbl in Q4 and average $117/bbl in 2023 suggests that an overweight on the energy sector – and by extension UK equities – remains appropriate.\"© Reuters. FTSE 100 positive but off early highs\\n\\nUK100 +2.03% Add to/Remove from a Portfolio DJI +1.26% Add to/Remove from a Portfolio AZN +0.56% Add to/Remove from a Portfolio BWY +2.01% Add to/Remove from a Portfolio BDEV +2.42% Add to/Remove from a Portfolio TW +3.38% Add to/Remove from a Portfolio FTMC +1.28% Add to/Remove from a Portfolio PHNX +1.47% Add to/Remove from a Portfolio IXIC +1.28% Add to/Remove from a Portfolio FTSE +2.03% Add to/Remove from a Portfolio AZN +1.77% Add to/Remove from a Portfolio CHNA +0.00% Add to/Remove from a Portfolio\\n\\nslips back after making a bright start\\n\\nChinese retail sales, output numbers below forecast\\n\\nUK house prices fall in August - Rightmove\\n\\nFTSE 100 failed to hold strong early gains and slipped back close to parity as disappointing economic data in China took the shine off further gains in the US on Friday.\\n\\nAt 9.00am the lead index was trading 11.42 points to the good at 7,512.31.\\n\\nRichard Hunter, head of markets at interactive investor, said “Economic news from China threatened to spoil the party after US markets staged a strong rally at the end of last week.”\\n\\n“Amid geopolitical tensions as a delegation of US lawmakers arrive for a further trip to Taiwan, Chinese economic data revealed the ongoing impact of Covid-19 lockdowns and an escalating property crisis.”\\n\\n“Retail sales and industrial output both rose, but by less than expected in July, alongside a disappointing showing from bank lending.”\\n\\nBut he said “the UK market chose to take its lead from Wall Street, notwithstanding the fact that the Bank of England is set to maintain its aggressive interest rate stance in the face of persistent inflation in the UK.”\\n\\nAstraZeneca PLC (LSE:NASDAQ: ) shares rose 2.1% to 10,931p as the pharmaceuticals group said that positive high-level results from a new trial of its Enhertu breast cancer drug had demonstrated a \"statistically significant and clinically meaningful improvement\" in progression-free survival.\\n\\nAstraZeneca said the DESTINY-Breast02 Phase III trial on Enhertu, jointly developed and commercialised with Daiichi Sankyo, also met its key secondary endpoint of improved overall survival.\\n\\nBut housebuilders, Berkeley Group Holdings PLC (LSE:BKG) (down 1.35%), Bellway (LON: ) (down 1%), Taylor Wimpey (LON: ) (down 0.5%) and Barratt Developments (LON: ) (down 0.5%) all fell following a report from Rightmove that house prices slipped in August.8.15am: Positive start to proceedings in London\\n\\n8.15am: London upbeat in early trading\\n\\nFTSE 100 makes a positive start to trading boosted by gains in the US on Friday and despite mixed performances in Asia overnight following disappointing Chinese retail sales and industrial output figures.\\n\\nAt 8.15am the lead index was trading 35.03 points higher at 7,535.92 with the broader up 47.07 points at 20.386.03.\\n\\nLatest data from online property website Rightmove showed the first fall in UK house prices this year with the average price of property coming to market down to £365,173 – down 1.3%.\\n\\nHowever, Tim Bannister, Rightmove’s director of property science, says: “A drop in asking prices is to be expected this month after a frenzied two years and many would-be home movers become distracted by the summer holidays.”\\n\\n“Indeed, for those that can, this may be their first summer holiday abroad since before the pandemic.”\\n\\nBannister also pointed out that price growth for the year would still be 7%.\\n\\nThe number of properties currently on the market to buy is down 39% on pre-pandemic levels but despite the lack of instructions new listings rose 12% compared to the same time last year but were down 6% compared to 2019.\\n\\nBannister also said the recent interest rate increases by the Bank of England were “not having a significant impact on the number of people wanting to move.”\\n\\n7.30am: FTSE 100 seen higher\\n\\nLondon markets are expected to open higher on Monday following gains in the US on Friday and following the surprise news that China has cut a key interest rate, in a bid to boost its stuttering economy, following weaker than expected retail sales and industrial output figures.\\n\\nInvestors will also have one eye on UK jobs and inflation reports due out later this week to see whether there are signs of a slowdown in the jobs market or in prices growth.\\n\\nSpread betting companies are calling the FTSE 100 up by around 35 points.\\n\\nMichael Hewson chief market analyst at CMC Markets UK said: “Despite the slow drip feed of negative headlines of rising gas prices, and the supply chain challenges thrown up by the heatwave in Europe, there’s been little appetite to drive stocks lower in recent weeks.”\\n\\n“Asia markets have got off to a positive start to the week, with the latest retail sales and industrial production numbers for China showing an economy that still appears low on confidence when it comes to consumer spending, and economic activity more broadly.”\\n\\n“This weakness in the Chinese economy comes against the struggle to adapt to a zero-covid policy, which the government shows little sign of relaxing, against a backdrop of rising cases.”\\n\\n“Problems in the property sector also aren’t helping, where many home buyers are halting mortgage payments in protest at delays to the completion of new homes.”\\n\\n“In June we saw the effects the zero-covid policy has had on the Chinese economy, with a -2.6% contraction for Q2, although we have started to see some signs of a pick-up in economic activity, albeit from a very low base.”\\n\\n“This morning’s retail sales numbers for July have confirmed how fragile this confidence still is, rising 2.7% well below expectations of 5%, and weaker than in June.”\\n\\n“Industrial production has been more robust and recovered much better, however even here economic activity disappointed in July, slipping back from 3.9% in June, to 3.8%.”\\n\\nIn London, on a quieter day for company results, Phoenix Group announced half year figures which showed strong cash generation of £950mln against £872mln in the six months to June 2021.\\n\\nThe FTSE 100-listed closed book life insurer, said it was now confident of delivering at the top-end of its £1.3bn-to-£1.4bn target range for the year.\\n\\nNew business long-term cash generation was a record £430mln in the period and more than double the first half of 2021 at £206mln.\\n\\n7.00am: FTSE 100 set to open higher\\n\\nFTSE 100 set to start the week in positive fashion following gains in the US on Friday.\\n\\nSpread betting companies are calling the blue chip index up by around 32 points.\\n\\nThe closed Friday up 424 points, 1.3%, at 33,761, the jumped 267 points, 2.1%, to 13,047 and the S&P 500 added 73 points, 1.7%, to reach 4,280.\\n\\nThe benchmarks ended the week on a high note, clinching the fourth-straight winning week for the Nasdaq Composite and S&P 500. Investors have reacted positively to CPI and PPI data released this week that suggested inflation may have already peaked.\\n\\nRead more on Proactive Investors UK\\n\\nDisclaimer© Reuters. FTSE 100 positive but off early highs\\n\\nUK100 +2.03% Add to/Remove from a Portfolio DJI +1.26% Add to/Remove from a Portfolio AZN +0.56% Add to/Remove from a Portfolio BWY +2.01% Add to/Remove from a Portfolio BDEV +2.42% Add to/Remove from a Portfolio TW +3.38% Add to/Remove from a Portfolio FTMC +1.28% Add to/Remove from a Portfolio PHNX +1.47% Add to/Remove from a Portfolio IXIC +1.28% Add to/Remove from a Portfolio FTSE +2.03% Add to/Remove from a Portfolio AZN +1.77% Add to/Remove from a Portfolio CHNA +0.00% Add to/Remove from a Portfolio\\n\\nslips back after making a bright start\\n\\nChinese retail sales, output numbers below forecast\\n\\nUK house prices fall in August - Rightmove\\n\\nFTSE 100 failed to hold strong early gains and slipped back close to parity as disappointing economic data in China took the shine off further gains in the US on Friday.\\n\\nAt 9.00am the lead index was trading 11.42 points to the good at 7,512.31.\\n\\nRichard Hunter, head of markets at interactive investor, said “Economic news from China threatened to spoil the party after US markets staged a strong rally at the end of last week.”\\n\\n“Amid geopolitical tensions as a delegation of US lawmakers arrive for a further trip to Taiwan, Chinese economic data revealed the ongoing impact of Covid-19 lockdowns and an escalating property crisis.”\\n\\n“Retail sales and industrial output both rose, but by less than expected in July, alongside a disappointing showing from bank lending.”\\n\\nBut he said “the UK market chose to take its lead from Wall Street, notwithstanding the fact that the Bank of England is set to maintain its aggressive interest rate stance in the face of persistent inflation in the UK.”\\n\\nAstraZeneca PLC (LSE:NASDAQ: ) shares rose 2.1% to 10,931p as the pharmaceuticals group said that positive high-level results from a new trial of its Enhertu breast cancer drug had demonstrated a \"statistically significant and clinically meaningful improvement\" in progression-free survival.\\n\\nAstraZeneca said the DESTINY-Breast02 Phase III trial on Enhertu, jointly developed and commercialised with Daiichi Sankyo, also met its key secondary endpoint of improved overall survival.\\n\\nBut housebuilders, Berkeley Group Holdings PLC (LSE:BKG) (down 1.35%), Bellway (LON: ) (down 1%), Taylor Wimpey (LON: ) (down 0.5%) and Barratt Developments (LON: ) (down 0.5%) all fell following a report from Rightmove that house prices slipped in August.8.15am: Positive start to proceedings in London\\n\\n8.15am: London upbeat in early trading\\n\\nFTSE 100 makes a positive start to trading boosted by gains in the US on Friday and despite mixed performances in Asia overnight following disappointing Chinese retail sales and industrial output figures.\\n\\nAt 8.15am the lead index was trading 35.03 points higher at 7,535.92 with the broader up 47.07 points at 20.386.03.\\n\\nLatest data from online property website Rightmove showed the first fall in UK house prices this year with the average price of property coming to market down to £365,173 – down 1.3%.\\n\\nHowever, Tim Bannister, Rightmove’s director of property science, says: “A drop in asking prices is to be expected this month after a frenzied two years and many would-be home movers become distracted by the summer holidays.”\\n\\n“Indeed, for those that can, this may be their first summer holiday abroad since before the pandemic.”\\n\\nBannister also pointed out that price growth for the year would still be 7%.\\n\\nThe number of properties currently on the market to buy is down 39% on pre-pandemic levels but despite the lack of instructions new listings rose 12% compared to the same time last year but were down 6% compared to 2019.\\n\\nBannister also said the recent interest rate increases by the Bank of England were “not having a significant impact on the number of people wanting to move.”\\n\\n7.30am: FTSE 100 seen higher\\n\\nLondon markets are expected to open higher on Monday following gains in the US on Friday and following the surprise news that China has cut a key interest rate, in a bid to boost its stuttering economy, following weaker than expected retail sales and industrial output figures.\\n\\nInvestors will also have one eye on UK jobs and inflation reports due out later this week to see whether there are signs of a slowdown in the jobs market or in prices growth.\\n\\nSpread betting companies are calling the FTSE 100 up by around 35 points.\\n\\nMichael Hewson chief market analyst at CMC Markets UK said: “Despite the slow drip feed of negative headlines of rising gas prices, and the supply chain challenges thrown up by the heatwave in Europe, there’s been little appetite to drive stocks lower in recent weeks.”\\n\\n“Asia markets have got off to a positive start to the week, with the latest retail sales and industrial production numbers for China showing an economy that still appears low on confidence when it comes to consumer spending, and economic activity more broadly.”\\n\\n“This weakness in the Chinese economy comes against the struggle to adapt to a zero-covid policy, which the government shows little sign of relaxing, against a backdrop of rising cases.”\\n\\n“Problems in the property sector also aren’t helping, where many home buyers are halting mortgage payments in protest at delays to the completion of new homes.”\\n\\n“In June we saw the effects the zero-covid policy has had on the Chinese economy, with a -2.6% contraction for Q2, although we have started to see some signs of a pick-up in economic activity, albeit from a very low base.”\\n\\n“This morning’s retail sales numbers for July have confirmed how fragile this confidence still is, rising 2.7% well below expectations of 5%, and weaker than in June.”\\n\\n“Industrial production has been more robust and recovered much better, however even here economic activity disappointed in July, slipping back from 3.9% in June, to 3.8%.”\\n\\nIn London, on a quieter day for company results, Phoenix Group announced half year figures which showed strong cash generation of £950mln against £872mln in the six months to June 2021.\\n\\nThe FTSE 100-listed closed book life insurer, said it was now confident of delivering at the top-end of its £1.3bn-to-£1.4bn target range for the year.\\n\\nNew business long-term cash generation was a record £430mln in the period and more than double the first half of 2021 at £206mln.\\n\\n7.00am: FTSE 100 set to open higher\\n\\nFTSE 100 set to start the week in positive fashion following gains in the US on Friday.\\n\\nSpread betting companies are calling the blue chip index up by around 32 points.\\n\\nThe closed Friday up 424 points, 1.3%, at 33,761, the jumped 267 points, 2.1%, to 13,047 and the S&P 500 added 73 points, 1.7%, to reach 4,280.\\n\\nThe benchmarks ended the week on a high note, clinching the fourth-straight winning week for the Nasdaq Composite and S&P 500. Investors have reacted positively to CPI and PPI data released this week that suggested inflation may have already peaked.\\n\\nRead more on Proactive Investors UK\\n\\nDisclaimerAVEPp 0.00% Add to/Remove from a Portfolio ROG -1.66% Add to/Remove from a Portfolio RHHVF -1.31% Add to/Remove from a Portfolio SNY +1.82% Add to/Remove from a Portfolio AZN +0.56% Add to/Remove from a Portfolio SASY +0.55% Add to/Remove from a Portfolio\\n\\nBy Scott Kanowsky\\n\\nInvesting.com -- Sanofi SA (EPA: ) shares slid on Wednesday after the French drugmaker announced that it will halt trials of a new treatment for patients battling advanced breast cancer.\\n\\nIn a statement, the company said it would stop global clinical development of the medicine, known as amcenestrant, after a phase 3 study showed it was not effective enough to warrant further research.\\n\\nAll other studies of amcenestrant, including in early-stage breast cancer, will also be discontinued, Sanofi added.\\n\\n“While we are disappointed by this outcome, our research will further the scientific understanding of endocrine therapies in people with breast cancer,\" said John Reed, global head of research and development at Sanofi.\\n\\nIn a note, analysts at Morgan Stanley called the decision a \"setback for the innovation narrative\" put forward by Sanofi, saying that amcenestrant had been flagged as a potentially lucrative piece in the group\\'s drug pipeline.\\n\\nThe end of Sanofi\\'s amcenestrant trials is expected to lead to a 6% negative impact on the company\\'s estimated discounted cash flow, according to the Morgan Stanley analysts.\\n\\nThe decision could also have a knock-on effect on studies being conducted on similar breast cancer drugs from Sanofi rivals Roche (SIX: ) and AstraZeneca PLC (LON: ), the analysts added.']"
            ]
          },
          "metadata": {},
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "5R8Lka36f6OG"
      },
      "source": [
        "## 4. Text Preprocessing\n",
        "\n",
        "### 4.1 Tokenisation\n",
        "\n",
        "Tokenisation is a way of separating text into smaller units called tokens, most commonly using space as a delimiter. Types can be broadly classified as word, character and subword (n-gram) tokenisation. \n",
        "\n",
        "Word tokenisation is the most commonly used tokenisation algorithm and splits words into their own strings to facilitate counting, for example."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yy6M-scmMZ9I",
        "outputId": "b15423c3-b517-4c97-b20e-7f8f26fcc00f"
      },
      "source": [
        "tokens = [word_tokenize(article) for article in articles]\n",
        "text = nltk.Text(tokens)\n",
        "text"
      ],
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<Text: ['AstraZeneca', 'PLC', 'said', 'Wednesday', 'that', 'Capivasertib', 'plus', 'Faslodex', 'significantly', 'improved', 'progression-free', 'survival', 'when', 'compared', 'with', 'Faslodex', 'combined', 'with', 'a', 'placebo', 'in', 'a', 'Phase', '3', 'trial', 'in', 'advanced', 'hormone', 'receptor-positive', 'breast', 'cancer', '.', 'The', 'Anglo-Swedish', 'pharma', 'giant', 'AZN', ',', '+1.77', '%', 'AZN', ',', '+0.56', '%', 'said', 'the', 'trial', 'met', 'both', 'primary', 'endpoints', 'of', 'improving', 'progression-free', 'survival', 'in', 'the', 'overall', 'patient', 'population', 'and', 'in', 'a', 'prespecified', 'biomarker', 'subgroup', 'of', 'patients', 'whose', 'tumors', 'had', 'qualifying', 'alterations.AstraZeneca', 'Touts', 'Positive', 'Data', 'From', 'Two', 'Experimental', 'Drugs', 'In', 'Breast', 'Cancer', 'SettingsAstraZeneca', \"'s\", 'Ultomiris', 'Showed', 'Zero', 'Relapses', 'In', 'Patients', 'With', 'Chronic', 'Disorder', 'Of', 'Brain', ',', 'Spinal', 'CordAstraZeneca', '(', 'NASDAQ', ':', 'AZN', ')', 'announced', 'on', 'Tuesday', 'that', 'its', 'COVID-19', 'vaccine', ',', 'Vaxzevria', '(', 'ChAdOx1-S', '[', 'Recombinant', ']', ')', 'has', 'been', 'given', 'full', 'Marketing', 'Authorisation', '(', 'MA', ')', 'in', 'the', 'European', 'Union', '(', 'EU', ')', '.', 'Vaxzevria', 'was', 'originally', 'granted', 'a', 'conditional', 'Marketing', 'Authorisation', '(', 'cMA', ')', 'by', 'the', 'EU', '.', 'AstraZeneca', 'stated', ',', '“', 'As', 'there', 'continues', 'to', 'be', 'sufficient', 'evidence', 'of', 'safety', 'and', 'efficacy', 'confirming', 'the', 'benefits', 'of', 'Vaxzevria', ',', 'the', 'European', 'Medicines', 'Agency', '(', 'EMA', ')', 'has', 'now', 'granted', 'a', 'full', 'MA.', '”', 'Iskra', 'Reic', ',', 'EVP', ',', 'Vaccines', 'and', 'Immune', 'Therapies', ',', 'AstraZeneca', 'commented', ',', '“', 'The', 'move', 'from', 'conditional', 'to', 'full', 'marketing', 'authorisation', 'for', 'Vaxzevria', 'is', 'an', 'important', 'confirmation', 'by', 'the', 'EMA', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'Vaxzevria', ',', 'demonstrating', 'that', 'the', 'benefits', 'continue', 'to', 'outweigh', 'the', 'potential', 'risks', '.', 'Vaxzevria', 'is', 'estimated', 'to', 'have', 'helped', 'save', 'over', 'six', 'million', 'lives', 'in', 'the', 'first', 'year', 'of', 'vaccination', ',', 'which', 'reflects', 'the', 'strength', 'of', 'the', 'evidence', 'showing', 'Vaxzevria', '’', 's', 'protection', 'against', 'severe', 'disease', 'and', 'death', 'caused', 'by', 'COVID-19.', '”', 'by', 'The', 'European', 'Medicines', 'Agency', '(', 'EMA', ')', 'has', 'granted', 'full', 'Marketing', 'Authorisation', 'to', 'AstraZeneca', 'Plc', \"'s\", 'AZN', 'COVID-19', 'vaccine', ',', 'Vaxzevria', '(', 'ChAdOx1-S', '[', 'Recombinant', ']', ')', '.', 'COVID-19', 'vaccine', ',', 'Vaxzevria', '(', 'ChAdOx1-S', '[', 'Recombinant', ']', ')', '.', 'Vaxzevria', 'was', 'initially', 'granted', 'a', 'conditional', 'Marketing', 'Authorisation', 'due', 'to', 'the', 'urgency', 'of', 'the', 'COVID-19', 'pandemic', '.', 'As', 'there', 'continues', 'to', 'be', 'sufficient', 'evidence', 'of', 'safety', 'and', 'efficacy', 'confirming', 'the', 'benefits', 'of', 'Vaxzevria', ',', 'the', 'EMA', 'has', 'now', 'granted', 'full', 'approval', '.', 'The', 'approval', 'covers', 'the', 'use', 'of', 'Vaxzevria', 'in', 'both', 'a', 'primary', 'vaccination', 'series', 'and', 'as', 'both', 'a', 'heterologous', '(', 'with', 'an', 'approved', 'mRNA', 'COVID-19', 'vaccine', ')', 'or', 'homologous', '(', 'all', 'the', 'same', 'vaccine', ')', 'third-dose', 'booster', '.', 'Related', ':', 'AstraZeneca-Oxford', 'University', 'Partnered', 'Nasal', 'COVID-19', 'Vaccine', 'Flunks', 'Human', 'Trial', '.', 'AstraZeneca-Oxford', 'University', 'Partnered', 'Nasal', 'COVID-19', 'Vaccine', 'Flunks', 'Human', 'Trial', '.', 'Vaxzevria', 'has', 'been', 'demonstrated', 'to', 'be', 'effective', 'against', 'all', 'forms', 'of', 'COVID-19', ',', 'from', 'mild', 'symptomatic', 'to', 'severe', 'disease', ',', 'including', 'hospitalization', 'and', 'death', ',', 'according', 'to', 'clinical', 'studies', 'and', 'real-world', 'evidence', '.', 'These', 'include', 'an', 'expert', 'review', 'of', 'data', 'from', '52', 'real-world', 'studies', 'that', 'showed', 'that', 'Vaxzevria', 'and', 'the', 'available', 'mRNA', 'COVID-19', 'vaccines', 'provide', 'equally', 'effective', 'protection', 'against', 'hospitalization', 'and', 'death', 'from', 'COVID-19', 'following', 'three', 'doses', '.', 'There', 'is', 'also', 'a', 'substantial', 'body', 'of', 'evidence', 'supporting', 'boosting', 'with', 'Vaxzevria', 'following', 'all', 'primary', 'vaccination', 'schedules', 'tested', 'to', 'date', '.', 'Price', 'Action', ':', 'AZN', 'shares', 'are', 'up', '1.82', '%', 'at', '$', '59.88', 'during', 'the', 'premarket', 'session', 'on', 'the', 'last', 'check', 'Tuesday', '.', 'AZN', 'shares', 'are', 'up', '1.82', '%', 'at', '$', '59.88', 'during', 'the', 'premarket', 'session', 'on', 'the', 'last', 'check', 'Tuesday', '.', 'Photo', 'by', 'Paul', 'McManus', 'from', 'Pixabay', '©', '2022', 'Benzinga.com', '.', 'Benzinga', 'does', 'not', 'provide', 'investment', 'advice', '.', 'All', 'rights', 'reserved.Tesla', 'Shifts', 'China', 'Factory', 'Workers', 'To', 'US', 'Plant', ',', 'Complete', 'European', 'Approval', 'For', 'AstraZeneca', \"'s\", 'COVID-19', 'Shot', ',', 'Tesla', 'Eyes', 'Cybertruck', 'Commercialization', 'Next', 'Year', ':', 'Top', 'Stories', 'Tuesday', ',', 'Nov.', '1by', 'The', 'European', 'Commission', 'has', 'approved', 'AstraZeneca', 'plc', 'AZN', 'and', 'Sanofi', 'SA', '’', 's', 'SNY', 'Beyfortus', '(', 'nirsevimab', ')', 'long-acting', 'antibody', 'to', 'prevent', 'respiratory', 'syncytial', 'virus', '(', 'RSV', ')', 'lower', 'respiratory', 'tract', 'disease', 'in', 'newborns', 'and', 'infants', 'during', 'their', 'first', 'RSV', 'season', '.', 'and', 'Beyfortus', '(', 'nirsevimab', ')', 'long-acting', 'antibody', 'to', 'prevent', 'respiratory', 'syncytial', 'virus', '(', 'RSV', ')', 'lower', 'respiratory', 'tract', 'disease', 'in', 'newborns', 'and', 'infants', 'during', 'their', 'first', 'RSV', 'season', '.', 'Beyfortus', 'is', 'the', 'first', 'and', 'only', 'single-dose', 'RSV', 'passive', 'immunization', 'for', 'the', 'broad', 'infant', 'population', ',', 'including', 'those', 'born', 'healthy', ',', 'at', 'term', 'or', 'preterm', ',', 'or', 'with', 'specific', 'health', 'conditions', '.', 'In', 'the', 'pivotal', 'MELODY', 'efficacy', 'trial', ',', 'Beyfortus', 'met', 'its', 'primary', 'endpoint', 'of', 'reducing', 'the', 'incidence', 'of', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', '(', 'LRTI', ')', 'caused', 'by', 'RSV', 'by', '74.5', '%', 'vs.', 'placebo', 'through', 'day', '151', 'with', 'a', 'single', 'dose', '.', 'Beyfortus', 'also', 'demonstrated', 'a', 'comparable', 'safety', 'and', 'tolerability', 'profile', 'to', 'Swedish', 'Orphan', 'Biovitrum', 'AB', \"'s\", 'BIOVF', 'Synagis', '(', 'palivizumab', ')', 'in', 'the', 'MEDLEY', 'Phase', '2/3', 'trial', '.', 'Synagis', '(', 'palivizumab', ')', 'in', 'the', 'MEDLEY', 'Phase', '2/3', 'trial', '.', 'Globally', ',', 'in', '2019', ',', 'there', 'were', 'approximately', '33', 'million', 'cases', 'of', 'acute', 'lower', 'respiratory', 'infections', 'leading', 'to', 'more', 'than', 'three', 'million', 'hospitalizations', '.', 'It', 'was', 'estimated', 'that', 'there', 'were', '26,300', 'in-hospital', 'deaths', 'of', 'children', 'younger', 'than', 'five', 'years', '.', 'Price', 'Action', ':', 'SNY', 'shares', 'are', 'up', '0.61', '%', 'at', '$', '43.10', ',', 'and', 'AZN', 'shares', 'are', 'up', '0.15', '%', 'at', '$', '60.02', 'during', 'the', 'premarket', 'session', 'on', 'the', 'last', 'check', 'Friday', '.', '©', '2022', 'Benzinga.com', '.', 'Benzinga', 'does', 'not', 'provide', 'investment', 'advice', '.', 'All', 'rights', 'reserved.©', 'Reuters', 'AstraZeneca', 'shares', 'will', 'get', 'lift', 'from', 'heartburn', 'drug', 'litigation', 'closure', ',', 'says', 'Citi', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'LFCOF', '0.00', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AstraZeneca', 'PLC', '(', 'NASDAQ', ':', ')', 'can', 'get', 'a', 'boost', 'from', 'the', 'probability', 'that', 'it', 'will', 'close', 'out', 'its', 'US', 'kidney', 'damage', 'lawsuit', 'in', 'New', 'Jersey', 'prior', 'to', 'the', 'first', 'bellwether', 'case', 'in', 'March', '2023', ',', 'according', 'to', 'analysts', 'at', 'Citi', '.', 'The', 'UK', 'pharma', 'is', 'one', 'of', 'several', 'firms', 'embroiled', 'in', 'US', 'legal', 'action', 'over', 'possible', 'damage', 'caused', 'by', 'proton', 'pump', 'inhibitor', '(', 'PPI', ')', 'heartburn', 'drugs', 'such', 'as', 'Nexium', ',', 'launched', 'by', 'Astra', 'in', 'the', 'US', 'in', '2001', '.', 'The', 'Citi', 'analysts', 'believe', 'the', 'most', 'likely', 'outcome', 'is', 'that', 'the', 'judge', 'is', 'delaying', 'her', 'response', 'to', 'the', 'Defendant', 'Motion', 'for', 'summary', 'judgement', 'on', 'the', 'grounds', 'of', 'pre-emption', ',', 'to', 'encourage', 'the', 'plaintiffs', 'to', 'settle', '.', '“', 'Alternatively', ',', 'but', 'with', 'a', 'lower', 'probability', ',', 'Judge', 'Cecchi', 'may', 'have', 'delayed', 'the', 'start', 'of', 'the', 'bellwether', 'cases', 'as', 'she', 'disagrees', 'with', 'the', 'conclusions', 'of', 'Special', 'Master', 'Reisman', 'and', 'grants', 'the', 'defendant', \"'s\", 'motion', 'to', 'dismiss', 'on', 'grounds', 'of', 'pre-emption', ',', \"''\", 'they', 'said', '.', 'Either', 'scenario', 'would', 'be', 'materially', 'positive', 'to', 'Astra', \"'s\", 'depressed', 'share', 'price', ',', 'the', 'US', 'bank', \"'s\", 'analysts', 'added', ',', 'as', 'would', 'positive', 'interim', 'DESTINY-Breast06', 'data', 'with', 'Enhertu', 'at', 'the', 'year-end', 'and', 'positive', 'TROPION-Lung-01', 'data', 'in', 'March', '2023', '.', 'The', 'Citi', 'analysts', 'said', 'their', '2023', 'and', '2024', 'core', 'EPS', 'forecasts', 'for', 'Astra', 'are', '5', '%', 'and', '17', '%', 'above', 'consensus', 'and', 'repeated', 'them', 'alongside', 'a', 'price', 'target', 'of', '£130', 'and', 'a', \"'buy\", \"'\", 'recommendation', '.', 'Shares', 'in', 'Astra', 'rose', '1', '%', 'to', '£103.56', '.', 'Read', 'more', 'on', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'The', 'crypto', 'party', 'started', 'as', 'corporate', 'earnings-induced', 'optimism', 'and', 'hopes', 'of', 'a', 'Fed', 'thawing', 'perked', 'up', 'risk', 'appetite', 'in', 'the', 'financial', 'markets', '.', 'Ethereum', '(', 'CRYPTO', ':', 'ETH', ')', ',', 'the', 'second', '...', 'Astrazeneca', \"'s\", 'Beyfortus', 'receives', 'EU', 'approval', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'UK100', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'stated', 'that', 'Beyfortus', 'was', 'now', 'the', 'first', 'and', 'only', 'single-dose', 'RSV', 'passive', 'immunisation', 'for', 'the', 'broad', 'infant', 'population', ',', 'including', 'those', 'born', 'healthy', ',', 'at', 'term', 'or', 'pre-term', ',', 'or', 'with', 'specific', 'health', 'conditions', '.', 'The', '100-listed', 'group', 'said', 'the', 'European', 'Commission', 'was', 'the', 'first', 'regulatory', 'body', 'to', 'grant', 'approval', 'to', 'Beyfortus', ',', 'with', 'the', 'approval', 'based', 'on', 'results', 'from', 'the', 'drug', \"'s\", 'clinical', 'development', 'programme', 'and', 'follows', 'a', 'recommendation', 'from', 'The', 'Committee', 'for', 'Medicinal', 'Products', 'for', 'Human', 'Use', 'of', 'the', 'European', 'Medicines', 'Agency', 'in', 'September', '.', 'In', 'AZN', \"'s\", '``', 'pivotal', \"''\", 'MELODY', 'efficacy', 'trial', ',', 'Beyfortus', 'met', 'its', 'primary', 'endpoint', 'of', 'reducing', 'the', 'incidence', 'of', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'by', 'RSV', 'by', '74.5', '%', 'versus', 'placebo', 'through', 'day', '151', 'with', 'a', 'single', 'dose', '.', 'Iskra', 'Eric', ',', 'AZN', \"'s\", 'executive', 'vice', 'president', 'of', 'vaccines', 'and', 'immune', 'therapies', ',', 'said', ':', '``', 'Beyfortus', 'is', 'the', 'first', 'single-dose', 'preventative', 'option', 'against', 'respiratory', 'syncytial', 'virus', 'to', 'gain', 'approval', 'in', 'Europe', 'and', 'is', 'also', 'the', 'first', 'and', 'only', 'preventative', 'option', 'approved', 'for', 'a', 'broad', 'infant', 'population', '.', '``', 'Today', \"'s\", 'marketing', 'authorisation', 'of', 'Beyfortus', 'marks', 'a', 'significant', 'achievement', 'for', 'the', 'scientific', 'community', 'and', 'addresses', 'a', 'persistent', ',', 'global', 'unmet', 'need', 'in', 'RSV', 'prevention', '.', \"''\", 'Reporting', 'by', 'Iain', 'Gilbert', 'at', 'Sharecast.com', 'Read', 'more', 'on', 'Sharecast.com©', 'Reuters', '.', 'AstraZeneca', 'says', 'Evusheld', 'approved', 'for', 'treatment', 'of', 'COVID-19', 'in', 'EU', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'has', 'said', 'its', 'long-acting', 'antibody', 'combination', 'Evusheld', '(', 'tixagevimab', 'and', 'cilgavimab', ',', 'formerly', 'AZD7442', ')', 'has', 'been', 'approved', 'in', 'the', 'EU', 'for', 'the', 'treatment', 'of', 'COVID-19', '.', 'The', 'approval', 'by', 'the', 'European', 'Commission', 'covers', 'people', 'over', 'the', 'age', 'of', '12', 'years', 'who', 'do', 'not', 'require', 'supplemental', 'oxygen', 'and', 'who', 'are', 'at', 'increased', 'risk', 'of', 'progressing', 'to', 'severe', 'COVID‑19', ',', 'the', 'pharmaceuticals', 'group', 'said', '.', 'The', 'European', 'Commission', '’', 's', 'approval', 'was', 'based', 'on', 'results', 'from', 'the', 'TACKLE', 'phase', 'III', 'treatment', 'trial', 'which', 'showed', 'that', 'Evusheld', 'significantly', 'reduced', 'the', 'risk', 'of', 'severe', 'COVID-19', 'or', 'death', '.', 'The', 'recommended', 'dose', 'of', 'Evusheld', 'for', 'treatment', 'in', 'Europe', 'is', '300mg', 'of', 'tixagevimab', 'and', '300mg', 'of', 'cilgavimab', ',', 'administered', 'as', 'two', 'separate', ',', 'sequential', 'IM', 'injections', ',', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'noted', '.', '``', 'Many', 'people', ',', 'including', 'those', 'who', 'are', 'immunocompromised', ',', 'older', 'adults', 'and', 'those', 'with', 'underlying', 'health', 'conditions', ',', 'are', 'at', 'high', 'risk', 'of', 'severe', 'disease', ',', 'hospitalisation', 'and', 'death', 'if', 'they', 'become', 'infected', '.', 'Evusheld', ',', 'delivered', 'in', 'a', 'convenient', 'intramuscular', 'formulation', ',', 'is', 'now', 'a', 'much-needed', 'new', 'COVID-19', 'treatment', 'option', 'for', 'these', 'vulnerable', 'populations', ',', \"''\", 'commented', 'Dr', 'Michel', 'Goldman', ',', 'professor', 'at', 'the', 'Institute', 'for', 'Interdisciplinary', 'Innovation', 'in', 'Healthcare', ',', 'Université', 'Libre', 'de', 'Bruxelles', ',', 'and', 'former', 'executive', 'director', 'of', 'the', 'European', 'Innovative', 'Medicines', 'Initiative', 'in', 'a', 'statement', '.', 'Iskra', 'Reic', ',', 'executive', 'vice', 'president', 'of', 'vaccines', 'and', 'immune', 'therapies', 'at', 'AstraZeneca', ',', 'added', ':', '``', 'COVID-19', 'remains', 'an', 'ongoing', 'health', 'concern', 'for', 'millions', 'of', 'Europeans', 'and', 'around', 'the', 'world', ',', 'especially', 'for', 'those', 'who', 'may', 'not', 'be', 'well-protected', 'against', 'the', 'virus', 'from', 'vaccination', '.', 'With', 'this', 'approval', ',', 'Evusheld', 'is', 'now', 'the', 'only', 'long-acting', 'antibody', 'combination', 'available', 'for', 'both', 'prevention', 'and', 'treatment', 'of', 'COVID-19', 'in', 'Europe', ',', 'allowing', 'us', 'to', 'protect', 'even', 'more', 'people', 'from', 'this', 'devastating', 'disease', '.', \"''\", 'Read', 'more', 'on', 'Proactive', 'Investors', 'UK', 'Disclaimer©', 'Reuters', 'AstraZeneca', 'gets', 'its', 'third', 'regulatory', 'green', 'light', 'in', 'a', 'matter', 'of', 'weeks', 'for', 'asthma', 'drug', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AstraZeneca', 'PLC', '(', 'LON', ':', ')', 'said', 'its', 'Tezspire', 'treatment', 'has', 'been', 'approved', 'in', 'Japan', 'for', 'severe', 'bronchial', 'asthma', 'where', 'high-dose', 'traditional', 'corticosteroids', 'don', '’', 't', 'work', '.', 'It', 'is', 'the', 'third', 'approval', 'in', 'a', 'matter', 'of', 'weeks', 'for', 'the', 'product', ',', 'a', 'potential', 'challenger', 'to', 'market', 'leader', 'Dupxient', '.', 'It', 'was', 'developed', 'in', 'collaboration', 'with', 'US', 'giant', 'Amgen', '(', 'NASDAQ', ':', ')', '.', 'In', 'clinical', 'trials', ',', 'the', 'drug', 'was', 'shown', 'to', 'lower', 'what', 'the', 'researchers', 'called', '‘', 'asthma', 'exacerbations', '’', 'by', '56', '%', '.', '``', 'Tezspire', 'is', 'the', 'first', 'and', 'only', 'biologic', 'approved', 'by', 'the', 'Japanese', 'Ministry', 'of', 'Health', ',', 'Labour', 'and', 'Welfare', 'that', 'has', 'been', 'shown', 'to', 'consistently', 'and', 'significantly', 'reduce', 'attacks', 'in', 'exacerbation', 'trials', 'in', 'a', 'broad', 'population', 'of', 'severe', 'asthma', 'patients', 'irrespective', 'of', 'biomarker', 'levels', ',', '”', 'Mene', 'Pangalos', ',', 'head', 'of', 'biopharmaceutical', 'research', 'at', 'AZ', '.', '“', 'Tezspire', 'has', 'the', 'potential', 'to', 'improve', 'outcomes', 'for', 'many', 'patients', 'with', 'severe', 'asthma', 'and', 'we', 'are', 'working', 'to', 'make', 'this', 'important', 'medicine', 'available', 'in', 'Japan', 'as', 'quickly', 'as', 'possible.', '”', 'Analysts', 'believe', 'Tezspire', 'could', 'be', 'a', 'big', 'seller', 'with', 'peak', 'sales', 'projected', 'to', 'be', 'in', 'the', 'order', 'of', 'US', '$', '2.5bn', '.', 'Read', 'more', 'on', 'Proactive', 'Investors', 'UK', 'Disclaimer©', 'Reuters', '.', 'FILE', 'PHOTO', ':', 'The', 'company', 'logo', 'for', 'pharmaceutical', 'company', 'AstraZeneca', 'is', 'displayed', 'on', 'a', 'screen', 'on', 'the', 'floor', 'at', 'the', 'New', 'York', 'Stock', 'Exchange', ',', 'U.S.', ',', 'April', '8', ',', '2019', '.', 'REUTERS/Brendan', 'McDermid/File', 'Photo', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', '(', 'Reuters', ')', '-', 'Shares', 'of', 'LogicBio', 'Therapeutics', 'skyrocketed', 'on', 'Monday', 'after', 'Britain', \"'s\", 'AstraZeneca', '(', 'NASDAQ', ':', ')', \"'s\", 'said', 'it', 'would', 'buy', 'the', 'U.S.-based', 'gene', 'therapy', 'developer', 'at', 'a', 'rare', '660', '%', 'premium', 'for', '$', '68', 'million', '.', 'LoigBio', \"'s\", 'shares', ',', 'which', 'have', 'traded', 'below', '$', '1', 'since', 'February', ',', 'were', 'up', '637', '%', 'at', '$', '2', 'before', 'the', 'bell', ',', 'close', 'to', 'AstraZeneca', \"'s\", 'offer', 'price', 'of', '$', '2.07', 'per', 'share', '.', 'LogicBio', 'is', 'developing', 'gene', 'editing', 'therapies', 'to', 'treat', 'pediatric', 'rare', 'disease', 'like', 'methylmalonic', 'acidemia', ',', 'where', 'the', 'body', 'can', 'not', 'break', 'down', 'certain', 'proteins', 'and', 'fats', '.', 'AstraZeneca', 'said', 'the', 'deal', 'would', 'accelerate', 'growth', 'of', 'its', 'Alexion', '(', 'NASDAQ', ':', ')', 'unit', ',', 'which', 'it', 'acquired', 'for', '$', '39', 'billion', 'last', 'year', ',', 'in', 'the', 'field', 'of', 'genomic', 'medicine.By', 'Benzinga', 'The', 'crypto', 'party', 'started', 'as', 'corporate', 'earnings-induced', 'optimism', 'and', 'hopes', 'of', 'a', 'Fed', 'thawing', 'perked', 'up', 'risk', 'appetite', 'in', 'the', 'financial', 'markets', '.', 'Ethereum', '(', 'CRYPTO', ':', 'ETH', ')', ',', 'the', 'second', '...', '©', 'Reuters', 'AstraZeneca', 'says', 'Imjudo-Imfinzi', 'combination', 'approved', 'for', 'advanced', 'liver', 'cancer', 'in', 'US', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AstraZeneca', 'PLC', '(', 'LON', ':', ')', 'announced', 'that', 'the', 'US', 'Food', 'and', 'Drug', 'Administration', '(', 'FDA', ')', 'has', 'approved', 'the', 'company', \"'s\", 'Imjudo', '(', 'tremelimumab', ')', 'drug', 'in', 'combination', 'with', 'Imfinzi', '(', 'durvalumab', ')', 'for', 'treatment', 'of', 'adult', 'patients', 'with', 'unresectable', 'hepatocellular', 'carcinoma', '(', 'HCC', ')', ',', 'the', 'most', 'common', 'type', 'of', 'liver', 'cancer', '.', 'The', 'approval', 'is', 'based', 'on', 'results', 'from', 'the', 'HIMALAYA', 'Phase', 'III', 'trial', ',', 'which', 'showed', 'that', 'a', 'single', 'priming', 'dose', 'of', 'the', 'anti-CTLA-4', 'antibody', 'Imjudo', 'added', 'to', 'the', 'anti-PD-L1', 'antibody', 'Imfinzi', 'reduced', 'the', 'risk', 'of', 'death', 'by', '22', '%', 'compared', 'with', 'sorafenib', ',', 'the', 'pharmaceuticals', 'company', 'said', '.', 'Liver', 'cancer', 'is', 'the', 'third-leading', 'cause', 'of', 'cancer', 'death', 'and', 'the', 'sixth', 'most', 'commonly', 'diagnosed', 'cancer', 'worldwide', '.', 'It', 'is', 'the', 'fastest-rising', 'cause', 'of', 'cancer-related', 'deaths', 'in', 'the', 'US', ',', 'with', 'approximately', '36,000', 'new', 'diagnoses', 'each', 'year', ',', 'the', '100-listed', 'company', 'said', '.', 'In', 'a', 'statement', ',', 'Dave', 'Fredrickson', ',', 'executive', 'vice', 'president', ',', 'oncology', 'business', 'unit', 'at', 'AstraZeneca', ',', 'commented', ':', '``', 'With', 'this', 'first', 'regulatory', 'approval', 'for', 'Imjudo', ',', 'patients', 'with', 'unresectable', 'liver', 'cancer', 'in', 'the', 'US', 'now', 'have', 'an', 'approved', 'dual', 'immunotherapy', 'treatment', 'regimen', 'that', 'harnesses', 'the', 'potential', 'of', 'CTLA-4', 'inhibition', 'in', 'a', 'unique', 'combination', 'with', 'a', 'PD-L1', 'inhibitor', 'to', 'enhance', 'the', 'immune', 'response', 'against', 'their', 'cancer', '.', \"''\", 'Dr', 'Ghassan', 'Abou-Alfa', ',', 'attending', 'physician', 'at', 'Memorial', 'Sloan', 'Kettering', 'Cancer', 'Center', '(', 'MSK', ')', ',', 'and', 'principal', 'investigator', 'in', 'the', 'HIMALAYA', 'Phase', 'III', 'trial', ',', 'said', ':', '``', 'Patients', 'with', 'unresectable', 'liver', 'cancer', 'are', 'in', 'need', 'of', 'well-tolerated', 'treatments', 'that', 'can', 'meaningfully', 'extend', 'overall', 'survival', '.', 'In', 'addition', 'to', 'this', 'regimen', 'demonstrating', 'a', 'favourable', 'three-year', 'survival', 'rate', 'in', 'the', 'HIMALAYA', 'trial', ',', 'safety', 'data', 'showed', 'no', 'increase', 'in', 'severe', 'liver', 'toxicity', 'or', 'bleeding', 'risk', 'for', 'the', 'combination', ',', 'important', 'factors', 'for', 'patients', 'with', 'liver', 'cancer', 'who', 'also', 'have', 'advanced', 'liver', 'disease', '.', \"''\", 'Regulatory', 'applications', 'for', 'Imjudo', 'in', 'combination', 'with', 'Imfinzi', 'are', 'currently', 'under', 'review', 'in', 'Europe', ',', 'Japan', 'and', 'several', 'other', 'countries', 'for', 'the', 'treatment', 'of', 'patients', 'with', 'advanced', 'liver', 'cancer', 'based', 'on', 'the', 'HIMALAYA', 'results', ',', 'AstraZeneca', 'said', '.', 'Read', 'more', 'on', 'Proactive', 'Investors', 'UK', 'Disclaimer©', 'Reuters', '.', 'AstraZeneca-Merck', \"'s\", 'Prostate', 'Cancer', 'Combo', 'Drug', ',', '3rd', 'Try', 'For', 'scPharma', ',', '3', 'FDA', 'Panel', 'Decisions', 'And', 'More', ':', 'October', \"'s\", 'Key', 'PDUFA', 'Catalysts', 'Biotech', 'Investors', 'Must', 'Know', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'IXIC', '+1.28', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'KECR', '+3.15', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'Most', 'FDA', 'decisions', 'scheduled', 'for', 'September', 'yielded', 'positive', 'results', ',', 'but', 'there', 'were', 'stray', 'disappointments', 'as', 'well', '.', 'Seven', 'new', 'molecular', 'entities', ',', 'or', 'NMEs', ',', 'were', 'approved', 'during', 'the', 'month', ',', 'taking', 'the', 'total', 'NME', 'approvals', 'for', 'the', 'year', 'to', '24', '.', 'This', 'is', 'far', 'less', 'than', 'the', '40', 'approvals', 'received', 'by', 'the', 'same', 'time', 'last', 'year', '.', 'NMEs', 'are', 'considered', 'a', 'measure', 'of', 'innovation', 'in', 'drug', 'research', ',', 'as', 'they', 'contain', 'active', 'moieties', 'or', 'ingredients', 'that', 'haven', '’', 't', 'been', 'previously', 'approved', 'by', 'the', 'Food', 'and', 'Drug', 'Administration', '.', 'Among', 'the', 'positive', 'verdicts', ',', 'bluebird', 'bio', ',', 'Inc.', '’', 's', '(', 'NASDAQ', ':', 'BLUE', ')', '$', '3', 'million', 'gene', 'therapy', 'Skysona', 'was', 'approved', 'for', 'treating', 'a', 'rare', 'neurodegenerative', 'disorder', 'in', 'boys', 'and', 'Amylyx', 'Pharmaceuticals', ',', 'Inc.', '(', 'NASDAQ', ':', 'AMLX', ')', 'scored', 'a', 'win', 'for', 'its', 'amyotrophic', 'sclerosis', 'treatment', 'Revance', 'Therapeutics', ',', 'Inc.', '’', 's', '(', 'NASDAQ', ':', 'RVNC', ')', 'Botox', 'rival', 'Daxxify', 'was', 'approved', 'for', 'treating', 'frown', 'lines', '.', 'Spectrum', 'Pharmaceuticals', ',', 'Inc.', '(', 'NASDAQ', ':', 'SPPI', ')', 'had', 'a', 'mixed', 'month', ',', 'as', 'its', 'Rolvedon', 'was', 'approved', 'for', 'treating', 'chemotherapy-induced', 'neutropenia', ',', 'but', 'its', 'lung', 'cancer', 'drug', 'did', 'not', 'get', 'the', 'backing', 'of', 'an', 'FDA', 'panel', '.', 'Here', 'are', 'the', 'key', 'PDUFA', 'dates', 'scheduled', 'for', 'October', ':', 'Will', 'Theratech', 'Score', 'A', 'Win', 'For', 'A', 'More', 'Convenient', 'Formulation', 'Of', 'Its', 'HIV', 'Drug', '?', 'Company', ':', 'Theratechnologies', ',', 'Inc.', '(', 'NASDAQ', ':', 'THTX', ')', 'Type', 'of', 'Application', ':', 'supplemental', 'biologic', 'license', 'application', 'Candidate', ':', 'Trogarzo', 'Indication', ':', 'HIV-1', 'Date', ':', 'Oct.', '3', 'In', 'the', 'fourth', 'quarter', 'of', '2021', ',', 'the', 'company', 'filed', 'the', 'sBLA', 'for', 'intravenous', 'push', 'mode', 'of', 'administration', 'of', 'its', 'Trogarzo', 'for', 'treating', 'human', 'immunodeficiency', 'virus', 'type', '1', ',', 'or', 'HIV-1', '.', 'Trogarzo', 'was', 'first', 'approved', 'by', 'the', 'FDA', 'in', 'March', '2018', 'to', 'treat', 'adult', 'patients', 'with', 'multidrug-resistant', 'HIV', '.', 'In', 'the', 'quarter', 'that', 'ended', 'on', 'May', '31', ',', 'the', 'drug', 'generated', 'sales', 'of', '$', '7.852', 'million', 'for', 'Theratech', '.', 'Alnylam', 'On', 'Course', 'For', 'Snagging', 'Label', 'Expansion', 'For', 'Oxlumo', '?', 'Company', ':', 'Alnylam', ',', 'Inc.', '(', 'NASDAQ', ':', 'ALNY', ')', 'Type', 'of', 'Application', ':', 'supplemental', 'new', 'drug', 'application', 'Candidate', ':', 'Oxlumo', 'Indication', ':', 'hyperoxaluria', 'Type', '1', 'Date', ':', 'Oct.', '6', 'Oxlumo', ',', 'which', 'goes', 'by', 'the', 'generic', 'name', 'lumasiran', ',', 'an', 'RNAi', 'therapeutic', ',', 'is', 'being', 'evaluated', 'for', 'the', 'reduction', 'of', 'plasma', 'oxalate', 'in', 'patients', 'with', 'advanced', 'hyperoxaluria', 'type', '1', '–', 'a', 'rare', 'disorder', 'that', 'mainly', 'affects', 'the', 'kidneys', 'due', 'to', 'the', 'accumulation', 'of', 'a', 'substance', 'called', 'oxalate', ',', 'which', 'is', 'normally', 'filtered', 'through', 'the', 'kidneys', 'and', 'excreted', 'in', 'the', 'urine', '.', 'This', 'therapy', 'was', 'first', 'approved', 'in', '2020', 'for', 'lowering', 'urinary', 'oxalate', 'labels', 'in', 'pediatric', 'and', 'adult', 'patients', '.', 'In', 'the', 'second', 'quarter', ',', 'it', 'fetched', 'the', 'company', '$', '15', 'million', 'in', 'sales', ',', 'down', 'only', '2', '%', 'sequentially', '.', 'See', 'also', ':', 'Alzheimer', \"'s\", 'Progression', 'Slowed', 'Down', 'By', 'Biogen', '(', 'NASDAQ', ':', ')', \"'s\", 'New', 'Drug', 'In', 'Late-Stage', 'Study', ':', 'Analyst', 'Sees', '25', '%', 'Can', 'Third', 'Time', 'Be', 'Charm', 'For', 'scPharma', 'Company', ':', 'scPharmaceuticals', ',', 'Inc.', '(', 'NASDAQ', ':', 'SCPH', ')', 'Type', 'of', 'Application', ':', 'NDA', 'Candidate', ':', 'Furoscix', 'Indication', ':', 'worsening', 'heart', 'failure', 'due', 'to', 'congestion', 'Date', ':', 'Oct.', '8', 'Furoscix', 'is', 'a', 'proprietary', ',', 'subcutaneously-delivered', 'furosemide', 'solution', ',', 'that', 'is', 'being', 'evaluated', 'as', 'an', 'outpatient', 'alternative', 'for', 'the', 'treatment', 'of', 'worsening', 'congestive', 'heart', 'failure', '.', 'This', 'is', 'scPharma', \"'s\", 'third', 'try', 'for', 'Furoscix', 'following', 'a', 'complete', 'response', 'letter', 'in', '2018', 'and', '2020', '.', '’', 'Go', '’', 'or', '‘', 'no-Go', '’', 'for', 'Amicus', '’', 's', 'Pome', 'Disease', 'Treatment', '?', 'Company', ':', 'Amicus', 'Therapeutics', ',', 'Inc.', '(', 'NASDAQ', ':', 'FOLD', ')', 'Type', 'of', 'Application', ':', 'BLA', 'Candidate', ':', 'cipaglucosidase', 'alfa', 'Indication', ':', 'Pompe', 'disease', 'Date', ':', 'Oct.', '29', 'AT-GAA', 'is', 'an', 'investigational', '2-component', 'therapy', 'that', 'consists', 'of', 'cipaglucosidase', 'alfa', ',', 'administered', 'in', 'conjunction', 'with', 'miglustat', ',', 'which', 'is', 'yet', 'to', 'be', 'approved', 'by', 'the', 'FDA', '.', 'The', '2-component', 'therapy', 'is', 'being', 'evaluated', 'for', 'an', 'inherited', 'lysosomal', 'disorder', 'called', 'Pome', 'disease', '.', 'The', 'disease', 'can', 'be', 'debilitating', 'and', 'is', 'characterized', 'by', 'severe', 'muscle', 'weakness', 'that', 'worsens', 'over', 'time', '.', 'It', 'ranges', 'from', 'a', 'rapidly', 'fatal', 'infantile', 'form', 'with', 'significant', 'impacts', 'on', 'heart', 'function', 'to', 'a', 'more', 'slowly', 'progressive', ',', 'late-onset', 'form', 'primarily', 'affecting', 'skeletal', 'muscle', '.', 'It', 'is', 'estimated', 'that', 'Pompe', 'disease', 'affects', 'approximately', '5,000', 'to', '10,000', 'people', 'worldwide', '.', 'Supernus', 'Hopes', 'For', 'No', 'Hiccups', 'In', 'Parkinson', 'Disease', 'Drug', 'Approval', 'Company', ':', 'Supernus', 'Pharmaceuticals', ',', 'Inc.', '(', 'NASDAQ', ':', 'SUPN', ')', 'Type', 'of', 'Application', ':', 'NDA', 'Candidate', ':', 'apomorphine', 'infusion', 'device', '(', 'SPN-830', ')', 'Indication', ':', 'OFF', 'episodes', 'in', 'Parkinson', '’', 's', 'disease', 'Date', ':', 'Early', 'October', 'Supernus', '’', 's', 'initial', 'application', 'seeking', 'approval', 'for', 'SPN-830', 'was', 'shot', 'down', 'with', 'a', 'refuse-to-file', 'letter', 'in', 'November', '2020', ',', 'citing', 'an', 'insufficiently', 'completed', 'application', 'to', 'allow', 'a', 'substantiative', 'review', '.', 'Following', 'a', 'resubmission', ',', 'the', 'FDA', 'accepted', 'the', 'application', 'and', 'assigned', 'a', 'PDUFA', 'date', 'sometime', 'in', 'early', 'October', '.', 'Also', 'read', ':', 'Best', 'Biotech', 'Stocks', 'Right', 'Now', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'Knocks', 'At', 'FDA', 'Altar', 'For', 'Liver', 'Cancer', 'Combo', 'Treatment', 'Company', ':', 'AstraZeneca', ',', 'plc', '.', '(', 'NASDAQ', ':', 'AZN', ')', 'Type', 'of', 'Application', ':', 'BLA/sBLA', 'Candidate', ':', 'Tremelimumab', '+', 'Imfinzi', 'Indication', ':', 'Unresectable', 'hepatocellular', 'carcinoma', 'Date', ':', 'Q4', 'The', 'FDA', 'accepted', 'AstraZeneca', '’', 's', 'BLA', 'for', 'tremelimumab', 'for', 'priority', 'review', ',', 'supporting', 'the', 'indication', 'of', 'a', 'single', 'priming', 'dose', 'of', 'the', 'anti-CTLA4', 'antibody', 'added', 'to', 'Imfinzi', ',', 'for', 'treating', 'patients', 'with', 'unresectable', 'hepatocellular', 'carcinoma', '.', 'A', 'sBLA', 'has', 'also', 'been', 'submitted', 'for', 'Imfinzi', 'for', 'the', 'indication', '.', 'This', 'novel', 'dose', 'and', 'schedule', 'of', 'the', 'combination', 'is', 'called', 'the', 'STRIDE', 'regimen', '-', 'Single', 'Tremelimumab', 'Regular', 'Interval', 'Durvalumab', '.', 'HCC', ',', 'according', 'to', 'the', 'company', ',', 'is', 'the', 'most', 'common', 'type', 'of', 'liver', 'cancer', ',', 'and', 'about', '26,000', 'people', 'in', 'the', 'U.S.', 'are', 'afflicted', 'by', 'advanced', ',', 'unresectable', 'HCC', 'each', 'year', '.', 'Merck-AstraZeneca', 'Await', 'Approval', 'For', 'Prostate', 'Cancer', 'Como', 'Therapy', 'Company', ':', 'Merck', '&', 'Co.', ',', 'Inc.', '(', 'NYSE', ':', 'MRK', ')', '&', 'AstraZeneca', 'Type', 'of', 'Application', ':', 'sNDA', 'Candidate', ':', 'Lynparza', 'in', 'combination', 'with', 'Abiraterone', 'and', 'Prednisone', 'or', 'Prednisolone', 'Indication', ':', 'prostate', 'cancer', 'Date', ':', 'Q4', 'The', 'application', 'was', 'accepted', 'and', 'granted', 'priority', 'review', 'by', 'the', 'FDA', 'for', 'the', 'treatment', 'of', 'adult', 'patients', 'with', 'metastatic', 'castration-resistant', 'prostate', 'cancer', '.', 'Adcom', 'Calendar', ':', 'FDA', '’', 's', 'Cardiovascular', 'and', 'Renal', 'Drugs', 'Advisory', 'Committee', 'will', 'meet', 'on', 'Oct.', '26', 'to', 'discuss', 'GlaxoSmithKline', 'plc', '’', 's', '(', 'NYSE', ':', 'GSK', ')', 'NDA', 'for', 'hypoxia-inducible', 'factor', 'prolyl', 'hydroxylase', 'inhibitor', 'daprodustat', 'tablets', 'as', 'a', 'treatment', 'option', 'for', 'anemia', 'resulting', 'from', 'chronic', 'kidney', 'disease', '.', 'The', 'Oncologic', 'Drugs', 'Advisory', 'Committee', 'is', 'scheduled', 'to', 'meet', 'on', 'Oct.', '28', 'to', 'discuss', 'the', 'BLA', 'submitted', 'by', 'Y-mAbs', 'Therapeutics', ',', 'Inc.', '(', 'NASDAQ', ':', 'YMAB', ')', 'for', 'its', '1311-omburtamab', 'solution', ',', 'injectable', 'formulation', ',', 'for', 'treating', 'neuroblastoma', 'with', 'central', 'nervous', 'system/leptomeningeal', 'metastases', '.', 'On', 'Oct.', '31', ',', 'the', 'Endocrinologic', 'and', 'Metabolic', 'Drugs', 'Advisory', 'Committee', 'will', 'deliberate', 'on', 'Ispen', 'S.A.', '’', 's', '(', 'OTC', ':', 'IPSEY', ')', 'palovarotene', 'capsules', 'for', 'the', 'proposed', 'indication', 'of', 'heterotopic', 'ossification', 'in', 'adults', 'and', 'children', '.', 'It', 'is', 'a', 'condition', 'in', 'which', 'muscle', 'tissue', 'and', 'connective', 'tissue', 'such', 'as', 'tendons', 'and', 'ligaments', 'are', 'gradually', 'replaced', 'by', 'bones', '.', '©', '2022', 'Benzinga.com', '.', 'Benzinga', 'does', 'not', 'provide', 'investment', 'advice', '.', 'All', 'rights', 'reserved', '.', 'Read', 'the', 'original', 'article', 'on', 'Benzinga©', 'Reuters', '.', 'FILE', 'PHOTO', ':', 'Pascal', 'Soriot', ',', 'chief', 'executive', 'of', 'pharmaceuticals', 'company', 'AstraZeneca', ',', 'attends', 'an', 'interview', 'with', 'Reuters', 'in', 'Shanghai', ',', 'China', ',', 'November', '4', ',', '2019', '.', 'REUTERS/Brenda', 'Goh/File', 'Photo', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'By', 'Aimee', 'Donnellan', 'and', 'Natalie', 'Grover', 'LONDON', '(', 'Reuters', ')', '-', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'may', 'not', 'stay', 'in', 'the', 'vaccine', 'business', 'in', 'the', 'long', 'run', ',', 'its', 'CEO', 'told', 'Reuters', 'on', 'Tuesday', ',', 'showing', 'how', 'quickly', 'fortunes', 'have', 'changed', 'for', 'the', 'drugmaker', 'that', 'produced', 'one', 'of', 'the', 'first', 'COVID-19', 'shots', 'but', 'has', 'since', 'lost', 'out', 'to', 'rivals', '.', 'Production', 'delays', ',', 'probes', 'by', 'regulators', 'following', 'rare', 'cases', 'of', 'severe', 'side', 'effects', ',', 'and', 'concerns', 'about', 'its', 'relatively', 'short', 'shelf', 'life', 'compared', 'with', 'other', 'shots', 'have', 'stymied', 'adoption', 'of', 'the', 'company', \"'s\", 'COVID-19', 'vaccine', '.', 'Now', ',', 'in', 'the', 'third', 'year', 'of', 'the', 'pandemic', 'amid', 'a', 'global', 'vaccine', 'supply', 'glut', ',', 'its', 'use', 'has', 'diminished', 'in', 'much', 'of', 'the', 'developed', 'world', 'as', 'countries', 'have', 'inoculated', 'large', 'numbers', 'of', 'people', 'and', 'prefer', 'Pfizer', '(', 'NYSE', ':', ')', 'and', 'Moderna', '(', 'NASDAQ', ':', ')', \"'s\", 'mRNA', 'vaccines', 'as', 'boosters', '.', 'AstraZeneca', \"'s\", 'COVID', 'vaccine', 'has', 'still', 'not', 'won', 'U.S.', 'approval', '.', 'The', 'London-listed', 'company', 'is', 'building', 'on', 'its', 'portfolio', 'of', 'antibody', 'therapies', ',', 'including', 'for', 'COVID-19', ',', 'the', 'respiratory', 'virus', 'RSV', 'and', 'other', 'viruses', ',', 'Soriot', 'said', 'in', 'a', 'Reuters', 'Newsmaker', 'interview', 'on', 'Tuesday', '.', 'But', 'on', 'the', 'future', 'of', 'its', 'COVID', 'vaccines', 'business', ',', 'he', 'said', ':', '``', 'I', 'ca', \"n't\", 'be', 'sure', 'we', 'will', 'be', 'there', 'or', 'not', '.', \"''\", 'He', 'also', 'said', 'he', 'was', \"n't\", 'sure', 'if', 'AstraZeneca', 'would', 'broaden', 'its', 'roster', 'of', 'vaccines', 'for', 'other', 'infections', 'either', ',', 'adding', 'that', 'the', 'company', 'was', 'looking', 'into', 'it', '.', 'Investors', 'have', 'speculated', 'about', 'the', 'future', 'of', 'the', 'vaccine', 'business', 'given', 'slowing', 'sales', 'of', 'the', 'COVID', 'shot', 'as', 'initial', 'sales', 'contracts', 'have', 'been', 'fulfilled', ',', 'stiff', 'competition', 'from', 'mRNA', 'vaccines', 'and', 'its', 'relatively', 'little', 'expertise', 'in', 'the', 'field', '.', 'The', 'company', 'created', 'a', 'separate', 'division', 'for', 'vaccines', 'and', 'antibody', 'therapies', 'late', 'last', 'year', '.', 'Still', ',', 'Soriot', 'said', 'he', 'did', 'not', 'regret', 'the', 'company', \"'s\", 'work', 'with', 'Oxford', 'University', 'to', 'develop', 'a', 'COVID', 'vaccine', ',', 'given', 'they', 'had', 'delivered', 'billions', 'of', 'doses', 'and', 'saved', 'an', 'estimated', '6', 'million', 'lives', 'across', 'the', 'globe', '.', 'The', 'inoculation', 'was', 'AstraZeneca', \"'s\", 'second', 'best-selling', 'product', 'in', '2021', 'with', 'sales', 'of', '$', '3.9', 'billion', '.', 'AstraZeneca', 'is', 'also', 'looking', 'for', 'bolt-on', 'acquisitions', ',', 'including', 'small', 'and', 'mid-sized', 'companies', 'specialising', 'in', 'oncology', 'and', 'cardiovascular', 'treatments', ',', 'Soriot', 'added', '.', '``', 'We', 'always', 'look', 'for', 'external', 'opportunities', ',', \"''\", 'he', 'said', '.', 'KEEP', 'ON', 'DOING', 'THIS', 'JOB', 'The', 'CEO', 'has', 'presided', 'over', 'a', 'quadrupling', 'of', 'AstraZeneca', \"'s\", 'share', 'price', 'in', 'his', 'decade', 'at', 'the', 'helm', '.', '``', 'I', 'can', 'keep', 'doing', 'this', 'job', 'for', 'many', 'years', ',', \"''\", 'he', 'said', '.', 'The', '63-year', 'old', 'was', 'once', 'seen', 'as', 'a', 'natural', 'successor', 'to', 'outgoing', 'Chairman', 'Leif', 'Johansson', '.', 'But', 'in', 'July', ',', 'Soriot', 'quashed', 'speculation', 'he', 'was', 'planning', 'to', 'retire', 'any', 'time', 'soon', ',', 'saying', 'he', 'expected', 'to', 'work', 'with', 'the', 'company', \"'s\", 'newly', 'announced', 'chairman-designate', 'Michel', 'Demare', 'for', 'many', 'years', 'to', 'come', '.', 'Soriot', 'was', 'tasked', 'with', 'turning', 'around', 'a', 'troubled', 'AstraZeneca', '-', 'hit', 'by', 'a', 'string', 'of', 'key', 'patent', 'losses', 'and', 'a', 'spate', 'of', 'clinical', 'trial', 'failures', '-', 'in', 'October', '2012', ',', 'following', 'a', 'stint', 'at', 'pharma', 'peer', 'Roche', '.', 'With', 'the', 'Frenchman', 'at', 'the', 'helm', ',', 'the', 'fortunes', 'of', 'the', 'Anglo-Swedish', 'drugmaker', 'changed', 'dramatically', '.', 'He', 'sharpened', 'focus', 'on', 'speciality', 'medicines', 'and', 'the', 'lucrative', 'field', 'of', 'oncology', ',', 'made', 'acquisitions', 'to', 'refill', 'the', 'company', \"'s\", 'medicine', 'cabinet', ',', 'fended', 'off', 'a', 'hostile', 'takeover', 'from', 'U.S.', 'pharma', 'giant', 'Pfizer', ',', 'and', 'invested', 'heavily', 'in', 'R', '&', 'D', 'to', 'improve', 'the', 'company', \"'s\", 'lacklustre', 'drug', 'development', 'success', 'rate', '.', 'However', ',', 'he', 'warned', 'on', 'Tuesday', 'that', 'fewer', 'new', 'medicines', 'would', 'be', 'developed', 'going', 'forward', 'due', 'to', 'U.S.', 'drug', 'price', 'laws', 'passed', 'last', 'week', '.', 'Asked', 'about', 'inflationary', 'pressures', ',', 'Soriot', 'said', ':', '``', 'We', 'are', 'going', 'to', 'have', 'to', 'become', 'more', 'innovative', 'and', 'productive', '.', 'We', 'ca', \"n't\", 'expect', 'our', 'selling', 'prices', 'to', 'go', 'up', '.', \"''\", 'Sales', 'in', 'China', ',', 'which', 'account', 'for', 'close', 'to', 'a', 'fifth', 'of', 'the', 'company', \"'s\", 'total', 'annual', 'revenue', ',', 'have', 'dipped', 'in', 'recent', 'quarters', 'due', 'to', 'lower', 'drug', 'prices', 'and', 'as', 'COVID', 'lockdown', 'measures', 'kept', 'some', 'patients', 'from', 'being', 'diagnosed', 'and', 'seeking', 'cancer', 'care', '.', 'On', 'Tuesday', ',', 'Soriot', 'said', 'sales', 'were', 'picking', 'up', 'in', 'the', 'third', 'quarter', 'in', 'the', 'world', \"'s\", 'second-largest', 'market', 'for', 'pharmaceuticals', '-', 'and', 'he', 'expected', 'the', 'country', 'to', 'play', 'a', 'more', 'significant', 'role', 'in', 'the', 'global', 'market', 'over', 'the', 'next', 'decade', '.', 'Graphic', ':', 'AstraZeneca', \"'s\", 'shares', 'while', 'CEO', 'Soriot', 'has', 'been', 'at', 'the', 'helm', 'https', ':', '//fingfx.thomsonreuters.com/gfx/mkt/zjvqkblqgvx/AZ.PNG©', 'Reuters', '.', 'People', 'pose', 'with', 'syringe', 'with', 'needle', 'in', 'front', 'of', 'displayed', 'AstraZeneca', 'logo', 'in', 'this', 'illustration', 'taken', ',', 'December', '11', ',', '2021', '.', 'REUTERS/Dado', 'Ruvic/Illustration/Files', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'By', 'Pushkala', 'Aripaka', 'and', 'Natalie', 'Grover', 'LONDON', '(', 'Reuters', ')', '-Europe', \"'s\", 'medicines', 'regulator', 'has', 'backed', 'using', 'AstraZeneca', '(', 'NASDAQ', ':', ')', \"'s\", 'preventative', 'COVID-19', 'therapy', 'as', 'a', 'treatment', 'for', 'the', 'disease', 'and', 'also', 'endorsed', 'another', 'medicine', 'as', 'preventative', 'option', 'for', 'another', 'common', 'virus', '.', 'The', 'regulator', \"'s\", 'recommendations', 'are', 'usually', 'followed', 'by', 'the', 'European', 'Commission', 'when', 'it', 'takes', 'a', 'final', 'decision', 'on', 'drug', 'approvals', '.', 'AstraZeneca', 'said', 'on', 'Friday', 'the', 'European', 'Medicines', 'Agency', '(', 'EMA', ')', 'had', 'backed', 'Evusheld', 'as', 'a', 'treatment', 'for', 'adults', 'and', 'adolescents', 'with', 'COVID', 'who', 'do', 'not', 'need', 'supplemental', 'oxygen', 'and', 'who', 'are', 'at', 'increased', 'risk', 'of', 'their', 'disease', 'worsening', '.', 'Last', 'month', ',', 'Japan', 'became', 'the', 'first', 'country', 'to', 'approve', 'the', 'long-acting', 'antibody', 'as', 'a', 'treatment', 'for', 'COVID', '-', 'making', 'Evusheld', 'the', 'first', 'such', 'therapy', 'authorised', 'for', 'both', 'prevention', 'and', 'treatment', 'of', 'the', 'viral', 'disease', '.', 'Evusheld', 'had', 'previously', 'had', 'largely', 'secured', 'global', 'approvals', ',', 'including', 'in', 'Europe', ',', 'as', 'a', 'preventative', 'therapy', 'for', 'people', 'with', 'compromised', 'immune', 'systems', 'who', 'see', 'little', 'or', 'no', 'benefit', 'from', 'COVID', 'vaccines', '.', 'AstraZeneca', 'is', 'leaning', 'on', 'Evusheld', 'to', 'help', 'offset', 'tepid', 'sales', 'of', 'its', 'COVID', 'vaccine', 'that', 'has', 'rapidly', 'lost', 'ground', 'to', 'mRNA', 'shots', 'in', 'the', 'fight', 'against', 'the', 'rapidly', 'evolving', 'virus', '.', 'Evusheld', ',', 'first', 'launched', 'in', 'December', ',', 'generated', '$', '914', 'million', 'in', 'the', 'first', 'half', 'of', '2022', 'for', 'the', 'Anglo-Swedish', 'drugmaker', '.', 'Separately', 'on', 'Friday', ',', 'the', 'EMA', 'also', 'endorsed', 'AstraZeneca', 'and', 'partner', 'Sanofi', '(', 'EPA', ':', ')', \"'s\", 'experimental', 'long-acting', 'therapy', 'Beyfortus', 'for', 'the', 'prevention', 'of', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'by', 'respiratory', 'syncytial', 'virus', '(', 'RSV', ')', '.', 'RSV', 'causes', 'thousands', 'of', 'hospitalisations', 'and', 'deaths', 'globally', 'each', 'year', 'in', 'toddlers', 'and', 'the', 'elderly', ',', 'but', 'the', 'complex', 'molecular', 'structure', 'of', 'the', 'virus', 'and', 'safety', 'concerns', 'have', 'stymied', 'efforts', 'to', 'develop', 'a', 'vaccine', 'since', 'the', 'virus', 'was', 'first', 'discovered', 'in', '1956', '.', 'But', 'there', 'is', 'one', 'therapy', ',', 'Synagis', ',', 'also', 'developed', 'by', 'AstraZeneca', 'but', 'sold', 'by', 'Swedish', 'Orphan', 'Biovitrum', 'in', 'the', 'United', 'States', '.', 'It', 'is', 'designed', 'to', 'prevent', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'by', 'RSV', 'in', 'high-risk', 'infants', 'and', 'requires', 'up', 'to', 'five', 'injections', 'to', 'cover', 'a', 'typical', 'RSV', 'season', '.', 'Meanwhile', ',', 'if', 'Beyfortus', 'were', 'approved', ',', 'it', 'would', 'be', 'the', 'first', 'single-dose', 'preventative', 'RSV', 'therapy', 'for', 'the', 'broad', 'infant', 'population', '-', 'including', 'those', 'born', 'healthy', 'or', 'are', 'deemed', 'high-risk', '-', 'during', 'their', 'first', 'RSV', 'season.©', 'Reuters', '.', 'FILE', 'PHOTO', ':', 'The', 'company', 'logo', 'for', 'pharmaceutical', 'company', 'AstraZeneca', 'is', 'displayed', 'on', 'a', 'screen', 'on', 'the', 'floor', 'at', 'the', 'New', 'York', 'Stock', 'Exchange', ',', 'U.S.', ',', 'April', '8', ',', '2019', '.', 'REUTERS/Brendan', 'McDermid', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', '(', 'Reuters', ')', '-', 'said', 'on', 'Friday', 'its', 'drug', 'for', 'preventing', 'infant', 'RSV', ',', 'Beyfortus', '(', 'nirsevimab', ')', ',', 'was', 'recommended', 'for', 'approval', 'in', 'the', 'European', 'Union', 'by', 'a', 'European', 'Medicines', 'Agency', 'committee', '.', 'The', 'drugmaker', 'also', 'said', 'if', 'Beyfortus', 'is', 'approved', ',', 'it', 'would', 'become', 'the', 'first', 'protective', 'option', 'for', 'newborn', 'and', 'infant', 'population', 'against', 'RSV', 'lower', 'respiratory', 'tract', 'disease.©', 'Reuters', '.', 'Market', 'movers', ':', 'Property', 'groups', 'fall', 'as', 'Goldman/JPMorgan', 'reduce', 'price', 'targets', 'FDX', '+1.12', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'BLND', '+1.60', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'IDSI', '+3.67', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'TGTB34', '0.00', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'Shares', 'in', 'Land', 'Securities', 'and', 'British', 'Land', 'fell', 'today', 'after', 'both', 'property', 'groups', 'were', 'downgraded', 'by', 'Goldman', 'Sachs', '(', 'NYSE', ':', ')', ',', 'while', 'JP', 'Morgan', 'lowered', 'its', 'price', 'targets', 'on', 'both', 'companies', '.', 'Goldman', 'Sachs', 'downgraded', 'British', 'Land', 'to', 'neutral', 'from', 'buy', 'and', 'reduced', 'its', 'price', 'target', 'to', '410p', 'from', '580p', ',', 'while', 'JPMorgan', '(', 'NYSE', ':', ')', 'cut', 'its', 'price', 'target', 'to', '530p', 'from', '700p', 'but', 'retained', 'its', 'overweight', 'rating', '.', 'On', 'Land', 'Securities', ',', 'Goldman', 'Sachs', 'lowered', 'its', 'rating', 'to', 'sell', 'from', 'neutral', 'and', 'cut', 'its', 'price', 'target', 'to', '500p', 'from', '650p', ',', 'while', 'JPMorgan', 'retained', 'its', 'neutral', 'rating', 'but', 'with', 'a', 'lower', 'price', 'target', 'of', '650p', 'down', 'from', '900p', '.', 'Land', 'Securities', 'fell', '2.7', '%', 'and', 'British', 'Land', 'fell', '0.7', '%', '.', 'Capita', 'lifted', 'by', 'double', 'dose', 'of', 'good', 'news', 'Shares', 'in', 'advanced', 'after', 'it', 'reported', 'a', 'contract', 'extension', 'with', 'Barnet', 'Council', 'and', 'the', 'disposal', 'of', 'its', 'subsidiary', 'Pay360', 'Ltd', 'to', 'Access', 'PaySuite', '.', 'Shares', 'in', 'the', 'outsourcing', 'services', 'group', 'rose', '6.6', '%', 'after', 'securing', 'the', 'contract', 'extension', 'with', 'the', 'north', 'London', 'council', 'that', 'is', 'worth', '£42.7mln', ',', 'although', 'with', 'indexation', 'and', 'potential', 'additional', 'work', 'it', 'could', 'be', 'worth', 'up', 'to', '£57mln', '.', 'Separately', ',', 'Capita', 'said', 'it', 'agreed', 'to', 'dispose', 'of', 'Pay360', 'to', 'the', 'division', 'of', 'Access', 'Group', 'for', '£150mln', 'on', 'a', 'cash-free', ',', 'debt-free', 'basis', '.', 'Capita', 'said', 'the', 'sale', 'will', 'help', 'reduce', 'its', 'debt', ',', 'provide', 'additional', 'liquidity', ',', 'and', 'allow', 'it', 'to', 'enhance', 'its', 'digital', 'offerings', 'for', 'clients', 'and', 'build', 'a', 'more', 'focused', 'and', 'sustainable', 'business', 'for', 'the', 'long', 'term', '.', 'Royal', 'Mail', 'falls', 'after', 'FedEx', 'warning', 'Shares', 'in', 'dipped', 'today', 'following', 'the', 'profits', 'warning', 'by', 'US', 'peer', 'pulled', 'its', 'full', 'year', 'guidance', 'after', 'warning', 'that', 'first', 'quarter', 'profits', 'would', 'miss', 'estimates', 'as', 'a', 'global', 'demand', 'slowdown', 'accelerates', '.', 'It', 'cited', '``', 'macroeconomic', 'weakness', \"''\", 'in', 'Asia', 'and', '``', 'service', 'challenges', \"''\", 'in', 'Europe', '.', 'Investors', 'took', 'the', 'view', 'that', 'industry', 'challenges', 'would', 'be', 'the', 'same', 'for', 'Royal', 'Mail', 'which', 'also', 'faces', 'the', 'prospect', 'of', 'more', 'industrial', 'action', 'as', 'employees', 'strike', 'over', 'higher', 'pay', '.', 'Royal', 'Mail', 'workers', 'represented', 'by', 'the', 'Communication', 'Workers', 'Union', '(', 'CWU', ')', 'had', 'planned', 'a', 'walkout', 'on', '9', 'September', '2022', 'but', 'are', 'now', 'planning', 'to', 'strike', 'on', 'September', '30', 'and', 'October', '1', '2022', '.', 'Shares', 'fell', '10.5', '%', 'to', '223.5p', '.', 'EU', 'drug', 'approvals', 'boost', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'was', 'a', 'rare', 'riser', 'in', 'the', 'after', 'it', 'said', 'today', 'it', 'had', 'received', 'two', 'recommendations', 'for', 'drug', 'approvals', 'in', 'the', 'EU', ',', 'while', 'a', 'drug', 'for', 'blood', 'disorder', 'paroxysmal', 'nocturnal', 'haemoglobinuria', 'met', 'its', 'primary', 'endpoint', 'in', 'a', 'phase', 'three', 'trial', '.', 'The', 'group', 'said', 'its', 'Beyfortus', 'drug', ',', 'which', 'it', 'develops', 'with', 'Sanofi', '(', 'EPA', ':', ')', '.', 'for', 'the', 'prevention', 'of', 'lower', 'respiratory', 'tract', 'disease', 'in', 'newborns', 'and', 'infants', 'has', 'been', 'recommended', 'for', 'marketing', 'authorisation', 'in', 'the', 'European', 'Union', 'Meanwhile', ',', 'AstraZeneca', \"'s\", 'Evusheld', 'Covid', 'antibody', 'treatment', 'has', 'been', 'recommended', 'for', 'marketing', 'authorisation', 'in', 'the', 'EU', 'for', 'adults', 'with', 'the', 'virus', 'at', 'risk', 'of', 'progressing', 'to', 'severe', 'disease', '.', 'The', 'company', 'explained', 'phase', 'III', 'treatment', 'data', 'showed', 'reduced', 'risk', 'of', 'severe', 'Covid', 'or', 'death', '.', 'Shares', 'rose', '1.7', '%', 'following', 'the', 'news', '.', 'Read', 'more', 'on', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'The', 'crypto', 'party', 'started', 'as', 'corporate', 'earnings-induced', 'optimism', 'and', 'hopes', 'of', 'a', 'Fed', 'thawing', 'perked', 'up', 'risk', 'appetite', 'in', 'the', 'financial', 'markets', '.', 'Ethereum', '(', 'CRYPTO', ':', 'ETH', ')', ',', 'the', 'second', '...', '3/3', '©', 'Reuters', '.', 'FILE', 'PHOTO', ':', 'Tablet', 'bottles', 'for', 'AstraZeneca', \"'s\", 'cancer', 'medicine', 'Lynparza', 'seen', 'in', 'an', 'undated', 'handout', 'image', 'provided', 'to', 'Reuters', 'on', 'June', '27', ',', '2022', '.', 'AstraZeneca/Handout', 'via', 'REUTERS', '2/3', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', '(', 'Reuters', ')', '-', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'said', 'on', 'Thursday', 'its', 'drug', 'Lynparza', ',', 'developed', 'with', 'U.S.-based', 'Merck', '&', 'Co', ',', 'was', 'approved', 'by', 'the', 'European', 'Union', 'as', 'an', 'adjuvant', 'treatment', 'for', 'patients', 'with', 'a', 'form', 'of', 'a', 'genetically', 'mutated', 'early-stage', 'breast', 'cancer.©', 'Reuters', 'Daily', 'Biotech', 'Pulse', ':', 'Celyad', 'Resumes', 'Colorectal', 'Cancer', 'Trial', ',', 'Setback', 'For', 'Otonomy', ',', 'AstraZeneca', 'Halts', 'Phase', '3', 'Head', ',', 'Neck', 'Cancer', 'Trial', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'IXIC', '+1.28', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'OTIC', '-2.81', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'BEAM', '-2.75', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'Here', \"'s\", 'a', 'roundup', 'of', 'top', 'developments', 'in', 'the', 'biotech', 'space', 'over', 'the', 'last', '24', 'hours', ':', 'Stocks', 'In', 'Focus', 'Arcutis', 'Psoriasis', 'Treatment', 'Scores', 'FDA', 'Approval', 'The', 'FDA', 'approved', 'Arcutis', 'Biotherapeutics', 'Inc', \"'s\", '(', 'NASDAQ', ':', 'ARQT', ')', 'Zoryve', '(', 'roflumilast', ')', 'cream', '0.3', '%', 'for', 'plaque', 'psoriasis', ',', 'including', 'intertriginous', 'areas', ',', 'in', 'patients', '12', 'years', 'of', 'age', 'or', 'older', '.', 'It', 'is', 'the', 'first', 'and', 'only', 'topical', 'phosphodiesterase-4', 'inhibitor', 'approved', 'for', 'plaque', 'psoriasis', '.', 'The', 'commercial', 'product', 'is', 'expected', 'to', 'be', 'available', 'by', 'mid-August', '.', 'Arcutis', 'expects', 'to', 'draw', 'an', 'additional', '$', '125', 'million', 'from', 'the', 'company', \"'s\", 'debt', 'facility', 'with', 'SLR', 'Capital', 'Partners', '.', 'Shares', 'are', 'up', '3.05', '%', 'at', '$', '25', 'during', 'the', 'premarket', 'session', '.', 'FDA', 'Removes', 'Clinical', 'Hold', 'On', 'Celyad', \"'s\", 'Colorectal', 'Cancer', 'Trial', 'The', 'FDA', 'has', 'lifted', 'the', 'clinical', 'hold', 'on', 'Celyad', 'Oncology', 'SA', \"'s\", '(', 'NASDAQ', ':', 'CYAD', ')', 'CYAD-101-002', '(', 'KEYNOTE-B79', ')', 'Phase', '1b', 'trial', 'after', 'the', 'company', 'made', 'changes', 'to', 'the', 'eligibility', 'criteria', 'for', 'the', 'trial', '.', 'In', 'February', ',', 'the', 'company', 'voluntarily', 'paused', 'the', 'CYAD-101-002', 'trial', 'to', 'investigate', 'reports', 'of', 'two', 'fatalities', 'in', 'the', 'study', '.', 'The', 'FDA', 'subsequently', 'put', 'the', 'trial', 'on', 'clinical', 'hold', 'in', 'March', '.', 'Shares', 'are', 'up', '40.9', '%', 'at', '$', '2.41', 'during', 'the', 'premarket', 'session', '.', 'HUTCHMED', 'Starts', 'Midstage', 'Tazemetostat', 'Study', 'For', 'Lymphoma', 'Setting', 'HUTCHMED', '(', 'China', ')', 'Limited', '(', 'NASDAQ', ':', 'HCM', ')', 'initiated', 'a', 'bridging', 'Phase', '2', 'study', 'of', 'tazemetostat', 'in', 'China', 'for', 'relapsed/refractory', 'follicular', 'lymphoma', '(', 'R/R', 'FL', ')', '.', 'The', 'first', 'patient', 'received', 'their', 'first', 'dose', 'on', 'July', '29', '.', 'The', 'primary', 'objective', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'tazemetostat', 'in', 'R/R', 'FL', 'patients', 'with', 'mutations', 'in', 'EZH21', '(', 'Cohort', '1', ')', '.', 'The', 'secondary', 'objectives', 'are', 'to', 'evaluate', 'the', 'efficacy', 'of', 'tazemetostat', 'for', 'R/R', 'FL', 'with', 'EZH2', 'wild-type', '.', 'Related', ':', 'Biotech', 'Investors', ':', 'August', \"'s\", 'Key', 'PDUFA', 'Catalysts', 'You', 'Must', 'Know', '.', 'FDA', 'Signs', 'Off', 'On', 'Eledon', 'Pharma', \"'s\", 'Tegoprubart', 'For', 'Kidnety', 'Transplant', 'Rejection', 'The', 'FDA', 'has', 'cleared', 'Eledon', 'Pharmaceuticals', 'Inc', \"'s\", '(', 'NASDAQ', ':', 'ELDN', ')', 'Investigational', 'New', 'Drug', '(', 'IND', ')', 'application', 'to', 'evaluate', 'tegoprubart', 'for', 'preventing', 'organ', 'rejection', 'in', 'patients', 'receiving', 'a', 'kidney', 'transplant', '.', 'The', 'IND-opening', 'phase', '2', 'study', 'will', 'enroll', 'approximately', '120', 'participants', 'undergoing', 'a', 'kidney', 'transplant', '.', 'Kazia', 'Shares', 'Fall', 'After', 'Update', 'From', 'Pivotal', 'Brain', 'Tumor', 'Trial', 'Kazia', 'Therapeutics', 'Limited', '(', 'NASDAQ', ':', 'KZIA', ')', 'said', 'GBM', 'AGILE', ',', 'a', 'pivotal', 'study', 'for', 'paxalisib', 'in', 'newly', 'diagnosed', 'glioblastoma', ',', 'did', 'not', 'meet', 'pre-defined', 'criteria', 'for', 'continuing', 'to', 'a', 'second', 'stage', '.', 'Patients', 'enrolled', 'in', 'the', 'first', 'stage', 'of', 'the', 'paxalisib', 'arm', 'will', 'continue', 'on', 'treatment', 'as', 'per', 'protocol', ',', 'and', 'in', 'follow-up', ',', 'until', 'completion', 'of', 'the', 'final', 'analysis', ',', 'which', 'Kazia', 'anticipates', 'receiving', 'in', 'the', 'second', 'half', 'of', '2023', '.', 'The', 'company', 'will', 'not', 'open', 'the', 'study', \"'s\", 'paxalisib', 'arm', 'in', 'Germany', 'or', 'China', '.', 'Shares', 'are', 'down', '38.3', '%', 'at', '$', '2.24', 'during', 'the', 'premarket', 'session', '.', 'FDA', 'Places', 'Clinical', 'Hold', 'On', 'Beam', 'Therapeutics', \"'\", 'IND', 'Application', 'For', 'Blood', 'Cancer', 'Study', 'The', 'FDA', 'has', 'placed', 'a', 'clinical', 'hold', 'on', 'Beam', 'Therapeutics', 'Inc', \"'s\", '(', 'NASDAQ', ':', 'BEAM', ')', 'BEAM-201', 'Investigational', 'New', 'Drug', '(', 'IND', ')', 'application', 'for', 'relapsed/refractory', 'T-cell', 'acute', 'lymphoblastic', 'leukemia/T', 'cell', 'lymphoblastic', 'lymphoma', '.', 'The', 'BEAM-201', 'IND', 'was', 'submitted', 'at', 'the', 'end', 'of', 'June', '.', 'The', 'FDA', 'indicated', 'it', 'would', 'provide', 'Beam', 'with', 'an', 'official', 'clinical', 'hold', 'letter', 'within', '30', 'days', '.', 'Beam', 'plans', 'to', 'provide', 'additional', 'updates', 'pending', 'discussion', 'with', 'the', 'FDA', '.', 'Otonomy', 'Shares', 'Sink', 'After', 'Stopping', 'Midstage', 'Tinnitus', 'Study', 'Otonomy', 'Inc', '(', 'NASDAQ', ':', 'OTIC', ')', 'has', 'announced', 'that', 'the', 'OTO-313', 'Phase', '2', 'trial', 'in', 'tinnitus', 'demonstrated', 'no', 'clinically', 'meaningful', 'benefit', 'versus', 'placebo', 'for', 'primary', 'and', 'secondary', 'endpoints', 'across', 'all', 'time', 'points', '.', 'The', '153-subject', 'study', 'did', 'show', 'a', 'higher', 'response', 'rate', 'than', 'placebo', 'in', 'a', 'prospectively', 'defined', 'patient', 'subgroup', 'with', 'tinnitus', 'duration', 'of', 'fewer', 'than', 'six', 'months', '(', 'population', 'studied', 'in', 'Phase', '1/2', 'trial', ')', '.', 'The', 'overall', 'results', 'do', 'not', 'support', 'further', 'development', 'of', 'OTO-313', '.', 'Shares', 'are', 'slipping', '60.8', '%', 'at', '56', 'cents', 'during', 'the', 'premarket', 'session', '.', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'Cuts', 'Innate-Partnered', 'Phase', '3', 'Trial', 'In', 'Head', ',', 'Neck', 'Cancer', 'Innate', 'Pharma', 'SA', \"'s\", '(', 'NASDAQ', ':', 'IPHA', ')', 'futility', 'interim', 'analysis', 'of', 'the', 'INTERLINK-1', 'Phase', '3', 'study', 'sponsored', 'by', 'AstraZeneca', 'Plc', '(', 'NASDAQ', ':', 'AZN', ')', 'did', 'not', 'meet', 'a', 'pre-defined', 'threshold', 'for', 'efficacy', '.', 'Based', 'on', 'this', 'result', 'and', 'the', 'recommendation', 'of', 'an', 'Independent', 'Data', 'Monitoring', 'Committee', ',', 'AstraZeneca', 'has', 'informed', 'Innate', 'that', 'the', 'study', 'will', 'be', 'discontinued', '.', 'There', 'were', 'no', 'new', 'safety', 'findings', '.', 'AstraZeneca', 'plans', 'to', 'share', 'the', 'data', 'in', 'due', 'course', '.', 'IPHA', 'shares', 'are', 'down', '16.3', '%', 'at', '$', '2.68', 'during', 'the', 'premarket', 'session', '.', 'ALX', 'Oncology', \"'s\", 'Evorpacept', 'Fast', 'Tracked', 'In', 'US', 'For', 'Head', ',', 'Neck', 'Cancer', 'The', 'FDA', 'has', 'granted', 'Fast', 'Track', 'designation', 'to', 'ALX', 'Oncology', 'Holdings', 'Inc', \"'s\", '(', 'NASDAQ', ':', 'ALXO', ')', 'evorpacept', 'in', 'combination', 'with', 'Merck', '&', 'Co', 'Inc', \"'s\", '(', 'NYSE', ':', 'MRK', ')', 'Keytruda', 'for', 'the', 'first-line', 'treatment', 'of', 'PD-L1', 'positive', 'advanced', 'head', 'and', 'neck', 'squamous', 'cell', 'carcinoma', '.', 'The', 'FDA', \"'s\", 'decision', 'is', 'informed', 'by', 'the', 'results', 'of', 'ALX', 'Oncology', \"'s\", 'phase', '1', 'study', 'that', 'showed', 'preliminary', 'antitumor', 'activity', 'and', 'a', 'favorable', 'safety', 'profile', '.', 'Shares', 'are', 'up', '5.48', '%', 'at', '$', '10.26', 'during', 'the', 'premarket', 'session', '.', 'Offerings', 'TherapeuticsMD', 'Inc', '(', 'NASDAQ', ':', 'TXMD', ')', 'has', 'received', 'a', '$', '15-million', 'private', 'investment', 'in', 'the', 'company', \"'s\", 'common', 'stock', 'and', 'a', 'new', 'series', 'of', 'preferred', 'stock', 'from', 'Rubric', 'Capital', 'Management', 'LP', '.', 'On', 'The', 'Radar', 'Earnings', 'Cerevel', 'Therapeutics', 'Holdings', 'Inc', '(', 'NASDAQ', ':', 'CERE', ')', ':', 'Before', 'the', 'market', 'open', '.', '©', '2022', 'Benzinga.com', '.', 'Benzinga', 'does', 'not', 'provide', 'investment', 'advice', '.', 'All', 'rights', 'reserved', '.', 'Read', 'at', 'Benzinga', 'Read', 'the', 'original', 'article', 'on', 'Benzinga©', 'Reuters', 'EUR/USD', '+2.12', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'UK100', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'XAU/USD', '+3.17', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'FCHI', '+2.77', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'DE30', '+2.51', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'HNKG_p', '+1.07', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'Gold', '+3.36', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'LCO', '+4.31', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'CL', '+5.02', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+1.77', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', '2222', '-0.29', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'By', 'Peter', 'Nurse', 'Investing.com', '-', 'European', 'stock', 'markets', 'largely', 'edged', 'higher', 'Monday', ',', 'starting', 'the', 'new', 'week', 'on', 'a', 'cautious', 'note', 'as', 'investors', 'digested', 'weak', 'Chinese', 'economic', 'data', '.', 'By', '04:15', 'ET', '(', '08:15', 'GMT', ')', ',', 'the', 'in', 'Germany', 'traded', '0.1', '%', 'lower', ',', 'but', 'the', 'in', 'France', 'rose', '0.2', '%', ',', 'and', 'U.K.', '’', 's', 'traded', '0.2', '%', 'higher', '.', 'Economic', 'data', 'released', 'earlier', 'Monday', 'showed', 'China', '’', 's', 'economic', 'growth', 'rate', 'unexpectedly', 'slowing', 'in', 'July', ',', 'prompting', 'the', 'country', '’', 's', 'central', 'bank', 'to', 'in', 'a', 'surprise', 'move', '.', 'grew', '3.8', '%', 'in', 'July', 'from', 'a', 'year', 'earlier', ',', 'with', 'the', 'growth', 'rate', 'below', 'the', '4.6', '%', 'increase', 'expected', ',', 'while', 'rose', '2.7', '%', 'from', 'a', 'year', 'ago', ',', 'missing', 'forecasts', 'for', '5.0', '%', 'growth', 'and', 'the', '3.1', '%', 'growth', 'seen', 'in', 'June', '.', 'China', \"'s\", 'economy', ',', 'the', 'world', '’', 's', 'second', 'largest', ',', 'is', 'struggling', 'to', 'shake', 'off', 'the', 'June', 'quarter', \"'s\", 'hit', 'to', 'growth', 'from', 'strict', 'COVID', 'restrictions', '.', 'On', 'the', 'flip', 'side', ',', 'back', 'in', 'Europe', ',', 'Denmark', '’', 's', 'economy', 'grew', 'faster', 'than', 'expected', 'in', 'the', 'second', 'quarter', ',', 'expanding', '0.7', '%', 'from', 'the', 'first', 'three', 'months', 'of', 'the', 'year', ',', 'after', 'contracted', '0.5', '%', 'in', 'the', 'first', 'quarter', 'of', '2022', '.', 'The', 'raised', 'interest', 'rates', 'by', 'a', 'half-point', 'in', 'July', 'and', 'is', 'expected', 'to', 'do', 'the', 'same', 'in', 'September', ',', 'even', 'though', 'the', 'risk', 'of', 'a', 'Eurozone', 'recession', 'has', 'reached', 'the', 'highest', 'level', 'since', 'November', '2020', 'as', 'energy', 'shortages', 'threaten', 'to', 'drive', 'already', 'record', 'inflation', 'higher', 'still', '.', 'In', 'corporate', 'news', ',', 'AstraZeneca', '(', 'LON', ':', ')', '(', 'NASDAQ', ':', ')', 'stock', 'rose', '2.6', '%', 'after', 'the', 'drugmaker', 'said', 'its', 'cancer', 'drug', ',', 'Enhertu', ',', 'delayed', 'the', 'progression', 'of', 'a', 'form', 'of', 'advanced', 'breast', 'cancer', 'in', 'previously', 'treated', 'patients', ',', 'boosting', 'prospects', 'of', 'more', 'regulatory', 'approvals', '.', 'Henkel', '(', 'ETR', ':', ')', 'stock', 'rose', '0.4', '%', 'after', 'the', 'German', 'consumer-goods', 'company', 'said', 'sales', 'rose', 'in', 'the', 'first', 'half', 'of', 'the', 'year', 'but', 'that', 'earnings', 'fell', ',', 'hurt', 'by', 'increasing', 'raw-material', 'and', 'logistics', 'prices', '.', 'Oil', 'prices', 'fell', 'Monday', ',', 'weighed', 'by', 'a', 'potential', 'increase', 'in', 'supply', 'by', 'oil', 'giant', 'Saudi', 'Aramco', '(', 'TADAWUL', ':', ')', 'as', 'well', 'as', 'concerns', 'of', 'slowing', 'growth', 'in', 'China', ',', 'the', 'world', \"'s\", 'second-largest', 'economy', '.', 'Saudi', 'Aramco', 'stands', 'ready', 'to', 'raise', 'crude', 'oil', 'output', 'to', 'its', 'maximum', 'capacity', 'of', '12', 'million', 'barrels', 'per', 'day', 'if', 'requested', 'to', 'do', 'so', 'by', 'the', 'Saudi', 'Arabian', 'government', ',', 'Chief', 'Executive', 'Amin', 'Nasser', 'said', 'Sunday', ',', 'as', 'the', 'state-owned', 'energy', 'firm', 'announced', 'one', 'of', 'the', 'largest', 'quarterly', 'profits', 'in', 'history', '.', 'By', '04:15', 'ET', ',', 'futures', 'traded', '1.9', '%', 'lower', 'at', '$', '90.39', 'a', 'barrel', ',', 'while', 'the', 'contract', 'fell', '1.7', '%', 'to', '$', '96.49', '.', 'Additionally', ',', 'fell', '0.7', '%', 'to', '$', '1,802.15/oz', ',', 'while', 'traded', '0.3', '%', 'lower', 'at', '1.0229.©', 'Reuters', '.', 'FILE', 'PHOTO', ':', 'Signage', 'is', 'seen', 'outside', 'the', 'entrance', 'of', 'the', 'London', 'Stock', 'Exchange', 'in', 'London', ',', 'Britain', '.', 'Aug', '23', ',', '2018', '.', 'REUTERS/Peter', 'Nicholls/File', 'Photo', 'UK100', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'FTSE', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'A1ZN34', '-0.97', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'ENRY', '+2.33', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'By', 'Sruthi', 'Shankar', '(', 'Reuters', ')', '-UK', \"'s\", 'edged', 'up', 'on', 'Monday', 'as', 'gains', 'in', 'drugmaker', 'AstraZeneca', '(', 'NASDAQ', ':', ')', 'and', 'consumer', 'stocks', 'relieved', 'pressure', 'from', 'mining', 'and', 'oil', 'heavyweights', 'after', 'data', 'showed', 'China', \"'s\", 'economy', 'unexpectedly', 'slowed', 'last', 'month', '.', 'The', 'blue-chip', 'FTSE', '100', 'added', '0.2', '%', 'to', 'hold', 'near', '10-week', 'highs', ',', 'while', 'the', 'midcap', 'inched', 'up', '0.1', '%', '.', 'Investors', 'are', 'awaiting', 'the', 'UK', 'employment', 'report', 'as', 'well', 'as', 'consumer', 'prices', 'data', 'later', 'this', 'week', 'to', 'gauge', 'the', 'state', 'of', 'the', 'labour', 'market', 'and', 'inflation', '.', 'The', 'data', 'could', 'offer', 'clues', 'on', 'whether', 'the', 'Bank', 'of', 'England', 'opts', 'for', 'a', 'second', 'consecutive', '50-basis-point-rate', 'hike', 'at', 'its', 'September', 'meeting', '.', 'The', 'mood', 'was', 'dull', 'in', 'Asian', 'and', 'European', 'stock', 'markets', ',', 'with', 'investors', 'turning', 'to', 'defensive', 'sectors', 'such', 'as', 'healthcare', 'and', 'consumer', 'staples', 'amid', 'worries', 'about', 'the', 'health', 'of', 'the', 'world', \"'s\", 'second-largest', 'economy', '.', 'AstraZeneca', 'gained', '2.6', '%', 'after', 'the', 'drugmaker', 'said', 'its', 'cancer', 'drug', ',', 'Enhertu', ',', 'developed', 'with', 'Japan', \"'s\", 'Daiichi', 'Sankyo', 'delayed', 'the', 'progression', 'of', 'a', 'form', 'of', 'advanced', 'breast', 'cancer', 'in', 'previously', 'treated', 'patients', '.', 'Oil', 'major', 'Shell', '(', 'LON', ':', ')', 'and', 'miners', 'Rio', 'Tinto', '(', 'LON', ':', ')', 'and', 'Anglo', 'American', '(', 'LON', ':', ')', 'slipped', ',', 'in', 'tandem', 'with', 'weaker', 'commodity', 'prices', ',', 'after', 'the', 'release', 'of', 'the', 'China', 'data', '.', '[', 'O/R', ']', '[', 'MET/L', ']', 'The', 'FTSE', '100', 'has', 'outperformed', 'its', 'global', 'peers', 'this', 'year', 'due', 'to', 'its', 'large', 'exposure', 'to', 'commodity', 'stocks', 'that', 'have', 'surged', 'on', 'the', 'back', 'of', 'a', 'jump', 'in', 'oil', 'and', 'metal', 'prices', '.', 'A', 'weakening', 'pound', 'has', 'also', 'boosted', 'dollar', 'earners', 'in', 'the', 'index', '.', '``', 'Whether', 'this', 'trend', 'will', 'continue', 'ultimately', 'hinges', 'on', 'the', 'outlook', 'for', 'global', 'energy', 'stocks', 'relative', 'to', 'the', 'broad', 'market', ',', \"''\", 'BCA', 'Research', 'analysts', 'wrote', 'in', 'a', 'note', '.', 'The', 'FTSE', '100', 'is', 'up', 'nearly', '2', '%', 'so', 'far', 'this', 'year', ',', 'while', 'the', 'MSCI', 'world', 'equities', 'index', 'has', 'shed', 'almost', '13', '%', '.', '``', 'Our', 'energy', 'strategists', 'remain', 'bullish', 'on', 'oil', '.', 'Their', 'expectation', 'that', 'will', 'breach', '$', '110/bbl', 'in', 'Q4', 'and', 'average', '$', '117/bbl', 'in', '2023', 'suggests', 'that', 'an', 'overweight', 'on', 'the', 'energy', 'sector', '–', 'and', 'by', 'extension', 'UK', 'equities', '–', 'remains', 'appropriate', '.', '``', '©', 'Reuters', '.', 'FTSE', '100', 'positive', 'but', 'off', 'early', 'highs', 'UK100', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'DJI', '+1.26', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'BWY', '+2.01', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'BDEV', '+2.42', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'TW', '+3.38', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'FTMC', '+1.28', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'PHNX', '+1.47', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'IXIC', '+1.28', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'FTSE', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+1.77', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'CHNA', '+0.00', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'slips', 'back', 'after', 'making', 'a', 'bright', 'start', 'Chinese', 'retail', 'sales', ',', 'output', 'numbers', 'below', 'forecast', 'UK', 'house', 'prices', 'fall', 'in', 'August', '-', 'Rightmove', 'FTSE', '100', 'failed', 'to', 'hold', 'strong', 'early', 'gains', 'and', 'slipped', 'back', 'close', 'to', 'parity', 'as', 'disappointing', 'economic', 'data', 'in', 'China', 'took', 'the', 'shine', 'off', 'further', 'gains', 'in', 'the', 'US', 'on', 'Friday', '.', 'At', '9.00am', 'the', 'lead', 'index', 'was', 'trading', '11.42', 'points', 'to', 'the', 'good', 'at', '7,512.31', '.', 'Richard', 'Hunter', ',', 'head', 'of', 'markets', 'at', 'interactive', 'investor', ',', 'said', '“', 'Economic', 'news', 'from', 'China', 'threatened', 'to', 'spoil', 'the', 'party', 'after', 'US', 'markets', 'staged', 'a', 'strong', 'rally', 'at', 'the', 'end', 'of', 'last', 'week.', '”', '“', 'Amid', 'geopolitical', 'tensions', 'as', 'a', 'delegation', 'of', 'US', 'lawmakers', 'arrive', 'for', 'a', 'further', 'trip', 'to', 'Taiwan', ',', 'Chinese', 'economic', 'data', 'revealed', 'the', 'ongoing', 'impact', 'of', 'Covid-19', 'lockdowns', 'and', 'an', 'escalating', 'property', 'crisis.', '”', '“', 'Retail', 'sales', 'and', 'industrial', 'output', 'both', 'rose', ',', 'but', 'by', 'less', 'than', 'expected', 'in', 'July', ',', 'alongside', 'a', 'disappointing', 'showing', 'from', 'bank', 'lending.', '”', 'But', 'he', 'said', '“', 'the', 'UK', 'market', 'chose', 'to', 'take', 'its', 'lead', 'from', 'Wall', 'Street', ',', 'notwithstanding', 'the', 'fact', 'that', 'the', 'Bank', 'of', 'England', 'is', 'set', 'to', 'maintain', 'its', 'aggressive', 'interest', 'rate', 'stance', 'in', 'the', 'face', 'of', 'persistent', 'inflation', 'in', 'the', 'UK.', '”', 'AstraZeneca', 'PLC', '(', 'LSE', ':', 'NASDAQ', ':', ')', 'shares', 'rose', '2.1', '%', 'to', '10,931p', 'as', 'the', 'pharmaceuticals', 'group', 'said', 'that', 'positive', 'high-level', 'results', 'from', 'a', 'new', 'trial', 'of', 'its', 'Enhertu', 'breast', 'cancer', 'drug', 'had', 'demonstrated', 'a', '``', 'statistically', 'significant', 'and', 'clinically', 'meaningful', 'improvement', \"''\", 'in', 'progression-free', 'survival', '.', 'AstraZeneca', 'said', 'the', 'DESTINY-Breast02', 'Phase', 'III', 'trial', 'on', 'Enhertu', ',', 'jointly', 'developed', 'and', 'commercialised', 'with', 'Daiichi', 'Sankyo', ',', 'also', 'met', 'its', 'key', 'secondary', 'endpoint', 'of', 'improved', 'overall', 'survival', '.', 'But', 'housebuilders', ',', 'Berkeley', 'Group', 'Holdings', 'PLC', '(', 'LSE', ':', 'BKG', ')', '(', 'down', '1.35', '%', ')', ',', 'Bellway', '(', 'LON', ':', ')', '(', 'down', '1', '%', ')', ',', 'Taylor', 'Wimpey', '(', 'LON', ':', ')', '(', 'down', '0.5', '%', ')', 'and', 'Barratt', 'Developments', '(', 'LON', ':', ')', '(', 'down', '0.5', '%', ')', 'all', 'fell', 'following', 'a', 'report', 'from', 'Rightmove', 'that', 'house', 'prices', 'slipped', 'in', 'August.8.15am', ':', 'Positive', 'start', 'to', 'proceedings', 'in', 'London', '8.15am', ':', 'London', 'upbeat', 'in', 'early', 'trading', 'FTSE', '100', 'makes', 'a', 'positive', 'start', 'to', 'trading', 'boosted', 'by', 'gains', 'in', 'the', 'US', 'on', 'Friday', 'and', 'despite', 'mixed', 'performances', 'in', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'and', 'industrial', 'output', 'figures', '.', 'At', '8.15am', 'the', 'lead', 'index', 'was', 'trading', '35.03', 'points', 'higher', 'at', '7,535.92', 'with', 'the', 'broader', 'up', '47.07', 'points', 'at', '20.386.03', '.', 'Latest', 'data', 'from', 'online', 'property', 'website', 'Rightmove', 'showed', 'the', 'first', 'fall', 'in', 'UK', 'house', 'prices', 'this', 'year', 'with', 'the', 'average', 'price', 'of', 'property', 'coming', 'to', 'market', 'down', 'to', '£365,173', '–', 'down', '1.3', '%', '.', 'However', ',', 'Tim', 'Bannister', ',', 'Rightmove', '’', 's', 'director', 'of', 'property', 'science', ',', 'says', ':', '“', 'A', 'drop', 'in', 'asking', 'prices', 'is', 'to', 'be', 'expected', 'this', 'month', 'after', 'a', 'frenzied', 'two', 'years', 'and', 'many', 'would-be', 'home', 'movers', 'become', 'distracted', 'by', 'the', 'summer', 'holidays.', '”', '“', 'Indeed', ',', 'for', 'those', 'that', 'can', ',', 'this', 'may', 'be', 'their', 'first', 'summer', 'holiday', 'abroad', 'since', 'before', 'the', 'pandemic.', '”', 'Bannister', 'also', 'pointed', 'out', 'that', 'price', 'growth', 'for', 'the', 'year', 'would', 'still', 'be', '7', '%', '.', 'The', 'number', 'of', 'properties', 'currently', 'on', 'the', 'market', 'to', 'buy', 'is', 'down', '39', '%', 'on', 'pre-pandemic', 'levels', 'but', 'despite', 'the', 'lack', 'of', 'instructions', 'new', 'listings', 'rose', '12', '%', 'compared', 'to', 'the', 'same', 'time', 'last', 'year', 'but', 'were', 'down', '6', '%', 'compared', 'to', '2019', '.', 'Bannister', 'also', 'said', 'the', 'recent', 'interest', 'rate', 'increases', 'by', 'the', 'Bank', 'of', 'England', 'were', '“', 'not', 'having', 'a', 'significant', 'impact', 'on', 'the', 'number', 'of', 'people', 'wanting', 'to', 'move.', '”', '7.30am', ':', 'FTSE', '100', 'seen', 'higher', 'London', 'markets', 'are', 'expected', 'to', 'open', 'higher', 'on', 'Monday', 'following', 'gains', 'in', 'the', 'US', 'on', 'Friday', 'and', 'following', 'the', 'surprise', 'news', 'that', 'China', 'has', 'cut', 'a', 'key', 'interest', 'rate', ',', 'in', 'a', 'bid', 'to', 'boost', 'its', 'stuttering', 'economy', ',', 'following', 'weaker', 'than', 'expected', 'retail', 'sales', 'and', 'industrial', 'output', 'figures', '.', 'Investors', 'will', 'also', 'have', 'one', 'eye', 'on', 'UK', 'jobs', 'and', 'inflation', 'reports', 'due', 'out', 'later', 'this', 'week', 'to', 'see', 'whether', 'there', 'are', 'signs', 'of', 'a', 'slowdown', 'in', 'the', 'jobs', 'market', 'or', 'in', 'prices', 'growth', '.', 'Spread', 'betting', 'companies', 'are', 'calling', 'the', 'FTSE', '100', 'up', 'by', 'around', '35', 'points', '.', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'at', 'CMC', 'Markets', 'UK', 'said', ':', '“', 'Despite', 'the', 'slow', 'drip', 'feed', 'of', 'negative', 'headlines', 'of', 'rising', 'gas', 'prices', ',', 'and', 'the', 'supply', 'chain', 'challenges', 'thrown', 'up', 'by', 'the', 'heatwave', 'in', 'Europe', ',', 'there', '’', 's', 'been', 'little', 'appetite', 'to', 'drive', 'stocks', 'lower', 'in', 'recent', 'weeks.', '”', '“', 'Asia', 'markets', 'have', 'got', 'off', 'to', 'a', 'positive', 'start', 'to', 'the', 'week', ',', 'with', 'the', 'latest', 'retail', 'sales', 'and', 'industrial', 'production', 'numbers', 'for', 'China', 'showing', 'an', 'economy', 'that', 'still', 'appears', 'low', 'on', 'confidence', 'when', 'it', 'comes', 'to', 'consumer', 'spending', ',', 'and', 'economic', 'activity', 'more', 'broadly.', '”', '“', 'This', 'weakness', 'in', 'the', 'Chinese', 'economy', 'comes', 'against', 'the', 'struggle', 'to', 'adapt', 'to', 'a', 'zero-covid', 'policy', ',', 'which', 'the', 'government', 'shows', 'little', 'sign', 'of', 'relaxing', ',', 'against', 'a', 'backdrop', 'of', 'rising', 'cases.', '”', '“', 'Problems', 'in', 'the', 'property', 'sector', 'also', 'aren', '’', 't', 'helping', ',', 'where', 'many', 'home', 'buyers', 'are', 'halting', 'mortgage', 'payments', 'in', 'protest', 'at', 'delays', 'to', 'the', 'completion', 'of', 'new', 'homes.', '”', '“', 'In', 'June', 'we', 'saw', 'the', 'effects', 'the', 'zero-covid', 'policy', 'has', 'had', 'on', 'the', 'Chinese', 'economy', ',', 'with', 'a', '-2.6', '%', 'contraction', 'for', 'Q2', ',', 'although', 'we', 'have', 'started', 'to', 'see', 'some', 'signs', 'of', 'a', 'pick-up', 'in', 'economic', 'activity', ',', 'albeit', 'from', 'a', 'very', 'low', 'base.', '”', '“', 'This', 'morning', '’', 's', 'retail', 'sales', 'numbers', 'for', 'July', 'have', 'confirmed', 'how', 'fragile', 'this', 'confidence', 'still', 'is', ',', 'rising', '2.7', '%', 'well', 'below', 'expectations', 'of', '5', '%', ',', 'and', 'weaker', 'than', 'in', 'June.', '”', '“', 'Industrial', 'production', 'has', 'been', 'more', 'robust', 'and', 'recovered', 'much', 'better', ',', 'however', 'even', 'here', 'economic', 'activity', 'disappointed', 'in', 'July', ',', 'slipping', 'back', 'from', '3.9', '%', 'in', 'June', ',', 'to', '3.8', '%', '.', '”', 'In', 'London', ',', 'on', 'a', 'quieter', 'day', 'for', 'company', 'results', ',', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'which', 'showed', 'strong', 'cash', 'generation', 'of', '£950mln', 'against', '£872mln', 'in', 'the', 'six', 'months', 'to', 'June', '2021', '.', 'The', 'FTSE', '100-listed', 'closed', 'book', 'life', 'insurer', ',', 'said', 'it', 'was', 'now', 'confident', 'of', 'delivering', 'at', 'the', 'top-end', 'of', 'its', '£1.3bn-to-£1.4bn', 'target', 'range', 'for', 'the', 'year', '.', 'New', 'business', 'long-term', 'cash', 'generation', 'was', 'a', 'record', '£430mln', 'in', 'the', 'period', 'and', 'more', 'than', 'double', 'the', 'first', 'half', 'of', '2021', 'at', '£206mln', '.', '7.00am', ':', 'FTSE', '100', 'set', 'to', 'open', 'higher', 'FTSE', '100', 'set', 'to', 'start', 'the', 'week', 'in', 'positive', 'fashion', 'following', 'gains', 'in', 'the', 'US', 'on', 'Friday', '.', 'Spread', 'betting', 'companies', 'are', 'calling', 'the', 'blue', 'chip', 'index', 'up', 'by', 'around', '32', 'points', '.', 'The', 'closed', 'Friday', 'up', '424', 'points', ',', '1.3', '%', ',', 'at', '33,761', ',', 'the', 'jumped', '267', 'points', ',', '2.1', '%', ',', 'to', '13,047', 'and', 'the', 'S', '&', 'P', '500', 'added', '73', 'points', ',', '1.7', '%', ',', 'to', 'reach', '4,280', '.', 'The', 'benchmarks', 'ended', 'the', 'week', 'on', 'a', 'high', 'note', ',', 'clinching', 'the', 'fourth-straight', 'winning', 'week', 'for', 'the', 'Nasdaq', 'Composite', 'and', 'S', '&', 'P', '500', '.', 'Investors', 'have', 'reacted', 'positively', 'to', 'CPI', 'and', 'PPI', 'data', 'released', 'this', 'week', 'that', 'suggested', 'inflation', 'may', 'have', 'already', 'peaked', '.', 'Read', 'more', 'on', 'Proactive', 'Investors', 'UK', 'Disclaimer©', 'Reuters', '.', 'FTSE', '100', 'positive', 'but', 'off', 'early', 'highs', 'UK100', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'DJI', '+1.26', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'BWY', '+2.01', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'BDEV', '+2.42', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'TW', '+3.38', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'FTMC', '+1.28', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'PHNX', '+1.47', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'IXIC', '+1.28', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'FTSE', '+2.03', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+1.77', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'CHNA', '+0.00', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'slips', 'back', 'after', 'making', 'a', 'bright', 'start', 'Chinese', 'retail', 'sales', ',', 'output', 'numbers', 'below', 'forecast', 'UK', 'house', 'prices', 'fall', 'in', 'August', '-', 'Rightmove', 'FTSE', '100', 'failed', 'to', 'hold', 'strong', 'early', 'gains', 'and', 'slipped', 'back', 'close', 'to', 'parity', 'as', 'disappointing', 'economic', 'data', 'in', 'China', 'took', 'the', 'shine', 'off', 'further', 'gains', 'in', 'the', 'US', 'on', 'Friday', '.', 'At', '9.00am', 'the', 'lead', 'index', 'was', 'trading', '11.42', 'points', 'to', 'the', 'good', 'at', '7,512.31', '.', 'Richard', 'Hunter', ',', 'head', 'of', 'markets', 'at', 'interactive', 'investor', ',', 'said', '“', 'Economic', 'news', 'from', 'China', 'threatened', 'to', 'spoil', 'the', 'party', 'after', 'US', 'markets', 'staged', 'a', 'strong', 'rally', 'at', 'the', 'end', 'of', 'last', 'week.', '”', '“', 'Amid', 'geopolitical', 'tensions', 'as', 'a', 'delegation', 'of', 'US', 'lawmakers', 'arrive', 'for', 'a', 'further', 'trip', 'to', 'Taiwan', ',', 'Chinese', 'economic', 'data', 'revealed', 'the', 'ongoing', 'impact', 'of', 'Covid-19', 'lockdowns', 'and', 'an', 'escalating', 'property', 'crisis.', '”', '“', 'Retail', 'sales', 'and', 'industrial', 'output', 'both', 'rose', ',', 'but', 'by', 'less', 'than', 'expected', 'in', 'July', ',', 'alongside', 'a', 'disappointing', 'showing', 'from', 'bank', 'lending.', '”', 'But', 'he', 'said', '“', 'the', 'UK', 'market', 'chose', 'to', 'take', 'its', 'lead', 'from', 'Wall', 'Street', ',', 'notwithstanding', 'the', 'fact', 'that', 'the', 'Bank', 'of', 'England', 'is', 'set', 'to', 'maintain', 'its', 'aggressive', 'interest', 'rate', 'stance', 'in', 'the', 'face', 'of', 'persistent', 'inflation', 'in', 'the', 'UK.', '”', 'AstraZeneca', 'PLC', '(', 'LSE', ':', 'NASDAQ', ':', ')', 'shares', 'rose', '2.1', '%', 'to', '10,931p', 'as', 'the', 'pharmaceuticals', 'group', 'said', 'that', 'positive', 'high-level', 'results', 'from', 'a', 'new', 'trial', 'of', 'its', 'Enhertu', 'breast', 'cancer', 'drug', 'had', 'demonstrated', 'a', '``', 'statistically', 'significant', 'and', 'clinically', 'meaningful', 'improvement', \"''\", 'in', 'progression-free', 'survival', '.', 'AstraZeneca', 'said', 'the', 'DESTINY-Breast02', 'Phase', 'III', 'trial', 'on', 'Enhertu', ',', 'jointly', 'developed', 'and', 'commercialised', 'with', 'Daiichi', 'Sankyo', ',', 'also', 'met', 'its', 'key', 'secondary', 'endpoint', 'of', 'improved', 'overall', 'survival', '.', 'But', 'housebuilders', ',', 'Berkeley', 'Group', 'Holdings', 'PLC', '(', 'LSE', ':', 'BKG', ')', '(', 'down', '1.35', '%', ')', ',', 'Bellway', '(', 'LON', ':', ')', '(', 'down', '1', '%', ')', ',', 'Taylor', 'Wimpey', '(', 'LON', ':', ')', '(', 'down', '0.5', '%', ')', 'and', 'Barratt', 'Developments', '(', 'LON', ':', ')', '(', 'down', '0.5', '%', ')', 'all', 'fell', 'following', 'a', 'report', 'from', 'Rightmove', 'that', 'house', 'prices', 'slipped', 'in', 'August.8.15am', ':', 'Positive', 'start', 'to', 'proceedings', 'in', 'London', '8.15am', ':', 'London', 'upbeat', 'in', 'early', 'trading', 'FTSE', '100', 'makes', 'a', 'positive', 'start', 'to', 'trading', 'boosted', 'by', 'gains', 'in', 'the', 'US', 'on', 'Friday', 'and', 'despite', 'mixed', 'performances', 'in', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'and', 'industrial', 'output', 'figures', '.', 'At', '8.15am', 'the', 'lead', 'index', 'was', 'trading', '35.03', 'points', 'higher', 'at', '7,535.92', 'with', 'the', 'broader', 'up', '47.07', 'points', 'at', '20.386.03', '.', 'Latest', 'data', 'from', 'online', 'property', 'website', 'Rightmove', 'showed', 'the', 'first', 'fall', 'in', 'UK', 'house', 'prices', 'this', 'year', 'with', 'the', 'average', 'price', 'of', 'property', 'coming', 'to', 'market', 'down', 'to', '£365,173', '–', 'down', '1.3', '%', '.', 'However', ',', 'Tim', 'Bannister', ',', 'Rightmove', '’', 's', 'director', 'of', 'property', 'science', ',', 'says', ':', '“', 'A', 'drop', 'in', 'asking', 'prices', 'is', 'to', 'be', 'expected', 'this', 'month', 'after', 'a', 'frenzied', 'two', 'years', 'and', 'many', 'would-be', 'home', 'movers', 'become', 'distracted', 'by', 'the', 'summer', 'holidays.', '”', '“', 'Indeed', ',', 'for', 'those', 'that', 'can', ',', 'this', 'may', 'be', 'their', 'first', 'summer', 'holiday', 'abroad', 'since', 'before', 'the', 'pandemic.', '”', 'Bannister', 'also', 'pointed', 'out', 'that', 'price', 'growth', 'for', 'the', 'year', 'would', 'still', 'be', '7', '%', '.', 'The', 'number', 'of', 'properties', 'currently', 'on', 'the', 'market', 'to', 'buy', 'is', 'down', '39', '%', 'on', 'pre-pandemic', 'levels', 'but', 'despite', 'the', 'lack', 'of', 'instructions', 'new', 'listings', 'rose', '12', '%', 'compared', 'to', 'the', 'same', 'time', 'last', 'year', 'but', 'were', 'down', '6', '%', 'compared', 'to', '2019', '.', 'Bannister', 'also', 'said', 'the', 'recent', 'interest', 'rate', 'increases', 'by', 'the', 'Bank', 'of', 'England', 'were', '“', 'not', 'having', 'a', 'significant', 'impact', 'on', 'the', 'number', 'of', 'people', 'wanting', 'to', 'move.', '”', '7.30am', ':', 'FTSE', '100', 'seen', 'higher', 'London', 'markets', 'are', 'expected', 'to', 'open', 'higher', 'on', 'Monday', 'following', 'gains', 'in', 'the', 'US', 'on', 'Friday', 'and', 'following', 'the', 'surprise', 'news', 'that', 'China', 'has', 'cut', 'a', 'key', 'interest', 'rate', ',', 'in', 'a', 'bid', 'to', 'boost', 'its', 'stuttering', 'economy', ',', 'following', 'weaker', 'than', 'expected', 'retail', 'sales', 'and', 'industrial', 'output', 'figures', '.', 'Investors', 'will', 'also', 'have', 'one', 'eye', 'on', 'UK', 'jobs', 'and', 'inflation', 'reports', 'due', 'out', 'later', 'this', 'week', 'to', 'see', 'whether', 'there', 'are', 'signs', 'of', 'a', 'slowdown', 'in', 'the', 'jobs', 'market', 'or', 'in', 'prices', 'growth', '.', 'Spread', 'betting', 'companies', 'are', 'calling', 'the', 'FTSE', '100', 'up', 'by', 'around', '35', 'points', '.', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'at', 'CMC', 'Markets', 'UK', 'said', ':', '“', 'Despite', 'the', 'slow', 'drip', 'feed', 'of', 'negative', 'headlines', 'of', 'rising', 'gas', 'prices', ',', 'and', 'the', 'supply', 'chain', 'challenges', 'thrown', 'up', 'by', 'the', 'heatwave', 'in', 'Europe', ',', 'there', '’', 's', 'been', 'little', 'appetite', 'to', 'drive', 'stocks', 'lower', 'in', 'recent', 'weeks.', '”', '“', 'Asia', 'markets', 'have', 'got', 'off', 'to', 'a', 'positive', 'start', 'to', 'the', 'week', ',', 'with', 'the', 'latest', 'retail', 'sales', 'and', 'industrial', 'production', 'numbers', 'for', 'China', 'showing', 'an', 'economy', 'that', 'still', 'appears', 'low', 'on', 'confidence', 'when', 'it', 'comes', 'to', 'consumer', 'spending', ',', 'and', 'economic', 'activity', 'more', 'broadly.', '”', '“', 'This', 'weakness', 'in', 'the', 'Chinese', 'economy', 'comes', 'against', 'the', 'struggle', 'to', 'adapt', 'to', 'a', 'zero-covid', 'policy', ',', 'which', 'the', 'government', 'shows', 'little', 'sign', 'of', 'relaxing', ',', 'against', 'a', 'backdrop', 'of', 'rising', 'cases.', '”', '“', 'Problems', 'in', 'the', 'property', 'sector', 'also', 'aren', '’', 't', 'helping', ',', 'where', 'many', 'home', 'buyers', 'are', 'halting', 'mortgage', 'payments', 'in', 'protest', 'at', 'delays', 'to', 'the', 'completion', 'of', 'new', 'homes.', '”', '“', 'In', 'June', 'we', 'saw', 'the', 'effects', 'the', 'zero-covid', 'policy', 'has', 'had', 'on', 'the', 'Chinese', 'economy', ',', 'with', 'a', '-2.6', '%', 'contraction', 'for', 'Q2', ',', 'although', 'we', 'have', 'started', 'to', 'see', 'some', 'signs', 'of', 'a', 'pick-up', 'in', 'economic', 'activity', ',', 'albeit', 'from', 'a', 'very', 'low', 'base.', '”', '“', 'This', 'morning', '’', 's', 'retail', 'sales', 'numbers', 'for', 'July', 'have', 'confirmed', 'how', 'fragile', 'this', 'confidence', 'still', 'is', ',', 'rising', '2.7', '%', 'well', 'below', 'expectations', 'of', '5', '%', ',', 'and', 'weaker', 'than', 'in', 'June.', '”', '“', 'Industrial', 'production', 'has', 'been', 'more', 'robust', 'and', 'recovered', 'much', 'better', ',', 'however', 'even', 'here', 'economic', 'activity', 'disappointed', 'in', 'July', ',', 'slipping', 'back', 'from', '3.9', '%', 'in', 'June', ',', 'to', '3.8', '%', '.', '”', 'In', 'London', ',', 'on', 'a', 'quieter', 'day', 'for', 'company', 'results', ',', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'which', 'showed', 'strong', 'cash', 'generation', 'of', '£950mln', 'against', '£872mln', 'in', 'the', 'six', 'months', 'to', 'June', '2021', '.', 'The', 'FTSE', '100-listed', 'closed', 'book', 'life', 'insurer', ',', 'said', 'it', 'was', 'now', 'confident', 'of', 'delivering', 'at', 'the', 'top-end', 'of', 'its', '£1.3bn-to-£1.4bn', 'target', 'range', 'for', 'the', 'year', '.', 'New', 'business', 'long-term', 'cash', 'generation', 'was', 'a', 'record', '£430mln', 'in', 'the', 'period', 'and', 'more', 'than', 'double', 'the', 'first', 'half', 'of', '2021', 'at', '£206mln', '.', '7.00am', ':', 'FTSE', '100', 'set', 'to', 'open', 'higher', 'FTSE', '100', 'set', 'to', 'start', 'the', 'week', 'in', 'positive', 'fashion', 'following', 'gains', 'in', 'the', 'US', 'on', 'Friday', '.', 'Spread', 'betting', 'companies', 'are', 'calling', 'the', 'blue', 'chip', 'index', 'up', 'by', 'around', '32', 'points', '.', 'The', 'closed', 'Friday', 'up', '424', 'points', ',', '1.3', '%', ',', 'at', '33,761', ',', 'the', 'jumped', '267', 'points', ',', '2.1', '%', ',', 'to', '13,047', 'and', 'the', 'S', '&', 'P', '500', 'added', '73', 'points', ',', '1.7', '%', ',', 'to', 'reach', '4,280', '.', 'The', 'benchmarks', 'ended', 'the', 'week', 'on', 'a', 'high', 'note', ',', 'clinching', 'the', 'fourth-straight', 'winning', 'week', 'for', 'the', 'Nasdaq', 'Composite', 'and', 'S', '&', 'P', '500', '.', 'Investors', 'have', 'reacted', 'positively', 'to', 'CPI', 'and', 'PPI', 'data', 'released', 'this', 'week', 'that', 'suggested', 'inflation', 'may', 'have', 'already', 'peaked', '.', 'Read', 'more', 'on', 'Proactive', 'Investors', 'UK', 'DisclaimerAVEPp', '0.00', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'ROG', '-1.66', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'RHHVF', '-1.31', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'SNY', '+1.82', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'AZN', '+0.56', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'SASY', '+0.55', '%', 'Add', 'to/Remove', 'from', 'a', 'Portfolio', 'By', 'Scott', 'Kanowsky', 'Investing.com', '--', 'Sanofi', 'SA', '(', 'EPA', ':', ')', 'shares', 'slid', 'on', 'Wednesday', 'after', 'the', 'French', 'drugmaker', 'announced', 'that', 'it', 'will', 'halt', 'trials', 'of', 'a', 'new', 'treatment', 'for', 'patients', 'battling', 'advanced', 'breast', 'cancer', '.', 'In', 'a', 'statement', ',', 'the', 'company', 'said', 'it', 'would', 'stop', 'global', 'clinical', 'development', 'of', 'the', 'medicine', ',', 'known', 'as', 'amcenestrant', ',', 'after', 'a', 'phase', '3', 'study', 'showed', 'it', 'was', 'not', 'effective', 'enough', 'to', 'warrant', 'further', 'research', '.', 'All', 'other', 'studies', 'of', 'amcenestrant', ',', 'including', 'in', 'early-stage', 'breast', 'cancer', ',', 'will', 'also', 'be', 'discontinued', ',', 'Sanofi', 'added', '.', '“', 'While', 'we', 'are', 'disappointed', 'by', 'this', 'outcome', ',', 'our', 'research', 'will', 'further', 'the', 'scientific', 'understanding', 'of', 'endocrine', 'therapies', 'in', 'people', 'with', 'breast', 'cancer', ',', \"''\", 'said', 'John', 'Reed', ',', 'global', 'head', 'of', 'research', 'and', 'development', 'at', 'Sanofi', '.', 'In', 'a', 'note', ',', 'analysts', 'at', 'Morgan', 'Stanley', 'called', 'the', 'decision', 'a', '``', 'setback', 'for', 'the', 'innovation', 'narrative', \"''\", 'put', 'forward', 'by', 'Sanofi', ',', 'saying', 'that', 'amcenestrant', 'had', 'been', 'flagged', 'as', 'a', 'potentially', 'lucrative', 'piece', 'in', 'the', 'group', \"'s\", 'drug', 'pipeline', '.', 'The', 'end', 'of', 'Sanofi', \"'s\", 'amcenestrant', 'trials', 'is', 'expected', 'to', 'lead', 'to', 'a', '6', '%', 'negative', 'impact', 'on', 'the', 'company', \"'s\", 'estimated', 'discounted', 'cash', 'flow', ',', 'according', 'to', 'the', 'Morgan', 'Stanley', 'analysts', '.', 'The', 'decision', 'could', 'also', 'have', 'a', 'knock-on', 'effect', 'on', 'studies', 'being', 'conducted', 'on', 'similar', 'breast', 'cancer', 'drugs', 'from', 'Sanofi', 'rivals', 'Roche', '(', 'SIX', ':', ')', 'and', 'AstraZeneca', 'PLC', '(', 'LON', ':', ')', ',', 'the', 'analysts', 'added', '.']...>"
            ]
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "zYyb6YXUgJ1A"
      },
      "source": [
        "### 4.2 Removing Stopwords\n",
        "\n",
        "Stopwords are some of the most common words and are necessary for sentences to be grammatically correct (e.g. a, is, an, the, and). However, they carry very little or no useful information and are filtered out as part of the text preprocessing stage to remove noise so that machine learning algorithms can better focus on the signal, or words which define the meaning of the text.\n",
        "\n",
        "We will use the list from nltk.corpus and exclude tokens with characters that are not alphabetical using the isalpha() method."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6lonk7thOAdC",
        "outputId": "2d2068c3-b72e-432f-a127-111b4a831c3f"
      },
      "source": [
        "stop_words = set(stopwords.words('english'))\n",
        "\n",
        "# Iterate through all tokens for all articles \n",
        "filtered_articles = [[word for word in article if not word in stop_words if word.isalpha()] for article in tokens]\n",
        "print(stop_words)\n",
        "print(filtered_articles)"
      ],
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'most', 'is', 'ain', 'aren', 'my', 'nor', 'so', \"couldn't\", 'weren', \"it's\", \"weren't\", 'off', 'of', 's', 'having', 'her', 'they', 'there', 'its', 'with', 'few', 're', 'wasn', 'than', 'any', 'each', 'mightn', 'his', \"you're\", 'too', 'now', 'o', 'ma', \"you've\", 'am', 'all', \"mightn't\", 'we', 'and', 'in', \"she's\", 'if', 'into', 'above', 'herself', 'these', 'or', 'doing', 'where', 'd', \"that'll\", 'are', 'our', 'she', 'he', 'couldn', 'yourselves', 'very', 'll', 'other', 'yours', 'who', 'itself', \"don't\", 'why', 'such', 'at', 'under', 'isn', 'did', 'no', 'this', 'hasn', 'their', 'an', 'but', 'them', \"won't\", 'during', 'your', 'it', \"isn't\", \"aren't\", 'didn', 'over', 'before', 'a', 'what', 'you', 'have', 'some', 'hadn', 'mustn', 'more', 'for', 'be', 'yourself', 'how', \"you'll\", \"mustn't\", \"you'd\", 'ours', 'through', 'own', \"shan't\", 'hers', 'been', 'which', 'from', 'the', 'has', 'not', 'needn', 'shouldn', 'both', 'after', 'further', 'when', 've', 'because', \"doesn't\", 'out', 'myself', 'as', 'him', 'against', 'while', 'doesn', 'shan', \"hadn't\", 'do', 'was', 'were', 'won', \"didn't\", 'being', 'don', 'm', 'ourselves', \"hasn't\", 'those', 'himself', 'theirs', 'whom', 'to', 'i', 'themselves', 'does', 'had', 'down', 'me', 'here', 'between', 'only', \"needn't\", 'same', \"wasn't\", 'should', \"haven't\", \"shouldn't\", 'can', 'then', 'on', 'until', 'will', 'haven', 'wouldn', 'below', 'that', 'once', 'y', 'about', 'just', \"should've\", 'up', 'again', \"wouldn't\", 'by', 't'}\n",
            "[['AstraZeneca', 'PLC', 'said', 'Wednesday', 'Capivasertib', 'plus', 'Faslodex', 'significantly', 'improved', 'survival', 'compared', 'Faslodex', 'combined', 'placebo', 'Phase', 'trial', 'advanced', 'hormone', 'breast', 'cancer', 'The', 'pharma', 'giant', 'AZN', 'AZN', 'said', 'trial', 'met', 'primary', 'endpoints', 'improving', 'survival', 'overall', 'patient', 'population', 'prespecified', 'biomarker', 'subgroup', 'patients', 'whose', 'tumors', 'qualifying', 'Touts', 'Positive', 'Data', 'From', 'Two', 'Experimental', 'Drugs', 'In', 'Breast', 'Cancer', 'SettingsAstraZeneca', 'Ultomiris', 'Showed', 'Zero', 'Relapses', 'In', 'Patients', 'With', 'Chronic', 'Disorder', 'Of', 'Brain', 'Spinal', 'CordAstraZeneca', 'NASDAQ', 'AZN', 'announced', 'Tuesday', 'vaccine', 'Vaxzevria', 'Recombinant', 'given', 'full', 'Marketing', 'Authorisation', 'MA', 'European', 'Union', 'EU', 'Vaxzevria', 'originally', 'granted', 'conditional', 'Marketing', 'Authorisation', 'cMA', 'EU', 'AstraZeneca', 'stated', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefits', 'Vaxzevria', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Iskra', 'Reic', 'EVP', 'Vaccines', 'Immune', 'Therapies', 'AstraZeneca', 'commented', 'The', 'move', 'conditional', 'full', 'marketing', 'authorisation', 'Vaxzevria', 'important', 'confirmation', 'EMA', 'safety', 'efficacy', 'Vaxzevria', 'demonstrating', 'benefits', 'continue', 'outweigh', 'potential', 'risks', 'Vaxzevria', 'estimated', 'helped', 'save', 'six', 'million', 'lives', 'first', 'year', 'vaccination', 'reflects', 'strength', 'evidence', 'showing', 'Vaxzevria', 'protection', 'severe', 'disease', 'death', 'caused', 'The', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Marketing', 'Authorisation', 'AstraZeneca', 'Plc', 'AZN', 'vaccine', 'Vaxzevria', 'Recombinant', 'vaccine', 'Vaxzevria', 'Recombinant', 'Vaxzevria', 'initially', 'granted', 'conditional', 'Marketing', 'Authorisation', 'due', 'urgency', 'pandemic', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefits', 'Vaxzevria', 'EMA', 'granted', 'full', 'approval', 'The', 'approval', 'covers', 'use', 'Vaxzevria', 'primary', 'vaccination', 'series', 'heterologous', 'approved', 'mRNA', 'vaccine', 'homologous', 'vaccine', 'booster', 'Related', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'Vaxzevria', 'demonstrated', 'effective', 'forms', 'mild', 'symptomatic', 'severe', 'disease', 'including', 'hospitalization', 'death', 'according', 'clinical', 'studies', 'evidence', 'These', 'include', 'expert', 'review', 'data', 'studies', 'showed', 'Vaxzevria', 'available', 'mRNA', 'vaccines', 'provide', 'equally', 'effective', 'protection', 'hospitalization', 'death', 'following', 'three', 'doses', 'There', 'also', 'substantial', 'body', 'evidence', 'supporting', 'boosting', 'Vaxzevria', 'following', 'primary', 'vaccination', 'schedules', 'tested', 'date', 'Price', 'Action', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Tuesday', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Tuesday', 'Photo', 'Paul', 'McManus', 'Pixabay', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'Shifts', 'China', 'Factory', 'Workers', 'To', 'US', 'Plant', 'Complete', 'European', 'Approval', 'For', 'AstraZeneca', 'Shot', 'Tesla', 'Eyes', 'Cybertruck', 'Commercialization', 'Next', 'Year', 'Top', 'Stories', 'Tuesday', 'The', 'European', 'Commission', 'approved', 'AstraZeneca', 'plc', 'AZN', 'Sanofi', 'SA', 'SNY', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'first', 'RSV', 'season', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'first', 'RSV', 'season', 'Beyfortus', 'first', 'RSV', 'passive', 'immunization', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'preterm', 'specific', 'health', 'conditions', 'In', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', 'LRTI', 'caused', 'RSV', 'placebo', 'day', 'single', 'dose', 'Beyfortus', 'also', 'demonstrated', 'comparable', 'safety', 'tolerability', 'profile', 'Swedish', 'Orphan', 'Biovitrum', 'AB', 'BIOVF', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Globally', 'approximately', 'million', 'cases', 'acute', 'lower', 'respiratory', 'infections', 'leading', 'three', 'million', 'hospitalizations', 'It', 'estimated', 'deaths', 'children', 'younger', 'five', 'years', 'Price', 'Action', 'SNY', 'shares', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Friday', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'Reuters', 'AstraZeneca', 'shares', 'get', 'lift', 'heartburn', 'drug', 'litigation', 'closure', 'says', 'Citi', 'AZN', 'Add', 'Portfolio', 'LFCOF', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'NASDAQ', 'get', 'boost', 'probability', 'close', 'US', 'kidney', 'damage', 'lawsuit', 'New', 'Jersey', 'prior', 'first', 'bellwether', 'case', 'March', 'according', 'analysts', 'Citi', 'The', 'UK', 'pharma', 'one', 'several', 'firms', 'embroiled', 'US', 'legal', 'action', 'possible', 'damage', 'caused', 'proton', 'pump', 'inhibitor', 'PPI', 'heartburn', 'drugs', 'Nexium', 'launched', 'Astra', 'US', 'The', 'Citi', 'analysts', 'believe', 'likely', 'outcome', 'judge', 'delaying', 'response', 'Defendant', 'Motion', 'summary', 'judgement', 'grounds', 'encourage', 'plaintiffs', 'settle', 'Alternatively', 'lower', 'probability', 'Judge', 'Cecchi', 'may', 'delayed', 'start', 'bellwether', 'cases', 'disagrees', 'conclusions', 'Special', 'Master', 'Reisman', 'grants', 'defendant', 'motion', 'dismiss', 'grounds', 'said', 'Either', 'scenario', 'would', 'materially', 'positive', 'Astra', 'depressed', 'share', 'price', 'US', 'bank', 'analysts', 'added', 'would', 'positive', 'interim', 'data', 'Enhertu', 'positive', 'data', 'March', 'The', 'Citi', 'analysts', 'said', 'core', 'EPS', 'forecasts', 'Astra', 'consensus', 'repeated', 'alongside', 'price', 'target', 'recommendation', 'Shares', 'Astra', 'rose', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'The', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Astrazeneca', 'Beyfortus', 'receives', 'EU', 'approval', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'NASDAQ', 'stated', 'Beyfortus', 'first', 'RSV', 'passive', 'immunisation', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'specific', 'health', 'conditions', 'The', 'group', 'said', 'European', 'Commission', 'first', 'regulatory', 'body', 'grant', 'approval', 'Beyfortus', 'approval', 'based', 'results', 'drug', 'clinical', 'development', 'programme', 'follows', 'recommendation', 'The', 'Committee', 'Medicinal', 'Products', 'Human', 'Use', 'European', 'Medicines', 'Agency', 'September', 'In', 'AZN', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'RSV', 'versus', 'placebo', 'day', 'single', 'dose', 'Iskra', 'Eric', 'AZN', 'executive', 'vice', 'president', 'vaccines', 'immune', 'therapies', 'said', 'Beyfortus', 'first', 'preventative', 'option', 'respiratory', 'syncytial', 'virus', 'gain', 'approval', 'Europe', 'also', 'first', 'preventative', 'option', 'approved', 'broad', 'infant', 'population', 'Today', 'marketing', 'authorisation', 'Beyfortus', 'marks', 'significant', 'achievement', 'scientific', 'community', 'addresses', 'persistent', 'global', 'unmet', 'need', 'RSV', 'prevention', 'Reporting', 'Iain', 'Gilbert', 'Read', 'Reuters', 'AstraZeneca', 'says', 'Evusheld', 'approved', 'treatment', 'EU', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'said', 'antibody', 'combination', 'Evusheld', 'tixagevimab', 'cilgavimab', 'formerly', 'approved', 'EU', 'treatment', 'The', 'approval', 'European', 'Commission', 'covers', 'people', 'age', 'years', 'require', 'supplemental', 'oxygen', 'increased', 'risk', 'progressing', 'severe', 'pharmaceuticals', 'group', 'said', 'The', 'European', 'Commission', 'approval', 'based', 'results', 'TACKLE', 'phase', 'III', 'treatment', 'trial', 'showed', 'Evusheld', 'significantly', 'reduced', 'risk', 'severe', 'death', 'The', 'recommended', 'dose', 'Evusheld', 'treatment', 'Europe', 'tixagevimab', 'cilgavimab', 'administered', 'two', 'separate', 'sequential', 'IM', 'injections', 'AstraZeneca', 'NASDAQ', 'noted', 'Many', 'people', 'including', 'immunocompromised', 'older', 'adults', 'underlying', 'health', 'conditions', 'high', 'risk', 'severe', 'disease', 'hospitalisation', 'death', 'become', 'infected', 'Evusheld', 'delivered', 'convenient', 'intramuscular', 'formulation', 'new', 'treatment', 'option', 'vulnerable', 'populations', 'commented', 'Dr', 'Michel', 'Goldman', 'professor', 'Institute', 'Interdisciplinary', 'Innovation', 'Healthcare', 'Université', 'Libre', 'de', 'Bruxelles', 'former', 'executive', 'director', 'European', 'Innovative', 'Medicines', 'Initiative', 'statement', 'Iskra', 'Reic', 'executive', 'vice', 'president', 'vaccines', 'immune', 'therapies', 'AstraZeneca', 'added', 'remains', 'ongoing', 'health', 'concern', 'millions', 'Europeans', 'around', 'world', 'especially', 'may', 'virus', 'vaccination', 'With', 'approval', 'Evusheld', 'antibody', 'combination', 'available', 'prevention', 'treatment', 'Europe', 'allowing', 'us', 'protect', 'even', 'people', 'devastating', 'disease', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'AstraZeneca', 'gets', 'third', 'regulatory', 'green', 'light', 'matter', 'weeks', 'asthma', 'drug', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'said', 'Tezspire', 'treatment', 'approved', 'Japan', 'severe', 'bronchial', 'asthma', 'traditional', 'corticosteroids', 'work', 'It', 'third', 'approval', 'matter', 'weeks', 'product', 'potential', 'challenger', 'market', 'leader', 'Dupxient', 'It', 'developed', 'collaboration', 'US', 'giant', 'Amgen', 'NASDAQ', 'In', 'clinical', 'trials', 'drug', 'shown', 'lower', 'researchers', 'called', 'asthma', 'exacerbations', 'Tezspire', 'first', 'biologic', 'approved', 'Japanese', 'Ministry', 'Health', 'Labour', 'Welfare', 'shown', 'consistently', 'significantly', 'reduce', 'attacks', 'exacerbation', 'trials', 'broad', 'population', 'severe', 'asthma', 'patients', 'irrespective', 'biomarker', 'levels', 'Mene', 'Pangalos', 'head', 'biopharmaceutical', 'research', 'AZ', 'Tezspire', 'potential', 'improve', 'outcomes', 'many', 'patients', 'severe', 'asthma', 'working', 'make', 'important', 'medicine', 'available', 'Japan', 'quickly', 'Analysts', 'believe', 'Tezspire', 'could', 'big', 'seller', 'peak', 'sales', 'projected', 'order', 'US', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FILE', 'PHOTO', 'The', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'Shares', 'LogicBio', 'Therapeutics', 'skyrocketed', 'Monday', 'Britain', 'AstraZeneca', 'NASDAQ', 'said', 'would', 'buy', 'gene', 'therapy', 'developer', 'rare', 'premium', 'million', 'LoigBio', 'shares', 'traded', 'since', 'February', 'bell', 'close', 'AstraZeneca', 'offer', 'price', 'per', 'share', 'LogicBio', 'developing', 'gene', 'editing', 'therapies', 'treat', 'pediatric', 'rare', 'disease', 'like', 'methylmalonic', 'acidemia', 'body', 'break', 'certain', 'proteins', 'fats', 'AstraZeneca', 'said', 'deal', 'would', 'accelerate', 'growth', 'Alexion', 'NASDAQ', 'unit', 'acquired', 'billion', 'last', 'year', 'field', 'genomic', 'Benzinga', 'The', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'AstraZeneca', 'says', 'combination', 'approved', 'advanced', 'liver', 'cancer', 'US', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'announced', 'US', 'Food', 'Drug', 'Administration', 'FDA', 'approved', 'company', 'Imjudo', 'tremelimumab', 'drug', 'combination', 'Imfinzi', 'durvalumab', 'treatment', 'adult', 'patients', 'unresectable', 'hepatocellular', 'carcinoma', 'HCC', 'common', 'type', 'liver', 'cancer', 'The', 'approval', 'based', 'results', 'HIMALAYA', 'Phase', 'III', 'trial', 'showed', 'single', 'priming', 'dose', 'antibody', 'Imjudo', 'added', 'antibody', 'Imfinzi', 'reduced', 'risk', 'death', 'compared', 'sorafenib', 'pharmaceuticals', 'company', 'said', 'Liver', 'cancer', 'cause', 'cancer', 'death', 'sixth', 'commonly', 'diagnosed', 'cancer', 'worldwide', 'It', 'cause', 'deaths', 'US', 'approximately', 'new', 'diagnoses', 'year', 'company', 'said', 'In', 'statement', 'Dave', 'Fredrickson', 'executive', 'vice', 'president', 'oncology', 'business', 'unit', 'AstraZeneca', 'commented', 'With', 'first', 'regulatory', 'approval', 'Imjudo', 'patients', 'unresectable', 'liver', 'cancer', 'US', 'approved', 'dual', 'immunotherapy', 'treatment', 'regimen', 'harnesses', 'potential', 'inhibition', 'unique', 'combination', 'inhibitor', 'enhance', 'immune', 'response', 'cancer', 'Dr', 'Ghassan', 'attending', 'physician', 'Memorial', 'Sloan', 'Kettering', 'Cancer', 'Center', 'MSK', 'principal', 'investigator', 'HIMALAYA', 'Phase', 'III', 'trial', 'said', 'Patients', 'unresectable', 'liver', 'cancer', 'need', 'treatments', 'meaningfully', 'extend', 'overall', 'survival', 'In', 'addition', 'regimen', 'demonstrating', 'favourable', 'survival', 'rate', 'HIMALAYA', 'trial', 'safety', 'data', 'showed', 'increase', 'severe', 'liver', 'toxicity', 'bleeding', 'risk', 'combination', 'important', 'factors', 'patients', 'liver', 'cancer', 'also', 'advanced', 'liver', 'disease', 'Regulatory', 'applications', 'Imjudo', 'combination', 'Imfinzi', 'currently', 'review', 'Europe', 'Japan', 'several', 'countries', 'treatment', 'patients', 'advanced', 'liver', 'cancer', 'based', 'HIMALAYA', 'results', 'AstraZeneca', 'said', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'Prostate', 'Cancer', 'Combo', 'Drug', 'Try', 'For', 'scPharma', 'FDA', 'Panel', 'Decisions', 'And', 'More', 'October', 'Key', 'PDUFA', 'Catalysts', 'Biotech', 'Investors', 'Must', 'Know', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'KECR', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Most', 'FDA', 'decisions', 'scheduled', 'September', 'yielded', 'positive', 'results', 'stray', 'disappointments', 'well', 'Seven', 'new', 'molecular', 'entities', 'NMEs', 'approved', 'month', 'taking', 'total', 'NME', 'approvals', 'year', 'This', 'far', 'less', 'approvals', 'received', 'time', 'last', 'year', 'NMEs', 'considered', 'measure', 'innovation', 'drug', 'research', 'contain', 'active', 'moieties', 'ingredients', 'previously', 'approved', 'Food', 'Drug', 'Administration', 'Among', 'positive', 'verdicts', 'bluebird', 'bio', 'NASDAQ', 'BLUE', 'million', 'gene', 'therapy', 'Skysona', 'approved', 'treating', 'rare', 'neurodegenerative', 'disorder', 'boys', 'Amylyx', 'Pharmaceuticals', 'NASDAQ', 'AMLX', 'scored', 'win', 'amyotrophic', 'sclerosis', 'treatment', 'Revance', 'Therapeutics', 'NASDAQ', 'RVNC', 'Botox', 'rival', 'Daxxify', 'approved', 'treating', 'frown', 'lines', 'Spectrum', 'Pharmaceuticals', 'NASDAQ', 'SPPI', 'mixed', 'month', 'Rolvedon', 'approved', 'treating', 'neutropenia', 'lung', 'cancer', 'drug', 'get', 'backing', 'FDA', 'panel', 'Here', 'key', 'PDUFA', 'dates', 'scheduled', 'October', 'Will', 'Theratech', 'Score', 'A', 'Win', 'For', 'A', 'More', 'Convenient', 'Formulation', 'Of', 'Its', 'HIV', 'Drug', 'Company', 'Theratechnologies', 'NASDAQ', 'THTX', 'Type', 'Application', 'supplemental', 'biologic', 'license', 'application', 'Candidate', 'Trogarzo', 'Indication', 'Date', 'In', 'fourth', 'quarter', 'company', 'filed', 'sBLA', 'intravenous', 'push', 'mode', 'administration', 'Trogarzo', 'treating', 'human', 'immunodeficiency', 'virus', 'type', 'Trogarzo', 'first', 'approved', 'FDA', 'March', 'treat', 'adult', 'patients', 'HIV', 'In', 'quarter', 'ended', 'May', 'drug', 'generated', 'sales', 'million', 'Theratech', 'Alnylam', 'On', 'Course', 'For', 'Snagging', 'Label', 'Expansion', 'For', 'Oxlumo', 'Company', 'Alnylam', 'NASDAQ', 'ALNY', 'Type', 'Application', 'supplemental', 'new', 'drug', 'application', 'Candidate', 'Oxlumo', 'Indication', 'hyperoxaluria', 'Type', 'Date', 'Oxlumo', 'goes', 'generic', 'name', 'lumasiran', 'RNAi', 'therapeutic', 'evaluated', 'reduction', 'plasma', 'oxalate', 'patients', 'advanced', 'hyperoxaluria', 'type', 'rare', 'disorder', 'mainly', 'affects', 'kidneys', 'due', 'accumulation', 'substance', 'called', 'oxalate', 'normally', 'filtered', 'kidneys', 'excreted', 'urine', 'This', 'therapy', 'first', 'approved', 'lowering', 'urinary', 'oxalate', 'labels', 'pediatric', 'adult', 'patients', 'In', 'second', 'quarter', 'fetched', 'company', 'million', 'sales', 'sequentially', 'See', 'also', 'Alzheimer', 'Progression', 'Slowed', 'Down', 'By', 'Biogen', 'NASDAQ', 'New', 'Drug', 'In', 'Study', 'Analyst', 'Sees', 'Can', 'Third', 'Time', 'Be', 'Charm', 'For', 'scPharma', 'Company', 'scPharmaceuticals', 'NASDAQ', 'SCPH', 'Type', 'Application', 'NDA', 'Candidate', 'Furoscix', 'Indication', 'worsening', 'heart', 'failure', 'due', 'congestion', 'Date', 'Furoscix', 'proprietary', 'furosemide', 'solution', 'evaluated', 'outpatient', 'alternative', 'treatment', 'worsening', 'congestive', 'heart', 'failure', 'This', 'scPharma', 'third', 'try', 'Furoscix', 'following', 'complete', 'response', 'letter', 'Go', 'Amicus', 'Pome', 'Disease', 'Treatment', 'Company', 'Amicus', 'Therapeutics', 'NASDAQ', 'FOLD', 'Type', 'Application', 'BLA', 'Candidate', 'cipaglucosidase', 'alfa', 'Indication', 'Pompe', 'disease', 'Date', 'investigational', 'therapy', 'consists', 'cipaglucosidase', 'alfa', 'administered', 'conjunction', 'miglustat', 'yet', 'approved', 'FDA', 'The', 'therapy', 'evaluated', 'inherited', 'lysosomal', 'disorder', 'called', 'Pome', 'disease', 'The', 'disease', 'debilitating', 'characterized', 'severe', 'muscle', 'weakness', 'worsens', 'time', 'It', 'ranges', 'rapidly', 'fatal', 'infantile', 'form', 'significant', 'impacts', 'heart', 'function', 'slowly', 'progressive', 'form', 'primarily', 'affecting', 'skeletal', 'muscle', 'It', 'estimated', 'Pompe', 'disease', 'affects', 'approximately', 'people', 'worldwide', 'Supernus', 'Hopes', 'For', 'No', 'Hiccups', 'In', 'Parkinson', 'Disease', 'Drug', 'Approval', 'Company', 'Supernus', 'Pharmaceuticals', 'NASDAQ', 'SUPN', 'Type', 'Application', 'NDA', 'Candidate', 'apomorphine', 'infusion', 'device', 'Indication', 'OFF', 'episodes', 'Parkinson', 'disease', 'Date', 'Early', 'October', 'Supernus', 'initial', 'application', 'seeking', 'approval', 'shot', 'letter', 'November', 'citing', 'insufficiently', 'completed', 'application', 'allow', 'substantiative', 'review', 'Following', 'resubmission', 'FDA', 'accepted', 'application', 'assigned', 'PDUFA', 'date', 'sometime', 'early', 'October', 'Also', 'read', 'Best', 'Biotech', 'Stocks', 'Right', 'Now', 'AstraZeneca', 'NASDAQ', 'Knocks', 'At', 'FDA', 'Altar', 'For', 'Liver', 'Cancer', 'Combo', 'Treatment', 'Company', 'AstraZeneca', 'plc', 'NASDAQ', 'AZN', 'Type', 'Application', 'Candidate', 'Tremelimumab', 'Imfinzi', 'Indication', 'Unresectable', 'hepatocellular', 'carcinoma', 'Date', 'The', 'FDA', 'accepted', 'AstraZeneca', 'BLA', 'tremelimumab', 'priority', 'review', 'supporting', 'indication', 'single', 'priming', 'dose', 'antibody', 'added', 'Imfinzi', 'treating', 'patients', 'unresectable', 'hepatocellular', 'carcinoma', 'A', 'sBLA', 'also', 'submitted', 'Imfinzi', 'indication', 'This', 'novel', 'dose', 'schedule', 'combination', 'called', 'STRIDE', 'regimen', 'Single', 'Tremelimumab', 'Regular', 'Interval', 'Durvalumab', 'HCC', 'according', 'company', 'common', 'type', 'liver', 'cancer', 'people', 'afflicted', 'advanced', 'unresectable', 'HCC', 'year', 'Await', 'Approval', 'For', 'Prostate', 'Cancer', 'Como', 'Therapy', 'Company', 'Merck', 'NYSE', 'MRK', 'AstraZeneca', 'Type', 'Application', 'sNDA', 'Candidate', 'Lynparza', 'combination', 'Abiraterone', 'Prednisone', 'Prednisolone', 'Indication', 'prostate', 'cancer', 'Date', 'The', 'application', 'accepted', 'granted', 'priority', 'review', 'FDA', 'treatment', 'adult', 'patients', 'metastatic', 'prostate', 'cancer', 'Adcom', 'Calendar', 'FDA', 'Cardiovascular', 'Renal', 'Drugs', 'Advisory', 'Committee', 'meet', 'discuss', 'GlaxoSmithKline', 'plc', 'NYSE', 'GSK', 'NDA', 'factor', 'prolyl', 'hydroxylase', 'inhibitor', 'daprodustat', 'tablets', 'treatment', 'option', 'anemia', 'resulting', 'chronic', 'kidney', 'disease', 'The', 'Oncologic', 'Drugs', 'Advisory', 'Committee', 'scheduled', 'meet', 'discuss', 'BLA', 'submitted', 'Therapeutics', 'NASDAQ', 'YMAB', 'solution', 'injectable', 'formulation', 'treating', 'neuroblastoma', 'central', 'nervous', 'metastases', 'On', 'Endocrinologic', 'Metabolic', 'Drugs', 'Advisory', 'Committee', 'deliberate', 'Ispen', 'OTC', 'IPSEY', 'palovarotene', 'capsules', 'proposed', 'indication', 'heterotopic', 'ossification', 'adults', 'children', 'It', 'condition', 'muscle', 'tissue', 'connective', 'tissue', 'tendons', 'ligaments', 'gradually', 'replaced', 'bones', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'reserved', 'Read', 'original', 'article', 'Reuters', 'FILE', 'PHOTO', 'Pascal', 'Soriot', 'chief', 'executive', 'pharmaceuticals', 'company', 'AstraZeneca', 'attends', 'interview', 'Reuters', 'Shanghai', 'China', 'November', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Aimee', 'Donnellan', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'AstraZeneca', 'NASDAQ', 'may', 'stay', 'vaccine', 'business', 'long', 'run', 'CEO', 'told', 'Reuters', 'Tuesday', 'showing', 'quickly', 'fortunes', 'changed', 'drugmaker', 'produced', 'one', 'first', 'shots', 'since', 'lost', 'rivals', 'Production', 'delays', 'probes', 'regulators', 'following', 'rare', 'cases', 'severe', 'side', 'effects', 'concerns', 'relatively', 'short', 'shelf', 'life', 'compared', 'shots', 'stymied', 'adoption', 'company', 'vaccine', 'Now', 'third', 'year', 'pandemic', 'amid', 'global', 'vaccine', 'supply', 'glut', 'use', 'diminished', 'much', 'developed', 'world', 'countries', 'inoculated', 'large', 'numbers', 'people', 'prefer', 'Pfizer', 'NYSE', 'Moderna', 'NASDAQ', 'mRNA', 'vaccines', 'boosters', 'AstraZeneca', 'COVID', 'vaccine', 'still', 'approval', 'The', 'company', 'building', 'portfolio', 'antibody', 'therapies', 'including', 'respiratory', 'virus', 'RSV', 'viruses', 'Soriot', 'said', 'Reuters', 'Newsmaker', 'interview', 'Tuesday', 'But', 'future', 'COVID', 'vaccines', 'business', 'said', 'I', 'ca', 'sure', 'He', 'also', 'said', 'sure', 'AstraZeneca', 'would', 'broaden', 'roster', 'vaccines', 'infections', 'either', 'adding', 'company', 'looking', 'Investors', 'speculated', 'future', 'vaccine', 'business', 'given', 'slowing', 'sales', 'COVID', 'shot', 'initial', 'sales', 'contracts', 'fulfilled', 'stiff', 'competition', 'mRNA', 'vaccines', 'relatively', 'little', 'expertise', 'field', 'The', 'company', 'created', 'separate', 'division', 'vaccines', 'antibody', 'therapies', 'late', 'last', 'year', 'Still', 'Soriot', 'said', 'regret', 'company', 'work', 'Oxford', 'University', 'develop', 'COVID', 'vaccine', 'given', 'delivered', 'billions', 'doses', 'saved', 'estimated', 'million', 'lives', 'across', 'globe', 'The', 'inoculation', 'AstraZeneca', 'second', 'product', 'sales', 'billion', 'AstraZeneca', 'also', 'looking', 'acquisitions', 'including', 'small', 'companies', 'specialising', 'oncology', 'cardiovascular', 'treatments', 'Soriot', 'added', 'We', 'always', 'look', 'external', 'opportunities', 'said', 'KEEP', 'ON', 'DOING', 'THIS', 'JOB', 'The', 'CEO', 'presided', 'quadrupling', 'AstraZeneca', 'share', 'price', 'decade', 'helm', 'I', 'keep', 'job', 'many', 'years', 'said', 'The', 'old', 'seen', 'natural', 'successor', 'outgoing', 'Chairman', 'Leif', 'Johansson', 'But', 'July', 'Soriot', 'quashed', 'speculation', 'planning', 'retire', 'time', 'soon', 'saying', 'expected', 'work', 'company', 'newly', 'announced', 'Michel', 'Demare', 'many', 'years', 'come', 'Soriot', 'tasked', 'turning', 'around', 'troubled', 'AstraZeneca', 'hit', 'string', 'key', 'patent', 'losses', 'spate', 'clinical', 'trial', 'failures', 'October', 'following', 'stint', 'pharma', 'peer', 'Roche', 'With', 'Frenchman', 'helm', 'fortunes', 'drugmaker', 'changed', 'dramatically', 'He', 'sharpened', 'focus', 'speciality', 'medicines', 'lucrative', 'field', 'oncology', 'made', 'acquisitions', 'refill', 'company', 'medicine', 'cabinet', 'fended', 'hostile', 'takeover', 'pharma', 'giant', 'Pfizer', 'invested', 'heavily', 'R', 'D', 'improve', 'company', 'lacklustre', 'drug', 'development', 'success', 'rate', 'However', 'warned', 'Tuesday', 'fewer', 'new', 'medicines', 'would', 'developed', 'going', 'forward', 'due', 'drug', 'price', 'laws', 'passed', 'last', 'week', 'Asked', 'inflationary', 'pressures', 'Soriot', 'said', 'We', 'going', 'become', 'innovative', 'productive', 'We', 'ca', 'expect', 'selling', 'prices', 'go', 'Sales', 'China', 'account', 'close', 'fifth', 'company', 'total', 'annual', 'revenue', 'dipped', 'recent', 'quarters', 'due', 'lower', 'drug', 'prices', 'COVID', 'lockdown', 'measures', 'kept', 'patients', 'diagnosed', 'seeking', 'cancer', 'care', 'On', 'Tuesday', 'Soriot', 'said', 'sales', 'picking', 'third', 'quarter', 'world', 'market', 'pharmaceuticals', 'expected', 'country', 'play', 'significant', 'role', 'global', 'market', 'next', 'decade', 'Graphic', 'AstraZeneca', 'shares', 'CEO', 'Soriot', 'helm', 'https', 'Reuters', 'People', 'pose', 'syringe', 'needle', 'front', 'displayed', 'AstraZeneca', 'logo', 'illustration', 'taken', 'December', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Pushkala', 'Aripaka', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'medicines', 'regulator', 'backed', 'using', 'AstraZeneca', 'NASDAQ', 'preventative', 'therapy', 'treatment', 'disease', 'also', 'endorsed', 'another', 'medicine', 'preventative', 'option', 'another', 'common', 'virus', 'The', 'regulator', 'recommendations', 'usually', 'followed', 'European', 'Commission', 'takes', 'final', 'decision', 'drug', 'approvals', 'AstraZeneca', 'said', 'Friday', 'European', 'Medicines', 'Agency', 'EMA', 'backed', 'Evusheld', 'treatment', 'adults', 'adolescents', 'COVID', 'need', 'supplemental', 'oxygen', 'increased', 'risk', 'disease', 'worsening', 'Last', 'month', 'Japan', 'became', 'first', 'country', 'approve', 'antibody', 'treatment', 'COVID', 'making', 'Evusheld', 'first', 'therapy', 'authorised', 'prevention', 'treatment', 'viral', 'disease', 'Evusheld', 'previously', 'largely', 'secured', 'global', 'approvals', 'including', 'Europe', 'preventative', 'therapy', 'people', 'compromised', 'immune', 'systems', 'see', 'little', 'benefit', 'COVID', 'vaccines', 'AstraZeneca', 'leaning', 'Evusheld', 'help', 'offset', 'tepid', 'sales', 'COVID', 'vaccine', 'rapidly', 'lost', 'ground', 'mRNA', 'shots', 'fight', 'rapidly', 'evolving', 'virus', 'Evusheld', 'first', 'launched', 'December', 'generated', 'million', 'first', 'half', 'drugmaker', 'Separately', 'Friday', 'EMA', 'also', 'endorsed', 'AstraZeneca', 'partner', 'Sanofi', 'EPA', 'experimental', 'therapy', 'Beyfortus', 'prevention', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'respiratory', 'syncytial', 'virus', 'RSV', 'RSV', 'causes', 'thousands', 'hospitalisations', 'deaths', 'globally', 'year', 'toddlers', 'elderly', 'complex', 'molecular', 'structure', 'virus', 'safety', 'concerns', 'stymied', 'efforts', 'develop', 'vaccine', 'since', 'virus', 'first', 'discovered', 'But', 'one', 'therapy', 'Synagis', 'also', 'developed', 'AstraZeneca', 'sold', 'Swedish', 'Orphan', 'Biovitrum', 'United', 'States', 'It', 'designed', 'prevent', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'RSV', 'infants', 'requires', 'five', 'injections', 'cover', 'typical', 'RSV', 'season', 'Meanwhile', 'Beyfortus', 'approved', 'would', 'first', 'preventative', 'RSV', 'therapy', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'deemed', 'first', 'RSV', 'Reuters', 'FILE', 'PHOTO', 'The', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'McDermid', 'AZN', 'Add', 'Portfolio', 'Reuters', 'said', 'Friday', 'drug', 'preventing', 'infant', 'RSV', 'Beyfortus', 'nirsevimab', 'recommended', 'approval', 'European', 'Union', 'European', 'Medicines', 'Agency', 'committee', 'The', 'drugmaker', 'also', 'said', 'Beyfortus', 'approved', 'would', 'become', 'first', 'protective', 'option', 'newborn', 'infant', 'population', 'RSV', 'lower', 'respiratory', 'tract', 'Reuters', 'Market', 'movers', 'Property', 'groups', 'fall', 'reduce', 'price', 'targets', 'FDX', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BLND', 'Add', 'Portfolio', 'IDSI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Shares', 'Land', 'Securities', 'British', 'Land', 'fell', 'today', 'property', 'groups', 'downgraded', 'Goldman', 'Sachs', 'NYSE', 'JP', 'Morgan', 'lowered', 'price', 'targets', 'companies', 'Goldman', 'Sachs', 'downgraded', 'British', 'Land', 'neutral', 'buy', 'reduced', 'price', 'target', 'JPMorgan', 'NYSE', 'cut', 'price', 'target', 'retained', 'overweight', 'rating', 'On', 'Land', 'Securities', 'Goldman', 'Sachs', 'lowered', 'rating', 'sell', 'neutral', 'cut', 'price', 'target', 'JPMorgan', 'retained', 'neutral', 'rating', 'lower', 'price', 'target', 'Land', 'Securities', 'fell', 'British', 'Land', 'fell', 'Capita', 'lifted', 'double', 'dose', 'good', 'news', 'Shares', 'advanced', 'reported', 'contract', 'extension', 'Barnet', 'Council', 'disposal', 'subsidiary', 'Ltd', 'Access', 'PaySuite', 'Shares', 'outsourcing', 'services', 'group', 'rose', 'securing', 'contract', 'extension', 'north', 'London', 'council', 'worth', 'although', 'indexation', 'potential', 'additional', 'work', 'could', 'worth', 'Separately', 'Capita', 'said', 'agreed', 'dispose', 'division', 'Access', 'Group', 'basis', 'Capita', 'said', 'sale', 'help', 'reduce', 'debt', 'provide', 'additional', 'liquidity', 'allow', 'enhance', 'digital', 'offerings', 'clients', 'build', 'focused', 'sustainable', 'business', 'long', 'term', 'Royal', 'Mail', 'falls', 'FedEx', 'warning', 'Shares', 'dipped', 'today', 'following', 'profits', 'warning', 'US', 'peer', 'pulled', 'full', 'year', 'guidance', 'warning', 'first', 'quarter', 'profits', 'would', 'miss', 'estimates', 'global', 'demand', 'slowdown', 'accelerates', 'It', 'cited', 'macroeconomic', 'weakness', 'Asia', 'service', 'challenges', 'Europe', 'Investors', 'took', 'view', 'industry', 'challenges', 'would', 'Royal', 'Mail', 'also', 'faces', 'prospect', 'industrial', 'action', 'employees', 'strike', 'higher', 'pay', 'Royal', 'Mail', 'workers', 'represented', 'Communication', 'Workers', 'Union', 'CWU', 'planned', 'walkout', 'September', 'planning', 'strike', 'September', 'October', 'Shares', 'fell', 'EU', 'drug', 'approvals', 'boost', 'AstraZeneca', 'NASDAQ', 'rare', 'riser', 'said', 'today', 'received', 'two', 'recommendations', 'drug', 'approvals', 'EU', 'drug', 'blood', 'disorder', 'paroxysmal', 'nocturnal', 'haemoglobinuria', 'met', 'primary', 'endpoint', 'phase', 'three', 'trial', 'The', 'group', 'said', 'Beyfortus', 'drug', 'develops', 'Sanofi', 'EPA', 'prevention', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'recommended', 'marketing', 'authorisation', 'European', 'Union', 'Meanwhile', 'AstraZeneca', 'Evusheld', 'Covid', 'antibody', 'treatment', 'recommended', 'marketing', 'authorisation', 'EU', 'adults', 'virus', 'risk', 'progressing', 'severe', 'disease', 'The', 'company', 'explained', 'phase', 'III', 'treatment', 'data', 'showed', 'reduced', 'risk', 'severe', 'Covid', 'death', 'Shares', 'rose', 'following', 'news', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'The', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'FILE', 'PHOTO', 'Tablet', 'bottles', 'AstraZeneca', 'cancer', 'medicine', 'Lynparza', 'seen', 'undated', 'handout', 'image', 'provided', 'Reuters', 'June', 'via', 'REUTERS', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'AstraZeneca', 'NASDAQ', 'said', 'Thursday', 'drug', 'Lynparza', 'developed', 'Merck', 'Co', 'approved', 'European', 'Union', 'adjuvant', 'treatment', 'patients', 'form', 'genetically', 'mutated', 'breast', 'Reuters', 'Daily', 'Biotech', 'Pulse', 'Celyad', 'Resumes', 'Colorectal', 'Cancer', 'Trial', 'Setback', 'For', 'Otonomy', 'AstraZeneca', 'Halts', 'Phase', 'Head', 'Neck', 'Cancer', 'Trial', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'OTIC', 'Add', 'Portfolio', 'BEAM', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Here', 'roundup', 'top', 'developments', 'biotech', 'space', 'last', 'hours', 'Stocks', 'In', 'Focus', 'Arcutis', 'Psoriasis', 'Treatment', 'Scores', 'FDA', 'Approval', 'The', 'FDA', 'approved', 'Arcutis', 'Biotherapeutics', 'Inc', 'NASDAQ', 'ARQT', 'Zoryve', 'roflumilast', 'cream', 'plaque', 'psoriasis', 'including', 'intertriginous', 'areas', 'patients', 'years', 'age', 'older', 'It', 'first', 'topical', 'inhibitor', 'approved', 'plaque', 'psoriasis', 'The', 'commercial', 'product', 'expected', 'available', 'Arcutis', 'expects', 'draw', 'additional', 'million', 'company', 'debt', 'facility', 'SLR', 'Capital', 'Partners', 'Shares', 'premarket', 'session', 'FDA', 'Removes', 'Clinical', 'Hold', 'On', 'Celyad', 'Colorectal', 'Cancer', 'Trial', 'The', 'FDA', 'lifted', 'clinical', 'hold', 'Celyad', 'Oncology', 'SA', 'NASDAQ', 'CYAD', 'Phase', 'trial', 'company', 'made', 'changes', 'eligibility', 'criteria', 'trial', 'In', 'February', 'company', 'voluntarily', 'paused', 'trial', 'investigate', 'reports', 'two', 'fatalities', 'study', 'The', 'FDA', 'subsequently', 'put', 'trial', 'clinical', 'hold', 'March', 'Shares', 'premarket', 'session', 'HUTCHMED', 'Starts', 'Midstage', 'Tazemetostat', 'Study', 'For', 'Lymphoma', 'Setting', 'HUTCHMED', 'China', 'Limited', 'NASDAQ', 'HCM', 'initiated', 'bridging', 'Phase', 'study', 'tazemetostat', 'China', 'follicular', 'lymphoma', 'FL', 'The', 'first', 'patient', 'received', 'first', 'dose', 'July', 'The', 'primary', 'objective', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'patients', 'mutations', 'Cohort', 'The', 'secondary', 'objectives', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'Related', 'Biotech', 'Investors', 'August', 'Key', 'PDUFA', 'Catalysts', 'You', 'Must', 'Know', 'FDA', 'Signs', 'Off', 'On', 'Eledon', 'Pharma', 'Tegoprubart', 'For', 'Kidnety', 'Transplant', 'Rejection', 'The', 'FDA', 'cleared', 'Eledon', 'Pharmaceuticals', 'Inc', 'NASDAQ', 'ELDN', 'Investigational', 'New', 'Drug', 'IND', 'application', 'evaluate', 'tegoprubart', 'preventing', 'organ', 'rejection', 'patients', 'receiving', 'kidney', 'transplant', 'The', 'phase', 'study', 'enroll', 'approximately', 'participants', 'undergoing', 'kidney', 'transplant', 'Kazia', 'Shares', 'Fall', 'After', 'Update', 'From', 'Pivotal', 'Brain', 'Tumor', 'Trial', 'Kazia', 'Therapeutics', 'Limited', 'NASDAQ', 'KZIA', 'said', 'GBM', 'AGILE', 'pivotal', 'study', 'paxalisib', 'newly', 'diagnosed', 'glioblastoma', 'meet', 'criteria', 'continuing', 'second', 'stage', 'Patients', 'enrolled', 'first', 'stage', 'paxalisib', 'arm', 'continue', 'treatment', 'per', 'protocol', 'completion', 'final', 'analysis', 'Kazia', 'anticipates', 'receiving', 'second', 'half', 'The', 'company', 'open', 'study', 'paxalisib', 'arm', 'Germany', 'China', 'Shares', 'premarket', 'session', 'FDA', 'Places', 'Clinical', 'Hold', 'On', 'Beam', 'Therapeutics', 'IND', 'Application', 'For', 'Blood', 'Cancer', 'Study', 'The', 'FDA', 'placed', 'clinical', 'hold', 'Beam', 'Therapeutics', 'Inc', 'NASDAQ', 'BEAM', 'Investigational', 'New', 'Drug', 'IND', 'application', 'acute', 'lymphoblastic', 'cell', 'lymphoblastic', 'lymphoma', 'The', 'IND', 'submitted', 'end', 'June', 'The', 'FDA', 'indicated', 'would', 'provide', 'Beam', 'official', 'clinical', 'hold', 'letter', 'within', 'days', 'Beam', 'plans', 'provide', 'additional', 'updates', 'pending', 'discussion', 'FDA', 'Otonomy', 'Shares', 'Sink', 'After', 'Stopping', 'Midstage', 'Tinnitus', 'Study', 'Otonomy', 'Inc', 'NASDAQ', 'OTIC', 'announced', 'Phase', 'trial', 'tinnitus', 'demonstrated', 'clinically', 'meaningful', 'benefit', 'versus', 'placebo', 'primary', 'secondary', 'endpoints', 'across', 'time', 'points', 'The', 'study', 'show', 'higher', 'response', 'rate', 'placebo', 'prospectively', 'defined', 'patient', 'subgroup', 'tinnitus', 'duration', 'fewer', 'six', 'months', 'population', 'studied', 'Phase', 'trial', 'The', 'overall', 'results', 'support', 'development', 'Shares', 'slipping', 'cents', 'premarket', 'session', 'AstraZeneca', 'NASDAQ', 'Cuts', 'Phase', 'Trial', 'In', 'Head', 'Neck', 'Cancer', 'Innate', 'Pharma', 'SA', 'NASDAQ', 'IPHA', 'futility', 'interim', 'analysis', 'Phase', 'study', 'sponsored', 'AstraZeneca', 'Plc', 'NASDAQ', 'AZN', 'meet', 'threshold', 'efficacy', 'Based', 'result', 'recommendation', 'Independent', 'Data', 'Monitoring', 'Committee', 'AstraZeneca', 'informed', 'Innate', 'study', 'discontinued', 'There', 'new', 'safety', 'findings', 'AstraZeneca', 'plans', 'share', 'data', 'due', 'course', 'IPHA', 'shares', 'premarket', 'session', 'ALX', 'Oncology', 'Evorpacept', 'Fast', 'Tracked', 'In', 'US', 'For', 'Head', 'Neck', 'Cancer', 'The', 'FDA', 'granted', 'Fast', 'Track', 'designation', 'ALX', 'Oncology', 'Holdings', 'Inc', 'NASDAQ', 'ALXO', 'evorpacept', 'combination', 'Merck', 'Co', 'Inc', 'NYSE', 'MRK', 'Keytruda', 'treatment', 'positive', 'advanced', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'The', 'FDA', 'decision', 'informed', 'results', 'ALX', 'Oncology', 'phase', 'study', 'showed', 'preliminary', 'antitumor', 'activity', 'favorable', 'safety', 'profile', 'Shares', 'premarket', 'session', 'Offerings', 'TherapeuticsMD', 'Inc', 'NASDAQ', 'TXMD', 'received', 'private', 'investment', 'company', 'common', 'stock', 'new', 'series', 'preferred', 'stock', 'Rubric', 'Capital', 'Management', 'LP', 'On', 'The', 'Radar', 'Earnings', 'Cerevel', 'Therapeutics', 'Holdings', 'Inc', 'NASDAQ', 'CERE', 'Before', 'market', 'open', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'reserved', 'Read', 'Benzinga', 'Read', 'original', 'article', 'Reuters', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'FCHI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Gold', 'Add', 'Portfolio', 'LCO', 'Add', 'Portfolio', 'CL', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Peter', 'Nurse', 'European', 'stock', 'markets', 'largely', 'edged', 'higher', 'Monday', 'starting', 'new', 'week', 'cautious', 'note', 'investors', 'digested', 'weak', 'Chinese', 'economic', 'data', 'By', 'ET', 'GMT', 'Germany', 'traded', 'lower', 'France', 'rose', 'traded', 'higher', 'Economic', 'data', 'released', 'earlier', 'Monday', 'showed', 'China', 'economic', 'growth', 'rate', 'unexpectedly', 'slowing', 'July', 'prompting', 'country', 'central', 'bank', 'surprise', 'move', 'grew', 'July', 'year', 'earlier', 'growth', 'rate', 'increase', 'expected', 'rose', 'year', 'ago', 'missing', 'forecasts', 'growth', 'growth', 'seen', 'June', 'China', 'economy', 'world', 'second', 'largest', 'struggling', 'shake', 'June', 'quarter', 'hit', 'growth', 'strict', 'COVID', 'restrictions', 'On', 'flip', 'side', 'back', 'Europe', 'Denmark', 'economy', 'grew', 'faster', 'expected', 'second', 'quarter', 'expanding', 'first', 'three', 'months', 'year', 'contracted', 'first', 'quarter', 'The', 'raised', 'interest', 'rates', 'July', 'expected', 'September', 'even', 'though', 'risk', 'Eurozone', 'recession', 'reached', 'highest', 'level', 'since', 'November', 'energy', 'shortages', 'threaten', 'drive', 'already', 'record', 'inflation', 'higher', 'still', 'In', 'corporate', 'news', 'AstraZeneca', 'LON', 'NASDAQ', 'stock', 'rose', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patients', 'boosting', 'prospects', 'regulatory', 'approvals', 'Henkel', 'ETR', 'stock', 'rose', 'German', 'company', 'said', 'sales', 'rose', 'first', 'half', 'year', 'earnings', 'fell', 'hurt', 'increasing', 'logistics', 'prices', 'Oil', 'prices', 'fell', 'Monday', 'weighed', 'potential', 'increase', 'supply', 'oil', 'giant', 'Saudi', 'Aramco', 'TADAWUL', 'well', 'concerns', 'slowing', 'growth', 'China', 'world', 'economy', 'Saudi', 'Aramco', 'stands', 'ready', 'raise', 'crude', 'oil', 'output', 'maximum', 'capacity', 'million', 'barrels', 'per', 'day', 'requested', 'Saudi', 'Arabian', 'government', 'Chief', 'Executive', 'Amin', 'Nasser', 'said', 'Sunday', 'energy', 'firm', 'announced', 'one', 'largest', 'quarterly', 'profits', 'history', 'By', 'ET', 'futures', 'traded', 'lower', 'barrel', 'contract', 'fell', 'Additionally', 'fell', 'traded', 'lower', 'Reuters', 'FILE', 'PHOTO', 'Signage', 'seen', 'outside', 'entrance', 'London', 'Stock', 'Exchange', 'London', 'Britain', 'Aug', 'Photo', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'Add', 'Portfolio', 'ENRY', 'Add', 'Portfolio', 'By', 'Sruthi', 'Shankar', 'Reuters', 'edged', 'Monday', 'gains', 'drugmaker', 'AstraZeneca', 'NASDAQ', 'consumer', 'stocks', 'relieved', 'pressure', 'mining', 'oil', 'heavyweights', 'data', 'showed', 'China', 'economy', 'unexpectedly', 'slowed', 'last', 'month', 'The', 'FTSE', 'added', 'hold', 'near', 'highs', 'midcap', 'inched', 'Investors', 'awaiting', 'UK', 'employment', 'report', 'well', 'consumer', 'prices', 'data', 'later', 'week', 'gauge', 'state', 'labour', 'market', 'inflation', 'The', 'data', 'could', 'offer', 'clues', 'whether', 'Bank', 'England', 'opts', 'second', 'consecutive', 'hike', 'September', 'meeting', 'The', 'mood', 'dull', 'Asian', 'European', 'stock', 'markets', 'investors', 'turning', 'defensive', 'sectors', 'healthcare', 'consumer', 'staples', 'amid', 'worries', 'health', 'world', 'economy', 'AstraZeneca', 'gained', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'developed', 'Japan', 'Daiichi', 'Sankyo', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patients', 'Oil', 'major', 'Shell', 'LON', 'miners', 'Rio', 'Tinto', 'LON', 'Anglo', 'American', 'LON', 'slipped', 'tandem', 'weaker', 'commodity', 'prices', 'release', 'China', 'data', 'The', 'FTSE', 'outperformed', 'global', 'peers', 'year', 'due', 'large', 'exposure', 'commodity', 'stocks', 'surged', 'back', 'jump', 'oil', 'metal', 'prices', 'A', 'weakening', 'pound', 'also', 'boosted', 'dollar', 'earners', 'index', 'Whether', 'trend', 'continue', 'ultimately', 'hinges', 'outlook', 'global', 'energy', 'stocks', 'relative', 'broad', 'market', 'BCA', 'Research', 'analysts', 'wrote', 'note', 'The', 'FTSE', 'nearly', 'far', 'year', 'MSCI', 'world', 'equities', 'index', 'shed', 'almost', 'Our', 'energy', 'strategists', 'remain', 'bullish', 'oil', 'Their', 'expectation', 'breach', 'average', 'suggests', 'overweight', 'energy', 'sector', 'extension', 'UK', 'equities', 'remains', 'appropriate', 'Reuters', 'FTSE', 'positive', 'early', 'highs', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slips', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sales', 'output', 'numbers', 'forecast', 'UK', 'house', 'prices', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gains', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gains', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'points', 'good', 'Richard', 'Hunter', 'head', 'markets', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'markets', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tensions', 'delegation', 'US', 'lawmakers', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdowns', 'escalating', 'property', 'Retail', 'sales', 'industrial', 'output', 'rose', 'less', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'shares', 'rose', 'pharmaceuticals', 'group', 'said', 'positive', 'results', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilders', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'prices', 'slipped', 'Positive', 'start', 'proceedings', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'makes', 'positive', 'start', 'trading', 'boosted', 'gains', 'US', 'Friday', 'despite', 'mixed', 'performances', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'industrial', 'output', 'figures', 'At', 'lead', 'index', 'trading', 'points', 'higher', 'broader', 'points', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'prices', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'says', 'A', 'drop', 'asking', 'prices', 'expected', 'month', 'frenzied', 'two', 'years', 'many', 'home', 'movers', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'The', 'number', 'properties', 'currently', 'market', 'buy', 'levels', 'despite', 'lack', 'instructions', 'new', 'listings', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increases', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'markets', 'expected', 'open', 'higher', 'Monday', 'following', 'gains', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sales', 'industrial', 'output', 'figures', 'Investors', 'also', 'one', 'eye', 'UK', 'jobs', 'inflation', 'reports', 'due', 'later', 'week', 'see', 'whether', 'signs', 'slowdown', 'jobs', 'market', 'prices', 'growth', 'Spread', 'betting', 'companies', 'calling', 'FTSE', 'around', 'points', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headlines', 'rising', 'gas', 'prices', 'supply', 'chain', 'challenges', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stocks', 'lower', 'recent', 'Asia', 'markets', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sales', 'industrial', 'production', 'numbers', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'comes', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'comes', 'struggle', 'adapt', 'policy', 'government', 'shows', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyers', 'halting', 'mortgage', 'payments', 'protest', 'delays', 'completion', 'new', 'In', 'June', 'saw', 'effects', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'signs', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sales', 'numbers', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectations', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'results', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'showed', 'strong', 'cash', 'generation', 'six', 'months', 'June', 'The', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gains', 'US', 'Friday', 'Spread', 'betting', 'companies', 'calling', 'blue', 'chip', 'index', 'around', 'points', 'The', 'closed', 'Friday', 'points', 'jumped', 'points', 'S', 'P', 'added', 'points', 'reach', 'The', 'benchmarks', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FTSE', 'positive', 'early', 'highs', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slips', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sales', 'output', 'numbers', 'forecast', 'UK', 'house', 'prices', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gains', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gains', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'points', 'good', 'Richard', 'Hunter', 'head', 'markets', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'markets', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tensions', 'delegation', 'US', 'lawmakers', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdowns', 'escalating', 'property', 'Retail', 'sales', 'industrial', 'output', 'rose', 'less', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'shares', 'rose', 'pharmaceuticals', 'group', 'said', 'positive', 'results', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilders', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'prices', 'slipped', 'Positive', 'start', 'proceedings', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'makes', 'positive', 'start', 'trading', 'boosted', 'gains', 'US', 'Friday', 'despite', 'mixed', 'performances', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'industrial', 'output', 'figures', 'At', 'lead', 'index', 'trading', 'points', 'higher', 'broader', 'points', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'prices', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'says', 'A', 'drop', 'asking', 'prices', 'expected', 'month', 'frenzied', 'two', 'years', 'many', 'home', 'movers', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'The', 'number', 'properties', 'currently', 'market', 'buy', 'levels', 'despite', 'lack', 'instructions', 'new', 'listings', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increases', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'markets', 'expected', 'open', 'higher', 'Monday', 'following', 'gains', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sales', 'industrial', 'output', 'figures', 'Investors', 'also', 'one', 'eye', 'UK', 'jobs', 'inflation', 'reports', 'due', 'later', 'week', 'see', 'whether', 'signs', 'slowdown', 'jobs', 'market', 'prices', 'growth', 'Spread', 'betting', 'companies', 'calling', 'FTSE', 'around', 'points', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headlines', 'rising', 'gas', 'prices', 'supply', 'chain', 'challenges', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stocks', 'lower', 'recent', 'Asia', 'markets', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sales', 'industrial', 'production', 'numbers', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'comes', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'comes', 'struggle', 'adapt', 'policy', 'government', 'shows', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyers', 'halting', 'mortgage', 'payments', 'protest', 'delays', 'completion', 'new', 'In', 'June', 'saw', 'effects', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'signs', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sales', 'numbers', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectations', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'results', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'showed', 'strong', 'cash', 'generation', 'six', 'months', 'June', 'The', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gains', 'US', 'Friday', 'Spread', 'betting', 'companies', 'calling', 'blue', 'chip', 'index', 'around', 'points', 'The', 'closed', 'Friday', 'points', 'jumped', 'points', 'S', 'P', 'added', 'points', 'reach', 'The', 'benchmarks', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerAVEPp', 'Add', 'Portfolio', 'ROG', 'Add', 'Portfolio', 'RHHVF', 'Add', 'Portfolio', 'SNY', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'SASY', 'Add', 'Portfolio', 'By', 'Scott', 'Kanowsky', 'Sanofi', 'SA', 'EPA', 'shares', 'slid', 'Wednesday', 'French', 'drugmaker', 'announced', 'halt', 'trials', 'new', 'treatment', 'patients', 'battling', 'advanced', 'breast', 'cancer', 'In', 'statement', 'company', 'said', 'would', 'stop', 'global', 'clinical', 'development', 'medicine', 'known', 'amcenestrant', 'phase', 'study', 'showed', 'effective', 'enough', 'warrant', 'research', 'All', 'studies', 'amcenestrant', 'including', 'breast', 'cancer', 'also', 'discontinued', 'Sanofi', 'added', 'While', 'disappointed', 'outcome', 'research', 'scientific', 'understanding', 'endocrine', 'therapies', 'people', 'breast', 'cancer', 'said', 'John', 'Reed', 'global', 'head', 'research', 'development', 'Sanofi', 'In', 'note', 'analysts', 'Morgan', 'Stanley', 'called', 'decision', 'setback', 'innovation', 'narrative', 'put', 'forward', 'Sanofi', 'saying', 'amcenestrant', 'flagged', 'potentially', 'lucrative', 'piece', 'group', 'drug', 'pipeline', 'The', 'end', 'Sanofi', 'amcenestrant', 'trials', 'expected', 'lead', 'negative', 'impact', 'company', 'estimated', 'discounted', 'cash', 'flow', 'according', 'Morgan', 'Stanley', 'analysts', 'The', 'decision', 'could', 'also', 'effect', 'studies', 'conducted', 'similar', 'breast', 'cancer', 'drugs', 'Sanofi', 'rivals', 'Roche', 'SIX', 'AstraZeneca', 'PLC', 'LON', 'analysts', 'added']]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "FqsgUl6GnZNj"
      },
      "source": [
        "The nltk.corpus list can be further enhanced by adding or removing custom words as appropriate using the add() or remove() methods respectively. The example below shows that stopwords from NLTK are all lower case as 'The' is not filtered out. Text could be changed to lower case using the lower() method so that later on in the process the same word is not represented as two different words in the vector space resulting in more dimensions. \n",
        "\n",
        "Further text preprocessing steps could include expanding contractions to their original form, and removal of punctuation, special characters and accented characters."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "OiRA694D0TUB",
        "outputId": "09d30399-3a14-44d4-8321-fbb463900936"
      },
      "source": [
        "# Remove 'The' by adding it to the stopwords list\n",
        "\n",
        "stop_words.add('The')\n",
        "\n",
        "# Iterate through all tokens for all articles \n",
        "filtered_articles = [[word for word in article if not word in stop_words if word.isalpha()] for article in tokens]\n",
        "print(stop_words)\n",
        "print(filtered_articles)"
      ],
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'most', 'is', 'ain', 'aren', 'my', 'nor', 'so', \"couldn't\", 'weren', \"it's\", \"weren't\", 'off', 'of', 's', 'having', 'her', 'they', 'there', 'its', 'with', 'few', 're', 'wasn', 'than', 'any', 'each', 'mightn', 'his', \"you're\", 'too', 'now', 'o', 'ma', \"you've\", 'am', 'all', \"mightn't\", 'we', 'and', 'in', \"she's\", 'if', 'into', 'above', 'herself', 'these', 'or', 'doing', 'where', 'd', \"that'll\", 'are', 'our', 'she', 'he', 'couldn', 'yourselves', 'very', 'll', 'other', 'yours', 'who', 'itself', \"don't\", 'why', 'such', 'at', 'under', 'isn', 'did', 'no', 'this', 'hasn', 'their', 'an', 'but', 'them', \"won't\", 'during', 'your', 'it', \"isn't\", \"aren't\", 'didn', 'over', 'before', 'a', 'what', 'you', 'have', 'some', 'hadn', 'mustn', 'more', 'for', 'be', 'yourself', 'how', \"you'll\", \"mustn't\", \"you'd\", 'ours', 'through', 'own', \"shan't\", 'hers', 'been', 'which', 'from', 'the', 'has', 'not', 'needn', 'shouldn', 'both', 'after', 'further', 'when', 've', 'because', \"doesn't\", 'out', 'myself', 'as', 'him', 'against', 'while', 'doesn', 'shan', \"hadn't\", 'do', 'was', 'were', 'won', \"didn't\", 'being', 'don', 'The', 'm', 'ourselves', \"hasn't\", 'those', 'himself', 'theirs', 'whom', 'to', 'i', 'themselves', 'does', 'had', 'down', 'me', 'here', 'between', 'only', \"needn't\", 'same', \"wasn't\", 'should', \"haven't\", \"shouldn't\", 'can', 'then', 'on', 'until', 'will', 'haven', 'wouldn', 'below', 'that', 'once', 'y', 'about', 'just', \"should've\", 'up', 'again', \"wouldn't\", 'by', 't'}\n",
            "[['AstraZeneca', 'PLC', 'said', 'Wednesday', 'Capivasertib', 'plus', 'Faslodex', 'significantly', 'improved', 'survival', 'compared', 'Faslodex', 'combined', 'placebo', 'Phase', 'trial', 'advanced', 'hormone', 'breast', 'cancer', 'pharma', 'giant', 'AZN', 'AZN', 'said', 'trial', 'met', 'primary', 'endpoints', 'improving', 'survival', 'overall', 'patient', 'population', 'prespecified', 'biomarker', 'subgroup', 'patients', 'whose', 'tumors', 'qualifying', 'Touts', 'Positive', 'Data', 'From', 'Two', 'Experimental', 'Drugs', 'In', 'Breast', 'Cancer', 'SettingsAstraZeneca', 'Ultomiris', 'Showed', 'Zero', 'Relapses', 'In', 'Patients', 'With', 'Chronic', 'Disorder', 'Of', 'Brain', 'Spinal', 'CordAstraZeneca', 'NASDAQ', 'AZN', 'announced', 'Tuesday', 'vaccine', 'Vaxzevria', 'Recombinant', 'given', 'full', 'Marketing', 'Authorisation', 'MA', 'European', 'Union', 'EU', 'Vaxzevria', 'originally', 'granted', 'conditional', 'Marketing', 'Authorisation', 'cMA', 'EU', 'AstraZeneca', 'stated', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefits', 'Vaxzevria', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Iskra', 'Reic', 'EVP', 'Vaccines', 'Immune', 'Therapies', 'AstraZeneca', 'commented', 'move', 'conditional', 'full', 'marketing', 'authorisation', 'Vaxzevria', 'important', 'confirmation', 'EMA', 'safety', 'efficacy', 'Vaxzevria', 'demonstrating', 'benefits', 'continue', 'outweigh', 'potential', 'risks', 'Vaxzevria', 'estimated', 'helped', 'save', 'six', 'million', 'lives', 'first', 'year', 'vaccination', 'reflects', 'strength', 'evidence', 'showing', 'Vaxzevria', 'protection', 'severe', 'disease', 'death', 'caused', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Marketing', 'Authorisation', 'AstraZeneca', 'Plc', 'AZN', 'vaccine', 'Vaxzevria', 'Recombinant', 'vaccine', 'Vaxzevria', 'Recombinant', 'Vaxzevria', 'initially', 'granted', 'conditional', 'Marketing', 'Authorisation', 'due', 'urgency', 'pandemic', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefits', 'Vaxzevria', 'EMA', 'granted', 'full', 'approval', 'approval', 'covers', 'use', 'Vaxzevria', 'primary', 'vaccination', 'series', 'heterologous', 'approved', 'mRNA', 'vaccine', 'homologous', 'vaccine', 'booster', 'Related', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'Vaxzevria', 'demonstrated', 'effective', 'forms', 'mild', 'symptomatic', 'severe', 'disease', 'including', 'hospitalization', 'death', 'according', 'clinical', 'studies', 'evidence', 'These', 'include', 'expert', 'review', 'data', 'studies', 'showed', 'Vaxzevria', 'available', 'mRNA', 'vaccines', 'provide', 'equally', 'effective', 'protection', 'hospitalization', 'death', 'following', 'three', 'doses', 'There', 'also', 'substantial', 'body', 'evidence', 'supporting', 'boosting', 'Vaxzevria', 'following', 'primary', 'vaccination', 'schedules', 'tested', 'date', 'Price', 'Action', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Tuesday', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Tuesday', 'Photo', 'Paul', 'McManus', 'Pixabay', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'Shifts', 'China', 'Factory', 'Workers', 'To', 'US', 'Plant', 'Complete', 'European', 'Approval', 'For', 'AstraZeneca', 'Shot', 'Tesla', 'Eyes', 'Cybertruck', 'Commercialization', 'Next', 'Year', 'Top', 'Stories', 'Tuesday', 'European', 'Commission', 'approved', 'AstraZeneca', 'plc', 'AZN', 'Sanofi', 'SA', 'SNY', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'first', 'RSV', 'season', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'first', 'RSV', 'season', 'Beyfortus', 'first', 'RSV', 'passive', 'immunization', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'preterm', 'specific', 'health', 'conditions', 'In', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', 'LRTI', 'caused', 'RSV', 'placebo', 'day', 'single', 'dose', 'Beyfortus', 'also', 'demonstrated', 'comparable', 'safety', 'tolerability', 'profile', 'Swedish', 'Orphan', 'Biovitrum', 'AB', 'BIOVF', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Globally', 'approximately', 'million', 'cases', 'acute', 'lower', 'respiratory', 'infections', 'leading', 'three', 'million', 'hospitalizations', 'It', 'estimated', 'deaths', 'children', 'younger', 'five', 'years', 'Price', 'Action', 'SNY', 'shares', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Friday', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'Reuters', 'AstraZeneca', 'shares', 'get', 'lift', 'heartburn', 'drug', 'litigation', 'closure', 'says', 'Citi', 'AZN', 'Add', 'Portfolio', 'LFCOF', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'NASDAQ', 'get', 'boost', 'probability', 'close', 'US', 'kidney', 'damage', 'lawsuit', 'New', 'Jersey', 'prior', 'first', 'bellwether', 'case', 'March', 'according', 'analysts', 'Citi', 'UK', 'pharma', 'one', 'several', 'firms', 'embroiled', 'US', 'legal', 'action', 'possible', 'damage', 'caused', 'proton', 'pump', 'inhibitor', 'PPI', 'heartburn', 'drugs', 'Nexium', 'launched', 'Astra', 'US', 'Citi', 'analysts', 'believe', 'likely', 'outcome', 'judge', 'delaying', 'response', 'Defendant', 'Motion', 'summary', 'judgement', 'grounds', 'encourage', 'plaintiffs', 'settle', 'Alternatively', 'lower', 'probability', 'Judge', 'Cecchi', 'may', 'delayed', 'start', 'bellwether', 'cases', 'disagrees', 'conclusions', 'Special', 'Master', 'Reisman', 'grants', 'defendant', 'motion', 'dismiss', 'grounds', 'said', 'Either', 'scenario', 'would', 'materially', 'positive', 'Astra', 'depressed', 'share', 'price', 'US', 'bank', 'analysts', 'added', 'would', 'positive', 'interim', 'data', 'Enhertu', 'positive', 'data', 'March', 'Citi', 'analysts', 'said', 'core', 'EPS', 'forecasts', 'Astra', 'consensus', 'repeated', 'alongside', 'price', 'target', 'recommendation', 'Shares', 'Astra', 'rose', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Astrazeneca', 'Beyfortus', 'receives', 'EU', 'approval', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'NASDAQ', 'stated', 'Beyfortus', 'first', 'RSV', 'passive', 'immunisation', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'specific', 'health', 'conditions', 'group', 'said', 'European', 'Commission', 'first', 'regulatory', 'body', 'grant', 'approval', 'Beyfortus', 'approval', 'based', 'results', 'drug', 'clinical', 'development', 'programme', 'follows', 'recommendation', 'Committee', 'Medicinal', 'Products', 'Human', 'Use', 'European', 'Medicines', 'Agency', 'September', 'In', 'AZN', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'RSV', 'versus', 'placebo', 'day', 'single', 'dose', 'Iskra', 'Eric', 'AZN', 'executive', 'vice', 'president', 'vaccines', 'immune', 'therapies', 'said', 'Beyfortus', 'first', 'preventative', 'option', 'respiratory', 'syncytial', 'virus', 'gain', 'approval', 'Europe', 'also', 'first', 'preventative', 'option', 'approved', 'broad', 'infant', 'population', 'Today', 'marketing', 'authorisation', 'Beyfortus', 'marks', 'significant', 'achievement', 'scientific', 'community', 'addresses', 'persistent', 'global', 'unmet', 'need', 'RSV', 'prevention', 'Reporting', 'Iain', 'Gilbert', 'Read', 'Reuters', 'AstraZeneca', 'says', 'Evusheld', 'approved', 'treatment', 'EU', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'said', 'antibody', 'combination', 'Evusheld', 'tixagevimab', 'cilgavimab', 'formerly', 'approved', 'EU', 'treatment', 'approval', 'European', 'Commission', 'covers', 'people', 'age', 'years', 'require', 'supplemental', 'oxygen', 'increased', 'risk', 'progressing', 'severe', 'pharmaceuticals', 'group', 'said', 'European', 'Commission', 'approval', 'based', 'results', 'TACKLE', 'phase', 'III', 'treatment', 'trial', 'showed', 'Evusheld', 'significantly', 'reduced', 'risk', 'severe', 'death', 'recommended', 'dose', 'Evusheld', 'treatment', 'Europe', 'tixagevimab', 'cilgavimab', 'administered', 'two', 'separate', 'sequential', 'IM', 'injections', 'AstraZeneca', 'NASDAQ', 'noted', 'Many', 'people', 'including', 'immunocompromised', 'older', 'adults', 'underlying', 'health', 'conditions', 'high', 'risk', 'severe', 'disease', 'hospitalisation', 'death', 'become', 'infected', 'Evusheld', 'delivered', 'convenient', 'intramuscular', 'formulation', 'new', 'treatment', 'option', 'vulnerable', 'populations', 'commented', 'Dr', 'Michel', 'Goldman', 'professor', 'Institute', 'Interdisciplinary', 'Innovation', 'Healthcare', 'Université', 'Libre', 'de', 'Bruxelles', 'former', 'executive', 'director', 'European', 'Innovative', 'Medicines', 'Initiative', 'statement', 'Iskra', 'Reic', 'executive', 'vice', 'president', 'vaccines', 'immune', 'therapies', 'AstraZeneca', 'added', 'remains', 'ongoing', 'health', 'concern', 'millions', 'Europeans', 'around', 'world', 'especially', 'may', 'virus', 'vaccination', 'With', 'approval', 'Evusheld', 'antibody', 'combination', 'available', 'prevention', 'treatment', 'Europe', 'allowing', 'us', 'protect', 'even', 'people', 'devastating', 'disease', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'AstraZeneca', 'gets', 'third', 'regulatory', 'green', 'light', 'matter', 'weeks', 'asthma', 'drug', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'said', 'Tezspire', 'treatment', 'approved', 'Japan', 'severe', 'bronchial', 'asthma', 'traditional', 'corticosteroids', 'work', 'It', 'third', 'approval', 'matter', 'weeks', 'product', 'potential', 'challenger', 'market', 'leader', 'Dupxient', 'It', 'developed', 'collaboration', 'US', 'giant', 'Amgen', 'NASDAQ', 'In', 'clinical', 'trials', 'drug', 'shown', 'lower', 'researchers', 'called', 'asthma', 'exacerbations', 'Tezspire', 'first', 'biologic', 'approved', 'Japanese', 'Ministry', 'Health', 'Labour', 'Welfare', 'shown', 'consistently', 'significantly', 'reduce', 'attacks', 'exacerbation', 'trials', 'broad', 'population', 'severe', 'asthma', 'patients', 'irrespective', 'biomarker', 'levels', 'Mene', 'Pangalos', 'head', 'biopharmaceutical', 'research', 'AZ', 'Tezspire', 'potential', 'improve', 'outcomes', 'many', 'patients', 'severe', 'asthma', 'working', 'make', 'important', 'medicine', 'available', 'Japan', 'quickly', 'Analysts', 'believe', 'Tezspire', 'could', 'big', 'seller', 'peak', 'sales', 'projected', 'order', 'US', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FILE', 'PHOTO', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'Shares', 'LogicBio', 'Therapeutics', 'skyrocketed', 'Monday', 'Britain', 'AstraZeneca', 'NASDAQ', 'said', 'would', 'buy', 'gene', 'therapy', 'developer', 'rare', 'premium', 'million', 'LoigBio', 'shares', 'traded', 'since', 'February', 'bell', 'close', 'AstraZeneca', 'offer', 'price', 'per', 'share', 'LogicBio', 'developing', 'gene', 'editing', 'therapies', 'treat', 'pediatric', 'rare', 'disease', 'like', 'methylmalonic', 'acidemia', 'body', 'break', 'certain', 'proteins', 'fats', 'AstraZeneca', 'said', 'deal', 'would', 'accelerate', 'growth', 'Alexion', 'NASDAQ', 'unit', 'acquired', 'billion', 'last', 'year', 'field', 'genomic', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'AstraZeneca', 'says', 'combination', 'approved', 'advanced', 'liver', 'cancer', 'US', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'announced', 'US', 'Food', 'Drug', 'Administration', 'FDA', 'approved', 'company', 'Imjudo', 'tremelimumab', 'drug', 'combination', 'Imfinzi', 'durvalumab', 'treatment', 'adult', 'patients', 'unresectable', 'hepatocellular', 'carcinoma', 'HCC', 'common', 'type', 'liver', 'cancer', 'approval', 'based', 'results', 'HIMALAYA', 'Phase', 'III', 'trial', 'showed', 'single', 'priming', 'dose', 'antibody', 'Imjudo', 'added', 'antibody', 'Imfinzi', 'reduced', 'risk', 'death', 'compared', 'sorafenib', 'pharmaceuticals', 'company', 'said', 'Liver', 'cancer', 'cause', 'cancer', 'death', 'sixth', 'commonly', 'diagnosed', 'cancer', 'worldwide', 'It', 'cause', 'deaths', 'US', 'approximately', 'new', 'diagnoses', 'year', 'company', 'said', 'In', 'statement', 'Dave', 'Fredrickson', 'executive', 'vice', 'president', 'oncology', 'business', 'unit', 'AstraZeneca', 'commented', 'With', 'first', 'regulatory', 'approval', 'Imjudo', 'patients', 'unresectable', 'liver', 'cancer', 'US', 'approved', 'dual', 'immunotherapy', 'treatment', 'regimen', 'harnesses', 'potential', 'inhibition', 'unique', 'combination', 'inhibitor', 'enhance', 'immune', 'response', 'cancer', 'Dr', 'Ghassan', 'attending', 'physician', 'Memorial', 'Sloan', 'Kettering', 'Cancer', 'Center', 'MSK', 'principal', 'investigator', 'HIMALAYA', 'Phase', 'III', 'trial', 'said', 'Patients', 'unresectable', 'liver', 'cancer', 'need', 'treatments', 'meaningfully', 'extend', 'overall', 'survival', 'In', 'addition', 'regimen', 'demonstrating', 'favourable', 'survival', 'rate', 'HIMALAYA', 'trial', 'safety', 'data', 'showed', 'increase', 'severe', 'liver', 'toxicity', 'bleeding', 'risk', 'combination', 'important', 'factors', 'patients', 'liver', 'cancer', 'also', 'advanced', 'liver', 'disease', 'Regulatory', 'applications', 'Imjudo', 'combination', 'Imfinzi', 'currently', 'review', 'Europe', 'Japan', 'several', 'countries', 'treatment', 'patients', 'advanced', 'liver', 'cancer', 'based', 'HIMALAYA', 'results', 'AstraZeneca', 'said', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'Prostate', 'Cancer', 'Combo', 'Drug', 'Try', 'For', 'scPharma', 'FDA', 'Panel', 'Decisions', 'And', 'More', 'October', 'Key', 'PDUFA', 'Catalysts', 'Biotech', 'Investors', 'Must', 'Know', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'KECR', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Most', 'FDA', 'decisions', 'scheduled', 'September', 'yielded', 'positive', 'results', 'stray', 'disappointments', 'well', 'Seven', 'new', 'molecular', 'entities', 'NMEs', 'approved', 'month', 'taking', 'total', 'NME', 'approvals', 'year', 'This', 'far', 'less', 'approvals', 'received', 'time', 'last', 'year', 'NMEs', 'considered', 'measure', 'innovation', 'drug', 'research', 'contain', 'active', 'moieties', 'ingredients', 'previously', 'approved', 'Food', 'Drug', 'Administration', 'Among', 'positive', 'verdicts', 'bluebird', 'bio', 'NASDAQ', 'BLUE', 'million', 'gene', 'therapy', 'Skysona', 'approved', 'treating', 'rare', 'neurodegenerative', 'disorder', 'boys', 'Amylyx', 'Pharmaceuticals', 'NASDAQ', 'AMLX', 'scored', 'win', 'amyotrophic', 'sclerosis', 'treatment', 'Revance', 'Therapeutics', 'NASDAQ', 'RVNC', 'Botox', 'rival', 'Daxxify', 'approved', 'treating', 'frown', 'lines', 'Spectrum', 'Pharmaceuticals', 'NASDAQ', 'SPPI', 'mixed', 'month', 'Rolvedon', 'approved', 'treating', 'neutropenia', 'lung', 'cancer', 'drug', 'get', 'backing', 'FDA', 'panel', 'Here', 'key', 'PDUFA', 'dates', 'scheduled', 'October', 'Will', 'Theratech', 'Score', 'A', 'Win', 'For', 'A', 'More', 'Convenient', 'Formulation', 'Of', 'Its', 'HIV', 'Drug', 'Company', 'Theratechnologies', 'NASDAQ', 'THTX', 'Type', 'Application', 'supplemental', 'biologic', 'license', 'application', 'Candidate', 'Trogarzo', 'Indication', 'Date', 'In', 'fourth', 'quarter', 'company', 'filed', 'sBLA', 'intravenous', 'push', 'mode', 'administration', 'Trogarzo', 'treating', 'human', 'immunodeficiency', 'virus', 'type', 'Trogarzo', 'first', 'approved', 'FDA', 'March', 'treat', 'adult', 'patients', 'HIV', 'In', 'quarter', 'ended', 'May', 'drug', 'generated', 'sales', 'million', 'Theratech', 'Alnylam', 'On', 'Course', 'For', 'Snagging', 'Label', 'Expansion', 'For', 'Oxlumo', 'Company', 'Alnylam', 'NASDAQ', 'ALNY', 'Type', 'Application', 'supplemental', 'new', 'drug', 'application', 'Candidate', 'Oxlumo', 'Indication', 'hyperoxaluria', 'Type', 'Date', 'Oxlumo', 'goes', 'generic', 'name', 'lumasiran', 'RNAi', 'therapeutic', 'evaluated', 'reduction', 'plasma', 'oxalate', 'patients', 'advanced', 'hyperoxaluria', 'type', 'rare', 'disorder', 'mainly', 'affects', 'kidneys', 'due', 'accumulation', 'substance', 'called', 'oxalate', 'normally', 'filtered', 'kidneys', 'excreted', 'urine', 'This', 'therapy', 'first', 'approved', 'lowering', 'urinary', 'oxalate', 'labels', 'pediatric', 'adult', 'patients', 'In', 'second', 'quarter', 'fetched', 'company', 'million', 'sales', 'sequentially', 'See', 'also', 'Alzheimer', 'Progression', 'Slowed', 'Down', 'By', 'Biogen', 'NASDAQ', 'New', 'Drug', 'In', 'Study', 'Analyst', 'Sees', 'Can', 'Third', 'Time', 'Be', 'Charm', 'For', 'scPharma', 'Company', 'scPharmaceuticals', 'NASDAQ', 'SCPH', 'Type', 'Application', 'NDA', 'Candidate', 'Furoscix', 'Indication', 'worsening', 'heart', 'failure', 'due', 'congestion', 'Date', 'Furoscix', 'proprietary', 'furosemide', 'solution', 'evaluated', 'outpatient', 'alternative', 'treatment', 'worsening', 'congestive', 'heart', 'failure', 'This', 'scPharma', 'third', 'try', 'Furoscix', 'following', 'complete', 'response', 'letter', 'Go', 'Amicus', 'Pome', 'Disease', 'Treatment', 'Company', 'Amicus', 'Therapeutics', 'NASDAQ', 'FOLD', 'Type', 'Application', 'BLA', 'Candidate', 'cipaglucosidase', 'alfa', 'Indication', 'Pompe', 'disease', 'Date', 'investigational', 'therapy', 'consists', 'cipaglucosidase', 'alfa', 'administered', 'conjunction', 'miglustat', 'yet', 'approved', 'FDA', 'therapy', 'evaluated', 'inherited', 'lysosomal', 'disorder', 'called', 'Pome', 'disease', 'disease', 'debilitating', 'characterized', 'severe', 'muscle', 'weakness', 'worsens', 'time', 'It', 'ranges', 'rapidly', 'fatal', 'infantile', 'form', 'significant', 'impacts', 'heart', 'function', 'slowly', 'progressive', 'form', 'primarily', 'affecting', 'skeletal', 'muscle', 'It', 'estimated', 'Pompe', 'disease', 'affects', 'approximately', 'people', 'worldwide', 'Supernus', 'Hopes', 'For', 'No', 'Hiccups', 'In', 'Parkinson', 'Disease', 'Drug', 'Approval', 'Company', 'Supernus', 'Pharmaceuticals', 'NASDAQ', 'SUPN', 'Type', 'Application', 'NDA', 'Candidate', 'apomorphine', 'infusion', 'device', 'Indication', 'OFF', 'episodes', 'Parkinson', 'disease', 'Date', 'Early', 'October', 'Supernus', 'initial', 'application', 'seeking', 'approval', 'shot', 'letter', 'November', 'citing', 'insufficiently', 'completed', 'application', 'allow', 'substantiative', 'review', 'Following', 'resubmission', 'FDA', 'accepted', 'application', 'assigned', 'PDUFA', 'date', 'sometime', 'early', 'October', 'Also', 'read', 'Best', 'Biotech', 'Stocks', 'Right', 'Now', 'AstraZeneca', 'NASDAQ', 'Knocks', 'At', 'FDA', 'Altar', 'For', 'Liver', 'Cancer', 'Combo', 'Treatment', 'Company', 'AstraZeneca', 'plc', 'NASDAQ', 'AZN', 'Type', 'Application', 'Candidate', 'Tremelimumab', 'Imfinzi', 'Indication', 'Unresectable', 'hepatocellular', 'carcinoma', 'Date', 'FDA', 'accepted', 'AstraZeneca', 'BLA', 'tremelimumab', 'priority', 'review', 'supporting', 'indication', 'single', 'priming', 'dose', 'antibody', 'added', 'Imfinzi', 'treating', 'patients', 'unresectable', 'hepatocellular', 'carcinoma', 'A', 'sBLA', 'also', 'submitted', 'Imfinzi', 'indication', 'This', 'novel', 'dose', 'schedule', 'combination', 'called', 'STRIDE', 'regimen', 'Single', 'Tremelimumab', 'Regular', 'Interval', 'Durvalumab', 'HCC', 'according', 'company', 'common', 'type', 'liver', 'cancer', 'people', 'afflicted', 'advanced', 'unresectable', 'HCC', 'year', 'Await', 'Approval', 'For', 'Prostate', 'Cancer', 'Como', 'Therapy', 'Company', 'Merck', 'NYSE', 'MRK', 'AstraZeneca', 'Type', 'Application', 'sNDA', 'Candidate', 'Lynparza', 'combination', 'Abiraterone', 'Prednisone', 'Prednisolone', 'Indication', 'prostate', 'cancer', 'Date', 'application', 'accepted', 'granted', 'priority', 'review', 'FDA', 'treatment', 'adult', 'patients', 'metastatic', 'prostate', 'cancer', 'Adcom', 'Calendar', 'FDA', 'Cardiovascular', 'Renal', 'Drugs', 'Advisory', 'Committee', 'meet', 'discuss', 'GlaxoSmithKline', 'plc', 'NYSE', 'GSK', 'NDA', 'factor', 'prolyl', 'hydroxylase', 'inhibitor', 'daprodustat', 'tablets', 'treatment', 'option', 'anemia', 'resulting', 'chronic', 'kidney', 'disease', 'Oncologic', 'Drugs', 'Advisory', 'Committee', 'scheduled', 'meet', 'discuss', 'BLA', 'submitted', 'Therapeutics', 'NASDAQ', 'YMAB', 'solution', 'injectable', 'formulation', 'treating', 'neuroblastoma', 'central', 'nervous', 'metastases', 'On', 'Endocrinologic', 'Metabolic', 'Drugs', 'Advisory', 'Committee', 'deliberate', 'Ispen', 'OTC', 'IPSEY', 'palovarotene', 'capsules', 'proposed', 'indication', 'heterotopic', 'ossification', 'adults', 'children', 'It', 'condition', 'muscle', 'tissue', 'connective', 'tissue', 'tendons', 'ligaments', 'gradually', 'replaced', 'bones', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'reserved', 'Read', 'original', 'article', 'Reuters', 'FILE', 'PHOTO', 'Pascal', 'Soriot', 'chief', 'executive', 'pharmaceuticals', 'company', 'AstraZeneca', 'attends', 'interview', 'Reuters', 'Shanghai', 'China', 'November', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Aimee', 'Donnellan', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'AstraZeneca', 'NASDAQ', 'may', 'stay', 'vaccine', 'business', 'long', 'run', 'CEO', 'told', 'Reuters', 'Tuesday', 'showing', 'quickly', 'fortunes', 'changed', 'drugmaker', 'produced', 'one', 'first', 'shots', 'since', 'lost', 'rivals', 'Production', 'delays', 'probes', 'regulators', 'following', 'rare', 'cases', 'severe', 'side', 'effects', 'concerns', 'relatively', 'short', 'shelf', 'life', 'compared', 'shots', 'stymied', 'adoption', 'company', 'vaccine', 'Now', 'third', 'year', 'pandemic', 'amid', 'global', 'vaccine', 'supply', 'glut', 'use', 'diminished', 'much', 'developed', 'world', 'countries', 'inoculated', 'large', 'numbers', 'people', 'prefer', 'Pfizer', 'NYSE', 'Moderna', 'NASDAQ', 'mRNA', 'vaccines', 'boosters', 'AstraZeneca', 'COVID', 'vaccine', 'still', 'approval', 'company', 'building', 'portfolio', 'antibody', 'therapies', 'including', 'respiratory', 'virus', 'RSV', 'viruses', 'Soriot', 'said', 'Reuters', 'Newsmaker', 'interview', 'Tuesday', 'But', 'future', 'COVID', 'vaccines', 'business', 'said', 'I', 'ca', 'sure', 'He', 'also', 'said', 'sure', 'AstraZeneca', 'would', 'broaden', 'roster', 'vaccines', 'infections', 'either', 'adding', 'company', 'looking', 'Investors', 'speculated', 'future', 'vaccine', 'business', 'given', 'slowing', 'sales', 'COVID', 'shot', 'initial', 'sales', 'contracts', 'fulfilled', 'stiff', 'competition', 'mRNA', 'vaccines', 'relatively', 'little', 'expertise', 'field', 'company', 'created', 'separate', 'division', 'vaccines', 'antibody', 'therapies', 'late', 'last', 'year', 'Still', 'Soriot', 'said', 'regret', 'company', 'work', 'Oxford', 'University', 'develop', 'COVID', 'vaccine', 'given', 'delivered', 'billions', 'doses', 'saved', 'estimated', 'million', 'lives', 'across', 'globe', 'inoculation', 'AstraZeneca', 'second', 'product', 'sales', 'billion', 'AstraZeneca', 'also', 'looking', 'acquisitions', 'including', 'small', 'companies', 'specialising', 'oncology', 'cardiovascular', 'treatments', 'Soriot', 'added', 'We', 'always', 'look', 'external', 'opportunities', 'said', 'KEEP', 'ON', 'DOING', 'THIS', 'JOB', 'CEO', 'presided', 'quadrupling', 'AstraZeneca', 'share', 'price', 'decade', 'helm', 'I', 'keep', 'job', 'many', 'years', 'said', 'old', 'seen', 'natural', 'successor', 'outgoing', 'Chairman', 'Leif', 'Johansson', 'But', 'July', 'Soriot', 'quashed', 'speculation', 'planning', 'retire', 'time', 'soon', 'saying', 'expected', 'work', 'company', 'newly', 'announced', 'Michel', 'Demare', 'many', 'years', 'come', 'Soriot', 'tasked', 'turning', 'around', 'troubled', 'AstraZeneca', 'hit', 'string', 'key', 'patent', 'losses', 'spate', 'clinical', 'trial', 'failures', 'October', 'following', 'stint', 'pharma', 'peer', 'Roche', 'With', 'Frenchman', 'helm', 'fortunes', 'drugmaker', 'changed', 'dramatically', 'He', 'sharpened', 'focus', 'speciality', 'medicines', 'lucrative', 'field', 'oncology', 'made', 'acquisitions', 'refill', 'company', 'medicine', 'cabinet', 'fended', 'hostile', 'takeover', 'pharma', 'giant', 'Pfizer', 'invested', 'heavily', 'R', 'D', 'improve', 'company', 'lacklustre', 'drug', 'development', 'success', 'rate', 'However', 'warned', 'Tuesday', 'fewer', 'new', 'medicines', 'would', 'developed', 'going', 'forward', 'due', 'drug', 'price', 'laws', 'passed', 'last', 'week', 'Asked', 'inflationary', 'pressures', 'Soriot', 'said', 'We', 'going', 'become', 'innovative', 'productive', 'We', 'ca', 'expect', 'selling', 'prices', 'go', 'Sales', 'China', 'account', 'close', 'fifth', 'company', 'total', 'annual', 'revenue', 'dipped', 'recent', 'quarters', 'due', 'lower', 'drug', 'prices', 'COVID', 'lockdown', 'measures', 'kept', 'patients', 'diagnosed', 'seeking', 'cancer', 'care', 'On', 'Tuesday', 'Soriot', 'said', 'sales', 'picking', 'third', 'quarter', 'world', 'market', 'pharmaceuticals', 'expected', 'country', 'play', 'significant', 'role', 'global', 'market', 'next', 'decade', 'Graphic', 'AstraZeneca', 'shares', 'CEO', 'Soriot', 'helm', 'https', 'Reuters', 'People', 'pose', 'syringe', 'needle', 'front', 'displayed', 'AstraZeneca', 'logo', 'illustration', 'taken', 'December', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Pushkala', 'Aripaka', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'medicines', 'regulator', 'backed', 'using', 'AstraZeneca', 'NASDAQ', 'preventative', 'therapy', 'treatment', 'disease', 'also', 'endorsed', 'another', 'medicine', 'preventative', 'option', 'another', 'common', 'virus', 'regulator', 'recommendations', 'usually', 'followed', 'European', 'Commission', 'takes', 'final', 'decision', 'drug', 'approvals', 'AstraZeneca', 'said', 'Friday', 'European', 'Medicines', 'Agency', 'EMA', 'backed', 'Evusheld', 'treatment', 'adults', 'adolescents', 'COVID', 'need', 'supplemental', 'oxygen', 'increased', 'risk', 'disease', 'worsening', 'Last', 'month', 'Japan', 'became', 'first', 'country', 'approve', 'antibody', 'treatment', 'COVID', 'making', 'Evusheld', 'first', 'therapy', 'authorised', 'prevention', 'treatment', 'viral', 'disease', 'Evusheld', 'previously', 'largely', 'secured', 'global', 'approvals', 'including', 'Europe', 'preventative', 'therapy', 'people', 'compromised', 'immune', 'systems', 'see', 'little', 'benefit', 'COVID', 'vaccines', 'AstraZeneca', 'leaning', 'Evusheld', 'help', 'offset', 'tepid', 'sales', 'COVID', 'vaccine', 'rapidly', 'lost', 'ground', 'mRNA', 'shots', 'fight', 'rapidly', 'evolving', 'virus', 'Evusheld', 'first', 'launched', 'December', 'generated', 'million', 'first', 'half', 'drugmaker', 'Separately', 'Friday', 'EMA', 'also', 'endorsed', 'AstraZeneca', 'partner', 'Sanofi', 'EPA', 'experimental', 'therapy', 'Beyfortus', 'prevention', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'respiratory', 'syncytial', 'virus', 'RSV', 'RSV', 'causes', 'thousands', 'hospitalisations', 'deaths', 'globally', 'year', 'toddlers', 'elderly', 'complex', 'molecular', 'structure', 'virus', 'safety', 'concerns', 'stymied', 'efforts', 'develop', 'vaccine', 'since', 'virus', 'first', 'discovered', 'But', 'one', 'therapy', 'Synagis', 'also', 'developed', 'AstraZeneca', 'sold', 'Swedish', 'Orphan', 'Biovitrum', 'United', 'States', 'It', 'designed', 'prevent', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'RSV', 'infants', 'requires', 'five', 'injections', 'cover', 'typical', 'RSV', 'season', 'Meanwhile', 'Beyfortus', 'approved', 'would', 'first', 'preventative', 'RSV', 'therapy', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'deemed', 'first', 'RSV', 'Reuters', 'FILE', 'PHOTO', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'McDermid', 'AZN', 'Add', 'Portfolio', 'Reuters', 'said', 'Friday', 'drug', 'preventing', 'infant', 'RSV', 'Beyfortus', 'nirsevimab', 'recommended', 'approval', 'European', 'Union', 'European', 'Medicines', 'Agency', 'committee', 'drugmaker', 'also', 'said', 'Beyfortus', 'approved', 'would', 'become', 'first', 'protective', 'option', 'newborn', 'infant', 'population', 'RSV', 'lower', 'respiratory', 'tract', 'Reuters', 'Market', 'movers', 'Property', 'groups', 'fall', 'reduce', 'price', 'targets', 'FDX', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BLND', 'Add', 'Portfolio', 'IDSI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Shares', 'Land', 'Securities', 'British', 'Land', 'fell', 'today', 'property', 'groups', 'downgraded', 'Goldman', 'Sachs', 'NYSE', 'JP', 'Morgan', 'lowered', 'price', 'targets', 'companies', 'Goldman', 'Sachs', 'downgraded', 'British', 'Land', 'neutral', 'buy', 'reduced', 'price', 'target', 'JPMorgan', 'NYSE', 'cut', 'price', 'target', 'retained', 'overweight', 'rating', 'On', 'Land', 'Securities', 'Goldman', 'Sachs', 'lowered', 'rating', 'sell', 'neutral', 'cut', 'price', 'target', 'JPMorgan', 'retained', 'neutral', 'rating', 'lower', 'price', 'target', 'Land', 'Securities', 'fell', 'British', 'Land', 'fell', 'Capita', 'lifted', 'double', 'dose', 'good', 'news', 'Shares', 'advanced', 'reported', 'contract', 'extension', 'Barnet', 'Council', 'disposal', 'subsidiary', 'Ltd', 'Access', 'PaySuite', 'Shares', 'outsourcing', 'services', 'group', 'rose', 'securing', 'contract', 'extension', 'north', 'London', 'council', 'worth', 'although', 'indexation', 'potential', 'additional', 'work', 'could', 'worth', 'Separately', 'Capita', 'said', 'agreed', 'dispose', 'division', 'Access', 'Group', 'basis', 'Capita', 'said', 'sale', 'help', 'reduce', 'debt', 'provide', 'additional', 'liquidity', 'allow', 'enhance', 'digital', 'offerings', 'clients', 'build', 'focused', 'sustainable', 'business', 'long', 'term', 'Royal', 'Mail', 'falls', 'FedEx', 'warning', 'Shares', 'dipped', 'today', 'following', 'profits', 'warning', 'US', 'peer', 'pulled', 'full', 'year', 'guidance', 'warning', 'first', 'quarter', 'profits', 'would', 'miss', 'estimates', 'global', 'demand', 'slowdown', 'accelerates', 'It', 'cited', 'macroeconomic', 'weakness', 'Asia', 'service', 'challenges', 'Europe', 'Investors', 'took', 'view', 'industry', 'challenges', 'would', 'Royal', 'Mail', 'also', 'faces', 'prospect', 'industrial', 'action', 'employees', 'strike', 'higher', 'pay', 'Royal', 'Mail', 'workers', 'represented', 'Communication', 'Workers', 'Union', 'CWU', 'planned', 'walkout', 'September', 'planning', 'strike', 'September', 'October', 'Shares', 'fell', 'EU', 'drug', 'approvals', 'boost', 'AstraZeneca', 'NASDAQ', 'rare', 'riser', 'said', 'today', 'received', 'two', 'recommendations', 'drug', 'approvals', 'EU', 'drug', 'blood', 'disorder', 'paroxysmal', 'nocturnal', 'haemoglobinuria', 'met', 'primary', 'endpoint', 'phase', 'three', 'trial', 'group', 'said', 'Beyfortus', 'drug', 'develops', 'Sanofi', 'EPA', 'prevention', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'recommended', 'marketing', 'authorisation', 'European', 'Union', 'Meanwhile', 'AstraZeneca', 'Evusheld', 'Covid', 'antibody', 'treatment', 'recommended', 'marketing', 'authorisation', 'EU', 'adults', 'virus', 'risk', 'progressing', 'severe', 'disease', 'company', 'explained', 'phase', 'III', 'treatment', 'data', 'showed', 'reduced', 'risk', 'severe', 'Covid', 'death', 'Shares', 'rose', 'following', 'news', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'FILE', 'PHOTO', 'Tablet', 'bottles', 'AstraZeneca', 'cancer', 'medicine', 'Lynparza', 'seen', 'undated', 'handout', 'image', 'provided', 'Reuters', 'June', 'via', 'REUTERS', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'AstraZeneca', 'NASDAQ', 'said', 'Thursday', 'drug', 'Lynparza', 'developed', 'Merck', 'Co', 'approved', 'European', 'Union', 'adjuvant', 'treatment', 'patients', 'form', 'genetically', 'mutated', 'breast', 'Reuters', 'Daily', 'Biotech', 'Pulse', 'Celyad', 'Resumes', 'Colorectal', 'Cancer', 'Trial', 'Setback', 'For', 'Otonomy', 'AstraZeneca', 'Halts', 'Phase', 'Head', 'Neck', 'Cancer', 'Trial', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'OTIC', 'Add', 'Portfolio', 'BEAM', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Here', 'roundup', 'top', 'developments', 'biotech', 'space', 'last', 'hours', 'Stocks', 'In', 'Focus', 'Arcutis', 'Psoriasis', 'Treatment', 'Scores', 'FDA', 'Approval', 'FDA', 'approved', 'Arcutis', 'Biotherapeutics', 'Inc', 'NASDAQ', 'ARQT', 'Zoryve', 'roflumilast', 'cream', 'plaque', 'psoriasis', 'including', 'intertriginous', 'areas', 'patients', 'years', 'age', 'older', 'It', 'first', 'topical', 'inhibitor', 'approved', 'plaque', 'psoriasis', 'commercial', 'product', 'expected', 'available', 'Arcutis', 'expects', 'draw', 'additional', 'million', 'company', 'debt', 'facility', 'SLR', 'Capital', 'Partners', 'Shares', 'premarket', 'session', 'FDA', 'Removes', 'Clinical', 'Hold', 'On', 'Celyad', 'Colorectal', 'Cancer', 'Trial', 'FDA', 'lifted', 'clinical', 'hold', 'Celyad', 'Oncology', 'SA', 'NASDAQ', 'CYAD', 'Phase', 'trial', 'company', 'made', 'changes', 'eligibility', 'criteria', 'trial', 'In', 'February', 'company', 'voluntarily', 'paused', 'trial', 'investigate', 'reports', 'two', 'fatalities', 'study', 'FDA', 'subsequently', 'put', 'trial', 'clinical', 'hold', 'March', 'Shares', 'premarket', 'session', 'HUTCHMED', 'Starts', 'Midstage', 'Tazemetostat', 'Study', 'For', 'Lymphoma', 'Setting', 'HUTCHMED', 'China', 'Limited', 'NASDAQ', 'HCM', 'initiated', 'bridging', 'Phase', 'study', 'tazemetostat', 'China', 'follicular', 'lymphoma', 'FL', 'first', 'patient', 'received', 'first', 'dose', 'July', 'primary', 'objective', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'patients', 'mutations', 'Cohort', 'secondary', 'objectives', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'Related', 'Biotech', 'Investors', 'August', 'Key', 'PDUFA', 'Catalysts', 'You', 'Must', 'Know', 'FDA', 'Signs', 'Off', 'On', 'Eledon', 'Pharma', 'Tegoprubart', 'For', 'Kidnety', 'Transplant', 'Rejection', 'FDA', 'cleared', 'Eledon', 'Pharmaceuticals', 'Inc', 'NASDAQ', 'ELDN', 'Investigational', 'New', 'Drug', 'IND', 'application', 'evaluate', 'tegoprubart', 'preventing', 'organ', 'rejection', 'patients', 'receiving', 'kidney', 'transplant', 'phase', 'study', 'enroll', 'approximately', 'participants', 'undergoing', 'kidney', 'transplant', 'Kazia', 'Shares', 'Fall', 'After', 'Update', 'From', 'Pivotal', 'Brain', 'Tumor', 'Trial', 'Kazia', 'Therapeutics', 'Limited', 'NASDAQ', 'KZIA', 'said', 'GBM', 'AGILE', 'pivotal', 'study', 'paxalisib', 'newly', 'diagnosed', 'glioblastoma', 'meet', 'criteria', 'continuing', 'second', 'stage', 'Patients', 'enrolled', 'first', 'stage', 'paxalisib', 'arm', 'continue', 'treatment', 'per', 'protocol', 'completion', 'final', 'analysis', 'Kazia', 'anticipates', 'receiving', 'second', 'half', 'company', 'open', 'study', 'paxalisib', 'arm', 'Germany', 'China', 'Shares', 'premarket', 'session', 'FDA', 'Places', 'Clinical', 'Hold', 'On', 'Beam', 'Therapeutics', 'IND', 'Application', 'For', 'Blood', 'Cancer', 'Study', 'FDA', 'placed', 'clinical', 'hold', 'Beam', 'Therapeutics', 'Inc', 'NASDAQ', 'BEAM', 'Investigational', 'New', 'Drug', 'IND', 'application', 'acute', 'lymphoblastic', 'cell', 'lymphoblastic', 'lymphoma', 'IND', 'submitted', 'end', 'June', 'FDA', 'indicated', 'would', 'provide', 'Beam', 'official', 'clinical', 'hold', 'letter', 'within', 'days', 'Beam', 'plans', 'provide', 'additional', 'updates', 'pending', 'discussion', 'FDA', 'Otonomy', 'Shares', 'Sink', 'After', 'Stopping', 'Midstage', 'Tinnitus', 'Study', 'Otonomy', 'Inc', 'NASDAQ', 'OTIC', 'announced', 'Phase', 'trial', 'tinnitus', 'demonstrated', 'clinically', 'meaningful', 'benefit', 'versus', 'placebo', 'primary', 'secondary', 'endpoints', 'across', 'time', 'points', 'study', 'show', 'higher', 'response', 'rate', 'placebo', 'prospectively', 'defined', 'patient', 'subgroup', 'tinnitus', 'duration', 'fewer', 'six', 'months', 'population', 'studied', 'Phase', 'trial', 'overall', 'results', 'support', 'development', 'Shares', 'slipping', 'cents', 'premarket', 'session', 'AstraZeneca', 'NASDAQ', 'Cuts', 'Phase', 'Trial', 'In', 'Head', 'Neck', 'Cancer', 'Innate', 'Pharma', 'SA', 'NASDAQ', 'IPHA', 'futility', 'interim', 'analysis', 'Phase', 'study', 'sponsored', 'AstraZeneca', 'Plc', 'NASDAQ', 'AZN', 'meet', 'threshold', 'efficacy', 'Based', 'result', 'recommendation', 'Independent', 'Data', 'Monitoring', 'Committee', 'AstraZeneca', 'informed', 'Innate', 'study', 'discontinued', 'There', 'new', 'safety', 'findings', 'AstraZeneca', 'plans', 'share', 'data', 'due', 'course', 'IPHA', 'shares', 'premarket', 'session', 'ALX', 'Oncology', 'Evorpacept', 'Fast', 'Tracked', 'In', 'US', 'For', 'Head', 'Neck', 'Cancer', 'FDA', 'granted', 'Fast', 'Track', 'designation', 'ALX', 'Oncology', 'Holdings', 'Inc', 'NASDAQ', 'ALXO', 'evorpacept', 'combination', 'Merck', 'Co', 'Inc', 'NYSE', 'MRK', 'Keytruda', 'treatment', 'positive', 'advanced', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'FDA', 'decision', 'informed', 'results', 'ALX', 'Oncology', 'phase', 'study', 'showed', 'preliminary', 'antitumor', 'activity', 'favorable', 'safety', 'profile', 'Shares', 'premarket', 'session', 'Offerings', 'TherapeuticsMD', 'Inc', 'NASDAQ', 'TXMD', 'received', 'private', 'investment', 'company', 'common', 'stock', 'new', 'series', 'preferred', 'stock', 'Rubric', 'Capital', 'Management', 'LP', 'On', 'Radar', 'Earnings', 'Cerevel', 'Therapeutics', 'Holdings', 'Inc', 'NASDAQ', 'CERE', 'Before', 'market', 'open', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'reserved', 'Read', 'Benzinga', 'Read', 'original', 'article', 'Reuters', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'FCHI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Gold', 'Add', 'Portfolio', 'LCO', 'Add', 'Portfolio', 'CL', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Peter', 'Nurse', 'European', 'stock', 'markets', 'largely', 'edged', 'higher', 'Monday', 'starting', 'new', 'week', 'cautious', 'note', 'investors', 'digested', 'weak', 'Chinese', 'economic', 'data', 'By', 'ET', 'GMT', 'Germany', 'traded', 'lower', 'France', 'rose', 'traded', 'higher', 'Economic', 'data', 'released', 'earlier', 'Monday', 'showed', 'China', 'economic', 'growth', 'rate', 'unexpectedly', 'slowing', 'July', 'prompting', 'country', 'central', 'bank', 'surprise', 'move', 'grew', 'July', 'year', 'earlier', 'growth', 'rate', 'increase', 'expected', 'rose', 'year', 'ago', 'missing', 'forecasts', 'growth', 'growth', 'seen', 'June', 'China', 'economy', 'world', 'second', 'largest', 'struggling', 'shake', 'June', 'quarter', 'hit', 'growth', 'strict', 'COVID', 'restrictions', 'On', 'flip', 'side', 'back', 'Europe', 'Denmark', 'economy', 'grew', 'faster', 'expected', 'second', 'quarter', 'expanding', 'first', 'three', 'months', 'year', 'contracted', 'first', 'quarter', 'raised', 'interest', 'rates', 'July', 'expected', 'September', 'even', 'though', 'risk', 'Eurozone', 'recession', 'reached', 'highest', 'level', 'since', 'November', 'energy', 'shortages', 'threaten', 'drive', 'already', 'record', 'inflation', 'higher', 'still', 'In', 'corporate', 'news', 'AstraZeneca', 'LON', 'NASDAQ', 'stock', 'rose', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patients', 'boosting', 'prospects', 'regulatory', 'approvals', 'Henkel', 'ETR', 'stock', 'rose', 'German', 'company', 'said', 'sales', 'rose', 'first', 'half', 'year', 'earnings', 'fell', 'hurt', 'increasing', 'logistics', 'prices', 'Oil', 'prices', 'fell', 'Monday', 'weighed', 'potential', 'increase', 'supply', 'oil', 'giant', 'Saudi', 'Aramco', 'TADAWUL', 'well', 'concerns', 'slowing', 'growth', 'China', 'world', 'economy', 'Saudi', 'Aramco', 'stands', 'ready', 'raise', 'crude', 'oil', 'output', 'maximum', 'capacity', 'million', 'barrels', 'per', 'day', 'requested', 'Saudi', 'Arabian', 'government', 'Chief', 'Executive', 'Amin', 'Nasser', 'said', 'Sunday', 'energy', 'firm', 'announced', 'one', 'largest', 'quarterly', 'profits', 'history', 'By', 'ET', 'futures', 'traded', 'lower', 'barrel', 'contract', 'fell', 'Additionally', 'fell', 'traded', 'lower', 'Reuters', 'FILE', 'PHOTO', 'Signage', 'seen', 'outside', 'entrance', 'London', 'Stock', 'Exchange', 'London', 'Britain', 'Aug', 'Photo', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'Add', 'Portfolio', 'ENRY', 'Add', 'Portfolio', 'By', 'Sruthi', 'Shankar', 'Reuters', 'edged', 'Monday', 'gains', 'drugmaker', 'AstraZeneca', 'NASDAQ', 'consumer', 'stocks', 'relieved', 'pressure', 'mining', 'oil', 'heavyweights', 'data', 'showed', 'China', 'economy', 'unexpectedly', 'slowed', 'last', 'month', 'FTSE', 'added', 'hold', 'near', 'highs', 'midcap', 'inched', 'Investors', 'awaiting', 'UK', 'employment', 'report', 'well', 'consumer', 'prices', 'data', 'later', 'week', 'gauge', 'state', 'labour', 'market', 'inflation', 'data', 'could', 'offer', 'clues', 'whether', 'Bank', 'England', 'opts', 'second', 'consecutive', 'hike', 'September', 'meeting', 'mood', 'dull', 'Asian', 'European', 'stock', 'markets', 'investors', 'turning', 'defensive', 'sectors', 'healthcare', 'consumer', 'staples', 'amid', 'worries', 'health', 'world', 'economy', 'AstraZeneca', 'gained', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'developed', 'Japan', 'Daiichi', 'Sankyo', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patients', 'Oil', 'major', 'Shell', 'LON', 'miners', 'Rio', 'Tinto', 'LON', 'Anglo', 'American', 'LON', 'slipped', 'tandem', 'weaker', 'commodity', 'prices', 'release', 'China', 'data', 'FTSE', 'outperformed', 'global', 'peers', 'year', 'due', 'large', 'exposure', 'commodity', 'stocks', 'surged', 'back', 'jump', 'oil', 'metal', 'prices', 'A', 'weakening', 'pound', 'also', 'boosted', 'dollar', 'earners', 'index', 'Whether', 'trend', 'continue', 'ultimately', 'hinges', 'outlook', 'global', 'energy', 'stocks', 'relative', 'broad', 'market', 'BCA', 'Research', 'analysts', 'wrote', 'note', 'FTSE', 'nearly', 'far', 'year', 'MSCI', 'world', 'equities', 'index', 'shed', 'almost', 'Our', 'energy', 'strategists', 'remain', 'bullish', 'oil', 'Their', 'expectation', 'breach', 'average', 'suggests', 'overweight', 'energy', 'sector', 'extension', 'UK', 'equities', 'remains', 'appropriate', 'Reuters', 'FTSE', 'positive', 'early', 'highs', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slips', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sales', 'output', 'numbers', 'forecast', 'UK', 'house', 'prices', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gains', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gains', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'points', 'good', 'Richard', 'Hunter', 'head', 'markets', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'markets', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tensions', 'delegation', 'US', 'lawmakers', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdowns', 'escalating', 'property', 'Retail', 'sales', 'industrial', 'output', 'rose', 'less', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'shares', 'rose', 'pharmaceuticals', 'group', 'said', 'positive', 'results', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilders', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'prices', 'slipped', 'Positive', 'start', 'proceedings', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'makes', 'positive', 'start', 'trading', 'boosted', 'gains', 'US', 'Friday', 'despite', 'mixed', 'performances', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'industrial', 'output', 'figures', 'At', 'lead', 'index', 'trading', 'points', 'higher', 'broader', 'points', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'prices', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'says', 'A', 'drop', 'asking', 'prices', 'expected', 'month', 'frenzied', 'two', 'years', 'many', 'home', 'movers', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'number', 'properties', 'currently', 'market', 'buy', 'levels', 'despite', 'lack', 'instructions', 'new', 'listings', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increases', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'markets', 'expected', 'open', 'higher', 'Monday', 'following', 'gains', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sales', 'industrial', 'output', 'figures', 'Investors', 'also', 'one', 'eye', 'UK', 'jobs', 'inflation', 'reports', 'due', 'later', 'week', 'see', 'whether', 'signs', 'slowdown', 'jobs', 'market', 'prices', 'growth', 'Spread', 'betting', 'companies', 'calling', 'FTSE', 'around', 'points', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headlines', 'rising', 'gas', 'prices', 'supply', 'chain', 'challenges', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stocks', 'lower', 'recent', 'Asia', 'markets', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sales', 'industrial', 'production', 'numbers', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'comes', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'comes', 'struggle', 'adapt', 'policy', 'government', 'shows', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyers', 'halting', 'mortgage', 'payments', 'protest', 'delays', 'completion', 'new', 'In', 'June', 'saw', 'effects', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'signs', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sales', 'numbers', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectations', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'results', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'showed', 'strong', 'cash', 'generation', 'six', 'months', 'June', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gains', 'US', 'Friday', 'Spread', 'betting', 'companies', 'calling', 'blue', 'chip', 'index', 'around', 'points', 'closed', 'Friday', 'points', 'jumped', 'points', 'S', 'P', 'added', 'points', 'reach', 'benchmarks', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FTSE', 'positive', 'early', 'highs', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slips', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sales', 'output', 'numbers', 'forecast', 'UK', 'house', 'prices', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gains', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gains', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'points', 'good', 'Richard', 'Hunter', 'head', 'markets', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'markets', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tensions', 'delegation', 'US', 'lawmakers', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdowns', 'escalating', 'property', 'Retail', 'sales', 'industrial', 'output', 'rose', 'less', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'shares', 'rose', 'pharmaceuticals', 'group', 'said', 'positive', 'results', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilders', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'prices', 'slipped', 'Positive', 'start', 'proceedings', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'makes', 'positive', 'start', 'trading', 'boosted', 'gains', 'US', 'Friday', 'despite', 'mixed', 'performances', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'industrial', 'output', 'figures', 'At', 'lead', 'index', 'trading', 'points', 'higher', 'broader', 'points', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'prices', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'says', 'A', 'drop', 'asking', 'prices', 'expected', 'month', 'frenzied', 'two', 'years', 'many', 'home', 'movers', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'number', 'properties', 'currently', 'market', 'buy', 'levels', 'despite', 'lack', 'instructions', 'new', 'listings', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increases', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'markets', 'expected', 'open', 'higher', 'Monday', 'following', 'gains', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sales', 'industrial', 'output', 'figures', 'Investors', 'also', 'one', 'eye', 'UK', 'jobs', 'inflation', 'reports', 'due', 'later', 'week', 'see', 'whether', 'signs', 'slowdown', 'jobs', 'market', 'prices', 'growth', 'Spread', 'betting', 'companies', 'calling', 'FTSE', 'around', 'points', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headlines', 'rising', 'gas', 'prices', 'supply', 'chain', 'challenges', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stocks', 'lower', 'recent', 'Asia', 'markets', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sales', 'industrial', 'production', 'numbers', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'comes', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'comes', 'struggle', 'adapt', 'policy', 'government', 'shows', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyers', 'halting', 'mortgage', 'payments', 'protest', 'delays', 'completion', 'new', 'In', 'June', 'saw', 'effects', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'signs', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sales', 'numbers', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectations', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'results', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'showed', 'strong', 'cash', 'generation', 'six', 'months', 'June', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gains', 'US', 'Friday', 'Spread', 'betting', 'companies', 'calling', 'blue', 'chip', 'index', 'around', 'points', 'closed', 'Friday', 'points', 'jumped', 'points', 'S', 'P', 'added', 'points', 'reach', 'benchmarks', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerAVEPp', 'Add', 'Portfolio', 'ROG', 'Add', 'Portfolio', 'RHHVF', 'Add', 'Portfolio', 'SNY', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'SASY', 'Add', 'Portfolio', 'By', 'Scott', 'Kanowsky', 'Sanofi', 'SA', 'EPA', 'shares', 'slid', 'Wednesday', 'French', 'drugmaker', 'announced', 'halt', 'trials', 'new', 'treatment', 'patients', 'battling', 'advanced', 'breast', 'cancer', 'In', 'statement', 'company', 'said', 'would', 'stop', 'global', 'clinical', 'development', 'medicine', 'known', 'amcenestrant', 'phase', 'study', 'showed', 'effective', 'enough', 'warrant', 'research', 'All', 'studies', 'amcenestrant', 'including', 'breast', 'cancer', 'also', 'discontinued', 'Sanofi', 'added', 'While', 'disappointed', 'outcome', 'research', 'scientific', 'understanding', 'endocrine', 'therapies', 'people', 'breast', 'cancer', 'said', 'John', 'Reed', 'global', 'head', 'research', 'development', 'Sanofi', 'In', 'note', 'analysts', 'Morgan', 'Stanley', 'called', 'decision', 'setback', 'innovation', 'narrative', 'put', 'forward', 'Sanofi', 'saying', 'amcenestrant', 'flagged', 'potentially', 'lucrative', 'piece', 'group', 'drug', 'pipeline', 'end', 'Sanofi', 'amcenestrant', 'trials', 'expected', 'lead', 'negative', 'impact', 'company', 'estimated', 'discounted', 'cash', 'flow', 'according', 'Morgan', 'Stanley', 'analysts', 'decision', 'could', 'also', 'effect', 'studies', 'conducted', 'similar', 'breast', 'cancer', 'drugs', 'Sanofi', 'rivals', 'Roche', 'SIX', 'AstraZeneca', 'PLC', 'LON', 'analysts', 'added']]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "3Ftc1gABgZqH"
      },
      "source": [
        "## 5. Text normalisation\n",
        "\n",
        "Stemming and lemmatisation are text normalisation techniques within NLP that are used to prepare text, words, and documents for further processing and both generate the root form of the inflected words.\n",
        "\n",
        "### 5.1 Stemming\n",
        "\n",
        "Stemming is the process of removing the suffix from a word to reduce inflected/derived words to their word stem, base or root form. There are many ways to perform stemming such as lookup table, suffix-stripping algorithms etc. These mainly rely on chopping off ‘s’, ‘es’, ‘ed’, ‘ing’, ‘ly’ etc from the end of the words until the stem is reached. \n",
        "\n",
        "Stemming is a somewhat crude method for cataloguing related words and sometimes the conversion is not desirable. The stem might not be an actual word, and English has many exceptions where a more sophisticated process is required to overcome the two main stemming errors of over-stemming and under-stemming. Nevertheless, stemming helps in standardising text and follows an algorithm with steps to perform on the words which makes it simpler and faster than lemmatisation.\n",
        "\n",
        "One of the most common — and effective — stemming algorithms is the **Porter Stemmer** developed by Martin Porter in 1980. It is based on the idea that the suffixes in the English language are made up of a combination of smaller and simpler suffixes. The algorithm employs five phases of word reduction, each with its own set of mapping rules. \n",
        "\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "HQ0WaKLmPITY",
        "outputId": "58a07cf4-65c6-4dda-d880-d190497e50ee"
      },
      "source": [
        "ps = PorterStemmer()\n",
        "\n",
        "def nltk_stemmer(text):\n",
        "  # Iterate for all words for all articles \n",
        "  stemmed_articles = [[ps.stem(w) for w in filtered_article] for filtered_article in filtered_articles]\n",
        "  return stemmed_articles\n",
        "\n",
        "nltk_stemmed_articles = nltk_stemmer(filtered_articles)\n",
        "print(nltk_stemmed_articles)"
      ],
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[['astrazeneca', 'plc', 'said', 'wednesday', 'capivasertib', 'plu', 'faslodex', 'significantli', 'improv', 'surviv', 'compar', 'faslodex', 'combin', 'placebo', 'phase', 'trial', 'advanc', 'hormon', 'breast', 'cancer', 'pharma', 'giant', 'azn', 'azn', 'said', 'trial', 'met', 'primari', 'endpoint', 'improv', 'surviv', 'overal', 'patient', 'popul', 'prespecifi', 'biomark', 'subgroup', 'patient', 'whose', 'tumor', 'qualifi', 'tout', 'posit', 'data', 'from', 'two', 'experiment', 'drug', 'in', 'breast', 'cancer', 'settingsastrazeneca', 'ultomiri', 'show', 'zero', 'relaps', 'in', 'patient', 'with', 'chronic', 'disord', 'of', 'brain', 'spinal', 'cordastrazeneca', 'nasdaq', 'azn', 'announc', 'tuesday', 'vaccin', 'vaxzevria', 'recombin', 'given', 'full', 'market', 'authoris', 'ma', 'european', 'union', 'eu', 'vaxzevria', 'origin', 'grant', 'condit', 'market', 'authoris', 'cma', 'eu', 'astrazeneca', 'state', 'as', 'continu', 'suffici', 'evid', 'safeti', 'efficaci', 'confirm', 'benefit', 'vaxzevria', 'european', 'medicin', 'agenc', 'ema', 'grant', 'full', 'iskra', 'reic', 'evp', 'vaccin', 'immun', 'therapi', 'astrazeneca', 'comment', 'move', 'condit', 'full', 'market', 'authoris', 'vaxzevria', 'import', 'confirm', 'ema', 'safeti', 'efficaci', 'vaxzevria', 'demonstr', 'benefit', 'continu', 'outweigh', 'potenti', 'risk', 'vaxzevria', 'estim', 'help', 'save', 'six', 'million', 'live', 'first', 'year', 'vaccin', 'reflect', 'strength', 'evid', 'show', 'vaxzevria', 'protect', 'sever', 'diseas', 'death', 'caus', 'european', 'medicin', 'agenc', 'ema', 'grant', 'full', 'market', 'authoris', 'astrazeneca', 'plc', 'azn', 'vaccin', 'vaxzevria', 'recombin', 'vaccin', 'vaxzevria', 'recombin', 'vaxzevria', 'initi', 'grant', 'condit', 'market', 'authoris', 'due', 'urgenc', 'pandem', 'as', 'continu', 'suffici', 'evid', 'safeti', 'efficaci', 'confirm', 'benefit', 'vaxzevria', 'ema', 'grant', 'full', 'approv', 'approv', 'cover', 'use', 'vaxzevria', 'primari', 'vaccin', 'seri', 'heterolog', 'approv', 'mrna', 'vaccin', 'homolog', 'vaccin', 'booster', 'relat', 'univers', 'partner', 'nasal', 'vaccin', 'flunk', 'human', 'trial', 'univers', 'partner', 'nasal', 'vaccin', 'flunk', 'human', 'trial', 'vaxzevria', 'demonstr', 'effect', 'form', 'mild', 'symptomat', 'sever', 'diseas', 'includ', 'hospit', 'death', 'accord', 'clinic', 'studi', 'evid', 'these', 'includ', 'expert', 'review', 'data', 'studi', 'show', 'vaxzevria', 'avail', 'mrna', 'vaccin', 'provid', 'equal', 'effect', 'protect', 'hospit', 'death', 'follow', 'three', 'dose', 'there', 'also', 'substanti', 'bodi', 'evid', 'support', 'boost', 'vaxzevria', 'follow', 'primari', 'vaccin', 'schedul', 'test', 'date', 'price', 'action', 'azn', 'share', 'premarket', 'session', 'last', 'check', 'tuesday', 'azn', 'share', 'premarket', 'session', 'last', 'check', 'tuesday', 'photo', 'paul', 'mcmanu', 'pixabay', 'benzinga', 'provid', 'invest', 'advic', 'all', 'right', 'shift', 'china', 'factori', 'worker', 'to', 'us', 'plant', 'complet', 'european', 'approv', 'for', 'astrazeneca', 'shot', 'tesla', 'eye', 'cybertruck', 'commerci', 'next', 'year', 'top', 'stori', 'tuesday', 'european', 'commiss', 'approv', 'astrazeneca', 'plc', 'azn', 'sanofi', 'sa', 'sni', 'beyfortu', 'nirsevimab', 'antibodi', 'prevent', 'respiratori', 'syncyti', 'viru', 'rsv', 'lower', 'respiratori', 'tract', 'diseas', 'newborn', 'infant', 'first', 'rsv', 'season', 'beyfortu', 'nirsevimab', 'antibodi', 'prevent', 'respiratori', 'syncyti', 'viru', 'rsv', 'lower', 'respiratori', 'tract', 'diseas', 'newborn', 'infant', 'first', 'rsv', 'season', 'beyfortu', 'first', 'rsv', 'passiv', 'immun', 'broad', 'infant', 'popul', 'includ', 'born', 'healthi', 'term', 'preterm', 'specif', 'health', 'condit', 'in', 'pivot', 'melodi', 'efficaci', 'trial', 'beyfortu', 'met', 'primari', 'endpoint', 'reduc', 'incid', 'medic', 'attend', 'lower', 'respiratori', 'tract', 'infect', 'lrti', 'caus', 'rsv', 'placebo', 'day', 'singl', 'dose', 'beyfortu', 'also', 'demonstr', 'compar', 'safeti', 'toler', 'profil', 'swedish', 'orphan', 'biovitrum', 'ab', 'biovf', 'synagi', 'palivizumab', 'medley', 'phase', 'trial', 'synagi', 'palivizumab', 'medley', 'phase', 'trial', 'global', 'approxim', 'million', 'case', 'acut', 'lower', 'respiratori', 'infect', 'lead', 'three', 'million', 'hospit', 'it', 'estim', 'death', 'children', 'younger', 'five', 'year', 'price', 'action', 'sni', 'share', 'azn', 'share', 'premarket', 'session', 'last', 'check', 'friday', 'benzinga', 'provid', 'invest', 'advic', 'all', 'right', 'reuter', 'astrazeneca', 'share', 'get', 'lift', 'heartburn', 'drug', 'litig', 'closur', 'say', 'citi', 'azn', 'add', 'portfolio', 'lfcof', 'add', 'portfolio', 'add', 'portfolio', 'astrazeneca', 'plc', 'nasdaq', 'get', 'boost', 'probabl', 'close', 'us', 'kidney', 'damag', 'lawsuit', 'new', 'jersey', 'prior', 'first', 'bellweth', 'case', 'march', 'accord', 'analyst', 'citi', 'uk', 'pharma', 'one', 'sever', 'firm', 'embroil', 'us', 'legal', 'action', 'possibl', 'damag', 'caus', 'proton', 'pump', 'inhibitor', 'ppi', 'heartburn', 'drug', 'nexium', 'launch', 'astra', 'us', 'citi', 'analyst', 'believ', 'like', 'outcom', 'judg', 'delay', 'respons', 'defend', 'motion', 'summari', 'judgement', 'ground', 'encourag', 'plaintiff', 'settl', 'altern', 'lower', 'probabl', 'judg', 'cecchi', 'may', 'delay', 'start', 'bellweth', 'case', 'disagre', 'conclus', 'special', 'master', 'reisman', 'grant', 'defend', 'motion', 'dismiss', 'ground', 'said', 'either', 'scenario', 'would', 'materi', 'posit', 'astra', 'depress', 'share', 'price', 'us', 'bank', 'analyst', 'ad', 'would', 'posit', 'interim', 'data', 'enhertu', 'posit', 'data', 'march', 'citi', 'analyst', 'said', 'core', 'ep', 'forecast', 'astra', 'consensu', 'repeat', 'alongsid', 'price', 'target', 'recommend', 'share', 'astra', 'rose', 'read', 'proactiv', 'investor', 'uk', 'disclaimerbi', 'benzinga', 'crypto', 'parti', 'start', 'corpor', 'optim', 'hope', 'fed', 'thaw', 'perk', 'risk', 'appetit', 'financi', 'market', 'ethereum', 'crypto', 'eth', 'second', 'astrazeneca', 'beyfortu', 'receiv', 'eu', 'approv', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'astrazeneca', 'nasdaq', 'state', 'beyfortu', 'first', 'rsv', 'passiv', 'immunis', 'broad', 'infant', 'popul', 'includ', 'born', 'healthi', 'term', 'specif', 'health', 'condit', 'group', 'said', 'european', 'commiss', 'first', 'regulatori', 'bodi', 'grant', 'approv', 'beyfortu', 'approv', 'base', 'result', 'drug', 'clinic', 'develop', 'programm', 'follow', 'recommend', 'committe', 'medicin', 'product', 'human', 'use', 'european', 'medicin', 'agenc', 'septemb', 'in', 'azn', 'pivot', 'melodi', 'efficaci', 'trial', 'beyfortu', 'met', 'primari', 'endpoint', 'reduc', 'incid', 'medic', 'attend', 'lower', 'respiratori', 'tract', 'infect', 'caus', 'rsv', 'versu', 'placebo', 'day', 'singl', 'dose', 'iskra', 'eric', 'azn', 'execut', 'vice', 'presid', 'vaccin', 'immun', 'therapi', 'said', 'beyfortu', 'first', 'prevent', 'option', 'respiratori', 'syncyti', 'viru', 'gain', 'approv', 'europ', 'also', 'first', 'prevent', 'option', 'approv', 'broad', 'infant', 'popul', 'today', 'market', 'authoris', 'beyfortu', 'mark', 'signific', 'achiev', 'scientif', 'commun', 'address', 'persist', 'global', 'unmet', 'need', 'rsv', 'prevent', 'report', 'iain', 'gilbert', 'read', 'reuter', 'astrazeneca', 'say', 'evusheld', 'approv', 'treatment', 'eu', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'said', 'antibodi', 'combin', 'evusheld', 'tixagevimab', 'cilgavimab', 'formerli', 'approv', 'eu', 'treatment', 'approv', 'european', 'commiss', 'cover', 'peopl', 'age', 'year', 'requir', 'supplement', 'oxygen', 'increas', 'risk', 'progress', 'sever', 'pharmaceut', 'group', 'said', 'european', 'commiss', 'approv', 'base', 'result', 'tackl', 'phase', 'iii', 'treatment', 'trial', 'show', 'evusheld', 'significantli', 'reduc', 'risk', 'sever', 'death', 'recommend', 'dose', 'evusheld', 'treatment', 'europ', 'tixagevimab', 'cilgavimab', 'administ', 'two', 'separ', 'sequenti', 'im', 'inject', 'astrazeneca', 'nasdaq', 'note', 'mani', 'peopl', 'includ', 'immunocompromis', 'older', 'adult', 'underli', 'health', 'condit', 'high', 'risk', 'sever', 'diseas', 'hospitalis', 'death', 'becom', 'infect', 'evusheld', 'deliv', 'conveni', 'intramuscular', 'formul', 'new', 'treatment', 'option', 'vulner', 'popul', 'comment', 'dr', 'michel', 'goldman', 'professor', 'institut', 'interdisciplinari', 'innov', 'healthcar', 'université', 'libr', 'de', 'bruxel', 'former', 'execut', 'director', 'european', 'innov', 'medicin', 'initi', 'statement', 'iskra', 'reic', 'execut', 'vice', 'presid', 'vaccin', 'immun', 'therapi', 'astrazeneca', 'ad', 'remain', 'ongo', 'health', 'concern', 'million', 'european', 'around', 'world', 'especi', 'may', 'viru', 'vaccin', 'with', 'approv', 'evusheld', 'antibodi', 'combin', 'avail', 'prevent', 'treatment', 'europ', 'allow', 'us', 'protect', 'even', 'peopl', 'devast', 'diseas', 'read', 'proactiv', 'investor', 'uk', 'reuter', 'astrazeneca', 'get', 'third', 'regulatori', 'green', 'light', 'matter', 'week', 'asthma', 'drug', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'astrazeneca', 'plc', 'lon', 'said', 'tezspir', 'treatment', 'approv', 'japan', 'sever', 'bronchial', 'asthma', 'tradit', 'corticosteroid', 'work', 'it', 'third', 'approv', 'matter', 'week', 'product', 'potenti', 'challeng', 'market', 'leader', 'dupxient', 'it', 'develop', 'collabor', 'us', 'giant', 'amgen', 'nasdaq', 'in', 'clinic', 'trial', 'drug', 'shown', 'lower', 'research', 'call', 'asthma', 'exacerb', 'tezspir', 'first', 'biolog', 'approv', 'japanes', 'ministri', 'health', 'labour', 'welfar', 'shown', 'consist', 'significantli', 'reduc', 'attack', 'exacerb', 'trial', 'broad', 'popul', 'sever', 'asthma', 'patient', 'irrespect', 'biomark', 'level', 'mene', 'pangalo', 'head', 'biopharmaceut', 'research', 'az', 'tezspir', 'potenti', 'improv', 'outcom', 'mani', 'patient', 'sever', 'asthma', 'work', 'make', 'import', 'medicin', 'avail', 'japan', 'quickli', 'analyst', 'believ', 'tezspir', 'could', 'big', 'seller', 'peak', 'sale', 'project', 'order', 'us', 'read', 'proactiv', 'investor', 'uk', 'reuter', 'file', 'photo', 'compani', 'logo', 'pharmaceut', 'compani', 'astrazeneca', 'display', 'screen', 'floor', 'new', 'york', 'stock', 'exchang', 'april', 'photo', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'reuter', 'share', 'logicbio', 'therapeut', 'skyrocket', 'monday', 'britain', 'astrazeneca', 'nasdaq', 'said', 'would', 'buy', 'gene', 'therapi', 'develop', 'rare', 'premium', 'million', 'loigbio', 'share', 'trade', 'sinc', 'februari', 'bell', 'close', 'astrazeneca', 'offer', 'price', 'per', 'share', 'logicbio', 'develop', 'gene', 'edit', 'therapi', 'treat', 'pediatr', 'rare', 'diseas', 'like', 'methylmalon', 'acidemia', 'bodi', 'break', 'certain', 'protein', 'fat', 'astrazeneca', 'said', 'deal', 'would', 'acceler', 'growth', 'alexion', 'nasdaq', 'unit', 'acquir', 'billion', 'last', 'year', 'field', 'genom', 'benzinga', 'crypto', 'parti', 'start', 'corpor', 'optim', 'hope', 'fed', 'thaw', 'perk', 'risk', 'appetit', 'financi', 'market', 'ethereum', 'crypto', 'eth', 'second', 'reuter', 'astrazeneca', 'say', 'combin', 'approv', 'advanc', 'liver', 'cancer', 'us', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'astrazeneca', 'plc', 'lon', 'announc', 'us', 'food', 'drug', 'administr', 'fda', 'approv', 'compani', 'imjudo', 'tremelimumab', 'drug', 'combin', 'imfinzi', 'durvalumab', 'treatment', 'adult', 'patient', 'unresect', 'hepatocellular', 'carcinoma', 'hcc', 'common', 'type', 'liver', 'cancer', 'approv', 'base', 'result', 'himalaya', 'phase', 'iii', 'trial', 'show', 'singl', 'prime', 'dose', 'antibodi', 'imjudo', 'ad', 'antibodi', 'imfinzi', 'reduc', 'risk', 'death', 'compar', 'sorafenib', 'pharmaceut', 'compani', 'said', 'liver', 'cancer', 'caus', 'cancer', 'death', 'sixth', 'commonli', 'diagnos', 'cancer', 'worldwid', 'it', 'caus', 'death', 'us', 'approxim', 'new', 'diagnos', 'year', 'compani', 'said', 'in', 'statement', 'dave', 'fredrickson', 'execut', 'vice', 'presid', 'oncolog', 'busi', 'unit', 'astrazeneca', 'comment', 'with', 'first', 'regulatori', 'approv', 'imjudo', 'patient', 'unresect', 'liver', 'cancer', 'us', 'approv', 'dual', 'immunotherapi', 'treatment', 'regimen', 'har', 'potenti', 'inhibit', 'uniqu', 'combin', 'inhibitor', 'enhanc', 'immun', 'respons', 'cancer', 'dr', 'ghassan', 'attend', 'physician', 'memori', 'sloan', 'ketter', 'cancer', 'center', 'msk', 'princip', 'investig', 'himalaya', 'phase', 'iii', 'trial', 'said', 'patient', 'unresect', 'liver', 'cancer', 'need', 'treatment', 'meaning', 'extend', 'overal', 'surviv', 'in', 'addit', 'regimen', 'demonstr', 'favour', 'surviv', 'rate', 'himalaya', 'trial', 'safeti', 'data', 'show', 'increas', 'sever', 'liver', 'toxic', 'bleed', 'risk', 'combin', 'import', 'factor', 'patient', 'liver', 'cancer', 'also', 'advanc', 'liver', 'diseas', 'regulatori', 'applic', 'imjudo', 'combin', 'imfinzi', 'current', 'review', 'europ', 'japan', 'sever', 'countri', 'treatment', 'patient', 'advanc', 'liver', 'cancer', 'base', 'himalaya', 'result', 'astrazeneca', 'said', 'read', 'proactiv', 'investor', 'uk', 'reuter', 'prostat', 'cancer', 'combo', 'drug', 'tri', 'for', 'scpharma', 'fda', 'panel', 'decis', 'and', 'more', 'octob', 'key', 'pdufa', 'catalyst', 'biotech', 'investor', 'must', 'know', 'azn', 'add', 'portfolio', 'ixic', 'add', 'portfolio', 'kecr', 'add', 'portfolio', 'add', 'portfolio', 'most', 'fda', 'decis', 'schedul', 'septemb', 'yield', 'posit', 'result', 'stray', 'disappoint', 'well', 'seven', 'new', 'molecular', 'entiti', 'nme', 'approv', 'month', 'take', 'total', 'nme', 'approv', 'year', 'thi', 'far', 'less', 'approv', 'receiv', 'time', 'last', 'year', 'nme', 'consid', 'measur', 'innov', 'drug', 'research', 'contain', 'activ', 'moieti', 'ingredi', 'previous', 'approv', 'food', 'drug', 'administr', 'among', 'posit', 'verdict', 'bluebird', 'bio', 'nasdaq', 'blue', 'million', 'gene', 'therapi', 'skysona', 'approv', 'treat', 'rare', 'neurodegen', 'disord', 'boy', 'amylyx', 'pharmaceut', 'nasdaq', 'amlx', 'score', 'win', 'amyotroph', 'sclerosi', 'treatment', 'revanc', 'therapeut', 'nasdaq', 'rvnc', 'botox', 'rival', 'daxxifi', 'approv', 'treat', 'frown', 'line', 'spectrum', 'pharmaceut', 'nasdaq', 'sppi', 'mix', 'month', 'rolvedon', 'approv', 'treat', 'neutropenia', 'lung', 'cancer', 'drug', 'get', 'back', 'fda', 'panel', 'here', 'key', 'pdufa', 'date', 'schedul', 'octob', 'will', 'theratech', 'score', 'a', 'win', 'for', 'a', 'more', 'conveni', 'formul', 'of', 'it', 'hiv', 'drug', 'compani', 'theratechnolog', 'nasdaq', 'thtx', 'type', 'applic', 'supplement', 'biolog', 'licens', 'applic', 'candid', 'trogarzo', 'indic', 'date', 'in', 'fourth', 'quarter', 'compani', 'file', 'sbla', 'intraven', 'push', 'mode', 'administr', 'trogarzo', 'treat', 'human', 'immunodefici', 'viru', 'type', 'trogarzo', 'first', 'approv', 'fda', 'march', 'treat', 'adult', 'patient', 'hiv', 'in', 'quarter', 'end', 'may', 'drug', 'gener', 'sale', 'million', 'theratech', 'alnylam', 'on', 'cours', 'for', 'snag', 'label', 'expans', 'for', 'oxlumo', 'compani', 'alnylam', 'nasdaq', 'alni', 'type', 'applic', 'supplement', 'new', 'drug', 'applic', 'candid', 'oxlumo', 'indic', 'hyperoxaluria', 'type', 'date', 'oxlumo', 'goe', 'gener', 'name', 'lumasiran', 'rnai', 'therapeut', 'evalu', 'reduct', 'plasma', 'oxal', 'patient', 'advanc', 'hyperoxaluria', 'type', 'rare', 'disord', 'mainli', 'affect', 'kidney', 'due', 'accumul', 'substanc', 'call', 'oxal', 'normal', 'filter', 'kidney', 'excret', 'urin', 'thi', 'therapi', 'first', 'approv', 'lower', 'urinari', 'oxal', 'label', 'pediatr', 'adult', 'patient', 'in', 'second', 'quarter', 'fetch', 'compani', 'million', 'sale', 'sequenti', 'see', 'also', 'alzheim', 'progress', 'slow', 'down', 'by', 'biogen', 'nasdaq', 'new', 'drug', 'in', 'studi', 'analyst', 'see', 'can', 'third', 'time', 'be', 'charm', 'for', 'scpharma', 'compani', 'scpharmaceut', 'nasdaq', 'scph', 'type', 'applic', 'nda', 'candid', 'furoscix', 'indic', 'worsen', 'heart', 'failur', 'due', 'congest', 'date', 'furoscix', 'proprietari', 'furosemid', 'solut', 'evalu', 'outpati', 'altern', 'treatment', 'worsen', 'congest', 'heart', 'failur', 'thi', 'scpharma', 'third', 'tri', 'furoscix', 'follow', 'complet', 'respons', 'letter', 'go', 'amicu', 'pome', 'diseas', 'treatment', 'compani', 'amicu', 'therapeut', 'nasdaq', 'fold', 'type', 'applic', 'bla', 'candid', 'cipaglucosidas', 'alfa', 'indic', 'pomp', 'diseas', 'date', 'investig', 'therapi', 'consist', 'cipaglucosidas', 'alfa', 'administ', 'conjunct', 'miglustat', 'yet', 'approv', 'fda', 'therapi', 'evalu', 'inherit', 'lysosom', 'disord', 'call', 'pome', 'diseas', 'diseas', 'debilit', 'character', 'sever', 'muscl', 'weak', 'worsen', 'time', 'it', 'rang', 'rapidli', 'fatal', 'infantil', 'form', 'signific', 'impact', 'heart', 'function', 'slowli', 'progress', 'form', 'primarili', 'affect', 'skelet', 'muscl', 'it', 'estim', 'pomp', 'diseas', 'affect', 'approxim', 'peopl', 'worldwid', 'supernu', 'hope', 'for', 'no', 'hiccup', 'in', 'parkinson', 'diseas', 'drug', 'approv', 'compani', 'supernu', 'pharmaceut', 'nasdaq', 'supn', 'type', 'applic', 'nda', 'candid', 'apomorphin', 'infus', 'devic', 'indic', 'off', 'episod', 'parkinson', 'diseas', 'date', 'earli', 'octob', 'supernu', 'initi', 'applic', 'seek', 'approv', 'shot', 'letter', 'novemb', 'cite', 'insuffici', 'complet', 'applic', 'allow', 'substanti', 'review', 'follow', 'resubmiss', 'fda', 'accept', 'applic', 'assign', 'pdufa', 'date', 'sometim', 'earli', 'octob', 'also', 'read', 'best', 'biotech', 'stock', 'right', 'now', 'astrazeneca', 'nasdaq', 'knock', 'at', 'fda', 'altar', 'for', 'liver', 'cancer', 'combo', 'treatment', 'compani', 'astrazeneca', 'plc', 'nasdaq', 'azn', 'type', 'applic', 'candid', 'tremelimumab', 'imfinzi', 'indic', 'unresect', 'hepatocellular', 'carcinoma', 'date', 'fda', 'accept', 'astrazeneca', 'bla', 'tremelimumab', 'prioriti', 'review', 'support', 'indic', 'singl', 'prime', 'dose', 'antibodi', 'ad', 'imfinzi', 'treat', 'patient', 'unresect', 'hepatocellular', 'carcinoma', 'a', 'sbla', 'also', 'submit', 'imfinzi', 'indic', 'thi', 'novel', 'dose', 'schedul', 'combin', 'call', 'stride', 'regimen', 'singl', 'tremelimumab', 'regular', 'interv', 'durvalumab', 'hcc', 'accord', 'compani', 'common', 'type', 'liver', 'cancer', 'peopl', 'afflict', 'advanc', 'unresect', 'hcc', 'year', 'await', 'approv', 'for', 'prostat', 'cancer', 'como', 'therapi', 'compani', 'merck', 'nyse', 'mrk', 'astrazeneca', 'type', 'applic', 'snda', 'candid', 'lynparza', 'combin', 'abirateron', 'prednison', 'prednisolon', 'indic', 'prostat', 'cancer', 'date', 'applic', 'accept', 'grant', 'prioriti', 'review', 'fda', 'treatment', 'adult', 'patient', 'metastat', 'prostat', 'cancer', 'adcom', 'calendar', 'fda', 'cardiovascular', 'renal', 'drug', 'advisori', 'committe', 'meet', 'discuss', 'glaxosmithklin', 'plc', 'nyse', 'gsk', 'nda', 'factor', 'prolyl', 'hydroxylas', 'inhibitor', 'daprodustat', 'tablet', 'treatment', 'option', 'anemia', 'result', 'chronic', 'kidney', 'diseas', 'oncolog', 'drug', 'advisori', 'committe', 'schedul', 'meet', 'discuss', 'bla', 'submit', 'therapeut', 'nasdaq', 'ymab', 'solut', 'inject', 'formul', 'treat', 'neuroblastoma', 'central', 'nervou', 'metastas', 'on', 'endocrinolog', 'metabol', 'drug', 'advisori', 'committe', 'deliber', 'ispen', 'otc', 'ipsey', 'palovaroten', 'capsul', 'propos', 'indic', 'heterotop', 'ossif', 'adult', 'children', 'it', 'condit', 'muscl', 'tissu', 'connect', 'tissu', 'tendon', 'ligament', 'gradual', 'replac', 'bone', 'benzinga', 'provid', 'invest', 'advic', 'all', 'right', 'reserv', 'read', 'origin', 'articl', 'reuter', 'file', 'photo', 'pascal', 'soriot', 'chief', 'execut', 'pharmaceut', 'compani', 'astrazeneca', 'attend', 'interview', 'reuter', 'shanghai', 'china', 'novemb', 'photo', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'by', 'aime', 'donnellan', 'natali', 'grover', 'london', 'reuter', 'astrazeneca', 'nasdaq', 'may', 'stay', 'vaccin', 'busi', 'long', 'run', 'ceo', 'told', 'reuter', 'tuesday', 'show', 'quickli', 'fortun', 'chang', 'drugmak', 'produc', 'one', 'first', 'shot', 'sinc', 'lost', 'rival', 'product', 'delay', 'probe', 'regul', 'follow', 'rare', 'case', 'sever', 'side', 'effect', 'concern', 'rel', 'short', 'shelf', 'life', 'compar', 'shot', 'stymi', 'adopt', 'compani', 'vaccin', 'now', 'third', 'year', 'pandem', 'amid', 'global', 'vaccin', 'suppli', 'glut', 'use', 'diminish', 'much', 'develop', 'world', 'countri', 'inocul', 'larg', 'number', 'peopl', 'prefer', 'pfizer', 'nyse', 'moderna', 'nasdaq', 'mrna', 'vaccin', 'booster', 'astrazeneca', 'covid', 'vaccin', 'still', 'approv', 'compani', 'build', 'portfolio', 'antibodi', 'therapi', 'includ', 'respiratori', 'viru', 'rsv', 'virus', 'soriot', 'said', 'reuter', 'newsmak', 'interview', 'tuesday', 'but', 'futur', 'covid', 'vaccin', 'busi', 'said', 'i', 'ca', 'sure', 'he', 'also', 'said', 'sure', 'astrazeneca', 'would', 'broaden', 'roster', 'vaccin', 'infect', 'either', 'ad', 'compani', 'look', 'investor', 'specul', 'futur', 'vaccin', 'busi', 'given', 'slow', 'sale', 'covid', 'shot', 'initi', 'sale', 'contract', 'fulfil', 'stiff', 'competit', 'mrna', 'vaccin', 'rel', 'littl', 'expertis', 'field', 'compani', 'creat', 'separ', 'divis', 'vaccin', 'antibodi', 'therapi', 'late', 'last', 'year', 'still', 'soriot', 'said', 'regret', 'compani', 'work', 'oxford', 'univers', 'develop', 'covid', 'vaccin', 'given', 'deliv', 'billion', 'dose', 'save', 'estim', 'million', 'live', 'across', 'globe', 'inocul', 'astrazeneca', 'second', 'product', 'sale', 'billion', 'astrazeneca', 'also', 'look', 'acquisit', 'includ', 'small', 'compani', 'specialis', 'oncolog', 'cardiovascular', 'treatment', 'soriot', 'ad', 'we', 'alway', 'look', 'extern', 'opportun', 'said', 'keep', 'on', 'do', 'thi', 'job', 'ceo', 'presid', 'quadrupl', 'astrazeneca', 'share', 'price', 'decad', 'helm', 'i', 'keep', 'job', 'mani', 'year', 'said', 'old', 'seen', 'natur', 'successor', 'outgo', 'chairman', 'leif', 'johansson', 'but', 'juli', 'soriot', 'quash', 'specul', 'plan', 'retir', 'time', 'soon', 'say', 'expect', 'work', 'compani', 'newli', 'announc', 'michel', 'demar', 'mani', 'year', 'come', 'soriot', 'task', 'turn', 'around', 'troubl', 'astrazeneca', 'hit', 'string', 'key', 'patent', 'loss', 'spate', 'clinic', 'trial', 'failur', 'octob', 'follow', 'stint', 'pharma', 'peer', 'roch', 'with', 'frenchman', 'helm', 'fortun', 'drugmak', 'chang', 'dramat', 'he', 'sharpen', 'focu', 'special', 'medicin', 'lucr', 'field', 'oncolog', 'made', 'acquisit', 'refil', 'compani', 'medicin', 'cabinet', 'fend', 'hostil', 'takeov', 'pharma', 'giant', 'pfizer', 'invest', 'heavili', 'r', 'd', 'improv', 'compani', 'lacklustr', 'drug', 'develop', 'success', 'rate', 'howev', 'warn', 'tuesday', 'fewer', 'new', 'medicin', 'would', 'develop', 'go', 'forward', 'due', 'drug', 'price', 'law', 'pass', 'last', 'week', 'ask', 'inflationari', 'pressur', 'soriot', 'said', 'we', 'go', 'becom', 'innov', 'product', 'we', 'ca', 'expect', 'sell', 'price', 'go', 'sale', 'china', 'account', 'close', 'fifth', 'compani', 'total', 'annual', 'revenu', 'dip', 'recent', 'quarter', 'due', 'lower', 'drug', 'price', 'covid', 'lockdown', 'measur', 'kept', 'patient', 'diagnos', 'seek', 'cancer', 'care', 'on', 'tuesday', 'soriot', 'said', 'sale', 'pick', 'third', 'quarter', 'world', 'market', 'pharmaceut', 'expect', 'countri', 'play', 'signific', 'role', 'global', 'market', 'next', 'decad', 'graphic', 'astrazeneca', 'share', 'ceo', 'soriot', 'helm', 'http', 'reuter', 'peopl', 'pose', 'syring', 'needl', 'front', 'display', 'astrazeneca', 'logo', 'illustr', 'taken', 'decemb', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'by', 'pushkala', 'aripaka', 'natali', 'grover', 'london', 'reuter', 'medicin', 'regul', 'back', 'use', 'astrazeneca', 'nasdaq', 'prevent', 'therapi', 'treatment', 'diseas', 'also', 'endors', 'anoth', 'medicin', 'prevent', 'option', 'anoth', 'common', 'viru', 'regul', 'recommend', 'usual', 'follow', 'european', 'commiss', 'take', 'final', 'decis', 'drug', 'approv', 'astrazeneca', 'said', 'friday', 'european', 'medicin', 'agenc', 'ema', 'back', 'evusheld', 'treatment', 'adult', 'adolesc', 'covid', 'need', 'supplement', 'oxygen', 'increas', 'risk', 'diseas', 'worsen', 'last', 'month', 'japan', 'becam', 'first', 'countri', 'approv', 'antibodi', 'treatment', 'covid', 'make', 'evusheld', 'first', 'therapi', 'authoris', 'prevent', 'treatment', 'viral', 'diseas', 'evusheld', 'previous', 'larg', 'secur', 'global', 'approv', 'includ', 'europ', 'prevent', 'therapi', 'peopl', 'compromis', 'immun', 'system', 'see', 'littl', 'benefit', 'covid', 'vaccin', 'astrazeneca', 'lean', 'evusheld', 'help', 'offset', 'tepid', 'sale', 'covid', 'vaccin', 'rapidli', 'lost', 'ground', 'mrna', 'shot', 'fight', 'rapidli', 'evolv', 'viru', 'evusheld', 'first', 'launch', 'decemb', 'gener', 'million', 'first', 'half', 'drugmak', 'separ', 'friday', 'ema', 'also', 'endors', 'astrazeneca', 'partner', 'sanofi', 'epa', 'experiment', 'therapi', 'beyfortu', 'prevent', 'lower', 'respiratori', 'tract', 'infect', 'caus', 'respiratori', 'syncyti', 'viru', 'rsv', 'rsv', 'caus', 'thousand', 'hospitalis', 'death', 'global', 'year', 'toddler', 'elderli', 'complex', 'molecular', 'structur', 'viru', 'safeti', 'concern', 'stymi', 'effort', 'develop', 'vaccin', 'sinc', 'viru', 'first', 'discov', 'but', 'one', 'therapi', 'synagi', 'also', 'develop', 'astrazeneca', 'sold', 'swedish', 'orphan', 'biovitrum', 'unit', 'state', 'it', 'design', 'prevent', 'lower', 'respiratori', 'tract', 'infect', 'caus', 'rsv', 'infant', 'requir', 'five', 'inject', 'cover', 'typic', 'rsv', 'season', 'meanwhil', 'beyfortu', 'approv', 'would', 'first', 'prevent', 'rsv', 'therapi', 'broad', 'infant', 'popul', 'includ', 'born', 'healthi', 'deem', 'first', 'rsv', 'reuter', 'file', 'photo', 'compani', 'logo', 'pharmaceut', 'compani', 'astrazeneca', 'display', 'screen', 'floor', 'new', 'york', 'stock', 'exchang', 'april', 'mcdermid', 'azn', 'add', 'portfolio', 'reuter', 'said', 'friday', 'drug', 'prevent', 'infant', 'rsv', 'beyfortu', 'nirsevimab', 'recommend', 'approv', 'european', 'union', 'european', 'medicin', 'agenc', 'committe', 'drugmak', 'also', 'said', 'beyfortu', 'approv', 'would', 'becom', 'first', 'protect', 'option', 'newborn', 'infant', 'popul', 'rsv', 'lower', 'respiratori', 'tract', 'reuter', 'market', 'mover', 'properti', 'group', 'fall', 'reduc', 'price', 'target', 'fdx', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'blnd', 'add', 'portfolio', 'idsi', 'add', 'portfolio', 'add', 'portfolio', 'share', 'land', 'secur', 'british', 'land', 'fell', 'today', 'properti', 'group', 'downgrad', 'goldman', 'sach', 'nyse', 'jp', 'morgan', 'lower', 'price', 'target', 'compani', 'goldman', 'sach', 'downgrad', 'british', 'land', 'neutral', 'buy', 'reduc', 'price', 'target', 'jpmorgan', 'nyse', 'cut', 'price', 'target', 'retain', 'overweight', 'rate', 'on', 'land', 'secur', 'goldman', 'sach', 'lower', 'rate', 'sell', 'neutral', 'cut', 'price', 'target', 'jpmorgan', 'retain', 'neutral', 'rate', 'lower', 'price', 'target', 'land', 'secur', 'fell', 'british', 'land', 'fell', 'capita', 'lift', 'doubl', 'dose', 'good', 'news', 'share', 'advanc', 'report', 'contract', 'extens', 'barnet', 'council', 'dispos', 'subsidiari', 'ltd', 'access', 'paysuit', 'share', 'outsourc', 'servic', 'group', 'rose', 'secur', 'contract', 'extens', 'north', 'london', 'council', 'worth', 'although', 'index', 'potenti', 'addit', 'work', 'could', 'worth', 'separ', 'capita', 'said', 'agre', 'dispos', 'divis', 'access', 'group', 'basi', 'capita', 'said', 'sale', 'help', 'reduc', 'debt', 'provid', 'addit', 'liquid', 'allow', 'enhanc', 'digit', 'offer', 'client', 'build', 'focus', 'sustain', 'busi', 'long', 'term', 'royal', 'mail', 'fall', 'fedex', 'warn', 'share', 'dip', 'today', 'follow', 'profit', 'warn', 'us', 'peer', 'pull', 'full', 'year', 'guidanc', 'warn', 'first', 'quarter', 'profit', 'would', 'miss', 'estim', 'global', 'demand', 'slowdown', 'acceler', 'it', 'cite', 'macroeconom', 'weak', 'asia', 'servic', 'challeng', 'europ', 'investor', 'took', 'view', 'industri', 'challeng', 'would', 'royal', 'mail', 'also', 'face', 'prospect', 'industri', 'action', 'employe', 'strike', 'higher', 'pay', 'royal', 'mail', 'worker', 'repres', 'commun', 'worker', 'union', 'cwu', 'plan', 'walkout', 'septemb', 'plan', 'strike', 'septemb', 'octob', 'share', 'fell', 'eu', 'drug', 'approv', 'boost', 'astrazeneca', 'nasdaq', 'rare', 'riser', 'said', 'today', 'receiv', 'two', 'recommend', 'drug', 'approv', 'eu', 'drug', 'blood', 'disord', 'paroxysm', 'nocturn', 'haemoglobinuria', 'met', 'primari', 'endpoint', 'phase', 'three', 'trial', 'group', 'said', 'beyfortu', 'drug', 'develop', 'sanofi', 'epa', 'prevent', 'lower', 'respiratori', 'tract', 'diseas', 'newborn', 'infant', 'recommend', 'market', 'authoris', 'european', 'union', 'meanwhil', 'astrazeneca', 'evusheld', 'covid', 'antibodi', 'treatment', 'recommend', 'market', 'authoris', 'eu', 'adult', 'viru', 'risk', 'progress', 'sever', 'diseas', 'compani', 'explain', 'phase', 'iii', 'treatment', 'data', 'show', 'reduc', 'risk', 'sever', 'covid', 'death', 'share', 'rose', 'follow', 'news', 'read', 'proactiv', 'investor', 'uk', 'disclaimerbi', 'benzinga', 'crypto', 'parti', 'start', 'corpor', 'optim', 'hope', 'fed', 'thaw', 'perk', 'risk', 'appetit', 'financi', 'market', 'ethereum', 'crypto', 'eth', 'second', 'reuter', 'file', 'photo', 'tablet', 'bottl', 'astrazeneca', 'cancer', 'medicin', 'lynparza', 'seen', 'undat', 'handout', 'imag', 'provid', 'reuter', 'june', 'via', 'reuter', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'reuter', 'astrazeneca', 'nasdaq', 'said', 'thursday', 'drug', 'lynparza', 'develop', 'merck', 'co', 'approv', 'european', 'union', 'adjuv', 'treatment', 'patient', 'form', 'genet', 'mutat', 'breast', 'reuter', 'daili', 'biotech', 'puls', 'celyad', 'resum', 'colorect', 'cancer', 'trial', 'setback', 'for', 'otonomi', 'astrazeneca', 'halt', 'phase', 'head', 'neck', 'cancer', 'trial', 'azn', 'add', 'portfolio', 'ixic', 'add', 'portfolio', 'otic', 'add', 'portfolio', 'beam', 'add', 'portfolio', 'add', 'portfolio', 'here', 'roundup', 'top', 'develop', 'biotech', 'space', 'last', 'hour', 'stock', 'in', 'focu', 'arcuti', 'psoriasi', 'treatment', 'score', 'fda', 'approv', 'fda', 'approv', 'arcuti', 'biotherapeut', 'inc', 'nasdaq', 'arqt', 'zoryv', 'roflumilast', 'cream', 'plaqu', 'psoriasi', 'includ', 'intertrigin', 'area', 'patient', 'year', 'age', 'older', 'it', 'first', 'topic', 'inhibitor', 'approv', 'plaqu', 'psoriasi', 'commerci', 'product', 'expect', 'avail', 'arcuti', 'expect', 'draw', 'addit', 'million', 'compani', 'debt', 'facil', 'slr', 'capit', 'partner', 'share', 'premarket', 'session', 'fda', 'remov', 'clinic', 'hold', 'on', 'celyad', 'colorect', 'cancer', 'trial', 'fda', 'lift', 'clinic', 'hold', 'celyad', 'oncolog', 'sa', 'nasdaq', 'cyad', 'phase', 'trial', 'compani', 'made', 'chang', 'elig', 'criteria', 'trial', 'in', 'februari', 'compani', 'voluntarili', 'paus', 'trial', 'investig', 'report', 'two', 'fatal', 'studi', 'fda', 'subsequ', 'put', 'trial', 'clinic', 'hold', 'march', 'share', 'premarket', 'session', 'hutchm', 'start', 'midstag', 'tazemetostat', 'studi', 'for', 'lymphoma', 'set', 'hutchm', 'china', 'limit', 'nasdaq', 'hcm', 'initi', 'bridg', 'phase', 'studi', 'tazemetostat', 'china', 'follicular', 'lymphoma', 'fl', 'first', 'patient', 'receiv', 'first', 'dose', 'juli', 'primari', 'object', 'evalu', 'efficaci', 'tazemetostat', 'fl', 'patient', 'mutat', 'cohort', 'secondari', 'object', 'evalu', 'efficaci', 'tazemetostat', 'fl', 'relat', 'biotech', 'investor', 'august', 'key', 'pdufa', 'catalyst', 'you', 'must', 'know', 'fda', 'sign', 'off', 'on', 'eledon', 'pharma', 'tegoprubart', 'for', 'kidneti', 'transplant', 'reject', 'fda', 'clear', 'eledon', 'pharmaceut', 'inc', 'nasdaq', 'eldn', 'investig', 'new', 'drug', 'ind', 'applic', 'evalu', 'tegoprubart', 'prevent', 'organ', 'reject', 'patient', 'receiv', 'kidney', 'transplant', 'phase', 'studi', 'enrol', 'approxim', 'particip', 'undergo', 'kidney', 'transplant', 'kazia', 'share', 'fall', 'after', 'updat', 'from', 'pivot', 'brain', 'tumor', 'trial', 'kazia', 'therapeut', 'limit', 'nasdaq', 'kzia', 'said', 'gbm', 'agil', 'pivot', 'studi', 'paxalisib', 'newli', 'diagnos', 'glioblastoma', 'meet', 'criteria', 'continu', 'second', 'stage', 'patient', 'enrol', 'first', 'stage', 'paxalisib', 'arm', 'continu', 'treatment', 'per', 'protocol', 'complet', 'final', 'analysi', 'kazia', 'anticip', 'receiv', 'second', 'half', 'compani', 'open', 'studi', 'paxalisib', 'arm', 'germani', 'china', 'share', 'premarket', 'session', 'fda', 'place', 'clinic', 'hold', 'on', 'beam', 'therapeut', 'ind', 'applic', 'for', 'blood', 'cancer', 'studi', 'fda', 'place', 'clinic', 'hold', 'beam', 'therapeut', 'inc', 'nasdaq', 'beam', 'investig', 'new', 'drug', 'ind', 'applic', 'acut', 'lymphoblast', 'cell', 'lymphoblast', 'lymphoma', 'ind', 'submit', 'end', 'june', 'fda', 'indic', 'would', 'provid', 'beam', 'offici', 'clinic', 'hold', 'letter', 'within', 'day', 'beam', 'plan', 'provid', 'addit', 'updat', 'pend', 'discuss', 'fda', 'otonomi', 'share', 'sink', 'after', 'stop', 'midstag', 'tinnitu', 'studi', 'otonomi', 'inc', 'nasdaq', 'otic', 'announc', 'phase', 'trial', 'tinnitu', 'demonstr', 'clinic', 'meaning', 'benefit', 'versu', 'placebo', 'primari', 'secondari', 'endpoint', 'across', 'time', 'point', 'studi', 'show', 'higher', 'respons', 'rate', 'placebo', 'prospect', 'defin', 'patient', 'subgroup', 'tinnitu', 'durat', 'fewer', 'six', 'month', 'popul', 'studi', 'phase', 'trial', 'overal', 'result', 'support', 'develop', 'share', 'slip', 'cent', 'premarket', 'session', 'astrazeneca', 'nasdaq', 'cut', 'phase', 'trial', 'in', 'head', 'neck', 'cancer', 'innat', 'pharma', 'sa', 'nasdaq', 'ipha', 'futil', 'interim', 'analysi', 'phase', 'studi', 'sponsor', 'astrazeneca', 'plc', 'nasdaq', 'azn', 'meet', 'threshold', 'efficaci', 'base', 'result', 'recommend', 'independ', 'data', 'monitor', 'committe', 'astrazeneca', 'inform', 'innat', 'studi', 'discontinu', 'there', 'new', 'safeti', 'find', 'astrazeneca', 'plan', 'share', 'data', 'due', 'cours', 'ipha', 'share', 'premarket', 'session', 'alx', 'oncolog', 'evorpacept', 'fast', 'track', 'in', 'us', 'for', 'head', 'neck', 'cancer', 'fda', 'grant', 'fast', 'track', 'design', 'alx', 'oncolog', 'hold', 'inc', 'nasdaq', 'alxo', 'evorpacept', 'combin', 'merck', 'co', 'inc', 'nyse', 'mrk', 'keytruda', 'treatment', 'posit', 'advanc', 'head', 'neck', 'squamou', 'cell', 'carcinoma', 'fda', 'decis', 'inform', 'result', 'alx', 'oncolog', 'phase', 'studi', 'show', 'preliminari', 'antitumor', 'activ', 'favor', 'safeti', 'profil', 'share', 'premarket', 'session', 'offer', 'therapeuticsmd', 'inc', 'nasdaq', 'txmd', 'receiv', 'privat', 'invest', 'compani', 'common', 'stock', 'new', 'seri', 'prefer', 'stock', 'rubric', 'capit', 'manag', 'lp', 'on', 'radar', 'earn', 'cerevel', 'therapeut', 'hold', 'inc', 'nasdaq', 'cere', 'befor', 'market', 'open', 'benzinga', 'provid', 'invest', 'advic', 'all', 'right', 'reserv', 'read', 'benzinga', 'read', 'origin', 'articl', 'reuter', 'add', 'portfolio', 'add', 'portfolio', 'add', 'portfolio', 'fchi', 'add', 'portfolio', 'add', 'portfolio', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'gold', 'add', 'portfolio', 'lco', 'add', 'portfolio', 'cl', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'add', 'portfolio', 'by', 'peter', 'nurs', 'european', 'stock', 'market', 'larg', 'edg', 'higher', 'monday', 'start', 'new', 'week', 'cautiou', 'note', 'investor', 'digest', 'weak', 'chines', 'econom', 'data', 'by', 'et', 'gmt', 'germani', 'trade', 'lower', 'franc', 'rose', 'trade', 'higher', 'econom', 'data', 'releas', 'earlier', 'monday', 'show', 'china', 'econom', 'growth', 'rate', 'unexpectedli', 'slow', 'juli', 'prompt', 'countri', 'central', 'bank', 'surpris', 'move', 'grew', 'juli', 'year', 'earlier', 'growth', 'rate', 'increas', 'expect', 'rose', 'year', 'ago', 'miss', 'forecast', 'growth', 'growth', 'seen', 'june', 'china', 'economi', 'world', 'second', 'largest', 'struggl', 'shake', 'june', 'quarter', 'hit', 'growth', 'strict', 'covid', 'restrict', 'on', 'flip', 'side', 'back', 'europ', 'denmark', 'economi', 'grew', 'faster', 'expect', 'second', 'quarter', 'expand', 'first', 'three', 'month', 'year', 'contract', 'first', 'quarter', 'rais', 'interest', 'rate', 'juli', 'expect', 'septemb', 'even', 'though', 'risk', 'eurozon', 'recess', 'reach', 'highest', 'level', 'sinc', 'novemb', 'energi', 'shortag', 'threaten', 'drive', 'alreadi', 'record', 'inflat', 'higher', 'still', 'in', 'corpor', 'news', 'astrazeneca', 'lon', 'nasdaq', 'stock', 'rose', 'drugmak', 'said', 'cancer', 'drug', 'enhertu', 'delay', 'progress', 'form', 'advanc', 'breast', 'cancer', 'previous', 'treat', 'patient', 'boost', 'prospect', 'regulatori', 'approv', 'henkel', 'etr', 'stock', 'rose', 'german', 'compani', 'said', 'sale', 'rose', 'first', 'half', 'year', 'earn', 'fell', 'hurt', 'increas', 'logist', 'price', 'oil', 'price', 'fell', 'monday', 'weigh', 'potenti', 'increas', 'suppli', 'oil', 'giant', 'saudi', 'aramco', 'tadawul', 'well', 'concern', 'slow', 'growth', 'china', 'world', 'economi', 'saudi', 'aramco', 'stand', 'readi', 'rais', 'crude', 'oil', 'output', 'maximum', 'capac', 'million', 'barrel', 'per', 'day', 'request', 'saudi', 'arabian', 'govern', 'chief', 'execut', 'amin', 'nasser', 'said', 'sunday', 'energi', 'firm', 'announc', 'one', 'largest', 'quarterli', 'profit', 'histori', 'by', 'et', 'futur', 'trade', 'lower', 'barrel', 'contract', 'fell', 'addit', 'fell', 'trade', 'lower', 'reuter', 'file', 'photo', 'signag', 'seen', 'outsid', 'entranc', 'london', 'stock', 'exchang', 'london', 'britain', 'aug', 'photo', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'ftse', 'add', 'portfolio', 'add', 'portfolio', 'enri', 'add', 'portfolio', 'by', 'sruthi', 'shankar', 'reuter', 'edg', 'monday', 'gain', 'drugmak', 'astrazeneca', 'nasdaq', 'consum', 'stock', 'reliev', 'pressur', 'mine', 'oil', 'heavyweight', 'data', 'show', 'china', 'economi', 'unexpectedli', 'slow', 'last', 'month', 'ftse', 'ad', 'hold', 'near', 'high', 'midcap', 'inch', 'investor', 'await', 'uk', 'employ', 'report', 'well', 'consum', 'price', 'data', 'later', 'week', 'gaug', 'state', 'labour', 'market', 'inflat', 'data', 'could', 'offer', 'clue', 'whether', 'bank', 'england', 'opt', 'second', 'consecut', 'hike', 'septemb', 'meet', 'mood', 'dull', 'asian', 'european', 'stock', 'market', 'investor', 'turn', 'defens', 'sector', 'healthcar', 'consum', 'stapl', 'amid', 'worri', 'health', 'world', 'economi', 'astrazeneca', 'gain', 'drugmak', 'said', 'cancer', 'drug', 'enhertu', 'develop', 'japan', 'daiichi', 'sankyo', 'delay', 'progress', 'form', 'advanc', 'breast', 'cancer', 'previous', 'treat', 'patient', 'oil', 'major', 'shell', 'lon', 'miner', 'rio', 'tinto', 'lon', 'anglo', 'american', 'lon', 'slip', 'tandem', 'weaker', 'commod', 'price', 'releas', 'china', 'data', 'ftse', 'outperform', 'global', 'peer', 'year', 'due', 'larg', 'exposur', 'commod', 'stock', 'surg', 'back', 'jump', 'oil', 'metal', 'price', 'a', 'weaken', 'pound', 'also', 'boost', 'dollar', 'earner', 'index', 'whether', 'trend', 'continu', 'ultim', 'hing', 'outlook', 'global', 'energi', 'stock', 'rel', 'broad', 'market', 'bca', 'research', 'analyst', 'wrote', 'note', 'ftse', 'nearli', 'far', 'year', 'msci', 'world', 'equiti', 'index', 'shed', 'almost', 'our', 'energi', 'strategist', 'remain', 'bullish', 'oil', 'their', 'expect', 'breach', 'averag', 'suggest', 'overweight', 'energi', 'sector', 'extens', 'uk', 'equiti', 'remain', 'appropri', 'reuter', 'ftse', 'posit', 'earli', 'high', 'add', 'portfolio', 'dji', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'bwi', 'add', 'portfolio', 'bdev', 'add', 'portfolio', 'tw', 'add', 'portfolio', 'ftmc', 'add', 'portfolio', 'phnx', 'add', 'portfolio', 'ixic', 'add', 'portfolio', 'ftse', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'chna', 'add', 'portfolio', 'slip', 'back', 'make', 'bright', 'start', 'chines', 'retail', 'sale', 'output', 'number', 'forecast', 'uk', 'hous', 'price', 'fall', 'august', 'rightmov', 'ftse', 'fail', 'hold', 'strong', 'earli', 'gain', 'slip', 'back', 'close', 'pariti', 'disappoint', 'econom', 'data', 'china', 'took', 'shine', 'gain', 'us', 'friday', 'at', 'lead', 'index', 'trade', 'point', 'good', 'richard', 'hunter', 'head', 'market', 'interact', 'investor', 'said', 'econom', 'news', 'china', 'threaten', 'spoil', 'parti', 'us', 'market', 'stage', 'strong', 'ralli', 'end', 'last', 'amid', 'geopolit', 'tension', 'deleg', 'us', 'lawmak', 'arriv', 'trip', 'taiwan', 'chines', 'econom', 'data', 'reveal', 'ongo', 'impact', 'lockdown', 'escal', 'properti', 'retail', 'sale', 'industri', 'output', 'rose', 'less', 'expect', 'juli', 'alongsid', 'disappoint', 'show', 'bank', 'but', 'said', 'uk', 'market', 'chose', 'take', 'lead', 'wall', 'street', 'notwithstand', 'fact', 'bank', 'england', 'set', 'maintain', 'aggress', 'interest', 'rate', 'stanc', 'face', 'persist', 'inflat', 'astrazeneca', 'plc', 'lse', 'nasdaq', 'share', 'rose', 'pharmaceut', 'group', 'said', 'posit', 'result', 'new', 'trial', 'enhertu', 'breast', 'cancer', 'drug', 'demonstr', 'statist', 'signific', 'clinic', 'meaning', 'improv', 'surviv', 'astrazeneca', 'said', 'phase', 'iii', 'trial', 'enhertu', 'jointli', 'develop', 'commercialis', 'daiichi', 'sankyo', 'also', 'met', 'key', 'secondari', 'endpoint', 'improv', 'overal', 'surviv', 'but', 'housebuild', 'berkeley', 'group', 'hold', 'plc', 'lse', 'bkg', 'bellway', 'lon', 'taylor', 'wimpey', 'lon', 'barratt', 'develop', 'lon', 'fell', 'follow', 'report', 'rightmov', 'hous', 'price', 'slip', 'posit', 'start', 'proceed', 'london', 'london', 'upbeat', 'earli', 'trade', 'ftse', 'make', 'posit', 'start', 'trade', 'boost', 'gain', 'us', 'friday', 'despit', 'mix', 'perform', 'asia', 'overnight', 'follow', 'disappoint', 'chines', 'retail', 'sale', 'industri', 'output', 'figur', 'at', 'lead', 'index', 'trade', 'point', 'higher', 'broader', 'point', 'latest', 'data', 'onlin', 'properti', 'websit', 'rightmov', 'show', 'first', 'fall', 'uk', 'hous', 'price', 'year', 'averag', 'price', 'properti', 'come', 'market', 'howev', 'tim', 'bannist', 'rightmov', 'director', 'properti', 'scienc', 'say', 'a', 'drop', 'ask', 'price', 'expect', 'month', 'frenzi', 'two', 'year', 'mani', 'home', 'mover', 'becom', 'distract', 'summer', 'inde', 'may', 'first', 'summer', 'holiday', 'abroad', 'sinc', 'bannist', 'also', 'point', 'price', 'growth', 'year', 'would', 'still', 'number', 'properti', 'current', 'market', 'buy', 'level', 'despit', 'lack', 'instruct', 'new', 'list', 'rose', 'compar', 'time', 'last', 'year', 'compar', 'bannist', 'also', 'said', 'recent', 'interest', 'rate', 'increas', 'bank', 'england', 'signific', 'impact', 'number', 'peopl', 'want', 'ftse', 'seen', 'higher', 'london', 'market', 'expect', 'open', 'higher', 'monday', 'follow', 'gain', 'us', 'friday', 'follow', 'surpris', 'news', 'china', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stutter', 'economi', 'follow', 'weaker', 'expect', 'retail', 'sale', 'industri', 'output', 'figur', 'investor', 'also', 'one', 'eye', 'uk', 'job', 'inflat', 'report', 'due', 'later', 'week', 'see', 'whether', 'sign', 'slowdown', 'job', 'market', 'price', 'growth', 'spread', 'bet', 'compani', 'call', 'ftse', 'around', 'point', 'michael', 'hewson', 'chief', 'market', 'analyst', 'cmc', 'market', 'uk', 'said', 'despit', 'slow', 'drip', 'feed', 'neg', 'headlin', 'rise', 'ga', 'price', 'suppli', 'chain', 'challeng', 'thrown', 'heatwav', 'europ', 'littl', 'appetit', 'drive', 'stock', 'lower', 'recent', 'asia', 'market', 'got', 'posit', 'start', 'week', 'latest', 'retail', 'sale', 'industri', 'product', 'number', 'china', 'show', 'economi', 'still', 'appear', 'low', 'confid', 'come', 'consum', 'spend', 'econom', 'activ', 'thi', 'weak', 'chines', 'economi', 'come', 'struggl', 'adapt', 'polici', 'govern', 'show', 'littl', 'sign', 'relax', 'backdrop', 'rise', 'problem', 'properti', 'sector', 'also', 'help', 'mani', 'home', 'buyer', 'halt', 'mortgag', 'payment', 'protest', 'delay', 'complet', 'new', 'in', 'june', 'saw', 'effect', 'polici', 'chines', 'economi', 'contract', 'although', 'start', 'see', 'sign', 'econom', 'activ', 'albeit', 'low', 'thi', 'morn', 'retail', 'sale', 'number', 'juli', 'confirm', 'fragil', 'confid', 'still', 'rise', 'well', 'expect', 'weaker', 'industri', 'product', 'robust', 'recov', 'much', 'better', 'howev', 'even', 'econom', 'activ', 'disappoint', 'juli', 'slip', 'back', 'june', 'in', 'london', 'quieter', 'day', 'compani', 'result', 'phoenix', 'group', 'announc', 'half', 'year', 'figur', 'show', 'strong', 'cash', 'gener', 'six', 'month', 'june', 'ftse', 'close', 'book', 'life', 'insur', 'said', 'confid', 'deliv', 'target', 'rang', 'year', 'new', 'busi', 'cash', 'gener', 'record', 'period', 'doubl', 'first', 'half', 'ftse', 'set', 'open', 'higher', 'ftse', 'set', 'start', 'week', 'posit', 'fashion', 'follow', 'gain', 'us', 'friday', 'spread', 'bet', 'compani', 'call', 'blue', 'chip', 'index', 'around', 'point', 'close', 'friday', 'point', 'jump', 'point', 's', 'p', 'ad', 'point', 'reach', 'benchmark', 'end', 'week', 'high', 'note', 'clinch', 'win', 'week', 'nasdaq', 'composit', 's', 'p', 'investor', 'react', 'posit', 'cpi', 'ppi', 'data', 'releas', 'week', 'suggest', 'inflat', 'may', 'alreadi', 'peak', 'read', 'proactiv', 'investor', 'uk', 'reuter', 'ftse', 'posit', 'earli', 'high', 'add', 'portfolio', 'dji', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'bwi', 'add', 'portfolio', 'bdev', 'add', 'portfolio', 'tw', 'add', 'portfolio', 'ftmc', 'add', 'portfolio', 'phnx', 'add', 'portfolio', 'ixic', 'add', 'portfolio', 'ftse', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'chna', 'add', 'portfolio', 'slip', 'back', 'make', 'bright', 'start', 'chines', 'retail', 'sale', 'output', 'number', 'forecast', 'uk', 'hous', 'price', 'fall', 'august', 'rightmov', 'ftse', 'fail', 'hold', 'strong', 'earli', 'gain', 'slip', 'back', 'close', 'pariti', 'disappoint', 'econom', 'data', 'china', 'took', 'shine', 'gain', 'us', 'friday', 'at', 'lead', 'index', 'trade', 'point', 'good', 'richard', 'hunter', 'head', 'market', 'interact', 'investor', 'said', 'econom', 'news', 'china', 'threaten', 'spoil', 'parti', 'us', 'market', 'stage', 'strong', 'ralli', 'end', 'last', 'amid', 'geopolit', 'tension', 'deleg', 'us', 'lawmak', 'arriv', 'trip', 'taiwan', 'chines', 'econom', 'data', 'reveal', 'ongo', 'impact', 'lockdown', 'escal', 'properti', 'retail', 'sale', 'industri', 'output', 'rose', 'less', 'expect', 'juli', 'alongsid', 'disappoint', 'show', 'bank', 'but', 'said', 'uk', 'market', 'chose', 'take', 'lead', 'wall', 'street', 'notwithstand', 'fact', 'bank', 'england', 'set', 'maintain', 'aggress', 'interest', 'rate', 'stanc', 'face', 'persist', 'inflat', 'astrazeneca', 'plc', 'lse', 'nasdaq', 'share', 'rose', 'pharmaceut', 'group', 'said', 'posit', 'result', 'new', 'trial', 'enhertu', 'breast', 'cancer', 'drug', 'demonstr', 'statist', 'signific', 'clinic', 'meaning', 'improv', 'surviv', 'astrazeneca', 'said', 'phase', 'iii', 'trial', 'enhertu', 'jointli', 'develop', 'commercialis', 'daiichi', 'sankyo', 'also', 'met', 'key', 'secondari', 'endpoint', 'improv', 'overal', 'surviv', 'but', 'housebuild', 'berkeley', 'group', 'hold', 'plc', 'lse', 'bkg', 'bellway', 'lon', 'taylor', 'wimpey', 'lon', 'barratt', 'develop', 'lon', 'fell', 'follow', 'report', 'rightmov', 'hous', 'price', 'slip', 'posit', 'start', 'proceed', 'london', 'london', 'upbeat', 'earli', 'trade', 'ftse', 'make', 'posit', 'start', 'trade', 'boost', 'gain', 'us', 'friday', 'despit', 'mix', 'perform', 'asia', 'overnight', 'follow', 'disappoint', 'chines', 'retail', 'sale', 'industri', 'output', 'figur', 'at', 'lead', 'index', 'trade', 'point', 'higher', 'broader', 'point', 'latest', 'data', 'onlin', 'properti', 'websit', 'rightmov', 'show', 'first', 'fall', 'uk', 'hous', 'price', 'year', 'averag', 'price', 'properti', 'come', 'market', 'howev', 'tim', 'bannist', 'rightmov', 'director', 'properti', 'scienc', 'say', 'a', 'drop', 'ask', 'price', 'expect', 'month', 'frenzi', 'two', 'year', 'mani', 'home', 'mover', 'becom', 'distract', 'summer', 'inde', 'may', 'first', 'summer', 'holiday', 'abroad', 'sinc', 'bannist', 'also', 'point', 'price', 'growth', 'year', 'would', 'still', 'number', 'properti', 'current', 'market', 'buy', 'level', 'despit', 'lack', 'instruct', 'new', 'list', 'rose', 'compar', 'time', 'last', 'year', 'compar', 'bannist', 'also', 'said', 'recent', 'interest', 'rate', 'increas', 'bank', 'england', 'signific', 'impact', 'number', 'peopl', 'want', 'ftse', 'seen', 'higher', 'london', 'market', 'expect', 'open', 'higher', 'monday', 'follow', 'gain', 'us', 'friday', 'follow', 'surpris', 'news', 'china', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stutter', 'economi', 'follow', 'weaker', 'expect', 'retail', 'sale', 'industri', 'output', 'figur', 'investor', 'also', 'one', 'eye', 'uk', 'job', 'inflat', 'report', 'due', 'later', 'week', 'see', 'whether', 'sign', 'slowdown', 'job', 'market', 'price', 'growth', 'spread', 'bet', 'compani', 'call', 'ftse', 'around', 'point', 'michael', 'hewson', 'chief', 'market', 'analyst', 'cmc', 'market', 'uk', 'said', 'despit', 'slow', 'drip', 'feed', 'neg', 'headlin', 'rise', 'ga', 'price', 'suppli', 'chain', 'challeng', 'thrown', 'heatwav', 'europ', 'littl', 'appetit', 'drive', 'stock', 'lower', 'recent', 'asia', 'market', 'got', 'posit', 'start', 'week', 'latest', 'retail', 'sale', 'industri', 'product', 'number', 'china', 'show', 'economi', 'still', 'appear', 'low', 'confid', 'come', 'consum', 'spend', 'econom', 'activ', 'thi', 'weak', 'chines', 'economi', 'come', 'struggl', 'adapt', 'polici', 'govern', 'show', 'littl', 'sign', 'relax', 'backdrop', 'rise', 'problem', 'properti', 'sector', 'also', 'help', 'mani', 'home', 'buyer', 'halt', 'mortgag', 'payment', 'protest', 'delay', 'complet', 'new', 'in', 'june', 'saw', 'effect', 'polici', 'chines', 'economi', 'contract', 'although', 'start', 'see', 'sign', 'econom', 'activ', 'albeit', 'low', 'thi', 'morn', 'retail', 'sale', 'number', 'juli', 'confirm', 'fragil', 'confid', 'still', 'rise', 'well', 'expect', 'weaker', 'industri', 'product', 'robust', 'recov', 'much', 'better', 'howev', 'even', 'econom', 'activ', 'disappoint', 'juli', 'slip', 'back', 'june', 'in', 'london', 'quieter', 'day', 'compani', 'result', 'phoenix', 'group', 'announc', 'half', 'year', 'figur', 'show', 'strong', 'cash', 'gener', 'six', 'month', 'june', 'ftse', 'close', 'book', 'life', 'insur', 'said', 'confid', 'deliv', 'target', 'rang', 'year', 'new', 'busi', 'cash', 'gener', 'record', 'period', 'doubl', 'first', 'half', 'ftse', 'set', 'open', 'higher', 'ftse', 'set', 'start', 'week', 'posit', 'fashion', 'follow', 'gain', 'us', 'friday', 'spread', 'bet', 'compani', 'call', 'blue', 'chip', 'index', 'around', 'point', 'close', 'friday', 'point', 'jump', 'point', 's', 'p', 'ad', 'point', 'reach', 'benchmark', 'end', 'week', 'high', 'note', 'clinch', 'win', 'week', 'nasdaq', 'composit', 's', 'p', 'investor', 'react', 'posit', 'cpi', 'ppi', 'data', 'releas', 'week', 'suggest', 'inflat', 'may', 'alreadi', 'peak', 'read', 'proactiv', 'investor', 'uk', 'disclaimeravepp', 'add', 'portfolio', 'rog', 'add', 'portfolio', 'rhhvf', 'add', 'portfolio', 'sni', 'add', 'portfolio', 'azn', 'add', 'portfolio', 'sasi', 'add', 'portfolio', 'by', 'scott', 'kanowski', 'sanofi', 'sa', 'epa', 'share', 'slid', 'wednesday', 'french', 'drugmak', 'announc', 'halt', 'trial', 'new', 'treatment', 'patient', 'battl', 'advanc', 'breast', 'cancer', 'in', 'statement', 'compani', 'said', 'would', 'stop', 'global', 'clinic', 'develop', 'medicin', 'known', 'amcenestr', 'phase', 'studi', 'show', 'effect', 'enough', 'warrant', 'research', 'all', 'studi', 'amcenestr', 'includ', 'breast', 'cancer', 'also', 'discontinu', 'sanofi', 'ad', 'while', 'disappoint', 'outcom', 'research', 'scientif', 'understand', 'endocrin', 'therapi', 'peopl', 'breast', 'cancer', 'said', 'john', 'reed', 'global', 'head', 'research', 'develop', 'sanofi', 'in', 'note', 'analyst', 'morgan', 'stanley', 'call', 'decis', 'setback', 'innov', 'narr', 'put', 'forward', 'sanofi', 'say', 'amcenestr', 'flag', 'potenti', 'lucr', 'piec', 'group', 'drug', 'pipelin', 'end', 'sanofi', 'amcenestr', 'trial', 'expect', 'lead', 'neg', 'impact', 'compani', 'estim', 'discount', 'cash', 'flow', 'accord', 'morgan', 'stanley', 'analyst', 'decis', 'could', 'also', 'effect', 'studi', 'conduct', 'similar', 'breast', 'cancer', 'drug', 'sanofi', 'rival', 'roch', 'six', 'astrazeneca', 'plc', 'lon', 'analyst', 'ad']]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "c_EVhFGVDZe7"
      },
      "source": [
        "We can see that the algorithm has stemmed 'ready' to the unusual root of 'readi', and there are other output stems such as 'provid' and 'hospit' which are not linguistically valid."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "rKuSg_l-geI1"
      },
      "source": [
        "### 5.2 Lemmatisation\n",
        "\n",
        "In contrast to stemming, which just removes the last few characters, lemmatisation does conversion properly with the use of a corpus. It removes inflectional endings and considers a language’s full vocabulary to return the base or dictionary form of a word which belongs to the language and is known as a lemma.\n",
        "\n",
        "Lemmatisation looks at the surrounding text to determine a given word’s part of speech, which might have to be defined to obtain the correct lemma.\n",
        "\n",
        "\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "5Bs5tVpjbCAy"
      },
      "source": [
        "### Lemmatisation using NLTK \n",
        "\n",
        "NLTK uses the WordNet corpus, a large, free and publicly available lexical database for the English language aiming to establish structured semantic relationships between words. This has to be imported as WordNetLemmatizer."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6cvbGpyQRVj4",
        "outputId": "87c30232-243b-4a75-8a24-f86767325a5e"
      },
      "source": [
        "# Create an instance of the WordNetLemmatizer() and call the lemmatize() function on each token iteratively\n",
        "import nltk\n",
        "nltk.download('omw-1.4')\n",
        "wnl = WordNetLemmatizer()\n",
        "\n",
        "def nltk_lemmatiser(text):\n",
        "  lemmatised_articles = [[wnl.lemmatize(w) for w in filtered_article] for filtered_article in filtered_articles]\n",
        "  return lemmatised_articles\n",
        "\n",
        "nltk_lemmatised_articles = nltk_lemmatiser(filtered_articles)\n",
        "print(nltk_lemmatised_articles)"
      ],
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package omw-1.4 to /root/nltk_data...\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[['AstraZeneca', 'PLC', 'said', 'Wednesday', 'Capivasertib', 'plus', 'Faslodex', 'significantly', 'improved', 'survival', 'compared', 'Faslodex', 'combined', 'placebo', 'Phase', 'trial', 'advanced', 'hormone', 'breast', 'cancer', 'pharma', 'giant', 'AZN', 'AZN', 'said', 'trial', 'met', 'primary', 'endpoint', 'improving', 'survival', 'overall', 'patient', 'population', 'prespecified', 'biomarker', 'subgroup', 'patient', 'whose', 'tumor', 'qualifying', 'Touts', 'Positive', 'Data', 'From', 'Two', 'Experimental', 'Drugs', 'In', 'Breast', 'Cancer', 'SettingsAstraZeneca', 'Ultomiris', 'Showed', 'Zero', 'Relapses', 'In', 'Patients', 'With', 'Chronic', 'Disorder', 'Of', 'Brain', 'Spinal', 'CordAstraZeneca', 'NASDAQ', 'AZN', 'announced', 'Tuesday', 'vaccine', 'Vaxzevria', 'Recombinant', 'given', 'full', 'Marketing', 'Authorisation', 'MA', 'European', 'Union', 'EU', 'Vaxzevria', 'originally', 'granted', 'conditional', 'Marketing', 'Authorisation', 'cMA', 'EU', 'AstraZeneca', 'stated', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefit', 'Vaxzevria', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Iskra', 'Reic', 'EVP', 'Vaccines', 'Immune', 'Therapies', 'AstraZeneca', 'commented', 'move', 'conditional', 'full', 'marketing', 'authorisation', 'Vaxzevria', 'important', 'confirmation', 'EMA', 'safety', 'efficacy', 'Vaxzevria', 'demonstrating', 'benefit', 'continue', 'outweigh', 'potential', 'risk', 'Vaxzevria', 'estimated', 'helped', 'save', 'six', 'million', 'life', 'first', 'year', 'vaccination', 'reflects', 'strength', 'evidence', 'showing', 'Vaxzevria', 'protection', 'severe', 'disease', 'death', 'caused', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Marketing', 'Authorisation', 'AstraZeneca', 'Plc', 'AZN', 'vaccine', 'Vaxzevria', 'Recombinant', 'vaccine', 'Vaxzevria', 'Recombinant', 'Vaxzevria', 'initially', 'granted', 'conditional', 'Marketing', 'Authorisation', 'due', 'urgency', 'pandemic', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefit', 'Vaxzevria', 'EMA', 'granted', 'full', 'approval', 'approval', 'cover', 'use', 'Vaxzevria', 'primary', 'vaccination', 'series', 'heterologous', 'approved', 'mRNA', 'vaccine', 'homologous', 'vaccine', 'booster', 'Related', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'Vaxzevria', 'demonstrated', 'effective', 'form', 'mild', 'symptomatic', 'severe', 'disease', 'including', 'hospitalization', 'death', 'according', 'clinical', 'study', 'evidence', 'These', 'include', 'expert', 'review', 'data', 'study', 'showed', 'Vaxzevria', 'available', 'mRNA', 'vaccine', 'provide', 'equally', 'effective', 'protection', 'hospitalization', 'death', 'following', 'three', 'dos', 'There', 'also', 'substantial', 'body', 'evidence', 'supporting', 'boosting', 'Vaxzevria', 'following', 'primary', 'vaccination', 'schedule', 'tested', 'date', 'Price', 'Action', 'AZN', 'share', 'premarket', 'session', 'last', 'check', 'Tuesday', 'AZN', 'share', 'premarket', 'session', 'last', 'check', 'Tuesday', 'Photo', 'Paul', 'McManus', 'Pixabay', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'right', 'Shifts', 'China', 'Factory', 'Workers', 'To', 'US', 'Plant', 'Complete', 'European', 'Approval', 'For', 'AstraZeneca', 'Shot', 'Tesla', 'Eyes', 'Cybertruck', 'Commercialization', 'Next', 'Year', 'Top', 'Stories', 'Tuesday', 'European', 'Commission', 'approved', 'AstraZeneca', 'plc', 'AZN', 'Sanofi', 'SA', 'SNY', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborn', 'infant', 'first', 'RSV', 'season', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborn', 'infant', 'first', 'RSV', 'season', 'Beyfortus', 'first', 'RSV', 'passive', 'immunization', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'preterm', 'specific', 'health', 'condition', 'In', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infection', 'LRTI', 'caused', 'RSV', 'placebo', 'day', 'single', 'dose', 'Beyfortus', 'also', 'demonstrated', 'comparable', 'safety', 'tolerability', 'profile', 'Swedish', 'Orphan', 'Biovitrum', 'AB', 'BIOVF', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Globally', 'approximately', 'million', 'case', 'acute', 'lower', 'respiratory', 'infection', 'leading', 'three', 'million', 'hospitalization', 'It', 'estimated', 'death', 'child', 'younger', 'five', 'year', 'Price', 'Action', 'SNY', 'share', 'AZN', 'share', 'premarket', 'session', 'last', 'check', 'Friday', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'right', 'Reuters', 'AstraZeneca', 'share', 'get', 'lift', 'heartburn', 'drug', 'litigation', 'closure', 'say', 'Citi', 'AZN', 'Add', 'Portfolio', 'LFCOF', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'NASDAQ', 'get', 'boost', 'probability', 'close', 'US', 'kidney', 'damage', 'lawsuit', 'New', 'Jersey', 'prior', 'first', 'bellwether', 'case', 'March', 'according', 'analyst', 'Citi', 'UK', 'pharma', 'one', 'several', 'firm', 'embroiled', 'US', 'legal', 'action', 'possible', 'damage', 'caused', 'proton', 'pump', 'inhibitor', 'PPI', 'heartburn', 'drug', 'Nexium', 'launched', 'Astra', 'US', 'Citi', 'analyst', 'believe', 'likely', 'outcome', 'judge', 'delaying', 'response', 'Defendant', 'Motion', 'summary', 'judgement', 'ground', 'encourage', 'plaintiff', 'settle', 'Alternatively', 'lower', 'probability', 'Judge', 'Cecchi', 'may', 'delayed', 'start', 'bellwether', 'case', 'disagrees', 'conclusion', 'Special', 'Master', 'Reisman', 'grant', 'defendant', 'motion', 'dismiss', 'ground', 'said', 'Either', 'scenario', 'would', 'materially', 'positive', 'Astra', 'depressed', 'share', 'price', 'US', 'bank', 'analyst', 'added', 'would', 'positive', 'interim', 'data', 'Enhertu', 'positive', 'data', 'March', 'Citi', 'analyst', 'said', 'core', 'EPS', 'forecast', 'Astra', 'consensus', 'repeated', 'alongside', 'price', 'target', 'recommendation', 'Shares', 'Astra', 'rose', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hope', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'market', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Astrazeneca', 'Beyfortus', 'receives', 'EU', 'approval', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'NASDAQ', 'stated', 'Beyfortus', 'first', 'RSV', 'passive', 'immunisation', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'specific', 'health', 'condition', 'group', 'said', 'European', 'Commission', 'first', 'regulatory', 'body', 'grant', 'approval', 'Beyfortus', 'approval', 'based', 'result', 'drug', 'clinical', 'development', 'programme', 'follows', 'recommendation', 'Committee', 'Medicinal', 'Products', 'Human', 'Use', 'European', 'Medicines', 'Agency', 'September', 'In', 'AZN', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infection', 'caused', 'RSV', 'versus', 'placebo', 'day', 'single', 'dose', 'Iskra', 'Eric', 'AZN', 'executive', 'vice', 'president', 'vaccine', 'immune', 'therapy', 'said', 'Beyfortus', 'first', 'preventative', 'option', 'respiratory', 'syncytial', 'virus', 'gain', 'approval', 'Europe', 'also', 'first', 'preventative', 'option', 'approved', 'broad', 'infant', 'population', 'Today', 'marketing', 'authorisation', 'Beyfortus', 'mark', 'significant', 'achievement', 'scientific', 'community', 'address', 'persistent', 'global', 'unmet', 'need', 'RSV', 'prevention', 'Reporting', 'Iain', 'Gilbert', 'Read', 'Reuters', 'AstraZeneca', 'say', 'Evusheld', 'approved', 'treatment', 'EU', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'said', 'antibody', 'combination', 'Evusheld', 'tixagevimab', 'cilgavimab', 'formerly', 'approved', 'EU', 'treatment', 'approval', 'European', 'Commission', 'cover', 'people', 'age', 'year', 'require', 'supplemental', 'oxygen', 'increased', 'risk', 'progressing', 'severe', 'pharmaceutical', 'group', 'said', 'European', 'Commission', 'approval', 'based', 'result', 'TACKLE', 'phase', 'III', 'treatment', 'trial', 'showed', 'Evusheld', 'significantly', 'reduced', 'risk', 'severe', 'death', 'recommended', 'dose', 'Evusheld', 'treatment', 'Europe', 'tixagevimab', 'cilgavimab', 'administered', 'two', 'separate', 'sequential', 'IM', 'injection', 'AstraZeneca', 'NASDAQ', 'noted', 'Many', 'people', 'including', 'immunocompromised', 'older', 'adult', 'underlying', 'health', 'condition', 'high', 'risk', 'severe', 'disease', 'hospitalisation', 'death', 'become', 'infected', 'Evusheld', 'delivered', 'convenient', 'intramuscular', 'formulation', 'new', 'treatment', 'option', 'vulnerable', 'population', 'commented', 'Dr', 'Michel', 'Goldman', 'professor', 'Institute', 'Interdisciplinary', 'Innovation', 'Healthcare', 'Université', 'Libre', 'de', 'Bruxelles', 'former', 'executive', 'director', 'European', 'Innovative', 'Medicines', 'Initiative', 'statement', 'Iskra', 'Reic', 'executive', 'vice', 'president', 'vaccine', 'immune', 'therapy', 'AstraZeneca', 'added', 'remains', 'ongoing', 'health', 'concern', 'million', 'Europeans', 'around', 'world', 'especially', 'may', 'virus', 'vaccination', 'With', 'approval', 'Evusheld', 'antibody', 'combination', 'available', 'prevention', 'treatment', 'Europe', 'allowing', 'u', 'protect', 'even', 'people', 'devastating', 'disease', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'AstraZeneca', 'get', 'third', 'regulatory', 'green', 'light', 'matter', 'week', 'asthma', 'drug', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'said', 'Tezspire', 'treatment', 'approved', 'Japan', 'severe', 'bronchial', 'asthma', 'traditional', 'corticosteroid', 'work', 'It', 'third', 'approval', 'matter', 'week', 'product', 'potential', 'challenger', 'market', 'leader', 'Dupxient', 'It', 'developed', 'collaboration', 'US', 'giant', 'Amgen', 'NASDAQ', 'In', 'clinical', 'trial', 'drug', 'shown', 'lower', 'researcher', 'called', 'asthma', 'exacerbation', 'Tezspire', 'first', 'biologic', 'approved', 'Japanese', 'Ministry', 'Health', 'Labour', 'Welfare', 'shown', 'consistently', 'significantly', 'reduce', 'attack', 'exacerbation', 'trial', 'broad', 'population', 'severe', 'asthma', 'patient', 'irrespective', 'biomarker', 'level', 'Mene', 'Pangalos', 'head', 'biopharmaceutical', 'research', 'AZ', 'Tezspire', 'potential', 'improve', 'outcome', 'many', 'patient', 'severe', 'asthma', 'working', 'make', 'important', 'medicine', 'available', 'Japan', 'quickly', 'Analysts', 'believe', 'Tezspire', 'could', 'big', 'seller', 'peak', 'sale', 'projected', 'order', 'US', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FILE', 'PHOTO', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'Shares', 'LogicBio', 'Therapeutics', 'skyrocketed', 'Monday', 'Britain', 'AstraZeneca', 'NASDAQ', 'said', 'would', 'buy', 'gene', 'therapy', 'developer', 'rare', 'premium', 'million', 'LoigBio', 'share', 'traded', 'since', 'February', 'bell', 'close', 'AstraZeneca', 'offer', 'price', 'per', 'share', 'LogicBio', 'developing', 'gene', 'editing', 'therapy', 'treat', 'pediatric', 'rare', 'disease', 'like', 'methylmalonic', 'acidemia', 'body', 'break', 'certain', 'protein', 'fat', 'AstraZeneca', 'said', 'deal', 'would', 'accelerate', 'growth', 'Alexion', 'NASDAQ', 'unit', 'acquired', 'billion', 'last', 'year', 'field', 'genomic', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hope', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'market', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'AstraZeneca', 'say', 'combination', 'approved', 'advanced', 'liver', 'cancer', 'US', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'announced', 'US', 'Food', 'Drug', 'Administration', 'FDA', 'approved', 'company', 'Imjudo', 'tremelimumab', 'drug', 'combination', 'Imfinzi', 'durvalumab', 'treatment', 'adult', 'patient', 'unresectable', 'hepatocellular', 'carcinoma', 'HCC', 'common', 'type', 'liver', 'cancer', 'approval', 'based', 'result', 'HIMALAYA', 'Phase', 'III', 'trial', 'showed', 'single', 'priming', 'dose', 'antibody', 'Imjudo', 'added', 'antibody', 'Imfinzi', 'reduced', 'risk', 'death', 'compared', 'sorafenib', 'pharmaceutical', 'company', 'said', 'Liver', 'cancer', 'cause', 'cancer', 'death', 'sixth', 'commonly', 'diagnosed', 'cancer', 'worldwide', 'It', 'cause', 'death', 'US', 'approximately', 'new', 'diagnosis', 'year', 'company', 'said', 'In', 'statement', 'Dave', 'Fredrickson', 'executive', 'vice', 'president', 'oncology', 'business', 'unit', 'AstraZeneca', 'commented', 'With', 'first', 'regulatory', 'approval', 'Imjudo', 'patient', 'unresectable', 'liver', 'cancer', 'US', 'approved', 'dual', 'immunotherapy', 'treatment', 'regimen', 'harness', 'potential', 'inhibition', 'unique', 'combination', 'inhibitor', 'enhance', 'immune', 'response', 'cancer', 'Dr', 'Ghassan', 'attending', 'physician', 'Memorial', 'Sloan', 'Kettering', 'Cancer', 'Center', 'MSK', 'principal', 'investigator', 'HIMALAYA', 'Phase', 'III', 'trial', 'said', 'Patients', 'unresectable', 'liver', 'cancer', 'need', 'treatment', 'meaningfully', 'extend', 'overall', 'survival', 'In', 'addition', 'regimen', 'demonstrating', 'favourable', 'survival', 'rate', 'HIMALAYA', 'trial', 'safety', 'data', 'showed', 'increase', 'severe', 'liver', 'toxicity', 'bleeding', 'risk', 'combination', 'important', 'factor', 'patient', 'liver', 'cancer', 'also', 'advanced', 'liver', 'disease', 'Regulatory', 'application', 'Imjudo', 'combination', 'Imfinzi', 'currently', 'review', 'Europe', 'Japan', 'several', 'country', 'treatment', 'patient', 'advanced', 'liver', 'cancer', 'based', 'HIMALAYA', 'result', 'AstraZeneca', 'said', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'Prostate', 'Cancer', 'Combo', 'Drug', 'Try', 'For', 'scPharma', 'FDA', 'Panel', 'Decisions', 'And', 'More', 'October', 'Key', 'PDUFA', 'Catalysts', 'Biotech', 'Investors', 'Must', 'Know', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'KECR', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Most', 'FDA', 'decision', 'scheduled', 'September', 'yielded', 'positive', 'result', 'stray', 'disappointment', 'well', 'Seven', 'new', 'molecular', 'entity', 'NMEs', 'approved', 'month', 'taking', 'total', 'NME', 'approval', 'year', 'This', 'far', 'le', 'approval', 'received', 'time', 'last', 'year', 'NMEs', 'considered', 'measure', 'innovation', 'drug', 'research', 'contain', 'active', 'moiety', 'ingredient', 'previously', 'approved', 'Food', 'Drug', 'Administration', 'Among', 'positive', 'verdict', 'bluebird', 'bio', 'NASDAQ', 'BLUE', 'million', 'gene', 'therapy', 'Skysona', 'approved', 'treating', 'rare', 'neurodegenerative', 'disorder', 'boy', 'Amylyx', 'Pharmaceuticals', 'NASDAQ', 'AMLX', 'scored', 'win', 'amyotrophic', 'sclerosis', 'treatment', 'Revance', 'Therapeutics', 'NASDAQ', 'RVNC', 'Botox', 'rival', 'Daxxify', 'approved', 'treating', 'frown', 'line', 'Spectrum', 'Pharmaceuticals', 'NASDAQ', 'SPPI', 'mixed', 'month', 'Rolvedon', 'approved', 'treating', 'neutropenia', 'lung', 'cancer', 'drug', 'get', 'backing', 'FDA', 'panel', 'Here', 'key', 'PDUFA', 'date', 'scheduled', 'October', 'Will', 'Theratech', 'Score', 'A', 'Win', 'For', 'A', 'More', 'Convenient', 'Formulation', 'Of', 'Its', 'HIV', 'Drug', 'Company', 'Theratechnologies', 'NASDAQ', 'THTX', 'Type', 'Application', 'supplemental', 'biologic', 'license', 'application', 'Candidate', 'Trogarzo', 'Indication', 'Date', 'In', 'fourth', 'quarter', 'company', 'filed', 'sBLA', 'intravenous', 'push', 'mode', 'administration', 'Trogarzo', 'treating', 'human', 'immunodeficiency', 'virus', 'type', 'Trogarzo', 'first', 'approved', 'FDA', 'March', 'treat', 'adult', 'patient', 'HIV', 'In', 'quarter', 'ended', 'May', 'drug', 'generated', 'sale', 'million', 'Theratech', 'Alnylam', 'On', 'Course', 'For', 'Snagging', 'Label', 'Expansion', 'For', 'Oxlumo', 'Company', 'Alnylam', 'NASDAQ', 'ALNY', 'Type', 'Application', 'supplemental', 'new', 'drug', 'application', 'Candidate', 'Oxlumo', 'Indication', 'hyperoxaluria', 'Type', 'Date', 'Oxlumo', 'go', 'generic', 'name', 'lumasiran', 'RNAi', 'therapeutic', 'evaluated', 'reduction', 'plasma', 'oxalate', 'patient', 'advanced', 'hyperoxaluria', 'type', 'rare', 'disorder', 'mainly', 'affect', 'kidney', 'due', 'accumulation', 'substance', 'called', 'oxalate', 'normally', 'filtered', 'kidney', 'excreted', 'urine', 'This', 'therapy', 'first', 'approved', 'lowering', 'urinary', 'oxalate', 'label', 'pediatric', 'adult', 'patient', 'In', 'second', 'quarter', 'fetched', 'company', 'million', 'sale', 'sequentially', 'See', 'also', 'Alzheimer', 'Progression', 'Slowed', 'Down', 'By', 'Biogen', 'NASDAQ', 'New', 'Drug', 'In', 'Study', 'Analyst', 'Sees', 'Can', 'Third', 'Time', 'Be', 'Charm', 'For', 'scPharma', 'Company', 'scPharmaceuticals', 'NASDAQ', 'SCPH', 'Type', 'Application', 'NDA', 'Candidate', 'Furoscix', 'Indication', 'worsening', 'heart', 'failure', 'due', 'congestion', 'Date', 'Furoscix', 'proprietary', 'furosemide', 'solution', 'evaluated', 'outpatient', 'alternative', 'treatment', 'worsening', 'congestive', 'heart', 'failure', 'This', 'scPharma', 'third', 'try', 'Furoscix', 'following', 'complete', 'response', 'letter', 'Go', 'Amicus', 'Pome', 'Disease', 'Treatment', 'Company', 'Amicus', 'Therapeutics', 'NASDAQ', 'FOLD', 'Type', 'Application', 'BLA', 'Candidate', 'cipaglucosidase', 'alfa', 'Indication', 'Pompe', 'disease', 'Date', 'investigational', 'therapy', 'consists', 'cipaglucosidase', 'alfa', 'administered', 'conjunction', 'miglustat', 'yet', 'approved', 'FDA', 'therapy', 'evaluated', 'inherited', 'lysosomal', 'disorder', 'called', 'Pome', 'disease', 'disease', 'debilitating', 'characterized', 'severe', 'muscle', 'weakness', 'worsens', 'time', 'It', 'range', 'rapidly', 'fatal', 'infantile', 'form', 'significant', 'impact', 'heart', 'function', 'slowly', 'progressive', 'form', 'primarily', 'affecting', 'skeletal', 'muscle', 'It', 'estimated', 'Pompe', 'disease', 'affect', 'approximately', 'people', 'worldwide', 'Supernus', 'Hopes', 'For', 'No', 'Hiccups', 'In', 'Parkinson', 'Disease', 'Drug', 'Approval', 'Company', 'Supernus', 'Pharmaceuticals', 'NASDAQ', 'SUPN', 'Type', 'Application', 'NDA', 'Candidate', 'apomorphine', 'infusion', 'device', 'Indication', 'OFF', 'episode', 'Parkinson', 'disease', 'Date', 'Early', 'October', 'Supernus', 'initial', 'application', 'seeking', 'approval', 'shot', 'letter', 'November', 'citing', 'insufficiently', 'completed', 'application', 'allow', 'substantiative', 'review', 'Following', 'resubmission', 'FDA', 'accepted', 'application', 'assigned', 'PDUFA', 'date', 'sometime', 'early', 'October', 'Also', 'read', 'Best', 'Biotech', 'Stocks', 'Right', 'Now', 'AstraZeneca', 'NASDAQ', 'Knocks', 'At', 'FDA', 'Altar', 'For', 'Liver', 'Cancer', 'Combo', 'Treatment', 'Company', 'AstraZeneca', 'plc', 'NASDAQ', 'AZN', 'Type', 'Application', 'Candidate', 'Tremelimumab', 'Imfinzi', 'Indication', 'Unresectable', 'hepatocellular', 'carcinoma', 'Date', 'FDA', 'accepted', 'AstraZeneca', 'BLA', 'tremelimumab', 'priority', 'review', 'supporting', 'indication', 'single', 'priming', 'dose', 'antibody', 'added', 'Imfinzi', 'treating', 'patient', 'unresectable', 'hepatocellular', 'carcinoma', 'A', 'sBLA', 'also', 'submitted', 'Imfinzi', 'indication', 'This', 'novel', 'dose', 'schedule', 'combination', 'called', 'STRIDE', 'regimen', 'Single', 'Tremelimumab', 'Regular', 'Interval', 'Durvalumab', 'HCC', 'according', 'company', 'common', 'type', 'liver', 'cancer', 'people', 'afflicted', 'advanced', 'unresectable', 'HCC', 'year', 'Await', 'Approval', 'For', 'Prostate', 'Cancer', 'Como', 'Therapy', 'Company', 'Merck', 'NYSE', 'MRK', 'AstraZeneca', 'Type', 'Application', 'sNDA', 'Candidate', 'Lynparza', 'combination', 'Abiraterone', 'Prednisone', 'Prednisolone', 'Indication', 'prostate', 'cancer', 'Date', 'application', 'accepted', 'granted', 'priority', 'review', 'FDA', 'treatment', 'adult', 'patient', 'metastatic', 'prostate', 'cancer', 'Adcom', 'Calendar', 'FDA', 'Cardiovascular', 'Renal', 'Drugs', 'Advisory', 'Committee', 'meet', 'discus', 'GlaxoSmithKline', 'plc', 'NYSE', 'GSK', 'NDA', 'factor', 'prolyl', 'hydroxylase', 'inhibitor', 'daprodustat', 'tablet', 'treatment', 'option', 'anemia', 'resulting', 'chronic', 'kidney', 'disease', 'Oncologic', 'Drugs', 'Advisory', 'Committee', 'scheduled', 'meet', 'discus', 'BLA', 'submitted', 'Therapeutics', 'NASDAQ', 'YMAB', 'solution', 'injectable', 'formulation', 'treating', 'neuroblastoma', 'central', 'nervous', 'metastasis', 'On', 'Endocrinologic', 'Metabolic', 'Drugs', 'Advisory', 'Committee', 'deliberate', 'Ispen', 'OTC', 'IPSEY', 'palovarotene', 'capsule', 'proposed', 'indication', 'heterotopic', 'ossification', 'adult', 'child', 'It', 'condition', 'muscle', 'tissue', 'connective', 'tissue', 'tendon', 'ligament', 'gradually', 'replaced', 'bone', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'right', 'reserved', 'Read', 'original', 'article', 'Reuters', 'FILE', 'PHOTO', 'Pascal', 'Soriot', 'chief', 'executive', 'pharmaceutical', 'company', 'AstraZeneca', 'attends', 'interview', 'Reuters', 'Shanghai', 'China', 'November', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Aimee', 'Donnellan', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'AstraZeneca', 'NASDAQ', 'may', 'stay', 'vaccine', 'business', 'long', 'run', 'CEO', 'told', 'Reuters', 'Tuesday', 'showing', 'quickly', 'fortune', 'changed', 'drugmaker', 'produced', 'one', 'first', 'shot', 'since', 'lost', 'rival', 'Production', 'delay', 'probe', 'regulator', 'following', 'rare', 'case', 'severe', 'side', 'effect', 'concern', 'relatively', 'short', 'shelf', 'life', 'compared', 'shot', 'stymied', 'adoption', 'company', 'vaccine', 'Now', 'third', 'year', 'pandemic', 'amid', 'global', 'vaccine', 'supply', 'glut', 'use', 'diminished', 'much', 'developed', 'world', 'country', 'inoculated', 'large', 'number', 'people', 'prefer', 'Pfizer', 'NYSE', 'Moderna', 'NASDAQ', 'mRNA', 'vaccine', 'booster', 'AstraZeneca', 'COVID', 'vaccine', 'still', 'approval', 'company', 'building', 'portfolio', 'antibody', 'therapy', 'including', 'respiratory', 'virus', 'RSV', 'virus', 'Soriot', 'said', 'Reuters', 'Newsmaker', 'interview', 'Tuesday', 'But', 'future', 'COVID', 'vaccine', 'business', 'said', 'I', 'ca', 'sure', 'He', 'also', 'said', 'sure', 'AstraZeneca', 'would', 'broaden', 'roster', 'vaccine', 'infection', 'either', 'adding', 'company', 'looking', 'Investors', 'speculated', 'future', 'vaccine', 'business', 'given', 'slowing', 'sale', 'COVID', 'shot', 'initial', 'sale', 'contract', 'fulfilled', 'stiff', 'competition', 'mRNA', 'vaccine', 'relatively', 'little', 'expertise', 'field', 'company', 'created', 'separate', 'division', 'vaccine', 'antibody', 'therapy', 'late', 'last', 'year', 'Still', 'Soriot', 'said', 'regret', 'company', 'work', 'Oxford', 'University', 'develop', 'COVID', 'vaccine', 'given', 'delivered', 'billion', 'dos', 'saved', 'estimated', 'million', 'life', 'across', 'globe', 'inoculation', 'AstraZeneca', 'second', 'product', 'sale', 'billion', 'AstraZeneca', 'also', 'looking', 'acquisition', 'including', 'small', 'company', 'specialising', 'oncology', 'cardiovascular', 'treatment', 'Soriot', 'added', 'We', 'always', 'look', 'external', 'opportunity', 'said', 'KEEP', 'ON', 'DOING', 'THIS', 'JOB', 'CEO', 'presided', 'quadrupling', 'AstraZeneca', 'share', 'price', 'decade', 'helm', 'I', 'keep', 'job', 'many', 'year', 'said', 'old', 'seen', 'natural', 'successor', 'outgoing', 'Chairman', 'Leif', 'Johansson', 'But', 'July', 'Soriot', 'quashed', 'speculation', 'planning', 'retire', 'time', 'soon', 'saying', 'expected', 'work', 'company', 'newly', 'announced', 'Michel', 'Demare', 'many', 'year', 'come', 'Soriot', 'tasked', 'turning', 'around', 'troubled', 'AstraZeneca', 'hit', 'string', 'key', 'patent', 'loss', 'spate', 'clinical', 'trial', 'failure', 'October', 'following', 'stint', 'pharma', 'peer', 'Roche', 'With', 'Frenchman', 'helm', 'fortune', 'drugmaker', 'changed', 'dramatically', 'He', 'sharpened', 'focus', 'speciality', 'medicine', 'lucrative', 'field', 'oncology', 'made', 'acquisition', 'refill', 'company', 'medicine', 'cabinet', 'fended', 'hostile', 'takeover', 'pharma', 'giant', 'Pfizer', 'invested', 'heavily', 'R', 'D', 'improve', 'company', 'lacklustre', 'drug', 'development', 'success', 'rate', 'However', 'warned', 'Tuesday', 'fewer', 'new', 'medicine', 'would', 'developed', 'going', 'forward', 'due', 'drug', 'price', 'law', 'passed', 'last', 'week', 'Asked', 'inflationary', 'pressure', 'Soriot', 'said', 'We', 'going', 'become', 'innovative', 'productive', 'We', 'ca', 'expect', 'selling', 'price', 'go', 'Sales', 'China', 'account', 'close', 'fifth', 'company', 'total', 'annual', 'revenue', 'dipped', 'recent', 'quarter', 'due', 'lower', 'drug', 'price', 'COVID', 'lockdown', 'measure', 'kept', 'patient', 'diagnosed', 'seeking', 'cancer', 'care', 'On', 'Tuesday', 'Soriot', 'said', 'sale', 'picking', 'third', 'quarter', 'world', 'market', 'pharmaceutical', 'expected', 'country', 'play', 'significant', 'role', 'global', 'market', 'next', 'decade', 'Graphic', 'AstraZeneca', 'share', 'CEO', 'Soriot', 'helm', 'http', 'Reuters', 'People', 'pose', 'syringe', 'needle', 'front', 'displayed', 'AstraZeneca', 'logo', 'illustration', 'taken', 'December', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Pushkala', 'Aripaka', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'medicine', 'regulator', 'backed', 'using', 'AstraZeneca', 'NASDAQ', 'preventative', 'therapy', 'treatment', 'disease', 'also', 'endorsed', 'another', 'medicine', 'preventative', 'option', 'another', 'common', 'virus', 'regulator', 'recommendation', 'usually', 'followed', 'European', 'Commission', 'take', 'final', 'decision', 'drug', 'approval', 'AstraZeneca', 'said', 'Friday', 'European', 'Medicines', 'Agency', 'EMA', 'backed', 'Evusheld', 'treatment', 'adult', 'adolescent', 'COVID', 'need', 'supplemental', 'oxygen', 'increased', 'risk', 'disease', 'worsening', 'Last', 'month', 'Japan', 'became', 'first', 'country', 'approve', 'antibody', 'treatment', 'COVID', 'making', 'Evusheld', 'first', 'therapy', 'authorised', 'prevention', 'treatment', 'viral', 'disease', 'Evusheld', 'previously', 'largely', 'secured', 'global', 'approval', 'including', 'Europe', 'preventative', 'therapy', 'people', 'compromised', 'immune', 'system', 'see', 'little', 'benefit', 'COVID', 'vaccine', 'AstraZeneca', 'leaning', 'Evusheld', 'help', 'offset', 'tepid', 'sale', 'COVID', 'vaccine', 'rapidly', 'lost', 'ground', 'mRNA', 'shot', 'fight', 'rapidly', 'evolving', 'virus', 'Evusheld', 'first', 'launched', 'December', 'generated', 'million', 'first', 'half', 'drugmaker', 'Separately', 'Friday', 'EMA', 'also', 'endorsed', 'AstraZeneca', 'partner', 'Sanofi', 'EPA', 'experimental', 'therapy', 'Beyfortus', 'prevention', 'lower', 'respiratory', 'tract', 'infection', 'caused', 'respiratory', 'syncytial', 'virus', 'RSV', 'RSV', 'cause', 'thousand', 'hospitalisation', 'death', 'globally', 'year', 'toddler', 'elderly', 'complex', 'molecular', 'structure', 'virus', 'safety', 'concern', 'stymied', 'effort', 'develop', 'vaccine', 'since', 'virus', 'first', 'discovered', 'But', 'one', 'therapy', 'Synagis', 'also', 'developed', 'AstraZeneca', 'sold', 'Swedish', 'Orphan', 'Biovitrum', 'United', 'States', 'It', 'designed', 'prevent', 'lower', 'respiratory', 'tract', 'infection', 'caused', 'RSV', 'infant', 'requires', 'five', 'injection', 'cover', 'typical', 'RSV', 'season', 'Meanwhile', 'Beyfortus', 'approved', 'would', 'first', 'preventative', 'RSV', 'therapy', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'deemed', 'first', 'RSV', 'Reuters', 'FILE', 'PHOTO', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'McDermid', 'AZN', 'Add', 'Portfolio', 'Reuters', 'said', 'Friday', 'drug', 'preventing', 'infant', 'RSV', 'Beyfortus', 'nirsevimab', 'recommended', 'approval', 'European', 'Union', 'European', 'Medicines', 'Agency', 'committee', 'drugmaker', 'also', 'said', 'Beyfortus', 'approved', 'would', 'become', 'first', 'protective', 'option', 'newborn', 'infant', 'population', 'RSV', 'lower', 'respiratory', 'tract', 'Reuters', 'Market', 'mover', 'Property', 'group', 'fall', 'reduce', 'price', 'target', 'FDX', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BLND', 'Add', 'Portfolio', 'IDSI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Shares', 'Land', 'Securities', 'British', 'Land', 'fell', 'today', 'property', 'group', 'downgraded', 'Goldman', 'Sachs', 'NYSE', 'JP', 'Morgan', 'lowered', 'price', 'target', 'company', 'Goldman', 'Sachs', 'downgraded', 'British', 'Land', 'neutral', 'buy', 'reduced', 'price', 'target', 'JPMorgan', 'NYSE', 'cut', 'price', 'target', 'retained', 'overweight', 'rating', 'On', 'Land', 'Securities', 'Goldman', 'Sachs', 'lowered', 'rating', 'sell', 'neutral', 'cut', 'price', 'target', 'JPMorgan', 'retained', 'neutral', 'rating', 'lower', 'price', 'target', 'Land', 'Securities', 'fell', 'British', 'Land', 'fell', 'Capita', 'lifted', 'double', 'dose', 'good', 'news', 'Shares', 'advanced', 'reported', 'contract', 'extension', 'Barnet', 'Council', 'disposal', 'subsidiary', 'Ltd', 'Access', 'PaySuite', 'Shares', 'outsourcing', 'service', 'group', 'rose', 'securing', 'contract', 'extension', 'north', 'London', 'council', 'worth', 'although', 'indexation', 'potential', 'additional', 'work', 'could', 'worth', 'Separately', 'Capita', 'said', 'agreed', 'dispose', 'division', 'Access', 'Group', 'basis', 'Capita', 'said', 'sale', 'help', 'reduce', 'debt', 'provide', 'additional', 'liquidity', 'allow', 'enhance', 'digital', 'offering', 'client', 'build', 'focused', 'sustainable', 'business', 'long', 'term', 'Royal', 'Mail', 'fall', 'FedEx', 'warning', 'Shares', 'dipped', 'today', 'following', 'profit', 'warning', 'US', 'peer', 'pulled', 'full', 'year', 'guidance', 'warning', 'first', 'quarter', 'profit', 'would', 'miss', 'estimate', 'global', 'demand', 'slowdown', 'accelerates', 'It', 'cited', 'macroeconomic', 'weakness', 'Asia', 'service', 'challenge', 'Europe', 'Investors', 'took', 'view', 'industry', 'challenge', 'would', 'Royal', 'Mail', 'also', 'face', 'prospect', 'industrial', 'action', 'employee', 'strike', 'higher', 'pay', 'Royal', 'Mail', 'worker', 'represented', 'Communication', 'Workers', 'Union', 'CWU', 'planned', 'walkout', 'September', 'planning', 'strike', 'September', 'October', 'Shares', 'fell', 'EU', 'drug', 'approval', 'boost', 'AstraZeneca', 'NASDAQ', 'rare', 'riser', 'said', 'today', 'received', 'two', 'recommendation', 'drug', 'approval', 'EU', 'drug', 'blood', 'disorder', 'paroxysmal', 'nocturnal', 'haemoglobinuria', 'met', 'primary', 'endpoint', 'phase', 'three', 'trial', 'group', 'said', 'Beyfortus', 'drug', 'develops', 'Sanofi', 'EPA', 'prevention', 'lower', 'respiratory', 'tract', 'disease', 'newborn', 'infant', 'recommended', 'marketing', 'authorisation', 'European', 'Union', 'Meanwhile', 'AstraZeneca', 'Evusheld', 'Covid', 'antibody', 'treatment', 'recommended', 'marketing', 'authorisation', 'EU', 'adult', 'virus', 'risk', 'progressing', 'severe', 'disease', 'company', 'explained', 'phase', 'III', 'treatment', 'data', 'showed', 'reduced', 'risk', 'severe', 'Covid', 'death', 'Shares', 'rose', 'following', 'news', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hope', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'market', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'FILE', 'PHOTO', 'Tablet', 'bottle', 'AstraZeneca', 'cancer', 'medicine', 'Lynparza', 'seen', 'undated', 'handout', 'image', 'provided', 'Reuters', 'June', 'via', 'REUTERS', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'AstraZeneca', 'NASDAQ', 'said', 'Thursday', 'drug', 'Lynparza', 'developed', 'Merck', 'Co', 'approved', 'European', 'Union', 'adjuvant', 'treatment', 'patient', 'form', 'genetically', 'mutated', 'breast', 'Reuters', 'Daily', 'Biotech', 'Pulse', 'Celyad', 'Resumes', 'Colorectal', 'Cancer', 'Trial', 'Setback', 'For', 'Otonomy', 'AstraZeneca', 'Halts', 'Phase', 'Head', 'Neck', 'Cancer', 'Trial', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'OTIC', 'Add', 'Portfolio', 'BEAM', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Here', 'roundup', 'top', 'development', 'biotech', 'space', 'last', 'hour', 'Stocks', 'In', 'Focus', 'Arcutis', 'Psoriasis', 'Treatment', 'Scores', 'FDA', 'Approval', 'FDA', 'approved', 'Arcutis', 'Biotherapeutics', 'Inc', 'NASDAQ', 'ARQT', 'Zoryve', 'roflumilast', 'cream', 'plaque', 'psoriasis', 'including', 'intertriginous', 'area', 'patient', 'year', 'age', 'older', 'It', 'first', 'topical', 'inhibitor', 'approved', 'plaque', 'psoriasis', 'commercial', 'product', 'expected', 'available', 'Arcutis', 'expects', 'draw', 'additional', 'million', 'company', 'debt', 'facility', 'SLR', 'Capital', 'Partners', 'Shares', 'premarket', 'session', 'FDA', 'Removes', 'Clinical', 'Hold', 'On', 'Celyad', 'Colorectal', 'Cancer', 'Trial', 'FDA', 'lifted', 'clinical', 'hold', 'Celyad', 'Oncology', 'SA', 'NASDAQ', 'CYAD', 'Phase', 'trial', 'company', 'made', 'change', 'eligibility', 'criterion', 'trial', 'In', 'February', 'company', 'voluntarily', 'paused', 'trial', 'investigate', 'report', 'two', 'fatality', 'study', 'FDA', 'subsequently', 'put', 'trial', 'clinical', 'hold', 'March', 'Shares', 'premarket', 'session', 'HUTCHMED', 'Starts', 'Midstage', 'Tazemetostat', 'Study', 'For', 'Lymphoma', 'Setting', 'HUTCHMED', 'China', 'Limited', 'NASDAQ', 'HCM', 'initiated', 'bridging', 'Phase', 'study', 'tazemetostat', 'China', 'follicular', 'lymphoma', 'FL', 'first', 'patient', 'received', 'first', 'dose', 'July', 'primary', 'objective', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'patient', 'mutation', 'Cohort', 'secondary', 'objective', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'Related', 'Biotech', 'Investors', 'August', 'Key', 'PDUFA', 'Catalysts', 'You', 'Must', 'Know', 'FDA', 'Signs', 'Off', 'On', 'Eledon', 'Pharma', 'Tegoprubart', 'For', 'Kidnety', 'Transplant', 'Rejection', 'FDA', 'cleared', 'Eledon', 'Pharmaceuticals', 'Inc', 'NASDAQ', 'ELDN', 'Investigational', 'New', 'Drug', 'IND', 'application', 'evaluate', 'tegoprubart', 'preventing', 'organ', 'rejection', 'patient', 'receiving', 'kidney', 'transplant', 'phase', 'study', 'enroll', 'approximately', 'participant', 'undergoing', 'kidney', 'transplant', 'Kazia', 'Shares', 'Fall', 'After', 'Update', 'From', 'Pivotal', 'Brain', 'Tumor', 'Trial', 'Kazia', 'Therapeutics', 'Limited', 'NASDAQ', 'KZIA', 'said', 'GBM', 'AGILE', 'pivotal', 'study', 'paxalisib', 'newly', 'diagnosed', 'glioblastoma', 'meet', 'criterion', 'continuing', 'second', 'stage', 'Patients', 'enrolled', 'first', 'stage', 'paxalisib', 'arm', 'continue', 'treatment', 'per', 'protocol', 'completion', 'final', 'analysis', 'Kazia', 'anticipates', 'receiving', 'second', 'half', 'company', 'open', 'study', 'paxalisib', 'arm', 'Germany', 'China', 'Shares', 'premarket', 'session', 'FDA', 'Places', 'Clinical', 'Hold', 'On', 'Beam', 'Therapeutics', 'IND', 'Application', 'For', 'Blood', 'Cancer', 'Study', 'FDA', 'placed', 'clinical', 'hold', 'Beam', 'Therapeutics', 'Inc', 'NASDAQ', 'BEAM', 'Investigational', 'New', 'Drug', 'IND', 'application', 'acute', 'lymphoblastic', 'cell', 'lymphoblastic', 'lymphoma', 'IND', 'submitted', 'end', 'June', 'FDA', 'indicated', 'would', 'provide', 'Beam', 'official', 'clinical', 'hold', 'letter', 'within', 'day', 'Beam', 'plan', 'provide', 'additional', 'update', 'pending', 'discussion', 'FDA', 'Otonomy', 'Shares', 'Sink', 'After', 'Stopping', 'Midstage', 'Tinnitus', 'Study', 'Otonomy', 'Inc', 'NASDAQ', 'OTIC', 'announced', 'Phase', 'trial', 'tinnitus', 'demonstrated', 'clinically', 'meaningful', 'benefit', 'versus', 'placebo', 'primary', 'secondary', 'endpoint', 'across', 'time', 'point', 'study', 'show', 'higher', 'response', 'rate', 'placebo', 'prospectively', 'defined', 'patient', 'subgroup', 'tinnitus', 'duration', 'fewer', 'six', 'month', 'population', 'studied', 'Phase', 'trial', 'overall', 'result', 'support', 'development', 'Shares', 'slipping', 'cent', 'premarket', 'session', 'AstraZeneca', 'NASDAQ', 'Cuts', 'Phase', 'Trial', 'In', 'Head', 'Neck', 'Cancer', 'Innate', 'Pharma', 'SA', 'NASDAQ', 'IPHA', 'futility', 'interim', 'analysis', 'Phase', 'study', 'sponsored', 'AstraZeneca', 'Plc', 'NASDAQ', 'AZN', 'meet', 'threshold', 'efficacy', 'Based', 'result', 'recommendation', 'Independent', 'Data', 'Monitoring', 'Committee', 'AstraZeneca', 'informed', 'Innate', 'study', 'discontinued', 'There', 'new', 'safety', 'finding', 'AstraZeneca', 'plan', 'share', 'data', 'due', 'course', 'IPHA', 'share', 'premarket', 'session', 'ALX', 'Oncology', 'Evorpacept', 'Fast', 'Tracked', 'In', 'US', 'For', 'Head', 'Neck', 'Cancer', 'FDA', 'granted', 'Fast', 'Track', 'designation', 'ALX', 'Oncology', 'Holdings', 'Inc', 'NASDAQ', 'ALXO', 'evorpacept', 'combination', 'Merck', 'Co', 'Inc', 'NYSE', 'MRK', 'Keytruda', 'treatment', 'positive', 'advanced', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'FDA', 'decision', 'informed', 'result', 'ALX', 'Oncology', 'phase', 'study', 'showed', 'preliminary', 'antitumor', 'activity', 'favorable', 'safety', 'profile', 'Shares', 'premarket', 'session', 'Offerings', 'TherapeuticsMD', 'Inc', 'NASDAQ', 'TXMD', 'received', 'private', 'investment', 'company', 'common', 'stock', 'new', 'series', 'preferred', 'stock', 'Rubric', 'Capital', 'Management', 'LP', 'On', 'Radar', 'Earnings', 'Cerevel', 'Therapeutics', 'Holdings', 'Inc', 'NASDAQ', 'CERE', 'Before', 'market', 'open', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'right', 'reserved', 'Read', 'Benzinga', 'Read', 'original', 'article', 'Reuters', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'FCHI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Gold', 'Add', 'Portfolio', 'LCO', 'Add', 'Portfolio', 'CL', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Peter', 'Nurse', 'European', 'stock', 'market', 'largely', 'edged', 'higher', 'Monday', 'starting', 'new', 'week', 'cautious', 'note', 'investor', 'digested', 'weak', 'Chinese', 'economic', 'data', 'By', 'ET', 'GMT', 'Germany', 'traded', 'lower', 'France', 'rose', 'traded', 'higher', 'Economic', 'data', 'released', 'earlier', 'Monday', 'showed', 'China', 'economic', 'growth', 'rate', 'unexpectedly', 'slowing', 'July', 'prompting', 'country', 'central', 'bank', 'surprise', 'move', 'grew', 'July', 'year', 'earlier', 'growth', 'rate', 'increase', 'expected', 'rose', 'year', 'ago', 'missing', 'forecast', 'growth', 'growth', 'seen', 'June', 'China', 'economy', 'world', 'second', 'largest', 'struggling', 'shake', 'June', 'quarter', 'hit', 'growth', 'strict', 'COVID', 'restriction', 'On', 'flip', 'side', 'back', 'Europe', 'Denmark', 'economy', 'grew', 'faster', 'expected', 'second', 'quarter', 'expanding', 'first', 'three', 'month', 'year', 'contracted', 'first', 'quarter', 'raised', 'interest', 'rate', 'July', 'expected', 'September', 'even', 'though', 'risk', 'Eurozone', 'recession', 'reached', 'highest', 'level', 'since', 'November', 'energy', 'shortage', 'threaten', 'drive', 'already', 'record', 'inflation', 'higher', 'still', 'In', 'corporate', 'news', 'AstraZeneca', 'LON', 'NASDAQ', 'stock', 'rose', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patient', 'boosting', 'prospect', 'regulatory', 'approval', 'Henkel', 'ETR', 'stock', 'rose', 'German', 'company', 'said', 'sale', 'rose', 'first', 'half', 'year', 'earnings', 'fell', 'hurt', 'increasing', 'logistics', 'price', 'Oil', 'price', 'fell', 'Monday', 'weighed', 'potential', 'increase', 'supply', 'oil', 'giant', 'Saudi', 'Aramco', 'TADAWUL', 'well', 'concern', 'slowing', 'growth', 'China', 'world', 'economy', 'Saudi', 'Aramco', 'stand', 'ready', 'raise', 'crude', 'oil', 'output', 'maximum', 'capacity', 'million', 'barrel', 'per', 'day', 'requested', 'Saudi', 'Arabian', 'government', 'Chief', 'Executive', 'Amin', 'Nasser', 'said', 'Sunday', 'energy', 'firm', 'announced', 'one', 'largest', 'quarterly', 'profit', 'history', 'By', 'ET', 'future', 'traded', 'lower', 'barrel', 'contract', 'fell', 'Additionally', 'fell', 'traded', 'lower', 'Reuters', 'FILE', 'PHOTO', 'Signage', 'seen', 'outside', 'entrance', 'London', 'Stock', 'Exchange', 'London', 'Britain', 'Aug', 'Photo', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'Add', 'Portfolio', 'ENRY', 'Add', 'Portfolio', 'By', 'Sruthi', 'Shankar', 'Reuters', 'edged', 'Monday', 'gain', 'drugmaker', 'AstraZeneca', 'NASDAQ', 'consumer', 'stock', 'relieved', 'pressure', 'mining', 'oil', 'heavyweight', 'data', 'showed', 'China', 'economy', 'unexpectedly', 'slowed', 'last', 'month', 'FTSE', 'added', 'hold', 'near', 'high', 'midcap', 'inched', 'Investors', 'awaiting', 'UK', 'employment', 'report', 'well', 'consumer', 'price', 'data', 'later', 'week', 'gauge', 'state', 'labour', 'market', 'inflation', 'data', 'could', 'offer', 'clue', 'whether', 'Bank', 'England', 'opts', 'second', 'consecutive', 'hike', 'September', 'meeting', 'mood', 'dull', 'Asian', 'European', 'stock', 'market', 'investor', 'turning', 'defensive', 'sector', 'healthcare', 'consumer', 'staple', 'amid', 'worry', 'health', 'world', 'economy', 'AstraZeneca', 'gained', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'developed', 'Japan', 'Daiichi', 'Sankyo', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patient', 'Oil', 'major', 'Shell', 'LON', 'miner', 'Rio', 'Tinto', 'LON', 'Anglo', 'American', 'LON', 'slipped', 'tandem', 'weaker', 'commodity', 'price', 'release', 'China', 'data', 'FTSE', 'outperformed', 'global', 'peer', 'year', 'due', 'large', 'exposure', 'commodity', 'stock', 'surged', 'back', 'jump', 'oil', 'metal', 'price', 'A', 'weakening', 'pound', 'also', 'boosted', 'dollar', 'earner', 'index', 'Whether', 'trend', 'continue', 'ultimately', 'hinge', 'outlook', 'global', 'energy', 'stock', 'relative', 'broad', 'market', 'BCA', 'Research', 'analyst', 'wrote', 'note', 'FTSE', 'nearly', 'far', 'year', 'MSCI', 'world', 'equity', 'index', 'shed', 'almost', 'Our', 'energy', 'strategist', 'remain', 'bullish', 'oil', 'Their', 'expectation', 'breach', 'average', 'suggests', 'overweight', 'energy', 'sector', 'extension', 'UK', 'equity', 'remains', 'appropriate', 'Reuters', 'FTSE', 'positive', 'early', 'high', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slip', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sale', 'output', 'number', 'forecast', 'UK', 'house', 'price', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gain', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gain', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'point', 'good', 'Richard', 'Hunter', 'head', 'market', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'market', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tension', 'delegation', 'US', 'lawmaker', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdown', 'escalating', 'property', 'Retail', 'sale', 'industrial', 'output', 'rose', 'le', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'share', 'rose', 'pharmaceutical', 'group', 'said', 'positive', 'result', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilder', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'price', 'slipped', 'Positive', 'start', 'proceeding', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'make', 'positive', 'start', 'trading', 'boosted', 'gain', 'US', 'Friday', 'despite', 'mixed', 'performance', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sale', 'industrial', 'output', 'figure', 'At', 'lead', 'index', 'trading', 'point', 'higher', 'broader', 'point', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'price', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'say', 'A', 'drop', 'asking', 'price', 'expected', 'month', 'frenzied', 'two', 'year', 'many', 'home', 'mover', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'number', 'property', 'currently', 'market', 'buy', 'level', 'despite', 'lack', 'instruction', 'new', 'listing', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increase', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'market', 'expected', 'open', 'higher', 'Monday', 'following', 'gain', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sale', 'industrial', 'output', 'figure', 'Investors', 'also', 'one', 'eye', 'UK', 'job', 'inflation', 'report', 'due', 'later', 'week', 'see', 'whether', 'sign', 'slowdown', 'job', 'market', 'price', 'growth', 'Spread', 'betting', 'company', 'calling', 'FTSE', 'around', 'point', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headline', 'rising', 'gas', 'price', 'supply', 'chain', 'challenge', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stock', 'lower', 'recent', 'Asia', 'market', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sale', 'industrial', 'production', 'number', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'come', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'come', 'struggle', 'adapt', 'policy', 'government', 'show', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyer', 'halting', 'mortgage', 'payment', 'protest', 'delay', 'completion', 'new', 'In', 'June', 'saw', 'effect', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'sign', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sale', 'number', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectation', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'result', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figure', 'showed', 'strong', 'cash', 'generation', 'six', 'month', 'June', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gain', 'US', 'Friday', 'Spread', 'betting', 'company', 'calling', 'blue', 'chip', 'index', 'around', 'point', 'closed', 'Friday', 'point', 'jumped', 'point', 'S', 'P', 'added', 'point', 'reach', 'benchmark', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FTSE', 'positive', 'early', 'high', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slip', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sale', 'output', 'number', 'forecast', 'UK', 'house', 'price', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gain', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gain', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'point', 'good', 'Richard', 'Hunter', 'head', 'market', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'market', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tension', 'delegation', 'US', 'lawmaker', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdown', 'escalating', 'property', 'Retail', 'sale', 'industrial', 'output', 'rose', 'le', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'share', 'rose', 'pharmaceutical', 'group', 'said', 'positive', 'result', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilder', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'price', 'slipped', 'Positive', 'start', 'proceeding', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'make', 'positive', 'start', 'trading', 'boosted', 'gain', 'US', 'Friday', 'despite', 'mixed', 'performance', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sale', 'industrial', 'output', 'figure', 'At', 'lead', 'index', 'trading', 'point', 'higher', 'broader', 'point', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'price', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'say', 'A', 'drop', 'asking', 'price', 'expected', 'month', 'frenzied', 'two', 'year', 'many', 'home', 'mover', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'number', 'property', 'currently', 'market', 'buy', 'level', 'despite', 'lack', 'instruction', 'new', 'listing', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increase', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'market', 'expected', 'open', 'higher', 'Monday', 'following', 'gain', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sale', 'industrial', 'output', 'figure', 'Investors', 'also', 'one', 'eye', 'UK', 'job', 'inflation', 'report', 'due', 'later', 'week', 'see', 'whether', 'sign', 'slowdown', 'job', 'market', 'price', 'growth', 'Spread', 'betting', 'company', 'calling', 'FTSE', 'around', 'point', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headline', 'rising', 'gas', 'price', 'supply', 'chain', 'challenge', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stock', 'lower', 'recent', 'Asia', 'market', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sale', 'industrial', 'production', 'number', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'come', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'come', 'struggle', 'adapt', 'policy', 'government', 'show', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyer', 'halting', 'mortgage', 'payment', 'protest', 'delay', 'completion', 'new', 'In', 'June', 'saw', 'effect', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'sign', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sale', 'number', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectation', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'result', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figure', 'showed', 'strong', 'cash', 'generation', 'six', 'month', 'June', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gain', 'US', 'Friday', 'Spread', 'betting', 'company', 'calling', 'blue', 'chip', 'index', 'around', 'point', 'closed', 'Friday', 'point', 'jumped', 'point', 'S', 'P', 'added', 'point', 'reach', 'benchmark', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerAVEPp', 'Add', 'Portfolio', 'ROG', 'Add', 'Portfolio', 'RHHVF', 'Add', 'Portfolio', 'SNY', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'SASY', 'Add', 'Portfolio', 'By', 'Scott', 'Kanowsky', 'Sanofi', 'SA', 'EPA', 'share', 'slid', 'Wednesday', 'French', 'drugmaker', 'announced', 'halt', 'trial', 'new', 'treatment', 'patient', 'battling', 'advanced', 'breast', 'cancer', 'In', 'statement', 'company', 'said', 'would', 'stop', 'global', 'clinical', 'development', 'medicine', 'known', 'amcenestrant', 'phase', 'study', 'showed', 'effective', 'enough', 'warrant', 'research', 'All', 'study', 'amcenestrant', 'including', 'breast', 'cancer', 'also', 'discontinued', 'Sanofi', 'added', 'While', 'disappointed', 'outcome', 'research', 'scientific', 'understanding', 'endocrine', 'therapy', 'people', 'breast', 'cancer', 'said', 'John', 'Reed', 'global', 'head', 'research', 'development', 'Sanofi', 'In', 'note', 'analyst', 'Morgan', 'Stanley', 'called', 'decision', 'setback', 'innovation', 'narrative', 'put', 'forward', 'Sanofi', 'saying', 'amcenestrant', 'flagged', 'potentially', 'lucrative', 'piece', 'group', 'drug', 'pipeline', 'end', 'Sanofi', 'amcenestrant', 'trial', 'expected', 'lead', 'negative', 'impact', 'company', 'estimated', 'discounted', 'cash', 'flow', 'according', 'Morgan', 'Stanley', 'analyst', 'decision', 'could', 'also', 'effect', 'study', 'conducted', 'similar', 'breast', 'cancer', 'drug', 'Sanofi', 'rival', 'Roche', 'SIX', 'AstraZeneca', 'PLC', 'LON', 'analyst', 'added']]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "50xk-EF_bOBN"
      },
      "source": [
        "### Lemmatisation using spaCy\n",
        "\n",
        "spaCy is a free and open source NLP library with a lot of prebuilt models. The default model for the English language is en_core_web_sm, a pipeline trained on written web text (blogs, news, comments), that includes vocabulary, syntax and entities. Components included in the model are tok2vec, tagger, parser, senter, ner, attribute_ruler, lemmatize. Once the language model instance is downloaded, an nlp object can be created. Here nlp refers to the the language model loaded by en_core_web_sm.\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "paGYHDeltCFT"
      },
      "source": [
        "# Load the installed pre-built statistical model \"en_core_web_sm\"\n",
        "nlp = spacy.load('en_core_web_sm')"
      ],
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "pAUaqLUS5qM9"
      },
      "source": [
        "We will define a function to lemmatise a list of lists, or a list of articles each containing a list of tokens. This can be done by iterating over the articles, joining them and then using nlp to input text into the spaCy NLP pipeline. Processing text with the nlp object returns a Doc object which is a container for accessing linguistic annotations for a  given input string. It holds all the information about the tokens, their linguistic features and their relationships. Next, get the lemma for each item in the list and return to a list of lists again by lemmatising the item at the index where the item occurs. "
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Ud6UhZLmT-XS",
        "outputId": "d147356d-4df1-4e27-df81-dc28bf456c14"
      },
      "source": [
        "def spacy_lemmatiser(text):\n",
        "  for filtered_article in filtered_articles:\n",
        "    doc = nlp(' '.join(filtered_article))     \n",
        "    for indexer, i in enumerate(doc):\n",
        "      return filtered_articles\n",
        "\n",
        "spacy_lemmatised_articles = spacy_lemmatiser(filtered_articles)\n",
        "print(spacy_lemmatised_articles)\n"
      ],
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[['AstraZeneca', 'PLC', 'said', 'Wednesday', 'Capivasertib', 'plus', 'Faslodex', 'significantly', 'improved', 'survival', 'compared', 'Faslodex', 'combined', 'placebo', 'Phase', 'trial', 'advanced', 'hormone', 'breast', 'cancer', 'pharma', 'giant', 'AZN', 'AZN', 'said', 'trial', 'met', 'primary', 'endpoints', 'improving', 'survival', 'overall', 'patient', 'population', 'prespecified', 'biomarker', 'subgroup', 'patients', 'whose', 'tumors', 'qualifying', 'Touts', 'Positive', 'Data', 'From', 'Two', 'Experimental', 'Drugs', 'In', 'Breast', 'Cancer', 'SettingsAstraZeneca', 'Ultomiris', 'Showed', 'Zero', 'Relapses', 'In', 'Patients', 'With', 'Chronic', 'Disorder', 'Of', 'Brain', 'Spinal', 'CordAstraZeneca', 'NASDAQ', 'AZN', 'announced', 'Tuesday', 'vaccine', 'Vaxzevria', 'Recombinant', 'given', 'full', 'Marketing', 'Authorisation', 'MA', 'European', 'Union', 'EU', 'Vaxzevria', 'originally', 'granted', 'conditional', 'Marketing', 'Authorisation', 'cMA', 'EU', 'AstraZeneca', 'stated', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefits', 'Vaxzevria', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Iskra', 'Reic', 'EVP', 'Vaccines', 'Immune', 'Therapies', 'AstraZeneca', 'commented', 'move', 'conditional', 'full', 'marketing', 'authorisation', 'Vaxzevria', 'important', 'confirmation', 'EMA', 'safety', 'efficacy', 'Vaxzevria', 'demonstrating', 'benefits', 'continue', 'outweigh', 'potential', 'risks', 'Vaxzevria', 'estimated', 'helped', 'save', 'six', 'million', 'lives', 'first', 'year', 'vaccination', 'reflects', 'strength', 'evidence', 'showing', 'Vaxzevria', 'protection', 'severe', 'disease', 'death', 'caused', 'European', 'Medicines', 'Agency', 'EMA', 'granted', 'full', 'Marketing', 'Authorisation', 'AstraZeneca', 'Plc', 'AZN', 'vaccine', 'Vaxzevria', 'Recombinant', 'vaccine', 'Vaxzevria', 'Recombinant', 'Vaxzevria', 'initially', 'granted', 'conditional', 'Marketing', 'Authorisation', 'due', 'urgency', 'pandemic', 'As', 'continues', 'sufficient', 'evidence', 'safety', 'efficacy', 'confirming', 'benefits', 'Vaxzevria', 'EMA', 'granted', 'full', 'approval', 'approval', 'covers', 'use', 'Vaxzevria', 'primary', 'vaccination', 'series', 'heterologous', 'approved', 'mRNA', 'vaccine', 'homologous', 'vaccine', 'booster', 'Related', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'University', 'Partnered', 'Nasal', 'Vaccine', 'Flunks', 'Human', 'Trial', 'Vaxzevria', 'demonstrated', 'effective', 'forms', 'mild', 'symptomatic', 'severe', 'disease', 'including', 'hospitalization', 'death', 'according', 'clinical', 'studies', 'evidence', 'These', 'include', 'expert', 'review', 'data', 'studies', 'showed', 'Vaxzevria', 'available', 'mRNA', 'vaccines', 'provide', 'equally', 'effective', 'protection', 'hospitalization', 'death', 'following', 'three', 'doses', 'There', 'also', 'substantial', 'body', 'evidence', 'supporting', 'boosting', 'Vaxzevria', 'following', 'primary', 'vaccination', 'schedules', 'tested', 'date', 'Price', 'Action', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Tuesday', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Tuesday', 'Photo', 'Paul', 'McManus', 'Pixabay', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'Shifts', 'China', 'Factory', 'Workers', 'To', 'US', 'Plant', 'Complete', 'European', 'Approval', 'For', 'AstraZeneca', 'Shot', 'Tesla', 'Eyes', 'Cybertruck', 'Commercialization', 'Next', 'Year', 'Top', 'Stories', 'Tuesday', 'European', 'Commission', 'approved', 'AstraZeneca', 'plc', 'AZN', 'Sanofi', 'SA', 'SNY', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'first', 'RSV', 'season', 'Beyfortus', 'nirsevimab', 'antibody', 'prevent', 'respiratory', 'syncytial', 'virus', 'RSV', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'first', 'RSV', 'season', 'Beyfortus', 'first', 'RSV', 'passive', 'immunization', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'preterm', 'specific', 'health', 'conditions', 'In', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', 'LRTI', 'caused', 'RSV', 'placebo', 'day', 'single', 'dose', 'Beyfortus', 'also', 'demonstrated', 'comparable', 'safety', 'tolerability', 'profile', 'Swedish', 'Orphan', 'Biovitrum', 'AB', 'BIOVF', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Synagis', 'palivizumab', 'MEDLEY', 'Phase', 'trial', 'Globally', 'approximately', 'million', 'cases', 'acute', 'lower', 'respiratory', 'infections', 'leading', 'three', 'million', 'hospitalizations', 'It', 'estimated', 'deaths', 'children', 'younger', 'five', 'years', 'Price', 'Action', 'SNY', 'shares', 'AZN', 'shares', 'premarket', 'session', 'last', 'check', 'Friday', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'Reuters', 'AstraZeneca', 'shares', 'get', 'lift', 'heartburn', 'drug', 'litigation', 'closure', 'says', 'Citi', 'AZN', 'Add', 'Portfolio', 'LFCOF', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'NASDAQ', 'get', 'boost', 'probability', 'close', 'US', 'kidney', 'damage', 'lawsuit', 'New', 'Jersey', 'prior', 'first', 'bellwether', 'case', 'March', 'according', 'analysts', 'Citi', 'UK', 'pharma', 'one', 'several', 'firms', 'embroiled', 'US', 'legal', 'action', 'possible', 'damage', 'caused', 'proton', 'pump', 'inhibitor', 'PPI', 'heartburn', 'drugs', 'Nexium', 'launched', 'Astra', 'US', 'Citi', 'analysts', 'believe', 'likely', 'outcome', 'judge', 'delaying', 'response', 'Defendant', 'Motion', 'summary', 'judgement', 'grounds', 'encourage', 'plaintiffs', 'settle', 'Alternatively', 'lower', 'probability', 'Judge', 'Cecchi', 'may', 'delayed', 'start', 'bellwether', 'cases', 'disagrees', 'conclusions', 'Special', 'Master', 'Reisman', 'grants', 'defendant', 'motion', 'dismiss', 'grounds', 'said', 'Either', 'scenario', 'would', 'materially', 'positive', 'Astra', 'depressed', 'share', 'price', 'US', 'bank', 'analysts', 'added', 'would', 'positive', 'interim', 'data', 'Enhertu', 'positive', 'data', 'March', 'Citi', 'analysts', 'said', 'core', 'EPS', 'forecasts', 'Astra', 'consensus', 'repeated', 'alongside', 'price', 'target', 'recommendation', 'Shares', 'Astra', 'rose', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Astrazeneca', 'Beyfortus', 'receives', 'EU', 'approval', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'NASDAQ', 'stated', 'Beyfortus', 'first', 'RSV', 'passive', 'immunisation', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'term', 'specific', 'health', 'conditions', 'group', 'said', 'European', 'Commission', 'first', 'regulatory', 'body', 'grant', 'approval', 'Beyfortus', 'approval', 'based', 'results', 'drug', 'clinical', 'development', 'programme', 'follows', 'recommendation', 'Committee', 'Medicinal', 'Products', 'Human', 'Use', 'European', 'Medicines', 'Agency', 'September', 'In', 'AZN', 'pivotal', 'MELODY', 'efficacy', 'trial', 'Beyfortus', 'met', 'primary', 'endpoint', 'reducing', 'incidence', 'medically', 'attended', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'RSV', 'versus', 'placebo', 'day', 'single', 'dose', 'Iskra', 'Eric', 'AZN', 'executive', 'vice', 'president', 'vaccines', 'immune', 'therapies', 'said', 'Beyfortus', 'first', 'preventative', 'option', 'respiratory', 'syncytial', 'virus', 'gain', 'approval', 'Europe', 'also', 'first', 'preventative', 'option', 'approved', 'broad', 'infant', 'population', 'Today', 'marketing', 'authorisation', 'Beyfortus', 'marks', 'significant', 'achievement', 'scientific', 'community', 'addresses', 'persistent', 'global', 'unmet', 'need', 'RSV', 'prevention', 'Reporting', 'Iain', 'Gilbert', 'Read', 'Reuters', 'AstraZeneca', 'says', 'Evusheld', 'approved', 'treatment', 'EU', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'said', 'antibody', 'combination', 'Evusheld', 'tixagevimab', 'cilgavimab', 'formerly', 'approved', 'EU', 'treatment', 'approval', 'European', 'Commission', 'covers', 'people', 'age', 'years', 'require', 'supplemental', 'oxygen', 'increased', 'risk', 'progressing', 'severe', 'pharmaceuticals', 'group', 'said', 'European', 'Commission', 'approval', 'based', 'results', 'TACKLE', 'phase', 'III', 'treatment', 'trial', 'showed', 'Evusheld', 'significantly', 'reduced', 'risk', 'severe', 'death', 'recommended', 'dose', 'Evusheld', 'treatment', 'Europe', 'tixagevimab', 'cilgavimab', 'administered', 'two', 'separate', 'sequential', 'IM', 'injections', 'AstraZeneca', 'NASDAQ', 'noted', 'Many', 'people', 'including', 'immunocompromised', 'older', 'adults', 'underlying', 'health', 'conditions', 'high', 'risk', 'severe', 'disease', 'hospitalisation', 'death', 'become', 'infected', 'Evusheld', 'delivered', 'convenient', 'intramuscular', 'formulation', 'new', 'treatment', 'option', 'vulnerable', 'populations', 'commented', 'Dr', 'Michel', 'Goldman', 'professor', 'Institute', 'Interdisciplinary', 'Innovation', 'Healthcare', 'Université', 'Libre', 'de', 'Bruxelles', 'former', 'executive', 'director', 'European', 'Innovative', 'Medicines', 'Initiative', 'statement', 'Iskra', 'Reic', 'executive', 'vice', 'president', 'vaccines', 'immune', 'therapies', 'AstraZeneca', 'added', 'remains', 'ongoing', 'health', 'concern', 'millions', 'Europeans', 'around', 'world', 'especially', 'may', 'virus', 'vaccination', 'With', 'approval', 'Evusheld', 'antibody', 'combination', 'available', 'prevention', 'treatment', 'Europe', 'allowing', 'us', 'protect', 'even', 'people', 'devastating', 'disease', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'AstraZeneca', 'gets', 'third', 'regulatory', 'green', 'light', 'matter', 'weeks', 'asthma', 'drug', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'said', 'Tezspire', 'treatment', 'approved', 'Japan', 'severe', 'bronchial', 'asthma', 'traditional', 'corticosteroids', 'work', 'It', 'third', 'approval', 'matter', 'weeks', 'product', 'potential', 'challenger', 'market', 'leader', 'Dupxient', 'It', 'developed', 'collaboration', 'US', 'giant', 'Amgen', 'NASDAQ', 'In', 'clinical', 'trials', 'drug', 'shown', 'lower', 'researchers', 'called', 'asthma', 'exacerbations', 'Tezspire', 'first', 'biologic', 'approved', 'Japanese', 'Ministry', 'Health', 'Labour', 'Welfare', 'shown', 'consistently', 'significantly', 'reduce', 'attacks', 'exacerbation', 'trials', 'broad', 'population', 'severe', 'asthma', 'patients', 'irrespective', 'biomarker', 'levels', 'Mene', 'Pangalos', 'head', 'biopharmaceutical', 'research', 'AZ', 'Tezspire', 'potential', 'improve', 'outcomes', 'many', 'patients', 'severe', 'asthma', 'working', 'make', 'important', 'medicine', 'available', 'Japan', 'quickly', 'Analysts', 'believe', 'Tezspire', 'could', 'big', 'seller', 'peak', 'sales', 'projected', 'order', 'US', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FILE', 'PHOTO', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'Shares', 'LogicBio', 'Therapeutics', 'skyrocketed', 'Monday', 'Britain', 'AstraZeneca', 'NASDAQ', 'said', 'would', 'buy', 'gene', 'therapy', 'developer', 'rare', 'premium', 'million', 'LoigBio', 'shares', 'traded', 'since', 'February', 'bell', 'close', 'AstraZeneca', 'offer', 'price', 'per', 'share', 'LogicBio', 'developing', 'gene', 'editing', 'therapies', 'treat', 'pediatric', 'rare', 'disease', 'like', 'methylmalonic', 'acidemia', 'body', 'break', 'certain', 'proteins', 'fats', 'AstraZeneca', 'said', 'deal', 'would', 'accelerate', 'growth', 'Alexion', 'NASDAQ', 'unit', 'acquired', 'billion', 'last', 'year', 'field', 'genomic', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'AstraZeneca', 'says', 'combination', 'approved', 'advanced', 'liver', 'cancer', 'US', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AstraZeneca', 'PLC', 'LON', 'announced', 'US', 'Food', 'Drug', 'Administration', 'FDA', 'approved', 'company', 'Imjudo', 'tremelimumab', 'drug', 'combination', 'Imfinzi', 'durvalumab', 'treatment', 'adult', 'patients', 'unresectable', 'hepatocellular', 'carcinoma', 'HCC', 'common', 'type', 'liver', 'cancer', 'approval', 'based', 'results', 'HIMALAYA', 'Phase', 'III', 'trial', 'showed', 'single', 'priming', 'dose', 'antibody', 'Imjudo', 'added', 'antibody', 'Imfinzi', 'reduced', 'risk', 'death', 'compared', 'sorafenib', 'pharmaceuticals', 'company', 'said', 'Liver', 'cancer', 'cause', 'cancer', 'death', 'sixth', 'commonly', 'diagnosed', 'cancer', 'worldwide', 'It', 'cause', 'deaths', 'US', 'approximately', 'new', 'diagnoses', 'year', 'company', 'said', 'In', 'statement', 'Dave', 'Fredrickson', 'executive', 'vice', 'president', 'oncology', 'business', 'unit', 'AstraZeneca', 'commented', 'With', 'first', 'regulatory', 'approval', 'Imjudo', 'patients', 'unresectable', 'liver', 'cancer', 'US', 'approved', 'dual', 'immunotherapy', 'treatment', 'regimen', 'harnesses', 'potential', 'inhibition', 'unique', 'combination', 'inhibitor', 'enhance', 'immune', 'response', 'cancer', 'Dr', 'Ghassan', 'attending', 'physician', 'Memorial', 'Sloan', 'Kettering', 'Cancer', 'Center', 'MSK', 'principal', 'investigator', 'HIMALAYA', 'Phase', 'III', 'trial', 'said', 'Patients', 'unresectable', 'liver', 'cancer', 'need', 'treatments', 'meaningfully', 'extend', 'overall', 'survival', 'In', 'addition', 'regimen', 'demonstrating', 'favourable', 'survival', 'rate', 'HIMALAYA', 'trial', 'safety', 'data', 'showed', 'increase', 'severe', 'liver', 'toxicity', 'bleeding', 'risk', 'combination', 'important', 'factors', 'patients', 'liver', 'cancer', 'also', 'advanced', 'liver', 'disease', 'Regulatory', 'applications', 'Imjudo', 'combination', 'Imfinzi', 'currently', 'review', 'Europe', 'Japan', 'several', 'countries', 'treatment', 'patients', 'advanced', 'liver', 'cancer', 'based', 'HIMALAYA', 'results', 'AstraZeneca', 'said', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'Prostate', 'Cancer', 'Combo', 'Drug', 'Try', 'For', 'scPharma', 'FDA', 'Panel', 'Decisions', 'And', 'More', 'October', 'Key', 'PDUFA', 'Catalysts', 'Biotech', 'Investors', 'Must', 'Know', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'KECR', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Most', 'FDA', 'decisions', 'scheduled', 'September', 'yielded', 'positive', 'results', 'stray', 'disappointments', 'well', 'Seven', 'new', 'molecular', 'entities', 'NMEs', 'approved', 'month', 'taking', 'total', 'NME', 'approvals', 'year', 'This', 'far', 'less', 'approvals', 'received', 'time', 'last', 'year', 'NMEs', 'considered', 'measure', 'innovation', 'drug', 'research', 'contain', 'active', 'moieties', 'ingredients', 'previously', 'approved', 'Food', 'Drug', 'Administration', 'Among', 'positive', 'verdicts', 'bluebird', 'bio', 'NASDAQ', 'BLUE', 'million', 'gene', 'therapy', 'Skysona', 'approved', 'treating', 'rare', 'neurodegenerative', 'disorder', 'boys', 'Amylyx', 'Pharmaceuticals', 'NASDAQ', 'AMLX', 'scored', 'win', 'amyotrophic', 'sclerosis', 'treatment', 'Revance', 'Therapeutics', 'NASDAQ', 'RVNC', 'Botox', 'rival', 'Daxxify', 'approved', 'treating', 'frown', 'lines', 'Spectrum', 'Pharmaceuticals', 'NASDAQ', 'SPPI', 'mixed', 'month', 'Rolvedon', 'approved', 'treating', 'neutropenia', 'lung', 'cancer', 'drug', 'get', 'backing', 'FDA', 'panel', 'Here', 'key', 'PDUFA', 'dates', 'scheduled', 'October', 'Will', 'Theratech', 'Score', 'A', 'Win', 'For', 'A', 'More', 'Convenient', 'Formulation', 'Of', 'Its', 'HIV', 'Drug', 'Company', 'Theratechnologies', 'NASDAQ', 'THTX', 'Type', 'Application', 'supplemental', 'biologic', 'license', 'application', 'Candidate', 'Trogarzo', 'Indication', 'Date', 'In', 'fourth', 'quarter', 'company', 'filed', 'sBLA', 'intravenous', 'push', 'mode', 'administration', 'Trogarzo', 'treating', 'human', 'immunodeficiency', 'virus', 'type', 'Trogarzo', 'first', 'approved', 'FDA', 'March', 'treat', 'adult', 'patients', 'HIV', 'In', 'quarter', 'ended', 'May', 'drug', 'generated', 'sales', 'million', 'Theratech', 'Alnylam', 'On', 'Course', 'For', 'Snagging', 'Label', 'Expansion', 'For', 'Oxlumo', 'Company', 'Alnylam', 'NASDAQ', 'ALNY', 'Type', 'Application', 'supplemental', 'new', 'drug', 'application', 'Candidate', 'Oxlumo', 'Indication', 'hyperoxaluria', 'Type', 'Date', 'Oxlumo', 'goes', 'generic', 'name', 'lumasiran', 'RNAi', 'therapeutic', 'evaluated', 'reduction', 'plasma', 'oxalate', 'patients', 'advanced', 'hyperoxaluria', 'type', 'rare', 'disorder', 'mainly', 'affects', 'kidneys', 'due', 'accumulation', 'substance', 'called', 'oxalate', 'normally', 'filtered', 'kidneys', 'excreted', 'urine', 'This', 'therapy', 'first', 'approved', 'lowering', 'urinary', 'oxalate', 'labels', 'pediatric', 'adult', 'patients', 'In', 'second', 'quarter', 'fetched', 'company', 'million', 'sales', 'sequentially', 'See', 'also', 'Alzheimer', 'Progression', 'Slowed', 'Down', 'By', 'Biogen', 'NASDAQ', 'New', 'Drug', 'In', 'Study', 'Analyst', 'Sees', 'Can', 'Third', 'Time', 'Be', 'Charm', 'For', 'scPharma', 'Company', 'scPharmaceuticals', 'NASDAQ', 'SCPH', 'Type', 'Application', 'NDA', 'Candidate', 'Furoscix', 'Indication', 'worsening', 'heart', 'failure', 'due', 'congestion', 'Date', 'Furoscix', 'proprietary', 'furosemide', 'solution', 'evaluated', 'outpatient', 'alternative', 'treatment', 'worsening', 'congestive', 'heart', 'failure', 'This', 'scPharma', 'third', 'try', 'Furoscix', 'following', 'complete', 'response', 'letter', 'Go', 'Amicus', 'Pome', 'Disease', 'Treatment', 'Company', 'Amicus', 'Therapeutics', 'NASDAQ', 'FOLD', 'Type', 'Application', 'BLA', 'Candidate', 'cipaglucosidase', 'alfa', 'Indication', 'Pompe', 'disease', 'Date', 'investigational', 'therapy', 'consists', 'cipaglucosidase', 'alfa', 'administered', 'conjunction', 'miglustat', 'yet', 'approved', 'FDA', 'therapy', 'evaluated', 'inherited', 'lysosomal', 'disorder', 'called', 'Pome', 'disease', 'disease', 'debilitating', 'characterized', 'severe', 'muscle', 'weakness', 'worsens', 'time', 'It', 'ranges', 'rapidly', 'fatal', 'infantile', 'form', 'significant', 'impacts', 'heart', 'function', 'slowly', 'progressive', 'form', 'primarily', 'affecting', 'skeletal', 'muscle', 'It', 'estimated', 'Pompe', 'disease', 'affects', 'approximately', 'people', 'worldwide', 'Supernus', 'Hopes', 'For', 'No', 'Hiccups', 'In', 'Parkinson', 'Disease', 'Drug', 'Approval', 'Company', 'Supernus', 'Pharmaceuticals', 'NASDAQ', 'SUPN', 'Type', 'Application', 'NDA', 'Candidate', 'apomorphine', 'infusion', 'device', 'Indication', 'OFF', 'episodes', 'Parkinson', 'disease', 'Date', 'Early', 'October', 'Supernus', 'initial', 'application', 'seeking', 'approval', 'shot', 'letter', 'November', 'citing', 'insufficiently', 'completed', 'application', 'allow', 'substantiative', 'review', 'Following', 'resubmission', 'FDA', 'accepted', 'application', 'assigned', 'PDUFA', 'date', 'sometime', 'early', 'October', 'Also', 'read', 'Best', 'Biotech', 'Stocks', 'Right', 'Now', 'AstraZeneca', 'NASDAQ', 'Knocks', 'At', 'FDA', 'Altar', 'For', 'Liver', 'Cancer', 'Combo', 'Treatment', 'Company', 'AstraZeneca', 'plc', 'NASDAQ', 'AZN', 'Type', 'Application', 'Candidate', 'Tremelimumab', 'Imfinzi', 'Indication', 'Unresectable', 'hepatocellular', 'carcinoma', 'Date', 'FDA', 'accepted', 'AstraZeneca', 'BLA', 'tremelimumab', 'priority', 'review', 'supporting', 'indication', 'single', 'priming', 'dose', 'antibody', 'added', 'Imfinzi', 'treating', 'patients', 'unresectable', 'hepatocellular', 'carcinoma', 'A', 'sBLA', 'also', 'submitted', 'Imfinzi', 'indication', 'This', 'novel', 'dose', 'schedule', 'combination', 'called', 'STRIDE', 'regimen', 'Single', 'Tremelimumab', 'Regular', 'Interval', 'Durvalumab', 'HCC', 'according', 'company', 'common', 'type', 'liver', 'cancer', 'people', 'afflicted', 'advanced', 'unresectable', 'HCC', 'year', 'Await', 'Approval', 'For', 'Prostate', 'Cancer', 'Como', 'Therapy', 'Company', 'Merck', 'NYSE', 'MRK', 'AstraZeneca', 'Type', 'Application', 'sNDA', 'Candidate', 'Lynparza', 'combination', 'Abiraterone', 'Prednisone', 'Prednisolone', 'Indication', 'prostate', 'cancer', 'Date', 'application', 'accepted', 'granted', 'priority', 'review', 'FDA', 'treatment', 'adult', 'patients', 'metastatic', 'prostate', 'cancer', 'Adcom', 'Calendar', 'FDA', 'Cardiovascular', 'Renal', 'Drugs', 'Advisory', 'Committee', 'meet', 'discuss', 'GlaxoSmithKline', 'plc', 'NYSE', 'GSK', 'NDA', 'factor', 'prolyl', 'hydroxylase', 'inhibitor', 'daprodustat', 'tablets', 'treatment', 'option', 'anemia', 'resulting', 'chronic', 'kidney', 'disease', 'Oncologic', 'Drugs', 'Advisory', 'Committee', 'scheduled', 'meet', 'discuss', 'BLA', 'submitted', 'Therapeutics', 'NASDAQ', 'YMAB', 'solution', 'injectable', 'formulation', 'treating', 'neuroblastoma', 'central', 'nervous', 'metastases', 'On', 'Endocrinologic', 'Metabolic', 'Drugs', 'Advisory', 'Committee', 'deliberate', 'Ispen', 'OTC', 'IPSEY', 'palovarotene', 'capsules', 'proposed', 'indication', 'heterotopic', 'ossification', 'adults', 'children', 'It', 'condition', 'muscle', 'tissue', 'connective', 'tissue', 'tendons', 'ligaments', 'gradually', 'replaced', 'bones', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'reserved', 'Read', 'original', 'article', 'Reuters', 'FILE', 'PHOTO', 'Pascal', 'Soriot', 'chief', 'executive', 'pharmaceuticals', 'company', 'AstraZeneca', 'attends', 'interview', 'Reuters', 'Shanghai', 'China', 'November', 'Photo', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Aimee', 'Donnellan', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'AstraZeneca', 'NASDAQ', 'may', 'stay', 'vaccine', 'business', 'long', 'run', 'CEO', 'told', 'Reuters', 'Tuesday', 'showing', 'quickly', 'fortunes', 'changed', 'drugmaker', 'produced', 'one', 'first', 'shots', 'since', 'lost', 'rivals', 'Production', 'delays', 'probes', 'regulators', 'following', 'rare', 'cases', 'severe', 'side', 'effects', 'concerns', 'relatively', 'short', 'shelf', 'life', 'compared', 'shots', 'stymied', 'adoption', 'company', 'vaccine', 'Now', 'third', 'year', 'pandemic', 'amid', 'global', 'vaccine', 'supply', 'glut', 'use', 'diminished', 'much', 'developed', 'world', 'countries', 'inoculated', 'large', 'numbers', 'people', 'prefer', 'Pfizer', 'NYSE', 'Moderna', 'NASDAQ', 'mRNA', 'vaccines', 'boosters', 'AstraZeneca', 'COVID', 'vaccine', 'still', 'approval', 'company', 'building', 'portfolio', 'antibody', 'therapies', 'including', 'respiratory', 'virus', 'RSV', 'viruses', 'Soriot', 'said', 'Reuters', 'Newsmaker', 'interview', 'Tuesday', 'But', 'future', 'COVID', 'vaccines', 'business', 'said', 'I', 'ca', 'sure', 'He', 'also', 'said', 'sure', 'AstraZeneca', 'would', 'broaden', 'roster', 'vaccines', 'infections', 'either', 'adding', 'company', 'looking', 'Investors', 'speculated', 'future', 'vaccine', 'business', 'given', 'slowing', 'sales', 'COVID', 'shot', 'initial', 'sales', 'contracts', 'fulfilled', 'stiff', 'competition', 'mRNA', 'vaccines', 'relatively', 'little', 'expertise', 'field', 'company', 'created', 'separate', 'division', 'vaccines', 'antibody', 'therapies', 'late', 'last', 'year', 'Still', 'Soriot', 'said', 'regret', 'company', 'work', 'Oxford', 'University', 'develop', 'COVID', 'vaccine', 'given', 'delivered', 'billions', 'doses', 'saved', 'estimated', 'million', 'lives', 'across', 'globe', 'inoculation', 'AstraZeneca', 'second', 'product', 'sales', 'billion', 'AstraZeneca', 'also', 'looking', 'acquisitions', 'including', 'small', 'companies', 'specialising', 'oncology', 'cardiovascular', 'treatments', 'Soriot', 'added', 'We', 'always', 'look', 'external', 'opportunities', 'said', 'KEEP', 'ON', 'DOING', 'THIS', 'JOB', 'CEO', 'presided', 'quadrupling', 'AstraZeneca', 'share', 'price', 'decade', 'helm', 'I', 'keep', 'job', 'many', 'years', 'said', 'old', 'seen', 'natural', 'successor', 'outgoing', 'Chairman', 'Leif', 'Johansson', 'But', 'July', 'Soriot', 'quashed', 'speculation', 'planning', 'retire', 'time', 'soon', 'saying', 'expected', 'work', 'company', 'newly', 'announced', 'Michel', 'Demare', 'many', 'years', 'come', 'Soriot', 'tasked', 'turning', 'around', 'troubled', 'AstraZeneca', 'hit', 'string', 'key', 'patent', 'losses', 'spate', 'clinical', 'trial', 'failures', 'October', 'following', 'stint', 'pharma', 'peer', 'Roche', 'With', 'Frenchman', 'helm', 'fortunes', 'drugmaker', 'changed', 'dramatically', 'He', 'sharpened', 'focus', 'speciality', 'medicines', 'lucrative', 'field', 'oncology', 'made', 'acquisitions', 'refill', 'company', 'medicine', 'cabinet', 'fended', 'hostile', 'takeover', 'pharma', 'giant', 'Pfizer', 'invested', 'heavily', 'R', 'D', 'improve', 'company', 'lacklustre', 'drug', 'development', 'success', 'rate', 'However', 'warned', 'Tuesday', 'fewer', 'new', 'medicines', 'would', 'developed', 'going', 'forward', 'due', 'drug', 'price', 'laws', 'passed', 'last', 'week', 'Asked', 'inflationary', 'pressures', 'Soriot', 'said', 'We', 'going', 'become', 'innovative', 'productive', 'We', 'ca', 'expect', 'selling', 'prices', 'go', 'Sales', 'China', 'account', 'close', 'fifth', 'company', 'total', 'annual', 'revenue', 'dipped', 'recent', 'quarters', 'due', 'lower', 'drug', 'prices', 'COVID', 'lockdown', 'measures', 'kept', 'patients', 'diagnosed', 'seeking', 'cancer', 'care', 'On', 'Tuesday', 'Soriot', 'said', 'sales', 'picking', 'third', 'quarter', 'world', 'market', 'pharmaceuticals', 'expected', 'country', 'play', 'significant', 'role', 'global', 'market', 'next', 'decade', 'Graphic', 'AstraZeneca', 'shares', 'CEO', 'Soriot', 'helm', 'https', 'Reuters', 'People', 'pose', 'syringe', 'needle', 'front', 'displayed', 'AstraZeneca', 'logo', 'illustration', 'taken', 'December', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Pushkala', 'Aripaka', 'Natalie', 'Grover', 'LONDON', 'Reuters', 'medicines', 'regulator', 'backed', 'using', 'AstraZeneca', 'NASDAQ', 'preventative', 'therapy', 'treatment', 'disease', 'also', 'endorsed', 'another', 'medicine', 'preventative', 'option', 'another', 'common', 'virus', 'regulator', 'recommendations', 'usually', 'followed', 'European', 'Commission', 'takes', 'final', 'decision', 'drug', 'approvals', 'AstraZeneca', 'said', 'Friday', 'European', 'Medicines', 'Agency', 'EMA', 'backed', 'Evusheld', 'treatment', 'adults', 'adolescents', 'COVID', 'need', 'supplemental', 'oxygen', 'increased', 'risk', 'disease', 'worsening', 'Last', 'month', 'Japan', 'became', 'first', 'country', 'approve', 'antibody', 'treatment', 'COVID', 'making', 'Evusheld', 'first', 'therapy', 'authorised', 'prevention', 'treatment', 'viral', 'disease', 'Evusheld', 'previously', 'largely', 'secured', 'global', 'approvals', 'including', 'Europe', 'preventative', 'therapy', 'people', 'compromised', 'immune', 'systems', 'see', 'little', 'benefit', 'COVID', 'vaccines', 'AstraZeneca', 'leaning', 'Evusheld', 'help', 'offset', 'tepid', 'sales', 'COVID', 'vaccine', 'rapidly', 'lost', 'ground', 'mRNA', 'shots', 'fight', 'rapidly', 'evolving', 'virus', 'Evusheld', 'first', 'launched', 'December', 'generated', 'million', 'first', 'half', 'drugmaker', 'Separately', 'Friday', 'EMA', 'also', 'endorsed', 'AstraZeneca', 'partner', 'Sanofi', 'EPA', 'experimental', 'therapy', 'Beyfortus', 'prevention', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'respiratory', 'syncytial', 'virus', 'RSV', 'RSV', 'causes', 'thousands', 'hospitalisations', 'deaths', 'globally', 'year', 'toddlers', 'elderly', 'complex', 'molecular', 'structure', 'virus', 'safety', 'concerns', 'stymied', 'efforts', 'develop', 'vaccine', 'since', 'virus', 'first', 'discovered', 'But', 'one', 'therapy', 'Synagis', 'also', 'developed', 'AstraZeneca', 'sold', 'Swedish', 'Orphan', 'Biovitrum', 'United', 'States', 'It', 'designed', 'prevent', 'lower', 'respiratory', 'tract', 'infections', 'caused', 'RSV', 'infants', 'requires', 'five', 'injections', 'cover', 'typical', 'RSV', 'season', 'Meanwhile', 'Beyfortus', 'approved', 'would', 'first', 'preventative', 'RSV', 'therapy', 'broad', 'infant', 'population', 'including', 'born', 'healthy', 'deemed', 'first', 'RSV', 'Reuters', 'FILE', 'PHOTO', 'company', 'logo', 'pharmaceutical', 'company', 'AstraZeneca', 'displayed', 'screen', 'floor', 'New', 'York', 'Stock', 'Exchange', 'April', 'McDermid', 'AZN', 'Add', 'Portfolio', 'Reuters', 'said', 'Friday', 'drug', 'preventing', 'infant', 'RSV', 'Beyfortus', 'nirsevimab', 'recommended', 'approval', 'European', 'Union', 'European', 'Medicines', 'Agency', 'committee', 'drugmaker', 'also', 'said', 'Beyfortus', 'approved', 'would', 'become', 'first', 'protective', 'option', 'newborn', 'infant', 'population', 'RSV', 'lower', 'respiratory', 'tract', 'Reuters', 'Market', 'movers', 'Property', 'groups', 'fall', 'reduce', 'price', 'targets', 'FDX', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BLND', 'Add', 'Portfolio', 'IDSI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Shares', 'Land', 'Securities', 'British', 'Land', 'fell', 'today', 'property', 'groups', 'downgraded', 'Goldman', 'Sachs', 'NYSE', 'JP', 'Morgan', 'lowered', 'price', 'targets', 'companies', 'Goldman', 'Sachs', 'downgraded', 'British', 'Land', 'neutral', 'buy', 'reduced', 'price', 'target', 'JPMorgan', 'NYSE', 'cut', 'price', 'target', 'retained', 'overweight', 'rating', 'On', 'Land', 'Securities', 'Goldman', 'Sachs', 'lowered', 'rating', 'sell', 'neutral', 'cut', 'price', 'target', 'JPMorgan', 'retained', 'neutral', 'rating', 'lower', 'price', 'target', 'Land', 'Securities', 'fell', 'British', 'Land', 'fell', 'Capita', 'lifted', 'double', 'dose', 'good', 'news', 'Shares', 'advanced', 'reported', 'contract', 'extension', 'Barnet', 'Council', 'disposal', 'subsidiary', 'Ltd', 'Access', 'PaySuite', 'Shares', 'outsourcing', 'services', 'group', 'rose', 'securing', 'contract', 'extension', 'north', 'London', 'council', 'worth', 'although', 'indexation', 'potential', 'additional', 'work', 'could', 'worth', 'Separately', 'Capita', 'said', 'agreed', 'dispose', 'division', 'Access', 'Group', 'basis', 'Capita', 'said', 'sale', 'help', 'reduce', 'debt', 'provide', 'additional', 'liquidity', 'allow', 'enhance', 'digital', 'offerings', 'clients', 'build', 'focused', 'sustainable', 'business', 'long', 'term', 'Royal', 'Mail', 'falls', 'FedEx', 'warning', 'Shares', 'dipped', 'today', 'following', 'profits', 'warning', 'US', 'peer', 'pulled', 'full', 'year', 'guidance', 'warning', 'first', 'quarter', 'profits', 'would', 'miss', 'estimates', 'global', 'demand', 'slowdown', 'accelerates', 'It', 'cited', 'macroeconomic', 'weakness', 'Asia', 'service', 'challenges', 'Europe', 'Investors', 'took', 'view', 'industry', 'challenges', 'would', 'Royal', 'Mail', 'also', 'faces', 'prospect', 'industrial', 'action', 'employees', 'strike', 'higher', 'pay', 'Royal', 'Mail', 'workers', 'represented', 'Communication', 'Workers', 'Union', 'CWU', 'planned', 'walkout', 'September', 'planning', 'strike', 'September', 'October', 'Shares', 'fell', 'EU', 'drug', 'approvals', 'boost', 'AstraZeneca', 'NASDAQ', 'rare', 'riser', 'said', 'today', 'received', 'two', 'recommendations', 'drug', 'approvals', 'EU', 'drug', 'blood', 'disorder', 'paroxysmal', 'nocturnal', 'haemoglobinuria', 'met', 'primary', 'endpoint', 'phase', 'three', 'trial', 'group', 'said', 'Beyfortus', 'drug', 'develops', 'Sanofi', 'EPA', 'prevention', 'lower', 'respiratory', 'tract', 'disease', 'newborns', 'infants', 'recommended', 'marketing', 'authorisation', 'European', 'Union', 'Meanwhile', 'AstraZeneca', 'Evusheld', 'Covid', 'antibody', 'treatment', 'recommended', 'marketing', 'authorisation', 'EU', 'adults', 'virus', 'risk', 'progressing', 'severe', 'disease', 'company', 'explained', 'phase', 'III', 'treatment', 'data', 'showed', 'reduced', 'risk', 'severe', 'Covid', 'death', 'Shares', 'rose', 'following', 'news', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerBy', 'Benzinga', 'crypto', 'party', 'started', 'corporate', 'optimism', 'hopes', 'Fed', 'thawing', 'perked', 'risk', 'appetite', 'financial', 'markets', 'Ethereum', 'CRYPTO', 'ETH', 'second', 'Reuters', 'FILE', 'PHOTO', 'Tablet', 'bottles', 'AstraZeneca', 'cancer', 'medicine', 'Lynparza', 'seen', 'undated', 'handout', 'image', 'provided', 'Reuters', 'June', 'via', 'REUTERS', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Reuters', 'AstraZeneca', 'NASDAQ', 'said', 'Thursday', 'drug', 'Lynparza', 'developed', 'Merck', 'Co', 'approved', 'European', 'Union', 'adjuvant', 'treatment', 'patients', 'form', 'genetically', 'mutated', 'breast', 'Reuters', 'Daily', 'Biotech', 'Pulse', 'Celyad', 'Resumes', 'Colorectal', 'Cancer', 'Trial', 'Setback', 'For', 'Otonomy', 'AstraZeneca', 'Halts', 'Phase', 'Head', 'Neck', 'Cancer', 'Trial', 'AZN', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'OTIC', 'Add', 'Portfolio', 'BEAM', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Here', 'roundup', 'top', 'developments', 'biotech', 'space', 'last', 'hours', 'Stocks', 'In', 'Focus', 'Arcutis', 'Psoriasis', 'Treatment', 'Scores', 'FDA', 'Approval', 'FDA', 'approved', 'Arcutis', 'Biotherapeutics', 'Inc', 'NASDAQ', 'ARQT', 'Zoryve', 'roflumilast', 'cream', 'plaque', 'psoriasis', 'including', 'intertriginous', 'areas', 'patients', 'years', 'age', 'older', 'It', 'first', 'topical', 'inhibitor', 'approved', 'plaque', 'psoriasis', 'commercial', 'product', 'expected', 'available', 'Arcutis', 'expects', 'draw', 'additional', 'million', 'company', 'debt', 'facility', 'SLR', 'Capital', 'Partners', 'Shares', 'premarket', 'session', 'FDA', 'Removes', 'Clinical', 'Hold', 'On', 'Celyad', 'Colorectal', 'Cancer', 'Trial', 'FDA', 'lifted', 'clinical', 'hold', 'Celyad', 'Oncology', 'SA', 'NASDAQ', 'CYAD', 'Phase', 'trial', 'company', 'made', 'changes', 'eligibility', 'criteria', 'trial', 'In', 'February', 'company', 'voluntarily', 'paused', 'trial', 'investigate', 'reports', 'two', 'fatalities', 'study', 'FDA', 'subsequently', 'put', 'trial', 'clinical', 'hold', 'March', 'Shares', 'premarket', 'session', 'HUTCHMED', 'Starts', 'Midstage', 'Tazemetostat', 'Study', 'For', 'Lymphoma', 'Setting', 'HUTCHMED', 'China', 'Limited', 'NASDAQ', 'HCM', 'initiated', 'bridging', 'Phase', 'study', 'tazemetostat', 'China', 'follicular', 'lymphoma', 'FL', 'first', 'patient', 'received', 'first', 'dose', 'July', 'primary', 'objective', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'patients', 'mutations', 'Cohort', 'secondary', 'objectives', 'evaluate', 'efficacy', 'tazemetostat', 'FL', 'Related', 'Biotech', 'Investors', 'August', 'Key', 'PDUFA', 'Catalysts', 'You', 'Must', 'Know', 'FDA', 'Signs', 'Off', 'On', 'Eledon', 'Pharma', 'Tegoprubart', 'For', 'Kidnety', 'Transplant', 'Rejection', 'FDA', 'cleared', 'Eledon', 'Pharmaceuticals', 'Inc', 'NASDAQ', 'ELDN', 'Investigational', 'New', 'Drug', 'IND', 'application', 'evaluate', 'tegoprubart', 'preventing', 'organ', 'rejection', 'patients', 'receiving', 'kidney', 'transplant', 'phase', 'study', 'enroll', 'approximately', 'participants', 'undergoing', 'kidney', 'transplant', 'Kazia', 'Shares', 'Fall', 'After', 'Update', 'From', 'Pivotal', 'Brain', 'Tumor', 'Trial', 'Kazia', 'Therapeutics', 'Limited', 'NASDAQ', 'KZIA', 'said', 'GBM', 'AGILE', 'pivotal', 'study', 'paxalisib', 'newly', 'diagnosed', 'glioblastoma', 'meet', 'criteria', 'continuing', 'second', 'stage', 'Patients', 'enrolled', 'first', 'stage', 'paxalisib', 'arm', 'continue', 'treatment', 'per', 'protocol', 'completion', 'final', 'analysis', 'Kazia', 'anticipates', 'receiving', 'second', 'half', 'company', 'open', 'study', 'paxalisib', 'arm', 'Germany', 'China', 'Shares', 'premarket', 'session', 'FDA', 'Places', 'Clinical', 'Hold', 'On', 'Beam', 'Therapeutics', 'IND', 'Application', 'For', 'Blood', 'Cancer', 'Study', 'FDA', 'placed', 'clinical', 'hold', 'Beam', 'Therapeutics', 'Inc', 'NASDAQ', 'BEAM', 'Investigational', 'New', 'Drug', 'IND', 'application', 'acute', 'lymphoblastic', 'cell', 'lymphoblastic', 'lymphoma', 'IND', 'submitted', 'end', 'June', 'FDA', 'indicated', 'would', 'provide', 'Beam', 'official', 'clinical', 'hold', 'letter', 'within', 'days', 'Beam', 'plans', 'provide', 'additional', 'updates', 'pending', 'discussion', 'FDA', 'Otonomy', 'Shares', 'Sink', 'After', 'Stopping', 'Midstage', 'Tinnitus', 'Study', 'Otonomy', 'Inc', 'NASDAQ', 'OTIC', 'announced', 'Phase', 'trial', 'tinnitus', 'demonstrated', 'clinically', 'meaningful', 'benefit', 'versus', 'placebo', 'primary', 'secondary', 'endpoints', 'across', 'time', 'points', 'study', 'show', 'higher', 'response', 'rate', 'placebo', 'prospectively', 'defined', 'patient', 'subgroup', 'tinnitus', 'duration', 'fewer', 'six', 'months', 'population', 'studied', 'Phase', 'trial', 'overall', 'results', 'support', 'development', 'Shares', 'slipping', 'cents', 'premarket', 'session', 'AstraZeneca', 'NASDAQ', 'Cuts', 'Phase', 'Trial', 'In', 'Head', 'Neck', 'Cancer', 'Innate', 'Pharma', 'SA', 'NASDAQ', 'IPHA', 'futility', 'interim', 'analysis', 'Phase', 'study', 'sponsored', 'AstraZeneca', 'Plc', 'NASDAQ', 'AZN', 'meet', 'threshold', 'efficacy', 'Based', 'result', 'recommendation', 'Independent', 'Data', 'Monitoring', 'Committee', 'AstraZeneca', 'informed', 'Innate', 'study', 'discontinued', 'There', 'new', 'safety', 'findings', 'AstraZeneca', 'plans', 'share', 'data', 'due', 'course', 'IPHA', 'shares', 'premarket', 'session', 'ALX', 'Oncology', 'Evorpacept', 'Fast', 'Tracked', 'In', 'US', 'For', 'Head', 'Neck', 'Cancer', 'FDA', 'granted', 'Fast', 'Track', 'designation', 'ALX', 'Oncology', 'Holdings', 'Inc', 'NASDAQ', 'ALXO', 'evorpacept', 'combination', 'Merck', 'Co', 'Inc', 'NYSE', 'MRK', 'Keytruda', 'treatment', 'positive', 'advanced', 'head', 'neck', 'squamous', 'cell', 'carcinoma', 'FDA', 'decision', 'informed', 'results', 'ALX', 'Oncology', 'phase', 'study', 'showed', 'preliminary', 'antitumor', 'activity', 'favorable', 'safety', 'profile', 'Shares', 'premarket', 'session', 'Offerings', 'TherapeuticsMD', 'Inc', 'NASDAQ', 'TXMD', 'received', 'private', 'investment', 'company', 'common', 'stock', 'new', 'series', 'preferred', 'stock', 'Rubric', 'Capital', 'Management', 'LP', 'On', 'Radar', 'Earnings', 'Cerevel', 'Therapeutics', 'Holdings', 'Inc', 'NASDAQ', 'CERE', 'Before', 'market', 'open', 'Benzinga', 'provide', 'investment', 'advice', 'All', 'rights', 'reserved', 'Read', 'Benzinga', 'Read', 'original', 'article', 'Reuters', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'FCHI', 'Add', 'Portfolio', 'Add', 'Portfolio', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Gold', 'Add', 'Portfolio', 'LCO', 'Add', 'Portfolio', 'CL', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'Add', 'Portfolio', 'By', 'Peter', 'Nurse', 'European', 'stock', 'markets', 'largely', 'edged', 'higher', 'Monday', 'starting', 'new', 'week', 'cautious', 'note', 'investors', 'digested', 'weak', 'Chinese', 'economic', 'data', 'By', 'ET', 'GMT', 'Germany', 'traded', 'lower', 'France', 'rose', 'traded', 'higher', 'Economic', 'data', 'released', 'earlier', 'Monday', 'showed', 'China', 'economic', 'growth', 'rate', 'unexpectedly', 'slowing', 'July', 'prompting', 'country', 'central', 'bank', 'surprise', 'move', 'grew', 'July', 'year', 'earlier', 'growth', 'rate', 'increase', 'expected', 'rose', 'year', 'ago', 'missing', 'forecasts', 'growth', 'growth', 'seen', 'June', 'China', 'economy', 'world', 'second', 'largest', 'struggling', 'shake', 'June', 'quarter', 'hit', 'growth', 'strict', 'COVID', 'restrictions', 'On', 'flip', 'side', 'back', 'Europe', 'Denmark', 'economy', 'grew', 'faster', 'expected', 'second', 'quarter', 'expanding', 'first', 'three', 'months', 'year', 'contracted', 'first', 'quarter', 'raised', 'interest', 'rates', 'July', 'expected', 'September', 'even', 'though', 'risk', 'Eurozone', 'recession', 'reached', 'highest', 'level', 'since', 'November', 'energy', 'shortages', 'threaten', 'drive', 'already', 'record', 'inflation', 'higher', 'still', 'In', 'corporate', 'news', 'AstraZeneca', 'LON', 'NASDAQ', 'stock', 'rose', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patients', 'boosting', 'prospects', 'regulatory', 'approvals', 'Henkel', 'ETR', 'stock', 'rose', 'German', 'company', 'said', 'sales', 'rose', 'first', 'half', 'year', 'earnings', 'fell', 'hurt', 'increasing', 'logistics', 'prices', 'Oil', 'prices', 'fell', 'Monday', 'weighed', 'potential', 'increase', 'supply', 'oil', 'giant', 'Saudi', 'Aramco', 'TADAWUL', 'well', 'concerns', 'slowing', 'growth', 'China', 'world', 'economy', 'Saudi', 'Aramco', 'stands', 'ready', 'raise', 'crude', 'oil', 'output', 'maximum', 'capacity', 'million', 'barrels', 'per', 'day', 'requested', 'Saudi', 'Arabian', 'government', 'Chief', 'Executive', 'Amin', 'Nasser', 'said', 'Sunday', 'energy', 'firm', 'announced', 'one', 'largest', 'quarterly', 'profits', 'history', 'By', 'ET', 'futures', 'traded', 'lower', 'barrel', 'contract', 'fell', 'Additionally', 'fell', 'traded', 'lower', 'Reuters', 'FILE', 'PHOTO', 'Signage', 'seen', 'outside', 'entrance', 'London', 'Stock', 'Exchange', 'London', 'Britain', 'Aug', 'Photo', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'Add', 'Portfolio', 'ENRY', 'Add', 'Portfolio', 'By', 'Sruthi', 'Shankar', 'Reuters', 'edged', 'Monday', 'gains', 'drugmaker', 'AstraZeneca', 'NASDAQ', 'consumer', 'stocks', 'relieved', 'pressure', 'mining', 'oil', 'heavyweights', 'data', 'showed', 'China', 'economy', 'unexpectedly', 'slowed', 'last', 'month', 'FTSE', 'added', 'hold', 'near', 'highs', 'midcap', 'inched', 'Investors', 'awaiting', 'UK', 'employment', 'report', 'well', 'consumer', 'prices', 'data', 'later', 'week', 'gauge', 'state', 'labour', 'market', 'inflation', 'data', 'could', 'offer', 'clues', 'whether', 'Bank', 'England', 'opts', 'second', 'consecutive', 'hike', 'September', 'meeting', 'mood', 'dull', 'Asian', 'European', 'stock', 'markets', 'investors', 'turning', 'defensive', 'sectors', 'healthcare', 'consumer', 'staples', 'amid', 'worries', 'health', 'world', 'economy', 'AstraZeneca', 'gained', 'drugmaker', 'said', 'cancer', 'drug', 'Enhertu', 'developed', 'Japan', 'Daiichi', 'Sankyo', 'delayed', 'progression', 'form', 'advanced', 'breast', 'cancer', 'previously', 'treated', 'patients', 'Oil', 'major', 'Shell', 'LON', 'miners', 'Rio', 'Tinto', 'LON', 'Anglo', 'American', 'LON', 'slipped', 'tandem', 'weaker', 'commodity', 'prices', 'release', 'China', 'data', 'FTSE', 'outperformed', 'global', 'peers', 'year', 'due', 'large', 'exposure', 'commodity', 'stocks', 'surged', 'back', 'jump', 'oil', 'metal', 'prices', 'A', 'weakening', 'pound', 'also', 'boosted', 'dollar', 'earners', 'index', 'Whether', 'trend', 'continue', 'ultimately', 'hinges', 'outlook', 'global', 'energy', 'stocks', 'relative', 'broad', 'market', 'BCA', 'Research', 'analysts', 'wrote', 'note', 'FTSE', 'nearly', 'far', 'year', 'MSCI', 'world', 'equities', 'index', 'shed', 'almost', 'Our', 'energy', 'strategists', 'remain', 'bullish', 'oil', 'Their', 'expectation', 'breach', 'average', 'suggests', 'overweight', 'energy', 'sector', 'extension', 'UK', 'equities', 'remains', 'appropriate', 'Reuters', 'FTSE', 'positive', 'early', 'highs', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slips', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sales', 'output', 'numbers', 'forecast', 'UK', 'house', 'prices', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gains', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gains', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'points', 'good', 'Richard', 'Hunter', 'head', 'markets', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'markets', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tensions', 'delegation', 'US', 'lawmakers', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdowns', 'escalating', 'property', 'Retail', 'sales', 'industrial', 'output', 'rose', 'less', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'shares', 'rose', 'pharmaceuticals', 'group', 'said', 'positive', 'results', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilders', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'prices', 'slipped', 'Positive', 'start', 'proceedings', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'makes', 'positive', 'start', 'trading', 'boosted', 'gains', 'US', 'Friday', 'despite', 'mixed', 'performances', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'industrial', 'output', 'figures', 'At', 'lead', 'index', 'trading', 'points', 'higher', 'broader', 'points', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'prices', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'says', 'A', 'drop', 'asking', 'prices', 'expected', 'month', 'frenzied', 'two', 'years', 'many', 'home', 'movers', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'number', 'properties', 'currently', 'market', 'buy', 'levels', 'despite', 'lack', 'instructions', 'new', 'listings', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increases', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'markets', 'expected', 'open', 'higher', 'Monday', 'following', 'gains', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sales', 'industrial', 'output', 'figures', 'Investors', 'also', 'one', 'eye', 'UK', 'jobs', 'inflation', 'reports', 'due', 'later', 'week', 'see', 'whether', 'signs', 'slowdown', 'jobs', 'market', 'prices', 'growth', 'Spread', 'betting', 'companies', 'calling', 'FTSE', 'around', 'points', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headlines', 'rising', 'gas', 'prices', 'supply', 'chain', 'challenges', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stocks', 'lower', 'recent', 'Asia', 'markets', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sales', 'industrial', 'production', 'numbers', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'comes', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'comes', 'struggle', 'adapt', 'policy', 'government', 'shows', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyers', 'halting', 'mortgage', 'payments', 'protest', 'delays', 'completion', 'new', 'In', 'June', 'saw', 'effects', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'signs', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sales', 'numbers', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectations', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'results', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'showed', 'strong', 'cash', 'generation', 'six', 'months', 'June', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gains', 'US', 'Friday', 'Spread', 'betting', 'companies', 'calling', 'blue', 'chip', 'index', 'around', 'points', 'closed', 'Friday', 'points', 'jumped', 'points', 'S', 'P', 'added', 'points', 'reach', 'benchmarks', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'Reuters', 'FTSE', 'positive', 'early', 'highs', 'Add', 'Portfolio', 'DJI', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'BWY', 'Add', 'Portfolio', 'BDEV', 'Add', 'Portfolio', 'TW', 'Add', 'Portfolio', 'FTMC', 'Add', 'Portfolio', 'PHNX', 'Add', 'Portfolio', 'IXIC', 'Add', 'Portfolio', 'FTSE', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'CHNA', 'Add', 'Portfolio', 'slips', 'back', 'making', 'bright', 'start', 'Chinese', 'retail', 'sales', 'output', 'numbers', 'forecast', 'UK', 'house', 'prices', 'fall', 'August', 'Rightmove', 'FTSE', 'failed', 'hold', 'strong', 'early', 'gains', 'slipped', 'back', 'close', 'parity', 'disappointing', 'economic', 'data', 'China', 'took', 'shine', 'gains', 'US', 'Friday', 'At', 'lead', 'index', 'trading', 'points', 'good', 'Richard', 'Hunter', 'head', 'markets', 'interactive', 'investor', 'said', 'Economic', 'news', 'China', 'threatened', 'spoil', 'party', 'US', 'markets', 'staged', 'strong', 'rally', 'end', 'last', 'Amid', 'geopolitical', 'tensions', 'delegation', 'US', 'lawmakers', 'arrive', 'trip', 'Taiwan', 'Chinese', 'economic', 'data', 'revealed', 'ongoing', 'impact', 'lockdowns', 'escalating', 'property', 'Retail', 'sales', 'industrial', 'output', 'rose', 'less', 'expected', 'July', 'alongside', 'disappointing', 'showing', 'bank', 'But', 'said', 'UK', 'market', 'chose', 'take', 'lead', 'Wall', 'Street', 'notwithstanding', 'fact', 'Bank', 'England', 'set', 'maintain', 'aggressive', 'interest', 'rate', 'stance', 'face', 'persistent', 'inflation', 'AstraZeneca', 'PLC', 'LSE', 'NASDAQ', 'shares', 'rose', 'pharmaceuticals', 'group', 'said', 'positive', 'results', 'new', 'trial', 'Enhertu', 'breast', 'cancer', 'drug', 'demonstrated', 'statistically', 'significant', 'clinically', 'meaningful', 'improvement', 'survival', 'AstraZeneca', 'said', 'Phase', 'III', 'trial', 'Enhertu', 'jointly', 'developed', 'commercialised', 'Daiichi', 'Sankyo', 'also', 'met', 'key', 'secondary', 'endpoint', 'improved', 'overall', 'survival', 'But', 'housebuilders', 'Berkeley', 'Group', 'Holdings', 'PLC', 'LSE', 'BKG', 'Bellway', 'LON', 'Taylor', 'Wimpey', 'LON', 'Barratt', 'Developments', 'LON', 'fell', 'following', 'report', 'Rightmove', 'house', 'prices', 'slipped', 'Positive', 'start', 'proceedings', 'London', 'London', 'upbeat', 'early', 'trading', 'FTSE', 'makes', 'positive', 'start', 'trading', 'boosted', 'gains', 'US', 'Friday', 'despite', 'mixed', 'performances', 'Asia', 'overnight', 'following', 'disappointing', 'Chinese', 'retail', 'sales', 'industrial', 'output', 'figures', 'At', 'lead', 'index', 'trading', 'points', 'higher', 'broader', 'points', 'Latest', 'data', 'online', 'property', 'website', 'Rightmove', 'showed', 'first', 'fall', 'UK', 'house', 'prices', 'year', 'average', 'price', 'property', 'coming', 'market', 'However', 'Tim', 'Bannister', 'Rightmove', 'director', 'property', 'science', 'says', 'A', 'drop', 'asking', 'prices', 'expected', 'month', 'frenzied', 'two', 'years', 'many', 'home', 'movers', 'become', 'distracted', 'summer', 'Indeed', 'may', 'first', 'summer', 'holiday', 'abroad', 'since', 'Bannister', 'also', 'pointed', 'price', 'growth', 'year', 'would', 'still', 'number', 'properties', 'currently', 'market', 'buy', 'levels', 'despite', 'lack', 'instructions', 'new', 'listings', 'rose', 'compared', 'time', 'last', 'year', 'compared', 'Bannister', 'also', 'said', 'recent', 'interest', 'rate', 'increases', 'Bank', 'England', 'significant', 'impact', 'number', 'people', 'wanting', 'FTSE', 'seen', 'higher', 'London', 'markets', 'expected', 'open', 'higher', 'Monday', 'following', 'gains', 'US', 'Friday', 'following', 'surprise', 'news', 'China', 'cut', 'key', 'interest', 'rate', 'bid', 'boost', 'stuttering', 'economy', 'following', 'weaker', 'expected', 'retail', 'sales', 'industrial', 'output', 'figures', 'Investors', 'also', 'one', 'eye', 'UK', 'jobs', 'inflation', 'reports', 'due', 'later', 'week', 'see', 'whether', 'signs', 'slowdown', 'jobs', 'market', 'prices', 'growth', 'Spread', 'betting', 'companies', 'calling', 'FTSE', 'around', 'points', 'Michael', 'Hewson', 'chief', 'market', 'analyst', 'CMC', 'Markets', 'UK', 'said', 'Despite', 'slow', 'drip', 'feed', 'negative', 'headlines', 'rising', 'gas', 'prices', 'supply', 'chain', 'challenges', 'thrown', 'heatwave', 'Europe', 'little', 'appetite', 'drive', 'stocks', 'lower', 'recent', 'Asia', 'markets', 'got', 'positive', 'start', 'week', 'latest', 'retail', 'sales', 'industrial', 'production', 'numbers', 'China', 'showing', 'economy', 'still', 'appears', 'low', 'confidence', 'comes', 'consumer', 'spending', 'economic', 'activity', 'This', 'weakness', 'Chinese', 'economy', 'comes', 'struggle', 'adapt', 'policy', 'government', 'shows', 'little', 'sign', 'relaxing', 'backdrop', 'rising', 'Problems', 'property', 'sector', 'also', 'helping', 'many', 'home', 'buyers', 'halting', 'mortgage', 'payments', 'protest', 'delays', 'completion', 'new', 'In', 'June', 'saw', 'effects', 'policy', 'Chinese', 'economy', 'contraction', 'although', 'started', 'see', 'signs', 'economic', 'activity', 'albeit', 'low', 'This', 'morning', 'retail', 'sales', 'numbers', 'July', 'confirmed', 'fragile', 'confidence', 'still', 'rising', 'well', 'expectations', 'weaker', 'Industrial', 'production', 'robust', 'recovered', 'much', 'better', 'however', 'even', 'economic', 'activity', 'disappointed', 'July', 'slipping', 'back', 'June', 'In', 'London', 'quieter', 'day', 'company', 'results', 'Phoenix', 'Group', 'announced', 'half', 'year', 'figures', 'showed', 'strong', 'cash', 'generation', 'six', 'months', 'June', 'FTSE', 'closed', 'book', 'life', 'insurer', 'said', 'confident', 'delivering', 'target', 'range', 'year', 'New', 'business', 'cash', 'generation', 'record', 'period', 'double', 'first', 'half', 'FTSE', 'set', 'open', 'higher', 'FTSE', 'set', 'start', 'week', 'positive', 'fashion', 'following', 'gains', 'US', 'Friday', 'Spread', 'betting', 'companies', 'calling', 'blue', 'chip', 'index', 'around', 'points', 'closed', 'Friday', 'points', 'jumped', 'points', 'S', 'P', 'added', 'points', 'reach', 'benchmarks', 'ended', 'week', 'high', 'note', 'clinching', 'winning', 'week', 'Nasdaq', 'Composite', 'S', 'P', 'Investors', 'reacted', 'positively', 'CPI', 'PPI', 'data', 'released', 'week', 'suggested', 'inflation', 'may', 'already', 'peaked', 'Read', 'Proactive', 'Investors', 'UK', 'DisclaimerAVEPp', 'Add', 'Portfolio', 'ROG', 'Add', 'Portfolio', 'RHHVF', 'Add', 'Portfolio', 'SNY', 'Add', 'Portfolio', 'AZN', 'Add', 'Portfolio', 'SASY', 'Add', 'Portfolio', 'By', 'Scott', 'Kanowsky', 'Sanofi', 'SA', 'EPA', 'shares', 'slid', 'Wednesday', 'French', 'drugmaker', 'announced', 'halt', 'trials', 'new', 'treatment', 'patients', 'battling', 'advanced', 'breast', 'cancer', 'In', 'statement', 'company', 'said', 'would', 'stop', 'global', 'clinical', 'development', 'medicine', 'known', 'amcenestrant', 'phase', 'study', 'showed', 'effective', 'enough', 'warrant', 'research', 'All', 'studies', 'amcenestrant', 'including', 'breast', 'cancer', 'also', 'discontinued', 'Sanofi', 'added', 'While', 'disappointed', 'outcome', 'research', 'scientific', 'understanding', 'endocrine', 'therapies', 'people', 'breast', 'cancer', 'said', 'John', 'Reed', 'global', 'head', 'research', 'development', 'Sanofi', 'In', 'note', 'analysts', 'Morgan', 'Stanley', 'called', 'decision', 'setback', 'innovation', 'narrative', 'put', 'forward', 'Sanofi', 'saying', 'amcenestrant', 'flagged', 'potentially', 'lucrative', 'piece', 'group', 'drug', 'pipeline', 'end', 'Sanofi', 'amcenestrant', 'trials', 'expected', 'lead', 'negative', 'impact', 'company', 'estimated', 'discounted', 'cash', 'flow', 'according', 'Morgan', 'Stanley', 'analysts', 'decision', 'could', 'also', 'effect', 'studies', 'conducted', 'similar', 'breast', 'cancer', 'drugs', 'Sanofi', 'rivals', 'Roche', 'SIX', 'AstraZeneca', 'PLC', 'LON', 'analysts', 'added']]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "H0MMS88cBBtx"
      },
      "source": [
        "\n",
        "### Stemming vs Lemmatisation and NLTK vs spaCy\n",
        "\n",
        "Lemmatisation is typically seen as much more accurate than simple stemming, which is why spaCy has opted to have only lemmatisation available instead of stemming, ensuring that morphological variants are always actual words.\n",
        "\n",
        "However, if speed and performance are a priority then stemming should be used since lemmatisers scan a corpus which consumes time and processing power. Ultimately, it depends on the application you are working on. For example, if you are building a language application in which language is important you should choose lemmatisation and use a corpus to match root forms.\n",
        "\n",
        "NLTK is a string processing library. It takes strings as input and returns strings or lists of strings as output. Whereas, spaCy uses an object-oriented approach. When we parse a text, spaCy returns a document object whose words and sentences are objects themselves.\n",
        "\n",
        "In word tokenisation and POS-tagging spaCy performs better, but in sentence tokenisation, NLTK outperforms spaCy.\n",
        "\n",
        "spaCy has support for word vectors whereas NLTK does not. spaCy also comes with pre-trained language models which can be used for better part-of-speech (POS) tagging, and named entity recognition (NER) to find out whether or not a word is a named entity, such as persons, locations, organisations, etc."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "c77ho20XiMc2"
      },
      "source": [
        "## 6. Text Classification\n",
        "\n",
        "Text classification is the problem of assigning categories to text data according to its content, and strategies include Bag of Words, TF-IDF and Word Embeddings.\n",
        "\n",
        "### 6.1 Bag of Words (BoW)\n",
        "\n",
        "The Bag of Words (BoW) model is the simplest form of text representation in numbers and is a method of feature extraction with text data. The model builds a vocabulary from a corpus of documents and is only concerned with keeping track of word counts and whether known words occur in the document, not the order or structure of the words. Each word in the vocabulary becomes a feature and a document is represented by a vector with the same length as the vocabulary (a “bag of words”).\n",
        "\n",
        "The scikit-learn library's CountVectorizer() class implements both tokenisation and occurrence counting in a single class. It is used to transform a given text into a vector on the basis of the frequency (count) of each word that occurs in the entire text.\n",
        "\n",
        "CountVectorizer's parameters will be set to stop_words='english' to use the built-in list, and the ngram_range will just be the default range of (1,1). An n-gram is just a string of n words in a row. For example an ngram_range of (1, 1) means only unigrams, (1, 2) means unigrams and bigrams, (2, 2) means only bigrams, and (3,3) means only trigrams.\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "OsbDv2tESHw6",
        "outputId": "4acfdc8d-42bf-4a3f-cffa-e089be21e115"
      },
      "source": [
        "# Create an instance of the CountVectorizer class\n",
        "CountVec = CountVectorizer(ngram_range=(1, 1), \n",
        "                           stop_words='english')\n",
        "# Learn the vocabulary dictionary and transform to a vector of token counts\n",
        "Count_data = CountVec.fit_transform(articles) \n",
        " \n",
        "# Create dataframe that can be used for building models\n",
        "cv_dataframe = pd.DataFrame(Count_data.toarray(),columns=CountVec.get_feature_names())\n",
        "print(cv_dataframe)"
      ],
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "   00  000  002  00am  01  02  0229  03  04  047  ...  xau  year  years  \\\n",
            "0   5    4    2     4   3   2     1  12   2    2  ...    1    30      7   \n",
            "\n",
            "   yielded  ymab  york  younger  zero  zjvqkblqgvx  zoryve  \n",
            "0        1     1     2        1     5            1       1  \n",
            "\n",
            "[1 rows x 1959 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "yx7tYYynZLTi"
      },
      "source": [
        "We get a dataframe for the unprocessed articles where the unique tokens are the columns and the count for each article are the rows. We will try the NLTK stemmed and lemmatised articles and the spaCy lemmatised articles in turn.\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "SJEhg5HZbozo"
      },
      "source": [
        "### NLTK preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fPs8xVo7Ytcy",
        "outputId": "cf92635a-bd65-4b4b-d22c-26b7eeb57a9a"
      },
      "source": [
        "# Join the NLTK stemmed tokens back into a list of articles\n",
        "\n",
        "nltk_preprocessed_articles_stem = [','.join(article).replace(',', ' ') for article in nltk_stemmed_articles]\n",
        "nltk_preprocessed_articles_stem"
      ],
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['astrazeneca plc said wednesday capivasertib plu faslodex significantli improv surviv compar faslodex combin placebo phase trial advanc hormon breast cancer pharma giant azn azn said trial met primari endpoint improv surviv overal patient popul prespecifi biomark subgroup patient whose tumor qualifi tout posit data from two experiment drug in breast cancer settingsastrazeneca ultomiri show zero relaps in patient with chronic disord of brain spinal cordastrazeneca nasdaq azn announc tuesday vaccin vaxzevria recombin given full market authoris ma european union eu vaxzevria origin grant condit market authoris cma eu astrazeneca state as continu suffici evid safeti efficaci confirm benefit vaxzevria european medicin agenc ema grant full iskra reic evp vaccin immun therapi astrazeneca comment move condit full market authoris vaxzevria import confirm ema safeti efficaci vaxzevria demonstr benefit continu outweigh potenti risk vaxzevria estim help save six million live first year vaccin reflect strength evid show vaxzevria protect sever diseas death caus european medicin agenc ema grant full market authoris astrazeneca plc azn vaccin vaxzevria recombin vaccin vaxzevria recombin vaxzevria initi grant condit market authoris due urgenc pandem as continu suffici evid safeti efficaci confirm benefit vaxzevria ema grant full approv approv cover use vaxzevria primari vaccin seri heterolog approv mrna vaccin homolog vaccin booster relat univers partner nasal vaccin flunk human trial univers partner nasal vaccin flunk human trial vaxzevria demonstr effect form mild symptomat sever diseas includ hospit death accord clinic studi evid these includ expert review data studi show vaxzevria avail mrna vaccin provid equal effect protect hospit death follow three dose there also substanti bodi evid support boost vaxzevria follow primari vaccin schedul test date price action azn share premarket session last check tuesday azn share premarket session last check tuesday photo paul mcmanu pixabay benzinga provid invest advic all right shift china factori worker to us plant complet european approv for astrazeneca shot tesla eye cybertruck commerci next year top stori tuesday european commiss approv astrazeneca plc azn sanofi sa sni beyfortu nirsevimab antibodi prevent respiratori syncyti viru rsv lower respiratori tract diseas newborn infant first rsv season beyfortu nirsevimab antibodi prevent respiratori syncyti viru rsv lower respiratori tract diseas newborn infant first rsv season beyfortu first rsv passiv immun broad infant popul includ born healthi term preterm specif health condit in pivot melodi efficaci trial beyfortu met primari endpoint reduc incid medic attend lower respiratori tract infect lrti caus rsv placebo day singl dose beyfortu also demonstr compar safeti toler profil swedish orphan biovitrum ab biovf synagi palivizumab medley phase trial synagi palivizumab medley phase trial global approxim million case acut lower respiratori infect lead three million hospit it estim death children younger five year price action sni share azn share premarket session last check friday benzinga provid invest advic all right reuter astrazeneca share get lift heartburn drug litig closur say citi azn add portfolio lfcof add portfolio add portfolio astrazeneca plc nasdaq get boost probabl close us kidney damag lawsuit new jersey prior first bellweth case march accord analyst citi uk pharma one sever firm embroil us legal action possibl damag caus proton pump inhibitor ppi heartburn drug nexium launch astra us citi analyst believ like outcom judg delay respons defend motion summari judgement ground encourag plaintiff settl altern lower probabl judg cecchi may delay start bellweth case disagre conclus special master reisman grant defend motion dismiss ground said either scenario would materi posit astra depress share price us bank analyst ad would posit interim data enhertu posit data march citi analyst said core ep forecast astra consensu repeat alongsid price target recommend share astra rose read proactiv investor uk disclaimerbi benzinga crypto parti start corpor optim hope fed thaw perk risk appetit financi market ethereum crypto eth second astrazeneca beyfortu receiv eu approv azn add portfolio add portfolio astrazeneca nasdaq state beyfortu first rsv passiv immunis broad infant popul includ born healthi term specif health condit group said european commiss first regulatori bodi grant approv beyfortu approv base result drug clinic develop programm follow recommend committe medicin product human use european medicin agenc septemb in azn pivot melodi efficaci trial beyfortu met primari endpoint reduc incid medic attend lower respiratori tract infect caus rsv versu placebo day singl dose iskra eric azn execut vice presid vaccin immun therapi said beyfortu first prevent option respiratori syncyti viru gain approv europ also first prevent option approv broad infant popul today market authoris beyfortu mark signific achiev scientif commun address persist global unmet need rsv prevent report iain gilbert read reuter astrazeneca say evusheld approv treatment eu azn add portfolio add portfolio said antibodi combin evusheld tixagevimab cilgavimab formerli approv eu treatment approv european commiss cover peopl age year requir supplement oxygen increas risk progress sever pharmaceut group said european commiss approv base result tackl phase iii treatment trial show evusheld significantli reduc risk sever death recommend dose evusheld treatment europ tixagevimab cilgavimab administ two separ sequenti im inject astrazeneca nasdaq note mani peopl includ immunocompromis older adult underli health condit high risk sever diseas hospitalis death becom infect evusheld deliv conveni intramuscular formul new treatment option vulner popul comment dr michel goldman professor institut interdisciplinari innov healthcar université libr de bruxel former execut director european innov medicin initi statement iskra reic execut vice presid vaccin immun therapi astrazeneca ad remain ongo health concern million european around world especi may viru vaccin with approv evusheld antibodi combin avail prevent treatment europ allow us protect even peopl devast diseas read proactiv investor uk reuter astrazeneca get third regulatori green light matter week asthma drug azn add portfolio add portfolio astrazeneca plc lon said tezspir treatment approv japan sever bronchial asthma tradit corticosteroid work it third approv matter week product potenti challeng market leader dupxient it develop collabor us giant amgen nasdaq in clinic trial drug shown lower research call asthma exacerb tezspir first biolog approv japanes ministri health labour welfar shown consist significantli reduc attack exacerb trial broad popul sever asthma patient irrespect biomark level mene pangalo head biopharmaceut research az tezspir potenti improv outcom mani patient sever asthma work make import medicin avail japan quickli analyst believ tezspir could big seller peak sale project order us read proactiv investor uk reuter file photo compani logo pharmaceut compani astrazeneca display screen floor new york stock exchang april photo azn add portfolio add portfolio reuter share logicbio therapeut skyrocket monday britain astrazeneca nasdaq said would buy gene therapi develop rare premium million loigbio share trade sinc februari bell close astrazeneca offer price per share logicbio develop gene edit therapi treat pediatr rare diseas like methylmalon acidemia bodi break certain protein fat astrazeneca said deal would acceler growth alexion nasdaq unit acquir billion last year field genom benzinga crypto parti start corpor optim hope fed thaw perk risk appetit financi market ethereum crypto eth second reuter astrazeneca say combin approv advanc liver cancer us azn add portfolio add portfolio astrazeneca plc lon announc us food drug administr fda approv compani imjudo tremelimumab drug combin imfinzi durvalumab treatment adult patient unresect hepatocellular carcinoma hcc common type liver cancer approv base result himalaya phase iii trial show singl prime dose antibodi imjudo ad antibodi imfinzi reduc risk death compar sorafenib pharmaceut compani said liver cancer caus cancer death sixth commonli diagnos cancer worldwid it caus death us approxim new diagnos year compani said in statement dave fredrickson execut vice presid oncolog busi unit astrazeneca comment with first regulatori approv imjudo patient unresect liver cancer us approv dual immunotherapi treatment regimen har potenti inhibit uniqu combin inhibitor enhanc immun respons cancer dr ghassan attend physician memori sloan ketter cancer center msk princip investig himalaya phase iii trial said patient unresect liver cancer need treatment meaning extend overal surviv in addit regimen demonstr favour surviv rate himalaya trial safeti data show increas sever liver toxic bleed risk combin import factor patient liver cancer also advanc liver diseas regulatori applic imjudo combin imfinzi current review europ japan sever countri treatment patient advanc liver cancer base himalaya result astrazeneca said read proactiv investor uk reuter prostat cancer combo drug tri for scpharma fda panel decis and more octob key pdufa catalyst biotech investor must know azn add portfolio ixic add portfolio kecr add portfolio add portfolio most fda decis schedul septemb yield posit result stray disappoint well seven new molecular entiti nme approv month take total nme approv year thi far less approv receiv time last year nme consid measur innov drug research contain activ moieti ingredi previous approv food drug administr among posit verdict bluebird bio nasdaq blue million gene therapi skysona approv treat rare neurodegen disord boy amylyx pharmaceut nasdaq amlx score win amyotroph sclerosi treatment revanc therapeut nasdaq rvnc botox rival daxxifi approv treat frown line spectrum pharmaceut nasdaq sppi mix month rolvedon approv treat neutropenia lung cancer drug get back fda panel here key pdufa date schedul octob will theratech score a win for a more conveni formul of it hiv drug compani theratechnolog nasdaq thtx type applic supplement biolog licens applic candid trogarzo indic date in fourth quarter compani file sbla intraven push mode administr trogarzo treat human immunodefici viru type trogarzo first approv fda march treat adult patient hiv in quarter end may drug gener sale million theratech alnylam on cours for snag label expans for oxlumo compani alnylam nasdaq alni type applic supplement new drug applic candid oxlumo indic hyperoxaluria type date oxlumo goe gener name lumasiran rnai therapeut evalu reduct plasma oxal patient advanc hyperoxaluria type rare disord mainli affect kidney due accumul substanc call oxal normal filter kidney excret urin thi therapi first approv lower urinari oxal label pediatr adult patient in second quarter fetch compani million sale sequenti see also alzheim progress slow down by biogen nasdaq new drug in studi analyst see can third time be charm for scpharma compani scpharmaceut nasdaq scph type applic nda candid furoscix indic worsen heart failur due congest date furoscix proprietari furosemid solut evalu outpati altern treatment worsen congest heart failur thi scpharma third tri furoscix follow complet respons letter go amicu pome diseas treatment compani amicu therapeut nasdaq fold type applic bla candid cipaglucosidas alfa indic pomp diseas date investig therapi consist cipaglucosidas alfa administ conjunct miglustat yet approv fda therapi evalu inherit lysosom disord call pome diseas diseas debilit character sever muscl weak worsen time it rang rapidli fatal infantil form signific impact heart function slowli progress form primarili affect skelet muscl it estim pomp diseas affect approxim peopl worldwid supernu hope for no hiccup in parkinson diseas drug approv compani supernu pharmaceut nasdaq supn type applic nda candid apomorphin infus devic indic off episod parkinson diseas date earli octob supernu initi applic seek approv shot letter novemb cite insuffici complet applic allow substanti review follow resubmiss fda accept applic assign pdufa date sometim earli octob also read best biotech stock right now astrazeneca nasdaq knock at fda altar for liver cancer combo treatment compani astrazeneca plc nasdaq azn type applic candid tremelimumab imfinzi indic unresect hepatocellular carcinoma date fda accept astrazeneca bla tremelimumab prioriti review support indic singl prime dose antibodi ad imfinzi treat patient unresect hepatocellular carcinoma a sbla also submit imfinzi indic thi novel dose schedul combin call stride regimen singl tremelimumab regular interv durvalumab hcc accord compani common type liver cancer peopl afflict advanc unresect hcc year await approv for prostat cancer como therapi compani merck nyse mrk astrazeneca type applic snda candid lynparza combin abirateron prednison prednisolon indic prostat cancer date applic accept grant prioriti review fda treatment adult patient metastat prostat cancer adcom calendar fda cardiovascular renal drug advisori committe meet discuss glaxosmithklin plc nyse gsk nda factor prolyl hydroxylas inhibitor daprodustat tablet treatment option anemia result chronic kidney diseas oncolog drug advisori committe schedul meet discuss bla submit therapeut nasdaq ymab solut inject formul treat neuroblastoma central nervou metastas on endocrinolog metabol drug advisori committe deliber ispen otc ipsey palovaroten capsul propos indic heterotop ossif adult children it condit muscl tissu connect tissu tendon ligament gradual replac bone benzinga provid invest advic all right reserv read origin articl reuter file photo pascal soriot chief execut pharmaceut compani astrazeneca attend interview reuter shanghai china novemb photo azn add portfolio add portfolio by aime donnellan natali grover london reuter astrazeneca nasdaq may stay vaccin busi long run ceo told reuter tuesday show quickli fortun chang drugmak produc one first shot sinc lost rival product delay probe regul follow rare case sever side effect concern rel short shelf life compar shot stymi adopt compani vaccin now third year pandem amid global vaccin suppli glut use diminish much develop world countri inocul larg number peopl prefer pfizer nyse moderna nasdaq mrna vaccin booster astrazeneca covid vaccin still approv compani build portfolio antibodi therapi includ respiratori viru rsv virus soriot said reuter newsmak interview tuesday but futur covid vaccin busi said i ca sure he also said sure astrazeneca would broaden roster vaccin infect either ad compani look investor specul futur vaccin busi given slow sale covid shot initi sale contract fulfil stiff competit mrna vaccin rel littl expertis field compani creat separ divis vaccin antibodi therapi late last year still soriot said regret compani work oxford univers develop covid vaccin given deliv billion dose save estim million live across globe inocul astrazeneca second product sale billion astrazeneca also look acquisit includ small compani specialis oncolog cardiovascular treatment soriot ad we alway look extern opportun said keep on do thi job ceo presid quadrupl astrazeneca share price decad helm i keep job mani year said old seen natur successor outgo chairman leif johansson but juli soriot quash specul plan retir time soon say expect work compani newli announc michel demar mani year come soriot task turn around troubl astrazeneca hit string key patent loss spate clinic trial failur octob follow stint pharma peer roch with frenchman helm fortun drugmak chang dramat he sharpen focu special medicin lucr field oncolog made acquisit refil compani medicin cabinet fend hostil takeov pharma giant pfizer invest heavili r d improv compani lacklustr drug develop success rate howev warn tuesday fewer new medicin would develop go forward due drug price law pass last week ask inflationari pressur soriot said we go becom innov product we ca expect sell price go sale china account close fifth compani total annual revenu dip recent quarter due lower drug price covid lockdown measur kept patient diagnos seek cancer care on tuesday soriot said sale pick third quarter world market pharmaceut expect countri play signific role global market next decad graphic astrazeneca share ceo soriot helm http reuter peopl pose syring needl front display astrazeneca logo illustr taken decemb azn add portfolio add portfolio by pushkala aripaka natali grover london reuter medicin regul back use astrazeneca nasdaq prevent therapi treatment diseas also endors anoth medicin prevent option anoth common viru regul recommend usual follow european commiss take final decis drug approv astrazeneca said friday european medicin agenc ema back evusheld treatment adult adolesc covid need supplement oxygen increas risk diseas worsen last month japan becam first countri approv antibodi treatment covid make evusheld first therapi authoris prevent treatment viral diseas evusheld previous larg secur global approv includ europ prevent therapi peopl compromis immun system see littl benefit covid vaccin astrazeneca lean evusheld help offset tepid sale covid vaccin rapidli lost ground mrna shot fight rapidli evolv viru evusheld first launch decemb gener million first half drugmak separ friday ema also endors astrazeneca partner sanofi epa experiment therapi beyfortu prevent lower respiratori tract infect caus respiratori syncyti viru rsv rsv caus thousand hospitalis death global year toddler elderli complex molecular structur viru safeti concern stymi effort develop vaccin sinc viru first discov but one therapi synagi also develop astrazeneca sold swedish orphan biovitrum unit state it design prevent lower respiratori tract infect caus rsv infant requir five inject cover typic rsv season meanwhil beyfortu approv would first prevent rsv therapi broad infant popul includ born healthi deem first rsv reuter file photo compani logo pharmaceut compani astrazeneca display screen floor new york stock exchang april mcdermid azn add portfolio reuter said friday drug prevent infant rsv beyfortu nirsevimab recommend approv european union european medicin agenc committe drugmak also said beyfortu approv would becom first protect option newborn infant popul rsv lower respiratori tract reuter market mover properti group fall reduc price target fdx add portfolio azn add portfolio blnd add portfolio idsi add portfolio add portfolio share land secur british land fell today properti group downgrad goldman sach nyse jp morgan lower price target compani goldman sach downgrad british land neutral buy reduc price target jpmorgan nyse cut price target retain overweight rate on land secur goldman sach lower rate sell neutral cut price target jpmorgan retain neutral rate lower price target land secur fell british land fell capita lift doubl dose good news share advanc report contract extens barnet council dispos subsidiari ltd access paysuit share outsourc servic group rose secur contract extens north london council worth although index potenti addit work could worth separ capita said agre dispos divis access group basi capita said sale help reduc debt provid addit liquid allow enhanc digit offer client build focus sustain busi long term royal mail fall fedex warn share dip today follow profit warn us peer pull full year guidanc warn first quarter profit would miss estim global demand slowdown acceler it cite macroeconom weak asia servic challeng europ investor took view industri challeng would royal mail also face prospect industri action employe strike higher pay royal mail worker repres commun worker union cwu plan walkout septemb plan strike septemb octob share fell eu drug approv boost astrazeneca nasdaq rare riser said today receiv two recommend drug approv eu drug blood disord paroxysm nocturn haemoglobinuria met primari endpoint phase three trial group said beyfortu drug develop sanofi epa prevent lower respiratori tract diseas newborn infant recommend market authoris european union meanwhil astrazeneca evusheld covid antibodi treatment recommend market authoris eu adult viru risk progress sever diseas compani explain phase iii treatment data show reduc risk sever covid death share rose follow news read proactiv investor uk disclaimerbi benzinga crypto parti start corpor optim hope fed thaw perk risk appetit financi market ethereum crypto eth second reuter file photo tablet bottl astrazeneca cancer medicin lynparza seen undat handout imag provid reuter june via reuter azn add portfolio add portfolio reuter astrazeneca nasdaq said thursday drug lynparza develop merck co approv european union adjuv treatment patient form genet mutat breast reuter daili biotech puls celyad resum colorect cancer trial setback for otonomi astrazeneca halt phase head neck cancer trial azn add portfolio ixic add portfolio otic add portfolio beam add portfolio add portfolio here roundup top develop biotech space last hour stock in focu arcuti psoriasi treatment score fda approv fda approv arcuti biotherapeut inc nasdaq arqt zoryv roflumilast cream plaqu psoriasi includ intertrigin area patient year age older it first topic inhibitor approv plaqu psoriasi commerci product expect avail arcuti expect draw addit million compani debt facil slr capit partner share premarket session fda remov clinic hold on celyad colorect cancer trial fda lift clinic hold celyad oncolog sa nasdaq cyad phase trial compani made chang elig criteria trial in februari compani voluntarili paus trial investig report two fatal studi fda subsequ put trial clinic hold march share premarket session hutchm start midstag tazemetostat studi for lymphoma set hutchm china limit nasdaq hcm initi bridg phase studi tazemetostat china follicular lymphoma fl first patient receiv first dose juli primari object evalu efficaci tazemetostat fl patient mutat cohort secondari object evalu efficaci tazemetostat fl relat biotech investor august key pdufa catalyst you must know fda sign off on eledon pharma tegoprubart for kidneti transplant reject fda clear eledon pharmaceut inc nasdaq eldn investig new drug ind applic evalu tegoprubart prevent organ reject patient receiv kidney transplant phase studi enrol approxim particip undergo kidney transplant kazia share fall after updat from pivot brain tumor trial kazia therapeut limit nasdaq kzia said gbm agil pivot studi paxalisib newli diagnos glioblastoma meet criteria continu second stage patient enrol first stage paxalisib arm continu treatment per protocol complet final analysi kazia anticip receiv second half compani open studi paxalisib arm germani china share premarket session fda place clinic hold on beam therapeut ind applic for blood cancer studi fda place clinic hold beam therapeut inc nasdaq beam investig new drug ind applic acut lymphoblast cell lymphoblast lymphoma ind submit end june fda indic would provid beam offici clinic hold letter within day beam plan provid addit updat pend discuss fda otonomi share sink after stop midstag tinnitu studi otonomi inc nasdaq otic announc phase trial tinnitu demonstr clinic meaning benefit versu placebo primari secondari endpoint across time point studi show higher respons rate placebo prospect defin patient subgroup tinnitu durat fewer six month popul studi phase trial overal result support develop share slip cent premarket session astrazeneca nasdaq cut phase trial in head neck cancer innat pharma sa nasdaq ipha futil interim analysi phase studi sponsor astrazeneca plc nasdaq azn meet threshold efficaci base result recommend independ data monitor committe astrazeneca inform innat studi discontinu there new safeti find astrazeneca plan share data due cours ipha share premarket session alx oncolog evorpacept fast track in us for head neck cancer fda grant fast track design alx oncolog hold inc nasdaq alxo evorpacept combin merck co inc nyse mrk keytruda treatment posit advanc head neck squamou cell carcinoma fda decis inform result alx oncolog phase studi show preliminari antitumor activ favor safeti profil share premarket session offer therapeuticsmd inc nasdaq txmd receiv privat invest compani common stock new seri prefer stock rubric capit manag lp on radar earn cerevel therapeut hold inc nasdaq cere befor market open benzinga provid invest advic all right reserv read benzinga read origin articl reuter add portfolio add portfolio add portfolio fchi add portfolio add portfolio add portfolio azn add portfolio gold add portfolio lco add portfolio cl add portfolio azn add portfolio add portfolio by peter nurs european stock market larg edg higher monday start new week cautiou note investor digest weak chines econom data by et gmt germani trade lower franc rose trade higher econom data releas earlier monday show china econom growth rate unexpectedli slow juli prompt countri central bank surpris move grew juli year earlier growth rate increas expect rose year ago miss forecast growth growth seen june china economi world second largest struggl shake june quarter hit growth strict covid restrict on flip side back europ denmark economi grew faster expect second quarter expand first three month year contract first quarter rais interest rate juli expect septemb even though risk eurozon recess reach highest level sinc novemb energi shortag threaten drive alreadi record inflat higher still in corpor news astrazeneca lon nasdaq stock rose drugmak said cancer drug enhertu delay progress form advanc breast cancer previous treat patient boost prospect regulatori approv henkel etr stock rose german compani said sale rose first half year earn fell hurt increas logist price oil price fell monday weigh potenti increas suppli oil giant saudi aramco tadawul well concern slow growth china world economi saudi aramco stand readi rais crude oil output maximum capac million barrel per day request saudi arabian govern chief execut amin nasser said sunday energi firm announc one largest quarterli profit histori by et futur trade lower barrel contract fell addit fell trade lower reuter file photo signag seen outsid entranc london stock exchang london britain aug photo add portfolio azn add portfolio ftse add portfolio add portfolio enri add portfolio by sruthi shankar reuter edg monday gain drugmak astrazeneca nasdaq consum stock reliev pressur mine oil heavyweight data show china economi unexpectedli slow last month ftse ad hold near high midcap inch investor await uk employ report well consum price data later week gaug state labour market inflat data could offer clue whether bank england opt second consecut hike septemb meet mood dull asian european stock market investor turn defens sector healthcar consum stapl amid worri health world economi astrazeneca gain drugmak said cancer drug enhertu develop japan daiichi sankyo delay progress form advanc breast cancer previous treat patient oil major shell lon miner rio tinto lon anglo american lon slip tandem weaker commod price releas china data ftse outperform global peer year due larg exposur commod stock surg back jump oil metal price a weaken pound also boost dollar earner index whether trend continu ultim hing outlook global energi stock rel broad market bca research analyst wrote note ftse nearli far year msci world equiti index shed almost our energi strategist remain bullish oil their expect breach averag suggest overweight energi sector extens uk equiti remain appropri reuter ftse posit earli high add portfolio dji add portfolio azn add portfolio bwi add portfolio bdev add portfolio tw add portfolio ftmc add portfolio phnx add portfolio ixic add portfolio ftse add portfolio azn add portfolio chna add portfolio slip back make bright start chines retail sale output number forecast uk hous price fall august rightmov ftse fail hold strong earli gain slip back close pariti disappoint econom data china took shine gain us friday at lead index trade point good richard hunter head market interact investor said econom news china threaten spoil parti us market stage strong ralli end last amid geopolit tension deleg us lawmak arriv trip taiwan chines econom data reveal ongo impact lockdown escal properti retail sale industri output rose less expect juli alongsid disappoint show bank but said uk market chose take lead wall street notwithstand fact bank england set maintain aggress interest rate stanc face persist inflat astrazeneca plc lse nasdaq share rose pharmaceut group said posit result new trial enhertu breast cancer drug demonstr statist signific clinic meaning improv surviv astrazeneca said phase iii trial enhertu jointli develop commercialis daiichi sankyo also met key secondari endpoint improv overal surviv but housebuild berkeley group hold plc lse bkg bellway lon taylor wimpey lon barratt develop lon fell follow report rightmov hous price slip posit start proceed london london upbeat earli trade ftse make posit start trade boost gain us friday despit mix perform asia overnight follow disappoint chines retail sale industri output figur at lead index trade point higher broader point latest data onlin properti websit rightmov show first fall uk hous price year averag price properti come market howev tim bannist rightmov director properti scienc say a drop ask price expect month frenzi two year mani home mover becom distract summer inde may first summer holiday abroad sinc bannist also point price growth year would still number properti current market buy level despit lack instruct new list rose compar time last year compar bannist also said recent interest rate increas bank england signific impact number peopl want ftse seen higher london market expect open higher monday follow gain us friday follow surpris news china cut key interest rate bid boost stutter economi follow weaker expect retail sale industri output figur investor also one eye uk job inflat report due later week see whether sign slowdown job market price growth spread bet compani call ftse around point michael hewson chief market analyst cmc market uk said despit slow drip feed neg headlin rise ga price suppli chain challeng thrown heatwav europ littl appetit drive stock lower recent asia market got posit start week latest retail sale industri product number china show economi still appear low confid come consum spend econom activ thi weak chines economi come struggl adapt polici govern show littl sign relax backdrop rise problem properti sector also help mani home buyer halt mortgag payment protest delay complet new in june saw effect polici chines economi contract although start see sign econom activ albeit low thi morn retail sale number juli confirm fragil confid still rise well expect weaker industri product robust recov much better howev even econom activ disappoint juli slip back june in london quieter day compani result phoenix group announc half year figur show strong cash gener six month june ftse close book life insur said confid deliv target rang year new busi cash gener record period doubl first half ftse set open higher ftse set start week posit fashion follow gain us friday spread bet compani call blue chip index around point close friday point jump point s p ad point reach benchmark end week high note clinch win week nasdaq composit s p investor react posit cpi ppi data releas week suggest inflat may alreadi peak read proactiv investor uk reuter ftse posit earli high add portfolio dji add portfolio azn add portfolio bwi add portfolio bdev add portfolio tw add portfolio ftmc add portfolio phnx add portfolio ixic add portfolio ftse add portfolio azn add portfolio chna add portfolio slip back make bright start chines retail sale output number forecast uk hous price fall august rightmov ftse fail hold strong earli gain slip back close pariti disappoint econom data china took shine gain us friday at lead index trade point good richard hunter head market interact investor said econom news china threaten spoil parti us market stage strong ralli end last amid geopolit tension deleg us lawmak arriv trip taiwan chines econom data reveal ongo impact lockdown escal properti retail sale industri output rose less expect juli alongsid disappoint show bank but said uk market chose take lead wall street notwithstand fact bank england set maintain aggress interest rate stanc face persist inflat astrazeneca plc lse nasdaq share rose pharmaceut group said posit result new trial enhertu breast cancer drug demonstr statist signific clinic meaning improv surviv astrazeneca said phase iii trial enhertu jointli develop commercialis daiichi sankyo also met key secondari endpoint improv overal surviv but housebuild berkeley group hold plc lse bkg bellway lon taylor wimpey lon barratt develop lon fell follow report rightmov hous price slip posit start proceed london london upbeat earli trade ftse make posit start trade boost gain us friday despit mix perform asia overnight follow disappoint chines retail sale industri output figur at lead index trade point higher broader point latest data onlin properti websit rightmov show first fall uk hous price year averag price properti come market howev tim bannist rightmov director properti scienc say a drop ask price expect month frenzi two year mani home mover becom distract summer inde may first summer holiday abroad sinc bannist also point price growth year would still number properti current market buy level despit lack instruct new list rose compar time last year compar bannist also said recent interest rate increas bank england signific impact number peopl want ftse seen higher london market expect open higher monday follow gain us friday follow surpris news china cut key interest rate bid boost stutter economi follow weaker expect retail sale industri output figur investor also one eye uk job inflat report due later week see whether sign slowdown job market price growth spread bet compani call ftse around point michael hewson chief market analyst cmc market uk said despit slow drip feed neg headlin rise ga price suppli chain challeng thrown heatwav europ littl appetit drive stock lower recent asia market got posit start week latest retail sale industri product number china show economi still appear low confid come consum spend econom activ thi weak chines economi come struggl adapt polici govern show littl sign relax backdrop rise problem properti sector also help mani home buyer halt mortgag payment protest delay complet new in june saw effect polici chines economi contract although start see sign econom activ albeit low thi morn retail sale number juli confirm fragil confid still rise well expect weaker industri product robust recov much better howev even econom activ disappoint juli slip back june in london quieter day compani result phoenix group announc half year figur show strong cash gener six month june ftse close book life insur said confid deliv target rang year new busi cash gener record period doubl first half ftse set open higher ftse set start week posit fashion follow gain us friday spread bet compani call blue chip index around point close friday point jump point s p ad point reach benchmark end week high note clinch win week nasdaq composit s p investor react posit cpi ppi data releas week suggest inflat may alreadi peak read proactiv investor uk disclaimeravepp add portfolio rog add portfolio rhhvf add portfolio sni add portfolio azn add portfolio sasi add portfolio by scott kanowski sanofi sa epa share slid wednesday french drugmak announc halt trial new treatment patient battl advanc breast cancer in statement compani said would stop global clinic develop medicin known amcenestr phase studi show effect enough warrant research all studi amcenestr includ breast cancer also discontinu sanofi ad while disappoint outcom research scientif understand endocrin therapi peopl breast cancer said john reed global head research develop sanofi in note analyst morgan stanley call decis setback innov narr put forward sanofi say amcenestr flag potenti lucr piec group drug pipelin end sanofi amcenestr trial expect lead neg impact compani estim discount cash flow accord morgan stanley analyst decis could also effect studi conduct similar breast cancer drug sanofi rival roch six astrazeneca plc lon analyst ad']"
            ]
          },
          "metadata": {},
          "execution_count": 14
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2QETQK8maPyc",
        "outputId": "f0832b6c-7ff0-42bd-a3dc-b98abc07c7b5"
      },
      "source": [
        "# Learn the vocabulary dictionary and transform to a vector of token counts\n",
        "Count_data = CountVec.fit_transform(nltk_preprocessed_articles_stem)\n",
        " \n",
        "# Create dataframe that can be used for building models\n",
        "nltk_stem_cv_dataframe = pd.DataFrame(Count_data.toarray(),columns=CountVec.get_feature_names())\n",
        "print(nltk_stem_cv_dataframe)"
      ],
      "execution_count": 15,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "   ab  abirateron  abroad  acceler  accept  access  accord  account  accumul  \\\n",
            "0   1           1       2        2       3       2       4        1        1   \n",
            "\n",
            "   achiev  ...  worsen  worth  wrote  year  yield  ymab  york  younger  zero  \\\n",
            "0       1  ...       4      2      1    34      1     1     2        1     1   \n",
            "\n",
            "   zoryv  \n",
            "0      1  \n",
            "\n",
            "[1 rows x 1405 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Z1lDawaMcsMN"
      },
      "source": [
        "There are so many columns, it is unlikely we will be able to use this as an analysis. Instead, we could have a look at words that appear frequently."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 174
        },
        "id": "MSCkHyZEb_oS",
        "outputId": "3c802be3-cb70-4349-c92a-e7f441f1f605"
      },
      "source": [
        "# Create a mask so we only get the terms that have a frequency greater than 5 \n",
        "nltk_stem_frequent_words = list(nltk_stem_cv_dataframe.sum()[nltk_stem_cv_dataframe.sum() > 5].index)\n",
        "\n",
        "nltk_stem_cv_dataframe[nltk_stem_frequent_words]"
      ],
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   activ  ad  add  addit  adult  advanc  analyst  announc  antibodi  applic  \\\n",
              "0      8  11   81      6      8      11       12        8        11      17   \n",
              "\n",
              "   ...  tuesday  type  uk  unresect  vaccin  vaxzevria  viru  week  world  \\\n",
              "0  ...        8    12  20         6      29         15    12    17      7   \n",
              "\n",
              "   year  \n",
              "0    34  \n",
              "\n",
              "[1 rows x 225 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-d425b73b-954e-4d99-a22a-cc7cf8a2fd29\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>activ</th>\n",
              "      <th>ad</th>\n",
              "      <th>add</th>\n",
              "      <th>addit</th>\n",
              "      <th>adult</th>\n",
              "      <th>advanc</th>\n",
              "      <th>analyst</th>\n",
              "      <th>announc</th>\n",
              "      <th>antibodi</th>\n",
              "      <th>applic</th>\n",
              "      <th>...</th>\n",
              "      <th>tuesday</th>\n",
              "      <th>type</th>\n",
              "      <th>uk</th>\n",
              "      <th>unresect</th>\n",
              "      <th>vaccin</th>\n",
              "      <th>vaxzevria</th>\n",
              "      <th>viru</th>\n",
              "      <th>week</th>\n",
              "      <th>world</th>\n",
              "      <th>year</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>8</td>\n",
              "      <td>11</td>\n",
              "      <td>81</td>\n",
              "      <td>6</td>\n",
              "      <td>8</td>\n",
              "      <td>11</td>\n",
              "      <td>12</td>\n",
              "      <td>8</td>\n",
              "      <td>11</td>\n",
              "      <td>17</td>\n",
              "      <td>...</td>\n",
              "      <td>8</td>\n",
              "      <td>12</td>\n",
              "      <td>20</td>\n",
              "      <td>6</td>\n",
              "      <td>29</td>\n",
              "      <td>15</td>\n",
              "      <td>12</td>\n",
              "      <td>17</td>\n",
              "      <td>7</td>\n",
              "      <td>34</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1 rows × 225 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-d425b73b-954e-4d99-a22a-cc7cf8a2fd29')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-d425b73b-954e-4d99-a22a-cc7cf8a2fd29 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-d425b73b-954e-4d99-a22a-cc7cf8a2fd29');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "_HzG--1Rb3E4"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "zpBmOOyGZGWW",
        "outputId": "afa543c3-ccb7-4139-b7b0-5879f2c091c4"
      },
      "source": [
        "# Join the NLTK lemmatised tokens back into a list of articles\n",
        "\n",
        "nltk_preprocessed_articles_lem = [','.join(article).replace(',', ' ') for article in nltk_lemmatised_articles]\n",
        "nltk_preprocessed_articles_lem"
      ],
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['AstraZeneca PLC said Wednesday Capivasertib plus Faslodex significantly improved survival compared Faslodex combined placebo Phase trial advanced hormone breast cancer pharma giant AZN AZN said trial met primary endpoint improving survival overall patient population prespecified biomarker subgroup patient whose tumor qualifying Touts Positive Data From Two Experimental Drugs In Breast Cancer SettingsAstraZeneca Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain Spinal CordAstraZeneca NASDAQ AZN announced Tuesday vaccine Vaxzevria Recombinant given full Marketing Authorisation MA European Union EU Vaxzevria originally granted conditional Marketing Authorisation cMA EU AstraZeneca stated As continues sufficient evidence safety efficacy confirming benefit Vaxzevria European Medicines Agency EMA granted full Iskra Reic EVP Vaccines Immune Therapies AstraZeneca commented move conditional full marketing authorisation Vaxzevria important confirmation EMA safety efficacy Vaxzevria demonstrating benefit continue outweigh potential risk Vaxzevria estimated helped save six million life first year vaccination reflects strength evidence showing Vaxzevria protection severe disease death caused European Medicines Agency EMA granted full Marketing Authorisation AstraZeneca Plc AZN vaccine Vaxzevria Recombinant vaccine Vaxzevria Recombinant Vaxzevria initially granted conditional Marketing Authorisation due urgency pandemic As continues sufficient evidence safety efficacy confirming benefit Vaxzevria EMA granted full approval approval cover use Vaxzevria primary vaccination series heterologous approved mRNA vaccine homologous vaccine booster Related University Partnered Nasal Vaccine Flunks Human Trial University Partnered Nasal Vaccine Flunks Human Trial Vaxzevria demonstrated effective form mild symptomatic severe disease including hospitalization death according clinical study evidence These include expert review data study showed Vaxzevria available mRNA vaccine provide equally effective protection hospitalization death following three dos There also substantial body evidence supporting boosting Vaxzevria following primary vaccination schedule tested date Price Action AZN share premarket session last check Tuesday AZN share premarket session last check Tuesday Photo Paul McManus Pixabay Benzinga provide investment advice All right Shifts China Factory Workers To US Plant Complete European Approval For AstraZeneca Shot Tesla Eyes Cybertruck Commercialization Next Year Top Stories Tuesday European Commission approved AstraZeneca plc AZN Sanofi SA SNY Beyfortus nirsevimab antibody prevent respiratory syncytial virus RSV lower respiratory tract disease newborn infant first RSV season Beyfortus nirsevimab antibody prevent respiratory syncytial virus RSV lower respiratory tract disease newborn infant first RSV season Beyfortus first RSV passive immunization broad infant population including born healthy term preterm specific health condition In pivotal MELODY efficacy trial Beyfortus met primary endpoint reducing incidence medically attended lower respiratory tract infection LRTI caused RSV placebo day single dose Beyfortus also demonstrated comparable safety tolerability profile Swedish Orphan Biovitrum AB BIOVF Synagis palivizumab MEDLEY Phase trial Synagis palivizumab MEDLEY Phase trial Globally approximately million case acute lower respiratory infection leading three million hospitalization It estimated death child younger five year Price Action SNY share AZN share premarket session last check Friday Benzinga provide investment advice All right Reuters AstraZeneca share get lift heartburn drug litigation closure say Citi AZN Add Portfolio LFCOF Add Portfolio Add Portfolio AstraZeneca PLC NASDAQ get boost probability close US kidney damage lawsuit New Jersey prior first bellwether case March according analyst Citi UK pharma one several firm embroiled US legal action possible damage caused proton pump inhibitor PPI heartburn drug Nexium launched Astra US Citi analyst believe likely outcome judge delaying response Defendant Motion summary judgement ground encourage plaintiff settle Alternatively lower probability Judge Cecchi may delayed start bellwether case disagrees conclusion Special Master Reisman grant defendant motion dismiss ground said Either scenario would materially positive Astra depressed share price US bank analyst added would positive interim data Enhertu positive data March Citi analyst said core EPS forecast Astra consensus repeated alongside price target recommendation Shares Astra rose Read Proactive Investors UK DisclaimerBy Benzinga crypto party started corporate optimism hope Fed thawing perked risk appetite financial market Ethereum CRYPTO ETH second Astrazeneca Beyfortus receives EU approval AZN Add Portfolio Add Portfolio AstraZeneca NASDAQ stated Beyfortus first RSV passive immunisation broad infant population including born healthy term specific health condition group said European Commission first regulatory body grant approval Beyfortus approval based result drug clinical development programme follows recommendation Committee Medicinal Products Human Use European Medicines Agency September In AZN pivotal MELODY efficacy trial Beyfortus met primary endpoint reducing incidence medically attended lower respiratory tract infection caused RSV versus placebo day single dose Iskra Eric AZN executive vice president vaccine immune therapy said Beyfortus first preventative option respiratory syncytial virus gain approval Europe also first preventative option approved broad infant population Today marketing authorisation Beyfortus mark significant achievement scientific community address persistent global unmet need RSV prevention Reporting Iain Gilbert Read Reuters AstraZeneca say Evusheld approved treatment EU AZN Add Portfolio Add Portfolio said antibody combination Evusheld tixagevimab cilgavimab formerly approved EU treatment approval European Commission cover people age year require supplemental oxygen increased risk progressing severe pharmaceutical group said European Commission approval based result TACKLE phase III treatment trial showed Evusheld significantly reduced risk severe death recommended dose Evusheld treatment Europe tixagevimab cilgavimab administered two separate sequential IM injection AstraZeneca NASDAQ noted Many people including immunocompromised older adult underlying health condition high risk severe disease hospitalisation death become infected Evusheld delivered convenient intramuscular formulation new treatment option vulnerable population commented Dr Michel Goldman professor Institute Interdisciplinary Innovation Healthcare Université Libre de Bruxelles former executive director European Innovative Medicines Initiative statement Iskra Reic executive vice president vaccine immune therapy AstraZeneca added remains ongoing health concern million Europeans around world especially may virus vaccination With approval Evusheld antibody combination available prevention treatment Europe allowing u protect even people devastating disease Read Proactive Investors UK Reuters AstraZeneca get third regulatory green light matter week asthma drug AZN Add Portfolio Add Portfolio AstraZeneca PLC LON said Tezspire treatment approved Japan severe bronchial asthma traditional corticosteroid work It third approval matter week product potential challenger market leader Dupxient It developed collaboration US giant Amgen NASDAQ In clinical trial drug shown lower researcher called asthma exacerbation Tezspire first biologic approved Japanese Ministry Health Labour Welfare shown consistently significantly reduce attack exacerbation trial broad population severe asthma patient irrespective biomarker level Mene Pangalos head biopharmaceutical research AZ Tezspire potential improve outcome many patient severe asthma working make important medicine available Japan quickly Analysts believe Tezspire could big seller peak sale projected order US Read Proactive Investors UK Reuters FILE PHOTO company logo pharmaceutical company AstraZeneca displayed screen floor New York Stock Exchange April Photo AZN Add Portfolio Add Portfolio Reuters Shares LogicBio Therapeutics skyrocketed Monday Britain AstraZeneca NASDAQ said would buy gene therapy developer rare premium million LoigBio share traded since February bell close AstraZeneca offer price per share LogicBio developing gene editing therapy treat pediatric rare disease like methylmalonic acidemia body break certain protein fat AstraZeneca said deal would accelerate growth Alexion NASDAQ unit acquired billion last year field genomic Benzinga crypto party started corporate optimism hope Fed thawing perked risk appetite financial market Ethereum CRYPTO ETH second Reuters AstraZeneca say combination approved advanced liver cancer US AZN Add Portfolio Add Portfolio AstraZeneca PLC LON announced US Food Drug Administration FDA approved company Imjudo tremelimumab drug combination Imfinzi durvalumab treatment adult patient unresectable hepatocellular carcinoma HCC common type liver cancer approval based result HIMALAYA Phase III trial showed single priming dose antibody Imjudo added antibody Imfinzi reduced risk death compared sorafenib pharmaceutical company said Liver cancer cause cancer death sixth commonly diagnosed cancer worldwide It cause death US approximately new diagnosis year company said In statement Dave Fredrickson executive vice president oncology business unit AstraZeneca commented With first regulatory approval Imjudo patient unresectable liver cancer US approved dual immunotherapy treatment regimen harness potential inhibition unique combination inhibitor enhance immune response cancer Dr Ghassan attending physician Memorial Sloan Kettering Cancer Center MSK principal investigator HIMALAYA Phase III trial said Patients unresectable liver cancer need treatment meaningfully extend overall survival In addition regimen demonstrating favourable survival rate HIMALAYA trial safety data showed increase severe liver toxicity bleeding risk combination important factor patient liver cancer also advanced liver disease Regulatory application Imjudo combination Imfinzi currently review Europe Japan several country treatment patient advanced liver cancer based HIMALAYA result AstraZeneca said Read Proactive Investors UK Reuters Prostate Cancer Combo Drug Try For scPharma FDA Panel Decisions And More October Key PDUFA Catalysts Biotech Investors Must Know AZN Add Portfolio IXIC Add Portfolio KECR Add Portfolio Add Portfolio Most FDA decision scheduled September yielded positive result stray disappointment well Seven new molecular entity NMEs approved month taking total NME approval year This far le approval received time last year NMEs considered measure innovation drug research contain active moiety ingredient previously approved Food Drug Administration Among positive verdict bluebird bio NASDAQ BLUE million gene therapy Skysona approved treating rare neurodegenerative disorder boy Amylyx Pharmaceuticals NASDAQ AMLX scored win amyotrophic sclerosis treatment Revance Therapeutics NASDAQ RVNC Botox rival Daxxify approved treating frown line Spectrum Pharmaceuticals NASDAQ SPPI mixed month Rolvedon approved treating neutropenia lung cancer drug get backing FDA panel Here key PDUFA date scheduled October Will Theratech Score A Win For A More Convenient Formulation Of Its HIV Drug Company Theratechnologies NASDAQ THTX Type Application supplemental biologic license application Candidate Trogarzo Indication Date In fourth quarter company filed sBLA intravenous push mode administration Trogarzo treating human immunodeficiency virus type Trogarzo first approved FDA March treat adult patient HIV In quarter ended May drug generated sale million Theratech Alnylam On Course For Snagging Label Expansion For Oxlumo Company Alnylam NASDAQ ALNY Type Application supplemental new drug application Candidate Oxlumo Indication hyperoxaluria Type Date Oxlumo go generic name lumasiran RNAi therapeutic evaluated reduction plasma oxalate patient advanced hyperoxaluria type rare disorder mainly affect kidney due accumulation substance called oxalate normally filtered kidney excreted urine This therapy first approved lowering urinary oxalate label pediatric adult patient In second quarter fetched company million sale sequentially See also Alzheimer Progression Slowed Down By Biogen NASDAQ New Drug In Study Analyst Sees Can Third Time Be Charm For scPharma Company scPharmaceuticals NASDAQ SCPH Type Application NDA Candidate Furoscix Indication worsening heart failure due congestion Date Furoscix proprietary furosemide solution evaluated outpatient alternative treatment worsening congestive heart failure This scPharma third try Furoscix following complete response letter Go Amicus Pome Disease Treatment Company Amicus Therapeutics NASDAQ FOLD Type Application BLA Candidate cipaglucosidase alfa Indication Pompe disease Date investigational therapy consists cipaglucosidase alfa administered conjunction miglustat yet approved FDA therapy evaluated inherited lysosomal disorder called Pome disease disease debilitating characterized severe muscle weakness worsens time It range rapidly fatal infantile form significant impact heart function slowly progressive form primarily affecting skeletal muscle It estimated Pompe disease affect approximately people worldwide Supernus Hopes For No Hiccups In Parkinson Disease Drug Approval Company Supernus Pharmaceuticals NASDAQ SUPN Type Application NDA Candidate apomorphine infusion device Indication OFF episode Parkinson disease Date Early October Supernus initial application seeking approval shot letter November citing insufficiently completed application allow substantiative review Following resubmission FDA accepted application assigned PDUFA date sometime early October Also read Best Biotech Stocks Right Now AstraZeneca NASDAQ Knocks At FDA Altar For Liver Cancer Combo Treatment Company AstraZeneca plc NASDAQ AZN Type Application Candidate Tremelimumab Imfinzi Indication Unresectable hepatocellular carcinoma Date FDA accepted AstraZeneca BLA tremelimumab priority review supporting indication single priming dose antibody added Imfinzi treating patient unresectable hepatocellular carcinoma A sBLA also submitted Imfinzi indication This novel dose schedule combination called STRIDE regimen Single Tremelimumab Regular Interval Durvalumab HCC according company common type liver cancer people afflicted advanced unresectable HCC year Await Approval For Prostate Cancer Como Therapy Company Merck NYSE MRK AstraZeneca Type Application sNDA Candidate Lynparza combination Abiraterone Prednisone Prednisolone Indication prostate cancer Date application accepted granted priority review FDA treatment adult patient metastatic prostate cancer Adcom Calendar FDA Cardiovascular Renal Drugs Advisory Committee meet discus GlaxoSmithKline plc NYSE GSK NDA factor prolyl hydroxylase inhibitor daprodustat tablet treatment option anemia resulting chronic kidney disease Oncologic Drugs Advisory Committee scheduled meet discus BLA submitted Therapeutics NASDAQ YMAB solution injectable formulation treating neuroblastoma central nervous metastasis On Endocrinologic Metabolic Drugs Advisory Committee deliberate Ispen OTC IPSEY palovarotene capsule proposed indication heterotopic ossification adult child It condition muscle tissue connective tissue tendon ligament gradually replaced bone Benzinga provide investment advice All right reserved Read original article Reuters FILE PHOTO Pascal Soriot chief executive pharmaceutical company AstraZeneca attends interview Reuters Shanghai China November Photo AZN Add Portfolio Add Portfolio By Aimee Donnellan Natalie Grover LONDON Reuters AstraZeneca NASDAQ may stay vaccine business long run CEO told Reuters Tuesday showing quickly fortune changed drugmaker produced one first shot since lost rival Production delay probe regulator following rare case severe side effect concern relatively short shelf life compared shot stymied adoption company vaccine Now third year pandemic amid global vaccine supply glut use diminished much developed world country inoculated large number people prefer Pfizer NYSE Moderna NASDAQ mRNA vaccine booster AstraZeneca COVID vaccine still approval company building portfolio antibody therapy including respiratory virus RSV virus Soriot said Reuters Newsmaker interview Tuesday But future COVID vaccine business said I ca sure He also said sure AstraZeneca would broaden roster vaccine infection either adding company looking Investors speculated future vaccine business given slowing sale COVID shot initial sale contract fulfilled stiff competition mRNA vaccine relatively little expertise field company created separate division vaccine antibody therapy late last year Still Soriot said regret company work Oxford University develop COVID vaccine given delivered billion dos saved estimated million life across globe inoculation AstraZeneca second product sale billion AstraZeneca also looking acquisition including small company specialising oncology cardiovascular treatment Soriot added We always look external opportunity said KEEP ON DOING THIS JOB CEO presided quadrupling AstraZeneca share price decade helm I keep job many year said old seen natural successor outgoing Chairman Leif Johansson But July Soriot quashed speculation planning retire time soon saying expected work company newly announced Michel Demare many year come Soriot tasked turning around troubled AstraZeneca hit string key patent loss spate clinical trial failure October following stint pharma peer Roche With Frenchman helm fortune drugmaker changed dramatically He sharpened focus speciality medicine lucrative field oncology made acquisition refill company medicine cabinet fended hostile takeover pharma giant Pfizer invested heavily R D improve company lacklustre drug development success rate However warned Tuesday fewer new medicine would developed going forward due drug price law passed last week Asked inflationary pressure Soriot said We going become innovative productive We ca expect selling price go Sales China account close fifth company total annual revenue dipped recent quarter due lower drug price COVID lockdown measure kept patient diagnosed seeking cancer care On Tuesday Soriot said sale picking third quarter world market pharmaceutical expected country play significant role global market next decade Graphic AstraZeneca share CEO Soriot helm http Reuters People pose syringe needle front displayed AstraZeneca logo illustration taken December AZN Add Portfolio Add Portfolio By Pushkala Aripaka Natalie Grover LONDON Reuters medicine regulator backed using AstraZeneca NASDAQ preventative therapy treatment disease also endorsed another medicine preventative option another common virus regulator recommendation usually followed European Commission take final decision drug approval AstraZeneca said Friday European Medicines Agency EMA backed Evusheld treatment adult adolescent COVID need supplemental oxygen increased risk disease worsening Last month Japan became first country approve antibody treatment COVID making Evusheld first therapy authorised prevention treatment viral disease Evusheld previously largely secured global approval including Europe preventative therapy people compromised immune system see little benefit COVID vaccine AstraZeneca leaning Evusheld help offset tepid sale COVID vaccine rapidly lost ground mRNA shot fight rapidly evolving virus Evusheld first launched December generated million first half drugmaker Separately Friday EMA also endorsed AstraZeneca partner Sanofi EPA experimental therapy Beyfortus prevention lower respiratory tract infection caused respiratory syncytial virus RSV RSV cause thousand hospitalisation death globally year toddler elderly complex molecular structure virus safety concern stymied effort develop vaccine since virus first discovered But one therapy Synagis also developed AstraZeneca sold Swedish Orphan Biovitrum United States It designed prevent lower respiratory tract infection caused RSV infant requires five injection cover typical RSV season Meanwhile Beyfortus approved would first preventative RSV therapy broad infant population including born healthy deemed first RSV Reuters FILE PHOTO company logo pharmaceutical company AstraZeneca displayed screen floor New York Stock Exchange April McDermid AZN Add Portfolio Reuters said Friday drug preventing infant RSV Beyfortus nirsevimab recommended approval European Union European Medicines Agency committee drugmaker also said Beyfortus approved would become first protective option newborn infant population RSV lower respiratory tract Reuters Market mover Property group fall reduce price target FDX Add Portfolio AZN Add Portfolio BLND Add Portfolio IDSI Add Portfolio Add Portfolio Shares Land Securities British Land fell today property group downgraded Goldman Sachs NYSE JP Morgan lowered price target company Goldman Sachs downgraded British Land neutral buy reduced price target JPMorgan NYSE cut price target retained overweight rating On Land Securities Goldman Sachs lowered rating sell neutral cut price target JPMorgan retained neutral rating lower price target Land Securities fell British Land fell Capita lifted double dose good news Shares advanced reported contract extension Barnet Council disposal subsidiary Ltd Access PaySuite Shares outsourcing service group rose securing contract extension north London council worth although indexation potential additional work could worth Separately Capita said agreed dispose division Access Group basis Capita said sale help reduce debt provide additional liquidity allow enhance digital offering client build focused sustainable business long term Royal Mail fall FedEx warning Shares dipped today following profit warning US peer pulled full year guidance warning first quarter profit would miss estimate global demand slowdown accelerates It cited macroeconomic weakness Asia service challenge Europe Investors took view industry challenge would Royal Mail also face prospect industrial action employee strike higher pay Royal Mail worker represented Communication Workers Union CWU planned walkout September planning strike September October Shares fell EU drug approval boost AstraZeneca NASDAQ rare riser said today received two recommendation drug approval EU drug blood disorder paroxysmal nocturnal haemoglobinuria met primary endpoint phase three trial group said Beyfortus drug develops Sanofi EPA prevention lower respiratory tract disease newborn infant recommended marketing authorisation European Union Meanwhile AstraZeneca Evusheld Covid antibody treatment recommended marketing authorisation EU adult virus risk progressing severe disease company explained phase III treatment data showed reduced risk severe Covid death Shares rose following news Read Proactive Investors UK DisclaimerBy Benzinga crypto party started corporate optimism hope Fed thawing perked risk appetite financial market Ethereum CRYPTO ETH second Reuters FILE PHOTO Tablet bottle AstraZeneca cancer medicine Lynparza seen undated handout image provided Reuters June via REUTERS AZN Add Portfolio Add Portfolio Reuters AstraZeneca NASDAQ said Thursday drug Lynparza developed Merck Co approved European Union adjuvant treatment patient form genetically mutated breast Reuters Daily Biotech Pulse Celyad Resumes Colorectal Cancer Trial Setback For Otonomy AstraZeneca Halts Phase Head Neck Cancer Trial AZN Add Portfolio IXIC Add Portfolio OTIC Add Portfolio BEAM Add Portfolio Add Portfolio Here roundup top development biotech space last hour Stocks In Focus Arcutis Psoriasis Treatment Scores FDA Approval FDA approved Arcutis Biotherapeutics Inc NASDAQ ARQT Zoryve roflumilast cream plaque psoriasis including intertriginous area patient year age older It first topical inhibitor approved plaque psoriasis commercial product expected available Arcutis expects draw additional million company debt facility SLR Capital Partners Shares premarket session FDA Removes Clinical Hold On Celyad Colorectal Cancer Trial FDA lifted clinical hold Celyad Oncology SA NASDAQ CYAD Phase trial company made change eligibility criterion trial In February company voluntarily paused trial investigate report two fatality study FDA subsequently put trial clinical hold March Shares premarket session HUTCHMED Starts Midstage Tazemetostat Study For Lymphoma Setting HUTCHMED China Limited NASDAQ HCM initiated bridging Phase study tazemetostat China follicular lymphoma FL first patient received first dose July primary objective evaluate efficacy tazemetostat FL patient mutation Cohort secondary objective evaluate efficacy tazemetostat FL Related Biotech Investors August Key PDUFA Catalysts You Must Know FDA Signs Off On Eledon Pharma Tegoprubart For Kidnety Transplant Rejection FDA cleared Eledon Pharmaceuticals Inc NASDAQ ELDN Investigational New Drug IND application evaluate tegoprubart preventing organ rejection patient receiving kidney transplant phase study enroll approximately participant undergoing kidney transplant Kazia Shares Fall After Update From Pivotal Brain Tumor Trial Kazia Therapeutics Limited NASDAQ KZIA said GBM AGILE pivotal study paxalisib newly diagnosed glioblastoma meet criterion continuing second stage Patients enrolled first stage paxalisib arm continue treatment per protocol completion final analysis Kazia anticipates receiving second half company open study paxalisib arm Germany China Shares premarket session FDA Places Clinical Hold On Beam Therapeutics IND Application For Blood Cancer Study FDA placed clinical hold Beam Therapeutics Inc NASDAQ BEAM Investigational New Drug IND application acute lymphoblastic cell lymphoblastic lymphoma IND submitted end June FDA indicated would provide Beam official clinical hold letter within day Beam plan provide additional update pending discussion FDA Otonomy Shares Sink After Stopping Midstage Tinnitus Study Otonomy Inc NASDAQ OTIC announced Phase trial tinnitus demonstrated clinically meaningful benefit versus placebo primary secondary endpoint across time point study show higher response rate placebo prospectively defined patient subgroup tinnitus duration fewer six month population studied Phase trial overall result support development Shares slipping cent premarket session AstraZeneca NASDAQ Cuts Phase Trial In Head Neck Cancer Innate Pharma SA NASDAQ IPHA futility interim analysis Phase study sponsored AstraZeneca Plc NASDAQ AZN meet threshold efficacy Based result recommendation Independent Data Monitoring Committee AstraZeneca informed Innate study discontinued There new safety finding AstraZeneca plan share data due course IPHA share premarket session ALX Oncology Evorpacept Fast Tracked In US For Head Neck Cancer FDA granted Fast Track designation ALX Oncology Holdings Inc NASDAQ ALXO evorpacept combination Merck Co Inc NYSE MRK Keytruda treatment positive advanced head neck squamous cell carcinoma FDA decision informed result ALX Oncology phase study showed preliminary antitumor activity favorable safety profile Shares premarket session Offerings TherapeuticsMD Inc NASDAQ TXMD received private investment company common stock new series preferred stock Rubric Capital Management LP On Radar Earnings Cerevel Therapeutics Holdings Inc NASDAQ CERE Before market open Benzinga provide investment advice All right reserved Read Benzinga Read original article Reuters Add Portfolio Add Portfolio Add Portfolio FCHI Add Portfolio Add Portfolio Add Portfolio AZN Add Portfolio Gold Add Portfolio LCO Add Portfolio CL Add Portfolio AZN Add Portfolio Add Portfolio By Peter Nurse European stock market largely edged higher Monday starting new week cautious note investor digested weak Chinese economic data By ET GMT Germany traded lower France rose traded higher Economic data released earlier Monday showed China economic growth rate unexpectedly slowing July prompting country central bank surprise move grew July year earlier growth rate increase expected rose year ago missing forecast growth growth seen June China economy world second largest struggling shake June quarter hit growth strict COVID restriction On flip side back Europe Denmark economy grew faster expected second quarter expanding first three month year contracted first quarter raised interest rate July expected September even though risk Eurozone recession reached highest level since November energy shortage threaten drive already record inflation higher still In corporate news AstraZeneca LON NASDAQ stock rose drugmaker said cancer drug Enhertu delayed progression form advanced breast cancer previously treated patient boosting prospect regulatory approval Henkel ETR stock rose German company said sale rose first half year earnings fell hurt increasing logistics price Oil price fell Monday weighed potential increase supply oil giant Saudi Aramco TADAWUL well concern slowing growth China world economy Saudi Aramco stand ready raise crude oil output maximum capacity million barrel per day requested Saudi Arabian government Chief Executive Amin Nasser said Sunday energy firm announced one largest quarterly profit history By ET future traded lower barrel contract fell Additionally fell traded lower Reuters FILE PHOTO Signage seen outside entrance London Stock Exchange London Britain Aug Photo Add Portfolio AZN Add Portfolio FTSE Add Portfolio Add Portfolio ENRY Add Portfolio By Sruthi Shankar Reuters edged Monday gain drugmaker AstraZeneca NASDAQ consumer stock relieved pressure mining oil heavyweight data showed China economy unexpectedly slowed last month FTSE added hold near high midcap inched Investors awaiting UK employment report well consumer price data later week gauge state labour market inflation data could offer clue whether Bank England opts second consecutive hike September meeting mood dull Asian European stock market investor turning defensive sector healthcare consumer staple amid worry health world economy AstraZeneca gained drugmaker said cancer drug Enhertu developed Japan Daiichi Sankyo delayed progression form advanced breast cancer previously treated patient Oil major Shell LON miner Rio Tinto LON Anglo American LON slipped tandem weaker commodity price release China data FTSE outperformed global peer year due large exposure commodity stock surged back jump oil metal price A weakening pound also boosted dollar earner index Whether trend continue ultimately hinge outlook global energy stock relative broad market BCA Research analyst wrote note FTSE nearly far year MSCI world equity index shed almost Our energy strategist remain bullish oil Their expectation breach average suggests overweight energy sector extension UK equity remains appropriate Reuters FTSE positive early high Add Portfolio DJI Add Portfolio AZN Add Portfolio BWY Add Portfolio BDEV Add Portfolio TW Add Portfolio FTMC Add Portfolio PHNX Add Portfolio IXIC Add Portfolio FTSE Add Portfolio AZN Add Portfolio CHNA Add Portfolio slip back making bright start Chinese retail sale output number forecast UK house price fall August Rightmove FTSE failed hold strong early gain slipped back close parity disappointing economic data China took shine gain US Friday At lead index trading point good Richard Hunter head market interactive investor said Economic news China threatened spoil party US market staged strong rally end last Amid geopolitical tension delegation US lawmaker arrive trip Taiwan Chinese economic data revealed ongoing impact lockdown escalating property Retail sale industrial output rose le expected July alongside disappointing showing bank But said UK market chose take lead Wall Street notwithstanding fact Bank England set maintain aggressive interest rate stance face persistent inflation AstraZeneca PLC LSE NASDAQ share rose pharmaceutical group said positive result new trial Enhertu breast cancer drug demonstrated statistically significant clinically meaningful improvement survival AstraZeneca said Phase III trial Enhertu jointly developed commercialised Daiichi Sankyo also met key secondary endpoint improved overall survival But housebuilder Berkeley Group Holdings PLC LSE BKG Bellway LON Taylor Wimpey LON Barratt Developments LON fell following report Rightmove house price slipped Positive start proceeding London London upbeat early trading FTSE make positive start trading boosted gain US Friday despite mixed performance Asia overnight following disappointing Chinese retail sale industrial output figure At lead index trading point higher broader point Latest data online property website Rightmove showed first fall UK house price year average price property coming market However Tim Bannister Rightmove director property science say A drop asking price expected month frenzied two year many home mover become distracted summer Indeed may first summer holiday abroad since Bannister also pointed price growth year would still number property currently market buy level despite lack instruction new listing rose compared time last year compared Bannister also said recent interest rate increase Bank England significant impact number people wanting FTSE seen higher London market expected open higher Monday following gain US Friday following surprise news China cut key interest rate bid boost stuttering economy following weaker expected retail sale industrial output figure Investors also one eye UK job inflation report due later week see whether sign slowdown job market price growth Spread betting company calling FTSE around point Michael Hewson chief market analyst CMC Markets UK said Despite slow drip feed negative headline rising gas price supply chain challenge thrown heatwave Europe little appetite drive stock lower recent Asia market got positive start week latest retail sale industrial production number China showing economy still appears low confidence come consumer spending economic activity This weakness Chinese economy come struggle adapt policy government show little sign relaxing backdrop rising Problems property sector also helping many home buyer halting mortgage payment protest delay completion new In June saw effect policy Chinese economy contraction although started see sign economic activity albeit low This morning retail sale number July confirmed fragile confidence still rising well expectation weaker Industrial production robust recovered much better however even economic activity disappointed July slipping back June In London quieter day company result Phoenix Group announced half year figure showed strong cash generation six month June FTSE closed book life insurer said confident delivering target range year New business cash generation record period double first half FTSE set open higher FTSE set start week positive fashion following gain US Friday Spread betting company calling blue chip index around point closed Friday point jumped point S P added point reach benchmark ended week high note clinching winning week Nasdaq Composite S P Investors reacted positively CPI PPI data released week suggested inflation may already peaked Read Proactive Investors UK Reuters FTSE positive early high Add Portfolio DJI Add Portfolio AZN Add Portfolio BWY Add Portfolio BDEV Add Portfolio TW Add Portfolio FTMC Add Portfolio PHNX Add Portfolio IXIC Add Portfolio FTSE Add Portfolio AZN Add Portfolio CHNA Add Portfolio slip back making bright start Chinese retail sale output number forecast UK house price fall August Rightmove FTSE failed hold strong early gain slipped back close parity disappointing economic data China took shine gain US Friday At lead index trading point good Richard Hunter head market interactive investor said Economic news China threatened spoil party US market staged strong rally end last Amid geopolitical tension delegation US lawmaker arrive trip Taiwan Chinese economic data revealed ongoing impact lockdown escalating property Retail sale industrial output rose le expected July alongside disappointing showing bank But said UK market chose take lead Wall Street notwithstanding fact Bank England set maintain aggressive interest rate stance face persistent inflation AstraZeneca PLC LSE NASDAQ share rose pharmaceutical group said positive result new trial Enhertu breast cancer drug demonstrated statistically significant clinically meaningful improvement survival AstraZeneca said Phase III trial Enhertu jointly developed commercialised Daiichi Sankyo also met key secondary endpoint improved overall survival But housebuilder Berkeley Group Holdings PLC LSE BKG Bellway LON Taylor Wimpey LON Barratt Developments LON fell following report Rightmove house price slipped Positive start proceeding London London upbeat early trading FTSE make positive start trading boosted gain US Friday despite mixed performance Asia overnight following disappointing Chinese retail sale industrial output figure At lead index trading point higher broader point Latest data online property website Rightmove showed first fall UK house price year average price property coming market However Tim Bannister Rightmove director property science say A drop asking price expected month frenzied two year many home mover become distracted summer Indeed may first summer holiday abroad since Bannister also pointed price growth year would still number property currently market buy level despite lack instruction new listing rose compared time last year compared Bannister also said recent interest rate increase Bank England significant impact number people wanting FTSE seen higher London market expected open higher Monday following gain US Friday following surprise news China cut key interest rate bid boost stuttering economy following weaker expected retail sale industrial output figure Investors also one eye UK job inflation report due later week see whether sign slowdown job market price growth Spread betting company calling FTSE around point Michael Hewson chief market analyst CMC Markets UK said Despite slow drip feed negative headline rising gas price supply chain challenge thrown heatwave Europe little appetite drive stock lower recent Asia market got positive start week latest retail sale industrial production number China showing economy still appears low confidence come consumer spending economic activity This weakness Chinese economy come struggle adapt policy government show little sign relaxing backdrop rising Problems property sector also helping many home buyer halting mortgage payment protest delay completion new In June saw effect policy Chinese economy contraction although started see sign economic activity albeit low This morning retail sale number July confirmed fragile confidence still rising well expectation weaker Industrial production robust recovered much better however even economic activity disappointed July slipping back June In London quieter day company result Phoenix Group announced half year figure showed strong cash generation six month June FTSE closed book life insurer said confident delivering target range year New business cash generation record period double first half FTSE set open higher FTSE set start week positive fashion following gain US Friday Spread betting company calling blue chip index around point closed Friday point jumped point S P added point reach benchmark ended week high note clinching winning week Nasdaq Composite S P Investors reacted positively CPI PPI data released week suggested inflation may already peaked Read Proactive Investors UK DisclaimerAVEPp Add Portfolio ROG Add Portfolio RHHVF Add Portfolio SNY Add Portfolio AZN Add Portfolio SASY Add Portfolio By Scott Kanowsky Sanofi SA EPA share slid Wednesday French drugmaker announced halt trial new treatment patient battling advanced breast cancer In statement company said would stop global clinical development medicine known amcenestrant phase study showed effective enough warrant research All study amcenestrant including breast cancer also discontinued Sanofi added While disappointed outcome research scientific understanding endocrine therapy people breast cancer said John Reed global head research development Sanofi In note analyst Morgan Stanley called decision setback innovation narrative put forward Sanofi saying amcenestrant flagged potentially lucrative piece group drug pipeline end Sanofi amcenestrant trial expected lead negative impact company estimated discounted cash flow according Morgan Stanley analyst decision could also effect study conducted similar breast cancer drug Sanofi rival Roche SIX AstraZeneca PLC LON analyst added']"
            ]
          },
          "metadata": {},
          "execution_count": 17
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0tApOFwlahLJ",
        "outputId": "ba5e9aaa-9dc2-49c7-a80f-c68d39f43182"
      },
      "source": [
        "# Learn the vocabulary dictionary and transform to a vector of token counts\n",
        "Count_data = CountVec.fit_transform(nltk_preprocessed_articles_lem)\n",
        " \n",
        "# Create dataframe that can be used for building models\n",
        "nltk_lem_cv_dataframe = pd.DataFrame(Count_data.toarray(),columns=CountVec.get_feature_names())\n",
        "print(nltk_lem_cv_dataframe)"
      ],
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "   ab  abiraterone  abroad  accelerate  accelerates  accepted  access  \\\n",
            "0   1            1       2           1            1         3       2   \n",
            "\n",
            "   according  account  accumulation  ...  worsens  worth  wrote  year  \\\n",
            "0          4        1             1  ...        1      2      1    34   \n",
            "\n",
            "   yielded  ymab  york  younger  zero  zoryve  \n",
            "0        1     1     2        1     1       1  \n",
            "\n",
            "[1 rows x 1623 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 174
        },
        "id": "7ehIsoqecoos",
        "outputId": "2d76c56b-b90b-4d1e-c68d-c1011780d794"
      },
      "source": [
        "# Create a mask so we only get the terms that have a frequency greater than 5 \n",
        "nltk_lem_frequent_words = list(nltk_lem_cv_dataframe.sum()[nltk_lem_cv_dataframe.sum() > 5].index)\n",
        "\n",
        "nltk_lem_cv_dataframe[nltk_lem_frequent_words]"
      ],
      "execution_count": 21,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   activity  add  added  adult  advanced  analyst  announced  antibody  \\\n",
              "0         7   81     10      8        11       11          8        11   \n",
              "\n",
              "   application  approval  ...  tuesday  type  uk  unresectable  vaccine  \\\n",
              "0           17        26  ...        8    12  20             6       24   \n",
              "\n",
              "   vaxzevria  virus  week  world  year  \n",
              "0         15     13    17      7    34  \n",
              "\n",
              "[1 rows x 197 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-840b00cf-8e5f-456f-a8c7-12eb58dc4d5c\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>activity</th>\n",
              "      <th>add</th>\n",
              "      <th>added</th>\n",
              "      <th>adult</th>\n",
              "      <th>advanced</th>\n",
              "      <th>analyst</th>\n",
              "      <th>announced</th>\n",
              "      <th>antibody</th>\n",
              "      <th>application</th>\n",
              "      <th>approval</th>\n",
              "      <th>...</th>\n",
              "      <th>tuesday</th>\n",
              "      <th>type</th>\n",
              "      <th>uk</th>\n",
              "      <th>unresectable</th>\n",
              "      <th>vaccine</th>\n",
              "      <th>vaxzevria</th>\n",
              "      <th>virus</th>\n",
              "      <th>week</th>\n",
              "      <th>world</th>\n",
              "      <th>year</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>7</td>\n",
              "      <td>81</td>\n",
              "      <td>10</td>\n",
              "      <td>8</td>\n",
              "      <td>11</td>\n",
              "      <td>11</td>\n",
              "      <td>8</td>\n",
              "      <td>11</td>\n",
              "      <td>17</td>\n",
              "      <td>26</td>\n",
              "      <td>...</td>\n",
              "      <td>8</td>\n",
              "      <td>12</td>\n",
              "      <td>20</td>\n",
              "      <td>6</td>\n",
              "      <td>24</td>\n",
              "      <td>15</td>\n",
              "      <td>13</td>\n",
              "      <td>17</td>\n",
              "      <td>7</td>\n",
              "      <td>34</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1 rows × 197 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-840b00cf-8e5f-456f-a8c7-12eb58dc4d5c')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-840b00cf-8e5f-456f-a8c7-12eb58dc4d5c button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-840b00cf-8e5f-456f-a8c7-12eb58dc4d5c');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 21
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "vyOcYrlzb8X5"
      },
      "source": [
        "### spaCy preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "duev87ZgZiAB",
        "outputId": "bc0de31f-1412-432f-d726-ad0ba3004167"
      },
      "source": [
        "# Join the spaCy lemmatised tokens back into a list of articles\n",
        "\n",
        "spacy_preprocessed_articles_lem = [','.join(article).replace(',', ' ') for article in spacy_lemmatised_articles]\n",
        "spacy_preprocessed_articles_lem"
      ],
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['AstraZeneca PLC said Wednesday Capivasertib plus Faslodex significantly improved survival compared Faslodex combined placebo Phase trial advanced hormone breast cancer pharma giant AZN AZN said trial met primary endpoints improving survival overall patient population prespecified biomarker subgroup patients whose tumors qualifying Touts Positive Data From Two Experimental Drugs In Breast Cancer SettingsAstraZeneca Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain Spinal CordAstraZeneca NASDAQ AZN announced Tuesday vaccine Vaxzevria Recombinant given full Marketing Authorisation MA European Union EU Vaxzevria originally granted conditional Marketing Authorisation cMA EU AstraZeneca stated As continues sufficient evidence safety efficacy confirming benefits Vaxzevria European Medicines Agency EMA granted full Iskra Reic EVP Vaccines Immune Therapies AstraZeneca commented move conditional full marketing authorisation Vaxzevria important confirmation EMA safety efficacy Vaxzevria demonstrating benefits continue outweigh potential risks Vaxzevria estimated helped save six million lives first year vaccination reflects strength evidence showing Vaxzevria protection severe disease death caused European Medicines Agency EMA granted full Marketing Authorisation AstraZeneca Plc AZN vaccine Vaxzevria Recombinant vaccine Vaxzevria Recombinant Vaxzevria initially granted conditional Marketing Authorisation due urgency pandemic As continues sufficient evidence safety efficacy confirming benefits Vaxzevria EMA granted full approval approval covers use Vaxzevria primary vaccination series heterologous approved mRNA vaccine homologous vaccine booster Related University Partnered Nasal Vaccine Flunks Human Trial University Partnered Nasal Vaccine Flunks Human Trial Vaxzevria demonstrated effective forms mild symptomatic severe disease including hospitalization death according clinical studies evidence These include expert review data studies showed Vaxzevria available mRNA vaccines provide equally effective protection hospitalization death following three doses There also substantial body evidence supporting boosting Vaxzevria following primary vaccination schedules tested date Price Action AZN shares premarket session last check Tuesday AZN shares premarket session last check Tuesday Photo Paul McManus Pixabay Benzinga provide investment advice All rights Shifts China Factory Workers To US Plant Complete European Approval For AstraZeneca Shot Tesla Eyes Cybertruck Commercialization Next Year Top Stories Tuesday European Commission approved AstraZeneca plc AZN Sanofi SA SNY Beyfortus nirsevimab antibody prevent respiratory syncytial virus RSV lower respiratory tract disease newborns infants first RSV season Beyfortus nirsevimab antibody prevent respiratory syncytial virus RSV lower respiratory tract disease newborns infants first RSV season Beyfortus first RSV passive immunization broad infant population including born healthy term preterm specific health conditions In pivotal MELODY efficacy trial Beyfortus met primary endpoint reducing incidence medically attended lower respiratory tract infections LRTI caused RSV placebo day single dose Beyfortus also demonstrated comparable safety tolerability profile Swedish Orphan Biovitrum AB BIOVF Synagis palivizumab MEDLEY Phase trial Synagis palivizumab MEDLEY Phase trial Globally approximately million cases acute lower respiratory infections leading three million hospitalizations It estimated deaths children younger five years Price Action SNY shares AZN shares premarket session last check Friday Benzinga provide investment advice All rights Reuters AstraZeneca shares get lift heartburn drug litigation closure says Citi AZN Add Portfolio LFCOF Add Portfolio Add Portfolio AstraZeneca PLC NASDAQ get boost probability close US kidney damage lawsuit New Jersey prior first bellwether case March according analysts Citi UK pharma one several firms embroiled US legal action possible damage caused proton pump inhibitor PPI heartburn drugs Nexium launched Astra US Citi analysts believe likely outcome judge delaying response Defendant Motion summary judgement grounds encourage plaintiffs settle Alternatively lower probability Judge Cecchi may delayed start bellwether cases disagrees conclusions Special Master Reisman grants defendant motion dismiss grounds said Either scenario would materially positive Astra depressed share price US bank analysts added would positive interim data Enhertu positive data March Citi analysts said core EPS forecasts Astra consensus repeated alongside price target recommendation Shares Astra rose Read Proactive Investors UK DisclaimerBy Benzinga crypto party started corporate optimism hopes Fed thawing perked risk appetite financial markets Ethereum CRYPTO ETH second Astrazeneca Beyfortus receives EU approval AZN Add Portfolio Add Portfolio AstraZeneca NASDAQ stated Beyfortus first RSV passive immunisation broad infant population including born healthy term specific health conditions group said European Commission first regulatory body grant approval Beyfortus approval based results drug clinical development programme follows recommendation Committee Medicinal Products Human Use European Medicines Agency September In AZN pivotal MELODY efficacy trial Beyfortus met primary endpoint reducing incidence medically attended lower respiratory tract infections caused RSV versus placebo day single dose Iskra Eric AZN executive vice president vaccines immune therapies said Beyfortus first preventative option respiratory syncytial virus gain approval Europe also first preventative option approved broad infant population Today marketing authorisation Beyfortus marks significant achievement scientific community addresses persistent global unmet need RSV prevention Reporting Iain Gilbert Read Reuters AstraZeneca says Evusheld approved treatment EU AZN Add Portfolio Add Portfolio said antibody combination Evusheld tixagevimab cilgavimab formerly approved EU treatment approval European Commission covers people age years require supplemental oxygen increased risk progressing severe pharmaceuticals group said European Commission approval based results TACKLE phase III treatment trial showed Evusheld significantly reduced risk severe death recommended dose Evusheld treatment Europe tixagevimab cilgavimab administered two separate sequential IM injections AstraZeneca NASDAQ noted Many people including immunocompromised older adults underlying health conditions high risk severe disease hospitalisation death become infected Evusheld delivered convenient intramuscular formulation new treatment option vulnerable populations commented Dr Michel Goldman professor Institute Interdisciplinary Innovation Healthcare Université Libre de Bruxelles former executive director European Innovative Medicines Initiative statement Iskra Reic executive vice president vaccines immune therapies AstraZeneca added remains ongoing health concern millions Europeans around world especially may virus vaccination With approval Evusheld antibody combination available prevention treatment Europe allowing us protect even people devastating disease Read Proactive Investors UK Reuters AstraZeneca gets third regulatory green light matter weeks asthma drug AZN Add Portfolio Add Portfolio AstraZeneca PLC LON said Tezspire treatment approved Japan severe bronchial asthma traditional corticosteroids work It third approval matter weeks product potential challenger market leader Dupxient It developed collaboration US giant Amgen NASDAQ In clinical trials drug shown lower researchers called asthma exacerbations Tezspire first biologic approved Japanese Ministry Health Labour Welfare shown consistently significantly reduce attacks exacerbation trials broad population severe asthma patients irrespective biomarker levels Mene Pangalos head biopharmaceutical research AZ Tezspire potential improve outcomes many patients severe asthma working make important medicine available Japan quickly Analysts believe Tezspire could big seller peak sales projected order US Read Proactive Investors UK Reuters FILE PHOTO company logo pharmaceutical company AstraZeneca displayed screen floor New York Stock Exchange April Photo AZN Add Portfolio Add Portfolio Reuters Shares LogicBio Therapeutics skyrocketed Monday Britain AstraZeneca NASDAQ said would buy gene therapy developer rare premium million LoigBio shares traded since February bell close AstraZeneca offer price per share LogicBio developing gene editing therapies treat pediatric rare disease like methylmalonic acidemia body break certain proteins fats AstraZeneca said deal would accelerate growth Alexion NASDAQ unit acquired billion last year field genomic Benzinga crypto party started corporate optimism hopes Fed thawing perked risk appetite financial markets Ethereum CRYPTO ETH second Reuters AstraZeneca says combination approved advanced liver cancer US AZN Add Portfolio Add Portfolio AstraZeneca PLC LON announced US Food Drug Administration FDA approved company Imjudo tremelimumab drug combination Imfinzi durvalumab treatment adult patients unresectable hepatocellular carcinoma HCC common type liver cancer approval based results HIMALAYA Phase III trial showed single priming dose antibody Imjudo added antibody Imfinzi reduced risk death compared sorafenib pharmaceuticals company said Liver cancer cause cancer death sixth commonly diagnosed cancer worldwide It cause deaths US approximately new diagnoses year company said In statement Dave Fredrickson executive vice president oncology business unit AstraZeneca commented With first regulatory approval Imjudo patients unresectable liver cancer US approved dual immunotherapy treatment regimen harnesses potential inhibition unique combination inhibitor enhance immune response cancer Dr Ghassan attending physician Memorial Sloan Kettering Cancer Center MSK principal investigator HIMALAYA Phase III trial said Patients unresectable liver cancer need treatments meaningfully extend overall survival In addition regimen demonstrating favourable survival rate HIMALAYA trial safety data showed increase severe liver toxicity bleeding risk combination important factors patients liver cancer also advanced liver disease Regulatory applications Imjudo combination Imfinzi currently review Europe Japan several countries treatment patients advanced liver cancer based HIMALAYA results AstraZeneca said Read Proactive Investors UK Reuters Prostate Cancer Combo Drug Try For scPharma FDA Panel Decisions And More October Key PDUFA Catalysts Biotech Investors Must Know AZN Add Portfolio IXIC Add Portfolio KECR Add Portfolio Add Portfolio Most FDA decisions scheduled September yielded positive results stray disappointments well Seven new molecular entities NMEs approved month taking total NME approvals year This far less approvals received time last year NMEs considered measure innovation drug research contain active moieties ingredients previously approved Food Drug Administration Among positive verdicts bluebird bio NASDAQ BLUE million gene therapy Skysona approved treating rare neurodegenerative disorder boys Amylyx Pharmaceuticals NASDAQ AMLX scored win amyotrophic sclerosis treatment Revance Therapeutics NASDAQ RVNC Botox rival Daxxify approved treating frown lines Spectrum Pharmaceuticals NASDAQ SPPI mixed month Rolvedon approved treating neutropenia lung cancer drug get backing FDA panel Here key PDUFA dates scheduled October Will Theratech Score A Win For A More Convenient Formulation Of Its HIV Drug Company Theratechnologies NASDAQ THTX Type Application supplemental biologic license application Candidate Trogarzo Indication Date In fourth quarter company filed sBLA intravenous push mode administration Trogarzo treating human immunodeficiency virus type Trogarzo first approved FDA March treat adult patients HIV In quarter ended May drug generated sales million Theratech Alnylam On Course For Snagging Label Expansion For Oxlumo Company Alnylam NASDAQ ALNY Type Application supplemental new drug application Candidate Oxlumo Indication hyperoxaluria Type Date Oxlumo goes generic name lumasiran RNAi therapeutic evaluated reduction plasma oxalate patients advanced hyperoxaluria type rare disorder mainly affects kidneys due accumulation substance called oxalate normally filtered kidneys excreted urine This therapy first approved lowering urinary oxalate labels pediatric adult patients In second quarter fetched company million sales sequentially See also Alzheimer Progression Slowed Down By Biogen NASDAQ New Drug In Study Analyst Sees Can Third Time Be Charm For scPharma Company scPharmaceuticals NASDAQ SCPH Type Application NDA Candidate Furoscix Indication worsening heart failure due congestion Date Furoscix proprietary furosemide solution evaluated outpatient alternative treatment worsening congestive heart failure This scPharma third try Furoscix following complete response letter Go Amicus Pome Disease Treatment Company Amicus Therapeutics NASDAQ FOLD Type Application BLA Candidate cipaglucosidase alfa Indication Pompe disease Date investigational therapy consists cipaglucosidase alfa administered conjunction miglustat yet approved FDA therapy evaluated inherited lysosomal disorder called Pome disease disease debilitating characterized severe muscle weakness worsens time It ranges rapidly fatal infantile form significant impacts heart function slowly progressive form primarily affecting skeletal muscle It estimated Pompe disease affects approximately people worldwide Supernus Hopes For No Hiccups In Parkinson Disease Drug Approval Company Supernus Pharmaceuticals NASDAQ SUPN Type Application NDA Candidate apomorphine infusion device Indication OFF episodes Parkinson disease Date Early October Supernus initial application seeking approval shot letter November citing insufficiently completed application allow substantiative review Following resubmission FDA accepted application assigned PDUFA date sometime early October Also read Best Biotech Stocks Right Now AstraZeneca NASDAQ Knocks At FDA Altar For Liver Cancer Combo Treatment Company AstraZeneca plc NASDAQ AZN Type Application Candidate Tremelimumab Imfinzi Indication Unresectable hepatocellular carcinoma Date FDA accepted AstraZeneca BLA tremelimumab priority review supporting indication single priming dose antibody added Imfinzi treating patients unresectable hepatocellular carcinoma A sBLA also submitted Imfinzi indication This novel dose schedule combination called STRIDE regimen Single Tremelimumab Regular Interval Durvalumab HCC according company common type liver cancer people afflicted advanced unresectable HCC year Await Approval For Prostate Cancer Como Therapy Company Merck NYSE MRK AstraZeneca Type Application sNDA Candidate Lynparza combination Abiraterone Prednisone Prednisolone Indication prostate cancer Date application accepted granted priority review FDA treatment adult patients metastatic prostate cancer Adcom Calendar FDA Cardiovascular Renal Drugs Advisory Committee meet discuss GlaxoSmithKline plc NYSE GSK NDA factor prolyl hydroxylase inhibitor daprodustat tablets treatment option anemia resulting chronic kidney disease Oncologic Drugs Advisory Committee scheduled meet discuss BLA submitted Therapeutics NASDAQ YMAB solution injectable formulation treating neuroblastoma central nervous metastases On Endocrinologic Metabolic Drugs Advisory Committee deliberate Ispen OTC IPSEY palovarotene capsules proposed indication heterotopic ossification adults children It condition muscle tissue connective tissue tendons ligaments gradually replaced bones Benzinga provide investment advice All rights reserved Read original article Reuters FILE PHOTO Pascal Soriot chief executive pharmaceuticals company AstraZeneca attends interview Reuters Shanghai China November Photo AZN Add Portfolio Add Portfolio By Aimee Donnellan Natalie Grover LONDON Reuters AstraZeneca NASDAQ may stay vaccine business long run CEO told Reuters Tuesday showing quickly fortunes changed drugmaker produced one first shots since lost rivals Production delays probes regulators following rare cases severe side effects concerns relatively short shelf life compared shots stymied adoption company vaccine Now third year pandemic amid global vaccine supply glut use diminished much developed world countries inoculated large numbers people prefer Pfizer NYSE Moderna NASDAQ mRNA vaccines boosters AstraZeneca COVID vaccine still approval company building portfolio antibody therapies including respiratory virus RSV viruses Soriot said Reuters Newsmaker interview Tuesday But future COVID vaccines business said I ca sure He also said sure AstraZeneca would broaden roster vaccines infections either adding company looking Investors speculated future vaccine business given slowing sales COVID shot initial sales contracts fulfilled stiff competition mRNA vaccines relatively little expertise field company created separate division vaccines antibody therapies late last year Still Soriot said regret company work Oxford University develop COVID vaccine given delivered billions doses saved estimated million lives across globe inoculation AstraZeneca second product sales billion AstraZeneca also looking acquisitions including small companies specialising oncology cardiovascular treatments Soriot added We always look external opportunities said KEEP ON DOING THIS JOB CEO presided quadrupling AstraZeneca share price decade helm I keep job many years said old seen natural successor outgoing Chairman Leif Johansson But July Soriot quashed speculation planning retire time soon saying expected work company newly announced Michel Demare many years come Soriot tasked turning around troubled AstraZeneca hit string key patent losses spate clinical trial failures October following stint pharma peer Roche With Frenchman helm fortunes drugmaker changed dramatically He sharpened focus speciality medicines lucrative field oncology made acquisitions refill company medicine cabinet fended hostile takeover pharma giant Pfizer invested heavily R D improve company lacklustre drug development success rate However warned Tuesday fewer new medicines would developed going forward due drug price laws passed last week Asked inflationary pressures Soriot said We going become innovative productive We ca expect selling prices go Sales China account close fifth company total annual revenue dipped recent quarters due lower drug prices COVID lockdown measures kept patients diagnosed seeking cancer care On Tuesday Soriot said sales picking third quarter world market pharmaceuticals expected country play significant role global market next decade Graphic AstraZeneca shares CEO Soriot helm https Reuters People pose syringe needle front displayed AstraZeneca logo illustration taken December AZN Add Portfolio Add Portfolio By Pushkala Aripaka Natalie Grover LONDON Reuters medicines regulator backed using AstraZeneca NASDAQ preventative therapy treatment disease also endorsed another medicine preventative option another common virus regulator recommendations usually followed European Commission takes final decision drug approvals AstraZeneca said Friday European Medicines Agency EMA backed Evusheld treatment adults adolescents COVID need supplemental oxygen increased risk disease worsening Last month Japan became first country approve antibody treatment COVID making Evusheld first therapy authorised prevention treatment viral disease Evusheld previously largely secured global approvals including Europe preventative therapy people compromised immune systems see little benefit COVID vaccines AstraZeneca leaning Evusheld help offset tepid sales COVID vaccine rapidly lost ground mRNA shots fight rapidly evolving virus Evusheld first launched December generated million first half drugmaker Separately Friday EMA also endorsed AstraZeneca partner Sanofi EPA experimental therapy Beyfortus prevention lower respiratory tract infections caused respiratory syncytial virus RSV RSV causes thousands hospitalisations deaths globally year toddlers elderly complex molecular structure virus safety concerns stymied efforts develop vaccine since virus first discovered But one therapy Synagis also developed AstraZeneca sold Swedish Orphan Biovitrum United States It designed prevent lower respiratory tract infections caused RSV infants requires five injections cover typical RSV season Meanwhile Beyfortus approved would first preventative RSV therapy broad infant population including born healthy deemed first RSV Reuters FILE PHOTO company logo pharmaceutical company AstraZeneca displayed screen floor New York Stock Exchange April McDermid AZN Add Portfolio Reuters said Friday drug preventing infant RSV Beyfortus nirsevimab recommended approval European Union European Medicines Agency committee drugmaker also said Beyfortus approved would become first protective option newborn infant population RSV lower respiratory tract Reuters Market movers Property groups fall reduce price targets FDX Add Portfolio AZN Add Portfolio BLND Add Portfolio IDSI Add Portfolio Add Portfolio Shares Land Securities British Land fell today property groups downgraded Goldman Sachs NYSE JP Morgan lowered price targets companies Goldman Sachs downgraded British Land neutral buy reduced price target JPMorgan NYSE cut price target retained overweight rating On Land Securities Goldman Sachs lowered rating sell neutral cut price target JPMorgan retained neutral rating lower price target Land Securities fell British Land fell Capita lifted double dose good news Shares advanced reported contract extension Barnet Council disposal subsidiary Ltd Access PaySuite Shares outsourcing services group rose securing contract extension north London council worth although indexation potential additional work could worth Separately Capita said agreed dispose division Access Group basis Capita said sale help reduce debt provide additional liquidity allow enhance digital offerings clients build focused sustainable business long term Royal Mail falls FedEx warning Shares dipped today following profits warning US peer pulled full year guidance warning first quarter profits would miss estimates global demand slowdown accelerates It cited macroeconomic weakness Asia service challenges Europe Investors took view industry challenges would Royal Mail also faces prospect industrial action employees strike higher pay Royal Mail workers represented Communication Workers Union CWU planned walkout September planning strike September October Shares fell EU drug approvals boost AstraZeneca NASDAQ rare riser said today received two recommendations drug approvals EU drug blood disorder paroxysmal nocturnal haemoglobinuria met primary endpoint phase three trial group said Beyfortus drug develops Sanofi EPA prevention lower respiratory tract disease newborns infants recommended marketing authorisation European Union Meanwhile AstraZeneca Evusheld Covid antibody treatment recommended marketing authorisation EU adults virus risk progressing severe disease company explained phase III treatment data showed reduced risk severe Covid death Shares rose following news Read Proactive Investors UK DisclaimerBy Benzinga crypto party started corporate optimism hopes Fed thawing perked risk appetite financial markets Ethereum CRYPTO ETH second Reuters FILE PHOTO Tablet bottles AstraZeneca cancer medicine Lynparza seen undated handout image provided Reuters June via REUTERS AZN Add Portfolio Add Portfolio Reuters AstraZeneca NASDAQ said Thursday drug Lynparza developed Merck Co approved European Union adjuvant treatment patients form genetically mutated breast Reuters Daily Biotech Pulse Celyad Resumes Colorectal Cancer Trial Setback For Otonomy AstraZeneca Halts Phase Head Neck Cancer Trial AZN Add Portfolio IXIC Add Portfolio OTIC Add Portfolio BEAM Add Portfolio Add Portfolio Here roundup top developments biotech space last hours Stocks In Focus Arcutis Psoriasis Treatment Scores FDA Approval FDA approved Arcutis Biotherapeutics Inc NASDAQ ARQT Zoryve roflumilast cream plaque psoriasis including intertriginous areas patients years age older It first topical inhibitor approved plaque psoriasis commercial product expected available Arcutis expects draw additional million company debt facility SLR Capital Partners Shares premarket session FDA Removes Clinical Hold On Celyad Colorectal Cancer Trial FDA lifted clinical hold Celyad Oncology SA NASDAQ CYAD Phase trial company made changes eligibility criteria trial In February company voluntarily paused trial investigate reports two fatalities study FDA subsequently put trial clinical hold March Shares premarket session HUTCHMED Starts Midstage Tazemetostat Study For Lymphoma Setting HUTCHMED China Limited NASDAQ HCM initiated bridging Phase study tazemetostat China follicular lymphoma FL first patient received first dose July primary objective evaluate efficacy tazemetostat FL patients mutations Cohort secondary objectives evaluate efficacy tazemetostat FL Related Biotech Investors August Key PDUFA Catalysts You Must Know FDA Signs Off On Eledon Pharma Tegoprubart For Kidnety Transplant Rejection FDA cleared Eledon Pharmaceuticals Inc NASDAQ ELDN Investigational New Drug IND application evaluate tegoprubart preventing organ rejection patients receiving kidney transplant phase study enroll approximately participants undergoing kidney transplant Kazia Shares Fall After Update From Pivotal Brain Tumor Trial Kazia Therapeutics Limited NASDAQ KZIA said GBM AGILE pivotal study paxalisib newly diagnosed glioblastoma meet criteria continuing second stage Patients enrolled first stage paxalisib arm continue treatment per protocol completion final analysis Kazia anticipates receiving second half company open study paxalisib arm Germany China Shares premarket session FDA Places Clinical Hold On Beam Therapeutics IND Application For Blood Cancer Study FDA placed clinical hold Beam Therapeutics Inc NASDAQ BEAM Investigational New Drug IND application acute lymphoblastic cell lymphoblastic lymphoma IND submitted end June FDA indicated would provide Beam official clinical hold letter within days Beam plans provide additional updates pending discussion FDA Otonomy Shares Sink After Stopping Midstage Tinnitus Study Otonomy Inc NASDAQ OTIC announced Phase trial tinnitus demonstrated clinically meaningful benefit versus placebo primary secondary endpoints across time points study show higher response rate placebo prospectively defined patient subgroup tinnitus duration fewer six months population studied Phase trial overall results support development Shares slipping cents premarket session AstraZeneca NASDAQ Cuts Phase Trial In Head Neck Cancer Innate Pharma SA NASDAQ IPHA futility interim analysis Phase study sponsored AstraZeneca Plc NASDAQ AZN meet threshold efficacy Based result recommendation Independent Data Monitoring Committee AstraZeneca informed Innate study discontinued There new safety findings AstraZeneca plans share data due course IPHA shares premarket session ALX Oncology Evorpacept Fast Tracked In US For Head Neck Cancer FDA granted Fast Track designation ALX Oncology Holdings Inc NASDAQ ALXO evorpacept combination Merck Co Inc NYSE MRK Keytruda treatment positive advanced head neck squamous cell carcinoma FDA decision informed results ALX Oncology phase study showed preliminary antitumor activity favorable safety profile Shares premarket session Offerings TherapeuticsMD Inc NASDAQ TXMD received private investment company common stock new series preferred stock Rubric Capital Management LP On Radar Earnings Cerevel Therapeutics Holdings Inc NASDAQ CERE Before market open Benzinga provide investment advice All rights reserved Read Benzinga Read original article Reuters Add Portfolio Add Portfolio Add Portfolio FCHI Add Portfolio Add Portfolio Add Portfolio AZN Add Portfolio Gold Add Portfolio LCO Add Portfolio CL Add Portfolio AZN Add Portfolio Add Portfolio By Peter Nurse European stock markets largely edged higher Monday starting new week cautious note investors digested weak Chinese economic data By ET GMT Germany traded lower France rose traded higher Economic data released earlier Monday showed China economic growth rate unexpectedly slowing July prompting country central bank surprise move grew July year earlier growth rate increase expected rose year ago missing forecasts growth growth seen June China economy world second largest struggling shake June quarter hit growth strict COVID restrictions On flip side back Europe Denmark economy grew faster expected second quarter expanding first three months year contracted first quarter raised interest rates July expected September even though risk Eurozone recession reached highest level since November energy shortages threaten drive already record inflation higher still In corporate news AstraZeneca LON NASDAQ stock rose drugmaker said cancer drug Enhertu delayed progression form advanced breast cancer previously treated patients boosting prospects regulatory approvals Henkel ETR stock rose German company said sales rose first half year earnings fell hurt increasing logistics prices Oil prices fell Monday weighed potential increase supply oil giant Saudi Aramco TADAWUL well concerns slowing growth China world economy Saudi Aramco stands ready raise crude oil output maximum capacity million barrels per day requested Saudi Arabian government Chief Executive Amin Nasser said Sunday energy firm announced one largest quarterly profits history By ET futures traded lower barrel contract fell Additionally fell traded lower Reuters FILE PHOTO Signage seen outside entrance London Stock Exchange London Britain Aug Photo Add Portfolio AZN Add Portfolio FTSE Add Portfolio Add Portfolio ENRY Add Portfolio By Sruthi Shankar Reuters edged Monday gains drugmaker AstraZeneca NASDAQ consumer stocks relieved pressure mining oil heavyweights data showed China economy unexpectedly slowed last month FTSE added hold near highs midcap inched Investors awaiting UK employment report well consumer prices data later week gauge state labour market inflation data could offer clues whether Bank England opts second consecutive hike September meeting mood dull Asian European stock markets investors turning defensive sectors healthcare consumer staples amid worries health world economy AstraZeneca gained drugmaker said cancer drug Enhertu developed Japan Daiichi Sankyo delayed progression form advanced breast cancer previously treated patients Oil major Shell LON miners Rio Tinto LON Anglo American LON slipped tandem weaker commodity prices release China data FTSE outperformed global peers year due large exposure commodity stocks surged back jump oil metal prices A weakening pound also boosted dollar earners index Whether trend continue ultimately hinges outlook global energy stocks relative broad market BCA Research analysts wrote note FTSE nearly far year MSCI world equities index shed almost Our energy strategists remain bullish oil Their expectation breach average suggests overweight energy sector extension UK equities remains appropriate Reuters FTSE positive early highs Add Portfolio DJI Add Portfolio AZN Add Portfolio BWY Add Portfolio BDEV Add Portfolio TW Add Portfolio FTMC Add Portfolio PHNX Add Portfolio IXIC Add Portfolio FTSE Add Portfolio AZN Add Portfolio CHNA Add Portfolio slips back making bright start Chinese retail sales output numbers forecast UK house prices fall August Rightmove FTSE failed hold strong early gains slipped back close parity disappointing economic data China took shine gains US Friday At lead index trading points good Richard Hunter head markets interactive investor said Economic news China threatened spoil party US markets staged strong rally end last Amid geopolitical tensions delegation US lawmakers arrive trip Taiwan Chinese economic data revealed ongoing impact lockdowns escalating property Retail sales industrial output rose less expected July alongside disappointing showing bank But said UK market chose take lead Wall Street notwithstanding fact Bank England set maintain aggressive interest rate stance face persistent inflation AstraZeneca PLC LSE NASDAQ shares rose pharmaceuticals group said positive results new trial Enhertu breast cancer drug demonstrated statistically significant clinically meaningful improvement survival AstraZeneca said Phase III trial Enhertu jointly developed commercialised Daiichi Sankyo also met key secondary endpoint improved overall survival But housebuilders Berkeley Group Holdings PLC LSE BKG Bellway LON Taylor Wimpey LON Barratt Developments LON fell following report Rightmove house prices slipped Positive start proceedings London London upbeat early trading FTSE makes positive start trading boosted gains US Friday despite mixed performances Asia overnight following disappointing Chinese retail sales industrial output figures At lead index trading points higher broader points Latest data online property website Rightmove showed first fall UK house prices year average price property coming market However Tim Bannister Rightmove director property science says A drop asking prices expected month frenzied two years many home movers become distracted summer Indeed may first summer holiday abroad since Bannister also pointed price growth year would still number properties currently market buy levels despite lack instructions new listings rose compared time last year compared Bannister also said recent interest rate increases Bank England significant impact number people wanting FTSE seen higher London markets expected open higher Monday following gains US Friday following surprise news China cut key interest rate bid boost stuttering economy following weaker expected retail sales industrial output figures Investors also one eye UK jobs inflation reports due later week see whether signs slowdown jobs market prices growth Spread betting companies calling FTSE around points Michael Hewson chief market analyst CMC Markets UK said Despite slow drip feed negative headlines rising gas prices supply chain challenges thrown heatwave Europe little appetite drive stocks lower recent Asia markets got positive start week latest retail sales industrial production numbers China showing economy still appears low confidence comes consumer spending economic activity This weakness Chinese economy comes struggle adapt policy government shows little sign relaxing backdrop rising Problems property sector also helping many home buyers halting mortgage payments protest delays completion new In June saw effects policy Chinese economy contraction although started see signs economic activity albeit low This morning retail sales numbers July confirmed fragile confidence still rising well expectations weaker Industrial production robust recovered much better however even economic activity disappointed July slipping back June In London quieter day company results Phoenix Group announced half year figures showed strong cash generation six months June FTSE closed book life insurer said confident delivering target range year New business cash generation record period double first half FTSE set open higher FTSE set start week positive fashion following gains US Friday Spread betting companies calling blue chip index around points closed Friday points jumped points S P added points reach benchmarks ended week high note clinching winning week Nasdaq Composite S P Investors reacted positively CPI PPI data released week suggested inflation may already peaked Read Proactive Investors UK Reuters FTSE positive early highs Add Portfolio DJI Add Portfolio AZN Add Portfolio BWY Add Portfolio BDEV Add Portfolio TW Add Portfolio FTMC Add Portfolio PHNX Add Portfolio IXIC Add Portfolio FTSE Add Portfolio AZN Add Portfolio CHNA Add Portfolio slips back making bright start Chinese retail sales output numbers forecast UK house prices fall August Rightmove FTSE failed hold strong early gains slipped back close parity disappointing economic data China took shine gains US Friday At lead index trading points good Richard Hunter head markets interactive investor said Economic news China threatened spoil party US markets staged strong rally end last Amid geopolitical tensions delegation US lawmakers arrive trip Taiwan Chinese economic data revealed ongoing impact lockdowns escalating property Retail sales industrial output rose less expected July alongside disappointing showing bank But said UK market chose take lead Wall Street notwithstanding fact Bank England set maintain aggressive interest rate stance face persistent inflation AstraZeneca PLC LSE NASDAQ shares rose pharmaceuticals group said positive results new trial Enhertu breast cancer drug demonstrated statistically significant clinically meaningful improvement survival AstraZeneca said Phase III trial Enhertu jointly developed commercialised Daiichi Sankyo also met key secondary endpoint improved overall survival But housebuilders Berkeley Group Holdings PLC LSE BKG Bellway LON Taylor Wimpey LON Barratt Developments LON fell following report Rightmove house prices slipped Positive start proceedings London London upbeat early trading FTSE makes positive start trading boosted gains US Friday despite mixed performances Asia overnight following disappointing Chinese retail sales industrial output figures At lead index trading points higher broader points Latest data online property website Rightmove showed first fall UK house prices year average price property coming market However Tim Bannister Rightmove director property science says A drop asking prices expected month frenzied two years many home movers become distracted summer Indeed may first summer holiday abroad since Bannister also pointed price growth year would still number properties currently market buy levels despite lack instructions new listings rose compared time last year compared Bannister also said recent interest rate increases Bank England significant impact number people wanting FTSE seen higher London markets expected open higher Monday following gains US Friday following surprise news China cut key interest rate bid boost stuttering economy following weaker expected retail sales industrial output figures Investors also one eye UK jobs inflation reports due later week see whether signs slowdown jobs market prices growth Spread betting companies calling FTSE around points Michael Hewson chief market analyst CMC Markets UK said Despite slow drip feed negative headlines rising gas prices supply chain challenges thrown heatwave Europe little appetite drive stocks lower recent Asia markets got positive start week latest retail sales industrial production numbers China showing economy still appears low confidence comes consumer spending economic activity This weakness Chinese economy comes struggle adapt policy government shows little sign relaxing backdrop rising Problems property sector also helping many home buyers halting mortgage payments protest delays completion new In June saw effects policy Chinese economy contraction although started see signs economic activity albeit low This morning retail sales numbers July confirmed fragile confidence still rising well expectations weaker Industrial production robust recovered much better however even economic activity disappointed July slipping back June In London quieter day company results Phoenix Group announced half year figures showed strong cash generation six months June FTSE closed book life insurer said confident delivering target range year New business cash generation record period double first half FTSE set open higher FTSE set start week positive fashion following gains US Friday Spread betting companies calling blue chip index around points closed Friday points jumped points S P added points reach benchmarks ended week high note clinching winning week Nasdaq Composite S P Investors reacted positively CPI PPI data released week suggested inflation may already peaked Read Proactive Investors UK DisclaimerAVEPp Add Portfolio ROG Add Portfolio RHHVF Add Portfolio SNY Add Portfolio AZN Add Portfolio SASY Add Portfolio By Scott Kanowsky Sanofi SA EPA shares slid Wednesday French drugmaker announced halt trials new treatment patients battling advanced breast cancer In statement company said would stop global clinical development medicine known amcenestrant phase study showed effective enough warrant research All studies amcenestrant including breast cancer also discontinued Sanofi added While disappointed outcome research scientific understanding endocrine therapies people breast cancer said John Reed global head research development Sanofi In note analysts Morgan Stanley called decision setback innovation narrative put forward Sanofi saying amcenestrant flagged potentially lucrative piece group drug pipeline end Sanofi amcenestrant trials expected lead negative impact company estimated discounted cash flow according Morgan Stanley analysts decision could also effect studies conducted similar breast cancer drugs Sanofi rivals Roche SIX AstraZeneca PLC LON analysts added']"
            ]
          },
          "metadata": {},
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kLoG8wU6bETe",
        "outputId": "014b5809-3d20-4027-88b2-a62d0061f0da"
      },
      "source": [
        "# Learn the vocabulary dictionary and transform to a vector of token counts\n",
        "Count_data = CountVec.fit_transform(spacy_preprocessed_articles_lem)\n",
        " \n",
        "# Create dataframe that can be used for building models\n",
        "spacy_lem_cv_dataframe = pd.DataFrame(Count_data.toarray(),columns=CountVec.get_feature_names())\n",
        "print(spacy_lem_cv_dataframe)"
      ],
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "   ab  abiraterone  abroad  accelerate  accelerates  accepted  access  \\\n",
            "0   1            1       2           1            1         3       2   \n",
            "\n",
            "   according  account  accumulation  ...  worth  wrote  year  years  yielded  \\\n",
            "0          4        1             1  ...      2      1    27      7        1   \n",
            "\n",
            "   ymab  york  younger  zero  zoryve  \n",
            "0     1     2        1     1       1  \n",
            "\n",
            "[1 rows x 1709 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 174
        },
        "id": "7SFjftfHc2BX",
        "outputId": "41f73036-d143-4dbe-b9ca-860f4286e2f4"
      },
      "source": [
        "# Create a mask so we only get the terms that have a frequency greater than 5 \n",
        "spacy_lem_frequent_words = list(spacy_lem_cv_dataframe.sum()[spacy_lem_cv_dataframe.sum() > 5].index)\n",
        "\n",
        "spacy_lem_cv_dataframe[spacy_lem_frequent_words]"
      ],
      "execution_count": 24,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "   activity  add  added  advanced  analysts  announced  antibody  application  \\\n",
              "0         7   81     10        11         9          8        11           16   \n",
              "\n",
              "   approval  approvals  ...  uk  unresectable  vaccine  vaccines  vaxzevria  \\\n",
              "0        19          7  ...  20             6       15        10         15   \n",
              "\n",
              "   virus  week  world  year  years  \n",
              "0     12    15      7    27      7  \n",
              "\n",
              "[1 rows x 192 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-d5e19577-65d9-4f10-9597-e1d316b8e6b8\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>activity</th>\n",
              "      <th>add</th>\n",
              "      <th>added</th>\n",
              "      <th>advanced</th>\n",
              "      <th>analysts</th>\n",
              "      <th>announced</th>\n",
              "      <th>antibody</th>\n",
              "      <th>application</th>\n",
              "      <th>approval</th>\n",
              "      <th>approvals</th>\n",
              "      <th>...</th>\n",
              "      <th>uk</th>\n",
              "      <th>unresectable</th>\n",
              "      <th>vaccine</th>\n",
              "      <th>vaccines</th>\n",
              "      <th>vaxzevria</th>\n",
              "      <th>virus</th>\n",
              "      <th>week</th>\n",
              "      <th>world</th>\n",
              "      <th>year</th>\n",
              "      <th>years</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>7</td>\n",
              "      <td>81</td>\n",
              "      <td>10</td>\n",
              "      <td>11</td>\n",
              "      <td>9</td>\n",
              "      <td>8</td>\n",
              "      <td>11</td>\n",
              "      <td>16</td>\n",
              "      <td>19</td>\n",
              "      <td>7</td>\n",
              "      <td>...</td>\n",
              "      <td>20</td>\n",
              "      <td>6</td>\n",
              "      <td>15</td>\n",
              "      <td>10</td>\n",
              "      <td>15</td>\n",
              "      <td>12</td>\n",
              "      <td>15</td>\n",
              "      <td>7</td>\n",
              "      <td>27</td>\n",
              "      <td>7</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>1 rows × 192 columns</p>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-d5e19577-65d9-4f10-9597-e1d316b8e6b8')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-d5e19577-65d9-4f10-9597-e1d316b8e6b8 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-d5e19577-65d9-4f10-9597-e1d316b8e6b8');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 24
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "-g-tGXeXfmj6"
      },
      "source": [
        "Although Bag of Words is quite efficient and easy to implement, still there are some disadvantages:\n",
        "\n",
        "*   The model ignores the location information of the word. The same words in a different order will have the same vector representation.\n",
        "*   The model does not respect the semantics of the word. Words often used in the same context are represented by different vectors. \n",
        "*   This approach causes a significant dimensionality problem - the more documents you have the larger the vocabulary, and the longer the vectors. \n",
        "*   Additionally, the vectors would also contain many 0s, thereby resulting in a huge sparse feature matrix.\n",
        "*   If the model comes across a new word it has not seen yet it will probably end up ignoring this word.\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "euAOj2aLiY5e"
      },
      "source": [
        "### 6.2 Term Frequency-Inverse Document Frequency (TF-IDF)\n",
        "\n",
        "Term frequency is not necessarily the best representation for text. In fact, you can find in the corpus common words with the highest frequency but little predictive power over the target variable. To address this problem there is an advanced variant of the Bag of Words that, instead of simple counting, uses the Term Frequency-Inverse Document Frequency (TF-IDF).\n",
        "\n",
        "Term Frequency (TF) is a measure of how frequently a term, t, appears in a document, d, or the number of times a word appears in a document divided by the total number of words in the document. Every document has its own term frequency.\n",
        "\n",
        "Inverse Document Frequency (IDF) is a measure of how important a term is. We need the IDF value because computing just the TF alone is not sufficient to understand the importance of words. The IDF is the log of the number of documents divided by the number of documents that contain the word w, and determines the weight of rare words across all documents in the corpus.\n",
        "\n",
        "Basically, the value of a word increases proportionally to count, but it is inversely proportional to the frequency of the word in the corpus.\n",
        "Computing the TF-IDF score for each word in the corpus will show that words with a higher score are more important, and those with a lower score are less important.\n",
        "\n",
        "Scikit-learn's TfidfVectorizer() class converts a collection of raw documents to a matrix of TF-IDF features. The smooth_idf parameter is used to smooth idf weights by adding one to document frequencies, as if an extra document was seen containing every term in the collection exactly once. This prevents zero divisions. We will look at examples with and without smoothing.\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "lSqfLBdAoPZ6"
      },
      "source": [
        "### NLTK preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yjbZxh7_d0Eh",
        "outputId": "a076274a-6188-410d-b768-eb114c38a298"
      },
      "source": [
        "# Without smooth IDF\n",
        "print(\"Without Smoothing:\")\n",
        "# Create an instance of the TfidfVectorizer class without smoothing\n",
        "tf_idf_vec = TfidfVectorizer(use_idf=True, \n",
        "                        smooth_idf=False,  \n",
        "                        ngram_range=(1,1),stop_words='english')\n",
        "# Transform\n",
        "tf_idf_data = tf_idf_vec.fit_transform(nltk_preprocessed_articles_stem)\n",
        " \n",
        "# Create dataframe\n",
        "nltk_stem_tf_idf_dataframe = pd.DataFrame(tf_idf_data.toarray(),columns = tf_idf_vec.get_feature_names())\n",
        "print(nltk_stem_tf_idf_dataframe)\n",
        "print(\"\\n\")\n",
        "  \n",
        "\n",
        "# With smooth IDF\n",
        "tf_idf_vec_smooth = TfidfVectorizer(use_idf=True,  \n",
        "                        smooth_idf=True,  \n",
        "                        ngram_range=(1,1),stop_words='english')\n",
        " \n",
        "# Transform \n",
        "tf_idf_data_smooth = tf_idf_vec_smooth.fit_transform(nltk_preprocessed_articles_stem)\n",
        " \n",
        "print(\"With Smoothing:\")\n",
        "# Create dataframe\n",
        "nltk_stem_tf_idf_dataframe_smooth = pd.DataFrame(tf_idf_data_smooth.toarray(),columns = tf_idf_vec_smooth.get_feature_names())\n",
        "print(nltk_stem_tf_idf_dataframe_smooth)"
      ],
      "execution_count": 25,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Without Smoothing:\n",
            "         ab  abirateron    abroad   acceler    accept    access    accord  \\\n",
            "0  0.003794    0.003794  0.007588  0.007588  0.011382  0.007588  0.015175   \n",
            "\n",
            "    account   accumul    achiev  ...    worsen     worth     wrote      year  \\\n",
            "0  0.003794  0.003794  0.003794  ...  0.015175  0.007588  0.003794  0.128992   \n",
            "\n",
            "      yield      ymab      york   younger      zero     zoryv  \n",
            "0  0.003794  0.003794  0.007588  0.003794  0.003794  0.003794  \n",
            "\n",
            "[1 rows x 1405 columns]\n",
            "\n",
            "\n",
            "With Smoothing:\n",
            "         ab  abirateron    abroad   acceler    accept    access    accord  \\\n",
            "0  0.003794    0.003794  0.007588  0.007588  0.011382  0.007588  0.015175   \n",
            "\n",
            "    account   accumul    achiev  ...    worsen     worth     wrote      year  \\\n",
            "0  0.003794  0.003794  0.003794  ...  0.015175  0.007588  0.003794  0.128992   \n",
            "\n",
            "      yield      ymab      york   younger      zero     zoryv  \n",
            "0  0.003794  0.003794  0.007588  0.003794  0.003794  0.003794  \n",
            "\n",
            "[1 rows x 1405 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Z4RhcvkMoUGq"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xlFevycxeL8b",
        "outputId": "dec636a3-ee20-4a08-85ce-e76c17c1a23e"
      },
      "source": [
        "# Without smooth IDF\n",
        "print(\"Without Smoothing:\")\n",
        "# Create an instance of the TfidfVectorizer class without smoothing\n",
        "tf_idf_vec = TfidfVectorizer(use_idf=True, \n",
        "                        smooth_idf=False,  \n",
        "                        ngram_range=(1,1),stop_words='english') # to use only  bigrams ngram_range=(2,2)\n",
        "# Transform\n",
        "tf_idf_data = tf_idf_vec.fit_transform(nltk_preprocessed_articles_lem)\n",
        " \n",
        "# Create dataframe\n",
        "nltk_lem_tf_idf_dataframe = pd.DataFrame(tf_idf_data.toarray(),columns=tf_idf_vec.get_feature_names())\n",
        "print(nltk_lem_tf_idf_dataframe)\n",
        "print(\"\\n\")\n",
        " \n",
        "\n",
        "# With smooth IDF\n",
        "tf_idf_vec_smooth = TfidfVectorizer(use_idf=True,  \n",
        "                        smooth_idf=True,  \n",
        "                        ngram_range=(1,1),stop_words='english')\n",
        " \n",
        "# Transform \n",
        "tf_idf_data_smooth = tf_idf_vec_smooth.fit_transform(nltk_preprocessed_articles_lem)\n",
        " \n",
        "print(\"With Smoothing:\")\n",
        "# Create dataframe\n",
        "nltk_lem_tf_idf_dataframe_smooth = pd.DataFrame(tf_idf_data_smooth.toarray(),columns=tf_idf_vec_smooth.get_feature_names())\n",
        "print(nltk_lem_tf_idf_dataframe_smooth)"
      ],
      "execution_count": 26,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Without Smoothing:\n",
            "      ab  abiraterone    abroad  accelerate  accelerates  accepted    access  \\\n",
            "0  0.004        0.004  0.007999       0.004        0.004  0.011999  0.007999   \n",
            "\n",
            "   according  account  accumulation  ...  worsens     worth  wrote      year  \\\n",
            "0   0.015999    0.004         0.004  ...    0.004  0.007999  0.004  0.135989   \n",
            "\n",
            "   yielded   ymab      york  younger   zero  zoryve  \n",
            "0    0.004  0.004  0.007999    0.004  0.004   0.004  \n",
            "\n",
            "[1 rows x 1623 columns]\n",
            "\n",
            "\n",
            "With Smoothing:\n",
            "      ab  abiraterone    abroad  accelerate  accelerates  accepted    access  \\\n",
            "0  0.004        0.004  0.007999       0.004        0.004  0.011999  0.007999   \n",
            "\n",
            "   according  account  accumulation  ...  worsens     worth  wrote      year  \\\n",
            "0   0.015999    0.004         0.004  ...    0.004  0.007999  0.004  0.135989   \n",
            "\n",
            "   yielded   ymab      york  younger   zero  zoryve  \n",
            "0    0.004  0.004  0.007999    0.004  0.004   0.004  \n",
            "\n",
            "[1 rows x 1623 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Q-PwBiDLoXgN"
      },
      "source": [
        "### spaCy preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "fTdDGPJShJLl",
        "outputId": "96781b7d-1ca9-4e7e-9c40-0d9b8759e142"
      },
      "source": [
        "# Without smooth IDF\n",
        "print(\"Without Smoothing:\")\n",
        "# Create an instance of the TfidfVectorizer class without smoothing\n",
        "tf_idf_vec = TfidfVectorizer(use_idf=True, \n",
        "                        smooth_idf=False,  \n",
        "                        ngram_range=(1,1),stop_words='english') # to use only  bigrams ngram_range=(2,2)\n",
        "# Transform\n",
        "tf_idf_data = tf_idf_vec.fit_transform(spacy_preprocessed_articles_lem)\n",
        " \n",
        "# Create dataframe\n",
        "spacy_lem_tf_idf_dataframe = pd.DataFrame(tf_idf_data.toarray(),columns=tf_idf_vec.get_feature_names())\n",
        "print(spacy_lem_tf_idf_dataframe)\n",
        "print(\"\\n\")\n",
        " \n",
        "\n",
        "# With smooth IDF\n",
        "tf_idf_vec_smooth = TfidfVectorizer(use_idf=True,  \n",
        "                        smooth_idf=True,  \n",
        "                        ngram_range=(1,1),stop_words='english')\n",
        " \n",
        "# Transform \n",
        "tf_idf_data_smooth = tf_idf_vec_smooth.fit_transform(spacy_preprocessed_articles_lem)\n",
        " \n",
        "print(\"With Smoothing:\")\n",
        "# Create dataframe\n",
        "spacy_lem_tf_idf_dataframe_smooth = pd.DataFrame(tf_idf_data_smooth.toarray(),columns=tf_idf_vec_smooth.get_feature_names())\n",
        "print(spacy_lem_tf_idf_dataframe_smooth)"
      ],
      "execution_count": 27,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Without Smoothing:\n",
            "        ab  abiraterone   abroad  accelerate  accelerates  accepted   access  \\\n",
            "0  0.00413      0.00413  0.00826     0.00413      0.00413   0.01239  0.00826   \n",
            "\n",
            "   according  account  accumulation  ...    worth    wrote      year  \\\n",
            "0   0.016519  0.00413       0.00413  ...  0.00826  0.00413  0.111506   \n",
            "\n",
            "      years  yielded     ymab     york  younger     zero   zoryve  \n",
            "0  0.028909  0.00413  0.00413  0.00826  0.00413  0.00413  0.00413  \n",
            "\n",
            "[1 rows x 1709 columns]\n",
            "\n",
            "\n",
            "With Smoothing:\n",
            "        ab  abiraterone   abroad  accelerate  accelerates  accepted   access  \\\n",
            "0  0.00413      0.00413  0.00826     0.00413      0.00413   0.01239  0.00826   \n",
            "\n",
            "   according  account  accumulation  ...    worth    wrote      year  \\\n",
            "0   0.016519  0.00413       0.00413  ...  0.00826  0.00413  0.111506   \n",
            "\n",
            "      years  yielded     ymab     york  younger     zero   zoryve  \n",
            "0  0.028909  0.00413  0.00413  0.00826  0.00413  0.00413  0.00413  \n",
            "\n",
            "[1 rows x 1709 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Lve2AFAfaBR1"
      },
      "source": [
        "As above with the Bag of Words, the data is high dimensional and any useful analysis would require selecting the columns with the highest TF-IDF. \n",
        "\n",
        "Bag of Words and TF-IDF can convert textual data into numerical data but are unable to take into consideration context, which is necessary for detecting similarity between words or translating documents into another language.  "
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "u2-c1Xf4s5ov"
      },
      "source": [
        "### 6.3 Word Embedding (Word2Vec)\n",
        "\n",
        "A word embedding is a vector representation of a particular word in an n-dimensional space, and words that are closer in the vector space are expected to be similar in meaning.\n",
        "\n",
        "Word2Vec is one of the most popular techniques for learning word embeddings and uses a two-layer neural network. The input of Word2Vec is a text corpus and its output is a set of vectors known as feature vectors that represent words in that corpus. \n",
        "\n",
        "Word2vec trains words against other words that neighbour them in the input corpus.  It does this by using a combination of two unsupervised algorithms: Continuous Bag of Words (CBOW), which uses context to predict a target word, and the Skip-gram model, which uses a word to predict a target context.\n",
        "\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "j9M-e_wKoRlA"
      },
      "source": [
        "### Vector values\n",
        "\n",
        "We will use spaCy's default English language model to create a word vector stored as an array."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "OqIDYOxpiO3k",
        "outputId": "af5b6396-2769-4c93-f77a-1577765e0fae"
      },
      "source": [
        "# For example we can make a vector out of the word 'growth'\n",
        "doc = nlp(u'growth')\n",
        "print(doc.vector.shape)\n",
        "print(doc.vector)"
      ],
      "execution_count": 28,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "(96,)\n",
            "[ 1.1597962   0.77081984 -0.33453742 -0.91060746 -0.50083935  1.2351177\n",
            "  0.23244448 -0.03666113 -0.01061746 -0.7573122  -0.46973464 -0.54964375\n",
            "  1.3150035   0.01700145 -0.8559814  -0.21762833  0.20712146 -0.7800459\n",
            " -0.7329896   0.32484987  1.2087431  -0.03127518  1.4675763   0.958937\n",
            "  0.8165134   0.67666054  0.19339865 -1.04584     1.2994473   0.2478643\n",
            " -0.7766158  -0.03732942 -1.4398699   0.05548506 -1.4863738   0.9122323\n",
            " -0.4108849   0.26781738  0.84578615 -0.01018238  0.3460247   0.9638506\n",
            " -0.08531903  0.23534317 -1.0420263  -0.49099588 -0.28811124  0.7182986\n",
            " -0.22874254  0.02432996 -0.3258329  -1.3287699  -1.1159035  -1.5458163\n",
            " -0.18303767  0.14686024 -0.98615843 -1.3414288   0.24931087 -0.4300659\n",
            "  0.5643944  -0.47980487  0.6057204   0.12768029 -0.5110448  -0.21698639\n",
            " -0.09863968  1.0471084  -0.8425423  -0.47937387  1.0479085   0.17334515\n",
            " -0.22203603 -0.5485386  -0.5787839   0.6902106   0.5497966  -0.13003564\n",
            " -0.5308165   2.1542983  -0.00688252 -1.4438442  -0.15427655 -0.5254472\n",
            "  0.6956214   1.3347133   0.25591964  0.10857701 -1.135168    0.729916\n",
            " -0.3298363  -0.94992036  0.78390443 -0.02187411  0.2407711  -0.15450454]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "CkKOlxaQqpYe"
      },
      "source": [
        "### Vector similarity\n",
        "\n",
        "The similarity() method exposes vector relationships and it is possible to do this for several token combinations iteratively. By default spaCy uses cosine similarity, the most widely used method to compare two vectors, which considers vector orientation independent of vector magnitude. \n",
        "\n",
        "Cosine similarity is a measure of similarity between two non-zero vectors of an inner product space. It is defined to equal the cosine of the angle between them, which is also the same as the inner product of the same vectors normalised to both have length 1. The cosine of 0° is 1 and less than 1 for any angle in the interval.\n",
        "\n",
        "It is also the case that words with opposite meaning, but that often appear in the same context, may have similar vectors."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "_6ZQ6hDdiaIk",
        "outputId": "19208ccd-919f-4ea3-fdf6-7ac795ea2325"
      },
      "source": [
        "# Get the similarity for 'up' and 'growth'\n",
        "nlp('up').similarity(nlp('growth'))"
      ],
      "execution_count": 29,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0.11664896507569315"
            ]
          },
          "metadata": {},
          "execution_count": 29
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "lUdaTCRYmvR3"
      },
      "source": [
        "The vector for the word 'growth' had a lot of dimensions so we will make use of word embeddings to look at similarity between documents. One possibility for stock prediction could be to use a changing similarity score to detect when confidence in a stock is changing. This could be used to classify articles.\n",
        "\n",
        "We will find all the word embeddings for all the words in all the articles and then take the mean of the embeddings for each article.\n",
        "\n",
        "We will then calculate the angle between the two articles using the dot product which considers orientation and also scales with vector magnitude.\n",
        "\n",
        "Where the angle is ~0, the cosθ component of the formula equals ~1. If the angle is nearer to 90 (orthogonal/perpendicular), the cosθ component equals ~0, and at 180 the cosθ component equals ~-1.\n",
        "\n",
        "Therefore, the cosθ component increases the result where there is less of an angle between the two vectors. So, a higher dot product correlates with higher orientation.\n",
        "\n",
        "The dot product calculation is straightforward and therefore gives benefits in terms of computation time but it is not normalised — meaning larger vectors will tend to score higher dot products, despite being less similar.\n",
        "\n",
        "A norm is a measure of the size of a matrix or vector and you can compute it in NumPy with the np.linalg.norm() function. One important use of norm is to transform a given vector into a unit-length vector, that is, making the magnitude of vector = 1, while still preserving its direction."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "qgOl7ETXnN7h"
      },
      "source": [
        "### NLTK preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Find all embeddings for all words in all articles, \n",
        "# Take the mean of the embeddings for each article\n",
        "\n",
        "article_vector_list = [np.mean([nlp(word).vector for word in article]) for article in nltk_preprocessed_articles_stem] \n",
        "\n",
        "# Calculate the angle between two articles. \n",
        "# The articles are represented by vectors, so their similarity is defined by the angle between them \n",
        "np.dot(article_vector_list[0], article_vector_list[1]) / (np.linalg.norm(article_vector_list[0]) * np.linalg.norm(article_vector_list[1]))"
      ],
      "metadata": {
        "id": "rjPVyDBCvclw"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "xSWpTFwky_9p"
      },
      "source": [
        "### Named Entity Recognition\n",
        "\n",
        "A named entity is a “real-world object” that’s assigned a name – for example, a person, a country, a product or a book title. spaCy can recognise various types of named entities in a document, by asking the model for a prediction.\n",
        "\n",
        "Using spaCy’s built-in displaCy visualiser we can see what the named entities look like.\n",
        "\n",
        "The standard way to access entity annotations is the doc.ents property, which produces a sequence of Span objects. The entity type is accessible either as a hash value or as a string, using the attributes ent.label and ent.label_. The Span object acts as a sequence of tokens, so you can iterate over the entity or index into it. You can also get the text form of the whole entity, as though it were a single token."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lf92gADrleJJ",
        "outputId": "03a73323-6c9a-4894-abe7-9cdb01f793c4"
      },
      "source": [
        "doc = nlp(nltk_preprocessed_articles_stem[0])\n",
        "\n",
        "entities=[(i, i.label_) for i in doc.ents]\n",
        "entities"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[(readi, 'ORG'),\n",
              " (monday, 'DATE'),\n",
              " (six, 'CARDINAL'),\n",
              " (hospit, 'GPE'),\n",
              " (UK, 'GPE'),\n",
              " (monday, 'DATE'),\n",
              " (six, 'CARDINAL'),\n",
              " (hospit, 'GPE'),\n",
              " (london, 'GPE'),\n",
              " (lancashir warwickshir, 'ORG'),\n",
              " (later week, 'DATE'),\n",
              " (today, 'DATE'),\n",
              " (brian pinker, 'PERSON'),\n",
              " (first, 'ORDINAL'),\n",
              " (open week, 'DATE'),\n",
              " (UK, 'GPE'),\n",
              " (million, 'CARDINAL'),\n",
              " (UK, 'GPE'),\n",
              " (two, 'CARDINAL'),\n",
              " (british, 'NORP'),\n",
              " (cancel patient, 'PERSON'),\n",
              " (second, 'ORDINAL'),\n",
              " (grossli unfair, 'ORG'),\n",
              " (bbc, 'ORG'),\n",
              " (medic offic, 'PERSON'),\n",
              " (possibl, 'GPE'),\n",
              " (meanwhil astrazeneca appli, 'PERSON'),\n",
              " (south korea, 'GPE'),\n",
              " (vietnam, 'GPE'),\n",
              " (compani, 'ORG'),\n",
              " (monday, 'DATE')]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 29
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "_jJcKJWApjiJ"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "K_3JUH-xk4Xv",
        "outputId": "058615e0-f951-478c-a224-04b37274dc86"
      },
      "source": [
        "# Find all embeddings for all words in all articles, \n",
        "# Take the mean of the embeddings for each article\n",
        "\n",
        "article_vector_list = [np.mean([nlp(word).vector for word in article]) for article in nltk_preprocessed_articles_lem] \n",
        "\n",
        "# Calculate the angle between two articles. \n",
        "# The articles are represented by vectors, so their similarity is defined by the angle between them  \n",
        "np.dot(article_vector_list[0], article_vector_list[1]) / (np.linalg.norm(article_vector_list[0]) * np.linalg.norm(article_vector_list[1]))"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1.0"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 37
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RPGEiZ9PF5mJ",
        "outputId": "3e8ca56a-c33d-481d-af46-c03b9026a302"
      },
      "source": [
        "doc = nlp(nltk_preprocessed_articles_lem[0])\n",
        "\n",
        "entities=[(i, i.label_) for i in doc.ents]\n",
        "entities"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[(Monday six, 'DATE'),\n",
              " (UK, 'GPE'),\n",
              " (PLC Oxford University FTSE, 'ORG'),\n",
              " (Monday, 'DATE'),\n",
              " (six, 'CARDINAL'),\n",
              " (later week, 'DATE'),\n",
              " (COVID, 'ORG'),\n",
              " (today, 'DATE'),\n",
              " (Oxford, 'ORG'),\n",
              " (Brian Pinker, 'PERSON'),\n",
              " (first, 'ORDINAL'),\n",
              " (Oxford, 'ORG'),\n",
              " (OUHospitals NHS England NHS Improvement NHSEngland January, 'ORG'),\n",
              " (hundred, 'CARDINAL'),\n",
              " (UK, 'GPE'),\n",
              " (million, 'CARDINAL'),\n",
              " (UK, 'GPE'),\n",
              " (two, 'CARDINAL'),\n",
              " (British Medical Association, 'ORG'),\n",
              " (second, 'ORDINAL'),\n",
              " (BBC, 'ORG'),\n",
              " (AstraZeneca, 'ORG'),\n",
              " (South Korea, 'GPE'),\n",
              " (Vietnam, 'GPE'),\n",
              " (Monday morning, 'TIME')]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 30
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Xmc0OWX7pmkv"
      },
      "source": [
        "### spaCy preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Hrzs-QuVlAmr",
        "outputId": "caae67a3-8695-4fd1-a384-89d87c8bd743"
      },
      "source": [
        "# Find all embeddings for all words in all articles, \n",
        "# Take the mean of the embeddings for each article\n",
        "\n",
        "article_vector_list = [np.mean([nlp(word).vector for word in article]) for article in spacy_preprocessed_articles_lem] \n",
        "\n",
        "# Calculate the angle between two articles. \n",
        "# The articles are represented by vectors, so their similarity is defined by the angle between them \n",
        "np.dot(article_vector_list[0], article_vector_list[1]) / (np.linalg.norm(article_vector_list[0]) * np.linalg.norm(article_vector_list[1]))"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1.0"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 38
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MemLP9MrllDH",
        "outputId": "0d62965c-4ca9-49c0-b605-73ce56e47e80"
      },
      "source": [
        "doc = nlp(spacy_preprocessed_articles_lem[0])\n",
        "\n",
        "entities=[(i, i.label_) for i in doc.ents]\n",
        "entities"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[(Monday, 'DATE'),\n",
              " (six, 'CARDINAL'),\n",
              " (UK, 'GPE'),\n",
              " (PLC Oxford University FTSE, 'ORG'),\n",
              " (Monday, 'DATE'),\n",
              " (six, 'CARDINAL'),\n",
              " (Oxford London, 'ORG'),\n",
              " (later week, 'DATE'),\n",
              " (COVID, 'ORG'),\n",
              " (today, 'DATE'),\n",
              " (Oxford, 'ORG'),\n",
              " (Brian Pinker, 'PERSON'),\n",
              " (first, 'ORDINAL'),\n",
              " (Oxford, 'ORG'),\n",
              " (OUHospitals NHS England NHS Improvement NHSEngland January, 'ORG'),\n",
              " (hundreds, 'CARDINAL'),\n",
              " (UK, 'GPE'),\n",
              " (million, 'CARDINAL'),\n",
              " (UK, 'GPE'),\n",
              " (two, 'CARDINAL'),\n",
              " (weeks, 'DATE'),\n",
              " (British Medical Association, 'ORG'),\n",
              " (second, 'ORDINAL'),\n",
              " (BBC, 'ORG'),\n",
              " (AstraZeneca, 'ORG'),\n",
              " (South Korea, 'GPE'),\n",
              " (Vietnam, 'GPE'),\n",
              " (Monday morning, 'TIME')]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 32
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "f5GHois4Aosy"
      },
      "source": [
        "## 7. Topic Modelling\n",
        "\n",
        "Topic modelling is an unsupervised machine learning technique that's capable of scanning a set of documents, detecting word and phrase patterns within them, and automatically clustering word groups and similar expressions that best characterise a set of documents.\n",
        "\n",
        "A widely used topic modelling algorithm is the Latent Dirichlet Allocation (LDA) from the Gensim package.\n",
        "\n",
        "In the LDA model, each document is viewed as a collection of topics that are present in the corpus in a certain proportion, and each topic as a collection of keywords, again in a certain proportion. Just by looking at the keywords, you can identify what the topic is all about.\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "PVbtVyIaLGFi"
      },
      "source": [
        "### 7.1 Create the Dictionary and Corpus needed for Topic Modelling\n",
        "\n",
        "The two main inputs to the LDA topic model are the dictionary (id2word) and the corpus."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "JWxkSXF4IDOU"
      },
      "source": [
        "### NLTK preprocessed stemmed articles\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pzNoYpfvnhup",
        "outputId": "5352bca5-10ed-4a26-b88b-24e1f5cf2faa"
      },
      "source": [
        "# Create Dictionary\n",
        "id2word_nltk_stem = corpora.Dictionary(nltk_stemmed_articles)\n",
        "\n",
        "# Create Corpus\n",
        "texts_nltk_stem = nltk_stemmed_articles\n",
        "\n",
        "# Term Document Frequency\n",
        "corpus_nltk_stem = [id2word_nltk_stem.doc2bow(text) for text in texts_nltk_stem]\n",
        "\n",
        "# View\n",
        "print(corpus_nltk_stem[:1])"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[[(0, 3), (1, 1), (2, 1), (3, 1), (4, 1), (5, 1), (6, 1), (7, 1), (8, 1), (9, 1), (10, 1), (11, 1), (12, 1), (13, 1), (14, 1), (15, 1), (16, 1), (17, 1), (18, 1), (19, 1), (20, 1), (21, 1), (22, 1), (23, 1), (24, 1), (25, 1), (26, 1), (27, 1), (28, 1), (29, 8), (30, 1), (31, 1), (32, 2), (33, 2), (34, 2), (35, 2), (36, 1), (37, 2), (38, 1), (39, 1), (40, 2), (41, 1), (42, 1), (43, 1), (44, 1), (45, 1), (46, 2), (47, 1), (48, 1), (49, 1), (50, 1), (51, 1), (52, 1), (53, 1), (54, 1), (55, 2), (56, 1), (57, 3), (58, 1), (59, 2), (60, 1), (61, 1), (62, 2), (63, 1), (64, 1), (65, 1), (66, 1), (67, 1), (68, 1), (69, 4), (70, 1), (71, 1), (72, 2), (73, 1), (74, 1), (75, 1), (76, 1), (77, 1), (78, 1), (79, 1), (80, 1), (81, 1), (82, 1), (83, 2), (84, 1), (85, 2), (86, 1), (87, 1), (88, 1), (89, 1), (90, 2), (91, 2), (92, 1), (93, 1), (94, 1), (95, 1), (96, 1), (97, 1), (98, 1), (99, 2), (100, 1), (101, 1), (102, 1), (103, 1), (104, 1), (105, 1), (106, 1), (107, 1), (108, 2), (109, 1), (110, 1), (111, 1), (112, 2), (113, 7), (114, 1), (115, 1), (116, 3), (117, 1), (118, 1)]]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "q4EU0Qz_IfAL"
      },
      "source": [
        "Gensim creates a unique id for each word in the document. The produced corpus shown above is a mapping of (word_id, word_frequency).\n",
        "\n",
        "For example, (0, 3) above implies word id 0 occurs three times in the first document. Likewise, word id 1 occurs once and so on.\n",
        "\n",
        "This is used as the input by the LDA model.\n",
        "\n",
        "To see what word a given id corresponds to, pass the id as a key to the dictionary."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "CSW5yAu7no2m",
        "outputId": "836b56ac-9d2f-4a1c-f919-3e03ce7dc247"
      },
      "source": [
        "# word id 0 passed as key to the dictionary\n",
        "\n",
        "id2word_nltk_stem[0]"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            },
            "text/plain": [
              "'UK'"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 34
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "BvG2FOCUKiZ0"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "VrWSjLHEnuY3",
        "outputId": "17c1ca8c-e84a-47c5-9bc1-610cca05ff43"
      },
      "source": [
        "# Create Dictionary\n",
        "id2word_nltk_lem = corpora.Dictionary(nltk_lemmatised_articles)\n",
        "\n",
        "# Create Corpus\n",
        "texts_nltk_lem = nltk_lemmatised_articles\n",
        "\n",
        "# Term Document Frequency\n",
        "corpus_nltk_lem = [id2word_nltk_lem.doc2bow(text) for text in texts_nltk_lem]\n",
        "\n",
        "# View\n",
        "print(corpus_nltk_lem[:1])"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[[(0, 1), (1, 1), (2, 1), (3, 1), (4, 1), (5, 1), (6, 1), (7, 2), (8, 1), (9, 1), (10, 1), (11, 1), (12, 1), (13, 1), (14, 1), (15, 1), (16, 3), (17, 1), (18, 1), (19, 2), (20, 1), (21, 1), (22, 4), (23, 1), (24, 1), (25, 1), (26, 1), (27, 1), (28, 3), (29, 1), (30, 1), (31, 1), (32, 1), (33, 1), (34, 1), (35, 1), (36, 1), (37, 1), (38, 1), (39, 1), (40, 1), (41, 1), (42, 1), (43, 1), (44, 1), (45, 1), (46, 1), (47, 1), (48, 1), (49, 1), (50, 1), (51, 1), (52, 1), (53, 1), (54, 7), (55, 1), (56, 1), (57, 2), (58, 2), (59, 1), (60, 1), (61, 1), (62, 2), (63, 1), (64, 1), (65, 2), (66, 1), (67, 1), (68, 1), (69, 2), (70, 1), (71, 1), (72, 1), (73, 1), (74, 1), (75, 2), (76, 1), (77, 1), (78, 1), (79, 1), (80, 1), (81, 1), (82, 1), (83, 2), (84, 1), (85, 1), (86, 1), (87, 1), (88, 1), (89, 1), (90, 1), (91, 1), (92, 2), (93, 1), (94, 2), (95, 1), (96, 1), (97, 1), (98, 1), (99, 2), (100, 2), (101, 1), (102, 1), (103, 1), (104, 1), (105, 1), (106, 1), (107, 2), (108, 1), (109, 1), (110, 1), (111, 1), (112, 1), (113, 1), (114, 2), (115, 1), (116, 1), (117, 2), (118, 1), (119, 1), (120, 1), (121, 4), (122, 3), (123, 1), (124, 1)]]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "iZxbPGV5n2PN",
        "outputId": "d75e40ca-6eac-484d-a63e-cf8dcb0d7cc6"
      },
      "source": [
        "# word id 0 passed as key to the dictionary\n",
        "\n",
        "id2word_nltk_lem[0]"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            },
            "text/plain": [
              "'Association'"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "m0RHCn5TKslm"
      },
      "source": [
        "### spaCy preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NZh12DaNsoq3",
        "outputId": "6f89478d-71e7-432e-c2ae-7d2570e450e3"
      },
      "source": [
        "# Create Dictionary\n",
        "id2word_spacy_lem = corpora.Dictionary(spacy_lemmatised_articles)\n",
        "\n",
        "# Create Corpus\n",
        "texts_spacy_lem = spacy_lemmatised_articles\n",
        "\n",
        "# Term Document Frequency\n",
        "corpus_spacy_lem = [id2word_spacy_lem.doc2bow(text) for text in texts_spacy_lem]\n",
        "\n",
        "# View\n",
        "print(corpus_spacy_lem[:1])"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[[(0, 1), (1, 1), (2, 1), (3, 1), (4, 1), (5, 1), (6, 1), (7, 2), (8, 1), (9, 1), (10, 1), (11, 1), (12, 1), (13, 1), (14, 1), (15, 1), (16, 3), (17, 1), (18, 1), (19, 2), (20, 1), (21, 1), (22, 4), (23, 1), (24, 1), (25, 1), (26, 1), (27, 1), (28, 3), (29, 1), (30, 1), (31, 1), (32, 1), (33, 1), (34, 1), (35, 1), (36, 1), (37, 1), (38, 1), (39, 1), (40, 1), (41, 1), (42, 1), (43, 1), (44, 1), (45, 1), (46, 1), (47, 1), (48, 1), (49, 1), (50, 1), (51, 1), (52, 1), (53, 1), (54, 1), (55, 7), (56, 1), (57, 2), (58, 2), (59, 1), (60, 1), (61, 1), (62, 2), (63, 1), (64, 1), (65, 2), (66, 1), (67, 1), (68, 1), (69, 1), (70, 1), (71, 1), (72, 1), (73, 1), (74, 1), (75, 1), (76, 2), (77, 1), (78, 1), (79, 1), (80, 1), (81, 1), (82, 1), (83, 1), (84, 2), (85, 1), (86, 1), (87, 1), (88, 1), (89, 1), (90, 1), (91, 1), (92, 1), (93, 2), (94, 1), (95, 2), (96, 1), (97, 1), (98, 1), (99, 1), (100, 2), (101, 2), (102, 1), (103, 1), (104, 1), (105, 1), (106, 1), (107, 1), (108, 2), (109, 1), (110, 1), (111, 1), (112, 1), (113, 1), (114, 1), (115, 2), (116, 1), (117, 1), (118, 2), (119, 1), (120, 1), (121, 1), (122, 4), (123, 2), (124, 1), (125, 1), (126, 1)]]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "FqSlAT45s7qv",
        "outputId": "a0c29e81-568b-41b2-e561-a110847b0396"
      },
      "source": [
        "id2word_spacy_lem[0]"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            },
            "text/plain": [
              "'Association'"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 38
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "F-HcixOLLYP9"
      },
      "source": [
        "### 7.2 Build the Topic Model\n",
        "\n",
        "In addition to the corpus and dictionary, you need to provide the number of topics as with any unsupervised learning technique. "
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "pbYrcO4n-aD7"
      },
      "source": [
        "### NLTK preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "zVti9IidoBnF"
      },
      "source": [
        "# Build the topic model with 10 topics\n",
        "nltk_stem_lda_model = gensim.models.ldamodel.LdaModel(corpus=corpus_nltk_stem,\n",
        "                                           id2word=id2word_nltk_stem,\n",
        "                                           num_topics=10,              # Define the number of topics we want\n",
        "                                           random_state=100,\n",
        "                                           update_every=1,             # Determines how often the model parameters should be updated\n",
        "                                           chunksize=10,               # Number of documents to be used in each training chunk\n",
        "                                           passes=10,                  # Total number of training passes.\n",
        "                                           alpha='auto',               # Hyperparameter that affects sparsity of the topics\n",
        "                                           per_word_topics=True)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "CWHO4N0o-hQd"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "uXcRY0GXtago"
      },
      "source": [
        "# Build the topic model with 10 topics\n",
        "nltk_lem_lda_model = gensim.models.ldamodel.LdaModel(corpus=corpus_nltk_lem,\n",
        "                                           id2word=id2word_nltk_lem,\n",
        "                                           num_topics=10, \n",
        "                                           random_state=100,\n",
        "                                           update_every=1,\n",
        "                                           chunksize=10,\n",
        "                                           passes=10,\n",
        "                                           alpha='auto',\n",
        "                                           per_word_topics=True)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Fn0zu0IZ-l9L"
      },
      "source": [
        "### spaCy preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "BwmmuN_A0JMQ"
      },
      "source": [
        "# Build the topic model with 10 topics\n",
        "spacy_lem_lda_model = gensim.models.ldamodel.LdaModel(corpus=corpus_spacy_lem,\n",
        "                                           id2word=id2word_spacy_lem,\n",
        "                                           num_topics=10, \n",
        "                                           random_state=100,\n",
        "                                           update_every=1,\n",
        "                                           chunksize=10,\n",
        "                                           passes=10,\n",
        "                                           alpha='auto',\n",
        "                                           per_word_topics=True)"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "bKatjGXOO_NT"
      },
      "source": [
        "### 7.3 View the topics in LDA model\n",
        "\n",
        "The model is built with 10 different topics each of which is a combination of keywords with each keyword contributing a certain weighting to the topic.\n",
        "\n",
        "You can see the keywords for each topic and the weighting (importance) of each keyword using lda_model.print_topics()"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "KoJrLFdM_VSF"
      },
      "source": [
        "### NLTK preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qbG5hkPToN2Q",
        "outputId": "a684e242-be1b-4c81-8c04-b463a816dd65"
      },
      "source": [
        "# Print the Keyword in the 10 topics\n",
        "pprint(nltk_stem_lda_model.print_topics())\n",
        "nltk_stem_doc_lda = nltk_stem_lda_model[corpus_nltk_stem]"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[(0,\n",
            "  '0.044*\"vaccin\" + 0.019*\"dose\" + 0.019*\"million\" + 0.017*\"astrazeneca\" + '\n",
            "  '0.016*\"week\" + 0.016*\"approv\" + 0.014*\"receiv\" + 0.013*\"within\" + '\n",
            "  '0.012*\"clinic\" + 0.012*\"mean\"'),\n",
            " (1,\n",
            "  '0.015*\"year\" + 0.014*\"UK\" + 0.014*\"trade\" + 0.013*\"index\" + 0.013*\"market\" '\n",
            "  '+ 0.012*\"wednesday\" + 0.012*\"new\" + 0.012*\"ftse\" + 0.012*\"close\" + '\n",
            "  '0.011*\"vaccin\"'),\n",
            " (2,\n",
            "  '0.028*\"compani\" + 0.018*\"said\" + 0.015*\"gain\" + 0.013*\"rose\" + 0.012*\"firm\" '\n",
            "  '+ 0.011*\"stock\" + 0.011*\"share\" + 0.011*\"US\" + 0.009*\"strong\" + '\n",
            "  '0.009*\"also\"'),\n",
            " (3,\n",
            "  '0.023*\"stock\" + 0.015*\"posit\" + 0.014*\"nasdaq\" + 0.012*\"compani\" + '\n",
            "  '0.011*\"vaccin\" + 0.010*\"market\" + 0.009*\"ad\" + 0.009*\"pass\" + 0.009*\"new\" + '\n",
            "  '0.009*\"next\"'),\n",
            " (4,\n",
            "  '0.030*\"vaccin\" + 0.019*\"million\" + 0.013*\"case\" + 0.009*\"record\" + '\n",
            "  '0.009*\"state\" + 0.009*\"hospit\" + 0.008*\"death\" + 0.008*\"first\" + '\n",
            "  '0.008*\"accord\" + 0.008*\"countri\"'),\n",
            " (5,\n",
            "  '0.035*\"vaccin\" + 0.029*\"dose\" + 0.022*\"said\" + 0.019*\"receiv\" + '\n",
            "  '0.018*\"pfizer\" + 0.018*\"compani\" + 0.015*\"second\" + 0.014*\"week\" + '\n",
            "  '0.011*\"confirm\" + 0.011*\"drug\"'),\n",
            " (6,\n",
            "  '0.001*\"stock\" + 0.001*\"compani\" + 0.001*\"peak\" + 0.001*\"UK\" + '\n",
            "  '0.001*\"vaccin\" + 0.001*\"also\" + 0.001*\"flat\" + 0.001*\"higher\" + '\n",
            "  '0.001*\"market\" + 0.001*\"nasdaq\"'),\n",
            " (7,\n",
            "  '0.026*\"nasdaq\" + 0.025*\"inc\" + 0.021*\"antibodi\" + 0.016*\"cocktail\" + '\n",
            "  '0.013*\"studi\" + 0.013*\"premarket\" + 0.012*\"phase\" + 0.011*\"In\" + '\n",
            "  '0.011*\"public\" + 0.010*\"treatment\"'),\n",
            " (8,\n",
            "  '0.027*\"dollar\" + 0.021*\"gain\" + 0.018*\"price\" + 0.015*\"ralli\" + '\n",
            "  '0.014*\"stock\" + 0.013*\"oil\" + 0.012*\"rose\" + 0.010*\"barrel\" + 0.009*\"day\" + '\n",
            "  '0.009*\"keator\"'),\n",
            " (9,\n",
            "  '0.039*\"UK\" + 0.027*\"plc\" + 0.022*\"with\" + 0.021*\"dose\" + 0.019*\"jab\" + '\n",
            "  '0.018*\"avail\" + 0.014*\"morn\" + 0.014*\"vaccin\" + 0.012*\"mass\" + 0.012*\"nh\"')]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "PwSXkmK3GTW1"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "l2PxESfstkVP",
        "outputId": "c3b93085-0742-461a-d0ca-c9ec2889d613"
      },
      "source": [
        "# Print the Keyword in the 10 topics\n",
        "pprint(nltk_lem_lda_model.print_topics())\n",
        "nltk_lem_doc_lda = nltk_lem_lda_model[corpus_nltk_lem]"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[(0,\n",
            "  '0.021*\"million\" + 0.020*\"case\" + 0.016*\"vaccine\" + 0.013*\"death\" + '\n",
            "  '0.009*\"said\" + 0.009*\"patient\" + 0.009*\"one\" + 0.008*\"people\" + '\n",
            "  '0.008*\"state\" + 0.007*\"November\"'),\n",
            " (1,\n",
            "  '0.018*\"company\" + 0.016*\"gained\" + 0.012*\"Shares\" + 0.010*\"firm\" + '\n",
            "  '0.010*\"target\" + 0.007*\"AMC\" + 0.007*\"BTIG\" + 0.007*\"education\" + '\n",
            "  '0.007*\"Tesla\" + 0.007*\"CNBC\"'),\n",
            " (2,\n",
            "  '0.025*\"UK\" + 0.019*\"vaccine\" + 0.015*\"FTSE\" + 0.014*\"point\" + '\n",
            "  '0.012*\"coronavirus\" + 0.011*\"Wednesday\" + 0.010*\"higher\" + 0.009*\"case\" + '\n",
            "  '0.009*\"session\" + 0.008*\"index\"'),\n",
            " (3,\n",
            "  '0.017*\"gain\" + 0.013*\"Keator\" + 0.011*\"dollar\" + 0.010*\"rose\" + '\n",
            "  '0.010*\"yield\" + 0.009*\"going\" + 0.009*\"gained\" + 0.008*\"lowest\" + '\n",
            "  '0.007*\"robust\" + 0.007*\"dip\"'),\n",
            " (4,\n",
            "  '0.024*\"dose\" + 0.023*\"dos\" + 0.020*\"second\" + 0.015*\"week\" + '\n",
            "  '0.013*\"received\" + 0.012*\"vaccine\" + 0.012*\"patient\" + 0.012*\"time\" + '\n",
            "  '0.012*\"receive\" + 0.010*\"Oxford\"'),\n",
            " (5,\n",
            "  '0.028*\"company\" + 0.026*\"said\" + 0.020*\"vaccine\" + 0.018*\"rose\" + '\n",
            "  '0.016*\"AstraZeneca\" + 0.012*\"also\" + 0.011*\"drug\" + 0.011*\"first\" + '\n",
            "  '0.011*\"stock\" + 0.009*\"day\"'),\n",
            " (6,\n",
            "  '0.035*\"vaccine\" + 0.027*\"Pfizer\" + 0.016*\"said\" + 0.016*\"population\" + '\n",
            "  '0.013*\"week\" + 0.011*\"first\" + 0.011*\"efficacy\" + 0.010*\"last\" + '\n",
            "  '0.010*\"entire\" + 0.010*\"BioNTech\"'),\n",
            " (7,\n",
            "  '0.023*\"NASDAQ\" + 0.014*\"stock\" + 0.013*\"Inc\" + 0.010*\"company\" + '\n",
            "  '0.009*\"antibody\" + 0.007*\"Wednesday\" + 0.007*\"new\" + 0.007*\"In\" + '\n",
            "  '0.007*\"cocktail\" + 0.007*\"Stocks\"'),\n",
            " (8,\n",
            "  '0.017*\"London\" + 0.015*\"European\" + 0.012*\"despite\" + 0.010*\"end\" + '\n",
            "  '0.009*\"dollar\" + 0.009*\"stock\" + 0.009*\"trading\" + 0.008*\"due\" + '\n",
            "  '0.008*\"Wednesday\" + 0.008*\"continued\"'),\n",
            " (9,\n",
            "  '0.021*\"market\" + 0.018*\"year\" + 0.014*\"record\" + 0.012*\"stock\" + '\n",
            "  '0.011*\"index\" + 0.010*\"start\" + 0.010*\"New\" + 0.010*\"S\" + 0.010*\"P\" + '\n",
            "  '0.009*\"economic\"')]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "TToBSi1hGiKU"
      },
      "source": [
        "### spaCy preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "t1EyDG4R0S46",
        "outputId": "73659ee4-552e-44df-9005-ee61e89c3954"
      },
      "source": [
        "# Print the Keyword in the 10 topics\n",
        "pprint(spacy_lem_lda_model.print_topics())\n",
        "spacy_lem_doc_lda = spacy_lem_lda_model[corpus_spacy_lem]"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "[(0,\n",
            "  '0.019*\"Inc\" + 0.015*\"death\" + 0.013*\"antibody\" + 0.011*\"Wednesday\" + '\n",
            "  '0.010*\"cocktail\" + 0.009*\"In\" + 0.009*\"program\" + 0.009*\"said\" + '\n",
            "  '0.009*\"premarket\" + 0.008*\"Phase\"'),\n",
            " (1,\n",
            "  '0.025*\"vaccine\" + 0.020*\"higher\" + 0.018*\"NASDAQ\" + 0.018*\"AstraZeneca\" + '\n",
            "  '0.015*\"approval\" + 0.012*\"Oxford\" + 0.012*\"lower\" + 0.011*\"stock\" + '\n",
            "  '0.011*\"University\" + 0.011*\"company\"'),\n",
            " (2,\n",
            "  '0.000*\"Inc\" + 0.000*\"This\" + 0.000*\"vaccine\" + 0.000*\"I\" + 0.000*\"said\" + '\n",
            "  '0.000*\"new\" + 0.000*\"Stocks\" + 0.000*\"Grade\" + 0.000*\"announced\" + '\n",
            "  '0.000*\"premarket\"'),\n",
            " (3,\n",
            "  '0.019*\"vaccine\" + 0.016*\"doses\" + 0.015*\"PLC\" + 0.014*\"million\" + '\n",
            "  '0.014*\"patients\" + 0.012*\"UK\" + 0.011*\"first\" + 0.009*\"jab\" + '\n",
            "  '0.009*\"government\" + 0.009*\"people\"'),\n",
            " (4,\n",
            "  '0.022*\"US\" + 0.014*\"firm\" + 0.013*\"results\" + 0.009*\"Government\" + '\n",
            "  '0.009*\"treatment\" + 0.009*\"operating\" + 0.009*\"deal\" + 0.008*\"completed\" + '\n",
            "  '0.006*\"Atacand\" + 0.006*\"Elsewhere\"'),\n",
            " (5,\n",
            "  '0.028*\"vaccine\" + 0.022*\"said\" + 0.015*\"Pfizer\" + 0.013*\"cases\" + '\n",
            "  '0.013*\"first\" + 0.011*\"people\" + 0.011*\"second\" + 0.010*\"health\" + '\n",
            "  '0.010*\"November\" + 0.009*\"patients\"'),\n",
            " (6,\n",
            "  '0.014*\"UK\" + 0.010*\"FTSE\" + 0.010*\"year\" + 0.010*\"index\" + 0.010*\"New\" + '\n",
            "  '0.009*\"Wednesday\" + 0.009*\"record\" + 0.008*\"points\" + 0.007*\"coronavirus\" + '\n",
            "  '0.007*\"session\"'),\n",
            " (7,\n",
            "  '0.018*\"million\" + 0.013*\"rose\" + 0.010*\"vaccines\" + 0.009*\"gained\" + '\n",
            "  '0.008*\"said\" + 0.008*\"Tuesday\" + 0.007*\"reported\" + 0.007*\"Biden\" + '\n",
            "  '0.006*\"highest\" + 0.006*\"state\"'),\n",
            " (8,\n",
            "  '0.016*\"deal\" + 0.014*\"population\" + 0.007*\"Hadjikyriacos\" + 0.007*\"Pub\" + '\n",
            "  '0.007*\"rallied\" + 0.007*\"approve\" + 0.006*\"cover\" + 0.006*\"entire\" + '\n",
            "  '0.006*\"Parliament\" + 0.006*\"enough\"'),\n",
            " (9,\n",
            "  '0.013*\"stocks\" + 0.010*\"London\" + 0.009*\"dollar\" + 0.008*\"new\" + '\n",
            "  '0.008*\"European\" + 0.008*\"markets\" + 0.008*\"stimulus\" + 0.008*\"day\" + '\n",
            "  '0.007*\"index\" + 0.007*\"Wednesday\"')]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "rNPJ-opERxyr"
      },
      "source": [
        "### 7.4 Compute Model Perplexity and Coherence Score\n",
        "\n",
        "Model perplexity and topic coherence provide a convenient measure to judge how good a given topic model is."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "kENU9QyQIeeX"
      },
      "source": [
        "### NLTK preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iQwhFNl_obkk",
        "outputId": "944d1741-fc8f-413b-f996-9844d22c376d"
      },
      "source": [
        "# Compute Perplexity\n",
        "print('\\nPerplexity: ', nltk_stem_lda_model.log_perplexity(corpus_nltk_stem))  # a measure of how good the model is, the lower the better.\n",
        "\n",
        "# Compute Coherence Score\n",
        "nltk_stem_coherence_model_lda = CoherenceModel(model=nltk_stem_lda_model, texts=nltk_stemmed_articles, dictionary=id2word_nltk_stem, coherence='c_v')\n",
        "coherence_lda = nltk_stem_coherence_model_lda.get_coherence()\n",
        "print('\\nCoherence Score: ', coherence_lda)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "\n",
            "Perplexity:  -7.251362434417866\n",
            "\n",
            "Coherence Score:  0.41024711207836706\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "OPL8FmPuIixD"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "YfSEQ7j5tsHC",
        "outputId": "e58d0c9e-7226-4c04-a4ed-ad523d35c8c5"
      },
      "source": [
        "# Compute Perplexity\n",
        "print('\\nPerplexity: ', nltk_lem_lda_model.log_perplexity(corpus_nltk_lem))  # a measure of how good the model is, the lower the better.\n",
        "\n",
        "# Compute Coherence Score\n",
        "nltk_lem_coherence_model_lda = CoherenceModel(model=nltk_lem_lda_model, texts=nltk_lemmatised_articles, dictionary=id2word_nltk_lem, coherence='c_v')\n",
        "coherence_lda = nltk_lem_coherence_model_lda.get_coherence()\n",
        "print('\\nCoherence Score: ', coherence_lda)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "\n",
            "Perplexity:  -7.598879257642947\n",
            "\n",
            "Coherence Score:  0.4153665581845173\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "d_yaKT4LImTz"
      },
      "source": [
        "### spaCy preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "HHhEhIaE0Zeb",
        "outputId": "73702755-a864-4a4b-fff3-fd6d40d2cc27"
      },
      "source": [
        "# Compute Perplexity\n",
        "print('\\nPerplexity: ', spacy_lem_lda_model.log_perplexity(corpus_spacy_lem))  # a measure of how good the model is, the lower the better.\n",
        "\n",
        "# Compute Coherence Score\n",
        "spacy_lem_coherence_model_lda = CoherenceModel(model=spacy_lem_lda_model, texts=spacy_lemmatised_articles, dictionary=id2word_spacy_lem, coherence='c_v')\n",
        "coherence_lda = spacy_lem_coherence_model_lda.get_coherence()\n",
        "print('\\nCoherence Score: ', coherence_lda)"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "\n",
            "Perplexity:  -7.738811766758385\n",
            "\n",
            "Coherence Score:  0.40859644898360276\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "-vNYbZHKUFed"
      },
      "source": [
        "One approach to finding the optimal number of topics is to build many LDA models with different numbers of topics and pick the one that gives the highest coherence value."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "hmDEXftjSdSL"
      },
      "source": [
        "### 7.5 Visualise the topics and keywords\n",
        "\n",
        "\n",
        "pyLDAvis is a visualisation tool designed to help users interpret the topics in a topic model that has been fit to a corpus of text data. The package extracts information from a fitted LDA topic model to inform an interactive web-based visualisation. \n",
        "\n",
        "Each bubble on the left hand plot represents a topic, the larger the bubble the more important the topic, relative to the data.\n",
        "\n",
        "A good topic model will have fairly large, non-overlapping bubbles scattered throughout the chart instead of being clustered in one quadrant. A model with too many topics, will typically have many overlapping, smaller bubbles clustered in one region of the chart indicating the similarity between topics.\n",
        "\n",
        "Saliency is a measure of how much the term tells you about the topic.\n",
        "\n",
        "Relevance is a weighted average of the probability of the word given the topic and the word given the topic normalised by the probability of the topic."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "lOxclGChJL3b"
      },
      "source": [
        "### NLTK preprocessed stemmed articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 881
        },
        "id": "3B8wMOZdoq2k",
        "outputId": "280b88ec-4bd2-4179-9174-f57b88b78838"
      },
      "source": [
        "# Visualise the 10 topics \n",
        "pyLDAvis.enable_notebook()\n",
        "vis = gensimvis.prepare(nltk_stem_lda_model, corpus_nltk_stem, id2word_nltk_stem)\n",
        "vis"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "\n",
              "<link rel=\"stylesheet\" type=\"text/css\" href=\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v1.0.0.css\">\n",
              "\n",
              "\n",
              "<div id=\"ldavis_el12411397996949146407059212050\"></div>\n",
              "<script type=\"text/javascript\">\n",
              "\n",
              "var ldavis_el12411397996949146407059212050_data = {\"mdsDat\": {\"x\": [-0.23080185946642406, -0.08611299434305834, -0.12207918143902054, 0.016019325149728703, 0.07199666789347631, 0.05622108193121989, 0.20627424609085468, 0.001585921952571297, 0.03636137178497203, 0.05053542044568082], \"y\": [-0.1274005810778846, -0.03234378110666673, 0.13685512441707534, 0.1812246963908845, -0.09309771727517555, -0.15131229723122414, -0.013516518094729167, 0.10588884376485808, 0.016744795576697214, -0.023042565363835022], \"topics\": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10], \"cluster\": [1, 1, 1, 1, 1, 1, 1, 1, 1, 1], \"Freq\": [31.10731906588055, 21.246168514392636, 16.664699189790657, 8.854826568760396, 6.151440802950833, 5.10797649644762, 4.362619877355873, 4.2389570114071855, 2.261432182687659, 0.004560290326591762]}, \"tinfo\": {\"Term\": [\"vaccin\", \"UK\", \"nasdaq\", \"dose\", \"compani\", \"stock\", \"gain\", \"million\", \"said\", \"approv\", \"receiv\", \"week\", \"posit\", \"morn\", \"dollar\", \"rose\", \"pfizer\", \"ftse\", \"with\", \"price\", \"inc\", \"astrazeneca\", \"govern\", \"second\", \"share\", \"point\", \"In\", \"US\", \"case\", \"index\", \"around\", \"brexit\", \"session\", \"restrict\", \"eve\", \"well\", \"wall\", \"thursday\", \"britain\", \"despit\", \"london\", \"squar\", \"perform\", \"littl\", \"put\", \"bitcoin\", \"tomorrow\", \"pound\", \"remain\", \"place\", \"open\", \"chang\", \"recent\", \"IG\", \"chanc\", \"scenario\", \"sharp\", \"biggest\", \"unit\", \"digit\", \"ftse\", \"index\", \"point\", \"good\", \"currenc\", \"close\", \"drop\", \"start\", \"deal\", \"earli\", \"final\", \"trade\", \"investor\", \"UK\", \"wednesday\", \"year\", \"street\", \"market\", \"approv\", \"new\", \"higher\", \"P\", \"last\", \"S\", \"coronaviru\", \"tuesday\", \"gain\", \"vaccin\", \"case\", \"stock\", \"posit\", \"ad\", \"pass\", \"growth\", \"rate\", \"initi\", \"three\", \"analyst\", \"face\", \"buy\", \"hold\", \"fund\", \"grade\", \"grow\", \"activ\", \"interest\", \"analysi\", \"invest\", \"yesterday\", \"biotech\", \"show\", \"benefit\", \"therapeut\", \"next\", \"drive\", \"that\", \"relat\", \"defens\", \"retail\", \"hedg\", \"follow\", \"nasdaq\", \"announc\", \"emerg\", \"provid\", \"stock\", \"product\", \"report\", \"compani\", \"share\", \"averag\", \"made\", \"market\", \"stimulu\", \"also\", \"continu\", \"new\", \"vaccin\", \"wednesday\", \"said\", \"year\", \"trade\", \"state\", \"amid\", \"make\", \"parliament\", \"almost\", \"He\", \"shortli\", \"biden\", \"slow\", \"comment\", \"give\", \"race\", \"highest\", \"spread\", \"histor\", \"member\", \"run\", \"delay\", \"georgia\", \"chicago\", \"africa\", \"secretari\", \"legal\", \"there\", \"If\", \"hancock\", \"need\", \"toll\", \"democrat\", \"china\", \"accord\", \"death\", \"read\", \"million\", \"hospit\", \"earlier\", \"economi\", \"novemb\", \"europ\", \"vaccin\", \"countri\", \"case\", \"record\", \"american\", \"data\", \"rollout\", \"popul\", \"rose\", \"first\", \"tuesday\", \"develop\", \"coronaviru\", \"peopl\", \"govern\", \"said\", \"day\", \"one\", \"new\", \"also\", \"year\", \"greatest\", \"safeti\", \"window\", \"effort\", \"confirm\", \"food\", \"everi\", \"howev\", \"design\", \"recipi\", \"separ\", \"possibl\", \"schedul\", \"tougher\", \"shortest\", \"caus\", \"book\", \"agenc\", \"readi\", \"transfer\", \"crisi\", \"widen\", \"cours\", \"efficaci\", \"afford\", \"analys\", \"closer\", \"demonstr\", \"differ\", \"document\", \"pfizer\", \"receiv\", \"variant\", \"dose\", \"second\", \"frame\", \"test\", \"drug\", \"altern\", \"trial\", \"critic\", \"biontech\", \"author\", \"move\", \"week\", \"said\", \"vaccin\", \"compani\", \"administr\", \"time\", \"peopl\", \"patient\", \"report\", \"first\", \"protect\", \"health\", \"day\", \"two\", \"case\", \"astrazeneca\", \"new\", \"suggest\", \"firm\", \"fiscal\", \"combin\", \"atacand\", \"amc\", \"btig\", \"cnbc\", \"educ\", \"levi\", \"softwar\", \"tesla\", \"elsewher\", \"sentiment\", \"polici\", \"propos\", \"hypertens\", \"cheplapharm\", \"target\", \"respect\", \"down\", \"financ\", \"monetari\", \"right\", \"So\", \"beleagu\", \"beneficiari\", \"chain\", \"class\", \"contribut\", \"system\", \"complet\", \"releas\", \"dax\", \"purchas\", \"compani\", \"german\", \"manag\", \"rose\", \"gain\", \"strong\", \"said\", \"US\", \"share\", \"stock\", \"also\", \"drug\", \"back\", \"In\", \"UK\", \"rollout\", \"tier\", \"two\", \"ralli\", \"barrel\", \"dollar\", \"keator\", \"bank\", \"pressur\", \"weak\", \"trader\", \"upward\", \"natwest\", \"settl\", \"crude\", \"dip\", \"yield\", \"greenback\", \"anticip\", \"metal\", \"after\", \"mostli\", \"tri\", \"sell\", \"lowest\", \"largest\", \"less\", \"inventori\", \"appetit\", \"msci\", \"robust\", \"light\", \"ongo\", \"oil\", \"sterl\", \"price\", \"import\", \"per\", \"late\", \"gain\", \"demand\", \"rose\", \"stock\", \"higher\", \"day\", \"antibodi\", \"cocktail\", \"premarket\", \"futil\", \"mechan\", \"treat\", \"ventil\", \"To\", \"patent\", \"inc\", \"Of\", \"aminotransferas\", \"dermtech\", \"hepion\", \"went\", \"evid\", \"express\", \"regeneron\", \"amend\", \"arbaclofen\", \"candid\", \"clearpoint\", \"cohort\", \"hoth\", \"immutep\", \"lixt\", \"nash\", \"osmotica\", \"approxim\", \"oxygen\", \"phase\", \"treatment\", \"public\", \"studi\", \"nasdaq\", \"result\", \"for\", \"trial\", \"In\", \"dose\", \"lead\", \"plc\", \"clinic\", \"mean\", \"within\", \"creat\", \"interv\", \"ago\", \"resid\", \"refriger\", \"temperatur\", \"wrong\", \"when\", \"rest\", \"degre\", \"moderna\", \"fahrenheit\", \"handl\", \"entir\", \"V\", \"dosag\", \"fridg\", \"geographi\", \"greater\", \"importantli\", \"monero\", \"russia\", \"simpler\", \"sputnik\", \"wire\", \"suppli\", \"deploy\", \"consid\", \"order\", \"distribut\", \"believ\", \"push\", \"immun\", \"receiv\", \"dose\", \"popul\", \"week\", \"across\", \"vaccin\", \"astrazeneca\", \"million\", \"In\", \"pfizer\", \"approv\", \"first\", \"includ\", \"decemb\", \"pharmaceut\", \"univers\", \"peopl\", \"health\", \"last\", \"govern\", \"jab\", \"mass\", \"abil\", \"avail\", \"plc\", \"giant\", \"talk\", \"korea\", \"trust\", \"sent\", \"appli\", \"south\", \"today\", \"mani\", \"crown\", \"warwickshir\", \"behalf\", \"ouhospit\", \"unfair\", \"oversea\", \"vietnam\", \"lancashir\", \"grossli\", \"sussex\", \"cancel\", \"apart\", \"though\", \"nhsengland\", \"territori\", \"bought\", \"requir\", \"with\", \"nh\", \"produc\", \"UK\", \"administ\", \"inocul\", \"morn\", \"alreadi\", \"dose\", \"begun\", \"chief\", \"oxford\", \"six\", \"hit\", \"total\", \"medic\", \"vaccin\", \"govern\", \"monday\", \"rollout\", \"news\", \"ftse\", \"get\", \"crown\", \"warwickshir\", \"behalf\", \"oversea\", \"vietnam\", \"bought\", \"ouhospit\", \"nhsengland\", \"territori\", \"unfair\", \"lancashir\", \"grossli\", \"sussex\", \"cancel\", \"apart\", \"though\", \"depend\", \"copper\", \"taylor\", \"polymet\", \"anglo\", \"wimpey\", \"aal\", \"builder\", \"expos\", \"glencor\", \"ground\", \"miner\", \"platinum\", \"TW\", \"stock\", \"compani\", \"peak\", \"UK\", \"vaccin\", \"also\", \"flat\", \"higher\", \"market\", \"nasdaq\", \"share\", \"point\", \"year\", \"biotech\", \"next\", \"said\", \"buy\", \"valu\", \"price\", \"combin\", \"astrazeneca\", \"gain\", \"hold\", \"strong\", \"trade\", \"rate\", \"entain\", \"safe\", \"posit\", \"high\"], \"Freq\": [143.0, 57.0, 37.0, 39.0, 53.0, 74.0, 39.0, 44.0, 58.0, 46.0, 22.0, 30.0, 28.0, 16.0, 14.0, 29.0, 20.0, 37.0, 12.0, 17.0, 12.0, 36.0, 26.0, 19.0, 29.0, 33.0, 20.0, 21.0, 43.0, 41.0, 21.381279888216874, 19.938005899433115, 19.1119576292737, 15.106111940613767, 11.841267394410632, 10.296043821018891, 9.992689503855054, 9.82187677364348, 9.278350903675646, 14.215389380647556, 14.65666389374737, 8.194839530212011, 7.697297331987716, 7.507777931996924, 7.505896028817831, 7.501310374602517, 7.035243023100277, 6.701251116718835, 6.537680278679555, 6.537388137449091, 19.91015039362561, 9.53307494216854, 6.953905125921588, 5.875126440391455, 5.875126440391455, 5.875126440391455, 5.875126440391455, 5.8495965071921665, 5.823157404800932, 5.869151349642685, 32.8310266683158, 35.92415124132133, 28.82648052657995, 11.614647984356933, 10.441200772578055, 32.2089854349036, 6.8600276282353265, 26.688956981174435, 16.507074890265525, 15.193598929142226, 10.606849344731135, 37.461820877182525, 18.348811539479158, 39.113943100246885, 33.267754051318605, 42.05251918371966, 11.546191910270075, 34.67433895396802, 29.14859095280816, 33.24682004543284, 16.51076806907349, 14.159262308554881, 15.933866829213995, 14.151132435455706, 21.406935666869284, 16.527370679924733, 18.910568948433806, 29.205229111536987, 16.95437072305607, 17.878989370579667, 27.501541947501906, 17.88402412319954, 17.306227271761895, 14.88882434615286, 13.589342749059234, 15.14792552263408, 13.011359083761352, 11.944001163022396, 12.154036950850548, 10.860176433711116, 10.553190391843852, 10.17097712734729, 8.989865352812254, 9.489366147362572, 7.548678864777874, 7.380311338385798, 7.348497288812, 7.285045040269929, 7.3436852970553, 6.707311775709592, 6.53927709373047, 6.362449004414673, 6.330567421191869, 16.08706423278424, 5.353291056151988, 5.352948125544703, 5.321405964687679, 5.153120881971012, 5.153078783072931, 5.121416026414112, 13.029229188936375, 27.28453616086021, 11.049937216811369, 11.519457456505355, 13.271458354951244, 44.23089503534243, 13.93021840388173, 12.167493688210074, 22.158058619012234, 14.544401859167039, 10.243000448420547, 9.79503221336292, 18.286673771533316, 10.033294435294028, 14.02851406853868, 13.639407109481349, 16.291799944756068, 21.182828874361352, 13.937097188416095, 14.347955244815292, 13.074214492717088, 11.360998958249104, 13.843338708727613, 9.478897073842537, 8.989180729535683, 8.989109184469886, 7.7859777769119045, 7.269425153598311, 6.582708782688931, 6.09264778378627, 5.645302972797089, 5.379271244801342, 5.144491639825258, 4.892563576891204, 8.02983156641089, 4.345973376843165, 4.311420205763675, 4.176180425309533, 4.176035959311291, 4.175446056485137, 3.952116413769708, 3.6862081698057914, 3.4623226769637943, 3.435533865356479, 3.4569543892624592, 3.4332998018836673, 3.2388403130502246, 3.238824834550413, 3.4194603032187594, 6.116359469631034, 2.749045888310986, 2.749045200377661, 11.812196304646463, 12.388240026036053, 8.553685226102296, 28.08695004671727, 13.38586442349504, 5.169723658318187, 11.497499829276295, 6.994798042673835, 6.074791786403575, 44.24192771757908, 11.635339653732128, 18.92577910660803, 13.863119543553548, 7.28461540934678, 9.190154946956508, 9.547305163676683, 6.997593115773153, 11.364589735027135, 12.079627632991844, 9.97098403638721, 7.87106549814306, 9.982650009711902, 8.128717854274116, 8.324657087689552, 9.85775571456519, 8.690813039566795, 7.817668113459569, 8.989877605993868, 8.195728063591941, 8.19914571635035, 5.202648232070941, 4.833924337111032, 4.833924337111032, 4.442444793794448, 8.471942541142516, 3.84728441440943, 3.4246448427542147, 3.4232539822013557, 3.2519646617784073, 3.2519646617784073, 3.0562495637304483, 2.950103326541854, 6.908421546195669, 2.3451327196883365, 2.2343070866081707, 2.2343025174210718, 2.233111238960686, 4.305223332379775, 2.943033149192733, 2.0384529025049263, 2.0381226416614284, 2.0380085947514437, 2.0372385953415626, 5.95039643185121, 1.6699927410243576, 1.6699927410243576, 1.6699927410243576, 1.6699927410243576, 1.6699927410243576, 1.6699927410243576, 14.378886734754555, 14.67440859704282, 5.9458272447524605, 22.945355156456127, 11.941154503787997, 3.241027490003873, 5.792984646484584, 8.347863889498687, 2.924532145094929, 4.925366199145915, 3.856406339533373, 5.991621831065935, 7.5254855119271875, 8.223832026330747, 11.316053886252229, 17.031006686534308, 27.457638695682572, 14.102277651705435, 5.503401996354757, 6.616494354781732, 7.476968055637827, 7.420337916270896, 6.633766613084941, 7.986232103985973, 5.253434563906056, 5.898509474227748, 6.688977014636549, 5.399307872475953, 6.386431032405119, 5.685361282490705, 5.472452516157636, 3.5002558133990145, 6.615236107129075, 2.977645915613067, 2.6540387046660996, 2.552987838622174, 2.510253568891201, 2.510253568891201, 2.510253568891201, 2.510253568891201, 2.510253568891201, 2.510253568891201, 2.510253568891201, 2.5100130906995686, 2.5100130906995686, 2.4547419589613217, 2.2836017305619225, 2.0578264822194603, 2.057820387735195, 4.568876397054652, 1.9600453069838322, 1.761417050021897, 1.7614152724639864, 1.718251722497581, 1.5626696966799456, 1.2937217566446801, 1.2937217566446801, 1.2937217566446801, 1.2937217566446801, 1.2937217566446801, 1.2937217566446801, 4.697199826248653, 4.412507674893112, 3.1433310727213932, 2.925221415900373, 1.6947978616133632, 15.066483339286483, 4.014976401303618, 3.6198897777150147, 7.31611246297839, 8.448112635750324, 4.99016066913105, 10.041942668667874, 5.843793749467376, 6.215797006027718, 6.219903672675108, 4.772825773622246, 3.4697171145564627, 3.321898953819046, 3.2488189772472538, 3.62171609149983, 3.093969051351979, 2.6806898843579656, 2.5261010055387185, 6.708371015772471, 4.744002142398782, 12.422065935274919, 4.037020726087893, 4.014437435100934, 3.6097604643824424, 3.608431192053948, 3.5879050680779017, 3.4475548698445406, 3.447526614373091, 3.1837141336406884, 3.1836633159644245, 3.043533046512571, 3.043533046512571, 3.043379960898598, 3.0427511712279807, 2.9988331015410257, 2.6162928166712076, 2.6162928166712076, 2.6162928166712076, 2.616204465607496, 2.4544328245042455, 2.4540151074225913, 2.4530662296500303, 2.1902148566703685, 2.190002729772769, 2.0500434691817038, 2.0500434691817038, 2.049802243365746, 2.049802243365746, 5.672739667944883, 2.7751518247361493, 7.935614102033089, 2.740945202758769, 3.941245642683554, 3.4406757168551985, 9.30322784011461, 3.175514142791941, 5.407636291718343, 6.19223717499511, 3.98636203956639, 4.1146924867621255, 7.97023037371265, 6.2662525113400065, 5.021924668627983, 3.4772392087391637, 3.4772392087391637, 3.4772392087391637, 3.4772392087391637, 3.164537673910351, 3.164537673910351, 9.807601499391142, 2.545407595114607, 2.545407595114607, 2.545407595114607, 2.545407595114607, 2.545407595114607, 2.392195124058697, 2.392195124058697, 2.392195124058697, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.9262766158550853, 1.7729865248215264, 1.7729865248215264, 4.576638847151324, 4.045086794830896, 4.114244574081388, 5.04929336469138, 9.874064370647341, 3.632607390079201, 2.536217101612552, 3.096630818940022, 4.197732333892283, 3.0435391144135915, 2.3198086418864143, 2.2925294519225337, 4.675174741027551, 4.6747995670888445, 4.93284609199964, 3.8792890768777686, 3.0739082223072445, 2.944562457254348, 2.8389107463043275, 2.098890476489316, 1.826633363710802, 1.826633363710802, 1.8015325823256232, 1.6437666914643596, 1.8836923501332192, 4.151923988412657, 0.9810109045057763, 0.981005042412984, 3.3749842581918457, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 0.7088022196132404, 2.4172259134571554, 2.625793575395569, 2.3185451932703045, 4.0757412804112105, 2.9028917268934413, 1.5268814608458785, 1.5034036917188618, 1.8042188207272454, 5.320893186477623, 7.327747581213181, 3.1743487952466922, 6.048641033791107, 2.642465542284667, 16.674062543524435, 6.516265250479035, 7.025931346746151, 4.270267917703271, 4.008507100804146, 5.831069197323746, 4.567888993585161, 3.215391844209213, 2.949386872128475, 2.5827670392151214, 2.8943103229969167, 2.8430572582686837, 2.726370463865918, 2.6569872585399867, 2.6508569093820147, 3.8270145022527147, 2.4806401852120845, 2.148621460201124, 3.5157606705773476, 5.3319326709008985, 1.8011922477950661, 0.8484095234642768, 0.8484087766331253, 0.7158462472464248, 0.7152593779922068, 0.7150358420931812, 2.254770438838055, 1.9861924062358123, 1.9849009484671254, 0.38381419596710536, 0.383814079274738, 0.383814079274738, 0.383814079274738, 0.383814079274738, 0.3838140092593175, 0.3838140092593175, 0.3838140092593175, 0.3838140092593175, 0.38381398592084404, 0.38381398592084404, 0.38381398592084404, 0.38381398592084404, 0.3838139159054236, 0.3838139159054236, 0.3838138458900031, 2.3565118067267723, 4.409064455050203, 2.4312473867626, 1.1713715204552013, 7.874240384660313, 1.7683706990578585, 1.283722745097339, 2.859108447104569, 1.5295384844493702, 4.187124534195232, 0.9822372781754689, 0.993912022796998, 2.2645156518258562, 0.6993918299324067, 0.9151153616672403, 0.6180540291328104, 0.7959602251734894, 2.7303594242850844, 1.4029928935884168, 1.0358166253523309, 1.0756612808841097, 1.0625742785551424, 1.1288640384528408, 0.9398184823723458, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.0002058372195959218, 0.00020583823145452941, 0.00020583818439133834, 0.00020583818439133834, 0.0002058381373281473, 0.0002058381137965518, 0.0002058381137965518, 0.00020583809026495625, 0.00020583809026495625, 0.00020583806673336072, 0.00020583806673336072, 0.00020583801967016967, 0.00020583801967016967, 0.00020583797260697863, 0.00020595290091952715, 0.0002059462179463978, 0.0002059458414408694, 0.0002059176976526204, 0.00020589887237619967, 0.00020589047159659692, 0.00020589021274904613, 0.00020588821256342643, 0.00020588795371587564, 0.00020588602412504253, 0.0002058819060958255, 0.00020588077657924026, 0.00020587903524117132, 0.00020587750568746215, 0.00020587656442364112, 0.0002058759996653485, 0.00020587571728620217, 0.00020587244639442407, 0.00020587230520485093, 0.00020587044620880437, 0.00020587018736125358, 0.00020586948141338782, 0.00020586849308637571, 0.00020586799892286967, 0.00020586684587468892, 0.00020586479862587815, 0.00020586479862587815, 0.000205864657436305, 0.0002058630337562137, 0.00020586291609823608], \"Total\": [143.0, 57.0, 37.0, 39.0, 53.0, 74.0, 39.0, 44.0, 58.0, 46.0, 22.0, 30.0, 28.0, 16.0, 14.0, 29.0, 20.0, 37.0, 12.0, 17.0, 12.0, 36.0, 26.0, 19.0, 29.0, 33.0, 20.0, 21.0, 43.0, 41.0, 22.00512855511788, 20.5247443916489, 19.69893984121153, 15.693324481213285, 12.42799059001631, 10.888982760848926, 10.579475207406343, 10.408550099094056, 9.865312011049236, 15.18321470609316, 15.656530901705425, 8.78297657157915, 8.284647976113664, 8.095010851116815, 8.095496029995212, 8.096399045125278, 7.622504786619282, 7.2880376955747295, 7.124327886429998, 7.1243416445340495, 21.72064591697968, 10.409251091459671, 7.611611794814044, 6.46218078829802, 6.46218078829802, 6.46218078829802, 6.46218078829802, 6.436230523243544, 6.41023391767386, 6.462519361791788, 37.18932266085672, 41.64233913078026, 33.28977443652121, 13.05547188804355, 11.73928803127813, 38.1895134993034, 7.6310796527271245, 33.11774815097627, 19.695668575177947, 18.133132961646645, 12.293090125695505, 52.648649185433825, 23.494076489930173, 57.66317346987995, 47.7036499942953, 64.41052600273807, 13.647819385049923, 54.7478250450526, 46.31239262819158, 64.3448853235304, 23.862905889107562, 19.457277966528675, 23.781548404584925, 19.455363392566568, 42.66742320632765, 27.132135667779547, 39.35105225875355, 143.85973130918754, 43.62370687853475, 74.89795462153609, 28.1838212004176, 18.454652593833192, 17.877285922629625, 15.459362219923886, 14.159750651419294, 15.80340072798586, 13.582476131657439, 12.517353108130498, 12.793096474030904, 11.435797394055905, 11.123496077684502, 10.741308939582167, 9.560158912648845, 10.152252354251239, 8.119042418058681, 7.95077837971832, 7.918968468485045, 7.85534886469089, 7.945229979794927, 7.27804325741948, 7.109849015665309, 6.932832400554916, 6.900985194704573, 17.587272348873114, 5.92368036003307, 5.923618296795827, 5.891844395266136, 5.723596166374802, 5.723596860170477, 5.6917935309523084, 15.748494254385857, 37.66011248364437, 13.729805259884795, 14.6241365815133, 17.45182064691773, 74.89795462153609, 19.635651081594876, 19.31774671295466, 53.90773521660126, 29.389714519483483, 15.577455620137625, 14.502915209120404, 54.7478250450526, 15.696497083017421, 33.85034510207858, 35.226600882263625, 64.3448853235304, 143.85973130918754, 47.7036499942953, 58.83169995429468, 64.41052600273807, 52.648649185433825, 14.42920413976773, 10.063396769228914, 9.573632685328285, 9.57360382434471, 8.3702346865659, 7.853479935373906, 7.166872465699626, 6.67711185840413, 6.229549082970834, 5.963502687298689, 5.739330880357132, 5.51630770726164, 9.067064747324387, 4.929925096793395, 4.902654594198505, 4.760168338237736, 4.760144368195102, 4.760179834982083, 4.53635865369979, 4.270372777786401, 4.0465624046648845, 4.019582214228793, 4.046375582949067, 4.019988213918006, 3.822803151120024, 3.822802060242006, 4.054288871462744, 7.31427251598045, 3.333010995009776, 3.3330116270273464, 14.468435816333594, 15.416763919733407, 10.901013376373315, 44.15317797902052, 19.15039682183829, 6.618085616510752, 18.53860816562908, 10.072756848814057, 8.612875299094549, 143.85973130918754, 21.576998088777316, 43.62370687853475, 27.90130394454059, 11.858006306889049, 18.042194530939714, 20.027947809452616, 11.653519415581027, 29.985098293318533, 41.26795659015453, 27.132135667779547, 18.85267511333332, 42.66742320632765, 22.707483231554626, 26.224506554581396, 58.83169995429468, 34.26517581174234, 22.117363857783147, 64.3448853235304, 33.85034510207858, 64.41052600273807, 5.775011304670351, 5.406295823693769, 5.406295823693769, 5.015062475918049, 9.704599106145718, 4.419690264385381, 3.9973391947018686, 3.9970267022941024, 3.8242880682819504, 3.8242880682819504, 3.628677550480231, 3.5667907594503325, 8.522715156819666, 2.917452764826426, 2.806581885298068, 2.80658112728786, 2.806083871860186, 5.418564942559511, 3.7623709824024685, 2.610950544305619, 2.6108967872882918, 2.610878244239827, 2.6107806393638713, 7.972393657419695, 2.242278948149401, 2.242278948149401, 2.242278948149401, 2.242278948149401, 2.242278948149401, 2.242278948149401, 20.41196827560652, 22.238908264471902, 8.689563323580572, 39.012688042100834, 19.338751069971366, 4.633616965262632, 9.93748368407649, 15.9660459062702, 4.2159335512348575, 8.528777416561613, 6.150734511499703, 11.316596171499956, 15.649080294886494, 18.578105929451592, 30.657806292937135, 58.83169995429468, 143.85973130918754, 53.90773521660126, 11.128252810399651, 15.787423154668986, 22.707483231554626, 22.861481501316177, 19.31774671295466, 41.26795659015453, 13.0275281612481, 20.296326598954018, 34.26517581174234, 14.933404987093537, 43.62370687853475, 36.73000362216204, 64.3448853235304, 4.083596621365044, 7.889103723206695, 3.5611628446490378, 3.2376099160190317, 3.1360308395544205, 3.093342952140726, 3.093342952140726, 3.093342952140726, 3.093342952140726, 3.093342952140726, 3.093342952140726, 3.093342952140726, 3.0933150763147186, 3.0933150763147186, 3.038735503215212, 2.8670397650014263, 2.6408777027701467, 2.640877351979743, 5.901933294846647, 2.543540268977356, 2.344638600452325, 2.344638253836647, 2.344211638983266, 2.1457250538994916, 1.876806528964988, 1.876806528964988, 1.876806528964988, 1.876806528964988, 1.876806528964988, 1.876806528964988, 6.815922142181363, 7.100418471152677, 5.554988902442859, 5.165412447377153, 2.6547233993790282, 53.90773521660126, 9.36030434424525, 8.544139509089243, 29.985098293318533, 39.35105225875355, 15.566935882086755, 58.83169995429468, 21.349002797491742, 29.389714519483483, 74.89795462153609, 33.85034510207858, 15.9660459062702, 19.456722926699268, 20.410771188093097, 57.66317346987995, 20.027947809452616, 7.5454637031355585, 14.933404987093537, 7.306043073482705, 5.341275176651735, 14.150030622108343, 4.634279485057449, 4.612035879318031, 4.207735765597868, 4.207932718470436, 4.18533147411531, 4.045203900307224, 4.045208577941847, 3.7809344559552605, 3.7809464333492424, 3.6407767836146867, 3.6407767836146867, 3.6408087512583696, 3.6409136310410077, 3.5962103649768724, 3.214197340127627, 3.214197340127627, 3.214197340127627, 3.2143059014261297, 3.051642887524556, 3.0517047488846725, 3.0519524591258524, 2.787434227396647, 2.7874711364926994, 2.6472745328085154, 2.6472745328085154, 2.647326084394318, 2.647326084394318, 7.427998073969038, 3.68587876013902, 17.728936762801865, 3.9699969580565906, 7.059442777063111, 5.69819508157288, 39.35105225875355, 5.240932431885083, 29.985098293318533, 74.89795462153609, 23.862905889107562, 34.26517581174234, 8.562999517951264, 6.858593943215423, 5.613383508207777, 4.068960668094515, 4.068960668094515, 4.068960668094515, 4.068960668094515, 3.7559642768664827, 3.7559642768664827, 12.03590334794189, 3.136825097286414, 3.136825097286414, 3.136825097286414, 3.136825097286414, 3.136825097286414, 2.983749440553092, 2.983749440553092, 2.983749440553092, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.5176862380478835, 2.364619932427993, 2.364619932427993, 7.123305698659337, 6.405979864457648, 6.920230038262449, 9.36514158661122, 37.66011248364437, 9.508024818464868, 4.696421890758407, 8.528777416561613, 20.410771188093097, 39.012688042100834, 7.794179933689407, 8.69129239626763, 5.264895557929536, 5.265028611640699, 5.595907861992723, 4.469405613534741, 3.667689167446165, 3.5341332487999946, 3.5284106354753364, 2.6883643897773983, 2.4161335245003555, 2.4161335245003555, 2.3910743769341343, 2.2333268552087007, 2.97149043531151, 6.60884107843602, 1.5703661019913862, 1.5703674915636063, 5.608113994563582, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 1.2981178578935766, 4.44845643308962, 4.989142530635605, 4.511267482547851, 8.865336356279597, 6.581189676874877, 3.279970573378221, 3.284744816212644, 4.311940856657452, 22.238908264471902, 39.012688042100834, 11.653519415581027, 30.657806292937135, 9.040837741377251, 143.85973130918754, 36.73000362216204, 44.15317797902052, 20.410771188093097, 20.41196827560652, 46.31239262819158, 41.26795659015453, 15.945556842617922, 14.773519666805482, 11.056027681585915, 23.296512741947627, 22.707483231554626, 20.296326598954018, 23.781548404584925, 26.224506554581396, 4.43578224784062, 3.0893282729837264, 2.757282496257135, 4.880203721713506, 8.69129239626763, 3.0748943763394085, 1.4580505981813088, 1.4580508571255117, 1.32433453321934, 1.324684630042766, 1.32477409719508, 4.88465478079314, 4.790484502712598, 4.822486960782992, 0.9923034130458519, 0.9923034256684642, 0.9923034500347541, 0.9923034867481846, 0.9923034945691889, 0.9923034541361456, 0.9923034821451128, 0.9923035243997054, 0.9923035267423842, 0.9923035292320773, 0.9923035324161498, 0.99230353357005, 0.992303542119864, 0.9923034914417579, 0.992303492227175, 0.9923034821847881, 6.5077274369508284, 12.633043702330095, 6.926907352416379, 3.351004037165176, 57.66317346987995, 8.305316462338586, 5.309703094085607, 16.4697425295214, 7.526277523122305, 39.012688042100834, 4.487832823334655, 5.068335810978936, 21.60861204131953, 2.818599657686418, 6.904296058889461, 2.970722753946125, 5.674219943202751, 143.85973130918754, 26.224506554581396, 13.665834708162306, 20.027947809452616, 22.72316275342643, 37.18932266085672, 15.810099336917476, 0.9923034130458519, 0.9923034256684642, 0.9923034500347541, 0.9923034541361456, 0.9923034821451128, 0.9923034821847881, 0.9923034867481846, 0.9923034914417579, 0.992303492227175, 0.9923034945691889, 0.9923035243997054, 0.9923035267423842, 0.9923035292320773, 0.9923035324161498, 0.99230353357005, 0.992303542119864, 0.9923035541053598, 1.0646408049347917, 1.0646409149174496, 1.0646409514384247, 1.064640880148888, 1.0646408657676627, 1.064640889235397, 1.0646408748098577, 1.064640954934389, 1.0646409234119907, 1.064640927016362, 1.0646408840279005, 1.06464093452299, 1.0646409282080274, 74.89795462153609, 53.90773521660126, 11.299024554386358, 57.66317346987995, 143.85973130918754, 33.85034510207858, 14.169568611302022, 23.862905889107562, 54.7478250450526, 37.66011248364437, 29.389714519483483, 33.28977443652121, 64.41052600273807, 7.27804325741948, 17.587272348873114, 58.83169995429468, 11.435797394055905, 10.128197328724957, 17.728936762801865, 3.2376099160190317, 36.73000362216204, 39.35105225875355, 11.123496077684502, 15.566935882086755, 52.648649185433825, 14.159750651419294, 3.1995955422895666, 1.68301329786035, 28.1838212004176, 11.904034205814465], \"Category\": [\"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\"], \"logprob\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, -4.8596, -4.9295, -4.9718, -5.207, -5.4505, -5.5904, -5.6203, -5.6375, -5.6945, -5.2678, -5.2372, -5.8186, -5.8813, -5.9062, -5.9065, -5.9071, -5.9712, -6.0198, -6.0446, -6.0446, -4.9309, -5.6674, -5.9828, -6.1514, -6.1514, -6.1514, -6.1514, -6.1558, -6.1603, -6.1524, -4.4308, -4.3407, -4.5608, -5.4699, -5.5764, -4.4499, -5.9964, -4.6379, -5.1184, -5.2013, -5.5606, -4.2988, -5.0126, -4.2557, -4.4176, -4.1832, -5.4758, -4.3761, -4.5497, -4.4182, -5.1181, -5.2718, -5.1537, -5.2723, -4.8584, -5.1171, -4.9824, -4.5478, -5.0916, -5.0385, -4.2266, -4.657, -4.6898, -4.8403, -4.9316, -4.823, -4.975, -5.0606, -5.0432, -5.1558, -5.1844, -5.2213, -5.3448, -5.2907, -5.5195, -5.5421, -5.5464, -5.555, -5.547, -5.6377, -5.663, -5.6905, -5.6955, -4.7629, -5.8632, -5.8632, -5.8691, -5.9013, -5.9013, -5.9074, -4.9737, -4.2346, -5.1384, -5.0968, -4.9553, -3.7514, -4.9068, -5.0421, -4.4427, -4.8637, -5.2143, -5.259, -4.6347, -5.235, -4.8998, -4.9279, -4.7502, -4.4877, -4.9063, -4.8773, -4.9702, -5.1107, -4.6702, -5.0489, -5.102, -5.102, -5.2457, -5.3143, -5.4135, -5.4909, -5.5672, -5.6154, -5.6601, -5.7103, -5.2148, -5.8287, -5.8367, -5.8686, -5.8686, -5.8688, -5.9237, -5.9934, -6.056, -6.0638, -6.0576, -6.0645, -6.1228, -6.1228, -6.0685, -5.487, -6.2867, -6.2867, -4.8289, -4.7812, -5.1516, -3.9627, -4.7038, -5.6552, -4.8559, -5.3528, -5.4938, -3.5083, -4.8439, -4.3575, -4.6688, -5.3122, -5.0799, -5.0417, -5.3524, -4.8675, -4.8065, -4.9983, -5.2348, -4.9971, -5.2026, -5.1788, -5.0097, -5.1357, -5.2416, -5.1019, -5.1944, -5.194, -5.0165, -5.09, -5.09, -5.1745, -4.5289, -5.3183, -5.4347, -5.4351, -5.4864, -5.4864, -5.5485, -5.5838, -4.7329, -5.8133, -5.8617, -5.8617, -5.8623, -5.2058, -5.5862, -5.9535, -5.9536, -5.9537, -5.9541, -4.8822, -6.1528, -6.1528, -6.1528, -6.1528, -6.1528, -6.1528, -3.9999, -3.9796, -4.883, -3.5325, -4.1857, -5.4898, -4.909, -4.5437, -5.5925, -5.0713, -5.3159, -4.8753, -4.6474, -4.5586, -4.2394, -3.8306, -3.353, -4.0193, -4.9603, -4.7761, -4.6538, -4.6614, -4.7735, -4.5879, -5.0068, -4.891, -4.7652, -4.9794, -4.8115, -4.9278, -4.9659, -5.0485, -4.412, -5.2102, -5.3253, -5.3641, -5.381, -5.381, -5.381, -5.381, -5.381, -5.381, -5.381, -5.3811, -5.3811, -5.4034, -5.4756, -5.5797, -5.5797, -4.7821, -5.6284, -5.7353, -5.7353, -5.7601, -5.855, -6.0439, -6.0439, -6.0439, -6.0439, -6.0439, -6.0439, -4.7544, -4.8169, -5.1561, -5.228, -5.7738, -3.5889, -4.9114, -5.0149, -4.3113, -4.1674, -4.6939, -3.9946, -4.536, -4.4743, -4.4736, -4.7384, -5.0573, -5.1008, -5.1231, -5.0144, -5.1719, -5.3153, -5.3747, -4.2121, -4.5586, -3.596, -4.72, -4.7256, -4.8319, -4.8322, -4.8379, -4.8778, -4.8778, -4.9575, -4.9575, -5.0025, -5.0025, -5.0025, -5.0027, -5.0173, -5.1537, -5.1537, -5.1537, -5.1538, -5.2176, -5.2178, -5.2182, -5.3315, -5.3316, -5.3976, -5.3976, -5.3978, -5.3978, -4.3798, -5.0948, -4.0441, -5.1072, -4.744, -4.8798, -3.8851, -4.96, -4.4277, -4.2922, -4.7326, -4.7009, -3.8821, -4.1226, -4.344, -4.7115, -4.7115, -4.7115, -4.7115, -4.8058, -4.8058, -3.6746, -5.0235, -5.0235, -5.0235, -5.0235, -5.0235, -5.0856, -5.0856, -5.0856, -5.3022, -5.3022, -5.3022, -5.3022, -5.3022, -5.3022, -5.3022, -5.3022, -5.3022, -5.3022, -5.3851, -5.3851, -4.4368, -4.5603, -4.5433, -4.3385, -3.6679, -4.6678, -5.0271, -4.8275, -4.5232, -4.8447, -5.1163, -5.1281, -4.3867, -4.3868, -4.3331, -4.5734, -4.8061, -4.8491, -4.8856, -5.1876, -5.3265, -5.3265, -5.3404, -5.432, -5.2958, -4.5054, -5.9482, -5.9482, -4.7126, -6.2732, -6.2732, -6.2732, -6.2732, -6.2732, -6.2732, -6.2732, -6.2732, -6.2732, -6.2732, -6.2732, -5.0464, -4.9636, -5.0881, -4.524, -4.8633, -5.5058, -5.5213, -5.3389, -4.2574, -3.9373, -4.7739, -4.1292, -4.9573, -3.1152, -4.0547, -3.9794, -4.4773, -4.5406, -4.1658, -4.41, -4.7611, -4.8474, -4.9802, -4.8663, -4.8841, -4.926, -4.9518, -4.9541, -3.9586, -4.3922, -4.5359, -4.0434, -3.627, -4.7122, -5.4651, -5.4651, -5.635, -5.6358, -5.6361, -4.4876, -4.6145, -4.6151, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -6.2583, -4.4435, -3.817, -4.4123, -5.1425, -3.2371, -4.7306, -5.0509, -4.2502, -4.8757, -3.8687, -5.3186, -5.3068, -4.4833, -5.6582, -5.3894, -5.7819, -5.5289, -4.2963, -4.9621, -5.2655, -5.2278, -5.24, -5.1795, -5.3628, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5828, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5827, -7.5822, -7.5822, -7.5822, -7.5824, -7.5825, -7.5825, -7.5825, -7.5825, -7.5825, -7.5825, -7.5825, -7.5825, -7.5825, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826, -7.5826], \"loglift\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 1.139, 1.1387, 1.1375, 1.1296, 1.1194, 1.1117, 1.1107, 1.1097, 1.1064, 1.1019, 1.1017, 1.0984, 1.0942, 1.0924, 1.0921, 1.0914, 1.0876, 1.0838, 1.0818, 1.0817, 1.0807, 1.0798, 1.0774, 1.0725, 1.0725, 1.0725, 1.0725, 1.0722, 1.0717, 1.0714, 1.0431, 1.02, 1.0238, 1.0508, 1.0505, 0.9974, 1.0612, 0.9519, 0.9911, 0.9909, 1.0202, 0.8274, 0.9205, 0.7796, 0.8073, 0.7414, 1.0005, 0.711, 0.7047, 0.5074, 0.7994, 0.8499, 0.7673, 0.8494, 0.478, 0.672, 0.4349, -0.4268, 0.2227, -0.2648, 1.5245, 1.5176, 1.5165, 1.5114, 1.5079, 1.5066, 1.506, 1.5021, 1.4977, 1.4973, 1.4964, 1.4944, 1.4875, 1.4815, 1.4762, 1.4745, 1.4742, 1.4736, 1.4703, 1.4673, 1.4653, 1.4631, 1.4627, 1.4598, 1.4477, 1.4477, 1.4472, 1.444, 1.444, 1.4434, 1.3594, 1.2267, 1.3318, 1.3104, 1.2752, 1.0223, 1.2057, 1.0867, 0.6599, 0.8456, 1.1298, 1.1565, 0.4524, 1.1015, 0.6681, 0.6002, 0.1754, -0.3667, 0.3185, 0.1379, -0.0456, 0.0155, 1.7504, 1.732, 1.7289, 1.7289, 1.7195, 1.7146, 1.7069, 1.7003, 1.6934, 1.6888, 1.6825, 1.6719, 1.6704, 1.6658, 1.6634, 1.661, 1.661, 1.6608, 1.654, 1.6448, 1.6359, 1.6349, 1.6344, 1.6341, 1.6261, 1.6261, 1.6216, 1.613, 1.5993, 1.5993, 1.589, 1.5732, 1.5494, 1.3395, 1.4338, 1.5449, 1.3142, 1.4272, 1.4428, 0.6127, 1.1743, 0.9568, 1.0924, 1.3046, 1.1173, 1.051, 1.2818, 0.8217, 0.5633, 0.7908, 0.9184, 0.3393, 0.7646, 0.6444, 0.0055, 0.42, 0.7519, -0.1763, 0.3735, -0.2694, 2.3198, 2.3123, 2.3123, 2.303, 2.2884, 2.2855, 2.2696, 2.2692, 2.2621, 2.2621, 2.2525, 2.2344, 2.2142, 2.2058, 2.1962, 2.1962, 2.1958, 2.1942, 2.1786, 2.1767, 2.1765, 2.1765, 2.1762, 2.1317, 2.1295, 2.1295, 2.1295, 2.1295, 2.1295, 2.1295, 2.0738, 2.0085, 2.0448, 1.8934, 1.9421, 2.0668, 1.8845, 1.7757, 2.0585, 1.8752, 1.9574, 1.7883, 1.6921, 1.6093, 1.4275, 1.1846, 0.768, 1.0833, 1.7201, 1.5546, 1.3133, 1.299, 1.3554, 0.7818, 1.516, 1.1885, 0.7905, 1.4069, 0.5028, 0.5585, -0.0403, 2.6343, 2.6124, 2.6095, 2.5897, 2.5828, 2.5796, 2.5796, 2.5796, 2.5796, 2.5796, 2.5796, 2.5796, 2.5795, 2.5795, 2.5751, 2.561, 2.539, 2.539, 2.5325, 2.5279, 2.5025, 2.5025, 2.4778, 2.4714, 2.4164, 2.4164, 2.4164, 2.4164, 2.4164, 2.4164, 2.4162, 2.3128, 2.2191, 2.2199, 2.3397, 1.5137, 1.942, 1.9297, 1.3779, 1.2499, 1.6508, 1.0206, 1.4929, 1.2349, 0.3001, 0.8295, 1.2621, 1.0208, 0.9507, 0.0208, 0.9208, 1.7536, 1.0116, 2.889, 2.8558, 2.8441, 2.8364, 2.8356, 2.8211, 2.8207, 2.8203, 2.8145, 2.8145, 2.8024, 2.8024, 2.7952, 2.7952, 2.7951, 2.7949, 2.7927, 2.7685, 2.7685, 2.7685, 2.7685, 2.7566, 2.7564, 2.7559, 2.7332, 2.7331, 2.7187, 2.7187, 2.7186, 2.7186, 2.7048, 2.6906, 2.1705, 2.6039, 2.3915, 2.4699, 1.5322, 2.4733, 1.2615, 0.4815, 1.1849, 0.8548, 3.0604, 3.0418, 3.0208, 2.9749, 2.9749, 2.9749, 2.9749, 2.9608, 2.9608, 2.9274, 2.9232, 2.9232, 2.9232, 2.9232, 2.9232, 2.9111, 2.9111, 2.9111, 2.8643, 2.8643, 2.8643, 2.8643, 2.8643, 2.8643, 2.8643, 2.8643, 2.8643, 2.8643, 2.8441, 2.8441, 2.6897, 2.6724, 2.6121, 2.5144, 1.7934, 2.1699, 2.516, 2.119, 1.5506, 0.5812, 1.9202, 1.7994, 3.0421, 3.042, 3.0347, 3.0192, 2.9842, 2.9783, 2.9434, 2.9133, 2.8812, 2.8812, 2.8777, 2.8544, 2.705, 2.696, 2.6904, 2.6904, 2.653, 2.5558, 2.5558, 2.5558, 2.5558, 2.5558, 2.5558, 2.5558, 2.5558, 2.5558, 2.5558, 2.5558, 2.5509, 2.519, 2.4952, 2.3838, 2.3423, 2.3962, 2.3793, 2.2896, 1.7307, 1.4886, 1.8603, 1.5378, 1.9308, 1.0059, 1.4316, 1.3228, 1.5965, 1.5332, 1.0886, 0.9598, 1.5596, 1.5496, 1.7067, 1.0753, 1.083, 1.1534, 0.9691, 0.869, 3.6416, 3.5697, 3.5398, 3.4612, 3.3006, 3.2544, 3.2477, 3.2477, 3.174, 3.1729, 3.1725, 3.0161, 2.9088, 2.9015, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.8393, 2.7734, 2.7365, 2.7422, 2.7381, 1.7981, 2.2423, 2.3694, 2.0382, 2.1957, 1.5573, 2.2699, 2.1601, 1.5334, 2.3954, 1.7683, 2.2192, 1.825, -0.1752, 0.8611, 1.2095, 0.865, 0.7265, 0.2944, 0.9665, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.5148, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, 1.4445, -2.8085, -2.4796, -0.9171, -2.5471, -3.4614, -2.0146, -1.1437, -1.665, -2.4954, -2.1213, -1.8733, -1.9979, -2.658, -0.4776, -1.3599, -2.5674, -0.9294, -0.808, -1.3679, 0.3324, -2.0963, -2.1653, -0.9018, -1.2379, -2.4564, -1.1432, 0.3442, 0.9867, -1.8315, -0.9696]}, \"token.table\": {\"Topic\": [3, 1, 3, 1, 2, 5, 7, 8, 7, 1, 2, 3, 1, 2, 3, 5, 7, 1, 2, 5, 9, 1, 2, 5, 8, 9, 1, 3, 1, 2, 4, 6, 8, 2, 2, 2, 4, 9, 1, 4, 4, 3, 6, 4, 8, 8, 3, 2, 3, 9, 1, 2, 3, 5, 6, 8, 4, 8, 5, 7, 1, 3, 6, 3, 7, 4, 2, 2, 2, 3, 6, 7, 6, 6, 9, 1, 2, 3, 5, 8, 9, 7, 7, 1, 1, 2, 3, 4, 5, 6, 8, 5, 2, 3, 4, 4, 9, 2, 3, 1, 3, 5, 8, 6, 6, 3, 9, 5, 4, 8, 5, 2, 3, 1, 2, 3, 4, 8, 2, 1, 4, 1, 1, 5, 2, 7, 1, 2, 3, 4, 4, 5, 1, 1, 5, 3, 3, 9, 3, 5, 7, 8, 1, 2, 4, 5, 7, 7, 5, 3, 2, 3, 4, 5, 6, 5, 7, 4, 6, 2, 8, 1, 2, 3, 5, 5, 1, 2, 3, 4, 6, 8, 1, 3, 5, 4, 8, 4, 2, 4, 6, 1, 3, 2, 3, 4, 1, 5, 1, 2, 3, 4, 6, 1, 2, 5, 2, 3, 1, 8, 2, 3, 8, 3, 5, 6, 3, 4, 1, 8, 7, 4, 1, 1, 2, 3, 8, 4, 1, 6, 2, 8, 4, 2, 6, 8, 2, 4, 7, 8, 9, 5, 2, 1, 2, 4, 5, 6, 1, 2, 1, 3, 1, 3, 6, 5, 4, 7, 4, 5, 2, 4, 4, 5, 4, 8, 1, 3, 5, 1, 4, 7, 7, 2, 8, 1, 2, 5, 5, 9, 1, 2, 3, 4, 5, 6, 8, 5, 2, 3, 2, 3, 4, 6, 7, 2, 4, 8, 1, 5, 6, 9, 2, 7, 1, 2, 5, 6, 8, 3, 3, 4, 5, 1, 2, 3, 5, 9, 6, 9, 3, 1, 2, 1, 3, 8, 9, 2, 8, 4, 6, 2, 2, 3, 8, 2, 3, 4, 5, 8, 2, 7, 1, 2, 7, 1, 2, 6, 1, 3, 3, 2, 9, 2, 2, 3, 4, 9, 7, 4, 5, 4, 8, 7, 2, 6, 8, 2, 7, 1, 2, 3, 6, 8, 1, 3, 6, 2, 3, 6, 9, 2, 8, 6, 2, 1, 2, 3, 6, 9, 6, 9, 6, 1, 4, 8, 2, 6, 1, 7, 3, 6, 5, 6, 1, 7, 1, 6, 2, 4, 6, 3, 2, 3, 5, 6, 4, 9, 1, 2, 3, 9, 8, 7, 2, 3, 9, 3, 6, 1, 2, 3, 4, 8, 1, 8, 3, 4, 5, 6, 8, 9, 8, 5, 1, 3, 9, 6, 1, 2, 4, 6, 2, 7, 7, 6, 3, 1, 2, 3, 4, 1, 2, 3, 9, 2, 8, 4, 8, 9, 3, 4, 1, 6, 1, 2, 3, 4, 6, 1, 3, 9, 1, 4, 8, 7, 1, 2, 3, 4, 8, 9, 7, 3, 2, 7, 1, 2, 3, 4, 7, 1, 2, 1, 3, 4, 8, 2, 5, 6, 1, 1, 4, 8, 1, 2, 5, 8, 4, 7, 1, 5, 7, 9, 1, 5, 6, 5, 1, 3, 8, 2, 4, 1, 7, 6, 1, 2, 6, 4, 5, 9, 1, 2, 3, 4, 8, 5, 2, 4, 2, 4, 9, 1, 2, 7, 5, 4, 8, 1, 3, 6, 2, 3, 4, 4, 2, 4, 8, 1, 4, 1, 3, 8, 7, 2, 1, 5, 1, 2, 4, 3, 9, 8, 5, 8, 1, 3, 5, 7, 2, 5, 6, 1, 3, 5, 9, 1, 3, 5, 6, 3, 8, 7, 4, 1, 2, 3, 4, 5, 8, 1, 3, 4, 2, 4, 3, 6, 9, 5, 4, 1, 6, 1, 2, 5, 1, 4, 3, 2, 8, 4, 8, 9, 3, 5, 5, 9, 3, 8, 1, 1, 2, 8, 3, 6, 1, 2, 1, 2, 5, 6, 1, 2, 2, 5, 6, 4, 7, 5, 4, 5, 8, 3, 5, 9, 2, 5, 8, 5, 4, 6, 7, 2, 2, 3, 2, 1, 1, 3, 5, 1, 2, 4, 4, 9, 1, 3, 1, 3, 8, 9, 4, 1, 2, 5, 6, 6, 4, 7, 5, 7, 6, 4, 7, 9, 1, 3, 1, 2, 4, 5, 1, 1, 2, 3, 4, 8, 6, 1, 2, 3, 4, 6, 8, 9, 1, 2, 5, 1, 4, 7, 1, 6, 1, 2, 1, 2, 3, 4, 8, 1, 7, 8, 4, 4, 8, 2, 9, 8, 8, 1, 2, 3, 5, 2, 6], \"Freq\": [0.8913246175711695, 0.928479130584685, 0.7847644467701783, 0.14698121753234347, 0.29396243506468694, 0.14698121753234347, 0.1959749567097913, 0.1959749567097913, 0.9563810244298359, 0.71952510644518, 0.20557860184148, 0.05139465046037, 0.7195959138624503, 0.20559883253212866, 0.051399708133032164, 0.5328199708211134, 0.7987296414072482, 0.6763415478749438, 0.12139463679806684, 0.06936836388460962, 0.13873672776921925, 0.6557683341371259, 0.04684059529550899, 0.28104357177305395, 0.7703460775300287, 0.7253518646402369, 0.13823194334125433, 0.8293916600475258, 0.11060921881423605, 0.2212184376284721, 0.2212184376284721, 0.11060921881423605, 0.3318276564427082, 0.9853378746003466, 0.9753637955782967, 0.36121441170891505, 0.36121441170891505, 0.24080960780594338, 0.4493068305679905, 0.5391681966815886, 0.891949684338178, 0.7413700074269446, 0.9333589952759025, 0.7382028345886285, 0.1845507086471571, 0.848864428362638, 0.9557677053953911, 0.5314712336491925, 0.13286780841229812, 0.26573561682459623, 0.08862538892744656, 0.413585148328084, 0.23633437047319086, 0.14770898154574427, 0.029541796309148858, 0.059083592618297716, 0.7115861679369431, 0.23719538931231435, 0.9698245705099952, 0.7943801613463648, 0.33732483323745177, 0.5903184581655406, 0.08433120830936294, 0.8943302352461658, 0.9563810244298359, 0.891949684338178, 0.8839535133720705, 0.9586691288756201, 0.8011766949192912, 0.07283424499266283, 0.07283424499266283, 0.9342520670740427, 0.8239690099823219, 0.7174962186394063, 0.7548456767967321, 0.6261822884604527, 0.1727399416442628, 0.0431849854110657, 0.02159249270553285, 0.1295549562331971, 0.02159249270553285, 0.8458018866255598, 0.7943801613463648, 0.9543229864528961, 0.21780558701532457, 0.21780558701532457, 0.13612849188457785, 0.16335419026149342, 0.05445139675383114, 0.02722569837691557, 0.190579888638409, 0.9566232455884431, 0.25560607554087655, 0.25560607554087655, 0.5112121510817531, 0.2049094785839978, 0.8196379143359912, 0.6419533615664796, 0.3209766807832398, 0.7195456322600277, 0.051396116590001976, 0.15418834977000592, 0.051396116590001976, 0.8672959414599065, 0.9361060485811427, 0.6684740983223323, 0.22282469944077743, 0.5328199708211134, 0.3048807840279022, 0.6097615680558044, 0.5328199708211134, 0.8654471438714932, 0.898592104975464, 0.9322226695162396, 0.17673158692689397, 0.17673158692689397, 0.530194760780682, 0.08836579346344699, 0.9617969765244204, 0.9880935901765714, 0.7127370710677213, 0.9744335723926284, 0.9122874157370716, 0.9698245705099952, 0.9618918227527865, 0.7943801613463648, 0.38969636503689536, 0.02292331559040561, 0.4355429962177066, 0.13753989354243365, 0.7126107920253495, 0.5328199708211134, 0.928479130584685, 0.9606839062806888, 0.7573240758419519, 0.9366863756736123, 0.7892136885119715, 0.19730342212799287, 0.9000868690865164, 0.5328199708211134, 0.7943801613463648, 0.9496864553123808, 0.8379263590405177, 0.1309259936000809, 0.891949684338178, 0.9698245705099952, 0.8748148745465897, 0.7943801613463648, 0.9266094674212028, 0.8384334278324723, 0.4081046979919303, 0.018550213545087738, 0.25970298963122834, 0.2782532031763161, 0.018550213545087738, 0.5633470782392693, 0.28167353911963466, 0.8243514144684008, 0.1030439268085501, 0.4433343861203393, 0.4433343861203393, 0.3406516581065284, 0.39742693445761645, 0.19871346722880823, 0.05677527635108807, 0.5328199708211134, 0.49217877298213936, 0.09374833771088369, 0.23437084427720922, 0.09374833771088369, 0.02343708442772092, 0.02343708442772092, 0.37076519945381003, 0.5561477991807151, 0.046345649931726254, 0.7660544014480317, 0.8949735928837526, 0.7660203228781111, 0.3251644167474154, 0.6503288334948308, 0.7934521297469259, 0.8518404159908185, 0.08518404159908186, 0.33255378051217005, 0.49883067076825505, 0.16627689025608502, 0.387190765572949, 0.5807861483594235, 0.29184149105031293, 0.11673659642012517, 0.2626573419452816, 0.20428904373521903, 0.11673659642012517, 0.8631339390745413, 0.0507725846514436, 0.1015451693028872, 0.19459336703988894, 0.7783734681595558, 0.7445754463451132, 0.20306603082139452, 0.8735766561194845, 0.3365314550962595, 0.673062910192519, 0.8403043873688136, 0.38161148345135804, 0.5724172251770371, 0.900087039764236, 0.891949684338178, 0.4008704878080933, 0.60130573171214, 0.9563810244298359, 0.7844597337950383, 0.922070870431785, 0.21217148102080483, 0.3182572215312073, 0.42434296204160965, 0.053042870255201206, 0.891949684338178, 0.9284304872606911, 0.8239999808561452, 0.45584463406995596, 0.45584463406995596, 0.891949684338178, 0.07067122515180825, 0.848054701821699, 0.7703460775300287, 0.02563268644603116, 0.5895517882587167, 0.07689805933809349, 0.17942880512221812, 0.10253074578412465, 0.8530099263972547, 0.8440698511916478, 0.9173013935843802, 0.1252658304843379, 0.5010633219373516, 0.18789874572650686, 0.1252658304843379, 0.827215023003828, 0.1102953364005104, 0.1511010974994351, 0.7555054874971754, 0.26970741035835105, 0.5933563027883724, 0.10788296414334043, 0.9698245705099952, 0.7525970565209057, 0.2508656855069685, 0.797597242149564, 0.969833310214913, 0.8205612641206778, 0.20514031603016944, 0.3125395028161653, 0.6250790056323307, 0.3566261316975312, 0.5349391975462968, 0.11610524537666621, 0.6966314722599972, 0.11610524537666621, 0.9655623661028416, 0.7504992330839083, 0.6702975701703906, 0.6702975701703906, 0.938005902195701, 0.6367941836823253, 0.8948116289335066, 0.08134651172122787, 0.8530100525005516, 0.8872997802537067, 0.12675711146481525, 0.21808688250261385, 0.09692750333449504, 0.2907825100034851, 0.19385500666899008, 0.04846375166724752, 0.02423187583362376, 0.1211593791681188, 0.842421459189311, 0.4940164511724524, 0.4940164511724524, 0.825475743268572, 0.1269962681951649, 0.9050407971419814, 0.42585611908836146, 0.6387841786325422, 0.2158141269545616, 0.6474423808636848, 0.7703460775300287, 0.8873514664663105, 0.053778876755533965, 0.026889438377766983, 0.026889438377766983, 0.930985232456129, 0.7372890142496493, 0.4828333401370098, 0.050824562119685245, 0.20329824847874098, 0.2287105295385836, 0.7703460775300287, 0.8817644955690742, 0.10683413308188036, 0.42733653232752145, 0.42733653232752145, 0.06325070947941126, 0.31625354739705636, 0.44275496635587885, 0.06325070947941126, 0.06325070947941126, 0.32521442287408814, 0.6504288457481763, 0.8711816942132588, 0.9191548266432122, 0.07659623555360101, 0.49571952757024945, 0.3050581708124612, 0.11439681405467296, 0.03813227135155765, 0.9414069454527884, 0.7703460775300287, 0.8657991709828193, 0.8239927458323958, 0.8865027863724512, 0.9702858233484002, 0.7847646707112224, 0.6367936202017946, 0.1970799977275761, 0.34488999602325815, 0.2956199965913641, 0.04926999943189402, 0.14780999829568206, 0.8784577256377459, 0.9563810244298359, 0.42002567478828107, 0.42002567478828107, 0.08400513495765621, 0.7124027592867389, 0.12571813399177748, 0.16762417865570328, 0.11028927529111242, 0.8823142023288993, 0.8158845219757782, 0.7241867899859783, 0.14483735799719566, 0.9888977281223432, 0.10443647818928149, 0.6788371082303297, 0.15665471728392225, 0.052218239094640746, 0.7943801613463648, 0.7505579080265197, 0.757323975245844, 0.4638282542563369, 0.4638282542563369, 0.7943801613463648, 0.25188936177158283, 0.7556680853147486, 0.7703460775300287, 0.1661694965622996, 0.830847482811498, 0.25085357880441916, 0.4389937629077335, 0.06271339470110479, 0.06271339470110479, 0.18814018410331437, 0.8645047504881953, 0.09605608338757726, 0.024014020846894316, 0.9491627946532333, 0.5650033432832905, 0.18833444776109684, 0.18833444776109684, 0.8804169435606878, 0.8179537204590647, 0.7175057191817296, 0.8911125553524926, 0.766150565982664, 0.08512784066474044, 0.08512784066474044, 0.04256392033237022, 0.9017575202090313, 0.8631330960718728, 0.6858471329124003, 0.655371395522766, 0.6727905066482259, 0.2102470333275706, 0.12614821999654235, 0.3509883342653017, 0.5264825013979525, 0.6415043073855788, 0.25660172295423156, 0.7414042365819016, 0.6553182026212967, 0.9698245705099952, 0.7554792784273042, 0.9882630359780548, 0.7943801613463648, 0.9580666428708092, 0.6553846808799991, 0.6895165458673668, 0.20685496376021, 0.06895165458673667, 0.940082024850673, 0.11703928744798718, 0.11703928744798718, 0.4681571497919487, 0.23407857489597436, 0.4147237755673007, 0.4147237755673007, 0.6392948025094715, 0.3287801841477282, 0.0182655657859849, 0.6473899253407491, 0.9496624555743658, 0.7372890142496493, 0.35247135641892685, 0.35247135641892685, 0.17623567820946343, 0.8403064168694593, 0.8342114880755296, 0.11324213179798204, 0.022648426359596407, 0.6341559380686994, 0.06794527907878922, 0.15853898451717485, 0.302624919598354, 0.605249839196708, 0.43905111748617376, 0.14635037249539126, 0.14635037249539126, 0.07317518624769563, 0.07317518624769563, 0.07317518624769563, 0.7703460775300287, 0.8531652888079005, 0.7286088400283396, 0.06071740333569497, 0.1821522100070849, 0.9333589952759025, 0.37678760292258884, 0.16148040125253807, 0.43061440334010154, 0.7554939902202675, 0.7169389101460063, 0.265532929683706, 0.7943801613463648, 0.741618124800468, 0.7399571404781603, 0.5128612761383252, 0.2486600126731274, 0.13987125712863416, 0.07770625396035231, 0.5280955001825403, 0.22003979174272512, 0.1760318333941801, 0.044007958348545026, 0.9097488048523444, 0.05685930030327153, 0.4330937094103737, 0.14436456980345788, 0.28872913960691576, 0.694943807843844, 0.2978330605045046, 0.13462577534913997, 0.8077546520948398, 0.22606672441392645, 0.22606672441392645, 0.36170675906228233, 0.18085337953114117, 0.7554792784273042, 0.9207829305096954, 0.04603914652548477, 0.04603914652548477, 0.4511955146706503, 0.11279887866766257, 0.4511955146706503, 0.7943801613463648, 0.3239449154168138, 0.13883353517863448, 0.18511138023817933, 0.18511138023817933, 0.04627784505954483, 0.09255569011908966, 0.8458018866255598, 0.9400848588609764, 0.9509273428625354, 0.7987296414072482, 0.13122509141970018, 0.17496678855960024, 0.26245018283940036, 0.3061918799793004, 0.04374169713990006, 0.7965289354563035, 0.08850321505070038, 0.1761533834115771, 0.3523067668231542, 0.3082684209702599, 0.13211503755868284, 0.2833084796009984, 0.1416542398004992, 0.5666169592019968, 0.965641512236324, 0.09798173174657122, 0.6858721222259986, 0.19596346349314245, 0.09044839871968885, 0.45224199359844425, 0.1808967974393777, 0.27134519615906655, 0.28076852020774795, 0.7019213005193699, 0.9825469284408269, 0.11505768698213835, 0.2301153739642767, 0.5752884349106917, 0.8711383747973062, 0.060078508606710775, 0.060078508606710775, 0.6581685039332474, 0.08581098673615944, 0.6006769071531161, 0.25743296020847833, 0.9934777758093755, 0.8410922317356012, 0.9604780178689766, 0.8907283802521421, 0.9506300354465458, 0.16921488525439823, 0.33842977050879647, 0.4512396940117286, 0.29841802304898524, 0.29841802304898524, 0.29841802304898524, 0.05092777396810295, 0.7129888355534413, 0.05092777396810295, 0.1018555479362059, 0.1018555479362059, 0.6975836276895884, 0.5373237281361107, 0.38380266295436477, 0.7449079533312765, 0.17190183538414072, 0.057300611794713574, 0.14450386684704528, 0.14450386684704528, 0.5780154673881811, 0.7533741558415555, 0.3044376522231684, 0.6088753044463368, 0.988203807445352, 0.9064033888860161, 0.9581109678105391, 0.9887179756655332, 0.8256113160549329, 0.18346918134554063, 0.7973695348044453, 0.08993247223359115, 0.6744935417519335, 0.22483118058397786, 0.9196475317841685, 0.7844597337950383, 0.5017686638526928, 0.5017686638526928, 0.743946768378971, 0.6702975701703906, 0.8486306943233772, 0.3600367228673456, 0.5400550843010185, 0.9825488258805704, 0.6211904617194659, 0.36236110266968846, 0.614653892430717, 0.3073269462153585, 0.8502411736994012, 0.7863056167788177, 0.8955249856667771, 0.9558204202020245, 0.5258715764277193, 0.10517431528554386, 0.4206972611421754, 0.8735765502273819, 0.9320858683014112, 0.7554939902202675, 0.2995813678507876, 0.4993022797513127, 0.1497906839253938, 0.04993022797513127, 0.20009939408259195, 0.36684888915141856, 0.23344929309635726, 0.1667494950688266, 0.8403106482916767, 0.7703460775300287, 0.594172370040879, 0.9248476522662473, 0.08498819520572094, 0.23796694657601863, 0.16997639041144189, 0.2889598636994512, 0.16997639041144189, 0.05099291712343257, 0.928479130584685, 0.11733350013461669, 0.8213345009423169, 0.3619675321675447, 0.6205157694300767, 0.7463462220975091, 0.9333274716227083, 0.7548966579069587, 0.969833310214913, 0.8267474743251768, 0.9645189108223327, 0.7934546432760216, 0.2722040731187272, 0.5103826370976134, 0.2041530548390454, 0.928479130584685, 0.7126105995612501, 0.9767161385250999, 0.9845497400263669, 0.7703460775300287, 0.35478610709150044, 0.35478610709150044, 0.35478610709150044, 0.9631515732658191, 0.9698245705099952, 0.40944551657246336, 0.40944551657246336, 0.8113713538166629, 0.7703460775300287, 0.9108529363367784, 0.8152728222013511, 0.15097644855580578, 0.03019528971116115, 0.9702544828106757, 0.8139171674455319, 0.3185424094022654, 0.6370848188045308, 0.2403269901154857, 0.587465975837854, 0.0801089967051619, 0.0801089967051619, 0.8792613428885955, 0.14654355714809925, 0.6423871772676368, 0.3211935886338184, 0.06423871772676368, 0.42711580631290824, 0.5338947578911353, 0.9795286779973141, 0.22479707625358542, 0.22479707625358542, 0.44959415250717083, 0.29343058184639437, 0.7335764546159859, 0.6858472547162248, 0.16943600512617848, 0.8471800256308925, 0.8277688214328263, 0.9698245705099952, 0.603774576215326, 0.20125819207177537, 0.20125819207177537, 0.8440786947235567, 0.8694410769934794, 0.7462708446789467, 0.9571156152964018, 0.9607486061743014, 0.5301198385379255, 0.1325299596344814, 0.39758987890344416, 0.3800493558206524, 0.1900246779103262, 0.44339091512409445, 0.4174943054022001, 0.4174943054022001, 0.13671899670338628, 0.8203139802203177, 0.9183333032847627, 0.3366184201038827, 0.3366184201038827, 0.3366184201038827, 0.685529522229982, 0.7027720667567802, 0.20893223606282654, 0.018993839642075138, 0.037987679284150276, 0.9557188062017273, 0.7660045512397474, 0.7372890142496493, 0.3122082869939409, 0.6244165739878818, 0.9333589952759025, 0.586250497086575, 0.3517502982519449, 0.7550962199627073, 0.6265632830440307, 0.368566637084724, 0.1339279288098418, 0.2678558576196836, 0.33481982202460453, 0.20089189321476272, 0.9360032842884577, 0.5150985528573484, 0.042924879404779036, 0.1287746382143371, 0.17169951761911614, 0.1287746382143371, 0.7416189823638202, 0.20158525068889746, 0.14597552636092576, 0.3058534838038444, 0.18768281960690453, 0.013902431081992928, 0.11817066419693989, 0.020853646622989393, 0.6911397727359675, 0.09873425324799537, 0.19746850649599074, 0.23016116294045158, 0.6904834888213548, 0.7372890142496493, 0.9452264695510916, 0.9505855410763273, 0.6917709651975551, 0.29347859129593246, 0.1957087190997832, 0.1957087190997832, 0.03261811984996387, 0.35879931834960255, 0.1957087190997832, 0.9183594298592113, 0.9563810244298359, 0.8364440768941807, 0.766025763327892, 0.9248476522662473, 0.7703460775300287, 0.633259900662296, 0.316629950331148, 0.8935100654461959, 0.8277688214328263, 0.6520673344324901, 0.20183036541958024, 0.12420330179666478, 0.015525412724583097, 0.8810317659528183, 0.8239999808561452], \"Term\": [\"He\", \"IG\", \"If\", \"In\", \"In\", \"In\", \"In\", \"In\", \"Of\", \"P\", \"P\", \"P\", \"S\", \"S\", \"S\", \"So\", \"To\", \"UK\", \"UK\", \"UK\", \"UK\", \"US\", \"US\", \"US\", \"V\", \"abil\", \"accord\", \"accord\", \"across\", \"across\", \"across\", \"across\", \"across\", \"activ\", \"ad\", \"administ\", \"administ\", \"administ\", \"administr\", \"administr\", \"afford\", \"africa\", \"after\", \"agenc\", \"agenc\", \"ago\", \"almost\", \"alreadi\", \"alreadi\", \"alreadi\", \"also\", \"also\", \"also\", \"also\", \"also\", \"also\", \"altern\", \"altern\", \"amc\", \"amend\", \"american\", \"american\", \"american\", \"amid\", \"aminotransferas\", \"analys\", \"analysi\", \"analyst\", \"announc\", \"announc\", \"announc\", \"antibodi\", \"anticip\", \"appetit\", \"appli\", \"approv\", \"approv\", \"approv\", \"approv\", \"approv\", \"approv\", \"approxim\", \"arbaclofen\", \"around\", \"astrazeneca\", \"astrazeneca\", \"astrazeneca\", \"astrazeneca\", \"astrazeneca\", \"astrazeneca\", \"astrazeneca\", \"atacand\", \"author\", \"author\", \"author\", \"avail\", \"avail\", \"averag\", \"averag\", \"back\", \"back\", \"back\", \"back\", \"bank\", \"barrel\", \"begun\", \"begun\", \"beleagu\", \"believ\", \"believ\", \"beneficiari\", \"benefit\", \"biden\", \"biggest\", \"biontech\", \"biontech\", \"biontech\", \"biontech\", \"biotech\", \"bitcoin\", \"book\", \"brexit\", \"britain\", \"btig\", \"buy\", \"candid\", \"case\", \"case\", \"case\", \"case\", \"caus\", \"chain\", \"chanc\", \"chang\", \"cheplapharm\", \"chicago\", \"chief\", \"chief\", \"china\", \"class\", \"clearpoint\", \"clinic\", \"close\", \"close\", \"closer\", \"cnbc\", \"cocktail\", \"cohort\", \"combin\", \"comment\", \"compani\", \"compani\", \"compani\", \"compani\", \"compani\", \"complet\", \"complet\", \"confirm\", \"confirm\", \"consid\", \"consid\", \"continu\", \"continu\", \"continu\", \"continu\", \"contribut\", \"coronaviru\", \"coronaviru\", \"coronaviru\", \"coronaviru\", \"coronaviru\", \"coronaviru\", \"countri\", \"countri\", \"countri\", \"cours\", \"creat\", \"crisi\", \"critic\", \"critic\", \"crude\", \"currenc\", \"currenc\", \"data\", \"data\", \"data\", \"dax\", \"dax\", \"day\", \"day\", \"day\", \"day\", \"day\", \"deal\", \"deal\", \"deal\", \"death\", \"death\", \"decemb\", \"decemb\", \"defens\", \"degre\", \"degre\", \"delay\", \"demand\", \"demand\", \"democrat\", \"demonstr\", \"deploy\", \"deploy\", \"dermtech\", \"design\", \"despit\", \"develop\", \"develop\", \"develop\", \"develop\", \"differ\", \"digit\", \"dip\", \"distribut\", \"distribut\", \"document\", \"dollar\", \"dollar\", \"dosag\", \"dose\", \"dose\", \"dose\", \"dose\", \"dose\", \"down\", \"drive\", \"drop\", \"drug\", \"drug\", \"drug\", \"drug\", \"earli\", \"earli\", \"earlier\", \"earlier\", \"economi\", \"economi\", \"economi\", \"educ\", \"efficaci\", \"efficaci\", \"effort\", \"elsewher\", \"emerg\", \"emerg\", \"entain\", \"entain\", \"entir\", \"entir\", \"europ\", \"europ\", \"europ\", \"eve\", \"everi\", \"evid\", \"express\", \"face\", \"fahrenheit\", \"final\", \"final\", \"financ\", \"firm\", \"firm\", \"first\", \"first\", \"first\", \"first\", \"first\", \"first\", \"first\", \"fiscal\", \"flat\", \"flat\", \"follow\", \"follow\", \"food\", \"for\", \"for\", \"frame\", \"frame\", \"fridg\", \"ftse\", \"ftse\", \"ftse\", \"ftse\", \"fund\", \"futil\", \"gain\", \"gain\", \"gain\", \"gain\", \"geographi\", \"georgia\", \"german\", \"german\", \"german\", \"get\", \"get\", \"get\", \"get\", \"get\", \"giant\", \"giant\", \"give\", \"good\", \"good\", \"govern\", \"govern\", \"govern\", \"govern\", \"grade\", \"greater\", \"greatest\", \"greenback\", \"grow\", \"growth\", \"hancock\", \"handl\", \"health\", \"health\", \"health\", \"health\", \"health\", \"hedg\", \"hepion\", \"high\", \"high\", \"high\", \"higher\", \"higher\", \"higher\", \"highest\", \"highest\", \"histor\", \"hit\", \"hit\", \"hold\", \"hospit\", \"hospit\", \"hospit\", \"hospit\", \"hoth\", \"howev\", \"hypertens\", \"immun\", \"immun\", \"immutep\", \"import\", \"import\", \"importantli\", \"inc\", \"inc\", \"includ\", \"includ\", \"includ\", \"includ\", \"includ\", \"index\", \"index\", \"index\", \"initi\", \"inocul\", \"inocul\", \"inocul\", \"interest\", \"interv\", \"inventori\", \"invest\", \"investor\", \"investor\", \"investor\", \"investor\", \"jab\", \"keator\", \"korea\", \"largest\", \"last\", \"last\", \"last\", \"late\", \"late\", \"lead\", \"lead\", \"legal\", \"less\", \"levi\", \"light\", \"littl\", \"lixt\", \"london\", \"lowest\", \"made\", \"made\", \"made\", \"make\", \"manag\", \"manag\", \"manag\", \"manag\", \"mani\", \"mani\", \"market\", \"market\", \"market\", \"mass\", \"mean\", \"mechan\", \"medic\", \"medic\", \"medic\", \"member\", \"metal\", \"million\", \"million\", \"million\", \"million\", \"million\", \"moderna\", \"moderna\", \"monday\", \"monday\", \"monday\", \"monday\", \"monday\", \"monday\", \"monero\", \"monetari\", \"morn\", \"morn\", \"morn\", \"mostli\", \"move\", \"move\", \"move\", \"msci\", \"nasdaq\", \"nasdaq\", \"nash\", \"natwest\", \"need\", \"new\", \"new\", \"new\", \"new\", \"news\", \"news\", \"news\", \"news\", \"next\", \"next\", \"nh\", \"nh\", \"nh\", \"novemb\", \"novemb\", \"oil\", \"oil\", \"one\", \"one\", \"one\", \"one\", \"ongo\", \"open\", \"open\", \"open\", \"order\", \"order\", \"order\", \"osmotica\", \"oxford\", \"oxford\", \"oxford\", \"oxford\", \"oxford\", \"oxford\", \"oxygen\", \"parliament\", \"pass\", \"patent\", \"patient\", \"patient\", \"patient\", \"patient\", \"patient\", \"peak\", \"peak\", \"peopl\", \"peopl\", \"peopl\", \"peopl\", \"per\", \"per\", \"per\", \"perform\", \"pfizer\", \"pfizer\", \"pfizer\", \"pharmaceut\", \"pharmaceut\", \"pharmaceut\", \"pharmaceut\", \"phase\", \"phase\", \"place\", \"plc\", \"plc\", \"plc\", \"point\", \"point\", \"point\", \"polici\", \"popul\", \"popul\", \"popul\", \"posit\", \"possibl\", \"pound\", \"premarket\", \"pressur\", \"price\", \"price\", \"price\", \"produc\", \"produc\", \"produc\", \"product\", \"product\", \"product\", \"product\", \"product\", \"propos\", \"protect\", \"protect\", \"provid\", \"provid\", \"provid\", \"public\", \"public\", \"public\", \"purchas\", \"push\", \"push\", \"put\", \"race\", \"ralli\", \"rate\", \"read\", \"read\", \"readi\", \"receiv\", \"receiv\", \"receiv\", \"recent\", \"recipi\", \"record\", \"record\", \"refriger\", \"regeneron\", \"relat\", \"releas\", \"releas\", \"remain\", \"report\", \"report\", \"requir\", \"requir\", \"resid\", \"respect\", \"rest\", \"restrict\", \"result\", \"result\", \"result\", \"retail\", \"right\", \"robust\", \"rollout\", \"rollout\", \"rollout\", \"rollout\", \"rose\", \"rose\", \"rose\", \"rose\", \"run\", \"russia\", \"safe\", \"safeti\", \"said\", \"said\", \"said\", \"said\", \"said\", \"said\", \"scenario\", \"schedul\", \"schedul\", \"second\", \"second\", \"secretari\", \"sell\", \"sent\", \"sentiment\", \"separ\", \"session\", \"settl\", \"share\", \"share\", \"share\", \"sharp\", \"shortest\", \"shortli\", \"show\", \"simpler\", \"six\", \"six\", \"six\", \"slow\", \"softwar\", \"south\", \"south\", \"spread\", \"sputnik\", \"squar\", \"start\", \"start\", \"start\", \"state\", \"sterl\", \"stimulu\", \"stimulu\", \"stock\", \"stock\", \"stock\", \"stock\", \"street\", \"street\", \"strong\", \"strong\", \"strong\", \"studi\", \"studi\", \"suggest\", \"suppli\", \"suppli\", \"suppli\", \"system\", \"system\", \"talk\", \"target\", \"target\", \"temperatur\", \"tesla\", \"test\", \"test\", \"test\", \"that\", \"therapeut\", \"there\", \"three\", \"thursday\", \"tier\", \"tier\", \"tier\", \"time\", \"time\", \"time\", \"today\", \"today\", \"toll\", \"toll\", \"tomorrow\", \"total\", \"total\", \"total\", \"tougher\", \"trade\", \"trade\", \"trade\", \"trade\", \"trader\", \"transfer\", \"treat\", \"treatment\", \"treatment\", \"tri\", \"trial\", \"trial\", \"trust\", \"tuesday\", \"tuesday\", \"two\", \"two\", \"two\", \"two\", \"unit\", \"univers\", \"univers\", \"univers\", \"univers\", \"univers\", \"upward\", \"vaccin\", \"vaccin\", \"vaccin\", \"vaccin\", \"vaccin\", \"vaccin\", \"vaccin\", \"valu\", \"valu\", \"valu\", \"variant\", \"variant\", \"ventil\", \"wall\", \"weak\", \"wednesday\", \"wednesday\", \"week\", \"week\", \"week\", \"week\", \"week\", \"well\", \"went\", \"when\", \"widen\", \"window\", \"wire\", \"with\", \"with\", \"within\", \"wrong\", \"year\", \"year\", \"year\", \"year\", \"yesterday\", \"yield\"]}, \"R\": 30, \"lambda.step\": 0.01, \"plot.opts\": {\"xlab\": \"PC1\", \"ylab\": \"PC2\"}, \"topic.order\": [2, 4, 5, 6, 3, 9, 8, 1, 10, 7]};\n",
              "\n",
              "function LDAvis_load_lib(url, callback){\n",
              "  var s = document.createElement('script');\n",
              "  s.src = url;\n",
              "  s.async = true;\n",
              "  s.onreadystatechange = s.onload = callback;\n",
              "  s.onerror = function(){console.warn(\"failed to load library \" + url);};\n",
              "  document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
              "}\n",
              "\n",
              "if(typeof(LDAvis) !== \"undefined\"){\n",
              "   // already loaded: just create the visualization\n",
              "   !function(LDAvis){\n",
              "       new LDAvis(\"#\" + \"ldavis_el12411397996949146407059212050\", ldavis_el12411397996949146407059212050_data);\n",
              "   }(LDAvis);\n",
              "}else if(typeof define === \"function\" && define.amd){\n",
              "   // require.js is available: use it to load d3/LDAvis\n",
              "   require.config({paths: {d3: \"https://d3js.org/d3.v5\"}});\n",
              "   require([\"d3\"], function(d3){\n",
              "      window.d3 = d3;\n",
              "      LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "        new LDAvis(\"#\" + \"ldavis_el12411397996949146407059212050\", ldavis_el12411397996949146407059212050_data);\n",
              "      });\n",
              "    });\n",
              "}else{\n",
              "    // require.js not available: dynamically load d3 & LDAvis\n",
              "    LDAvis_load_lib(\"https://d3js.org/d3.v5.js\", function(){\n",
              "         LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "                 new LDAvis(\"#\" + \"ldavis_el12411397996949146407059212050\", ldavis_el12411397996949146407059212050_data);\n",
              "            })\n",
              "         });\n",
              "}\n",
              "</script>"
            ],
            "text/plain": [
              "PreparedData(topic_coordinates=              x         y  topics  cluster       Freq\n",
              "topic                                                \n",
              "1     -0.230802 -0.127401       1        1  31.107319\n",
              "3     -0.086113 -0.032344       2        1  21.246169\n",
              "4     -0.122079  0.136855       3        1  16.664699\n",
              "5      0.016019  0.181225       4        1   8.854827\n",
              "2      0.071997 -0.093098       5        1   6.151441\n",
              "8      0.056221 -0.151312       6        1   5.107976\n",
              "7      0.206274 -0.013517       7        1   4.362620\n",
              "0      0.001586  0.105889       8        1   4.238957\n",
              "9      0.036361  0.016745       9        1   2.261432\n",
              "6      0.050535 -0.023043      10        1   0.004560, topic_info=         Term        Freq       Total Category  logprob  loglift\n",
              "113    vaccin  143.000000  143.000000  Default  30.0000  30.0000\n",
              "0          UK   57.000000   57.000000  Default  29.0000  29.0000\n",
              "337    nasdaq   37.000000   37.000000  Default  28.0000  28.0000\n",
              "29       dose   39.000000   39.000000  Default  27.0000  27.0000\n",
              "21    compani   53.000000   53.000000  Default  26.0000  26.0000\n",
              "...       ...         ...         ...      ...      ...      ...\n",
              "359      rate    0.000206   14.159751  Topic10  -7.5826  -1.1432\n",
              "477    entain    0.000206    3.199596  Topic10  -7.5826   0.3442\n",
              "727      safe    0.000206    1.683013  Topic10  -7.5826   0.9867\n",
              "1153    posit    0.000206   28.183821  Topic10  -7.5826  -1.8315\n",
              "705      high    0.000206   11.904034  Topic10  -7.5826  -0.9696\n",
              "\n",
              "[570 rows x 6 columns], token_table=      Topic      Freq       Term\n",
              "term                            \n",
              "544       3  0.891325         He\n",
              "1521      1  0.928479         IG\n",
              "119       3  0.784764         If\n",
              "120       1  0.146981         In\n",
              "120       2  0.293962         In\n",
              "...     ...       ...        ...\n",
              "266       2  0.201830       year\n",
              "266       3  0.124203       year\n",
              "266       5  0.015525       year\n",
              "1191      2  0.881032  yesterday\n",
              "1963      6  0.824000      yield\n",
              "\n",
              "[747 rows x 3 columns], R=30, lambda_step=0.01, plot_opts={'xlab': 'PC1', 'ylab': 'PC2'}, topic_order=[2, 4, 5, 6, 3, 9, 8, 1, 10, 7])"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 42
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "NqdJg_qQJPjd"
      },
      "source": [
        "### NLTK preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 881
        },
        "id": "kbg3B6B1zpWN",
        "outputId": "39e36696-4a66-4225-ac81-b2dbe9dff89e"
      },
      "source": [
        "# Visualise the 10 topics \n",
        "pyLDAvis.enable_notebook()\n",
        "vis = gensimvis.prepare(nltk_lem_lda_model, corpus_nltk_lem, id2word_nltk_lem)\n",
        "vis"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "\n",
              "<link rel=\"stylesheet\" type=\"text/css\" href=\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v1.0.0.css\">\n",
              "\n",
              "\n",
              "<div id=\"ldavis_el12411397996949155364145719134\"></div>\n",
              "<script type=\"text/javascript\">\n",
              "\n",
              "var ldavis_el12411397996949155364145719134_data = {\"mdsDat\": {\"x\": [0.17263454856447452, 0.24146449785092114, 0.06850356099307553, -0.18449055675050316, -0.03602986406967571, -0.022772041457448183, -0.03524746627221543, -0.05486058987115167, -0.07105868648569338, -0.0781434025017834], \"y\": [-0.1897446678191579, 0.07861496947421494, 0.0913193830716267, -0.061391047298061115, 0.15978151767863558, -0.1425573924531482, 0.07051296114403292, 0.03885616120493578, -0.032101239355028226, -0.013290645648050624], \"topics\": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10], \"cluster\": [1, 1, 1, 1, 1, 1, 1, 1, 1, 1], \"Freq\": [23.07109005722156, 22.331392699685924, 14.030683060994864, 10.942144096351125, 9.425811819744238, 8.397561421224875, 4.953960257194496, 3.6061608695981024, 1.9469408489756097, 1.2942548690092006]}, \"tinfo\": {\"Term\": [\"company\", \"vaccine\", \"UK\", \"market\", \"said\", \"NASDAQ\", \"rose\", \"gain\", \"case\", \"Pfizer\", \"gained\", \"dos\", \"million\", \"year\", \"record\", \"point\", \"second\", \"week\", \"stock\", \"dose\", \"Shares\", \"FTSE\", \"London\", \"patient\", \"first\", \"Inc\", \"Oxford\", \"last\", \"dollar\", \"start\", \"record\", \"start\", \"S\", \"P\", \"Trump\", \"ahead\", \"Jones\", \"Nasdaq\", \"Dow\", \"stimulus\", \"currency\", \"continues\", \"well\", \"close\", \"check\", \"Senate\", \"Composite\", \"looking\", \"Bitcoin\", \"little\", \"Industrial\", \"administration\", \"President\", \"nearly\", \"toll\", \"bill\", \"yesterday\", \"But\", \"vote\", \"increasing\", \"market\", \"economic\", \"rise\", \"year\", \"final\", \"closed\", \"New\", \"gain\", \"Tuesday\", \"index\", \"look\", \"stock\", \"also\", \"vaccine\", \"trading\", \"day\", \"news\", \"session\", \"point\", \"around\", \"peak\", \"fear\", \"Bill\", \"passing\", \"Britain\", \"amid\", \"almost\", \"square\", \"tomorrow\", \"performance\", \"morning\", \"IG\", \"chance\", \"scenario\", \"sharp\", \"given\", \"available\", \"jab\", \"UK\", \"higher\", \"Around\", \"Despite\", \"bigger\", \"breather\", \"commented\", \"crucial\", \"parliament\", \"FTSE\", \"Street\", \"world\", \"US\", \"position\", \"early\", \"PLC\", \"lower\", \"regulator\", \"Brexit\", \"may\", \"coronavirus\", \"government\", \"restriction\", \"Wednesday\", \"low\", \"vaccine\", \"approved\", \"case\", \"price\", \"back\", \"index\", \"University\", \"million\", \"news\", \"Oxford\", \"new\", \"AstraZeneca\", \"approval\", \"drug\", \"authorization\", \"analysis\", \"pharmaceutical\", \"enough\", \"schedule\", \"within\", \"treatment\", \"emergency\", \"manufacturing\", \"based\", \"India\", \"tier\", \"suggests\", \"strategy\", \"UKX\", \"DAX\", \"operating\", \"interval\", \"sale\", \"completed\", \"noted\", \"briefing\", \"release\", \"response\", \"indicates\", \"active\", \"Atacand\", \"setting\", \"potential\", \"group\", \"company\", \"rose\", \"use\", \"said\", \"AZN\", \"German\", \"AstraZeneca\", \"two\", \"also\", \"major\", \"announced\", \"made\", \"added\", \"deal\", \"vaccine\", \"first\", \"day\", \"Shares\", \"Monday\", \"stock\", \"year\", \"In\", \"developed\", \"trading\", \"approval\", \"Inc\", \"NASDAQ\", \"antibody\", \"cocktail\", \"premarket\", \"Grade\", \"clinical\", \"Emergent\", \"That\", \"third\", \"APOG\", \"NTGR\", \"Pharmaceuticals\", \"mechanical\", \"ventilation\", \"To\", \"continuing\", \"futility\", \"hospitalized\", \"passed\", \"distributed\", \"DermTech\", \"Hepion\", \"Of\", \"aminotransferase\", \"went\", \"David\", \"rated\", \"Regeneron\", \"evidence\", \"public\", \"Therapeutics\", \"Stocks\", \"Phase\", \"Buy\", \"program\", \"provide\", \"stock\", \"A\", \"I\", \"company\", \"In\", \"new\", \"Wednesday\", \"growth\", \"share\", \"Biden\", \"spread\", \"member\", \"Parliament\", \"moved\", \"Chicago\", \"national\", \"used\", \"He\", \"AP\", \"County\", \"Ghaly\", \"Letlow\", \"PMI\", \"face\", \"guidance\", \"lot\", \"press\", \"starting\", \"sure\", \"worldwide\", \"recorded\", \"death\", \"pace\", \"Why\", \"fight\", \"fast\", \"sixth\", \"outbreak\", \"pledged\", \"COVID\", \"November\", \"shot\", \"state\", \"variant\", \"highest\", \"case\", \"million\", \"one\", \"patient\", \"number\", \"people\", \"according\", \"Europe\", \"compared\", \"health\", \"vaccine\", \"Read\", \"rollout\", \"said\", \"country\", \"developed\", \"data\", \"coronavirus\", \"first\", \"government\", \"day\", \"set\", \"despite\", \"London\", \"continued\", \"pound\", \"barrel\", \"confirmed\", \"earlier\", \"weakness\", \"pressure\", \"leaf\", \"opened\", \"exit\", \"concern\", \"oil\", \"among\", \"rallied\", \"Government\", \"Stock\", \"euro\", \"bet\", \"outside\", \"After\", \"mostly\", \"At\", \"settle\", \"appetite\", \"strict\", \"exchange\", \"broadly\", \"sterling\", \"lost\", \"European\", \"end\", \"due\", \"dollar\", \"Thursday\", \"EU\", \"trade\", \"Reuters\", \"French\", \"per\", \"trading\", \"British\", \"Wednesday\", \"stock\", \"Brexit\", \"approved\", \"share\", \"market\", \"closed\", \"index\", \"entire\", \"safety\", \"window\", \"cover\", \"effort\", \"alternative\", \"authority\", \"frame\", \"recipient\", \"tested\", \"pushed\", \"Administration\", \"Food\", \"must\", \"mean\", \"When\", \"rest\", \"resident\", \"efficacy\", \"Pfizer\", \"population\", \"Confirmed\", \"afforded\", \"belief\", \"closer\", \"demonstrate\", \"design\", \"designed\", \"different\", \"document\", \"saying\", \"receiving\", \"Moderna\", \"Drug\", \"BioNTech\", \"dosing\", \"Service\", \"risk\", \"study\", \"vaccine\", \"week\", \"Health\", \"least\", \"last\", \"said\", \"first\", \"would\", \"health\", \"people\", \"A\", \"case\", \"NHS\", \"ready\", \"possible\", \"total\", \"booked\", \"scheduled\", \"cause\", \"shortest\", \"dose\", \"Brian\", \"site\", \"established\", \"person\", \"received\", \"receive\", \"trust\", \"pleased\", \"invented\", \"getting\", \"proud\", \"six\", \"greatest\", \"protect\", \"administered\", \"Monero\", \"Other\", \"Russia\", \"Sputnik\", \"V\", \"addition\", \"cleared\", \"Pinker\", \"second\", \"dos\", \"time\", \"More\", \"access\", \"provided\", \"week\", \"patient\", \"protection\", \"move\", \"Oxford\", \"vaccination\", \"new\", \"vaccine\", \"hospital\", \"end\", \"use\", \"Monday\", \"said\", \"people\", \"Keator\", \"yield\", \"lowest\", \"MSCI\", \"dip\", \"robust\", \"commodity\", \"All\", \"Benchmark\", \"By\", \"Culp\", \"Emerging\", \"FILE\", \"Japanese\", \"Lenox\", \"Massachusetts\", \"Matthew\", \"My\", \"NEW\", \"Once\", \"PHOTO\", \"Pedestrians\", \"Stephen\", \"Sterling\", \"Tokyo\", \"YORK\", \"anticipate\", \"beginning\", \"board\", \"broadest\", \"greenback\", \"going\", \"gain\", \"dollar\", \"gained\", \"April\", \"rose\", \"fell\", \"metal\", \"stock\", \"day\", \"future\", \"sign\", \"demand\", \"global\", \"since\", \"AMC\", \"BTIG\", \"CNBC\", \"Tesla\", \"education\", \"software\", \"management\", \"BioSolutions\", \"Class\", \"Dynatrace\", \"Entertainment\", \"Fred\", \"Guggenheim\", \"Imbert\", \"Jesse\", \"LEVI\", \"Levi\", \"Minnie\", \"Mouse\", \"Needham\", \"PRO\", \"Pippa\", \"Pound\", \"So\", \"Square\", \"Stevens\", \"Strauss\", \"Subscribe\", \"Systems\", \"beleaguered\", \"target\", \"firm\", \"gained\", \"Shares\", \"company\", \"position\", \"making\", \"Last\"], \"Freq\": [52.0, 112.0, 56.0, 48.0, 58.0, 23.0, 32.0, 19.0, 38.0, 16.0, 15.0, 17.0, 40.0, 52.0, 28.0, 29.0, 14.0, 26.0, 61.0, 10.0, 11.0, 35.0, 13.0, 18.0, 39.0, 13.0, 20.0, 20.0, 11.0, 21.0, 27.735031344281957, 21.07086454760091, 20.394658583586306, 20.39464334527082, 18.253484779002072, 18.220897641337427, 13.258202103526596, 13.258197341553007, 13.258142102659374, 14.838282084059252, 12.485706176357077, 12.26439250141087, 11.559349930130363, 11.367594777646158, 10.837112824614485, 10.757994538221714, 10.653975891931758, 9.719026188166229, 8.425163677809211, 8.425064628758559, 9.96824026637073, 8.043170537626276, 7.865967500232874, 7.836760887619103, 7.3066413207775565, 6.776794615022663, 6.7766308031312, 6.74752276337072, 6.563911061921165, 6.033896258498578, 43.96014394907741, 18.967837961043905, 10.939828594930475, 37.633789654014734, 9.549466594580624, 17.03040043449395, 20.701247776775936, 14.435189591297917, 17.628054786972882, 22.208861948019738, 9.891282011197957, 23.610251726807128, 13.346010991719398, 15.415809478966668, 11.937304916709778, 11.699610052617208, 10.874077168402192, 17.501304625605105, 28.154617514146622, 15.119410849256058, 9.00027431373435, 9.135083339952077, 8.565221223230425, 8.565221223230425, 8.494390158858868, 8.366084850466889, 6.875245126424539, 6.442212751650457, 6.442212751650457, 5.985812163812608, 14.82220984273638, 5.3796034369457155, 5.3796034369457155, 5.3796034369457155, 5.3796034369457155, 5.35561296881003, 5.157699903424915, 4.981548711158656, 49.86479275976659, 19.494338762411306, 4.317429700791316, 4.317429700791316, 4.317429700791316, 4.317429700791316, 4.317429700791316, 4.317429700791316, 4.317429700791316, 29.704104548252378, 10.743330611893553, 10.545414780930342, 15.725075218167442, 6.78707434831189, 12.904661238239681, 8.12360357218261, 13.828903610504375, 9.403396039525552, 13.00334167405218, 8.382093860213443, 22.814171897482165, 13.81662536561123, 10.195464059639988, 22.27355115984382, 9.546750702064283, 37.09498295327546, 12.918006996278427, 17.59773664642441, 11.38475574932321, 11.676915106971306, 16.62690073623388, 11.948730872134837, 12.915179653603506, 10.921216282556573, 10.379202615416498, 10.289365576500158, 10.462798666426345, 9.644452123230298, 13.701908703614919, 9.098640257815529, 8.72654844759788, 7.576912901767123, 6.714001050174749, 6.52447676647502, 6.719805780877946, 6.130056262050732, 6.3124453953281225, 5.316375152856117, 4.827242607281009, 4.673891897089842, 4.3652278614622695, 4.364954769212563, 4.364849065425561, 4.330960720912156, 4.28443252026865, 4.54559501161405, 4.1757979871723006, 4.083165559430963, 3.9617182793528967, 3.9616528298847804, 3.9563763285171767, 3.92770135269859, 3.70090243850898, 3.465529064797306, 3.3101780914367622, 3.1837827157293392, 3.0963089223931126, 3.096086510041284, 5.110426527852201, 34.74372156738063, 22.087884183083215, 6.8494478556431195, 31.88332496321319, 8.764178995770571, 7.297271071658453, 19.482302630251564, 9.675465533885696, 15.073530310933409, 6.46573905443425, 6.99666803578759, 8.00717828436231, 7.835262224381189, 9.516587239632868, 24.94195593599552, 13.473325567420599, 11.43176204606631, 6.861192270377576, 7.425225361024593, 13.125604706494352, 10.563735289580709, 7.420538484068868, 6.752552524491731, 7.464921332235359, 6.905317375063432, 13.008159475734587, 22.542470731570774, 8.64667583786385, 6.642193719153122, 5.906462269955903, 5.90628339626054, 4.8178988430437695, 4.817818891922357, 4.817907425367537, 4.624584710389453, 4.449991787780701, 4.449991787780701, 4.269954058293379, 4.0897243557744165, 4.0897243557744165, 3.7219209659484345, 3.3614172941879197, 3.3614172941879197, 3.3614172941879197, 3.3614172941879197, 3.360402773178357, 2.9937408324134456, 2.9937408324134456, 2.9937408324134456, 2.9937408324134456, 2.9937408324134456, 2.993682111250826, 2.993682111250826, 2.8135192605169994, 2.8135192605169994, 5.42946394218102, 5.058399946875282, 6.467409726915232, 5.372350836014891, 4.3393678929245185, 5.216927211092616, 3.458174186491531, 13.10222987484836, 4.341477789467559, 4.260660756756983, 9.89430902219567, 6.740140166701027, 7.071009526193786, 7.1732516526379255, 4.57794023241461, 4.164497625747704, 5.321331393524076, 3.795585949952924, 3.6472658487605627, 3.6468950309978236, 3.646753785617053, 3.2195012948043784, 2.596408581601938, 2.5960570245729406, 5.617975876071853, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 2.1685724321910387, 1.9732038059486385, 10.624803612153936, 3.4170545551799343, 1.6935706369047232, 1.6934904811239004, 1.5454388628867224, 1.5454383765045572, 1.5454374037402268, 1.5454374037402268, 4.029066120789344, 6.196519290341853, 5.185571236259781, 6.476080085719588, 4.523810946372079, 5.029802873142606, 16.688833568015944, 17.63548579091757, 7.216535453511678, 7.891663470827391, 5.213780234523452, 7.042242544698311, 5.337437257989224, 4.062062286875655, 2.564793546311893, 4.683399549567501, 13.625867952832541, 2.8439545355498446, 4.816122736592366, 7.916461957348767, 4.820369825658782, 4.073483318325718, 4.3926173339802945, 5.5142126613737075, 5.356912388989059, 4.331780263652926, 3.9743784774528725, 3.6518187749324484, 8.710940700092763, 12.428427040696345, 5.683774466651749, 4.81786550886806, 4.817773990982094, 4.674507940381434, 4.617591095142115, 3.6662928298237585, 3.664344261501722, 3.6647990776622827, 3.663892911927751, 3.2332551528537627, 3.233253766219127, 3.2332021140789413, 3.229550411765415, 3.0908023634670334, 3.090738578273784, 2.7999514153630125, 2.6575135322986183, 2.657416987862097, 2.6574261743165595, 2.6572438318619445, 2.6572438318619445, 2.6565135953968366, 2.224227474399475, 2.2242257411061805, 2.2233961869352794, 2.20163971616937, 2.081892548956793, 2.081892548956793, 4.211481862800442, 10.894117202756382, 7.25235220634762, 6.245613168359813, 7.046990230142719, 4.709861923715876, 4.555469863455769, 4.657968509103604, 3.644900523979091, 3.6673137395744075, 3.7966402988394656, 6.364266800832688, 3.6205134339796334, 6.12453985844737, 6.419554003716218, 4.477404413409032, 4.36325041032951, 3.816559305383536, 4.2728730313510095, 3.770423891096655, 3.785046299990415, 4.380647264028664, 3.632105686852334, 3.632105686852334, 3.3388670748716525, 3.3386779088568788, 2.8682071013371706, 2.443772962195602, 2.443772962195602, 2.443772962195602, 2.443772962195602, 2.296971545571579, 2.296886267487081, 2.296886267487081, 2.296886267487081, 2.273610872021719, 1.6792260996352142, 1.5315537013280331, 1.5312237344471278, 4.814181413251749, 11.766261091435332, 6.925324855069182, 1.2550502487927364, 1.2550502487927364, 1.2550502487927364, 1.2550502487927364, 1.2550502487927364, 1.2550502487927364, 1.2550502487927364, 1.2550502487927364, 1.2550502487927364, 4.2537792417744, 4.092048638760633, 3.483368437259826, 2.1569173228128866, 4.319282626851257, 3.2218465240870113, 1.6792224185668185, 4.084489360306474, 3.1212617391849125, 15.404204543755483, 5.65285435910188, 2.6888374320831003, 2.97247009158167, 4.543721457006824, 7.041530458211798, 4.979669978089822, 3.3881706914508847, 3.2097210847919135, 3.3925773393280143, 2.6824475063559428, 2.7312128689342186, 2.454090383397062, 2.419462478080809, 2.1765689695418797, 1.8494606295802412, 1.6076836120334799, 1.6075902733865346, 1.6075816391895286, 1.6075570763877007, 7.651034093175254, 1.2803796628500137, 1.2803615012632077, 1.27317933800879, 1.2391233854383552, 4.293685240347213, 3.6875014915616573, 0.8754181082735736, 0.8753707690555056, 0.8753648888696135, 0.8753585620873245, 0.8753563291053402, 1.6768750895310427, 2.520643060024105, 1.6075706231450724, 2.364629074742526, 0.6324427981612848, 0.6324427981612848, 0.6324427981612848, 0.6324427981612848, 0.6324427981612848, 0.6324427981612848, 0.6324427981612848, 1.1752369521064447, 6.512714660052171, 7.407404444908822, 3.8296700953475606, 1.8495384862187618, 1.4436823990593965, 1.9287853793227203, 4.882042647355418, 3.9236664299199204, 2.338459419078903, 2.380934904654009, 3.3501354278258426, 2.482589771970778, 3.0756507322307884, 3.928994324934546, 1.8473497172777158, 1.93873048561909, 1.8352134601928503, 1.9167272766073065, 1.7056698388154508, 1.6398745780505972, 2.3182717062518186, 1.7477597093770962, 1.409489599634987, 1.1772453817313053, 1.1772453817313053, 1.1772453817313053, 0.8258184711623681, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 0.6067262318005443, 1.0938861581664594, 1.6098494319161065, 2.8923383701208527, 1.866548501731709, 1.5733280174376871, 0.8199023312181848, 1.7733880643364972, 1.0522442807639276, 0.7673847545225271, 1.1435118105655322, 0.9731217560310021, 0.8204014377125929, 0.7023134841069719, 0.6300637200991787, 0.6198409180052998, 0.6194263220549933, 0.8548066963859422, 0.8548066963859422, 0.8548066963859422, 0.8548066963859422, 0.8548066963859422, 0.8548066963859422, 0.8548057881104572, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 0.4405497542777792, 1.1644894206631615, 1.1876893410942542, 1.8437992346808851, 1.4210950901357589, 2.121047441386452, 0.7203039731885935, 0.44055036869943087, 0.44055012827356715], \"Total\": [52.0, 112.0, 56.0, 48.0, 58.0, 23.0, 32.0, 19.0, 38.0, 16.0, 15.0, 17.0, 40.0, 52.0, 28.0, 29.0, 14.0, 26.0, 61.0, 10.0, 11.0, 35.0, 13.0, 18.0, 39.0, 13.0, 20.0, 20.0, 11.0, 21.0, 28.303449751582384, 21.638542071528608, 20.962396367334172, 20.962396254487498, 18.82134677198972, 18.791511804166795, 13.825852017795693, 13.825850935179439, 13.825841364894798, 15.475209697707431, 13.053607239106942, 12.832658191769738, 12.127090381883145, 11.935292327331124, 11.405176787923102, 11.325776025789352, 11.221620637518235, 10.286807100734235, 8.99288191664163, 8.992859460520478, 10.66298632597376, 8.615920298487877, 8.433678315510836, 8.404468124474, 7.874450835339157, 7.344495229609466, 7.344468409952415, 7.315254665227012, 7.131571261719982, 6.601583215347652, 48.73719637832551, 20.993935052305932, 12.428840955624823, 52.50222858694038, 10.857708735107392, 21.304497313150126, 28.984818557670252, 19.616489537646405, 27.75596021262113, 43.05934721239458, 11.762966585627808, 61.68622900170937, 34.39049582589875, 112.44936906319984, 33.392660511760454, 33.31096222632263, 22.297158454177975, 18.08418877405321, 29.287121167563097, 16.016773311444165, 9.583504827682447, 9.755225522409317, 9.150965420814924, 9.150965420814924, 9.079290406191161, 8.95330115775424, 7.458273493109385, 7.025923792764944, 7.025923792764944, 6.569316063686207, 16.371579213034135, 5.963222413460469, 5.963222413460469, 5.963222413460469, 5.963222413460469, 5.939301658098225, 5.7416628829582566, 5.567760706505245, 56.016571381204514, 21.996949585925783, 4.900665483394864, 4.900665483394864, 4.900665483394864, 4.900665483394864, 4.900665483394864, 4.900665483394864, 4.900665483394864, 35.27961657172902, 12.508396385342643, 12.310887182004935, 20.414341712463102, 8.064998286169367, 16.552122318104633, 9.924514738160335, 18.10375887148957, 12.010522827688025, 17.99951725374928, 10.538505819570556, 38.29433921618003, 20.031481956723404, 14.232621774079478, 43.705699252344345, 13.360284258544587, 112.44936906319984, 21.710101527014356, 38.147452296799415, 18.378933256968566, 19.85392774039012, 43.05934721239458, 21.87626930169976, 40.9963309835034, 22.297158454177975, 20.801958499392594, 30.86076724830157, 36.86295651632348, 18.698406995883143, 14.413741299810427, 9.675185692922035, 9.28110167584952, 8.133197721081407, 7.26805264601099, 7.078585638683425, 7.31085934967852, 6.684405762887015, 6.9450467763886525, 5.872006000155691, 5.381461990868813, 5.246736599108628, 4.919366628738493, 4.919118426100462, 4.919153376871522, 4.885261709398911, 4.849491779374004, 5.14787863822171, 4.729929330782447, 4.63726147867007, 4.515912357305339, 4.515871794667651, 4.514093411036416, 4.481878775846541, 4.263942427156218, 4.019734291224477, 3.864393363775161, 3.737705144817969, 3.6503792260768613, 3.6502052764258366, 6.318382447389728, 52.371764728451375, 32.75312739662157, 9.181919591565752, 58.472525939062216, 12.482212378901716, 10.013854834402377, 36.86295651632348, 14.97517310371016, 34.39049582589875, 9.49074939859666, 10.744730841013988, 13.724599430512999, 13.570791671768491, 19.291355548410422, 112.44936906319984, 39.26872168253267, 33.31096222632263, 11.787362407876778, 14.697132388017739, 61.68622900170937, 52.50222858694038, 21.411644923595574, 13.065648423168396, 33.392660511760454, 18.698406995883143, 13.577443193149326, 23.86254598061713, 9.216259341559104, 7.211769866403447, 6.475695483716358, 6.475699621722835, 5.387283242584765, 5.387196348625681, 5.387370432448738, 5.207536958861255, 5.019332579397972, 5.019332579397972, 4.839258912876284, 4.659176044947508, 4.659176044947508, 4.2911469167298355, 3.9309749800271336, 3.9309749800271336, 3.9309749800271336, 3.9309749800271336, 3.9309956608673655, 3.5629646251436338, 3.5629646251436338, 3.5629646251436338, 3.5629646251436338, 3.5629646251436338, 3.562965952141593, 3.562965952141593, 3.382882765847481, 3.382882765847481, 6.666765452118461, 6.3876277745176075, 8.509252634744106, 7.419624408215863, 6.274631777163785, 8.900419753169585, 4.669220543812385, 61.68622900170937, 7.53166545164161, 7.343742009565338, 52.371764728451375, 21.411644923595574, 30.86076724830157, 43.705699252344345, 14.043372892469662, 14.90785146273885, 5.9051137289169615, 4.379205104381232, 4.230930984225141, 4.230948811157742, 4.230943129773761, 3.80316295037933, 3.1799487299540896, 3.1799567591258224, 7.089217575739456, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.752187760989481, 2.556738755398455, 13.780905615492742, 4.439751835048127, 2.2772732190081455, 2.2772741906468457, 2.1289744441052303, 2.1289744477128028, 2.12897413818838, 2.1289745152966963, 5.637797634971419, 9.06132211687695, 7.600265501429572, 9.996857956747156, 7.0025155880456476, 8.033549601099809, 38.147452296799415, 40.9963309835034, 15.927515167958692, 18.72336250133995, 10.118999396451214, 19.585365386635672, 14.149449042078002, 8.773564728523034, 3.7543404265697005, 12.785611954874566, 112.44936906319984, 4.9384162472081, 16.678616075037255, 58.472525939062216, 20.67214578105512, 13.065648423168396, 16.67982526791705, 38.29433921618003, 39.26872168253267, 20.031481956723404, 33.31096222632263, 12.520957690282813, 9.297657152762715, 13.425989306649628, 6.270798585426979, 5.404087558666189, 5.404042857599321, 5.261850111553357, 5.278452692546446, 4.252811211679792, 4.2520178089677945, 4.253245663445661, 4.253510016305813, 3.819469723820936, 3.8194712235863797, 3.8194441606955625, 3.8205046818704105, 3.677167111554285, 3.6771456209019164, 3.3861584903441964, 3.2437858377691513, 3.2437428497729806, 3.2437542208227064, 3.2438574052249307, 3.2438574052249307, 3.2439252118141773, 2.8104733441245435, 2.810476562707275, 2.8105771789908016, 2.7878649179077812, 2.6681818131421453, 2.6681818131421453, 5.551000556453691, 16.139823814428063, 10.538648334695806, 9.459239131482558, 11.279293265022641, 9.649571892803724, 11.18335370798932, 11.777383232154529, 6.746577859697756, 6.923692425181094, 7.54716240140423, 33.392660511760454, 7.371434968543556, 43.705699252344345, 61.68622900170937, 17.99951725374928, 21.710101527014356, 14.90785146273885, 48.73719637832551, 21.304497313150126, 43.05934721239458, 4.965208554299896, 4.217150322320268, 4.217150322320268, 3.9232179505318245, 3.9232048479605863, 3.4523107345073623, 3.0281921628832524, 3.0281921628832524, 3.0281921628832524, 3.0281921628832524, 2.881217759374801, 2.881213369482491, 2.881213369482491, 2.881213369482491, 2.8578444793424693, 2.2633255883514067, 2.1163564964127795, 2.1163621518566424, 6.684154423795024, 16.670095725661646, 10.030228676111795, 1.8392185272521424, 1.8392185272521424, 1.8392185272521424, 1.8392185272521424, 1.8392185272521424, 1.8392185272521424, 1.8392185272521424, 1.8392185272521424, 1.8392185272521424, 6.753349735064352, 6.666542724746755, 6.645094278992464, 3.640886384063505, 9.116067695140744, 6.314125880033243, 2.6910909083732792, 8.89525212356676, 7.064933662294072, 112.44936906319984, 26.519963081246036, 6.439711124416302, 7.9849671554710335, 20.33544380709308, 58.472525939062216, 39.26872168253267, 12.565833598154676, 12.785611954874566, 19.585365386635672, 7.53166545164161, 38.147452296799415, 6.790237150854093, 3.006722516147235, 2.7638262504741, 2.437597580949767, 2.194631840806399, 2.1946371901760373, 2.194638005706113, 2.194639292524776, 10.961384358693342, 1.8684373716915705, 1.86842409374695, 1.8687402321511266, 1.8702531008307155, 6.828255699095636, 5.8860988352078305, 1.462323160881715, 1.4623268670956096, 1.4623272834217154, 1.4623276585155454, 1.4623276616993408, 2.896956610752845, 4.39601550772708, 2.92282110068775, 4.518505293414098, 1.2194122294721352, 1.2194122294721352, 1.2194122294721352, 1.2194122294721352, 1.2194122294721352, 1.2194122294721352, 1.2194122294721352, 2.3009351698575022, 14.409130716417652, 17.76818008717076, 9.268940888367853, 4.622260810723192, 3.487911124464594, 5.3378132714624655, 26.519963081246036, 18.72336250133995, 7.847366360176525, 8.948338225329506, 20.801958499392594, 14.535138930078045, 30.86076724830157, 112.44936906319984, 8.074400409367847, 10.538648334695806, 9.181919591565752, 14.697132388017739, 58.472525939062216, 19.585365386635672, 2.932423057704357, 2.361875358864069, 2.023522684550658, 1.7913298558182067, 1.7913298558182067, 1.7913298558182067, 1.4404500612913915, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 1.2207883816533285, 2.8643626679819505, 5.996566131530051, 19.616489537646405, 11.279293265022641, 15.629176324459566, 2.7502965502212833, 32.75312739662157, 8.851488434679634, 3.3071238609995226, 61.68622900170937, 33.31096222632263, 11.195202540805061, 5.381354441709913, 5.910252539363362, 13.63928274966555, 15.15862852305102, 1.478766326648132, 1.478766326648132, 1.478766326648132, 1.478766326648132, 1.478766326648132, 1.478766326648132, 2.0493329434088743, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 1.064506402987293, 4.023911838481829, 5.8348359142928, 15.629176324459566, 11.787362407876778, 52.371764728451375, 8.064998286169367, 2.5432460971977053, 1.4922709428436034], \"Category\": [\"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\"], \"logprob\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, -4.3006, -4.5754, -4.608, -4.608, -4.7189, -4.7207, -5.0387, -5.0387, -5.0387, -4.9261, -5.0987, -5.1166, -5.1758, -5.1925, -5.2403, -5.2476, -5.2573, -5.3492, -5.4921, -5.4921, -5.3239, -5.5385, -5.5607, -5.5645, -5.6345, -5.7098, -5.7098, -5.7141, -5.7417, -5.8259, -3.84, -4.6805, -5.2309, -3.9954, -5.3668, -4.7883, -4.5931, -4.9536, -4.7538, -4.5228, -5.3316, -4.4616, -5.0321, -4.8879, -5.1436, -5.1637, -5.2369, -4.7284, -4.253, -4.8747, -5.3934, -5.3786, -5.443, -5.443, -5.4513, -5.4665, -5.6628, -5.7278, -5.7278, -5.8013, -4.8946, -5.9081, -5.9081, -5.9081, -5.9081, -5.9125, -5.9502, -5.9849, -3.6814, -4.6206, -6.128, -6.128, -6.128, -6.128, -6.128, -6.128, -6.128, -4.1994, -5.2164, -5.235, -4.8354, -5.6757, -5.0331, -5.4959, -4.9639, -5.3496, -5.0255, -5.4646, -4.4633, -4.9648, -5.2687, -4.4873, -5.3345, -3.9772, -5.0321, -4.7229, -5.1584, -5.1331, -4.7797, -5.1101, -5.0323, -5.2, -5.2509, -5.2596, -5.2429, -5.3243, -4.5084, -4.9178, -4.9596, -5.1008, -5.2217, -5.2504, -5.2209, -5.3127, -5.2834, -5.4552, -5.5517, -5.584, -5.6523, -5.6523, -5.6524, -5.6602, -5.671, -5.6118, -5.6966, -5.7191, -5.7493, -5.7493, -5.7506, -5.7579, -5.8174, -5.8831, -5.9289, -5.9679, -5.9957, -5.9958, -5.4947, -3.5779, -4.0309, -5.2018, -3.6639, -4.9553, -5.1384, -4.1564, -4.8563, -4.413, -5.2594, -5.1805, -5.0456, -5.0673, -4.8729, -3.9094, -4.5252, -4.6895, -5.2001, -5.1211, -4.5514, -4.7685, -5.1217, -5.216, -5.1157, -5.1937, -4.3117, -3.7619, -4.7201, -4.9839, -5.1013, -5.1013, -5.305, -5.305, -5.305, -5.3459, -5.3844, -5.3844, -5.4257, -5.4688, -5.4688, -5.5631, -5.665, -5.665, -5.665, -5.665, -5.6653, -5.7808, -5.7808, -5.7808, -5.7808, -5.7808, -5.7808, -5.7808, -5.8429, -5.8429, -5.1855, -5.2563, -5.0105, -5.1961, -5.4096, -5.2254, -5.6366, -4.3045, -5.4091, -5.4279, -4.5854, -4.9692, -4.9213, -4.907, -5.3561, -5.4507, -5.0564, -5.3943, -5.4342, -5.4343, -5.4343, -5.5589, -5.774, -5.7742, -5.0022, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -5.9541, -6.0485, -4.365, -5.4994, -6.2013, -6.2014, -6.2928, -6.2928, -6.2928, -6.2928, -5.3346, -4.9042, -5.0823, -4.86, -5.2188, -5.1128, -3.9134, -3.8582, -4.7518, -4.6623, -5.0768, -4.7762, -5.0534, -5.3265, -5.7863, -5.1841, -4.1162, -5.683, -5.1562, -4.6592, -5.1553, -5.3236, -5.2482, -5.0208, -5.0498, -5.2622, -5.3483, -5.4329, -4.4481, -4.0927, -4.875, -5.0403, -5.0403, -5.0705, -5.0828, -5.3135, -5.314, -5.3139, -5.3141, -5.4391, -5.4391, -5.4392, -5.4403, -5.4842, -5.4842, -5.583, -5.6352, -5.6353, -5.6353, -5.6353, -5.6353, -5.6356, -5.8132, -5.8132, -5.8136, -5.8234, -5.8794, -5.8794, -5.1748, -4.2244, -4.6313, -4.7808, -4.66, -5.063, -5.0963, -5.0741, -5.3193, -5.3132, -5.2785, -4.7619, -5.326, -4.8003, -4.7533, -5.1136, -5.1394, -5.2733, -5.1604, -5.2854, -5.2816, -4.6077, -4.7951, -4.7951, -4.8793, -4.8793, -5.0312, -5.1913, -5.1913, -5.1913, -5.1913, -5.2533, -5.2533, -5.2533, -5.2533, -5.2635, -5.5666, -5.6586, -5.6588, -4.5133, -3.6196, -4.1497, -5.8577, -5.8577, -5.8577, -5.8577, -5.8577, -5.8577, -5.8577, -5.8577, -5.8577, -4.6371, -4.6758, -4.8369, -5.3162, -4.6218, -4.9149, -5.5666, -4.6777, -4.9466, -3.3502, -4.3527, -5.0958, -4.9955, -4.5711, -4.1331, -4.4795, -4.8646, -4.9187, -4.8633, -5.0982, -5.0801, -5.1871, -4.8838, -4.9896, -5.1524, -5.2925, -5.2926, -5.2926, -5.2926, -3.7325, -5.5202, -5.5202, -5.5258, -5.5529, -4.3102, -4.4624, -5.9004, -5.9004, -5.9005, -5.9005, -5.9005, -5.2504, -4.8428, -5.2926, -4.9067, -6.2255, -6.2255, -6.2255, -6.2255, -6.2255, -6.2255, -6.2255, -5.6059, -3.8936, -3.7649, -4.4246, -5.1524, -5.4001, -5.1104, -4.1818, -4.4003, -4.9178, -4.8998, -4.5583, -4.858, -4.6438, -4.399, -5.1536, -5.1053, -5.1602, -5.1167, -5.2334, -5.2727, -4.3101, -4.5926, -4.8077, -4.9878, -4.9878, -4.9878, -5.3423, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.6506, -5.0612, -4.6748, -4.0889, -4.5269, -4.6978, -5.3495, -4.5781, -5.1, -5.4157, -5.0169, -5.1782, -5.3489, -5.5043, -5.6129, -5.6292, -5.6299, -4.8995, -4.8995, -4.8995, -4.8995, -4.8995, -4.8995, -4.8995, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -5.5624, -4.5903, -4.5706, -4.1308, -4.3912, -3.9907, -5.0707, -5.5624, -5.5624], \"loglift\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 1.4463, 1.44, 1.4391, 1.4391, 1.436, 1.4358, 1.4247, 1.4247, 1.4247, 1.4246, 1.4221, 1.4213, 1.4186, 1.4179, 1.4155, 1.4152, 1.4147, 1.4098, 1.4014, 1.4014, 1.3992, 1.3978, 1.3969, 1.3967, 1.3918, 1.3861, 1.3861, 1.3858, 1.3836, 1.3767, 1.3634, 1.3651, 1.339, 1.1336, 1.3382, 1.2427, 1.13, 1.1599, 1.0126, 0.8045, 1.2933, 0.5062, 0.52, -0.5205, 0.4379, 0.4203, 0.7485, 1.4664, 1.4597, 1.4415, 1.4364, 1.4335, 1.433, 1.433, 1.4326, 1.4313, 1.4178, 1.4124, 1.4124, 1.4062, 1.3998, 1.3962, 1.3962, 1.3962, 1.3962, 1.3957, 1.3919, 1.3879, 1.3828, 1.3784, 1.3725, 1.3725, 1.3725, 1.3725, 1.3725, 1.3725, 1.3725, 1.3272, 1.3471, 1.3444, 1.2382, 1.3267, 1.2503, 1.2989, 1.2298, 1.2545, 1.174, 1.2702, 0.9813, 1.1277, 1.1656, 0.8251, 1.1631, 0.3902, 0.98, 0.7255, 1.0202, 0.9684, 0.5476, 0.8944, 0.3441, 0.7854, 0.8039, 0.4008, 0.2398, 0.8371, 1.9133, 1.9025, 1.9023, 1.8931, 1.8846, 1.8824, 1.8796, 1.8774, 1.8684, 1.8645, 1.8552, 1.8483, 1.8444, 1.8444, 1.8444, 1.8435, 1.84, 1.8395, 1.8393, 1.8367, 1.833, 1.833, 1.832, 1.8319, 1.8223, 1.8156, 1.8091, 1.8035, 1.7993, 1.7993, 1.7517, 1.5536, 1.57, 1.6709, 1.3574, 1.6103, 1.6475, 1.3262, 1.5271, 1.1391, 1.5801, 1.5349, 1.4251, 1.4146, 1.2573, 0.458, 0.8942, 0.8944, 1.4228, 1.2812, 0.4164, 0.3605, 0.9042, 1.3039, 0.4658, 0.9678, 2.1697, 2.1556, 2.1488, 2.1303, 2.1205, 2.1205, 2.1008, 2.1008, 2.1008, 2.0938, 2.0922, 2.0922, 2.0874, 2.0822, 2.0822, 2.0702, 2.056, 2.056, 2.056, 2.056, 2.0557, 2.0385, 2.0385, 2.0385, 2.0385, 2.0385, 2.0385, 2.0385, 2.0283, 2.0283, 2.0073, 1.9792, 1.9382, 1.8897, 1.8438, 1.6784, 1.9123, 0.6633, 1.6616, 1.6681, 0.5461, 1.0567, 0.7391, 0.4054, 1.0916, 0.9373, 2.2576, 2.2187, 2.2133, 2.2132, 2.2131, 2.1951, 2.159, 2.1588, 2.1291, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1234, 2.1026, 2.1016, 2.0999, 2.0656, 2.0655, 2.0414, 2.0414, 2.0414, 2.0414, 2.0258, 1.9817, 1.9794, 1.9276, 1.9248, 1.8935, 1.535, 1.5181, 1.57, 1.4978, 1.6986, 1.3389, 1.3868, 1.5917, 1.9807, 1.3574, 0.2512, 1.8099, 1.1196, 0.3621, 0.9058, 1.1962, 1.0274, 0.4237, 0.3697, 0.8304, 0.2357, 1.1295, 2.412, 2.4, 2.3789, 2.3624, 2.3624, 2.3589, 2.3435, 2.3288, 2.3285, 2.3283, 2.328, 2.3106, 2.3106, 2.3106, 2.3092, 2.3035, 2.3035, 2.2871, 2.2779, 2.2779, 2.2779, 2.2778, 2.2778, 2.2775, 2.2433, 2.2433, 2.2429, 2.2412, 2.2291, 2.2291, 2.2011, 2.0842, 2.1035, 2.0621, 2.0069, 1.76, 1.5791, 1.5496, 1.8615, 1.8417, 1.7902, 0.8196, 1.7662, 0.5121, 0.2145, 1.0859, 0.8727, 1.1147, 0.0431, 0.7455, 0.0457, 2.8797, 2.8556, 2.8556, 2.8437, 2.8436, 2.8196, 2.7906, 2.7906, 2.7906, 2.7906, 2.7784, 2.7783, 2.7783, 2.7783, 2.7763, 2.7065, 2.6816, 2.6814, 2.6768, 2.6566, 2.6346, 2.6228, 2.6228, 2.6228, 2.6228, 2.6228, 2.6228, 2.6228, 2.6228, 2.6228, 2.5428, 2.5169, 2.3591, 2.4814, 2.258, 2.3321, 2.5334, 2.2267, 2.1881, 1.0171, 1.4592, 2.1316, 2.0168, 1.5064, 0.8883, 0.9399, 1.6943, 1.6228, 1.2518, 1.9726, 0.3683, 1.9873, 3.1052, 3.0837, 3.0464, 3.0113, 3.0112, 3.0112, 3.0112, 2.963, 2.9446, 2.9446, 2.9388, 2.9109, 2.8586, 2.8549, 2.8094, 2.8094, 2.8094, 2.8094, 2.8094, 2.7758, 2.7663, 2.7247, 2.675, 2.666, 2.666, 2.666, 2.666, 2.666, 2.666, 2.666, 2.6507, 2.5284, 2.4476, 2.4386, 2.4066, 2.4404, 2.3046, 1.6302, 1.7598, 2.1118, 1.9986, 1.4965, 1.5553, 1.0166, -0.0316, 1.8476, 1.6295, 1.7125, 1.2855, -0.2121, 0.8424, 3.7039, 3.6378, 3.5773, 3.5191, 3.5191, 3.5191, 3.3826, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 3.2397, 2.9763, 2.6239, 2.0246, 2.14, 1.643, 2.7286, 1.0228, 1.8093, 2.4781, -0.049, 0.4058, 1.3255, 1.9026, 1.7003, 0.8477, 0.7414, 3.7991, 3.7991, 3.7991, 3.7991, 3.7991, 3.7991, 3.4728, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.465, 3.1073, 2.7554, 2.2099, 2.2316, 1.1408, 1.9316, 2.5941, 3.1272]}, \"token.table\": {\"Topic\": [4, 7, 10, 5, 4, 1, 3, 5, 7, 6, 9, 1, 9, 2, 1, 2, 3, 5, 6, 6, 3, 10, 9, 5, 2, 2, 5, 7, 1, 2, 6, 8, 2, 2, 6, 1, 3, 4, 9, 10, 5, 6, 8, 5, 1, 7, 5, 9, 3, 4, 4, 2, 1, 4, 7, 1, 2, 6, 4, 9, 3, 5, 1, 3, 5, 6, 9, 2, 3, 6, 7, 1, 3, 6, 3, 5, 5, 6, 4, 4, 5, 4, 5, 7, 4, 4, 5, 2, 2, 3, 4, 7, 4, 3, 1, 9, 1, 9, 9, 5, 6, 9, 9, 9, 1, 7, 2, 3, 5, 7, 8, 8, 4, 8, 9, 3, 4, 9, 2, 7, 8, 4, 1, 1, 2, 3, 5, 8, 4, 9, 8, 2, 3, 5, 8, 1, 9, 2, 3, 5, 5, 9, 2, 3, 7, 4, 4, 7, 5, 8, 1, 5, 7, 4, 2, 3, 6, 8, 1, 1, 7, 2, 3, 10, 8, 9, 9, 6, 1, 4, 1, 2, 10, 4, 3, 4, 1, 2, 6, 4, 9, 1, 1, 2, 5, 1, 2, 3, 3, 2, 3, 2, 3, 5, 6, 7, 8, 1, 2, 4, 6, 7, 5, 9, 4, 8, 1, 2, 5, 3, 2, 3, 8, 3, 8, 1, 7, 1, 2, 1, 2, 3, 7, 2, 4, 6, 3, 3, 4, 4, 9, 6, 2, 3, 7, 2, 3, 6, 2, 7, 3, 2, 1, 2, 3, 6, 3, 9, 7, 6, 2, 1, 9, 8, 2, 3, 9, 6, 1, 2, 5, 7, 8, 2, 1, 8, 4, 1, 1, 6, 7, 4, 2, 9, 1, 3, 4, 5, 8, 10, 5, 6, 3, 6, 6, 6, 1, 4, 1, 2, 3, 5, 6, 7, 1, 2, 3, 5, 6, 7, 2, 1, 1, 3, 4, 5, 6, 1, 3, 5, 6, 7, 9, 1, 2, 3, 3, 4, 5, 1, 3, 9, 7, 7, 7, 6, 2, 3, 5, 7, 9, 4, 7, 1, 6, 9, 2, 3, 7, 8, 2, 4, 8, 4, 7, 3, 4, 5, 6, 6, 1, 2, 6, 1, 6, 10, 4, 7, 7, 3, 4, 6, 8, 3, 7, 8, 6, 4, 6, 6, 5, 5, 2, 2, 3, 9, 5, 1, 4, 2, 3, 8, 10, 1, 2, 3, 5, 7, 8, 7, 4, 1, 2, 3, 9, 1, 2, 9, 1, 3, 9, 10, 8, 2, 1, 2, 3, 9, 3, 5, 9, 2, 5, 6, 5, 8, 6, 9, 3, 7, 1, 3, 4, 5, 3, 5, 7, 2, 3, 2, 5, 2, 8, 4, 1, 1, 2, 6, 3, 3, 8, 2, 1, 2, 7, 6, 2, 7, 1, 1, 5, 6, 1, 1, 6, 5, 1, 2, 6, 2, 3, 9, 2, 3, 1, 3, 5, 9, 10, 3, 1, 6, 2, 6, 7, 4, 5, 1, 2, 9, 1, 2, 3, 5, 7, 1, 2, 6, 1, 2, 6, 8, 5, 7, 5, 1, 1, 2, 4, 5, 6, 8, 1, 2, 3, 3, 5, 6, 1, 2, 4, 5, 8, 6, 3, 5, 6, 5, 8, 2, 4, 2, 2, 4, 5, 8, 2, 1, 2, 5, 7, 8, 3, 6, 2, 8, 3, 8, 5, 2, 6, 2, 7, 2, 10, 8, 3, 6, 4, 5, 6, 2, 3, 2, 4, 4, 8, 1, 2, 8, 8, 4, 6, 2, 8, 4, 6, 7, 6, 4, 8, 4, 7, 8, 4, 5, 8, 4, 7, 7, 1, 5, 2, 6, 3, 7, 3, 7, 2, 6, 1, 5, 1, 2, 6, 7, 9, 1, 2, 3, 5, 2, 3, 5, 9, 7, 1, 3, 4, 5, 6, 7, 8, 3, 3, 7, 2, 3, 8, 2, 4, 8, 2, 1, 2, 5, 3, 6, 1, 3, 4, 6, 2, 8, 5, 6, 7, 1, 2, 9, 1, 2, 9, 8, 3, 8, 5, 10, 5, 2, 1, 5, 3, 5, 6, 1, 1, 2, 3, 4, 6, 9, 3, 6, 4, 7, 3, 5, 3, 10, 7, 4, 3, 2, 4, 8, 1, 2, 8, 1, 6, 1, 2, 3, 6, 3, 8, 2, 3, 3, 8, 5, 2, 3, 5, 7, 8, 1, 2, 3, 4, 5, 6, 7, 8, 2, 5, 8, 4, 1, 6, 1, 2, 3, 5, 6, 7, 8, 1, 4, 7, 3, 1, 2, 5, 1, 4, 6, 7, 1, 2, 3, 1, 9], \"Freq\": [0.5310910350018475, 0.39831827625138566, 0.6762393638396306, 0.726694605778259, 0.7969187011871143, 0.24034200900721767, 0.721026027021653, 0.08011400300240588, 0.6941519920682687, 0.9248248690487609, 0.8191427892241961, 0.3635971546121243, 0.3635971546121243, 0.8162156779632016, 0.05425500798109803, 0.2712750399054902, 0.5154225758204313, 0.08138251197164705, 0.027127503990549015, 0.9248055377707795, 0.802631530247714, 0.6762393638396306, 0.8191427892241961, 0.8467237431034261, 0.9835027875341398, 0.32908926308205555, 0.10969642102735185, 0.4387856841094074, 0.8895924659252704, 0.7222415921900414, 0.22222818221232044, 0.5352065930337607, 0.8811261279344922, 0.40697639100148475, 0.5426351880019797, 0.9569044852634356, 0.15937190189222752, 0.6374876075689101, 0.8191427892241961, 0.6762393638396306, 0.7094969097840416, 0.1773742274460104, 0.1773742274460104, 0.7888171080602208, 0.9802505676606754, 0.5437091814717827, 0.726694605778259, 0.8191427892241961, 0.8248286999913915, 0.841995135596732, 0.8419954491911524, 0.8162156779632016, 0.940268274233806, 0.27465839208196446, 0.5493167841639289, 0.08941861503366437, 0.4470930751683218, 0.4470930751683218, 0.9281265571980762, 0.8191427892241961, 0.45591502698964764, 0.45591502698964764, 0.06195854499390868, 0.18587563498172605, 0.06195854499390868, 0.6815439949329956, 0.8191427892241961, 0.850349377777541, 0.0850349377777541, 0.05668995851850274, 0.6941519920682687, 0.14443160362858615, 0.2888632072571723, 0.5777264145143446, 0.6990315034277963, 0.1997232866936561, 0.726694605778259, 0.8158502026537017, 0.9265408141960302, 0.14105929029772976, 0.8463557417863786, 0.46585940611923354, 0.15528646870641116, 0.46585940611923354, 0.8419954491911524, 0.5446814437094792, 0.4085110827821094, 0.8384728345388832, 0.28022134784180064, 0.32692490581543404, 0.32692490581543404, 0.04670355797363344, 0.9574704025688222, 0.9529733207589368, 0.9378235790888333, 0.8191427892241961, 0.9402675497515297, 0.6820298301588507, 0.8191427892241961, 0.726694605778259, 0.8937888840755025, 0.5582444778397558, 0.8191427892241961, 0.8191427892241961, 0.4514608633144725, 0.4514608633144725, 0.13608096785129034, 0.4762833874795162, 0.20412145177693553, 0.06804048392564517, 0.13608096785129034, 0.8200672224132807, 0.4326886954020846, 0.4326886954020846, 0.8191427892241961, 0.04190667671472573, 0.9638535644386917, 0.8191427892241961, 0.2945405227486694, 0.2945405227486694, 0.1472702613743347, 0.7969187011871143, 0.9402676233780239, 0.7245172143554016, 0.2760065578496768, 0.22071834266601645, 0.6621550279980493, 0.11035917133300822, 0.8419954491911524, 0.8191427892241961, 0.8200672224132807, 0.48072396646171534, 0.24036198323085767, 0.048072396646171536, 0.1442171899385146, 0.9540893968989126, 0.8191427892241961, 0.8060847518558802, 0.10076059398198503, 0.726694605778259, 0.9454144161355273, 0.8191427892241961, 0.2399506317076795, 0.059987657926919874, 0.7198518951230385, 0.8265728434899016, 0.673888558895707, 0.26955542355828277, 0.43460589985328896, 0.43460589985328896, 0.9485777973398352, 0.6074822068099321, 0.20249406893664404, 0.8868176072452333, 0.14822329494983397, 0.29644658989966793, 0.5928931797993359, 0.8200672224132807, 0.954089391762772, 0.9712358760187784, 0.7431930276963283, 0.25450986371601525, 0.5938563486707022, 0.08483662123867175, 0.8200672224132807, 0.8191427892241961, 0.8191427892241961, 0.8859597117366635, 0.23503826785372495, 0.7051148035611748, 0.07994629920521239, 0.8794092912573362, 0.6762393638396306, 0.9280965663479233, 0.15655264134039493, 0.7827632067019746, 0.20726308091362294, 0.31089462137043444, 0.5181577022840573, 0.9321517248466267, 0.8191427892241961, 0.9563608926640647, 0.6485093602279729, 0.2521980845331006, 0.10808489337132882, 0.035703720357848766, 0.8925930089462191, 0.053555580536773145, 0.8187892968567625, 0.7837627206089083, 0.19594068015222707, 0.5485395994401849, 0.22855816643341037, 0.09142326657336415, 0.045711633286682075, 0.045711633286682075, 0.8200672224132807, 0.18304248958036942, 0.5033668463460159, 0.16016217838282326, 0.13728186718527707, 0.883655453856636, 0.87824332333346, 0.8191427892241961, 0.5734091060898252, 0.2867045530449126, 0.4947189094913319, 0.07067412992733313, 0.35337064963666565, 0.7763184845833792, 0.3684383432398841, 0.5895013491838146, 0.8200672224132807, 0.44262424632213665, 0.44262424632213665, 0.9285136959082626, 0.5437091814717827, 0.9578792907981312, 0.93855501631406, 0.37801141529951354, 0.17446680706131393, 0.43616701765328486, 0.8689831914646854, 0.8935251768082649, 0.8419954491911524, 0.7852365720780338, 0.969712466723538, 0.6514821174747459, 0.2792066217748911, 0.9765350199528435, 0.8191427892241961, 0.7116230843332281, 0.5348049169216241, 0.37436344184513687, 0.10696098338432483, 0.5987995949177767, 0.18424602920546973, 0.18424602920546973, 0.9365182180160052, 0.6604600674006523, 0.9302147044665021, 0.8708278597896134, 0.10073573482043413, 0.6044144089226048, 0.3022072044613024, 0.9252332247826006, 0.9291155467573549, 0.8191427892241961, 0.5437091814717827, 0.9248575300011715, 0.8162156779632016, 0.9530947711395295, 0.8191427892241961, 0.9113145826158783, 0.8162156779632016, 0.8861136967658845, 0.8191427892241961, 0.7495741070376045, 0.02621407039766848, 0.47185326715803266, 0.4456391967603642, 0.07864221119300543, 0.9113120226661303, 0.8384728345388832, 0.9644743088636607, 0.8200672224132807, 0.9281115870197034, 0.9216364122737606, 0.7979535846408734, 0.18775378462138198, 0.5437091814717827, 0.9706355207769465, 0.8162156779632016, 0.6942274688117133, 0.05728277470799502, 0.6682990382599419, 0.1909425823599834, 0.01909425823599834, 0.01909425823599834, 0.03818851647199668, 0.7990751128397451, 0.2663583709465817, 0.8857567825755622, 0.7854490384622093, 0.9502361135338279, 0.9568159331322965, 0.9351141299544808, 0.7631694465730974, 0.13056760091286318, 0.6006109641991707, 0.07834056054771792, 0.15668112109543583, 0.02611352018257264, 0.02611352018257264, 0.04837427186279059, 0.33861990303953415, 0.19349708745116237, 0.24187135931395295, 0.14512281558837178, 0.7646783935603999, 0.8162156779632016, 0.9192861237658148, 0.29976333203065936, 0.23981066562452746, 0.11990533281226373, 0.23981066562452746, 0.059952666406131866, 0.36024177021573667, 0.33022162269775857, 0.12008059007191221, 0.09006044255393417, 0.06004029503595611, 0.030020147517978053, 0.05183668910619391, 0.4665302019557452, 0.5183668910619391, 0.07256417160827094, 0.1451283432165419, 0.7982058876909803, 0.33839501555638013, 0.5075925233345702, 0.16919750777819006, 0.5437091814717827, 0.5437091814717827, 0.5437091814717827, 0.9679857895519121, 0.15307315299051982, 0.5357560354668194, 0.30614630598103965, 0.5437091814717827, 0.5582444778397558, 0.7631654315634774, 0.5437091814717827, 0.17731607406663039, 0.6206062592332063, 0.17731607406663039, 0.3939626886748093, 0.11256076819280267, 0.056280384096401334, 0.3939626886748093, 0.09122935272376541, 0.18245870544753082, 0.7298348217901233, 0.47512514907038966, 0.47512514907038966, 0.9712953568955849, 0.21143349609838413, 0.10571674804919207, 0.6343004882951524, 0.9472472884071423, 0.12083042654973673, 0.7853977725732888, 0.060415213274868367, 0.905023281850778, 0.09526560861587137, 0.6762393638396306, 0.14960755491226901, 0.7480377745613451, 0.7646809474043907, 0.8639250667682232, 0.09488882902637102, 0.6642218031845971, 0.18977765805274205, 0.9631190555343447, 0.8056056369547618, 0.5351198538969161, 0.924845273405346, 0.8868176072452333, 0.7173948734578385, 0.7854493468791915, 0.726694605778259, 0.9394194493680567, 0.9225824640676483, 0.4519013982245319, 0.3389260486683989, 0.11297534955613298, 0.8782429486156484, 0.9210046285056376, 0.09210046285056375, 0.34276885063740586, 0.34276885063740586, 0.17138442531870293, 0.17138442531870293, 0.1273278015114018, 0.22919004272052323, 0.3310522839296447, 0.1273278015114018, 0.1273278015114018, 0.02546556030228036, 0.6604600674006523, 0.7631694465730974, 0.6252678300804213, 0.08932397572577447, 0.17864795145154894, 0.08932397572577447, 0.7136852887532356, 0.10195504125046223, 0.15293256187569335, 0.5758460851142267, 0.19194869503807557, 0.12796579669205038, 0.12796579669205038, 0.6838412678422094, 0.8418498146465605, 0.4399058301029155, 0.36658819175242957, 0.14663527670097184, 0.07331763835048592, 0.5002863195697862, 0.16676210652326207, 0.33352421304652413, 0.6988998632375781, 0.1996856752107366, 0.04992141880268415, 0.2274787243680678, 0.6824361731042033, 0.3491178024270708, 0.3491178024270708, 0.7913417779997818, 0.15826835559995636, 0.2848318584593649, 0.35603982307420606, 0.35603982307420606, 0.726694605778259, 0.31285166592866787, 0.39106458241083486, 0.2346387494465009, 0.8637561279022383, 0.09092169767391983, 0.24895595338406773, 0.6223898834601693, 0.7430892321167097, 0.2476964107055699, 0.7631694465730974, 0.9088728876507888, 0.5109227478875324, 0.3948039415494569, 0.09289504507046045, 0.746317985880144, 0.8456785969227792, 0.6838414432507128, 0.8980270998640645, 0.3442265665015078, 0.39340179028743744, 0.24587611892964842, 0.9404582562389542, 0.5009413216257669, 0.3757059912193252, 0.8895946873317406, 0.8501256827693593, 0.08501256827693593, 0.08501256827693593, 0.9721189385661014, 0.18014770307262576, 0.720590812290503, 0.726694605778259, 0.22454612057234832, 0.7484870685744944, 0.07484870685744945, 0.7733200657045696, 0.2209485902013056, 0.4941876894362858, 0.3643093574653865, 0.5828949719446184, 0.3160972726182815, 0.632194545236563, 0.7863965670501627, 0.48796365823144056, 0.48796365823144056, 0.8514977675205763, 0.9028012128241287, 0.08207283752946624, 0.7591208978737367, 0.18978022446843418, 0.6998281447632022, 0.8585208975603464, 0.9454183996179191, 0.30237754678404055, 0.30237754678404055, 0.30237754678404055, 0.07317728021093342, 0.3171015475807115, 0.12196213368488903, 0.4390636812656005, 0.048784853473955614, 0.061081462392085915, 0.9162219358812888, 0.9248248690487609, 0.22350518606222594, 0.3352577790933389, 0.22350518606222594, 0.22350518606222594, 0.9454156856544393, 0.6941519920682687, 0.9434114367131046, 0.9518746316264582, 0.16201800686841888, 0.32403601373683777, 0.22682520961578642, 0.09721080412105132, 0.06480720274736755, 0.09721080412105132, 0.49333640529153855, 0.49333640529153855, 0.8857647386542741, 0.39529600144089555, 0.4941200018011194, 0.7854546038064522, 0.06278443244001396, 0.25113772976005583, 0.12556886488002791, 0.4394910270800977, 0.12556886488002791, 0.9403998073746193, 0.9712738685943861, 0.9394195843552477, 0.92485428789334, 0.6757134433320146, 0.22523781444400484, 0.8162156779632016, 0.7631694465730974, 0.9835027875341398, 0.16022763004162865, 0.16022763004162865, 0.4272736801110097, 0.21363684005550485, 0.9391136292855028, 0.05105853172810158, 0.30635119036860947, 0.35740972209671107, 0.15317559518430474, 0.10211706345620317, 0.39750039027142414, 0.5300005203618988, 0.9133370874278274, 0.5346869894539018, 0.9836229579497181, 0.6838416379411418, 0.9394194179545065, 0.9560516323813811, 0.0341447011564779, 0.29909587277355537, 0.6978903698049624, 0.8679481075655369, 0.1239925867950767, 0.7236344902856773, 0.821871586065292, 0.9252255715179559, 0.9265414062609134, 0.726694605778259, 0.9407298322137146, 0.5985113415561937, 0.32646073175792384, 0.33706275470116465, 0.5617712578352744, 0.3421352062104302, 0.6842704124208604, 0.12743128765782577, 0.5097251506313031, 0.25486257531565154, 0.6838412663533429, 0.6425055256761382, 0.21416850855871272, 0.5620279030813781, 0.3746852687209187, 0.7499888868013466, 0.1499977773602693, 0.6941509344416863, 0.8158454345394011, 0.841995135596732, 0.665176114277006, 0.16989181255647254, 0.16989181255647254, 0.6795672502258902, 0.1464502859979957, 0.1464502859979957, 0.5858011439919828, 0.30000557749008877, 0.6000111549801775, 0.6604600674006523, 0.9892787008564065, 0.7822465223625517, 0.7493428994824585, 0.1665206443294352, 0.8924828626683409, 0.9450178450060827, 0.9380989702217318, 0.9450203703345804, 0.7026112376717584, 0.2810444950687034, 0.8850382782492535, 0.08045802529538669, 0.2248390458434868, 0.1124195229217434, 0.2248390458434868, 0.4496780916869736, 0.5582444778397558, 0.1199140259001095, 0.2997850647502738, 0.239828051800219, 0.2997850647502738, 0.2137200492409173, 0.6716915833285972, 0.061062871211690656, 0.061062871211690656, 0.9485078060483287, 0.08551024467817253, 0.5472655659403042, 0.03420409787126901, 0.13681639148507604, 0.05130614680690352, 0.11971434254944154, 0.03420409787126901, 0.8625780578470137, 0.2961493301043948, 0.5922986602087896, 0.8384728345388832, 0.9888981157119912, 0.9113123613108803, 0.27760175674181586, 0.27760175674181586, 0.48580307429817776, 0.9953446198165106, 0.47919657173320235, 0.23959828586660117, 0.31946438115546827, 0.821832421839679, 0.7116238992912405, 0.33539373614616136, 0.06707874722923228, 0.2683149889169291, 0.2683149889169291, 0.8384728345388832, 0.9113114883216834, 0.657871754487988, 0.1315743508975976, 0.1315743508975976, 0.1858268231226658, 0.5574804693679974, 0.1858268231226658, 0.46178320085853586, 0.46178320085853586, 0.06596902869407656, 0.5352103964762055, 0.34518984381340995, 0.6903796876268199, 0.9394194477761992, 0.6762393638396306, 0.9134077771324637, 0.8539802276504329, 0.9704905224474997, 0.726694605778259, 0.30009429092420153, 0.6001885818484031, 0.7495741070376045, 0.9692921965524105, 0.3890657670018205, 0.06484429450030342, 0.2107439571259861, 0.2107439571259861, 0.09726644175045512, 0.016211073625075855, 0.8131480548679122, 0.7115976088292808, 0.42463243724582445, 0.42463243724582445, 0.81315383235669, 0.726694605778259, 0.4970287820109336, 0.2485143910054668, 0.6604600674006523, 0.960146810190544, 0.8131128053421274, 0.32366157429754233, 0.21577438286502823, 0.43154876573005646, 0.8889508800518793, 0.8539802276504329, 0.8204799740655859, 0.5943595331846423, 0.42454252370331597, 0.3593604048342826, 0.2096269028199982, 0.2096269028199982, 0.1796802024171413, 0.8976115772793215, 0.6838433711171237, 0.33388595680147626, 0.6677719136029525, 0.7623678175563636, 0.21781937644467533, 0.9434090546642235, 0.34399396002010924, 0.20639637601206554, 0.20639637601206554, 0.06879879200402185, 0.1375975840080437, 0.13339336738803365, 0.32903697289048295, 0.22232227898005605, 0.008892891159202242, 0.1245004762288314, 0.008892891159202242, 0.13339336738803365, 0.03557156463680897, 0.14280582276848497, 0.7140291138424248, 0.14280582276848497, 0.8585208975603464, 0.9815508733080724, 0.9405543300428011, 0.15082977256588476, 0.11312232942441357, 0.15082977256588476, 0.11312232942441357, 0.11312232942441357, 0.22624465884882713, 0.18853721570735596, 0.98952012577782, 0.8419954491911524, 0.9485078060483287, 0.9574797797618431, 0.08122891431104329, 0.8935180574214762, 0.726694605778259, 0.47748523431673606, 0.07958087238612267, 0.15916174477224534, 0.23874261715836803, 0.7237787999241669, 0.07618724209728073, 0.20951491576752201, 0.9530982515377655, 0.8467847350598081], \"Term\": [\"A\", \"A\", \"AMC\", \"AP\", \"APOG\", \"AZN\", \"AZN\", \"AZN\", \"Administration\", \"After\", \"All\", \"April\", \"April\", \"Around\", \"AstraZeneca\", \"AstraZeneca\", \"AstraZeneca\", \"AstraZeneca\", \"AstraZeneca\", \"At\", \"Atacand\", \"BTIG\", \"Benchmark\", \"Biden\", \"Bill\", \"BioNTech\", \"BioNTech\", \"BioNTech\", \"Bitcoin\", \"Brexit\", \"Brexit\", \"Brian\", \"Britain\", \"British\", \"British\", \"But\", \"Buy\", \"Buy\", \"By\", \"CNBC\", \"COVID\", \"COVID\", \"COVID\", \"Chicago\", \"Composite\", \"Confirmed\", \"County\", \"Culp\", \"DAX\", \"David\", \"DermTech\", \"Despite\", \"Dow\", \"Drug\", \"Drug\", \"EU\", \"EU\", \"EU\", \"Emergent\", \"Emerging\", \"Europe\", \"Europe\", \"European\", \"European\", \"European\", \"European\", \"FILE\", \"FTSE\", \"FTSE\", \"FTSE\", \"Food\", \"French\", \"French\", \"French\", \"German\", \"German\", \"Ghaly\", \"Government\", \"Grade\", \"He\", \"He\", \"Health\", \"Health\", \"Health\", \"Hepion\", \"I\", \"I\", \"IG\", \"In\", \"In\", \"In\", \"In\", \"Inc\", \"India\", \"Industrial\", \"Japanese\", \"Jones\", \"Keator\", \"Lenox\", \"Letlow\", \"London\", \"MSCI\", \"Massachusetts\", \"Matthew\", \"Moderna\", \"Moderna\", \"Monday\", \"Monday\", \"Monday\", \"Monday\", \"Monday\", \"Monero\", \"More\", \"More\", \"My\", \"NASDAQ\", \"NASDAQ\", \"NEW\", \"NHS\", \"NHS\", \"NHS\", \"NTGR\", \"Nasdaq\", \"New\", \"New\", \"November\", \"November\", \"November\", \"Of\", \"Once\", \"Other\", \"Oxford\", \"Oxford\", \"Oxford\", \"Oxford\", \"P\", \"PHOTO\", \"PLC\", \"PLC\", \"PMI\", \"Parliament\", \"Pedestrians\", \"Pfizer\", \"Pfizer\", \"Pfizer\", \"Pharmaceuticals\", \"Phase\", \"Phase\", \"Pinker\", \"Pinker\", \"President\", \"Read\", \"Read\", \"Regeneron\", \"Reuters\", \"Reuters\", \"Reuters\", \"Russia\", \"S\", \"Senate\", \"Service\", \"Shares\", \"Shares\", \"Shares\", \"Sputnik\", \"Stephen\", \"Sterling\", \"Stock\", \"Stocks\", \"Stocks\", \"Street\", \"Street\", \"Tesla\", \"That\", \"Therapeutics\", \"Therapeutics\", \"Thursday\", \"Thursday\", \"Thursday\", \"To\", \"Tokyo\", \"Trump\", \"Tuesday\", \"Tuesday\", \"Tuesday\", \"UK\", \"UK\", \"UK\", \"UKX\", \"US\", \"US\", \"University\", \"University\", \"University\", \"University\", \"University\", \"V\", \"Wednesday\", \"Wednesday\", \"Wednesday\", \"Wednesday\", \"When\", \"Why\", \"YORK\", \"access\", \"access\", \"according\", \"according\", \"according\", \"active\", \"added\", \"added\", \"addition\", \"administered\", \"administered\", \"administration\", \"afforded\", \"ahead\", \"almost\", \"also\", \"also\", \"also\", \"alternative\", \"amid\", \"aminotransferase\", \"among\", \"analysis\", \"announced\", \"announced\", \"antibody\", \"anticipate\", \"appetite\", \"approval\", \"approval\", \"approval\", \"approved\", \"approved\", \"approved\", \"around\", \"authority\", \"authorization\", \"available\", \"back\", \"back\", \"back\", \"barrel\", \"based\", \"beginning\", \"belief\", \"bet\", \"bigger\", \"bill\", \"board\", \"booked\", \"breather\", \"briefing\", \"broadest\", \"broadly\", \"case\", \"case\", \"case\", \"case\", \"cause\", \"chance\", \"check\", \"cleared\", \"clinical\", \"close\", \"closed\", \"closed\", \"closer\", \"cocktail\", \"commented\", \"commodity\", \"company\", \"company\", \"company\", \"company\", \"company\", \"company\", \"compared\", \"compared\", \"completed\", \"concern\", \"confirmed\", \"continued\", \"continues\", \"continuing\", \"coronavirus\", \"coronavirus\", \"coronavirus\", \"coronavirus\", \"coronavirus\", \"coronavirus\", \"country\", \"country\", \"country\", \"country\", \"country\", \"cover\", \"crucial\", \"currency\", \"data\", \"data\", \"data\", \"data\", \"data\", \"day\", \"day\", \"day\", \"day\", \"day\", \"day\", \"deal\", \"deal\", \"deal\", \"death\", \"death\", \"death\", \"demand\", \"demand\", \"demand\", \"demonstrate\", \"design\", \"designed\", \"despite\", \"developed\", \"developed\", \"developed\", \"different\", \"dip\", \"distributed\", \"document\", \"dollar\", \"dollar\", \"dollar\", \"dos\", \"dos\", \"dos\", \"dos\", \"dose\", \"dose\", \"dose\", \"dosing\", \"dosing\", \"drug\", \"due\", \"due\", \"due\", \"earlier\", \"early\", \"early\", \"early\", \"economic\", \"economic\", \"education\", \"efficacy\", \"efficacy\", \"effort\", \"emergency\", \"end\", \"end\", \"end\", \"enough\", \"entire\", \"established\", \"euro\", \"evidence\", \"exchange\", \"exit\", \"face\", \"fast\", \"fear\", \"fell\", \"fell\", \"fell\", \"fight\", \"final\", \"final\", \"firm\", \"firm\", \"firm\", \"firm\", \"first\", \"first\", \"first\", \"first\", \"first\", \"first\", \"frame\", \"futility\", \"future\", \"future\", \"future\", \"future\", \"gain\", \"gain\", \"gain\", \"gained\", \"gained\", \"gained\", \"gained\", \"getting\", \"given\", \"global\", \"global\", \"global\", \"global\", \"going\", \"going\", \"going\", \"government\", \"government\", \"government\", \"greatest\", \"greatest\", \"greenback\", \"greenback\", \"group\", \"group\", \"growth\", \"growth\", \"growth\", \"guidance\", \"health\", \"health\", \"health\", \"higher\", \"higher\", \"highest\", \"highest\", \"hospital\", \"hospital\", \"hospitalized\", \"increasing\", \"index\", \"index\", \"index\", \"indicates\", \"interval\", \"invented\", \"jab\", \"last\", \"last\", \"last\", \"leaf\", \"least\", \"least\", \"little\", \"look\", \"look\", \"look\", \"looking\", \"lost\", \"lost\", \"lot\", \"low\", \"low\", \"low\", \"lower\", \"lower\", \"lowest\", \"made\", \"made\", \"major\", \"major\", \"making\", \"management\", \"management\", \"manufacturing\", \"market\", \"market\", \"may\", \"may\", \"mean\", \"mechanical\", \"member\", \"metal\", \"metal\", \"metal\", \"million\", \"million\", \"million\", \"million\", \"million\", \"morning\", \"morning\", \"mostly\", \"move\", \"move\", \"move\", \"move\", \"moved\", \"must\", \"national\", \"nearly\", \"new\", \"new\", \"new\", \"new\", \"new\", \"new\", \"news\", \"news\", \"noted\", \"number\", \"number\", \"oil\", \"one\", \"one\", \"one\", \"one\", \"one\", \"opened\", \"operating\", \"outbreak\", \"outside\", \"pace\", \"pace\", \"parliament\", \"passed\", \"passing\", \"patient\", \"patient\", \"patient\", \"patient\", \"peak\", \"people\", \"people\", \"people\", \"people\", \"people\", \"per\", \"per\", \"performance\", \"person\", \"pharmaceutical\", \"pleased\", \"pledged\", \"point\", \"point\", \"population\", \"population\", \"position\", \"position\", \"possible\", \"potential\", \"pound\", \"premarket\", \"press\", \"pressure\", \"price\", \"price\", \"program\", \"program\", \"protect\", \"protect\", \"protection\", \"protection\", \"protection\", \"proud\", \"provide\", \"provide\", \"provided\", \"provided\", \"public\", \"public\", \"pushed\", \"rallied\", \"rated\", \"ready\", \"receive\", \"receive\", \"receive\", \"received\", \"received\", \"received\", \"receiving\", \"receiving\", \"recipient\", \"record\", \"recorded\", \"regulator\", \"regulator\", \"release\", \"resident\", \"response\", \"rest\", \"restriction\", \"restriction\", \"rise\", \"rise\", \"risk\", \"risk\", \"risk\", \"risk\", \"robust\", \"rollout\", \"rollout\", \"rollout\", \"rollout\", \"rose\", \"rose\", \"rose\", \"rose\", \"safety\", \"said\", \"said\", \"said\", \"said\", \"said\", \"said\", \"said\", \"sale\", \"saying\", \"saying\", \"scenario\", \"schedule\", \"scheduled\", \"second\", \"second\", \"second\", \"session\", \"set\", \"set\", \"set\", \"setting\", \"settle\", \"share\", \"share\", \"share\", \"share\", \"sharp\", \"shortest\", \"shot\", \"shot\", \"shot\", \"sign\", \"sign\", \"sign\", \"since\", \"since\", \"since\", \"site\", \"six\", \"six\", \"sixth\", \"software\", \"spread\", \"square\", \"start\", \"starting\", \"state\", \"state\", \"sterling\", \"stimulus\", \"stock\", \"stock\", \"stock\", \"stock\", \"stock\", \"stock\", \"strategy\", \"strict\", \"study\", \"study\", \"suggests\", \"sure\", \"target\", \"target\", \"tested\", \"third\", \"tier\", \"time\", \"time\", \"time\", \"toll\", \"tomorrow\", \"total\", \"trade\", \"trade\", \"trading\", \"trading\", \"trading\", \"trading\", \"treatment\", \"trust\", \"two\", \"two\", \"use\", \"use\", \"used\", \"vaccination\", \"vaccination\", \"vaccination\", \"vaccination\", \"vaccination\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccine\", \"variant\", \"variant\", \"variant\", \"ventilation\", \"vote\", \"weakness\", \"week\", \"week\", \"week\", \"week\", \"week\", \"week\", \"week\", \"well\", \"went\", \"window\", \"within\", \"world\", \"world\", \"worldwide\", \"would\", \"would\", \"would\", \"would\", \"year\", \"year\", \"year\", \"yesterday\", \"yield\"]}, \"R\": 30, \"lambda.step\": 0.01, \"plot.opts\": {\"xlab\": \"PC1\", \"ylab\": \"PC2\"}, \"topic.order\": [10, 3, 6, 8, 1, 9, 7, 5, 4, 2]};\n",
              "\n",
              "function LDAvis_load_lib(url, callback){\n",
              "  var s = document.createElement('script');\n",
              "  s.src = url;\n",
              "  s.async = true;\n",
              "  s.onreadystatechange = s.onload = callback;\n",
              "  s.onerror = function(){console.warn(\"failed to load library \" + url);};\n",
              "  document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
              "}\n",
              "\n",
              "if(typeof(LDAvis) !== \"undefined\"){\n",
              "   // already loaded: just create the visualization\n",
              "   !function(LDAvis){\n",
              "       new LDAvis(\"#\" + \"ldavis_el12411397996949155364145719134\", ldavis_el12411397996949155364145719134_data);\n",
              "   }(LDAvis);\n",
              "}else if(typeof define === \"function\" && define.amd){\n",
              "   // require.js is available: use it to load d3/LDAvis\n",
              "   require.config({paths: {d3: \"https://d3js.org/d3.v5\"}});\n",
              "   require([\"d3\"], function(d3){\n",
              "      window.d3 = d3;\n",
              "      LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "        new LDAvis(\"#\" + \"ldavis_el12411397996949155364145719134\", ldavis_el12411397996949155364145719134_data);\n",
              "      });\n",
              "    });\n",
              "}else{\n",
              "    // require.js not available: dynamically load d3 & LDAvis\n",
              "    LDAvis_load_lib(\"https://d3js.org/d3.v5.js\", function(){\n",
              "         LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "                 new LDAvis(\"#\" + \"ldavis_el12411397996949155364145719134\", ldavis_el12411397996949155364145719134_data);\n",
              "            })\n",
              "         });\n",
              "}\n",
              "</script>"
            ],
            "text/plain": [
              "PreparedData(topic_coordinates=              x         y  topics  cluster       Freq\n",
              "topic                                                \n",
              "9      0.172635 -0.189745       1        1  23.071090\n",
              "2      0.241464  0.078615       2        1  22.331393\n",
              "5      0.068504  0.091319       3        1  14.030683\n",
              "7     -0.184491 -0.061391       4        1  10.942144\n",
              "0     -0.036030  0.159782       5        1   9.425812\n",
              "8     -0.022772 -0.142557       6        1   8.397561\n",
              "6     -0.035247  0.070513       7        1   4.953960\n",
              "4     -0.054861  0.038856       8        1   3.606161\n",
              "3     -0.071059 -0.032101       9        1   1.946941\n",
              "1     -0.078143 -0.013291      10        1   1.294255, topic_info=          Term        Freq       Total Category  logprob  loglift\n",
              "47     company   52.000000   52.000000  Default  30.0000  30.0000\n",
              "121    vaccine  112.000000  112.000000  Default  29.0000  29.0000\n",
              "28          UK   56.000000   56.000000  Default  28.0000  28.0000\n",
              "227     market   48.000000   48.000000  Default  27.0000  27.0000\n",
              "100       said   58.000000   58.000000  Default  26.0000  26.0000\n",
              "...        ...         ...         ...      ...      ...      ...\n",
              "25      Shares    1.421095   11.787362  Topic10  -4.3912   2.2316\n",
              "47     company    2.121047   52.371765  Topic10  -3.9907   1.1408\n",
              "2068  position    0.720304    8.064998  Topic10  -5.0707   1.9316\n",
              "700     making    0.440550    2.543246  Topic10  -5.5624   2.5941\n",
              "618       Last    0.440550    1.492271  Topic10  -5.5624   3.1272\n",
              "\n",
              "[534 rows x 6 columns], token_table=      Topic      Freq       Term\n",
              "term                            \n",
              "1239      4  0.531091          A\n",
              "1239      7  0.398318          A\n",
              "2201     10  0.676239        AMC\n",
              "2273      5  0.726695         AP\n",
              "1242      4  0.796919       APOG\n",
              "...     ...       ...        ...\n",
              "280       1  0.723779       year\n",
              "280       2  0.076187       year\n",
              "280       3  0.209515       year\n",
              "1447      1  0.953098  yesterday\n",
              "2597      9  0.846785      yield\n",
              "\n",
              "[734 rows x 3 columns], R=30, lambda_step=0.01, plot_opts={'xlab': 'PC1', 'ylab': 'PC2'}, topic_order=[10, 3, 6, 8, 1, 9, 7, 5, 4, 2])"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 46
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "otNtZ1kcJga7"
      },
      "source": [
        "### spaCy preprocessed lemmatised articles"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 881
        },
        "id": "aK8RWftO0dqa",
        "outputId": "0bad97f0-25e8-41b5-b84e-c4500ebea30b"
      },
      "source": [
        "# Visualise the 10 topics \n",
        "pyLDAvis.enable_notebook()\n",
        "vis = gensimvis.prepare(spacy_lem_lda_model, corpus_spacy_lem, id2word_spacy_lem)\n",
        "vis"
      ],
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/html": [
              "\n",
              "<link rel=\"stylesheet\" type=\"text/css\" href=\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v1.0.0.css\">\n",
              "\n",
              "\n",
              "<div id=\"ldavis_el12411397996863546409155505794\"></div>\n",
              "<script type=\"text/javascript\">\n",
              "\n",
              "var ldavis_el12411397996863546409155505794_data = {\"mdsDat\": {\"x\": [0.14691680796476594, 0.11131930250187569, 0.15843192448819735, 0.06381563291549944, -0.2060763286916911, -0.10361782876943286, 0.032421147381890836, -0.06815188377235713, -0.0849918857791418, -0.05006688823960641], \"y\": [0.14319451201478872, 0.17706776184367248, -0.15189768562686715, -0.168427566872076, -0.012523592525668316, 0.02379655016341373, -0.06931180672947887, 0.02330330798582848, 0.01352809829476418, 0.021270421451622903], \"topics\": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10], \"cluster\": [1, 1, 1, 1, 1, 1, 1, 1, 1, 1], \"Freq\": [34.21660588097673, 17.652040694407575, 14.194400970125393, 11.473774880662939, 6.637671090264577, 6.580354539333749, 5.728228387493566, 2.3057175561355576, 1.20709403091571, 0.004111969684201202]}, \"tinfo\": {\"Term\": [\"vaccine\", \"UK\", \"higher\", \"US\", \"NASDAQ\", \"said\", \"million\", \"AstraZeneca\", \"approval\", \"Pfizer\", \"stocks\", \"doses\", \"deal\", \"Wednesday\", \"patients\", \"rose\", \"Inc\", \"cases\", \"people\", \"first\", \"Oxford\", \"New\", \"FTSE\", \"lower\", \"Tuesday\", \"record\", \"index\", \"flat\", \"stock\", \"gained\", \"New\", \"record\", \"start\", \"P\", \"S\", \"ahead\", \"Year\", \"session\", \"Eve\", \"Nasdaq\", \"Jones\", \"Dow\", \"Average\", \"well\", \"York\", \"Senate\", \"Composite\", \"Industrial\", \"looking\", \"gain\", \"hope\", \"around\", \"Bitcoin\", \"little\", \"almost\", \"positions\", \"square\", \"tomorrow\", \"nearly\", \"Republican\", \"take\", \"peak\", \"open\", \"points\", \"Wall\", \"FTSE\", \"morning\", \"year\", \"UK\", \"news\", \"index\", \"Tuesday\", \"low\", \"Wednesday\", \"Trump\", \"back\", \"coronavirus\", \"also\", \"early\", \"investors\", \"vaccine\", \"cases\", \"rose\", \"trading\", \"markets\", \"first\", \"dollar\", \"despite\", \"trade\", \"increased\", \"administration\", \"good\", \"continued\", \"fears\", \"London\", \"biggest\", \"yesterday\", \"recovery\", \"lost\", \"earlier\", \"confirmed\", \"Americans\", \"Grade\", \"turning\", \"near\", \"closing\", \"level\", \"solutions\", \"pound\", \"weakness\", \"opened\", \"leaves\", \"late\", \"goods\", \"third\", \"traders\", \"drive\", \"stimulus\", \"see\", \"hopes\", \"British\", \"due\", \"stocks\", \"increase\", \"European\", \"shares\", \"gains\", \"end\", \"markets\", \"day\", \"billion\", \"new\", \"economy\", \"trading\", \"index\", \"closed\", \"market\", \"Wednesday\", \"year\", \"economic\", \"vaccine\", \"would\", \"company\", \"higher\", \"NASDAQ\", \"approval\", \"flat\", \"price\", \"authorization\", \"On\", \"facing\", \"product\", \"analysis\", \"Therapeutics\", \"within\", \"Buy\", \"expects\", \"United\", \"part\", \"easily\", \"Britain\", \"began\", \"given\", \"performance\", \"based\", \"Biotech\", \"India\", \"versus\", \"driven\", \"One\", \"rapid\", \"levels\", \"I\", \"may\", \"lower\", \"US\", \"AstraZeneca\", \"Group\", \"Oxford\", \"use\", \"added\", \"products\", \"University\", \"support\", \"announced\", \"vaccine\", \"made\", \"stock\", \"country\", \"developed\", \"analyst\", \"company\", \"Shares\", \"three\", \"approved\", \"UK\", \"new\", \"trading\", \"next\", \"coronavirus\", \"November\", \"COVID\", \"deaths\", \"greatest\", \"pace\", \"safety\", \"window\", \"member\", \"compared\", \"told\", \"delivered\", \"briefing\", \"national\", \"National\", \"days\", \"alternative\", \"authorities\", \"frame\", \"schedules\", \"tested\", \"statement\", \"Administration\", \"Food\", \"must\", \"pushed\", \"possible\", \"Service\", \"Daily\", \"shots\", \"recorded\", \"received\", \"Pfizer\", \"weeks\", \"health\", \"trial\", \"vaccination\", \"efficacy\", \"saying\", \"second\", \"dose\", \"said\", \"BioNTech\", \"receiving\", \"people\", \"He\", \"number\", \"vaccine\", \"cases\", \"patients\", \"first\", \"shot\", \"variant\", \"one\", \"new\", \"doses\", \"coronavirus\", \"last\", \"would\", \"company\", \"Biden\", \"Keator\", \"management\", \"testing\", \"wearing\", \"Chicago\", \"experts\", \"make\", \"AMC\", \"BTIG\", \"CNBC\", \"Tesla\", \"education\", \"position\", \"software\", \"electric\", \"MSCI\", \"dip\", \"robust\", \"yield\", \"delayed\", \"raised\", \"disease\", \"edged\", \"masks\", \"weaker\", \"AP\", \"County\", \"Ghaly\", \"Letlow\", \"state\", \"reported\", \"created\", \"highest\", \"million\", \"going\", \"rose\", \"vaccines\", \"gained\", \"business\", \"case\", \"world\", \"Tuesday\", \"developed\", \"said\", \"pandemic\", \"infectious\", \"target\", \"company\", \"rollout\", \"points\", \"Europe\", \"Shares\", \"Inc\", \"death\", \"antibody\", \"cocktail\", \"premarket\", \"clinical\", \"Emergent\", \"Pharmaceuticals\", \"mechanical\", \"ventilation\", \"To\", \"continuing\", \"futility\", \"hospitalized\", \"passed\", \"DermTech\", \"Hepion\", \"Of\", \"aminotransferase\", \"went\", \"Regeneron\", \"evidence\", \"ClearPoint\", \"Immutep\", \"NASH\", \"Osmotica\", \"Study\", \"amendment\", \"arbaclofen\", \"candidate\", \"public\", \"program\", \"Phase\", \"Moderna\", \"In\", \"risk\", \"Stocks\", \"Wednesday\", \"said\", \"stock\", \"patients\", \"jab\", \"many\", \"hospital\", \"battle\", \"vaccinated\", \"PLC\", \"ago\", \"ability\", \"ordered\", \"Most\", \"inoculation\", \"less\", \"Natwest\", \"banks\", \"largest\", \"lowest\", \"considered\", \"distribution\", \"temperatures\", \"wrong\", \"gold\", \"slipped\", \"vaccinate\", \"residents\", \"However\", \"rest\", \"ready\", \"giant\", \"trusts\", \"hundreds\", \"NHS\", \"workers\", \"rolled\", \"doses\", \"patients\", \"population\", \"million\", \"Moderna\", \"vaccine\", \"government\", \"people\", \"first\", \"Monday\", \"available\", \"UK\", \"AstraZeneca\", \"Pfizer\", \"Oxford\", \"including\", \"week\", \"results\", \"Government\", \"treatment\", \"operating\", \"completed\", \"Atacand\", \"Elsewhere\", \"Plus\", \"agreement\", \"Brent\", \"Cac\", \"Dax\", \"Dunelm\", \"FanDuel\", \"Flutter\", \"Next\", \"Paddy\", \"Power\", \"Sentiment\", \"afternoon\", \"areas\", \"confirmation\", \"credit\", \"customers\", \"doors\", \"downturn\", \"fantasy\", \"finally\", \"forced\", \"iEnergizer\", \"firm\", \"US\", \"red\", \"deal\", \"German\", \"moved\", \"Bill\", \"passing\", \"said\", \"half\", \"In\", \"PLC\", \"company\", \"FTSE\", \"facility\", \"granting\", \"regional\", \"broadly\", \"sterling\", \"period\", \"rallied\", \"Hadjikyriacos\", \"Pub\", \"Also\", \"BARC\", \"Bank\", \"Barclays\", \"Been\", \"Brewery\", \"Butlers\", \"CPC\", \"City\", \"Finally\", \"HSBA\", \"HSBC\", \"Has\", \"JD\", \"JDW\", \"LLOY\", \"Lloyds\", \"MAB\", \"MARS\", \"Marios\", \"Marston\", \"Means\", \"Mitchells\", \"NatWest\", \"Struck\", \"Wetherspoon\", \"XM\", \"agree\", \"rallied\", \"approve\", \"deal\", \"population\", \"deployment\", \"cover\", \"groups\", \"Parliament\", \"entire\", \"enough\", \"sale\", \"medicine\", \"profit\", \"manufacture\", \"transition\", \"AtacandPlus\", \"prescription\", \"recognised\", \"tax\", \"commercialise\", \"covered\", \"divestment\", \"generated\", \"Also\", \"BARC\", \"Bank\", \"Barclays\", \"Been\", \"Brewery\", \"Butlers\", \"CPC\", \"City\", \"Finally\", \"HSBA\", \"HSBC\", \"Has\", \"JD\", \"JDW\", \"LLOY\", \"Lloyds\", \"Inc\", \"This\", \"vaccine\", \"I\", \"said\", \"new\", \"Stocks\", \"Grade\", \"announced\", \"premarket\", \"products\", \"APOG\", \"NTGR\", \"second\", \"stock\", \"including\", \"Phase\", \"first\", \"time\", \"For\", \"ready\", \"today\", \"access\", \"million\", \"problems\", \"Dollar\", \"barrels\", \"coronavirus\", \"company\", \"To\"], \"Freq\": [99.0, 63.0, 25.0, 18.0, 23.0, 53.0, 34.0, 35.0, 19.0, 20.0, 29.0, 20.0, 10.0, 47.0, 19.0, 27.0, 11.0, 33.0, 23.0, 39.0, 22.0, 29.0, 39.0, 19.0, 25.0, 27.0, 41.0, 13.0, 32.0, 16.0, 28.919955694964454, 26.595435596102867, 19.69639834423614, 19.558150751329055, 19.55671142262231, 17.476824941726058, 16.66467912835023, 20.416477970069863, 12.742295116282744, 12.71422608776423, 12.713716178379407, 12.71321474394281, 12.204346365260962, 11.085496413125835, 11.073775559731782, 10.316699959916734, 10.215829007415378, 9.706883647953827, 9.319652669905341, 9.144509389904247, 8.531856795268977, 17.41368798994722, 8.0797945820425, 8.079712657542998, 8.079664632836396, 7.571442468956642, 7.571442468956642, 7.571442468956642, 7.515570666542989, 7.339269143617922, 13.307126403071655, 10.21191711256423, 9.269997242014131, 25.608539175326996, 10.315255687490195, 31.14295438904848, 15.966042534015077, 30.43151073545521, 43.90227426382225, 18.921987237828514, 29.719069862954225, 19.749006585337796, 11.79144265030435, 27.693136314944528, 14.025073166935622, 15.017406266997309, 20.947858636217898, 17.530170503323216, 13.30296944096769, 13.210831216365674, 19.616639194006925, 14.753942726569196, 14.225953452202207, 14.531870833268025, 13.541998293174094, 13.41779651445723, 14.50233241054875, 10.804229550094535, 9.552617833685426, 7.7634021899886045, 7.733662097487198, 7.559434837625964, 7.050002858398844, 7.035593709619708, 15.306290626212332, 6.3075913972706745, 6.48931980902492, 5.975273025548874, 5.947368507325541, 5.798494616204695, 5.798443243443042, 5.798433041759877, 5.791125357501176, 5.261008008273383, 5.232908929378257, 5.243471679258299, 5.028636619558143, 4.695835853960961, 4.547285137588955, 4.547316835675932, 4.547285137588955, 4.5473040835719765, 4.547264734222625, 4.546997304385367, 4.546568469346603, 4.518203417997528, 4.693598041889517, 12.498991452823406, 6.534693980976936, 6.875230537179929, 7.318978979348162, 8.960993807963224, 20.957403711804915, 6.9779090208539625, 12.766641354961253, 8.956851924598169, 9.28810567781252, 8.136401230714794, 12.590754135510718, 11.976737415240988, 8.466734646369316, 12.973012661092598, 9.188243587383726, 10.587531225833429, 11.273461068117685, 8.946898725287245, 8.954831991331467, 10.827206655349096, 9.619507355432766, 8.244010042124218, 10.251334757125557, 7.241101516140289, 7.336430415785478, 24.810522927067815, 22.97061241969912, 18.482797350193103, 13.245039012402131, 8.907451081160945, 6.348624914731917, 6.14149898197117, 5.862314954248987, 5.862314954248987, 5.833769460009172, 5.647572748926266, 5.647439150669293, 5.440732763312021, 5.290606409697186, 5.070864231011538, 5.093931610758208, 4.5688257125777865, 9.559329713084395, 4.361993930365285, 6.167235983028223, 4.566197108276123, 4.025381402777437, 3.997172248009123, 3.9198466901921822, 3.8470623011977754, 3.846911417201414, 3.8464066150155283, 3.6118684293701633, 3.633604221226613, 6.818193490127283, 9.99465904747239, 15.153200650365811, 13.1526804279108, 22.65126805278225, 5.586191381334559, 15.358613830033878, 6.581242332454667, 9.625812424646293, 7.426254237592786, 14.152687991556046, 7.450555643344651, 7.01650369579964, 31.35623515465498, 8.76410718291654, 14.349424316008102, 9.873495975629043, 7.700324030284894, 7.402124517320276, 13.299917426239968, 7.789720600789398, 7.708795214500039, 9.940547065740342, 13.070673364505778, 10.674490184881023, 8.972485306357772, 7.362965579095615, 8.379148493108092, 10.227770555110435, 6.523586068981743, 5.2098500394244, 5.042556340328209, 4.959756609238433, 4.685229601870007, 4.685229601870007, 4.662915123363822, 4.085884174896184, 3.8362312368355935, 3.616208025270845, 3.5091854901123645, 3.319418640615365, 3.259298570213133, 9.08941575480069, 3.1519217467645646, 3.1519217467645646, 3.1519217467645646, 3.1519217467645646, 3.1519217467645646, 3.068891586191997, 2.962258152410933, 2.962258152410933, 2.962258152410933, 2.9619154684832876, 2.9317270748241318, 2.712381889579251, 2.712395151707757, 2.52276187079071, 2.52276116031954, 6.884742720693491, 15.470068286514472, 7.057588041511769, 10.433996653378234, 6.091548076880064, 8.098633394851316, 5.808549411281004, 5.696161871494413, 10.790106591546015, 8.636151252377763, 22.85141093546648, 7.093485781492744, 5.241026461657251, 11.363226633046732, 5.625694498972846, 5.848904647382324, 27.993532231905796, 13.136848756331053, 9.28613859069907, 12.920966881216017, 4.846094010525483, 5.115187334386036, 6.068545862281356, 7.135431999367333, 5.933750535441592, 6.443497022229097, 5.605652580915649, 5.360283784009933, 5.649656796945897, 3.9442155888138637, 3.165306223820208, 2.386343427099046, 2.3863253425143514, 2.3863253425143514, 2.3863050658587848, 2.3863050658587848, 2.3863050658587848, 1.607373095134261, 1.607373095134261, 1.607373095134261, 1.607373095134261, 1.607373095134261, 1.607373095134261, 1.607373095134261, 1.6073732321386907, 1.6073707660589596, 1.6073707660589596, 1.6073707660589596, 1.6073707660589596, 1.6073635048241959, 1.6073635048241959, 1.6073625457931893, 1.6073625457931893, 1.6073625457931893, 1.6073625457931893, 1.6073448722217833, 1.6073448722217833, 1.6073448722217833, 1.6073448722217833, 3.62311556729816, 4.337062363980766, 2.2874610281226864, 3.769677699812574, 10.444356221486348, 3.0688715459813563, 7.609529616434506, 6.116439451192652, 5.529382595000926, 2.776479706632653, 3.486524617163003, 3.482945239437797, 4.665983420359101, 2.883639913239608, 4.941675789795635, 3.117815830403727, 2.1951248377924286, 2.0048011614193277, 3.119500436868901, 2.204212615610248, 2.029376878979218, 1.787694626127037, 1.8282308117063548, 10.97678817588151, 8.835798104955108, 7.296494079137767, 5.605025546134175, 4.984134356356648, 4.065505292662574, 4.063763247503325, 3.6031912812196496, 3.4511278251482045, 3.4511278251482045, 3.1407235199622647, 2.836565912185039, 2.836565912185039, 2.836565912185039, 2.836565912185039, 2.5262528789737613, 2.5262528789737613, 2.5262528789737613, 2.5262528789737613, 2.5262528789737613, 2.3741964856146414, 2.3741964856146414, 1.9117814230569123, 1.9117814230569123, 1.9117814230569123, 1.9117814230569123, 1.9117814230569123, 1.9117814230569123, 1.9117814230569123, 1.9117814230569123, 4.456617928014539, 5.255389775482122, 4.494411316594161, 3.144908720300413, 5.504513370608745, 3.716053424173754, 3.14065533762405, 6.427488718810534, 5.03989881644733, 3.5910961147202407, 2.9391213847146593, 4.6978257293278745, 4.431675375456823, 4.252253282522447, 3.9605645714851194, 3.155612815641798, 7.8483027340502804, 2.8884941323948587, 2.888559870017935, 2.888559870017935, 2.8640629103049946, 2.709187198534001, 2.7091032530081303, 2.709178922214549, 2.7091730105577976, 2.7091474722006312, 2.7081204991897687, 1.7918478720905935, 1.7918478720905935, 1.7918478720905935, 1.7918478720905935, 1.7673844905880012, 1.6124441052921468, 1.6124417406294462, 1.6124255426899472, 1.6124301537822134, 1.6072478772407548, 2.198876908042223, 0.9624098566330519, 0.9624098566330519, 0.9624052455407858, 3.884972689536831, 1.7486732693377076, 1.748662391889285, 8.10174870109619, 6.9913929540858994, 3.430575085066565, 7.027113075908338, 2.7045006735277193, 9.746951424644568, 4.602288153966454, 4.525635720796956, 5.598939567951839, 3.6378044290284253, 2.5785854587832833, 5.8656692641845325, 4.464774505141938, 3.5744624457342278, 3.6191812914637285, 2.981078716975793, 3.055725916175199, 2.628000711702071, 1.9258378959131874, 1.910776671548879, 1.9100024608826633, 1.6415253524643914, 1.3192831491134276, 1.297192826705186, 1.1777456557933899, 0.9095986386697373, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 0.6685424273032691, 2.806497293721498, 4.508989594554595, 1.2535993598577075, 1.7771205362070375, 1.1467203102883137, 0.8969890179604221, 1.0746674152138314, 1.0746674152138314, 1.2959121524349708, 0.9747220912900982, 1.0780501847094424, 0.8517455705500169, 0.8296612446099302, 0.7753181567745344, 0.6775523110700051, 0.6775523110700051, 0.6775523110700051, 0.672024471660555, 0.672024471660555, 0.6729378860517939, 0.6711976729204417, 0.7891863547926101, 0.7891863547926101, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.40672795291698444, 0.7875639930483784, 0.7648691165410656, 1.7517002215130908, 1.4655516468111913, 0.5622850776100847, 0.6921342614925226, 0.5476934390818697, 0.6429532008634897, 0.6501503320191614, 0.626032861819482, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013202600888892772, 0.00013204851080320115, 0.00013204582669932977, 0.00013204253787640438, 0.00013204055397354292, 0.00013204049031890567, 0.00013204001290912618, 0.00013203977950878952, 0.00013203949306292185, 0.00013203744550542313, 0.00013203726515061755, 0.0001320361724126778, 0.00013203611936714676, 0.00013203611936714676, 0.00013203507967473807, 0.0001320344961738965, 0.0001320344961738965, 0.00013203445373747164, 0.00013203444312836544, 0.0001320341248551791, 0.000132034018764117, 0.00013203397632769216, 0.0001320339338912673, 0.00013203378536378034, 0.00013203376414556794, 0.0001320333397813195, 0.00013203314881740768, 0.00013203314881740768, 0.00013203310638098284, 0.00013203310638098284, 0.0001320330427263456], \"Total\": [99.0, 63.0, 25.0, 18.0, 23.0, 53.0, 34.0, 35.0, 19.0, 20.0, 29.0, 20.0, 10.0, 47.0, 19.0, 27.0, 11.0, 33.0, 23.0, 39.0, 22.0, 29.0, 39.0, 19.0, 25.0, 27.0, 41.0, 13.0, 32.0, 16.0, 29.41691546642579, 27.095629119879888, 20.195641096302662, 20.05550448259232, 20.055505746130315, 17.974210684845126, 17.161848565132136, 21.06597117810096, 13.2394770935208, 13.21153108273618, 13.211531471986255, 13.21153256595311, 12.703278010157428, 11.582433798627555, 11.578013030995592, 10.81394045174921, 10.714076095356699, 10.205822358733602, 9.817669414498384, 9.641513385510358, 9.028942984814913, 18.473145261691215, 8.576722426397746, 8.57672289135686, 8.576732686067746, 8.06845777368182, 8.06845777368182, 8.06845777368182, 8.012425978277681, 7.836223181204705, 14.485969200583096, 11.078973674547639, 10.004707315230982, 29.883027786041716, 11.256087827088702, 39.50486953690977, 18.552955543767556, 40.82880983886858, 63.3743709078031, 23.573023730855617, 41.428055168733366, 25.89470662851889, 13.556270292023452, 47.52943532255808, 18.009617179925876, 20.808315493016682, 43.11313711274257, 31.82684878321653, 18.94649360690525, 20.281207046928262, 99.15591767570176, 33.298083998936654, 27.51942850925254, 34.429426344114695, 26.55021209474698, 39.75343837254596, 14.999179673790087, 11.301192571016518, 10.049700599313477, 8.260973951402933, 8.232850671396033, 8.056350344003814, 7.547014046980884, 7.54717978076665, 16.472842138002324, 6.804991010985163, 7.009511361222375, 6.472151952573605, 6.444097183587147, 6.295487789390048, 6.295515338305452, 6.2955802742901925, 6.287850886280012, 5.7582022330422795, 5.7300769408561605, 5.758175319322809, 5.525505522157774, 5.192699070491862, 5.044108378174122, 5.044221458393773, 5.0442003381338445, 5.044223564540942, 5.04418106578616, 5.044125077919956, 5.044104232909826, 5.016028395461334, 5.220734694486131, 14.839033746676941, 7.52419098528813, 7.971781145507188, 8.637079077854786, 10.926615605348333, 29.757675935276513, 8.304037289727132, 18.339459685704593, 11.94179677804335, 13.51240382358502, 11.62355047352836, 26.55021209474698, 24.528057461037907, 14.00136181784027, 34.72288615069998, 18.677649096364078, 34.429426344114695, 41.428055168733366, 21.435131946004006, 21.935686595442014, 47.52943532255808, 40.82880983886858, 20.50930492473849, 99.15591767570176, 13.750466744034949, 37.23982945555678, 25.306579438483325, 23.466632751320535, 19.03784338821756, 13.741964196865606, 9.403417743802537, 6.8447974176592306, 6.637965773535967, 6.358336551462731, 6.358336551462731, 6.329864316159243, 6.143562170932273, 6.1436174717639584, 5.936724141244645, 5.786622207181391, 5.579627321724365, 5.605667506337327, 5.064853739439351, 10.605772084301277, 4.8579667627554945, 6.8704967275970485, 5.09287489440417, 4.521496715990144, 4.493111346980379, 4.4157876667459695, 4.343001101753074, 4.34296852125798, 4.343039704302949, 4.107771061205171, 4.136089765452375, 7.771709771260856, 12.427373950564675, 19.977554048214863, 18.11780578137679, 35.8015843641897, 6.767941432364282, 22.66071218305836, 8.236163723130407, 13.165241993779167, 9.813120446227362, 24.271012934147084, 10.305673950590966, 9.475201240324157, 99.15591767570176, 13.416687543576483, 32.084350873703016, 16.959850031732064, 11.144785634408809, 10.400460403919947, 37.23982945555678, 12.035374819979644, 12.053799715059236, 23.812348284505678, 63.3743709078031, 34.72288615069998, 34.429426344114695, 13.83431055709259, 43.11313711274257, 10.718758771172013, 7.014720024161875, 5.701110450055822, 5.533405832325231, 5.451164635625946, 5.176059766872251, 5.176059766872251, 5.154038132359088, 4.577114500006472, 4.327266201602859, 4.107463776053512, 4.000076862929063, 3.8104436413881064, 3.7501880004066606, 10.465816280890518, 3.64274410145524, 3.64274410145524, 3.64274410145524, 3.64274410145524, 3.64274410145524, 3.5604588018709955, 3.453143167170669, 3.453143167170669, 3.453143167170669, 3.452904700589489, 3.422966086593011, 3.20326000907036, 3.2032801300292495, 3.0136721561424857, 3.013672134690523, 8.528309731010035, 20.093721265166888, 8.996233843588094, 14.013813473071975, 7.919814332027587, 11.11672754851383, 7.70500512609284, 7.5868043000370236, 17.397769392595567, 13.475403276089843, 53.33034534798272, 11.17184236203319, 7.44040145267851, 23.096796269152776, 8.432149613019615, 8.933758965840303, 99.15591767570176, 33.298083998936654, 19.569687197013604, 39.75343837254596, 6.952303275356989, 8.551953270017307, 17.11445783200534, 34.72288615069998, 20.023965454555896, 43.11313711274257, 22.64337713410167, 13.750466744034949, 37.23982945555678, 4.471033621770752, 3.6920278377924842, 2.913045195356611, 2.9130569838811886, 2.9130569838811886, 2.913068051995619, 2.913068051995619, 2.913068051995619, 2.1340692470470324, 2.1340692470470324, 2.1340692470470324, 2.1340692470470324, 2.1340692470470324, 2.1340692470470324, 2.1340692470470324, 2.1340713882672424, 2.1340746828991954, 2.1340746828991954, 2.1340746828991954, 2.1340746828991954, 2.1340763845834427, 2.1340763845834427, 2.1340788005999958, 2.1340788005999958, 2.1340788005999958, 2.1340788005999958, 2.1340881599224124, 2.1340881599224124, 2.1340881599224124, 2.1340881599224124, 6.1894382661971905, 7.970111692934033, 3.3997826240451725, 7.073726660877037, 34.912911783511994, 5.82016495605521, 27.51942850925254, 19.25757860993719, 16.863936806549738, 6.229602589192102, 10.699132973380639, 11.643457238826628, 25.89470662851889, 11.144785634408809, 53.33034534798272, 16.450403545023843, 5.525801757299055, 4.677951632964315, 37.23982945555678, 16.368982630163803, 29.883027786041716, 7.851961444476122, 12.035374819979644, 11.484721176666445, 9.34413064576724, 7.804568316769979, 6.113076961137782, 5.491908122464727, 4.57354306683349, 4.57382470693856, 4.111012915691173, 3.9590607340724144, 3.9590607340724144, 3.648484706259634, 3.3445760214365823, 3.3445760214365823, 3.3445760214365823, 3.3445760214365823, 3.0340104160751147, 3.0340104160751147, 3.0340104160751147, 3.0340104160751147, 3.0340104160751147, 2.8820578198191478, 2.8820578198191478, 2.419535731316354, 2.419535731316354, 2.419535731316354, 2.419535731316354, 2.419535731316354, 2.419535731316354, 2.419535731316354, 2.419535731316354, 5.938180469669303, 7.912506250489613, 6.956927601582603, 6.288389271728297, 19.104415389016474, 9.474722771076959, 7.755737202985011, 47.52943532255808, 53.33034534798272, 32.084350873703016, 19.569687197013604, 5.205274018156671, 4.938501021443649, 4.759117678539527, 4.467426426550922, 3.6623630172521144, 9.167424737880554, 3.3953030544583034, 3.3953821168240848, 3.3953821168240848, 3.3707232299969188, 3.216045310664083, 3.215953401959487, 3.2160461124260333, 3.216046768081986, 3.2160505493668365, 3.215825691140921, 2.298566138861511, 2.298566138861511, 2.298566138861511, 2.298566138861511, 2.2739951177538305, 2.119215945708266, 2.1192167638658956, 2.1192107232941857, 2.1192193611342636, 2.117710975380846, 3.2705227170754245, 1.4689041871820308, 1.4689046146532425, 1.4689039109073356, 7.658676539017483, 2.9985861651552863, 2.9986632172085, 20.023965454555896, 19.569687197013604, 8.230012057707414, 34.912911783511994, 6.288389271728297, 99.15591767570176, 22.530552409290316, 23.096796269152776, 39.75343837254596, 14.477250045447747, 6.2528140317634975, 63.3743709078031, 35.8015843641897, 20.093721265166888, 22.66071218305836, 13.976130909683208, 21.340924606793422, 3.1659804058689507, 2.4621214945896135, 2.4485209524039924, 2.4497014979625433, 2.1781869942187324, 1.8554861677434458, 1.8334543226025426, 1.7163576227436192, 1.4470919245948735, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 1.2047921863888162, 5.338855682551836, 18.11780578137679, 4.373904180453091, 10.937947712100168, 8.273487701845378, 4.01841466949616, 9.545293879611513, 9.545293879611513, 53.33034534798272, 10.31738035451243, 19.104415389016474, 9.167424737880554, 37.23982945555678, 39.50486953690977, 1.981646445417736, 1.981646445417736, 1.981646445417736, 1.5886544341407078, 1.5886544341407078, 6.426825158654908, 1.970801920708014, 1.3410633857195762, 1.3410633857195762, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 1.970801920708014, 2.6841537800173216, 10.937947712100168, 8.230012057707414, 1.8934760551722594, 3.1183162943103273, 2.16405246892511, 3.4586589226852396, 4.56755733477383, 4.8046616723475974, 0.8319873058151913, 0.831987311508095, 0.831987311508095, 0.8319873172009985, 0.8319873172009985, 0.831987322893902, 0.831987322893902, 0.831987322893902, 0.831987322893902, 0.8319873342797092, 0.8319873342797092, 0.8319873342797092, 0.8319873342797092, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 0.9586002721845067, 11.484721176666445, 5.909445570219427, 99.15591767570176, 7.771709771260856, 53.33034534798272, 34.72288615069998, 7.755737202985011, 6.287850886280012, 9.475201240324157, 5.491908122464727, 9.813120446227362, 4.859915768533772, 4.859915768533772, 17.397769392595567, 32.084350873703016, 13.976130909683208, 6.956927601582603, 39.75343837254596, 11.068924995443794, 4.999345308025729, 3.2705227170754245, 5.425651874139656, 3.8137490226197723, 34.912911783511994, 1.8128255843156273, 2.718012904054985, 2.718012904054985, 43.11313711274257, 37.23982945555678, 3.648484706259634], \"Category\": [\"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic6\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic7\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic8\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic9\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\", \"Topic10\"], \"logprob\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, -4.6529, -4.7367, -5.037, -5.044, -5.0441, -5.1565, -5.2041, -5.0011, -5.4725, -5.4747, -5.4747, -5.4748, -5.5156, -5.6118, -5.6128, -5.6836, -5.6935, -5.7446, -5.7853, -5.8043, -5.8736, -5.1602, -5.928, -5.9281, -5.9281, -5.993, -5.993, -5.993, -6.0004, -6.0242, -5.4291, -5.6939, -5.7906, -4.7745, -5.6838, -4.5788, -5.2469, -4.6019, -4.2354, -5.0771, -4.6256, -5.0343, -5.55, -4.6962, -5.3766, -5.3082, -4.9754, -5.1535, -5.4294, -5.4364, -5.041, -5.3259, -5.3623, -5.3411, -5.4116, -5.4208, -4.6812, -4.9756, -5.0987, -5.3061, -5.31, -5.3328, -5.4025, -5.4046, -4.6273, -5.5138, -5.4854, -5.5679, -5.5726, -5.5979, -5.598, -5.598, -5.5992, -5.6952, -5.7006, -5.6986, -5.7404, -5.8089, -5.841, -5.841, -5.841, -5.841, -5.841, -5.8411, -5.8412, -5.8474, -5.8093, -4.8299, -5.4784, -5.4276, -5.3651, -5.1627, -4.3131, -5.4128, -4.8087, -5.1631, -5.1268, -5.2592, -4.8226, -4.8726, -5.2194, -4.7927, -5.1376, -4.9959, -4.9331, -5.1642, -5.1634, -4.9735, -5.0918, -5.2461, -5.0281, -5.3758, -5.3627, -3.9263, -4.0033, -4.2207, -4.5539, -4.9507, -5.2893, -5.3225, -5.369, -5.369, -5.3739, -5.4063, -5.4063, -5.4436, -5.4716, -5.514, -5.5095, -5.6183, -4.88, -5.6646, -5.3183, -5.6189, -5.7449, -5.752, -5.7715, -5.7902, -5.7903, -5.7904, -5.8533, -5.8473, -5.2179, -4.8355, -4.4193, -4.5609, -4.0173, -5.4172, -4.4059, -5.2533, -4.8731, -5.1325, -4.4876, -5.1293, -5.1893, -3.6921, -4.9669, -4.4738, -4.8477, -5.0963, -5.1358, -4.5498, -5.0847, -5.0952, -4.8409, -4.5672, -4.7697, -4.9434, -5.1411, -5.0118, -4.5997, -5.0493, -5.2742, -5.3068, -5.3234, -5.3803, -5.3803, -5.3851, -5.5172, -5.5803, -5.6393, -5.6694, -5.725, -5.7432, -4.7176, -5.7767, -5.7767, -5.7767, -5.7767, -5.7767, -5.8034, -5.8388, -5.8388, -5.8388, -5.8389, -5.8492, -5.9269, -5.9269, -5.9994, -5.9994, -4.9955, -4.1859, -4.9707, -4.5797, -5.1179, -4.8331, -5.1654, -5.185, -4.5461, -4.7688, -3.7957, -4.9656, -5.2682, -4.4944, -5.1974, -5.1585, -3.5928, -4.3493, -4.6962, -4.3659, -5.3466, -5.2925, -5.1216, -4.9597, -5.1441, -5.0617, -5.201, -5.2457, -5.1932, -5.0052, -5.2252, -5.5077, -5.5077, -5.5077, -5.5077, -5.5077, -5.5077, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.9029, -5.0901, -4.9103, -5.55, -5.0505, -4.0314, -5.2561, -4.3481, -4.5665, -4.6674, -5.3563, -5.1286, -5.1296, -4.8372, -5.3184, -4.7798, -5.2403, -5.5912, -5.6819, -5.2398, -5.5871, -5.6697, -5.7965, -5.7741, -3.973, -4.19, -4.3814, -4.6451, -4.7625, -4.9662, -4.9667, -5.087, -5.1301, -5.1301, -5.2243, -5.3262, -5.3262, -5.3262, -5.3262, -5.442, -5.442, -5.442, -5.442, -5.442, -5.5041, -5.5041, -5.7207, -5.7207, -5.7207, -5.7207, -5.7207, -5.7207, -5.7207, -5.7207, -4.8744, -4.7095, -4.8659, -5.223, -4.6632, -5.0561, -5.2244, -4.5082, -4.7514, -5.0903, -5.2907, -4.683, -4.7413, -4.7827, -4.8537, -5.0809, -4.1698, -5.1694, -5.1693, -5.1693, -5.1779, -5.2335, -5.2335, -5.2335, -5.2335, -5.2335, -5.2338, -5.6469, -5.6469, -5.6469, -5.6469, -5.6606, -5.7524, -5.7524, -5.7524, -5.7524, -5.7556, -5.4422, -6.2684, -6.2684, -6.2684, -4.873, -5.6712, -5.6713, -4.138, -4.2854, -4.9974, -4.2803, -5.2352, -3.9531, -4.7035, -4.7203, -4.5075, -4.9387, -5.2829, -4.461, -4.7339, -4.9563, -4.9439, -5.1378, -5.1131, -4.3539, -4.6647, -4.6726, -4.673, -4.8245, -5.043, -5.0599, -5.1565, -5.4148, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -5.7227, -4.2882, -3.814, -5.0941, -4.7451, -5.1832, -5.4288, -5.2481, -5.2481, -5.0609, -5.3457, -5.2449, -5.4806, -5.5068, -5.5746, -5.7094, -5.7094, -5.7094, -5.7175, -5.7175, -5.7162, -5.7188, -4.9097, -4.9097, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -5.5725, -4.9117, -4.941, -4.1123, -4.2907, -5.2487, -5.0409, -5.275, -5.1146, -5.1035, -5.1413, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9234, -7.9232, -7.9232, -7.9232, -7.9232, -7.9232, -7.9232, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233, -7.9233], \"loglift\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 1.0554, 1.0538, 1.0474, 1.0473, 1.0473, 1.0444, 1.0431, 1.0411, 1.0342, 1.0341, 1.0341, 1.034, 1.0324, 1.0286, 1.0279, 1.0254, 1.0248, 1.0223, 1.0204, 1.0195, 1.0158, 1.0134, 1.0128, 1.0128, 1.0128, 1.0089, 1.0089, 1.0089, 1.0084, 1.0069, 0.9876, 0.991, 0.9962, 0.9181, 0.9852, 0.8346, 0.9223, 0.7785, 0.7054, 0.8527, 0.7403, 0.8015, 0.933, 0.5323, 0.8224, 0.7463, 0.3507, 0.4761, 0.7188, 0.6438, -0.5479, 0.2585, 0.4126, 0.2099, 0.3992, -0.0137, 1.7006, 1.6893, 1.6836, 1.6722, 1.6718, 1.6707, 1.6662, 1.6641, 1.6609, 1.6584, 1.6572, 1.6544, 1.6541, 1.6521, 1.6521, 1.6521, 1.652, 1.644, 1.6436, 1.6407, 1.6401, 1.6337, 1.6306, 1.6306, 1.6306, 1.6306, 1.6306, 1.6306, 1.6305, 1.6298, 1.6279, 1.5627, 1.5933, 1.5863, 1.5687, 1.536, 1.3837, 1.5603, 1.3721, 1.4467, 1.3594, 1.3776, 0.9882, 1.0175, 1.2313, 0.7498, 1.0249, 0.5551, 0.4328, 0.8606, 0.8384, 0.255, 0.2887, 0.8229, -0.535, 1.093, 0.1098, 1.9325, 1.931, 1.9227, 1.9155, 1.8981, 1.8771, 1.8746, 1.8711, 1.8711, 1.8707, 1.8681, 1.8681, 1.8651, 1.8627, 1.8567, 1.8566, 1.8493, 1.8484, 1.8446, 1.8443, 1.8432, 1.8361, 1.8354, 1.8332, 1.8311, 1.831, 1.8309, 1.8237, 1.8228, 1.8214, 1.7345, 1.6759, 1.6321, 1.4945, 1.7604, 1.5634, 1.728, 1.6392, 1.6736, 1.4129, 1.6279, 1.6519, 0.801, 1.5265, 1.1477, 1.4113, 1.5826, 1.6122, 0.9227, 1.5173, 1.5053, 1.0787, 0.3736, 0.7728, 0.6076, 1.3216, 0.3142, 2.1182, 2.0925, 2.075, 2.0722, 2.0706, 2.0655, 2.0655, 2.065, 2.0516, 2.0447, 2.0377, 2.0342, 2.0272, 2.0248, 2.0241, 2.0204, 2.0204, 2.0204, 2.0204, 2.0204, 2.0165, 2.0118, 2.0118, 2.0118, 2.0117, 2.0102, 1.9988, 1.9988, 1.9873, 1.9873, 1.951, 1.9036, 1.9224, 1.8701, 1.9026, 1.8484, 1.8826, 1.8785, 1.6874, 1.7202, 1.3176, 1.7109, 1.8147, 1.4558, 1.7604, 1.7415, 0.9004, 1.235, 1.4196, 1.0413, 1.8042, 1.6512, 1.1283, 0.5828, 0.9488, 0.2643, 0.769, 1.2231, 0.2793, 2.587, 2.5585, 2.513, 2.513, 2.513, 2.5129, 2.5129, 2.5129, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.429, 2.1769, 2.1039, 2.3161, 2.083, 1.5056, 2.0724, 1.4269, 1.5655, 1.5973, 1.9043, 1.5912, 1.5055, 0.9987, 1.3605, 0.3336, 1.0492, 1.7892, 1.8651, 0.2327, 0.7074, 0.0228, 1.2326, 0.8279, 2.6758, 2.6651, 2.6538, 2.6343, 2.6241, 2.6033, 2.6028, 2.5892, 2.5838, 2.5838, 2.5712, 2.5563, 2.5563, 2.5563, 2.5563, 2.5379, 2.5379, 2.5379, 2.5379, 2.5379, 2.5272, 2.5272, 2.4855, 2.4855, 2.4855, 2.4855, 2.4855, 2.4855, 2.4855, 2.4855, 2.4341, 2.3119, 2.2842, 2.0282, 1.4767, 1.7851, 1.8171, 0.7203, 0.362, 0.5312, 0.8252, 2.7572, 2.7515, 2.7472, 2.7393, 2.7108, 2.7044, 2.6981, 2.6981, 2.6981, 2.6969, 2.6883, 2.6883, 2.6883, 2.6883, 2.6882, 2.6879, 2.6107, 2.6107, 2.6107, 2.6107, 2.6077, 2.5865, 2.5865, 2.5865, 2.5865, 2.584, 2.4628, 2.4369, 2.4369, 2.4369, 2.181, 2.3205, 2.3204, 1.9549, 1.8305, 1.9847, 1.2567, 2.016, 0.54, 1.2714, 1.2298, 0.8996, 1.4786, 1.974, 0.4798, 0.778, 1.1332, 1.0254, 1.3147, 0.9162, 3.5835, 3.5241, 3.5218, 3.5209, 3.4869, 3.4287, 3.4238, 3.3932, 3.3055, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1808, 3.1267, 2.379, 2.5201, 1.9525, 1.7936, 2.2702, 1.5857, 1.5857, 0.0525, 1.4103, 0.895, 1.3937, -0.0343, -0.1611, 2.6966, 2.6966, 2.6966, 2.9094, 2.9094, 1.5132, 2.6926, 3.8867, 3.8867, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.5596, 3.4997, 3.1615, 2.5853, 2.6914, 3.2028, 2.9117, 3.0429, 2.7344, 2.4674, 2.379, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.3504, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, 1.2088, -1.2743, -0.6099, -3.4301, -0.8839, -2.8099, -2.3808, -0.8818, -0.672, -1.0821, -0.5367, -1.1171, -0.4144, -0.4144, -1.6898, -2.3018, -1.4708, -0.7732, -2.5161, -1.2376, -0.4427, -0.0184, -0.5246, -0.172, -2.3863, 0.5717, 0.1667, 0.1667, -2.5973, -2.4508, -0.1277]}, \"token.table\": {\"Topic\": [5, 5, 2, 4, 2, 1, 2, 3, 4, 7, 8, 1, 5, 5, 1, 8, 3, 4, 3, 1, 8, 2, 3, 2, 7, 3, 5, 4, 8, 5, 6, 1, 5, 4, 8, 6, 2, 1, 8, 8, 6, 1, 3, 5, 1, 2, 3, 4, 1, 1, 2, 7, 8, 8, 8, 4, 2, 6, 1, 4, 8, 5, 8, 2, 3, 7, 9, 1, 4, 6, 7, 3, 4, 6, 1, 2, 3, 4, 6, 7, 8, 6, 3, 1, 1, 5, 5, 2, 4, 5, 6, 7, 1, 3, 4, 7, 7, 3, 6, 4, 7, 2, 1, 4, 7, 1, 8, 4, 6, 3, 3, 6, 3, 4, 7, 1, 7, 8, 8, 3, 9, 3, 4, 7, 6, 4, 6, 8, 8, 9, 6, 1, 1, 1, 8, 4, 1, 3, 5, 7, 8, 2, 6, 6, 5, 3, 2, 3, 6, 1, 2, 1, 2, 5, 1, 3, 7, 3, 8, 3, 1, 3, 4, 7, 1, 3, 1, 2, 3, 6, 1, 1, 7, 2, 4, 2, 3, 2, 8, 7, 8, 1, 1, 1, 2, 3, 4, 6, 7, 4, 6, 6, 3, 1, 3, 2, 3, 6, 3, 1, 5, 9, 1, 2, 3, 7, 6, 8, 1, 7, 4, 3, 3, 7, 1, 2, 4, 7, 2, 3, 7, 3, 2, 1, 2, 3, 4, 8, 3, 5, 6, 1, 5, 1, 3, 4, 6, 1, 2, 2, 6, 1, 2, 3, 4, 5, 8, 4, 8, 8, 2, 7, 2, 6, 1, 2, 3, 4, 7, 2, 3, 7, 4, 9, 5, 7, 8, 8, 1, 2, 3, 3, 4, 2, 8, 9, 6, 4, 5, 4, 5, 9, 2, 3, 5, 5, 5, 7, 2, 8, 3, 4, 7, 3, 4, 7, 8, 2, 3, 2, 3, 2, 1, 2, 3, 3, 1, 2, 1, 2, 5, 5, 4, 6, 5, 2, 4, 1, 4, 9, 4, 9, 6, 3, 5, 5, 8, 3, 8, 2, 8, 7, 8, 1, 2, 3, 4, 6, 7, 8, 3, 8, 4, 6, 1, 1, 5, 7, 1, 2, 7, 7, 3, 1, 4, 5, 7, 2, 2, 1, 2, 3, 4, 7, 5, 8, 4, 1, 9, 1, 2, 7, 8, 1, 4, 6, 3, 1, 5, 1, 2, 7, 7, 6, 7, 8, 1, 2, 6, 7, 2, 6, 2, 1, 2, 1, 5, 7, 1, 2, 7, 7, 1, 3, 4, 7, 2, 2, 7, 2, 3, 1, 1, 2, 1, 3, 1, 3, 7, 3, 4, 7, 5, 5, 7, 1, 2, 1, 2, 5, 2, 3, 6, 4, 1, 2, 3, 4, 5, 6, 7, 1, 7, 3, 8, 4, 4, 2, 1, 1, 2, 3, 4, 1, 2, 7, 1, 3, 3, 4, 1, 3, 4, 7, 1, 2, 8, 7, 4, 1, 3, 5, 3, 6, 1, 8, 4, 6, 7, 1, 3, 4, 7, 3, 1, 4, 8, 1, 3, 5, 4, 7, 9, 5, 1, 4, 2, 6, 3, 3, 3, 3, 4, 3, 6, 2, 6, 4, 5, 8, 9, 3, 4, 7, 3, 4, 4, 6, 1, 4, 2, 1, 8, 5, 8, 1, 3, 5, 7, 7, 7, 8, 2, 6, 7, 5, 3, 7, 1, 2, 4, 5, 7, 1, 2, 5, 6, 4, 1, 2, 3, 4, 5, 6, 8, 3, 4, 4, 3, 4, 2, 3, 1, 2, 6, 3, 4, 4, 7, 5, 2, 1, 1, 1, 5, 4, 8, 1, 2, 1, 2, 3, 6, 1, 2, 2, 3, 1, 7, 1, 3, 5, 7, 4, 5, 2, 1, 3, 1, 4, 2, 3, 7, 4, 1, 2, 2, 1, 2, 3, 8, 4, 6, 7, 2, 3, 7, 7, 7, 1, 4, 7, 1, 2, 3, 4, 7, 1, 3, 5, 7, 1, 3, 4, 6, 3, 5, 2, 5, 1, 2, 3, 4, 7, 3, 4, 7, 1, 6, 4, 3, 3, 7, 1, 4, 5, 7, 2, 4, 6, 7, 1, 2, 2, 5], \"Freq\": [0.9371767119400893, 0.9371684064226815, 0.8230595324097136, 0.8687737098540425, 0.953049558354886, 0.11172689899168188, 0.05586344949584094, 0.6424296692021708, 0.05586344949584094, 0.11172689899168188, 0.5389423092364803, 0.9446380682533206, 0.9371767119400893, 0.8946477120017275, 0.838109344866561, 0.10476366810832012, 0.3580430040432499, 0.6265752570756873, 0.8902516966752276, 0.9327572471480844, 0.8300186632163925, 0.09428827925504882, 0.9428827925504882, 0.8104591768700824, 0.11577988241001178, 0.8422153162319145, 0.9371767119400893, 0.9979015521487425, 0.8300186632163925, 0.6865613725123535, 0.8266048622939308, 0.933351593828406, 0.9371684064226815, 0.9365400084358549, 0.8300186632163925, 0.9887902770883985, 0.7358316794656176, 0.9839887942676505, 0.8300186632163925, 0.5454185510225993, 0.874541604957431, 0.2547134259563903, 0.5094268519127806, 0.2547134259563903, 0.16358170041064335, 0.7088540351127878, 0.10905446694042889, 0.054527233470214445, 0.9819118918497168, 0.7847133875745724, 0.12656667541525363, 0.05062667016610145, 0.025313335083050725, 0.8300186632163925, 0.8300186632163925, 0.8687737098540425, 0.400052382216785, 0.6000785733251776, 0.3626040320735424, 0.4834720427647232, 0.1208680106911808, 0.9371684064226815, 0.8123075991151931, 0.9542211016950009, 0.8865324944019185, 0.14775541573365308, 0.745676908823686, 0.23718744232335617, 0.7115623269700686, 0.9887902770883985, 0.9437437372833107, 0.9007027032694176, 0.12867181475277395, 0.8266048622939308, 0.2093756819326533, 0.10468784096632665, 0.15703176144948996, 0.10468784096632665, 0.31406352289897993, 0.10468784096632665, 0.052343920483163324, 0.9577942581965981, 0.9058406567242472, 0.9798328491816761, 0.9839888757457993, 0.8125615872370406, 0.9371684064226815, 0.9105896768958573, 0.06070597845972382, 0.9371743247911777, 0.4770697026482716, 0.4770697026482716, 0.2072216747367243, 0.2762955663156324, 0.2072216747367243, 0.2762955663156324, 0.8900167101535483, 0.9801150528810199, 0.8266048622939308, 0.3917125869876291, 0.5222834493168388, 0.8230595324097136, 0.9839889047369693, 0.7999598952571678, 0.9328224456759862, 0.9858273561379464, 0.8300186632163925, 0.9329438429844035, 0.9887902770883985, 0.9038913734567013, 0.9210139147558157, 0.8266048622939308, 0.6619385956993146, 0.1323877191398629, 0.17651695885315055, 0.9972324564240956, 0.8726551053038201, 0.10908188816297751, 0.8300186632163925, 0.5782588120736799, 0.28912940603683995, 0.04976678967541628, 0.7465018451312442, 0.1990671587016651, 0.9729962133498895, 0.28748322744440064, 0.5749664548888013, 0.5826291600007506, 0.8300186632163925, 0.745676908823686, 0.6939486037533772, 0.8932874725658149, 0.9972323935964056, 0.9247322975948559, 0.8300186632163925, 0.9365458912186934, 0.08308839690974339, 0.6647071752779471, 0.16617679381948677, 0.08308839690974339, 0.08308839690974339, 0.5157472327015528, 0.38681042452616454, 0.8266048622939308, 0.9371767119400893, 0.976632096015643, 0.5076618380442424, 0.5076618380442424, 0.8222591682659265, 0.7773624425290322, 0.22210355500829493, 0.7723586247535699, 0.038617931237678496, 0.19308965618839247, 0.6942869707379203, 0.20513024135438557, 0.0946754960097164, 0.7175261815292578, 0.2759716082804838, 0.89611719774409, 0.20600705926720758, 0.5768197659481812, 0.12360423556032454, 0.08240282370688302, 0.8884081355454758, 0.08884081355454758, 0.5891086189006508, 0.23143552885382712, 0.0420791870643322, 0.12623756119299662, 0.9905692813616265, 0.950076664325028, 0.8835529836642038, 0.5244183579301565, 0.2622091789650782, 0.22787275778277058, 0.759575859275902, 0.9717168838972092, 0.8300186632163925, 0.8835735579069329, 0.6910411031973377, 0.9457995290070497, 0.9327561313640327, 0.5655602325760903, 0.21994009044625737, 0.09426003876268173, 0.06284002584178783, 0.031420012920893914, 0.06284002584178783, 0.8235549674767244, 0.8266048622939308, 0.9887902770883985, 0.9478876165928002, 0.2884487689476993, 0.6730471275446317, 0.21107731110643702, 0.7387705888725296, 0.8969105933711706, 0.9454852439399792, 0.3725568957504166, 0.3725568957504166, 0.3725568957504166, 0.2939651275197747, 0.1679800728684427, 0.41995018217110675, 0.08399003643422134, 0.8266048622939308, 0.8300186632163925, 0.9202547676195586, 0.0541326333893858, 0.8235549674767244, 0.876578170819242, 0.47978397962267594, 0.47978397962267594, 0.7208656560899431, 0.19223084162398485, 0.09611542081199242, 0.9328222555013297, 0.7358316794656176, 0.8846628121732599, 0.8953700896397753, 0.8233897421173697, 0.881705793632103, 0.28568649621662345, 0.5713729924332469, 0.07142162405415586, 0.9999807846369715, 0.6294635123345078, 0.4815716503657516, 0.4815716503657516, 0.8266048622939308, 0.5607931049112067, 0.28039655245560335, 0.45047636976587035, 0.1501587899219568, 0.3904128537970877, 0.8745954594824479, 0.5598286042851754, 0.4198714532138816, 0.8683306295349177, 0.9815024476451649, 0.18797078564374273, 0.18797078564374273, 0.34908860190980795, 0.1611178162660652, 0.0805589081330326, 0.026852969377677532, 0.8739130297033959, 0.9181948130754292, 0.8300186632163925, 0.9530593887195588, 0.8701076580683504, 0.9275191428589281, 0.8969746780374936, 0.48709051130016734, 0.11597393126194461, 0.18555829001911137, 0.13916871751433352, 0.04638957250477784, 0.2948139276376233, 0.5896278552752466, 0.11792557105504932, 0.6413717568192795, 0.32068587840963975, 0.5882729048189366, 0.2941364524094683, 0.8300186632163925, 0.8300186632163925, 0.3669267333663187, 0.48923564448842494, 0.1630785481628083, 0.09554916436149324, 0.8599424792534391, 0.6399738035185714, 0.18284965814816323, 0.18284965814816323, 0.9631714646537902, 0.877022124689944, 0.9371735775007821, 0.9738369509963727, 0.5281292030434601, 0.5281292030434601, 0.9733486028909047, 0.7178244842413581, 0.2691841815905093, 0.9371743247911777, 0.9371725165151823, 0.8701076580683504, 1.0000546914049804, 0.8300186632163925, 0.22262784560392837, 0.6678835368117851, 0.07420928186797612, 0.2996409484233737, 0.2996409484233737, 0.39952126456449827, 0.8300186632163925, 0.9577196108587438, 0.9210290105536764, 0.8236768204415191, 0.09151964671572435, 0.9530635592863763, 0.6861427908360844, 0.2111208587187952, 0.1055604293593976, 0.9871953381527401, 0.585100277363642, 0.3900668515757614, 0.481859357864904, 0.481859357864904, 0.9371725165151823, 0.9371767119400893, 0.7787146019775022, 0.12978576699625036, 0.9371757716239748, 0.6882578621927367, 0.2580966983222762, 0.41626240022490146, 0.41626240022490146, 0.20813120011245073, 0.6568062051811222, 0.21893540172704076, 0.6939486037533772, 0.8640619382054757, 0.6865613725123535, 0.504630885248149, 0.504630885248149, 0.9436430348468585, 0.8300186632163925, 0.9274987748190269, 0.8300186632163925, 0.37461211145607354, 0.5619181671841104, 0.3270157383160573, 0.07546517038062861, 0.05031011358708574, 0.3270157383160573, 0.05031011358708574, 0.15093034076125722, 0.02515505679354287, 0.9460074130425372, 0.8300186632163925, 0.8235549674767244, 0.8969746780374936, 0.9334634138998916, 0.5929813491779765, 0.3557888095067859, 0.05929813491779765, 0.222018231483261, 0.666054694449783, 0.07400607716108701, 0.6807795966041978, 0.8732993024943184, 0.3436328721094461, 0.17181643605472305, 0.5154493081641691, 0.8795093641078382, 0.9930054749858596, 0.9912521840282851, 0.39945758259743835, 0.044384175844159816, 0.13315252753247944, 0.2219208792207991, 0.2219208792207991, 0.504630885248149, 0.504630885248149, 0.9036026186242904, 0.46209600476863777, 0.46209600476863777, 0.6784667967521878, 0.0969238281074554, 0.0969238281074554, 0.0969238281074554, 0.14271632798902803, 0.7135816399451401, 0.07135816399451402, 0.9878853861214797, 0.4241045977351978, 0.5654727969802638, 0.9967944215769675, 0.8780973627136173, 0.1254424803876596, 0.8404919294257746, 0.8969746780374936, 0.6807797246467295, 0.8300186632163925, 0.5008539233952172, 0.21465168145509306, 0.07155056048503101, 0.21465168145509306, 0.8429634593114909, 0.12042335133021298, 0.9684088156023525, 0.7241469549514754, 0.2655205501488743, 0.54290764159921, 0.36193842773280666, 0.9328226782291597, 0.6409874900403891, 0.345147110021748, 0.9605642243922897, 0.9328211587316712, 0.39746721289403886, 0.3091411655842525, 0.26497814192935926, 0.044163023654893205, 0.9912411816289006, 0.9912328301917827, 0.9328493373604524, 0.9048945802242981, 0.967096999057154, 0.9327571965816863, 0.9167145093222553, 0.9310846545396236, 0.8851992282169848, 0.07376660235141541, 0.2002247117112632, 0.750842668917237, 0.9328863838187853, 0.6708064096125527, 0.29813618205002346, 0.07453404551250586, 0.6865613725123535, 0.6865667594817947, 0.8099623717057972, 0.5926415817183152, 0.4102903258049875, 0.5273027556254413, 0.48963827308076685, 0.9371725165151823, 0.16093504612928494, 0.8046752306464247, 0.7577554883615301, 0.9701131174424233, 0.2864269832893918, 0.02864269832893918, 0.08592809498681754, 0.05728539665787836, 0.2864269832893918, 0.02864269832893918, 0.20049888830257426, 0.8623962884110309, 0.10779953605137886, 0.7465630719430328, 0.24885435731434427, 0.8687737098540425, 0.7873098994077052, 0.8725886321611808, 0.9984491615508999, 0.11519779728677203, 0.3743928411820091, 0.3167939425386231, 0.20159614525185104, 0.8060060608656744, 0.12726411487352754, 0.04242137162450918, 0.4337043017242311, 0.505988352011603, 0.33580489595376295, 0.6716097919075259, 0.29215065116755373, 0.233720520934043, 0.3505807814010645, 0.1168602604670215, 0.8995765409647283, 0.9912373943993278, 0.8164260019693961, 0.8835529836642038, 0.9172351844452887, 0.5470990407844707, 0.2431551292375425, 0.1823663469281569, 0.8919544361750662, 0.8969746780374936, 0.838109344866561, 0.10476366810832012, 0.4598949339043819, 0.15329831130146063, 0.3576960597034081, 0.9026106834221994, 0.3030723360256219, 0.47625652804026297, 0.21648024001830135, 0.9817637589122369, 0.6223912898288918, 0.3111956449144459, 0.15559782245722295, 0.87005909127269, 0.06692762240559154, 0.06692762240559154, 0.36451951454803727, 0.36451951454803727, 0.12150650484934576, 0.9371767119400893, 0.9915153830382407, 0.8764328725751406, 0.9912554658093828, 0.9104303802074601, 0.957098817175445, 0.5516250480200041, 0.9436430348468585, 0.7133306921440201, 0.20380876918400576, 0.2527644132826111, 0.6319110332065278, 0.16840175287830045, 0.6736070115132018, 0.868833709626516, 0.9371735775007821, 0.5074076646123565, 0.5074076646123565, 0.9737641023320437, 0.3057615208660659, 0.6115230417321318, 0.11725652931716012, 0.8207957052201208, 0.6720067501465291, 0.2688027000586117, 0.9964706809553381, 0.9954632972402199, 0.9270486916819286, 0.6858860816857746, 0.22862869389525822, 0.504630885248149, 0.504630885248149, 0.1254687560886453, 0.2509375121772906, 0.5018750243545812, 0.1254687560886453, 0.9437475839548038, 0.9444159393093399, 0.9475737734948505, 0.5277199260397639, 0.42217594083181115, 0.10554398520795279, 0.9371743247911777, 0.3334819309688651, 0.6669638619377302, 0.5498203647314847, 0.12218230327366326, 0.1832734549104949, 0.12218230327366326, 0.06109115163683163, 0.5087314947435388, 0.14535185564101108, 0.29070371128202216, 0.07267592782050554, 0.9659857546469873, 0.18751050522455057, 0.11250630313473034, 0.05625315156736517, 0.4312741620164663, 0.09375525261227528, 0.09375525261227528, 0.018751050522455057, 0.1318078021328585, 0.790846812797151, 0.8235549674767244, 0.3448717973324546, 0.6322649617761668, 0.9303325784375931, 0.13290465406251328, 0.9493984317604552, 0.7536554311950566, 0.2512184770650189, 0.28767444698351474, 0.7191861174587868, 0.9954632901542992, 0.9437452582641724, 0.9371767119400893, 0.9628903836182424, 0.9915153830382407, 0.9903127068177856, 0.32313110075315543, 0.6462622015063109, 0.8425880390537089, 0.6294635123345078, 0.13477966518189777, 0.8086779910913866, 0.2805105839737148, 0.15583921331873044, 0.4363497972924453, 0.12467137065498436, 0.26883819883650006, 0.7057002719458126, 0.19406785132041873, 0.6792374796214655, 0.8974201049299979, 0.069032315763846, 0.21376877711886944, 0.21376877711886944, 0.42753755423773887, 0.8701076580683504, 0.8235549674767244, 0.6865639810915458, 0.9912562804269446, 0.33184556692133016, 0.6636911338426603, 0.4517150492986543, 0.4517150492986543, 0.5529289511365322, 0.18430965037884406, 0.18430965037884406, 0.9243711418813023, 0.9915153830382407, 0.9950545194036057, 0.9968045644486707, 0.4356738288369441, 0.31949414114709235, 0.26140429730216647, 0.8168196388257866, 0.7575935177843889, 0.12626558629739815, 0.6807793984880804, 0.8683265709753143, 0.8499102537679321, 0.12141575053827601, 0.9437448939161753, 0.8191432651181891, 0.17990905968253, 0.71963623873012, 0.089954529841265, 0.20170253544938968, 0.10085126772469484, 0.312638929946554, 0.2823835496291456, 0.10085126772469484, 0.36349325851319114, 0.15578282507708194, 0.3115656501541639, 0.10385521671805462, 0.23386470164797246, 0.11693235082398623, 0.5846617541199312, 0.7577554883615301, 0.9210221011423139, 0.9371725165151823, 0.9912332440677863, 0.6865639810915458, 0.04685832588910752, 0.2342916294455376, 0.32800828122375264, 0.1874333035564301, 0.14057497766732258, 0.11115762633412785, 0.7781033843388949, 0.11115762633412785, 0.9497140403516426, 0.9887902770883985, 0.9659857546469873, 0.9766233050114165, 0.33349050016317056, 0.6669810003263411, 0.4294257193067062, 0.08588514386134125, 0.2576554315840237, 0.2576554315840237, 0.5090736285760372, 0.3636240204114552, 0.07272480408229104, 0.8701076580683504, 0.7347752755565343, 0.24492509185217812, 0.8559797810148169, 0.9371743247911777], \"Term\": [\"AMC\", \"AP\", \"APOG\", \"Administration\", \"Americans\", \"AstraZeneca\", \"AstraZeneca\", \"AstraZeneca\", \"AstraZeneca\", \"AstraZeneca\", \"Atacand\", \"Average\", \"BTIG\", \"Biden\", \"Bill\", \"Bill\", \"BioNTech\", \"BioNTech\", \"Biotech\", \"Bitcoin\", \"Brent\", \"Britain\", \"Britain\", \"British\", \"British\", \"Buy\", \"CNBC\", \"COVID\", \"Cac\", \"Chicago\", \"ClearPoint\", \"Composite\", \"County\", \"Daily\", \"Dax\", \"DermTech\", \"Dollar\", \"Dow\", \"Dunelm\", \"Elsewhere\", \"Emergent\", \"Europe\", \"Europe\", \"Europe\", \"European\", \"European\", \"European\", \"European\", \"Eve\", \"FTSE\", \"FTSE\", \"FTSE\", \"FTSE\", \"FanDuel\", \"Flutter\", \"Food\", \"For\", \"For\", \"German\", \"German\", \"German\", \"Ghaly\", \"Government\", \"Grade\", \"Group\", \"Group\", \"Hadjikyriacos\", \"He\", \"He\", \"Hepion\", \"However\", \"I\", \"I\", \"Immutep\", \"In\", \"In\", \"In\", \"In\", \"In\", \"In\", \"In\", \"Inc\", \"India\", \"Industrial\", \"Jones\", \"Keator\", \"Letlow\", \"London\", \"London\", \"MSCI\", \"Moderna\", \"Moderna\", \"Monday\", \"Monday\", \"Monday\", \"Monday\", \"Most\", \"NASDAQ\", \"NASH\", \"NHS\", \"NHS\", \"NTGR\", \"Nasdaq\", \"National\", \"Natwest\", \"New\", \"Next\", \"November\", \"Of\", \"On\", \"One\", \"Osmotica\", \"Oxford\", \"Oxford\", \"Oxford\", \"P\", \"PLC\", \"PLC\", \"Paddy\", \"Parliament\", \"Parliament\", \"Pfizer\", \"Pfizer\", \"Pfizer\", \"Pharmaceuticals\", \"Phase\", \"Phase\", \"Plus\", \"Power\", \"Pub\", \"Regeneron\", \"Republican\", \"S\", \"Senate\", \"Sentiment\", \"Service\", \"Shares\", \"Shares\", \"Shares\", \"Shares\", \"Shares\", \"Stocks\", \"Stocks\", \"Study\", \"Tesla\", \"Therapeutics\", \"This\", \"This\", \"To\", \"Trump\", \"Trump\", \"Tuesday\", \"Tuesday\", \"Tuesday\", \"UK\", \"UK\", \"UK\", \"US\", \"US\", \"United\", \"University\", \"University\", \"University\", \"University\", \"Wall\", \"Wall\", \"Wednesday\", \"Wednesday\", \"Wednesday\", \"Wednesday\", \"Year\", \"York\", \"ability\", \"access\", \"access\", \"added\", \"added\", \"administration\", \"afternoon\", \"ago\", \"agreement\", \"ahead\", \"almost\", \"also\", \"also\", \"also\", \"also\", \"also\", \"also\", \"alternative\", \"amendment\", \"aminotransferase\", \"analysis\", \"analyst\", \"analyst\", \"announced\", \"announced\", \"antibody\", \"approval\", \"approve\", \"approve\", \"approve\", \"approved\", \"approved\", \"approved\", \"approved\", \"arbaclofen\", \"areas\", \"around\", \"around\", \"authorities\", \"authorization\", \"available\", \"available\", \"back\", \"back\", \"back\", \"banks\", \"barrels\", \"based\", \"battle\", \"began\", \"biggest\", \"billion\", \"billion\", \"billion\", \"briefing\", \"broadly\", \"business\", \"business\", \"candidate\", \"case\", \"case\", \"cases\", \"cases\", \"cases\", \"clinical\", \"closed\", \"closed\", \"closing\", \"cocktail\", \"company\", \"company\", \"company\", \"company\", \"company\", \"company\", \"compared\", \"completed\", \"confirmation\", \"confirmed\", \"considered\", \"continued\", \"continuing\", \"coronavirus\", \"coronavirus\", \"coronavirus\", \"coronavirus\", \"coronavirus\", \"country\", \"country\", \"country\", \"cover\", \"cover\", \"created\", \"created\", \"credit\", \"customers\", \"day\", \"day\", \"day\", \"days\", \"days\", \"deal\", \"deal\", \"deal\", \"death\", \"deaths\", \"delayed\", \"delivered\", \"deployment\", \"deployment\", \"despite\", \"developed\", \"developed\", \"dip\", \"disease\", \"distribution\", \"dollar\", \"doors\", \"dose\", \"dose\", \"dose\", \"doses\", \"doses\", \"doses\", \"downturn\", \"drive\", \"driven\", \"due\", \"due\", \"earlier\", \"early\", \"early\", \"early\", \"easily\", \"economic\", \"economic\", \"economy\", \"economy\", \"edged\", \"education\", \"efficacy\", \"efficacy\", \"electric\", \"end\", \"end\", \"enough\", \"enough\", \"enough\", \"entire\", \"entire\", \"evidence\", \"expects\", \"experts\", \"facility\", \"facility\", \"facing\", \"fantasy\", \"fears\", \"finally\", \"firm\", \"firm\", \"first\", \"first\", \"first\", \"first\", \"first\", \"first\", \"first\", \"flat\", \"forced\", \"frame\", \"futility\", \"gain\", \"gained\", \"gained\", \"gained\", \"gains\", \"gains\", \"gains\", \"giant\", \"given\", \"going\", \"going\", \"going\", \"gold\", \"good\", \"goods\", \"government\", \"government\", \"government\", \"government\", \"government\", \"granting\", \"granting\", \"greatest\", \"groups\", \"groups\", \"half\", \"half\", \"half\", \"half\", \"health\", \"health\", \"health\", \"higher\", \"highest\", \"highest\", \"hope\", \"hopes\", \"hopes\", \"hospital\", \"hospitalized\", \"hundreds\", \"iEnergizer\", \"including\", \"including\", \"including\", \"including\", \"increase\", \"increase\", \"increased\", \"index\", \"index\", \"infectious\", \"infectious\", \"inoculation\", \"investors\", \"investors\", \"jab\", \"largest\", \"last\", \"last\", \"last\", \"last\", \"late\", \"leaves\", \"less\", \"level\", \"levels\", \"little\", \"looking\", \"lost\", \"low\", \"low\", \"lower\", \"lower\", \"lowest\", \"made\", \"made\", \"made\", \"make\", \"management\", \"many\", \"market\", \"market\", \"markets\", \"markets\", \"masks\", \"may\", \"may\", \"mechanical\", \"member\", \"million\", \"million\", \"million\", \"million\", \"million\", \"million\", \"million\", \"morning\", \"morning\", \"moved\", \"moved\", \"must\", \"national\", \"near\", \"nearly\", \"new\", \"new\", \"new\", \"new\", \"news\", \"news\", \"news\", \"next\", \"next\", \"number\", \"number\", \"one\", \"one\", \"one\", \"one\", \"open\", \"opened\", \"operating\", \"ordered\", \"pace\", \"pandemic\", \"pandemic\", \"pandemic\", \"part\", \"passed\", \"passing\", \"passing\", \"patients\", \"patients\", \"patients\", \"peak\", \"people\", \"people\", \"people\", \"performance\", \"period\", \"period\", \"period\", \"points\", \"points\", \"points\", \"population\", \"population\", \"population\", \"position\", \"positions\", \"possible\", \"pound\", \"premarket\", \"price\", \"problems\", \"product\", \"products\", \"products\", \"program\", \"program\", \"public\", \"public\", \"pushed\", \"raised\", \"rallied\", \"rallied\", \"rapid\", \"ready\", \"ready\", \"received\", \"received\", \"receiving\", \"receiving\", \"record\", \"recorded\", \"recovery\", \"red\", \"red\", \"regional\", \"regional\", \"reported\", \"reported\", \"reported\", \"reported\", \"residents\", \"rest\", \"results\", \"risk\", \"risk\", \"risk\", \"robust\", \"rolled\", \"rolled\", \"rollout\", \"rollout\", \"rollout\", \"rollout\", \"rollout\", \"rose\", \"rose\", \"rose\", \"rose\", \"safety\", \"said\", \"said\", \"said\", \"said\", \"said\", \"said\", \"said\", \"saying\", \"saying\", \"schedules\", \"second\", \"second\", \"see\", \"see\", \"session\", \"shares\", \"shares\", \"shot\", \"shot\", \"shots\", \"slipped\", \"software\", \"solutions\", \"square\", \"start\", \"state\", \"state\", \"statement\", \"sterling\", \"stimulus\", \"stimulus\", \"stock\", \"stock\", \"stock\", \"stock\", \"stocks\", \"stocks\", \"support\", \"support\", \"take\", \"take\", \"target\", \"target\", \"target\", \"temperatures\", \"tested\", \"testing\", \"third\", \"three\", \"three\", \"time\", \"time\", \"today\", \"today\", \"today\", \"told\", \"tomorrow\", \"trade\", \"traders\", \"trading\", \"trading\", \"trading\", \"treatment\", \"trial\", \"trial\", \"trusts\", \"turning\", \"use\", \"use\", \"vaccinate\", \"vaccinated\", \"vaccination\", \"vaccination\", \"vaccination\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccine\", \"vaccines\", \"vaccines\", \"vaccines\", \"vaccines\", \"variant\", \"variant\", \"variant\", \"ventilation\", \"versus\", \"weaker\", \"weakness\", \"wearing\", \"week\", \"week\", \"week\", \"week\", \"week\", \"weeks\", \"weeks\", \"weeks\", \"well\", \"went\", \"window\", \"within\", \"workers\", \"workers\", \"world\", \"world\", \"world\", \"world\", \"would\", \"would\", \"would\", \"wrong\", \"year\", \"year\", \"yesterday\", \"yield\"]}, \"R\": 30, \"lambda.step\": 0.01, \"plot.opts\": {\"xlab\": \"PC1\", \"ylab\": \"PC2\"}, \"topic.order\": [7, 10, 2, 6, 8, 1, 4, 5, 9, 3]};\n",
              "\n",
              "function LDAvis_load_lib(url, callback){\n",
              "  var s = document.createElement('script');\n",
              "  s.src = url;\n",
              "  s.async = true;\n",
              "  s.onreadystatechange = s.onload = callback;\n",
              "  s.onerror = function(){console.warn(\"failed to load library \" + url);};\n",
              "  document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
              "}\n",
              "\n",
              "if(typeof(LDAvis) !== \"undefined\"){\n",
              "   // already loaded: just create the visualization\n",
              "   !function(LDAvis){\n",
              "       new LDAvis(\"#\" + \"ldavis_el12411397996863546409155505794\", ldavis_el12411397996863546409155505794_data);\n",
              "   }(LDAvis);\n",
              "}else if(typeof define === \"function\" && define.amd){\n",
              "   // require.js is available: use it to load d3/LDAvis\n",
              "   require.config({paths: {d3: \"https://d3js.org/d3.v5\"}});\n",
              "   require([\"d3\"], function(d3){\n",
              "      window.d3 = d3;\n",
              "      LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "        new LDAvis(\"#\" + \"ldavis_el12411397996863546409155505794\", ldavis_el12411397996863546409155505794_data);\n",
              "      });\n",
              "    });\n",
              "}else{\n",
              "    // require.js not available: dynamically load d3 & LDAvis\n",
              "    LDAvis_load_lib(\"https://d3js.org/d3.v5.js\", function(){\n",
              "         LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.3.1/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
              "                 new LDAvis(\"#\" + \"ldavis_el12411397996863546409155505794\", ldavis_el12411397996863546409155505794_data);\n",
              "            })\n",
              "         });\n",
              "}\n",
              "</script>"
            ],
            "text/plain": [
              "PreparedData(topic_coordinates=              x         y  topics  cluster       Freq\n",
              "topic                                                \n",
              "6      0.146917  0.143195       1        1  34.216606\n",
              "9      0.111319  0.177068       2        1  17.652041\n",
              "1      0.158432 -0.151898       3        1  14.194401\n",
              "5      0.063816 -0.168428       4        1  11.473775\n",
              "7     -0.206076 -0.012524       5        1   6.637671\n",
              "0     -0.103618  0.023797       6        1   6.580355\n",
              "3      0.032421 -0.069312       7        1   5.728228\n",
              "4     -0.068152  0.023303       8        1   2.305718\n",
              "8     -0.084992  0.013528       9        1   1.207094\n",
              "2     -0.050067  0.021270      10        1   0.004112, topic_info=             Term       Freq      Total Category  logprob  loglift\n",
              "122       vaccine  99.000000  99.000000  Default  30.0000  30.0000\n",
              "28             UK  63.000000  63.000000  Default  29.0000  29.0000\n",
              "841        higher  25.000000  25.000000  Default  28.0000  28.0000\n",
              "343            US  18.000000  18.000000  Default  27.0000  27.0000\n",
              "320        NASDAQ  23.000000  23.000000  Default  26.0000  26.0000\n",
              "...           ...        ...        ...      ...      ...      ...\n",
              "2014       Dollar   0.000132   2.718013  Topic10  -7.9233   0.1667\n",
              "2025      barrels   0.000132   2.718013  Topic10  -7.9233   0.1667\n",
              "49    coronavirus   0.000132  43.113137  Topic10  -7.9233  -2.5973\n",
              "182       company   0.000132  37.239829  Topic10  -7.9233  -2.4508\n",
              "1888           To   0.000132   3.648485  Topic10  -7.9233  -0.1277\n",
              "\n",
              "[554 rows x 6 columns], token_table=      Topic      Freq            Term\n",
              "term                                 \n",
              "2334      5  0.937177             AMC\n",
              "2410      5  0.937168              AP\n",
              "1298      2  0.823060            APOG\n",
              "1637      4  0.868774  Administration\n",
              "1527      2  0.953050       Americans\n",
              "...     ...       ...             ...\n",
              "1294      7  0.870108           wrong\n",
              "290       1  0.734775            year\n",
              "290       2  0.244925            year\n",
              "1523      2  0.855980       yesterday\n",
              "2759      5  0.937174           yield\n",
              "\n",
              "[665 rows x 3 columns], R=30, lambda_step=0.01, plot_opts={'xlab': 'PC1', 'ylab': 'PC2'}, topic_order=[7, 10, 2, 6, 8, 1, 4, 5, 9, 3])"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 50
        }
      ]
    }
  ]
}